2 A
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Xeoflox
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 30's pack
Domider
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 1's pack
Flintex
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : None
Menida
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Menida
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Pedryl
	n : Diphenhydramine Hydrochloride
	Indications : Allergic rhinitis, Allergic conditions, Motion sickness, Common cold, Insomnia, Extrapyramidal symptoms
	Doses and administration : Oral
									Adult: As hydrochloride: 25-50 mg 3-4 times daily. Max: 300 mg/day. 
									Child: 6.25-25 mg 3-4 times daily, up to 5 mg/kg in divided doses. Max: 300 mg/day. 
									
									Treatment and prophylaxis of motion sickness
									Adult: As diphenhydramine di (acefyllinate): Usual dose: 90-135 mg, may repeat if needed at intervals of at least 6 hr. Max: 540 mg daily. For prevention, dose to be given at least 30 min before travelling. 
									
	Contara-indications : Hypersensitivity ; neonates, lactation.
	Side effects : CNS depression, dizziness, headache, sedation; paradoxical stimulation in children; dryness of mouth, thickened respiratory secretion, blurring of vision, urinary retention; GI disturbances; blood dyscrasias.
	Precaution : Epilepsy; elderly; performing tasks which require mental alertness; angle-closure glaucoma; pyroduodenal obstruction; urinary tract obstruction; hyperthyroidism; raised intraocular pressure; CV disease; acute asthma; pregnancy.
	Pregnancy category : 2
	Mode of action : Diphenhydramine blocks histamine H1-receptors on effector cells of the GI tract, blood vessels and respiratory tract. It also causes sedation and has some anticholinergic action.
	Interaction :  	Masks ototoxicity produced by aminoglycosides. Increases gastric degradation of levodopa and decreases its absorption by reduction of gastric emptying. Antagonises therapeutic effects of cholinergic agents e.g. tacrine, donezepil and neuroleptics. Valerian, St. John's wort, Kava Kava and gotu kola may increase CNS depression.
				Potentially Fatal: Potentiates CNS depression with alcohol, barbiturates, analgesics, sedatives and neuroleptics. Additive antimuscarinic action with MAOIs, atropine and TCAs.
	Therapeutic class : Sedating Anti-histamines
	Packsize : 100ml bot
Ranzo
	n : Omeprazole
	Indications : Peptic ulcer, H. pylori infection, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Oesophagitis, Acid-related dyspepsia, NSAID-associated ulceration
	Doses and administration : Adult: PO Peptic ulcer 20 mg once daily. Severe: 40 mg/day. Duration: Duodenal ulcers: 4 wk; Gastric ulcers: 8 wk. Maintenance: 10-20 mg once daily. NSAID-associated ulceration 20 mg/day. 
									
									Eradication of H. pylori infection Dose varies w/ regimen: 20 mg once daily or 40 mg/day in 1-2 divided doses. To use w/ antibiotics. GERD 20 mg once daily for 4 wk, may continue for another 8 wk if needed. Maintenance: 10 mg/day. Zollinger-Ellison syndrome Initial: 60 mg once daily. Maintenance: 20-120 mg/day. Give doses >80 mg in 2 divided doses. 
									
									Prophylaxis of acid aspiration during general anesth Initial: 40 mg the evening before surgery and another 40 mg 2-6 hr pre-op. Acid-related dyspepsia 10 or 20 mg/day 2-4 wkly. Erosive oesophagitis 20 mg/day for 4-8 wk. Maintenance: 20 mg/day for up to 12 mth of total therapy inclusive of treatment period. 
									
									IV Gastric and duodenal ulcers; Reflux oesophagitis 40 mg once daily. Prophylaxis of acid aspiration during general anesth 40 mg, to be completed 1 hr before the surgery.
	Contara-indications : Known hypersensitivity to any of its component.
	Side effects : Diarrhoea, nausea, fatigue, constipation, vomiting, flatulence, acid regurgitation, taste perversion, arthralgia, myalgia, urticaria, dry mouth, dizziness, headache, paraesthesia, abdominal pain, skin rashes, weakness, back pain, upper respiratory infection, cough.
									Potentially Fatal: Anaphylaxis.
	Precaution : Exclude malignancy, prolonged use, hepatic impairment. Pregnancy, lactation, children <1 yr. Elderly and Asians (increased bioavailability).
	Pregnancy category : 3
	Mode of action : Omeprazole is a substituted benzimidazole gastric antisecretory agent and is also known as PPI. It blocks the final step in gastric acid secretion by specific inhibition of H+/K+ ATPase enzyme system present on the secretory surface of the gastric parietal cell. Both basal and stimulated acid are inhibited.
	Interaction : Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.
				Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 60's pack 
3rd Cef
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 4's pack
5-Fluril
	n : Fluorouracil
	Indications : Malignant neoplasm, Basal cell carcinoma, Oesophageal carcinoma
	Doses and administration : Adult: IV Palliation of malignant neoplasms 12 mg/kg/day (max: 0.8-1g/day) for 3-4 days, if no toxicity occurs, may be followed after 1 day w/ 6 mg/kg on alternate days for another 3-4 doses. May repeat course 4-6 wk later or maintenance doses of 5-15 mg/kg (max: 1 g) may be given wkly. 
									
									As an infusion: 15 mg/kg/day (max: 1 g/day), continue until toxicity occurs or a total of 12-15 g is given. May repeat course 4-6 wk later. Intra-arterial Palliation of malignant neoplasms 5-7.5 mg/kg/day as continuous infusion (regional perfusion).  
									
									Child: Safety & efficacy not established.
	Contara-indications : Hypersensitivity. Depressed bone marrow function, poor nutritional status, potentially serious infections. Pregnancy and lactation.
	Side effects : Leucopenia, thrombocytopaenia, stomatitis, GI ulceration, bleeding and diarrhoea, haemorrhage from any site (stop treatment). Nausea, vomiting, rashes, hyperpigmentation, alopecia. Topical: Local inflammatory and photosensitivity reactions. Dermatitis and erythema multiforme (rare).
									Potentially Fatal: Central neurotoxicity, myocardial ischaemia.
	Precaution : Regular monitoring of blood counts. History of heart disease, hepatic or renal insufficiency, weak or malnourished patients, patients who with history of high-dose pelvic radiation or use of alkylating agents. Patients with widespread metastases to the bone marrow.
	Pregnancy category : 4
	Mode of action : Fluorouracil interferes with DNA synthesis by blocking the conversion of deoxyuridylic acid to thymidylic acid. It also interferes with RNA synthesis. This results in an unbalanced growth of the cells. Fluorouracil exerts greater effect on rapidly growing cells as they take up the drug at a faster rate.
	Interaction :  	May increase warfarin effects. May reduce response to vaccines; possibility of generalized infection with live vaccines. Action may be modified by allopurinol. Leucovorin calcium may enhance the toxicity of fluorouracil.
	Therapeutic class : Cytotoxic Chemotherapy
	Packsize : 1's pack
A B1
	n : Thiamine Hydrochloride
	Indications : Beriberi and Wernick's encephalopathy, neuritis associated with pregnancy and pellagra.
	Doses and administration : Treatment and prophylaxis of mild chronic thiamine deficiency
									Adult: 10-25 mg daily in single or divided doses.
									
									Thiamine deficiency
									Adult: Up to 300 mg daily.
									
									Wernicke-Korsakoff syndrome
									Adult: Initially, 100 mg by slow IV Inj over 10 min, then 50-100 mg/day IM or IV until the patient can take oral thiamine.
									
									Incompatibility: Alkaline or neutral solutions and with oxidizing and reducing agents.
	Contara-indications : None
	Side effects : IV: Warm sensation, tingling, pruritus, pain, urticaria, weakness, sweating, nausea, restlessness, tightness of the throat, angioedema, respiratory distress, cyanosis, pulmonary oedema, GI bleeding, transient vasodilation and hypotension, vascular collapse. IM: Tenderness and induration.
									Potentially Fatal: Very rarely, fatal anaphylactic shock.
	Precaution : Parenteral admin. Increased daily requirements in pregnancy and lactation.
	Pregnancy category : 1
	Mode of action : Thiamine, a water soluble vitamin, combines with ATP to form thiamine pyrophosphate, an essential coenzyme in carbohydrate metabolism.
	Interaction : None
	Therapeutic class : Vitamin-B preparations
	Packsize : 100'pack
A Cal 500
	n : Calcium Carbonate
	Indications : Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset
	Doses and administration : Adult: PO Hyperacidity: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets. 
									
									Hyperphosphataemia in chronic renal failure Initial: 2.5 g/day, up to 17 g/day in divided doses.
									
									Renal impairment:
									CrCl (ml/min)	
									<25	Dosage adjustments may be needed depending on serum calcium levels. 
	Contara-indications : Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.
	Side effects : Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).
	Precaution : Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.
	Pregnancy category : 3
	Mode of action : Calcium carbonate can neutralise gastric acid rapidly and effectively. However, it may adversely activate Ca dependent processes, leading to secretion of gastric and hydrochloric acid. It can induce rebound acid secretion and, prolonged high doses may cause hypercalcemia, alkalosis and milk-alkali syndrome.
	Interaction : Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
	Therapeutic class : Specific mineral preparations
	Packsize : 100's pack
A Cal Chewable 250
	n : Calcium Carbonate
	Indications : Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset
	Doses and administration : Adult: PO Hyperacidity: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets. 
									
									Hyperphosphataemia in chronic renal failure Initial: 2.5 g/day, up to 17 g/day in divided doses.
									
									Renal impairment:
									CrCl (ml/min)	
									<25	Dosage adjustments may be needed depending on serum calcium levels. 
	Contara-indications : Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.
	Side effects : Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).
	Precaution : Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.
	Pregnancy category : 3
	Mode of action : Calcium carbonate can neutralise gastric acid rapidly and effectively. However, it may adversely activate Ca dependent processes, leading to secretion of gastric and hydrochloric acid. It can induce rebound acid secretion and, prolonged high doses may cause hypercalcemia, alkalosis and milk-alkali syndrome.
	Interaction : Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
	Therapeutic class : Specific mineral preparations
	Packsize :  30's pack
A Card
	n : Isosorbide Mononitrate
	Indications : Heart failure,  Angina pectoris
	Doses and administration : Adult: PO 20 mg 2-3 times/day. Usual range: 20-120 mg/day.
									As LA form: One capsule once daily.
	Contara-indications : Severe hypotension or anaemia, hypovolaemia, heart failure due to obstruction, or raised intracranial pressure due to head trauma or cerebral haemorrhage.
	Side effects : Hypotension, tachycardia, flushing, headache, dizziness, palpitation, syncope, confusion. Nausea, vomiting, abdominal pain. Restlessness, weakness and vertigo. Dry mouth, chest pain, back pain, oedema, fatigue, abdominal pain, constipation, diarrhoea, dyspepsia and flatulence.
									Potentially Fatal: Severe hypotension and cardiac failure.
	Precaution : Severe renal or severe hepatic impairment, hypothyroidism, malnutrition, or hypothermia. Caution in patients who are already hypotensive. May aggravate angina caused by hypertrophic cardiomyopathy. Tolerance may develop after long-term treatment. Lactation.
	Pregnancy category : 3
	Mode of action : Isosorbide mononitrate relaxes vascular smooth muscles by stimulating cyclic-GMP. It decreases left ventricular pressure (preload) and arterial resistance (afterload).
	Interaction : Hypotensive effects may be increased when used with alcohol or vasodilators. Concurrent use with calcium channel blockers may lead to marked orthostatic hypotension.
				Potentially Fatal: Significant hypotension may occur when used with phosphodiesterase-5 inhibitors.
	Therapeutic class : Nitrates: Coronary vasodilators
	Packsize : 100's pack
A Care
	n : Betacarotene + Vitamin C + Vitamin E  (Anti-Oxidant Vitamins and Minerals)
	Indications : Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair.
									
	Doses and administration : One tablet/capsule daily or as directed by a physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.
	Pregnancy category : 1
	Mode of action : Beta carotene is 1 of a group of red, orange, and yellow pigments called carotenoids; Dietary sources include fruits, vegetables, and whole grains.  Photoprotective effects: Exact mechanism unknown; in vitro studies suggest antioxidant effects and that beta carotene reduces free radicals and singlet oxygen, which are produced when porphyrin is exposed to light and air.
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin preparations
	Packsize : 20's pack
A Clox
	n : Cloxacillin
	Indications : Bacterial infections, Staphylococcal infections resistant to benzylpenicillin, Bacterial Meningitis caused by Staphylococcus, Bacterial Pneumonia caused by Staphylococcus, Lower Respiratory Tract Infection, Urinary Tract Infection caused by Staphylococcus Aureus
	Doses and administration : Adult: PO 250-500 mg 4 times/day. 
									Child: 50-100 mg/kg in divided doses every 6 hr.
	Contara-indications : Hypersensitivity to penicillins.
	Side effects : Neutropenia, agranulocytosis; GI upsets; rash. Sore mouth or tongue. Black hairy tongue.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis; anaphylaxis.
	Precaution : Renal impairment; pregnancy and lactation. Porphyria.
	Pregnancy category : 2
	Mode of action : Cloxacillin is resistant to degradation by penicillinases. It is particularly useful against penicillinase-producing staphylococci. Highly active against S aureus, S pyogenes, S viridans and S pneumoniae.
	Interaction :  	May diminish the effect of BCG and typhoid vaccine. May increase risk of methotrexate toxicity. May diminish the therapeutic effect of Na picosulfate. May decrease serum concentrations of mycophenolate. May prolong bleeding time w/ anticoagulants. Increased serum concentrations w/ probenecid. Tetracycline may antagonise the bactericidal effect of cloxacillin.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 100ml
A Clox
	n : Cloxacillin
	Indications : Bacterial infections, Staphylococcal infections resistant to benzylpenicillin, Bacterial Meningitis caused by Staphylococcus, Bacterial Pneumonia caused by Staphylococcus, Lower Respiratory Tract Infection, Urinary Tract Infection caused by Staphylococcus Aureus
	Doses and administration : Adult: PO 250-500 mg 4 times/day. 
									Child: 50-100 mg/kg in divided doses every 6 hr.
	Contara-indications : Hypersensitivity to penicillins.
	Side effects : Neutropenia, agranulocytosis; GI upsets; rash. Sore mouth or tongue. Black hairy tongue.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis; anaphylaxis.
	Precaution : Renal impairment; pregnancy and lactation. Porphyria.
	Pregnancy category : 2
	Mode of action : Cloxacillin is resistant to degradation by penicillinases. It is particularly useful against penicillinase-producing staphylococci. Highly active against S aureus, S pyogenes, S viridans and S pneumoniae.
	Interaction :  	May diminish the effect of BCG and typhoid vaccine. May increase risk of methotrexate toxicity. May diminish the therapeutic effect of Na picosulfate. May decrease serum concentrations of mycophenolate. May prolong bleeding time w/ anticoagulants. Increased serum concentrations w/ probenecid. Tetracycline may antagonise the bactericidal effect of cloxacillin.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 5 Vials
A Clox
	n : Cloxacillin
	Indications : Bacterial infections, Staphylococcal infections resistant to benzylpenicillin, Bacterial Meningitis caused by Staphylococcus, Bacterial Pneumonia caused by Staphylococcus, Lower Respiratory Tract Infection, Urinary Tract Infection caused by Staphylococcus Aureus
	Doses and administration : Adult: PO 250-500 mg 4 times/day. 
									Child: 50-100 mg/kg in divided doses every 6 hr.
	Contara-indications : Hypersensitivity to penicillins.
	Side effects : Neutropenia, agranulocytosis; GI upsets; rash. Sore mouth or tongue. Black hairy tongue.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis; anaphylaxis.
	Precaution : Renal impairment; pregnancy and lactation. Porphyria.
	Pregnancy category : 2
	Mode of action : Cloxacillin is resistant to degradation by penicillinases. It is particularly useful against penicillinase-producing staphylococci. Highly active against S aureus, S pyogenes, S viridans and S pneumoniae.
	Interaction :  	May diminish the effect of BCG and typhoid vaccine. May increase risk of methotrexate toxicity. May diminish the therapeutic effect of Na picosulfate. May decrease serum concentrations of mycophenolate. May prolong bleeding time w/ anticoagulants. Increased serum concentrations w/ probenecid. Tetracycline may antagonise the bactericidal effect of cloxacillin.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 5 Vials
A Clox
	n : Cloxacillin
	Indications : Bacterial infections, Staphylococcal infections resistant to benzylpenicillin, Bacterial Meningitis caused by Staphylococcus, Bacterial Pneumonia caused by Staphylococcus, Lower Respiratory Tract Infection, Urinary Tract Infection caused by Staphylococcus Aureus
	Doses and administration : Adult: PO 250-500 mg 4 times/day. 
									Child: 50-100 mg/kg in divided doses every 6 hr.
	Contara-indications : Hypersensitivity to penicillins.
	Side effects : Neutropenia, agranulocytosis; GI upsets; rash. Sore mouth or tongue. Black hairy tongue.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis; anaphylaxis.
	Precaution : Renal impairment; pregnancy and lactation. Porphyria.
	Pregnancy category : 2
	Mode of action : Cloxacillin is resistant to degradation by penicillinases. It is particularly useful against penicillinase-producing staphylococci. Highly active against S aureus, S pyogenes, S viridans and S pneumoniae.
	Interaction :  	May diminish the effect of BCG and typhoid vaccine. May increase risk of methotrexate toxicity. May diminish the therapeutic effect of Na picosulfate. May decrease serum concentrations of mycophenolate. May prolong bleeding time w/ anticoagulants. Increased serum concentrations w/ probenecid. Tetracycline may antagonise the bactericidal effect of cloxacillin.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 100's pack
A Cold
	n : Bromhexine Hydrochloride
	Indications : Productive cough, Acute sore throat, Mucolytic
	Doses and administration : Tablet:
									Adults and children over 10 years: 8-16 mg 3 times daily. Children 5-10 years: 4 mg 3 times daily.
									
									Syrup:
									Adults: The recommended daily dose is 2 to 4 teaspoonful 3 times. Initially 4 teaspoonful 3 times daily and then as required.
									
									Children: Suggested dosage for children under 2 years is 1/4 teaspoonful 3 times daily, 
									2-5 years 1/2 teaspoonful 3 times daily 
									5-10 years 1 teaspoonful 3 times daily.
	Contara-indications : Contraindicated to those who are hypersensitive to Bromhexine Hydrochloride.
	Side effects : GI side effects; headache, dizziness, sweating, skin rashes. Inhalation: Cough or bronchospasm.
	Precaution : History of peptic ulceration; asthmatic patients. Severe hepatic or renal impairment.
	Pregnancy category : 0
	Mode of action : Bromhexine is a mucolytic.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 1'spack(100ml)
A Fenac
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 10 amps pack
A Fenac 1%
	n : Diclofenac Sodium 1% Topical
	Indications : Rheumatoid arthritis, Osteoarthritis, Joint and muscular pains
	Doses and administration : Gel: For external use only. Depending on the size of area to be treated, 2-4 g of  Gel should be applied to the skin 3-4 times daily. To the affected area gel should be rubbed in lightly.  
									Gel may also be given in addition to further treatment with other dosage forms of Diclofenac.
									
									
	Contara-indications : Contraindicated to the patients hypersensitive to any ingredient of the products. Peptic ulcer, hypersensitivity to Diclofenac like other non-steroid anti-inflammatory agents, Diclofenac is also contra-indicated in asthmatic patient in whom attack with asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or by other drugs with prostaglandin synthetase inhibitor.  Gel should not be used under occlusive airtight dressings.
	Side effects : Generally well tolerated. Adverse effects are mild, rare and transient. At the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. These effects are usually mild in nature. Peripheral edema and skin reactions, such as rash and eczema have also been encountered. Gel may cause local irritation and reddening of the skin and skin rash.
	Precaution : In rare instances where peptic ulceration or gastro-intestinal bleeding occurs in patients under treatment with Diclofenac. In patients with advanced age should be kept under close observation.Gel should not be allowed to come in contact with the eyes or mucus membranes, after application the hands should be washed properly and not to be taken by mouth.
	Pregnancy category : 3
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. Inhibits cyclooxygenase (COX)-1 and COX-2, thereby inhibiting prostaglandin synthesis. May also inhibit neutrophil aggregation/activation, inhibit chemotaxis, decrease proinflammatory cytokine level, and alter lymphocyte activity.
	Interaction : May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Topical Analgesics
	Packsize : 10gm tube
A Fenac
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 10's   pack
A Fenac
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
A Fenac
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 10's   pack
A Fenac
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
A Fenac K
	n : Diclofenac Potassium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Allergic conjunctivitis, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic, Miosis, Tendinitis, Actinic keratosis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses. Migraine As K: Initial: 50 mg taken at 1st sign of attack, repeat 2 hr later if needed and subsequently 4-6 hrly if needed. Max: 200 mg/day. 
	Contara-indications :  It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
	Precaution : History of GI ulceration; impaired cardiac, renal or hepatic function; hypertension; lactation. IV admin in patients with moderate or severe renal impairment; hypovolaemia or dehydration; asthma, porphyria. Monitor LFTs in patients on prolonged therapy. May prolong bleeding time; caution when used in patients with coagulation disorders or on anticoagulants. Prolonged therapy may increase risk of anaemia. 1st and 2nd trimester of pregnancy. Elderly, debilitated patients.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
A Fenac PLUS IM
	n : Diclofenac + Lidocaine Hydrochloride
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Acute gout, Inflammation, Tendinitis, Actinic keratoses, Bursitis
	Doses and administration : Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
	Contara-indications : In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									
									Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide-type.
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									The adverse effects due to Lidocaine mainly involve the CNS, are usually of short duration, and are dose related. The CNS reaction may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadness, etc. Incase of eye drops ocular burning sensation or allergic reaction may occur in 5-10% patients. 
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued.
	Pregnancy category : 19
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
									
									Lidocaine is an amide type local anaesth. It stabilises the neuronal membrane and inhibits Na ion movements, which are necessary for conduction of impulses. In the heart, lidocaine reduces depolarisation of the ventricles during diastole and automaticity in the His-Purkinje system. Duration of action potential and effective refractory period are also reduced.
	Interaction :  	May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
				May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 10's pack
A Fenac SR
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
A Flox
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 100ml bot
A Flox
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 48's pack
A Flox
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 5's pack
A Flox
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 48's pack
A Flox
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 5's pack
A FORTE
	n : Vitamin A (Retinol)
	Indications : Vitamin A deficiency, Night blindness, Xerophthalmia
	Doses and administration : Adult: PO Vitamin A deficiency For severe deficiency w/ corneal changes: 500,000 u/day for 3 days, followed by 50,000 u/day for 2 wk and then 10,000-20,000 u/day for 2 mth as follow-up therapy. 
									
									For cases w/o corneal changes: 10,000-25,000 u/day until clinical improvement occurs (usually 1-2 wk). 
									
									
	Contara-indications : Hypervitaminosis A; pregnancy (dose exceeding RDA).
	Side effects : Hypervitaminosis A characterised by fatigue, irritability, anorexia, weight loss, vomiting and other GI disturbances, low-grade fever, hepatosplenomegaly, skin changes, alopoecia, dry hair, cracking and bleeding lips, SC swelling, nocturia, pains in bones and joints.
	Precaution :  	Cholestatic jaundice; fat-malabsorption conditions. Monitor patients closely for toxicity. Liver impairment and children.
	Pregnancy category : 1
	Mode of action : Vitamin A plays an essential role in the function of retina and is essential for growh and differentiation of epithelial tissue.
	Interaction : Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.
	Therapeutic class : Vitamin-A preparations
	Packsize : 100'pack
A Mycin
	n : Erythromycin
	Indications : Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.						
									
	Doses and administration : Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. 
									
									Upper respiratory tract infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Lower respiratory infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Respiratory tract infections due to Mycoplasma pneumoniae:  500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.
									
									Skin and soft tissue infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae:  500 mg 4 times a day for 10 to 14 days.
									Urogenital infection during pregnancy caused by Chlamydia trachomatis:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Urethral, endocervical or rectal infections, uncomplicated:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Non-gonococcal urethritis:  500 mg 4 times daily for at least 7 days.
									Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG):  500 mg 4 times a day for 7 days.
									
									Early syphillis (primary, secondary or latent syphillis of < 1 year duration):  500 mg 4 times a day for 14 days.
									Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever:	250 mg 2 times daily.
									
									Bacterial endocarditis:	1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.
									Acne:	500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.
									
									Children:
									The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled. 
	Contara-indications : Hypersensitivity; porphyria; hepatic impairment; pregnancy.
	Side effects : Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
									Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
	Precaution : Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
	Pregnancy category : 2
	Mode of action : Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
	Therapeutic class : Macrolides
	Packsize : 100ml bot
A Mycin
	n : Erythromycin solution
	Indications : Acne
	Doses and administration : As  cream/solution: Apply onto affected areas 1-2 times daily. 
									Discontinue treatment if condition worsens or if there is no improvement after 6-8 wk of continuous usage.
	Contara-indications : Hypersensitivity; porphyria; hepatic impairment; pregnancy.
	Side effects : Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
									Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
	Precaution : Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
	Pregnancy category : 2
	Mode of action : Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : Rhabdomyolysis w/ or w/o renal impairment w/ HMG-CoA reductase inhibitors (e.g. simvastatin). Increased risk of colchicine toxicity. Increased sedation w/ triazolobenzodiazepines and related benzodiazepines (e.g. alprazolam, midazolam). Theophylline may decrease and cimetidine may increase erythromycin concentration. Hypotension, bradyarrhythmia and lactic acidosis w/ Ca channel blockers (e.g. verapamil, amlodipine, diltiazem). Increased systemic exposure of sildenafil. Increased or prolonged adverse effects w/ ciclosporin, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine and bromocriptine. Increased risk of digoxin toxicity. Increased bleeding w/ oral anticoagulants.
				Potentially Fatal: QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, torsades de pointes w/ cisapride, pimozide, astemizole or terfenadine. Acute ergot toxicity w/ ergotamine and dihydroergotamine.
	Therapeutic class : Topical antibiotics for Acne
	Packsize : 25ml bot
A Mycin
	n : Erythromycin
	Indications : Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.						
									
	Doses and administration : Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. 
									
									Upper respiratory tract infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Lower respiratory infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Respiratory tract infections due to Mycoplasma pneumoniae:  500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.
									
									Skin and soft tissue infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae:  500 mg 4 times a day for 10 to 14 days.
									Urogenital infection during pregnancy caused by Chlamydia trachomatis:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Urethral, endocervical or rectal infections, uncomplicated:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Non-gonococcal urethritis:  500 mg 4 times daily for at least 7 days.
									Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG):  500 mg 4 times a day for 7 days.
									
									Early syphillis (primary, secondary or latent syphillis of < 1 year duration):  500 mg 4 times a day for 14 days.
									Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever:	250 mg 2 times daily.
									
									Bacterial endocarditis:	1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.
									Acne:	500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.
									
									Children:
									The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled. 
	Contara-indications : Hypersensitivity; porphyria; hepatic impairment; pregnancy.
	Side effects : Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
									Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
	Precaution : Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
	Pregnancy category : 2
	Mode of action : Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
	Therapeutic class : Macrolides
	Packsize : 60ml bot
A Mycin
	n : Erythromycin
	Indications : Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.						
									
	Doses and administration : Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. 
									
									Upper respiratory tract infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Lower respiratory infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Respiratory tract infections due to Mycoplasma pneumoniae:  500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.
									
									Skin and soft tissue infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae:  500 mg 4 times a day for 10 to 14 days.
									Urogenital infection during pregnancy caused by Chlamydia trachomatis:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Urethral, endocervical or rectal infections, uncomplicated:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Non-gonococcal urethritis:  500 mg 4 times daily for at least 7 days.
									Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG):  500 mg 4 times a day for 7 days.
									
									Early syphillis (primary, secondary or latent syphillis of < 1 year duration):  500 mg 4 times a day for 14 days.
									Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever:	250 mg 2 times daily.
									
									Bacterial endocarditis:	1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.
									Acne:	500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.
									
									Children:
									The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled. 
	Contara-indications : Hypersensitivity; porphyria; hepatic impairment; pregnancy.
	Side effects : Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
									Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
	Precaution : Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
	Pregnancy category : 2
	Mode of action : Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
	Therapeutic class : Macrolides
	Packsize : 100's pack
A Mycin
	n : Erythromycin
	Indications : Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.						
									
	Doses and administration : Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. 
									
									Upper respiratory tract infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Lower respiratory infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Respiratory tract infections due to Mycoplasma pneumoniae:  500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.
									
									Skin and soft tissue infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae:  500 mg 4 times a day for 10 to 14 days.
									Urogenital infection during pregnancy caused by Chlamydia trachomatis:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Urethral, endocervical or rectal infections, uncomplicated:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Non-gonococcal urethritis:  500 mg 4 times daily for at least 7 days.
									Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG):  500 mg 4 times a day for 7 days.
									
									Early syphillis (primary, secondary or latent syphillis of < 1 year duration):  500 mg 4 times a day for 14 days.
									Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever:	250 mg 2 times daily.
									
									Bacterial endocarditis:	1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.
									Acne:	500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.
									
									Children:
									The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled. 
	Contara-indications : Hypersensitivity; porphyria; hepatic impairment; pregnancy.
	Side effects : Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
									Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
	Precaution : Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
	Pregnancy category : 2
	Mode of action : Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
	Therapeutic class : Macrolides
	Packsize : 50's pack
A Mycin DS
	n : Erythromycin
	Indications : Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.						
									
	Doses and administration : Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. 
									
									Upper respiratory tract infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Lower respiratory infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Respiratory tract infections due to Mycoplasma pneumoniae:  500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.
									
									Skin and soft tissue infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae:  500 mg 4 times a day for 10 to 14 days.
									Urogenital infection during pregnancy caused by Chlamydia trachomatis:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Urethral, endocervical or rectal infections, uncomplicated:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Non-gonococcal urethritis:  500 mg 4 times daily for at least 7 days.
									Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG):  500 mg 4 times a day for 7 days.
									
									Early syphillis (primary, secondary or latent syphillis of < 1 year duration):  500 mg 4 times a day for 14 days.
									Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever:	250 mg 2 times daily.
									
									Bacterial endocarditis:	1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.
									Acne:	500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.
									
									Children:
									The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled. 
	Contara-indications : Hypersensitivity; porphyria; hepatic impairment; pregnancy.
	Side effects : Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
									Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
	Precaution : Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
	Pregnancy category : 2
	Mode of action : Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
	Therapeutic class : Macrolides
	Packsize : 100ml bot
A Phenicol
	n : Chloramphenicol 0.5%  Eye drops
	Indications : Bacterial Conjunctivitis
	Doses and administration : Ocular infections
									Adult: Instill 1 drop of a 0.5% solution every 2 hr. Increase dosage interval upon improvement. To continue treatment for at least 48 hr after complete healing. Reduce dose once symptoms are controlled or apply a 1% ointment 3-4 times daily.
									Renal impairment: Dose reduction may be required.
									Hepatic impairment: Dose reduction may be required.
									
	Contara-indications : History of hypersensitivity or toxic reaction to the drug; Herpes simplex and other virul conditions of the eye or ear, mycosis.
	Side effects : Ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. 
	Precaution : Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. 
	Pregnancy category : 3
	Mode of action : Chloramphenicol inhibits bacterial protein synthesis by binding to 50s subunit of the bacterial ribosome, thus preventing peptide bond formation by peptidyl transferase. It has both bacteriostatic and bactericidal action against H. influenzae, N. meningitidis and S. pneumoniae.
	Interaction : Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.
				Potentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
	Therapeutic class : Ophthalmic Anti-bacterial products
	Packsize : 10 ml bot
A Phenicol
	n : Chloramphenicol 1%  Eye prep
	Indications : Bacterial Conjunctivitis
	Doses and administration : Ocular infections Adult: Apply a 1% ointment 3-4 times daily. 
									Renal impairment: Dose reduction may be required. Hepatic impairment: Dose reduction may be required. 
	Contara-indications : History of hypersensitivity to the drug; Herpes simplex and other virul conditions of the eye, mycosis.
	Side effects :  Ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. 
	Precaution : Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. 
	Pregnancy category : 3
	Mode of action : Chloramphenicol inhibits bacterial protein synthesis by binding to 50s subunit of the bacterial ribosome, thus preventing peptide bond formation by peptidyl transferase. It has both bacteriostatic and bactericidal action against H. influenzae, N. meningitidis and S. pneumoniae.
	Interaction : Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.
				Potentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
	Therapeutic class : Ophthalmic Anti-bacterial products
	Packsize : 5gm tube
A Rox
	n : Roxithromycin
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Cellulitis,Tonsillitis, Folliculitis, Carbuncles, Prostatitis, Urethritis, Acute and chronic bronchitis, Bronchopneumonia, Furuncles, Pyoderma, Impetigo and infected dermatitis, Cervicitis and salpingitis
	Doses and administration : Adult: PO 150 mg twice daily or 300 mg once daily for 5-10 days.
									
									Paediatric dose: The dose for children is 2.5 to 5 mg/kg body weight twice a day. 
									
	Contara-indications : Hypersensitivity. Porphyria.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, weakness, malaise, anorexia, constipation, dyspepsia, flatulence; hepatitis; rashes, headache, dizziness, weakness, changes in blood counts; increased liver enzyme values; eosinophilia; rarely, acute pancreatitis.
	Precaution : Hepatic impairment. Monitor liver function. Prolonged treatment increases risk of hepatotoxicity. History of arrhythmias.
	Pregnancy category : 2
	Mode of action : Roxithromycin inhibits protein synthesis by irreversibly binding to the 50s ribosomal subunits thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May raise serum levels of ciclosporin and digoxin. Increased risk of rhabdomyolysis when used with simvastatin.
	Therapeutic class : Macrolides
	Packsize : 50ml bot
A Rox
	n : Roxithromycin
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Cellulitis,Tonsillitis, Folliculitis, Carbuncles, Prostatitis, Urethritis, Acute and chronic bronchitis, Bronchopneumonia, Furuncles, Pyoderma, Impetigo and infected dermatitis, Cervicitis and salpingitis
	Doses and administration : Adult: PO 150 mg twice daily or 300 mg once daily for 5-10 days.
									
									Paediatric dose: The dose for children is 2.5 to 5 mg/kg body weight twice a day. 
									
	Contara-indications : Hypersensitivity. Porphyria.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, weakness, malaise, anorexia, constipation, dyspepsia, flatulence; hepatitis; rashes, headache, dizziness, weakness, changes in blood counts; increased liver enzyme values; eosinophilia; rarely, acute pancreatitis.
	Precaution : Hepatic impairment. Monitor liver function. Prolonged treatment increases risk of hepatotoxicity. History of arrhythmias.
	Pregnancy category : 2
	Mode of action : Roxithromycin inhibits protein synthesis by irreversibly binding to the 50s ribosomal subunits thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May raise serum levels of ciclosporin and digoxin. Increased risk of rhabdomyolysis when used with simvastatin.
	Therapeutic class : Macrolides
	Packsize : 30's pack
A Rox
	n : Roxithromycin
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Cellulitis,Tonsillitis, Folliculitis, Carbuncles, Prostatitis, Urethritis, Acute and chronic bronchitis, Bronchopneumonia, Furuncles, Pyoderma, Impetigo and infected dermatitis, Cervicitis and salpingitis
	Doses and administration : Adult: PO 150 mg twice daily or 300 mg once daily for 5-10 days.
									
									Paediatric dose: The dose for children is 2.5 to 5 mg/kg body weight twice a day. 
									
	Contara-indications : Hypersensitivity. Porphyria.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, weakness, malaise, anorexia, constipation, dyspepsia, flatulence; hepatitis; rashes, headache, dizziness, weakness, changes in blood counts; increased liver enzyme values; eosinophilia; rarely, acute pancreatitis.
	Precaution : Hepatic impairment. Monitor liver function. Prolonged treatment increases risk of hepatotoxicity. History of arrhythmias.
	Pregnancy category : 2
	Mode of action : Roxithromycin inhibits protein synthesis by irreversibly binding to the 50s ribosomal subunits thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May raise serum levels of ciclosporin and digoxin. Increased risk of rhabdomyolysis when used with simvastatin.
	Therapeutic class : Macrolides
	Packsize : 20's pack
A Spasm
	n : Oxyphenonium Bromide
	Indications : Peptic ulcer, Gastrointestinal tract spasm, Visceral spasms
	Doses and administration : Adults: 1-2  tablets 3-4 times daily.
									Children: 1/2-1 tablet 1-3 times daily.
	Contara-indications : Intestinal obstruction, renal function impairment , appendicitis, chronic diarrhea, sensitivity to aluminium, magnesium and simethicone.
	Side effects : Constipation , diarrhea, intestinal pain.
	Precaution : Should be caution , if allergic to any ingredient to  magaldrate and simethicone suspension, with a history of kidney problem or taking citrate salts ( found in some calcium supplements, antacids and laxative ) 
	Pregnancy category : 0
	Mode of action : Oxyphenonium is an anticholinergic drug. It exerts its action by inhibiting muscarinic (cholinergic) receptors on smooth muscles, cardiac muscles and prevents the effect of Acetylcholine. Inhibition of Acetylcholine produces relaxation of smooth muscles and prevents the muscle spasm in irritable bowel syndrome. 
									
									Oxyphenonium also has a direct relaxant effect on smooth muscle. It also inhibits gastrointestinal propulsive movement and decreases gastric acid secretion and control bronchial, pharyngeal and tracheal secretions. It also possesses nicotinic blocking activity and interferes with ganglionic or neuromuscular transmission. It cross the BBB poorly and does not produce CNS effect.
									
	Interaction : None
	Therapeutic class : Anticholinergics(antimuscarinics)/Anti-spasmodics
	Packsize : 100's pack
A Tetra 1%
	n : Tetracycline Hydrochloride 1% Eye prep
	Indications : Bacterial Conjunctivitis, trachoma.
	Doses and administration : Adult & Child: Apply 2 hourly in acute eye infection.
	Contara-indications : Hypersensitivity; pregnancy, lactation, children; renal impairment.
	Side effects :  Burning, irritation, visual disturbances, superinfections, photosensitivity, hypersensitivity,
									
	Precaution : Hepatic impairment. Avoid exposure to sunlight. Periodic evaluation of renal, hepatic and haematological system during prolonged therapy.
	Pregnancy category : 4
	Mode of action : Tetracycline exhibits its bacteriostatic action by reversibly binding to the 30S subunits of the ribosome, thus preventing protein synthesis and arresting cell growth. It has a broad spectrum of antimicrobial activity including Chlamydiaceae, Mycoplasma spp., Rickettsia spp., spirochaetes, many aerobic and anaerobic gm+ve and gm-ve pathogenic bacteria and some protozoa.
	Interaction : Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.
				
				Potentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).
	Therapeutic class : Ophthalmic Anti-bacterial products
	Packsize : 3.5 gm tube/5 gm tube
A-Tetra
	n : Tetracycline Hydrochloride
	Indications : Acne, Lyme disease, Uncomplicated gonorrhea, Syphilis, Psittacosis, Q fever, Pleural effusions, Rocky Mountain spotted fever, Lymphogranuloma venereum, Mycoplasma pneumoniae, Trachoma, Nongonococcal urethritis
	Doses and administration : Adult: PO Susceptible infections As HCl: 250 or 500 mg 6 hrly, up to 4 g/day in severe infections. 
									
									Acne As HCl: 0.5-1 g/day in 4 divided doses for 1-2 wk or till clinical improvement occurs. Maintenance: 125-500 mg/day till clinical improvement allows drug discontinuation. 
									
									Intrapleural Pleural effusions As HCl: 500 mg dissolved in 0.9% NaCl and instilled into pleural spaces.
									
									Children : 25-50 mg/kg daily.
									
									Hepatic impairment: Max: 1 g daily.
									
	Contara-indications : Hypersensitivity; pregnancy, lactation, children; renal impairment.
	Side effects : Oesophageal ulceration, nausea, vomiting, oral candidiasis, diarrhoea, epigastric burning, sore throat, black hairy tongue, pancreatitis, oncholysis, discolouration of tooth (children with developing teeth) and nails, tinnitus, visual disturbances, superinfections, photosensitivity, hypersensitivity,
									Potentially Fatal: Anaphylaxis, hepatotoxicity, nephrotoxicity, blood dyscrasias.
	Precaution : Hepatic impairment. Myasthenia gravis, SLE. Should be administered with plenty of water, while sitting or standing, and well before going to bed to avoid oesophageal ulceration. Avoid exposure to sunlight. Periodic evaluation of renal, hepatic and haematological system during prolonged therapy.
	Pregnancy category : 4
	Mode of action : Tetracycline exhibits its bacteriostatic action by reversibly binding to the 30S subunits of the ribosome, thus preventing protein synthesis and arresting cell growth. It has a broad spectrum of antimicrobial activity including Chlamydiaceae, Mycoplasma spp., Rickettsia spp., spirochaetes, many aerobic and anaerobic gm+ve and gm-ve pathogenic bacteria and some protozoa.
	Interaction : Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.
				
				Potentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).
	Therapeutic class : Tetracycline Group of drugs
	Packsize : 100's pack
A Tetra
	n : Tetracycline Hydrochloride
	Indications : Acne, Lyme disease, Uncomplicated gonorrhea, Syphilis, Psittacosis, Q fever, Pleural effusions, Rocky Mountain spotted fever, Lymphogranuloma venereum, Mycoplasma pneumoniae, Trachoma, Nongonococcal urethritis
	Doses and administration : Adult: PO Susceptible infections As HCl: 250 or 500 mg 6 hrly, up to 4 g/day in severe infections. 
									
									Acne As HCl: 0.5-1 g/day in 4 divided doses for 1-2 wk or till clinical improvement occurs. Maintenance: 125-500 mg/day till clinical improvement allows drug discontinuation. 
									
									Intrapleural Pleural effusions As HCl: 500 mg dissolved in 0.9% NaCl and instilled into pleural spaces.
									
									Children : 25-50 mg/kg daily.
									
									Hepatic impairment: Max: 1 g daily.
									
	Contara-indications : Hypersensitivity; pregnancy, lactation, children; renal impairment.
	Side effects : Oesophageal ulceration, nausea, vomiting, oral candidiasis, diarrhoea, epigastric burning, sore throat, black hairy tongue, pancreatitis, oncholysis, discolouration of tooth (children with developing teeth) and nails, tinnitus, visual disturbances, superinfections, photosensitivity, hypersensitivity,
									Potentially Fatal: Anaphylaxis, hepatotoxicity, nephrotoxicity, blood dyscrasias.
	Precaution : Hepatic impairment. Myasthenia gravis, SLE. Should be administered with plenty of water, while sitting or standing, and well before going to bed to avoid oesophageal ulceration. Avoid exposure to sunlight. Periodic evaluation of renal, hepatic and haematological system during prolonged therapy.
	Pregnancy category : 4
	Mode of action : Tetracycline exhibits its bacteriostatic action by reversibly binding to the 30S subunits of the ribosome, thus preventing protein synthesis and arresting cell growth. It has a broad spectrum of antimicrobial activity including Chlamydiaceae, Mycoplasma spp., Rickettsia spp., spirochaetes, many aerobic and anaerobic gm+ve and gm-ve pathogenic bacteria and some protozoa.
	Interaction : Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.
				
				Potentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).
	Therapeutic class : Tetracycline Group of drugs
	Packsize : 100's pack
A Tetra
	n : Tetracycline Hydrochloride
	Indications : Acne, Lyme disease, Uncomplicated gonorrhea, Syphilis, Psittacosis, Q fever, Pleural effusions, Rocky Mountain spotted fever, Lymphogranuloma venereum, Mycoplasma pneumoniae, Trachoma, Nongonococcal urethritis
	Doses and administration : Adult: PO Susceptible infections As HCl: 250 or 500 mg 6 hrly, up to 4 g/day in severe infections. 
									
									Acne As HCl: 0.5-1 g/day in 4 divided doses for 1-2 wk or till clinical improvement occurs. Maintenance: 125-500 mg/day till clinical improvement allows drug discontinuation. 
									
									Intrapleural Pleural effusions As HCl: 500 mg dissolved in 0.9% NaCl and instilled into pleural spaces.
									
									Children : 25-50 mg/kg daily.
									
									Hepatic impairment: Max: 1 g daily.
									
	Contara-indications : Hypersensitivity; pregnancy, lactation, children; renal impairment.
	Side effects : Oesophageal ulceration, nausea, vomiting, oral candidiasis, diarrhoea, epigastric burning, sore throat, black hairy tongue, pancreatitis, oncholysis, discolouration of tooth (children with developing teeth) and nails, tinnitus, visual disturbances, superinfections, photosensitivity, hypersensitivity,
									Potentially Fatal: Anaphylaxis, hepatotoxicity, nephrotoxicity, blood dyscrasias.
	Precaution : Hepatic impairment. Myasthenia gravis, SLE. Should be administered with plenty of water, while sitting or standing, and well before going to bed to avoid oesophageal ulceration. Avoid exposure to sunlight. Periodic evaluation of renal, hepatic and haematological system during prolonged therapy.
	Pregnancy category : 4
	Mode of action : Tetracycline exhibits its bacteriostatic action by reversibly binding to the 30S subunits of the ribosome, thus preventing protein synthesis and arresting cell growth. It has a broad spectrum of antimicrobial activity including Chlamydiaceae, Mycoplasma spp., Rickettsia spp., spirochaetes, many aerobic and anaerobic gm+ve and gm-ve pathogenic bacteria and some protozoa.
	Interaction : Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.
				
				Potentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).
	Therapeutic class : Tetracycline Group of drugs
	Packsize : 100's pack
A Zyme
	n : Pancreatin
	Indications : Pancreatic insufficiency
	Doses and administration : Adult: PO 1-3 tablets daily with meal.
	Contara-indications : Acute pancreatitis or acute exacerbation of chronic pancreatic disease.
	Side effects : GI effects e.g. abdominal discomfort, nausea and vomiting. Buccal and perianal irritation, particularly in infants. Colonic strictures may occur, mainly in children with cystic fibrosis receiving high doses of pancreatin preparations. Hyperuricaemia and hyperuricosuria may occur.
	Precaution : Avoid high doses in patients with cystic fibrosis. Maintain adequate hydration. Some products contain pork protein. Inactivated by heat; do not mix with hot food or liquids. May irritate oral mucosa; should not be held in mouth. Pregnancy and lactation.
	Pregnancy category : 0
	Mode of action : Pancreatin are pancreatic enzymes which hydrolyse fats to glycerol and fatty acids, break down protein into peptides, proteoses and derived substances, and convert starch into dextrins and sugars.
	Interaction : May impair the oral absorption of folic acid when taken together; antagonises hypoglycaemic effect of acarbose.
	Therapeutic class : Digestive Enzyme
	Packsize : 100's pack
Abac
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 15ml bot
Abac
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Abac
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack
Abaclor Pd
	n : Cefaclor
	Indications : Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis and Tonsillitis
	Doses and administration :  	Oral
									Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media
									Adult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.
									Child: >1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid.
									
									Suspension  & Paediatric Drops:
									1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
									1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d
									over 5 years 10 ml t.i.d 2.5 ml t.i.d
	Contara-indications : Known hypersensitivity to cephalosporins.
	Side effects : Allergic reactions; diarrhoea, nausea, vomiting; candidiasis, eosinophilia; elevated transaminases.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Severe renal impairment; history of allergy to penicillin; pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
	Interaction : May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 15ml
Abaclor
	n : Cefaclor
	Indications : Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis and Tonsillitis
	Doses and administration :  	Oral
									Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media
									Adult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.
									Child: >1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid.
									
									Suspension  & Paediatric Drops:
									1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
									1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d
									over 5 years 10 ml t.i.d 2.5 ml t.i.d
	Contara-indications : Known hypersensitivity to cephalosporins.
	Side effects : Allergic reactions; diarrhoea, nausea, vomiting; candidiasis, eosinophilia; elevated transaminases.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Severe renal impairment; history of allergy to penicillin; pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
	Interaction : May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 100ml
Abaclor
	n : Cefaclor
	Indications : Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis and Tonsillitis
	Doses and administration :  	Oral
									Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media
									Adult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.
									Child: >1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid.
									
									Suspension  & Paediatric Drops:
									1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
									1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d
									over 5 years 10 ml t.i.d 2.5 ml t.i.d
	Contara-indications : Known hypersensitivity to cephalosporins.
	Side effects : Allergic reactions; diarrhoea, nausea, vomiting; candidiasis, eosinophilia; elevated transaminases.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Severe renal impairment; history of allergy to penicillin; pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
	Interaction : May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 20's pack
Abaclor
	n : Cefaclor
	Indications : Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis and Tonsillitis
	Doses and administration :  	Oral
									Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media
									Adult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.
									Child: >1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid.
									
									Suspension  & Paediatric Drops:
									1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
									1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d
									over 5 years 10 ml t.i.d 2.5 ml t.i.d
	Contara-indications : Known hypersensitivity to cephalosporins.
	Side effects : Allergic reactions; diarrhoea, nausea, vomiting; candidiasis, eosinophilia; elevated transaminases.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Severe renal impairment; history of allergy to penicillin; pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
	Interaction : May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 100ml
Ancliz
	n : Meclizine Hydrochloride + Pyridoxine Hydrochloride
	Indications : Nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of vestibular motion sickness, radiation sickness and vertigo associated with diseases of vestibular system, morning sickness during pregnancy, drug induced nausea, vomiting induced by oral contraceptives or Estrogen preparations. 
	Doses and administration : Adult: PO: As combination preparation containing meclozine 25 mg and pyridoxine 50 mg per tablet: 1 tablet at night.
	Contara-indications : Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.
	Side effects : Drowsiness, thickening of bronchial secretions, dry mouth, fatigue, blurred vision.
	Precaution : Prostate hypertrophy, obstruction of bladder neck, narrow angle glaucoma, pyloric stenosis. May impair ability to drive or operate machinery. Pregnancy.
	Pregnancy category : 12
	Mode of action : Meclozine blocks vasopressor response to histamine and has a slight blocking action against acetylcholine. It decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways.
									
									Pyridoxine is a water-soluble vitamin which functions in the metabolism of carbohydrates, proteins and fats. It is essential in Hb formation and GABA synthesis within the CNS. It also aids in the release of glycogen stored in the liver and muscles.
	Interaction : Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
	Therapeutic class : Anti-emetic drugs
	Packsize : 50's pack
Abdorin
	n : Dicycloverine Hydrochloride
	Indications : Gastrointestinal tract spasm, Intestinal hypermotility, Irritable bowel syndrome (IBS)
	Doses and administration : Adults : 10 to 20 mg three to four times a day. Maximum recommended oral dose is 160 mg daily in divided dose. 
									
									Children : Children over 6 months of age- 5 to 10 mg three times a day. IM injection : Usual recommended injectable dose is 80 mg daily by IM route in 4 divided dose.
									
	Contara-indications : Intestinal obstruction; intestinal atony; myasthenia gravis; glaucoma; reflux oesophagitis; infants <6 mth; lactation.
	Side effects : Difficulty in accommodation, exacerbation of glaucoma; tachycardia, palpitations, arrhythmias; urinary retention; restlessness; confusion, excitement, hallucination and delirium.
									Potentially Fatal: Respiratory arrest in infants <10 wk.
	Precaution :  Hepatic or renal disease, urinary retention, paralytic ileus, hyperthyroidism, hypertension, congestive heart failure, cardiac tachyarrhythmia, children, elderly, pregnancy.
	Pregnancy category : 2
	Mode of action : Dicycloverine HCl relieves smooth muscle spasm in the GI and urinary tract. This effect is partly due to antimuscarinic action and partly direct action on the smooth muscle.
	Interaction : Antagonise the effect of drugs that affect GI motility e.g. metoclopramide. Absorption affected by concurrent admin with antacids.
	Therapeutic class : Anticholinergics(antimuscarinics)/Anti-spasmodics
	Packsize : 50's pack
Abdorin
	n : Dicycloverine Hydrochloride
	Indications : Gastrointestinal tract spasm, Intestinal hypermotility, Irritable bowel syndrome (IBS)
	Doses and administration : Adults : 10 to 20 mg three to four times a day. Maximum recommended oral dose is 160 mg daily in divided dose. 
									
									Children : Children over 6 months of age- 5 to 10 mg three times a day. IM injection : Usual recommended injectable dose is 80 mg daily by IM route in 4 divided dose.
									
	Contara-indications : Intestinal obstruction; intestinal atony; myasthenia gravis; glaucoma; reflux oesophagitis; infants <6 mth; lactation.
	Side effects : Difficulty in accommodation, exacerbation of glaucoma; tachycardia, palpitations, arrhythmias; urinary retention; restlessness; confusion, excitement, hallucination and delirium.
									Potentially Fatal: Respiratory arrest in infants <10 wk.
	Precaution :  Hepatic or renal disease, urinary retention, paralytic ileus, hyperthyroidism, hypertension, congestive heart failure, cardiac tachyarrhythmia, children, elderly, pregnancy.
	Pregnancy category : 2
	Mode of action : Dicycloverine HCl relieves smooth muscle spasm in the GI and urinary tract. This effect is partly due to antimuscarinic action and partly direct action on the smooth muscle.
	Interaction : Antagonise the effect of drugs that affect GI motility e.g. metoclopramide. Absorption affected by concurrent admin with antacids.
	Therapeutic class : Anticholinergics(antimuscarinics)/Anti-spasmodics
	Packsize : 50ml bot
Abecab 5/20
	n : Amlodipine + Olmesartan Medoxomil
	Indications : Hypertension
	Doses and administration : Adult: Initial: 10-20 mg once daily. Antihypertensive effect is substantially present within 2 wk of therapy initiation. Dose may be increased up to 40 mg once daily if needed. May consider a lower starting dose in patients with possible depletion of intravascular volume (e.g. patients receiving concomitant diuretics, especially those with renal impairment).
									 
									Child: 6 to 16 yr: 20-35 kg: 10 mg once daily, may increase to maximum of 20 mg once daily. >35 kg: 20 mg once daily, may increase to maximum of 40 mg once daily.
									
									Elderly: May consider lower starting dose of 5-10 mg daily.
	Contara-indications : Pregnancy (2nd and 3rd trimesters); biliary obstruction.
	Side effects : Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.
									Potentially Fatal: Acute renal failure.
	Precaution : Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.
	Pregnancy category : 17
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
									Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
					Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Abecab 5/40
	n : Amlodipine + Olmesartan Medoxomil
	Indications : Hypertension
	Doses and administration : Adult: Initial: 10-20 mg once daily. Antihypertensive effect is substantially present within 2 wk of therapy initiation. Dose may be increased up to 40 mg once daily if needed. May consider a lower starting dose in patients with possible depletion of intravascular volume (e.g. patients receiving concomitant diuretics, especially those with renal impairment).
									 
									Child: 6 to 16 yr: 20-35 kg: 10 mg once daily, may increase to maximum of 20 mg once daily. >35 kg: 20 mg once daily, may increase to maximum of 40 mg once daily.
									
									Elderly: May consider lower starting dose of 5-10 mg daily.
	Contara-indications : Pregnancy (2nd and 3rd trimesters); biliary obstruction.
	Side effects : Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.
									Potentially Fatal: Acute renal failure.
	Precaution : Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.
	Pregnancy category : 17
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
									Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
					Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Abentel
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Abetis
	n : Olmesartan Medoxomil
	Indications : Hypertension, Diabetic nephropathy, 
	Doses and administration :  	Oral
									Hypertension
									Adult: Initial: 10-20 mg once daily may then be increased up to max 40 mg once daily if needed.
									Child: 6-16 yr <35 kg: 10 mg once daily; >35 kg: 20 mg once daily. Doses may be doubled once if necessary after 2 wk.
									Elderly: No dosage adjustment needed.
									Hepatic impairment: Moderate: Initial: 10 mg once daily may increase up to max 20 mg once daily.
	Contara-indications : Pregnancy (2nd and 3rd trimesters); biliary obstruction.
	Side effects : Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.
									Potentially Fatal: Acute renal failure.
	Precaution : Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.
	Pregnancy category : 4
	Mode of action : Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
	Interaction : Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Abetis
	n : Olmesartan Medoxomil
	Indications : Hypertension, Diabetic nephropathy, 
	Doses and administration :  	Oral
									Hypertension
									Adult: Initial: 10-20 mg once daily may then be increased up to max 40 mg once daily if needed.
									Child: 6-16 yr <35 kg: 10 mg once daily; >35 kg: 20 mg once daily. Doses may be doubled once if necessary after 2 wk.
									Elderly: No dosage adjustment needed.
									Hepatic impairment: Moderate: Initial: 10 mg once daily may increase up to max 20 mg once daily.
	Contara-indications : Pregnancy (2nd and 3rd trimesters); biliary obstruction.
	Side effects : Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.
									Potentially Fatal: Acute renal failure.
	Precaution : Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.
	Pregnancy category : 4
	Mode of action : Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
	Interaction : Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Abetis
	n : Olmesartan Medoxomil
	Indications : Hypertension, Diabetic nephropathy, 
	Doses and administration :  	Oral
									Hypertension
									Adult: Initial: 10-20 mg once daily may then be increased up to max 40 mg once daily if needed.
									Child: 6-16 yr <35 kg: 10 mg once daily; >35 kg: 20 mg once daily. Doses may be doubled once if necessary after 2 wk.
									Elderly: No dosage adjustment needed.
									Hepatic impairment: Moderate: Initial: 10 mg once daily may increase up to max 20 mg once daily.
	Contara-indications : Pregnancy (2nd and 3rd trimesters); biliary obstruction.
	Side effects : Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.
									Potentially Fatal: Acute renal failure.
	Precaution : Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.
	Pregnancy category : 4
	Mode of action : Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
	Interaction : Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Abetis Plus
	n : Hydrochlorothiazide + Olmesartan Medoxomil
	Indications : Hypertension, Diabetic nephropathy
	Doses and administration : Adult: PO Initial: 20 mg/12.5 mg once daily, may be increased to 40 mg/25 mg once daily if needed.
	Contara-indications : Pregnancy (2nd and 3rd trimesters); biliary obstruction.
	Side effects : Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.
									Potentially Fatal: Acute renal failure.
	Precaution : Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions.
									
									Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
	Interaction : Olmesartan medoxomil: Increased risk of hypotension, hyperkalemia & changes in renal function w/ aliskiren. May result in deterioration of renal function w/ NSAIDs. May attenuate the antihypertensive effect of angiotensin II receptor antagonists. Reduces systemic exposure & peak plasma conc w/ colosevelam HCl. 
				
				Hydrochlorothiazide: Potentiation of orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs. Potentiation effect w/ other antihypertensives. Reduced absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroid, ACTH. Decreased response to pressor amines (eg norepinephrine). Increased responsiveness to skeletal muscle relaxants (eg tubocurarine). Reduce the renal clearance of lithium.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Abex
	n : Guaiphenesin + Pseudoephedrine Hydrochloride + Triprolidine Hydrochloride
	Indications : Pneumonia, Productive cough, Allergic rhinitis, Sneezing, Respiratory tract disorders, Cough & runny nose, Nasal congestion
	Doses and administration : Adult and Children over 12 years: 10 ml (2 teaspoonful) three times a day.
									Children 6-12 years: 5 ml (1 teaspoonful) three times a day.
									Children 2-5 years: 2.5 ml (1/2 teaspoonful) three times a day.
									
	Contara-indications : Patients with a known hypersensitivity to guaiphenesin, psedoephedrine or triprolidine. Contraindicated in persons under treatment with monoamine oxidase inhibitors within 2 weeks of stopping such treatment.
									Patients with severe hypertension or severe coronary artery disease
	Side effects : Central nervous system (CNS) depression or excitation may occur. Sleep disturbance and rarely hallucination have been reported. Skin rashes, tachycardia, dryness of mouth, nose and throat have occasionally been reported. Urinary retention has been reported occasionally in men receiving pseudoephedrine; prostatic enlargement could have been an important predisposing factor.
	Precaution :  It may cause drowsiness and impair performance in tests of auditory vigilance. It may also impair the patients ability to drive and also to use machineries. So, driving and operation of machineries should be avoided during treatment with Aquaphen. Although there are no objective data, Avoid the concomitant use of alcohol or other centrally acting sedatives.
				Although Pseudoephedrine has virtually no pressor effect in patients with normal blood pressure, Aquaphen should be used with caution in patients taking antihypertensive agents, tricyclic antidepressants or other sympathomimetic agents such as decongestant, appetite suppressants and amphetamine-like psychostimulants.  It effects   on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment.
				As with other sympathomimetic agents, caution should be exercised in patients with hypertension, heart disease, diabetes, hyperthyroidism, elevated intraocular pressure and prostatic enlargement.  It should not be used for persistent or chronic cough such as occurs with smoking, asthma or emphysema or where cough is accompanied by excessive secretions unless directed by a physician.
	Pregnancy category : 3
	Mode of action : Triprolidine hydrochloride is a potent competitive histamine H1-receptor antagonist with antimuscarinic and mild sedative properties.
									
									Pseudoephedrine is both an ?-and ?-adrenergic receptor agonist. It causes vasoconstriction via direct stimulation of ?-adrenergic receptors of the respiratory mucosa. It also directly stimulates ?-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility.
									
									Guaifenesin increases the volume and reduce the viscosity of tenacious sputum and is used as an expectorant for productive cough.
	Interaction : Sympathomimetics eg decongestants, TCAs, appetite suppressants, amphetamine-like psychostimulants; may increase BP w/ MAOIs. Bretylium, bethanidine, guanethidine, debrisoquine, methyldopa, ?- & ?-adrenergic blocker; furazolidone, alcohol, sedatives.
	Therapeutic class : Combined cough expectorants
	Packsize : 100ml bot
Abixa
	n : Memantine Hydrochloride
	Indications : Alzheimer's dementia.
	Doses and administration : Oral
									Moderate to severe dementia in Alzheimer's disease
									Adult: As hydrochloride: Initially, 5 mg daily in the morning for the 1st wk; increase dose wkly in steps of 5 mg. Max: 20 mg daily. Wait for at least 1 wk between dose changes. Doses >10 mg/day should be given in 2 divided doses. 
									
									Suggested titration: 5 mg daily for >1 wk; 5 mg bid for >1 wk; 15 mg daily given in 5- and 10-mg separated doses for >1 wk; then 10 mg bid.
									
									Renal impairment:
									CrCl (ml/min)	
									40-60	Per 1.73 m2: Max dose: Reduce to 10 mg daily.
	Contara-indications : Severe renal impairment.
	Side effects : Dizziness, confusion, headache, constipation, somnolence, hallucinations, tiredness, vomiting, anxiety, abnormal gait, hypertonia, cystitis and increased libido. Rarely, psychotic reactions, pancreatitis.
	Precaution : Renal impairment; epilepsy. Pregnancy and lactation. Closely monitor patients with recent MI, uncompensated CHF, uncontrolled hypertension. Predisposition to convulsions; conditions that increase urinary pH.
	Pregnancy category : 2
	Mode of action : Memantine, a derivative of amantadine, is a noncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist. It affects transmission of glutamate, the primary excitatory neurotransmitter in the CNS. Glutamate may contribute to the pathogenesis of Alzheimer's disease by overstimulating various glutamate receptors resulting in excitotoxicity and neuronal cell death.
	Interaction : May increase effects of antimuscarinics and dopaminergics. May reduce effects of antipsychotics and barbiturates. May alter effects of dantrolene, baclofen. Reduced clearance with carbonic anhydrase inhibitors and sodium bicarbonate.
				Potentially Fatal: Increased risk of adverse effects with amantadine, dextromethorphan or ketamine.
	Therapeutic class : Drugs for Dementia
	Packsize : 20's pack
A-Cal 250
	n : Calcium Carbonate
	Indications : Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset
	Doses and administration : Adult: PO Hyperacidity: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets. 
									
									Hyperphosphataemia in chronic renal failure Initial: 2.5 g/day, up to 17 g/day in divided doses.
									
									Renal impairment:
									CrCl (ml/min)	
									<25	Dosage adjustments may be needed depending on serum calcium levels. 
	Contara-indications : Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.
	Side effects : Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).
	Precaution : Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.
	Pregnancy category : 3
	Mode of action : Calcium carbonate can neutralise gastric acid rapidly and effectively. However, it may adversely activate Ca dependent processes, leading to secretion of gastric and hydrochloric acid. It can induce rebound acid secretion and, prolonged high doses may cause hypercalcemia, alkalosis and milk-alkali syndrome.
	Interaction : Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
	Therapeutic class : Specific mineral preparations
	Packsize : 100's pack
Acaril
	n : Acarbose
	Indications : Type 2 DM
	Doses and administration :  Dosage 	Adult: PO Initial: 25 mg/day. May adjust gradually. Maintenance: 50-100 mg 3 times/day. Max: <60 kg: 50 mg 3 times/day; >60 kg: 100 mg 3 times/day.
	Contara-indications : Patients <18 yr; diabetic ketoacidosis or cirrhosis; malabsorption; inflammatory bowel disease; with or pre-disposed to intestinal obstruction; intestinal diseases that affect digestion or absorption; conditions that worsen as a result of increased gas formation e.g. hernias; colonic ulcers; hepatic impairment; CrClr< 25 ml/min/1.73m2. Pregnancy, lactation.
	Side effects : Flatulence, abdominal pain, distension, diarrhoea, nausea, vomiting. Elevation of transaminases, hepatitis, jaundice. Rarely, skin reactions.
									Potentially Fatal: Hepatotoxicity.
	Precaution : Monitor LFT every 3 mth for 1st yr and periodically thereafter especially for doses >50 mg tid. Reduce dose or withdraw therapy if transaminases elevations persist. If hypoglycaemia occurs, give glucose orally as a 1st aid measure. Adhere strictly to the prescribed diabetic diet to avoid intensification of GI symptoms.
	Pregnancy category : 2
	Mode of action : Acarbose competitively and reversibly inhibits pancreatic ?-amylase and intestinal brush border ?-glucosidases, resulting in retardation of glucose absorption from hydrolysed complex carbohydrates and reduction of blood-glucose concentrations.
	Interaction : May enhance effects of other antidiabetics including insulin. Diminished effects w/ GI adsorbents (e.g. charcoal) and digestive enzyme preparations containing carbohydrate splitting enzymes (e.g. amylase, pancreatin). Neomycin and colestyramine may enhance effects of acarbose. May inhibit absorption of digoxin.
	Therapeutic class : Alpha-Glucosidase inhibitor
	Packsize : 30's pack
Ace
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Ace
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot/100ml bot
Ace
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 500's pack
Ace
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 15 ml bot/30ml bot
Ace
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 20's pack
Ace
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 20's pack
Ace
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 20's pack
Ace
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 10's pack
ACE XR
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 100's pack
Ace PLUS
	n : Paracetamol + Caffeine
	Indications : Pain,Fever,Headache,Influenza,Migraine,Sore throat,Backache,Toothache,Rheumatic pain,Dysmenorrhea,Colds
	Doses and administration : Adults : 1-2 tablets every 4-6 hours. Maximum dose: 8 tablets daily. Not recommended for children below 12 years.
	Contara-indications : History of hypersensitivity to any of the components.
	Side effects : Skin rash, diarrhoea, anorexia, GI disturbances, epistaxis (rare).
	Precaution : Severe hepatic or renal disorder.
	Pregnancy category : 3
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
									
									Caffeine, a methylxanthine, is a phosphodiesterase inhibitor. It has an antagonistic effect at central adenosine receptors. It is a CNS and resp stimulant. It has bronchodilating and diuretic properties and it facilitates the performance of muscular work.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non opioid analgesics
	Packsize : 200's pack
Acebid
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Acecard
	n : Ramipril
	Indications : Congestive heart failure, MI, HTN, CV events, Stroke
	Doses and administration : Adult: PO HTN Initial: 1.25 mg at bedtime. Maintenance: 2.5-5 mg/day as a single dose, up to 10 mg/day if needed. 
									Heart failure Initial: 1.25 mg once daily. Max: 10 mg/day. 
									
									MI Start 3-10 days after infarction. Initial: 2.5 mg twice daily after 2 days, then 5 mg twice daily. Maintenance: 2.5-5 mg twice daily. 
									Prophylaxis of CV events in high-risk patients Initial: 2.5 mg once daily for 1 wk, then increased if tolerated to 5 mg once daily for 3 wk, then maintenance: 10 mg once daily.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Initially, 1.25 mg/day. Max: 5 mg/day.
									30-60	Not necessary to adjust the initial dose. Max: 5 mg/day.
									Hepatic impairment: Max: 2.5 mg/day.
	Contara-indications : Hypersensitivity, bilateral renal artery stenosis, or a single kidney with unilateral renal artery stenosis. Aortic stenosis or outflow tract obstruction. Pregnancy and lactation.
	Side effects : Nausea, vomiting, diarrhoea, dizziness, fatigue, headache, abdominal pain, cough. Rarely symptomatic hypotension. Angioneurotic oedema of face, lips, tongue, glottis and larynx, syncope, renal impairment, hypersensitivity reactions.
									Potentially Fatal: Severe hypotension and renal failure, angioedema.
	Precaution : Renal impairment, hypovolaemia, hyperkalaemia, valvular stenosis; before, during or immediately after anaesthesia. Severe resistant hypertension, elderly, peripheral vascular disease or generalised atherosclerosis. Monitor renal function before and during treatment. Use with caution in patients with history of idiopathic or hereditary angioedema. Regular monitoring of WBC in patients with vascular collagen disorders is recommended.
	Pregnancy category : 4
	Mode of action : Ramipril, a prodrug of ramiprilat, competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation thus producing a hypotensive effect and a beneficial effect in CHF.
	Interaction : May enhance hypotensive effect w/ diuretics and other antihypertensives. May increase risk of renal function deterioration w/ NSAIDs. May increase serum levels and toxicity of lithum. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.
				
				Potentially Fatal: Concomitant use w/ aliskiren aliskiren may increase the risk of hyperkalaemia, hypotension and nephrotoxicity in patients w/ diabetes or renal impairment
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 30's pack
Acecard
	n : Ramipril
	Indications : Congestive heart failure, MI, HTN, CV events, Stroke
	Doses and administration : Adult: PO HTN Initial: 1.25 mg at bedtime. Maintenance: 2.5-5 mg/day as a single dose, up to 10 mg/day if needed. 
									Heart failure Initial: 1.25 mg once daily. Max: 10 mg/day. 
									
									MI Start 3-10 days after infarction. Initial: 2.5 mg twice daily after 2 days, then 5 mg twice daily. Maintenance: 2.5-5 mg twice daily. 
									Prophylaxis of CV events in high-risk patients Initial: 2.5 mg once daily for 1 wk, then increased if tolerated to 5 mg once daily for 3 wk, then maintenance: 10 mg once daily.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Initially, 1.25 mg/day. Max: 5 mg/day.
									30-60	Not necessary to adjust the initial dose. Max: 5 mg/day.
									Hepatic impairment: Max: 2.5 mg/day.
	Contara-indications : Hypersensitivity, bilateral renal artery stenosis, or a single kidney with unilateral renal artery stenosis. Aortic stenosis or outflow tract obstruction. Pregnancy and lactation.
	Side effects : Nausea, vomiting, diarrhoea, dizziness, fatigue, headache, abdominal pain, cough. Rarely symptomatic hypotension. Angioneurotic oedema of face, lips, tongue, glottis and larynx, syncope, renal impairment, hypersensitivity reactions.
									Potentially Fatal: Severe hypotension and renal failure, angioedema.
	Precaution : Renal impairment, hypovolaemia, hyperkalaemia, valvular stenosis; before, during or immediately after anaesthesia. Severe resistant hypertension, elderly, peripheral vascular disease or generalised atherosclerosis. Monitor renal function before and during treatment. Use with caution in patients with history of idiopathic or hereditary angioedema. Regular monitoring of WBC in patients with vascular collagen disorders is recommended.
	Pregnancy category : 4
	Mode of action : Ramipril, a prodrug of ramiprilat, competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation thus producing a hypotensive effect and a beneficial effect in CHF.
	Interaction : May enhance hypotensive effect w/ diuretics and other antihypertensives. May increase risk of renal function deterioration w/ NSAIDs. May increase serum levels and toxicity of lithum. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.
				
				Potentially Fatal: Concomitant use w/ aliskiren aliskiren may increase the risk of hyperkalaemia, hypotension and nephrotoxicity in patients w/ diabetes or renal impairment
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 30's pack
Acecard
	n : Ramipril
	Indications : Congestive heart failure, MI, HTN, CV events, Stroke
	Doses and administration : Adult: PO HTN Initial: 1.25 mg at bedtime. Maintenance: 2.5-5 mg/day as a single dose, up to 10 mg/day if needed. 
									Heart failure Initial: 1.25 mg once daily. Max: 10 mg/day. 
									
									MI Start 3-10 days after infarction. Initial: 2.5 mg twice daily after 2 days, then 5 mg twice daily. Maintenance: 2.5-5 mg twice daily. 
									Prophylaxis of CV events in high-risk patients Initial: 2.5 mg once daily for 1 wk, then increased if tolerated to 5 mg once daily for 3 wk, then maintenance: 10 mg once daily.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Initially, 1.25 mg/day. Max: 5 mg/day.
									30-60	Not necessary to adjust the initial dose. Max: 5 mg/day.
									Hepatic impairment: Max: 2.5 mg/day.
	Contara-indications : Hypersensitivity, bilateral renal artery stenosis, or a single kidney with unilateral renal artery stenosis. Aortic stenosis or outflow tract obstruction. Pregnancy and lactation.
	Side effects : Nausea, vomiting, diarrhoea, dizziness, fatigue, headache, abdominal pain, cough. Rarely symptomatic hypotension. Angioneurotic oedema of face, lips, tongue, glottis and larynx, syncope, renal impairment, hypersensitivity reactions.
									Potentially Fatal: Severe hypotension and renal failure, angioedema.
	Precaution : Renal impairment, hypovolaemia, hyperkalaemia, valvular stenosis; before, during or immediately after anaesthesia. Severe resistant hypertension, elderly, peripheral vascular disease or generalised atherosclerosis. Monitor renal function before and during treatment. Use with caution in patients with history of idiopathic or hereditary angioedema. Regular monitoring of WBC in patients with vascular collagen disorders is recommended.
	Pregnancy category : 4
	Mode of action : Ramipril, a prodrug of ramiprilat, competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation thus producing a hypotensive effect and a beneficial effect in CHF.
	Interaction : May enhance hypotensive effect w/ diuretics and other antihypertensives. May increase risk of renal function deterioration w/ NSAIDs. May increase serum levels and toxicity of lithum. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.
				
				Potentially Fatal: Concomitant use w/ aliskiren aliskiren may increase the risk of hyperkalaemia, hypotension and nephrotoxicity in patients w/ diabetes or renal impairment
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 30's pack
Acecloben
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Aceclofen
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 30's pack
Aceclora
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Acecol
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Acedol
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Acedone Z
	n : Aluminium Oxide + Magnesium Hydroxide
	Indications : Hyperacidity, Flatulence, Gastric ulcer, Duodenal ulcer, Gastritis, Stomach distension
	Doses and administration : Chew 1-2 tablets after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. For best results, drink a half glass of water or other liquid after each dose. Do not take more than 16 tablets in 24 hours
	Contara-indications : Hypophosphataemia.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200ml bot
Acedone-Z Plus
	n : Aluminium Oxide + Magnesium Hydroxide + Simethicon
	Indications : Hyperacidity, Gastric ulcer duodenal ulcer and gastritis
	Doses and administration : Chew1-2 tablets or 2-4 tsf after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. 
	Contara-indications : Hypophosphataemia. Simethicon is contrindicated in renal failure, severely debiliated patients, 1st trimester of pregnancy.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Aluminum hydroxide: Neutralizes stomach hydrocloride to form AlCl3 salt plus water; increases gastric pH.
									Magnesium hydroxide: Promotes bowel evacuation by causing osmotic retention of fluid, which causes the colon to distend with increased peristaltic activity; forms magnesium chloride when reacts with hydrochloric acid.
									Simethicone: Disperses and prevents gas pockets in the GI system by decreasing surface tension of gas bubles.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
				
				Simethicon: None well documented.
				
	Therapeutic class : Antacids
	Packsize : 200ml bot
Acefenac
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Acefra
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Acefra
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack
Acelex
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 15ml bot
Acelex
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Acelex
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack/ 50's pack
Acelex
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack/ 40's pack
Acelock
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Acemox
	n : Acetazolamide
	Indications : Glaucoma,Epilepsy,Idiopathic intracranial hypertension,Altitude sickness
	Doses and administration : Adult: PO Diuresis 250-375 mg/day. 
									Glaucoma; Epilepsy 250-1,000 mg/day. 
									Prophylaxis of high altitude sickness 500-1,000 mg/day. 
									
									Child: Glaucoma: 1 mth-12 yr: 10-20 mg/kg daily. Max: 750 mg daily, in 2-4 divided doses. Epilepsy: Neonates and up to 12 yr: Initially, 2.5 mg/kg bid-tid; maintenance: 5-7 mg/kg bid-tid. Max: 750 mg daily. 
									
									
									
	Contara-indications : Hypersensitivity to sulphonamides; sodium or potassium depletion, hepatic insufficiency; hepatic cirrhosis; hyperchloraemic acidosis; severe renal impairment; severe pulmonary obstruction; chronic noncongestive angle-closure glaucoma; adrenocortical insufficiency. Pregnancy, lactation.
	Side effects : Drowsiness, paraesthesia, ataxia, dizziness, thirst, anorexia, headache; confusion, malaise, depression; GI distress, metabolic acidosis, polyuria, hyperuricaemia, renal calculi, nephrotoxicity, hepatic dysfunction.
									Potentially Fatal: Rarely, skin reactions or blood dyscrasias.
	Precaution : Potassium supplements may be required. Impaired hepatic or renal function; diabetes. Monitor plasma electrolytes and blood count regularly. IM route is not recommended. Caution when driving or operating machinery. Elderly.
	Pregnancy category : 3
	Mode of action : Acetazolamide specifically inhibits the enzyme carbonic anhydrase which catalyses the reversible reaction involving the hydration of CO2 and dehydration of carbonic acid. It increases the excretion of HCO3 ions and as well as Na and K leading to alkaline diuresis. Carbonic anhydrase is also inhibited in the CNS to retard abnormal and excessive discharge from neurons.
	Interaction : Concomitant use w/ high-dose aspirin may cause anorexia, tachypnoea, lethargy, metabolic acidosis, coma and death. May increase serum levels of phenytoin, resulting to increased risk of osteomalacia. May decrease serum concentrations of primidone. Additive effects w/ other carbonic anhydrase inhibitors. May increase the effects of folic acid antagonists. May decrease urinary excretion of amphetamine and quinidine. May prevent the urinary antiseptic effect of methenamine. May increase lithium excretion. Increased risk of renal calculus formation w/ Na bicarbonate. May increase ciclosporin levels.
	Therapeutic class : Carbonic anhydrase inhibitor
	Packsize : 100's pack
Acenac
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Acep
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Acep
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 200's pack
Acep
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 15 ml bot
Acep Plus
	n : Paracetamol + Caffeine
	Indications : Pain,Fever,Headache,Influenza,Migraine,Sore throat,Backache,Toothache,Rheumatic pain,Dysmenorrhea,Colds
	Doses and administration : Adults : 1-2 tablets every 4-6 hours. Maximum dose: 8 tablets daily. Not recommended for children below 12 years.
	Contara-indications : History of hypersensitivity to any of the components.
	Side effects : Skin rash, diarrhoea, anorexia, GI disturbances, epistaxis (rare).
	Precaution : Severe hepatic or renal disorder.
	Pregnancy category : 3
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
									
									Caffeine, a methylxanthine, is a phosphodiesterase inhibitor. It has an antagonistic effect at central adenosine receptors. It is a CNS and resp stimulant. It has bronchodilating and diuretic properties and it facilitates the performance of muscular work.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non opioid analgesics
	Packsize : 100's pack
Acepril
	n : Lisinopril
	Indications : Heart failure, Myocardial infarction, Diabetic nephropathy, Hypertension
	Doses and administration : Oral
									Hypertension
									Adult: Initially, 10 mg/day, 1st dose given preferably at bedtime to avoid precipitous fall in BP. Patient w/ renovascular HTN, volume depletion, severe HTN: Initially, 2.5-5 mg once daily. Patient on diuretic: Initially, 5 mg once daily. Maintenance: 20 mg once daily, up to 80 mg/day may be given if needed.
									Child: >6 yr Initially, 0.07 mg/kg, up to 5 mg once daily.
									
									Renal impairment: Adult: CrCl <10 mL/min or on dialysis: Initially, 2.5 mg once daily. CrCl 10-30 mL/min: Initially, 2.5-5 mg once daily. CrCl 31-80 mL/min: Initially, 5-10 mg once daily. Dose can be adjusted up to max 40 mg once daily based on patient's response. Child: Do not give if GFR <30 mL/min/1.73 m2.
									
									CrCl (ml/min)	
									<10 	Initially, 2.5 mg once daily.
									10-30	Initially 2.5-5 mg once daily.
									31-80	Initially, 5-10 mg once daily.
									
									
									Heart failure
									Adult: As adjunct: Initially, 2.5 or 5 mg/day, increased by increments of >10 mg at intervals of at least 2 wk to max maintenance dose of 40 mg/day.
									
									Post myocardial infarction
									Adult: Initially, 5 mg once daily for 2 days started w/in 24 hr of the onset of symptoms. Increase to 10 mg once daily. Patients w/ low systolic BP: Initially, 2.5 mg once daily.
									
									Diabetic nephropathy
									Adult: Hypertensive type 2 diabetics w/ microalbuminuria: 10 mg once daily, may increase to 20 mg once daily to achieve a sitting diastolic BP <90 mmHg.
	Contara-indications : History of angioedema related to previous treatment with ACE inhibitors, hereditary or idiopathic angioedema. Bilateral renal artery stenosis. Pregnancy (2nd or 3rd trimester), lactation.
	Side effects : Dizziness, headache, fatigue; cough, upper respiratory tract infection; rash; diarrhoea, nausea, vomiting, abdominal pain; chest pain, weakness; orthostatic effects; hypotension; hyperkalaemia; impotence; decreased haemoglobin; increased serum creatinine.
									Potentially Fatal: Severe hypotension, angioedema.
	Precaution : Hypovolaemia, hyperkalaemia, collagen vascular disease, valvular stenosis; before, during or immediately after anaesthesia, preexisting renal insufficiency, unilateral renal artery stenosis. Children <6 yr. Assess renal function. May impair ability to drive or operate machinery.
	Pregnancy category : 4
	Mode of action : Lisinopril competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.
	Interaction : May enhance hypotensive effect w/ diuretics. May increase risk of renal function deterioration and decrease antihypertensive effect w/ NSAIDs. May increase serum levels and toxicity of lithium. Increased risk of hyperkalaemia w/ K-sparing diuretics and K supplements. May increase nitritoid reactions of gold Na thiomalate.
				Potentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function w/ aliskiren in patients w/ diabetes or renal impairment.
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 30's pack
Acepril
	n : Lisinopril
	Indications : Heart failure, Myocardial infarction, Diabetic nephropathy, Hypertension
	Doses and administration : Oral
									Hypertension
									Adult: Initially, 10 mg/day, 1st dose given preferably at bedtime to avoid precipitous fall in BP. Patient w/ renovascular HTN, volume depletion, severe HTN: Initially, 2.5-5 mg once daily. Patient on diuretic: Initially, 5 mg once daily. Maintenance: 20 mg once daily, up to 80 mg/day may be given if needed.
									Child: >6 yr Initially, 0.07 mg/kg, up to 5 mg once daily.
									
									Renal impairment: Adult: CrCl <10 mL/min or on dialysis: Initially, 2.5 mg once daily. CrCl 10-30 mL/min: Initially, 2.5-5 mg once daily. CrCl 31-80 mL/min: Initially, 5-10 mg once daily. Dose can be adjusted up to max 40 mg once daily based on patient's response. Child: Do not give if GFR <30 mL/min/1.73 m2.
									
									CrCl (ml/min)	
									<10 	Initially, 2.5 mg once daily.
									10-30	Initially 2.5-5 mg once daily.
									31-80	Initially, 5-10 mg once daily.
									
									
									Heart failure
									Adult: As adjunct: Initially, 2.5 or 5 mg/day, increased by increments of >10 mg at intervals of at least 2 wk to max maintenance dose of 40 mg/day.
									
									Post myocardial infarction
									Adult: Initially, 5 mg once daily for 2 days started w/in 24 hr of the onset of symptoms. Increase to 10 mg once daily. Patients w/ low systolic BP: Initially, 2.5 mg once daily.
									
									Diabetic nephropathy
									Adult: Hypertensive type 2 diabetics w/ microalbuminuria: 10 mg once daily, may increase to 20 mg once daily to achieve a sitting diastolic BP <90 mmHg.
	Contara-indications : History of angioedema related to previous treatment with ACE inhibitors, hereditary or idiopathic angioedema. Bilateral renal artery stenosis. Pregnancy (2nd or 3rd trimester), lactation.
	Side effects : Dizziness, headache, fatigue; cough, upper respiratory tract infection; rash; diarrhoea, nausea, vomiting, abdominal pain; chest pain, weakness; orthostatic effects; hypotension; hyperkalaemia; impotence; decreased haemoglobin; increased serum creatinine.
									Potentially Fatal: Severe hypotension, angioedema.
	Precaution : Hypovolaemia, hyperkalaemia, collagen vascular disease, valvular stenosis; before, during or immediately after anaesthesia, preexisting renal insufficiency, unilateral renal artery stenosis. Children <6 yr. Assess renal function. May impair ability to drive or operate machinery.
	Pregnancy category : 4
	Mode of action : Lisinopril competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.
	Interaction : May enhance hypotensive effect w/ diuretics. May increase risk of renal function deterioration and decrease antihypertensive effect w/ NSAIDs. May increase serum levels and toxicity of lithium. Increased risk of hyperkalaemia w/ K-sparing diuretics and K supplements. May increase nitritoid reactions of gold Na thiomalate.
				Potentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function w/ aliskiren in patients w/ diabetes or renal impairment.
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 50's pack
Aces PLUS
	n : Super Antioxidant Vitamins & Multimineral (Vitamin A + C + E + K ) + Copper  + Zinc + Manganese + Selenium
	Indications : To develop immune system.To prevent aging.Prevent certain types of cancer. Vitamin/mineral deficiency
	Doses and administration : One tablet daily or as recommended by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis, Should not use in over dosage or use continiously.
	Pregnancy category : 0
	Mode of action : Vitamin A plays an essential role in the function of retina and is essential for growh and differentiation of epithelial tissue.
									Vitamin C: Necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									Vitamins and minerals are essential for normal metabolic functions including hematopoiesis.
									Zinc is a cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system. Copper cofactor in many enzymes, including ceruloplasmin; involved in formation of iron carrier protein, transferrin. Helps maintain normal rates of red and white blood cell formation and helps prevent development of deficiency symptoms. 
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin Multimineral preparations
	Packsize : 30's pack
Aceta
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Aceta
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 15 ml bot
Aceta
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 200's pack
Aceto
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 100's pack
Acetophane
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Acetor
	n : Captopril
	Indications : Hypertension, Congestive heart failure, Post Myocardial infarction, Diabetic nephropathy
	Doses and administration : Adult: PO HTN Initial: 12.5 mg twice daily. Maintenance: 25-50 mg twice daily. Max: 50 mg 3 times/day. 
									
									Heart failure Initial: 6.25-12.5 mg 2-3 times/day. Max: 50 mg 3 times/day. 
									
									Post MI Start 3 days after MI. Initial: 6.25 mg/day, may increase after several wk to 150 mg/day in divided doses if needed and tolerated. 
									
									Diabetic nephropathy 25 mg 3 times/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	Initially, 6.25 mg/day. Max: 37.5 mg/day.
									10-20	Initially, 12.5 mg/day. Max: 75 mg/day.
									21-40	Initially, 25 mg/day. Max: 100 mg/day.
	Contara-indications : Known hypersensitivity to the drug. Bilateral renal artery stenosis, hereditary angioedema; renal impairment; pregnancy.
	Side effects : Hypotension, tachycardia, chest pain, palpitations, pruritus, hyperkalaemia. Proteinuria; angioedema, skin rashes; taste disturbance, nonproductive cough, headache.
									Potentially Fatal: Neutropenia, usually occurs within 3 mth of starting therapy especially in patients with renal dysfunction or collagen diseases. Hyperkalaemia. Anaphylactic reactions.
	Precaution : Patients on diuretics or with sodium depletion should discontinue diuretics or increase sodium intake prior to initiation of therapy. Renal impairment, SLE and other autoimmune collagen disorders and during concurrent use of immunosuppressant or leucopenic drugs, monitor WBC count and urinary protein before and during therapy. Lactation. Porphyria. Severe CHF.
	Pregnancy category : 4
	Mode of action : Captopril competitively inhibits the conversion of angiotensin I (ATI) to angiotensin II (ATII), thus resulting in reduced ATII levels and aldosterone secretion. It also increases plasma renin activity and bradykinin levels. Reduction of ATII leads to decreased Na and water retention. This promotes vasodilation and BP reduction.
	Interaction : Concurrent treatment w/ NSAIDs reduces hypotensive action and increases the risk of nephrotoxicity. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. heparin). May increase risk of leucopenia w/ procainamide, allopurinol, cytostatic or immunosuppressants. May increase risk of lithium toxicity. Increased risk of nitritoid reactions w/ gold (Na aurothiomalate).
				Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) w/ aliskiren in diabetic patients.
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 100's pack
Acetram
	n : Paracetamol + Tramadol Hydrochloride
	Indications : Moderate to severe pain
	Doses and administration : Adult: PO >12 yr: Per tab contains tramadol HCl 37.5 mg and paracetamol 325 mg: 2 tab 6 hrly. Max: 8 tab/day.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Increase dosing interva to 12 hr.ly
									<10	        Not recommended.
	Contara-indications : Hypersensitivity to tramadol, paracetamol or opioids. Situations where opioid use may be contra-indicated (e.g. acute intoxication with alcohol, hypnotic drugs, centrally-acting analgesics, opioids or psychotropic drugs). Severe hepatic impairment, uncontrolled epilepsy. Concurrent use or within 2 wk of discontinuation from MAOIs.
	Side effects : Nausea, vomiting, constipation, diarrhoea, abdominal pain, dry mouth, dyspepsia, flatulence, dizziness, somnolence, headache, confusion, mood changes, nightmares, amnesia, sweating, pruritus.
									Potentially Fatal: Severe anaphylactic reactions.
	Precaution : Not recommended in severe renal impairment (CrCl <10 ml/min), severe respiratory insufficiency, liver disease or opioid dependent patients. Increased intracranial pressure or head injury, patients at risk of seizures or on drugs that may lower the seizure threshold (e.g. SSRI, TCA, antipsychotics, centrally acting analgesics or local anaesthesia), biliary tract disorders, in a state of shock or unconsciousness. May impair ability to drive or operate machinery. Avoid abrupt withdrawal. May cause withdrawal symptoms, dependence and abuse. Elderly. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Tramadol is a centrally acting opioid analgesic which binds to mu-opioid receptors and weakly inhibits the reuptake of norepinephrine and serotonin. Paracetamol, a para-aminophenol derivative, has analgesic, antipyretic and weak anti-inflammatory activity. Together, tramadol and paracetamol has faster onset of action compared to tramadol alone and longer duration of action compared to paracetamol alone.
	Interaction : Concomitant use is contraindicated w/ non-selective MAOIs, selective-A & B MAOIs; not recommend w/ alcohol, carbamazepine & other enzyme inducers, opioid agonists-antagonists; needs consideration w/ selective serotonin re-uptake inhibitors, triptans, other opioid derivatives & anxiolytics, barbiturates, benzodiazepines, hypnotics, sedative antidepressants & antihistamines, neuroleptics, centrally-acting antihypertensives, TCAs, thalidomide, baclofen, warfarin-like compd, ketoconazole, erythromycin, bupropion, ondansetron.
	Therapeutic class : Combined analgesics
	Packsize : 30's pack
ACF
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Acical 500
	n : Calcium Carbonate
	Indications : Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset
	Doses and administration : Adult: PO Hyperacidity: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets. 
									
									Hyperphosphataemia in chronic renal failure Initial: 2.5 g/day, up to 17 g/day in divided doses.
									
									Renal impairment:
									CrCl (ml/min)	
									<25	Dosage adjustments may be needed depending on serum calcium levels. 
	Contara-indications : Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.
	Side effects : Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).
	Precaution : Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.
	Pregnancy category : 3
	Mode of action : Calcium carbonate can neutralise gastric acid rapidly and effectively. However, it may adversely activate Ca dependent processes, leading to secretion of gastric and hydrochloric acid. It can induce rebound acid secretion and, prolonged high doses may cause hypercalcemia, alkalosis and milk-alkali syndrome.
	Interaction : Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
	Therapeutic class : Specific mineral preparations
	Packsize : 100's pack
Acical D
	n : Calcium + Vitamin D3
	Indications : Postmenopausal osteoporosis, Osteoporosis, Osteomalacia/rickets, Hypoparathyroidism, Latent tetany, Hypocalcaemia, Calcium and vitamin D deficiency
	Doses and administration : Adult: PO Per tab contains Ca carbonate 1,500 mg and vitamin D3 10 mcg: 1 tab twice daily.
	Contara-indications : Patients with hypercalcaemia and/or hypercalciuria. Nephrolithiasis, hypervitaminosis D, hypophosphataemia.
	Side effects : Constipation, flatulence, nausea, abdominal pain and diarrhoea, pruritus, rash and urticaria.
	Precaution : Impaired calcium absorption in achlorhydria which is common in elderly. Increased risk of hypercalcaemia and hypercalciuria in hypoparathyroid patients receiving high doses of vitamin D. Caution when using in patients with history of kidney stones. Renal impairment; frequent monitoring of serum calcium and phosphorus is recommended.
	Pregnancy category : 3
	Mode of action : Calcium /vitamin D3 prevents or treats negative Ca balance. It also helps facilitate nerve and muscle performance as well as normal cardiac function. Bone mineral component; cofoactor in enzymatic reactions, essential for neurotransmission, muscle contraction, and many signal transduction pathways. Vitamin D3 is a fat-soluble sterol. It is necessary for the regulation and regulation of calcium and phosphate homoeostasis and bone mineralisation. Vitamin D is also essential for healthy bones as it aids in Calcium absorption from the GI tract. In addition to this it stimulates bone formation. Clinical studies also show that Calcium and Vitamin D has synergistic effects on bone growth as well as in Osteoporosis and fracture prevention.
	Interaction : May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 30's pack
Acical M
	n : Calcium + Vitamin D + Minerals
	Indications : Osteoporosis, Calcium deficiency, Post-menopausal osteoporosis, Rickets, Osteocalcaemia, Mineral supplement
	Doses and administration : Adults and Elderly and children above 12 years of age: 2 tablets per day, preferably one tablet each morning and evening.
									
									Children: Not recommended for children under 12 years.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Mild and transient effects of gastrointestinal disturbances, like constipation, flatulence, nausea, diarrhoea may be seen in some individuals. Following administration of vitamin D supplements may cause skin rash in some rare cases. Hypercalciuria have been seen with long term use at high dosage.
	Precaution : Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. Periodic checks of plasma calcium levels and urinary calcium excretion should be made in patients with mild to moderate renal failure or mild hypercalciuria. 
				
				Urinary calcium excretion should also be measured. In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria. With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5mmol/24 hours. 
	Pregnancy category : 3
	Mode of action : Calcium gluconate/lactate is used to prevent or treat negative calcium balance. It also helps facilitate nerve and muscle performance as well as normal cardiac function. Bone mineral component; cofoactor in enzymatic reactions, essential for neurotransmission, muscle contraction, and many signal transduction pathways.
									Vitamin D is also essential for healthy bones as it aids in Calcium absorption from the GI tract. In addition to this it stimulates bone formation. Clinical studies also show that Calcium and Vitamin D has synergistic effects on bone growth as well as in Osteoporosis and fracture prevention.
									
	Interaction : May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 30's pack
Aciclon
	n : Acyclovir 3%
	Indications : Herpes simplex keratitis
	Doses and administration :  As 3% oint: Apply 5 times/day until 3rd day of complete healing.
	Contara-indications : Hypersensitivity.
	Side effects :  Eye application may produce stinging, superficial punctate keratopathy, blepharitis or conjunctivitis.
	Precaution : Renal impairment. Pregnancy, lactation. Neurological abnormalities with significant hypoxia, serious hepatic or electrolyte abnormalities. Maintain adequate hydration.
	Pregnancy category : 2
	Mode of action : Activity against HSV types I and II and varicella-zoster virus is due to intracellular conversion of aciclovir to the monophosphate by viral thymidine kinase with subsequent conversion to the diphosphate and active triphosphate by cellular enzymes. This active form inhibits viral DNA synthesis and replication by interfering with viral DNA polymerase enzyme and being incorporated into viral DNA.
	Interaction : Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).
	Therapeutic class : Ophthalmic Anti-viral Products
	Packsize : 3 gm tube
Acicot
	n : Dexamethasone 0.1%  E/E prep
	Indications : Allergic conjunctivitis, Ocular inflammation, Superficial punctate keratitis , Herpes zoster keratitis, 	Iritis , Cyclitis, Otic inflammation, Steroid responsive inflammatory conditions of the external auditory meatus,  Allergic otitis externa, Infective otitis externa.
	Doses and administration : Eye:
									1 or 2 drops in conjunctival sac.
									Severe or acute inflammation: Every 30 to 60 minutes as initial therapy, reducing the dosage when favourable response is observed to every two to four hours. Further reduction may be made to one drop three or four times daily if sufficient to control inflammation.
									Chronic inflammation: Every three to six hours, or as necessary.
									Allergic inflammation: Every three to four hours until the desired response is obtained.
									Ear :
									Instill two or three drops to the ear at two or three hours interval.The frequency of dosage and duration of treatment may vary with the type of lession and severity.
	Contara-indications : Hypersensitivity; Contraindicated in epithelial herpes simplex, vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; tuberculosis of the eye; fungal disease of ocular structures; other diseases caused by micro-organisms, may be enhanced by the presence of the steroid. It is contraindicated in patients with perforated ear drum membrane.
	Side effects :  Topical application to eye: Corneal ulcers, glaucoma and reduced visual ability. The following side effects are common for patients taking Dexamethasone
									 Increased appetite
									 Insomnia
									 Fluid retention
									 Heartburn
									 Muscle weakness
	Precaution : Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity, and posterior subcapsular cataract formation.Elderly, children and adolescent; pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Dexamethasone is a synthetic glucocorticoid which decreases inflammation by inhibiting the migration of leukocytes and reversal of increased capillary permeability. It suppresses normal immune response.
	Interaction :  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.
				Potentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5 ml bot
Acicox 100
	n : Celecoxib
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Dysmenorrhea, Acute pain, Familial adenomatous polyposis
	Doses and administration : Adult: PO Osteoarthritis 200 mg 1-2 times/day. May increase to 200 mg 2 times daily if needed. Rheumatoid arthritis 100-200 mg 2 times daily. 
									Juvenile idiopathic arthritis
									Child: >2 yr ?10 kg to <25 kg: 50 mg bid; >25 kg: 100 mg bid.
									
									Pain relief; Dysmenorrhea Initial: 400 mg followed by 200 mg on the 1st day if needed. Maintenance: 200 mg 2 times daily. Familial adenomatous polyposis 400 mg 2 times daily.
									
									Hepatic impairment: Moderate (Child-Pugh category B): Reduce dose by 50%. Severe (Child-Pugh category C or >10 score): Contraindicated.
	Contara-indications : Hypersensitivity including those in whom attacks of angioedema, rhinitis and urticaria have been precipitated by aspirin, NSAIDs or sulfonamides. Severe hepatic impairment; severe heart failure; inflammatory bowel disease; peptic ulcer; renal impairment (creatinine clearance <30 mL/min); pregnancy and lactation.
	Side effects : Abdominal pain, diarrhea, nausea, oedema, dizziness, headache, insomnia, upper respiratory tract infections (URTI); rash.
									Potentially Fatal: Serious skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
	Precaution : History of GI bleeding; renal/hepatic insufficiency; asthma or allergic disorders; hypertension; monitor Hb or haematocrit levels for signs of anaemia. History of cerebrovascular disease or ischaemic heart disease (IHD).
	Pregnancy category : 4
	Mode of action : Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor primarily responsible to reduce mediators of pain and inflammation. Its action is due to inhibition of prostaglandin synthesis via inhibition of COX-2.
	Interaction : May increase plasma level w/ CYP2C9 isoenzymes (e.g. fluconazole). May increase serum level of lithium. May reduce effect of antihypertensives and diuretics. May increase anticoagulant effect of warfarin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 30's pack
Acidrox
	n : Aluminium Oxide + Magnesium Hydroxide
	Indications : Hyperacidity, Flatulence, Gastric ulcer, Duodenal ulcer, Gastritis, Stomach distension
	Doses and administration : Chew 1-2 tablets after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. For best results, drink a half glass of water or other liquid after each dose. Do not take more than 16 tablets in 24 hours
	Contara-indications : Hypophosphataemia.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200ml bot
Acidrox M
	n : Magaldrate
	Indications : Peptic ulcers, GERD, Heartburn, Gastritis
	Doses and administration : Adult: PO: 1-3 tablets, after meals and at bed time. 
									5-10 mL (1-2 teaspoonfuls) between meals and not to exceed 80 mL (16 teaspoonfuls) in 24-hour period
	Contara-indications : Magaldrate is contraindicated in patients with known hypersensitivity to magnesium and aluminium. It is also contraindicated in patients with impaired renal functions.
	Side effects : Constipation and diarrhea may occur.
	Precaution : Care should be taken in decreased kidney function, hypophosphataemia and weak people.
	Pregnancy category : 3
	Mode of action : Magaldrate is a hydroxymagnesium aluminate complex that is rapidly converted in gastric acid to magnesium and aluminium hydroxide, which is poorly absorbed and provides a sustained antacid effect with balanced efects on intestinal motility; increases lower esophageal sphincter tone and inhibits smooth muscle contraction and gastric emptying.
	Interaction : Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
	Therapeutic class : Anti-dyspeptic/Carminatives
	Packsize : 150's pack
Acifix
	n : Rabeprazole
	Indications : Peptic ulcer disease, H. pylori infection, Gastro-oesophageal reflux disease, Paediatric GERD
	Doses and administration : i) Duodenal ulcer: 20 mg tablet in the morning is indicated for 4 weeks treatment in the healing and symptomatic relief of duodenal ulcer. Most patients heal within 4 weeks.
									ii) Benign gastric ulcer: 20 mg daily in the morning for 6 weeks, followed by a further 6 weeks if not fully cured.
									iii) Duodenal ulcer and benign gastric ulcer associated with H. pylori infection: Rabeprazole in combination with Amoxicillin and Clarithromycin as a three drug regimen is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease. Rabeprazole offers a faster therapy option than other PPIs, up to 10 to 14 days 20 mg once daily.
									iv) Healing of erosive or ulcerative Gastroesophageal Reflux Disease (GERD): 20 mg daily in the morning 4 to 8 weeks. Those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole may be considered.
									v) Treatment of symptomatic GERD: The recommended adult oral dose  is 20 mg once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered.
									vi) Maintenance of healing of erosive or ulcerative GERD: It is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative GERD maintenance. Controlled studies do not extend beyond 12 months.
									vii) Prevention or treatment of NSAID-induced ulcers: 20 mg tablet once daily, in patients receiving treatment with NSAIDs.
									viii) Zollinger-Ellison Syndrome: The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg once daily and 60 mg twice daily have been administered.
									ix) Paediatric GERD: Treatment of GERD in Pediatric Patients 1 to 11 Years of Age: The recommended dosage for pediatric patients 1 to 11 years of age by body weight is:
									 Less than 15 kg: 5 mg once daily for up to 12 weeks with the option to increase to 10 mg if inadequate response.
									 15 kg or more: 10 mg once daily for up to 12 weeks.
									
	Contara-indications : Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, other PPIs or to any component of the formulation.
	Side effects : In general, Rabeprazole is well-tolerated in both short-term and long-term studies. Rabeprazole may some times cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, dizziness.
	Precaution : Rabeprazole Sodium tablets should not be splited, chewed or crushed.
	Pregnancy category : 2
	Mode of action : Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase at the secretory surface of the gastric parietal cell.
	Interaction : May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate.
				Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 50's pack
Aciflox
	n : Sparfloxacin
	Indications : Chronic bronchitis, Community-acquired pneumonia
	Doses and administration : Adult: PO Acute bacterial exacerbation of chronic bronchitis; Community-acquired pneumonia 100-300 mg/day in 1-2 divided doses.
	Contara-indications : Hypersensitivity; pregnancy and lactation; children <18 yr.
	Side effects : Diarrhoea, abdominal pain, nausea, vomiting; jaundice, renal failure, elevation of liver enzymes, BUN and creatinine; anaphylactoid reaction, headache, dizziness, convulsions; tremors, myalgia; rhabdomyolysis, thrombocytopenia and eosinophilia.
									Potentially Fatal: AV block; anaphylaxis.
	Precaution : History of CNS disorders, pseudomembranous colitis, superinfection, severe renal dysfunction, epilepsy, G6PD deficiency, myasthenia gravis, patients with QT prolongation, uncorrected electrolyte disturbances, bradycardia, or pre-existing cardiac disease. Avoid exposure to strong sunlight or sunlamps during treatment. Discontinue treatment if patients experience tendon pain, inflammation or rupture; subsequent use of fluoroquinolones in these patients is not recommended. Avoid in MRSA infections due to high risk of resistance. Ensure adequate fluid intake to reduce risk of crystalluria.
	Pregnancy category : 3
	Mode of action : Sparfloxacin inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp.
	Interaction : Cations such as aluminum, magnesium, zinc and iron may reduce the bioavailability of sparfloxacin. May increase the plasma concentrations of theophylline and tizanidine. May enhance the effect of warfarin and glibenclamide. May decrease the renal clearance of methotrexate. Excretion may be reduced by probenecid. May alter serum levels of phenytoin.
				Potentially Fatal: Corticosteroids may increase risk of tendon rupture. Increased risk of seizures with NSAIDs. Risk of additive QT prolongation effect when used with class Ia or III antiarrhythmic drugs, astemizole, terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs.
	Therapeutic class : 4-Quinolone preparations
	Packsize : 10's pack
Acin
	n : Ranitidine
	Indications : Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
	Doses and administration : Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. 
									For prevention of NSAID-associated ulceration: 150 mg bid. 
									Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. 
									GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.
									 Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. 
									Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. 
									Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. 
									Prophylaxis during NSAID treatment 150 mg twice daily. 
									
									IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. 
									
									IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
	Contara-indications : Porphyria.
	Side effects : Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
									Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
	Precaution : Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
	Interaction : Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
	Therapeutic class : H2 antagonists
	Packsize : 100ml bot
Acin
	n : Ranitidine
	Indications : Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
	Doses and administration : Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. 
									For prevention of NSAID-associated ulceration: 150 mg bid. 
									Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. 
									GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.
									 Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. 
									Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. 
									Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. 
									Prophylaxis during NSAID treatment 150 mg twice daily. 
									
									IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. 
									
									IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
	Contara-indications : Porphyria.
	Side effects : Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
									Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
	Precaution : Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
	Interaction : Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
	Therapeutic class : H2 antagonists
	Packsize : 150's pack
Acin
	n : Ranitidine
	Indications : Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
	Doses and administration : Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. 
									For prevention of NSAID-associated ulceration: 150 mg bid. 
									Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. 
									GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.
									 Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. 
									Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. 
									Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. 
									Prophylaxis during NSAID treatment 150 mg twice daily. 
									
									IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. 
									
									IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
	Contara-indications : Porphyria.
	Side effects : Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
									Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
	Precaution : Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
	Interaction : Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
	Therapeutic class : H2 antagonists
	Packsize : 50's pack
Aciphin IM
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : None
Aciphin IM
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with lidocaine
Aciphin IM
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with lidocaine
Aciphin IV
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with water
Aciphin IV
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with water
Aciphin IV
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with water
Aciphin IV
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with water
Aciprin CV
	n : Aspirin
	Indications : Fever, Headache, Pain/inflammation, Acute coronary syndrome, TIA,  MI, Stroke
	Doses and administration : Oral
									Acute symptoms 
									150-300 mg PO; (within minutes of symptoms)
									Prophylaxis of myocardial infarction
									Adult: 75-300 mg once daily. Lower doses should be used in patients receiving ACE inhibitors.
									Stent implantation
									Adult: 300 mg 2 hr before procedure followed by 150-300 mg/day thereafter.
									Juvenile rheumatoid arthritis
									Child: 80-100 mg/kg daily in 5 or 6 divided doses. Up to 130 mg/kg daily in acute exacerbations if necessary.
									Mild to moderate pain and fever
									Adult: 150-300 mg repeated every 4-6 hr according to response. Max: 4 g/day. 
									Pain and inflammation associated with musculoskeletal and joint disorders
									Adult: Initial: 2.4-3.6 g/day in divided doses. Usual maintenance: 3.6-5.4 g/day. Monitor serum concentrations.
									
	Contara-indications : Hypersensitivity (attacks of asthma, angioedema, urticaria or rhinitis), active peptic ulceration; pregnancy (3rd trimester), children <12 yr, patients with haemophilia or haemorrhagic disorders, gout, severe renal or hepatic impairment, lactation.
	Side effects : GI disturbances; prolonged bleeding time, rhinitis, urticaria and epigastric discomfort; angioedema, salicylism, tinnitus; bronchospasm.
									Potentially Fatal: Gastric erosion, ulceration and bleeding; severe, occasionally fatal exacerbation of airway obstruction in asthma; Reye's syndrome (children <12 yr). Hepatotoxicity; CNS depression which may lead to coma; CV collapse and resp failure; paroxysmal bronchospasm and dyspnoea.
	Precaution : Patients with history  of asthma, angioedema, urticaria or rhinitis, nasal polyp, severe renal or hepatic impairment, lactation.
	Pregnancy category : 4
	Mode of action : Aspirin is an analgesic, anti-inflammatory and antipyretic. It inhibits cyclooxygenase, which is responsible for the synthesis of prostaglandin and thromboxane. It also inhibits platelet aggregation.
	Interaction : Alcohol, corticosteroids, analgin, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Aspirin increases phenytoin levels. May antagonize actions of uricosurics and spironolactone.
				Potentially Fatal: May potentiate effects of anticoagulants, methotrexate and oral hypoglycaemics.
	Therapeutic class : Anti-platelet drugs
	Packsize : 100's pack
Acira
	n : Chlorpheniramine Maleate
	Indications : Urticaria, Sneezing, Watery eyes,  Allergic conditions, Anaphylactic shock, Rhinitis, Itching
	Doses and administration : Adult: 4 mg every 4-6 hr. Max: 24 mg daily. 
									Child: 1-2 yr: 1 mg bid, 2-5 yr: 1 mg every 4-6 hr, 6-12 yr: 2 mg every 4-6 hr. Max: 6 mg daily (1-5 yr); 12 mg daily (6-12 yr). 
									
									Parenteral
									Adjunct in the emergency treatment of anaphylactic shock
									Adult: 10-20 mg IM, SC, or slow IV inj over 1 min. Max dose: 40 mg daily.
									Child: 87.5 mcg/kg SC 4 times daily
									
									
	Contara-indications : Hypersensitivity, Neonates.
	Side effects : CNS depression, sedation, drowsiness, lassitude, dizziness. GI upsets, anorexia, or increased appetite, epigastric pain, blurring of vision, dysuria, dryness of mouth, tightness in chest, hypotension, muscular weakness, tinnitus, euphoria, headache, paradoxical CNS stimulation.
									Potentially Fatal: CV collapse and respiratory failure.
	Precaution : Elderly, pylori duodenal obstruction, angle-closure glaucoma, urinary retention, prostatic hyperplasia, epilepsy, renal and hepatic impairment. May affect performance of skilled tasks. BPH, bladder neck obstruction, hypertension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Chlorphenamine is an H1-receptor antagonist which competetively blocks H1-receptor sites on tissues.
	Interaction : Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).
	Therapeutic class : Sedating Anti-histamines
	Packsize : 200's pack
Acitrin
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Acitrin
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 15 ml bot
Acitrin
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Acitrin-L
	n : Levocetirizine Hydrochloride
	Indications : Allergic rhinitis,  Allergic conditions, Chronic idiopathic urticaria
	Doses and administration :  Adult and children 12 years of age and older: 5mg once daily
									 Children 6 to 11 years of age: 2.5mg (1/2 tablet or 1 teaspoon oral solution) once daily
									 Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) once daily
									
									Renal impairment:
									CrCl (ml/min)	
									<10 and patients undergoing dialysis	Contraindicated.
									10-29	5 mg once every 3 days.
									30-49	5 mg every other day.
									50-79	5 mg once daily.
									Hepatic impairment: No dosage adjustment needed.
	Contara-indications : Patients who are hypersensitive to this medication or to any of its ingredients.
	Side effects : Generally Levocetirizine is well tolerated. However, a few side effects like headache, dry mouth, fatigue and skin rash have been reported rarely.
	Precaution : N/A
	Pregnancy category : 2
	Mode of action : Levocetirizine is an active isomer of cetirizine which selectively competes w/ histamine for H1-receptor sites on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Possible additive adverse CNS effects w/ CNS depressants (e.g. sedatives, tranquilizers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Acitrin-L
	n : Levocetrizine Dihydrochloride 0.1%
	Indications : Allergic rhinitis, Chronic idiopathic urticaria
	Doses and administration :  Adult and children 12 years of age and older: 5mg once daily
									 Children 6 to 11 years of age: 2.5mg (1/2 tablet or 1 teaspoon oral solution) once daily
									 Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) once daily
	Contara-indications : Lactation. End-stage renal disease (CrCl <10 ml/min) or haemodialysis patients. Child 6-11 yr with renal impairment.
	Side effects : Fatigue, somnolence, dry mouth, nasopharyngitis, pyrexia, cough, epistaxis.
	Precaution : Renal impairment. May impair ability to drive or operate machinery.
	Pregnancy category : 2
	Mode of action : Levocetirizine is an active isomer of cetirizine which selectively competes w/ histamine for H1-receptor sites on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Possible additive adverse CNS effects w/ CNS depressants (e.g. sedatives, tranquilizers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Aclene
	n : Adapalene 0.1%
	Indications : Acne, Keratosis pilaris
	Doses and administration : Adult: Topical As 0.1% soln/cream/gel: Apply once daily at night.
	Contara-indications : Hypersensitivity.
	Side effects : Mild skin irritation, scaling, erythema, cutaneous dryness, sensations of stinging and burning, pruritus.
	Precaution : Patients with sunburn, eczema. Pregnancy, lactation. Avoid excessive exposure to sunlight or UV irradiation. Keep away from the eyes, lips, nostrils and mucous membranes. Do not apply to cuts, abrasions, scaly or flaky skin, or patches of sunburned skin. Use with caution with preparations containing sulfur, resorcinol, or salicylic acid.
	Pregnancy category : 3
	Mode of action : Adapalene binds to specific retinoic acid nuclear receptors which normalises the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.
	Interaction : Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.
	Therapeutic class : Topical antibiotic & retinoid preparations
	Packsize : 10gm tubex 1's pack
Acliz
	n : Meclizine Hydrochloride
	Indications : Motion sickness, Vertigo and Vestibular disorders
	Doses and administration : Adult and Children 12 years of age & over: Nausea and vomiting: 25-50 mg daily or as directed by a physician.
									Motion sickness: Take an initial dose of 25-50 mg, 1 hour prior to travel. May repeat the dose every 24 hours for the duration of the journey.
									Radiation sickness: 50 mg administered 2-12 hours prior to radiation treatment.
									Vertigo: 25-100 mg daily in divided doses.
									Prevention of nausea and vomiting associated with emergency contraceptive pill (ECP) : 25-50 mg, 1 hour before first ECP dose; repeat if needed in 24 hours.
									The safety and efficacy for use in children less than 12 years of age have not been established. 
	Contara-indications : Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.
	Side effects : Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.
	Precaution : Patients should be warned that Meclizine Hydrochloride may impair their ability to perform hazardous activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle). Patients should avoid alcoholic beverages while taking this drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.
	Pregnancy category : 2
	Mode of action : Meclozine blocks vasopressor response to histamine and has a slight blocking action against acetylcholine. It decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways.
	Interaction : Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
	Therapeutic class : Anti-emetic drugs
	Packsize : 100's pack
Acliz PLUS
	n : Meclizine Hydrochloride + Pyridoxine Hydrochloride
	Indications : Nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of vestibular motion sickness, radiation sickness and vertigo associated with diseases of vestibular system, morning sickness during pregnancy, drug induced nausea, vomiting induced by oral contraceptives or Estrogen preparations. 
	Doses and administration : Adult: PO: As combination preparation containing meclozine 25 mg and pyridoxine 50 mg per tablet: 1 tablet at night.
	Contara-indications : Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.
	Side effects : Drowsiness, thickening of bronchial secretions, dry mouth, fatigue, blurred vision.
	Precaution : Prostate hypertrophy, obstruction of bladder neck, narrow angle glaucoma, pyloric stenosis. May impair ability to drive or operate machinery. Pregnancy.
	Pregnancy category : 12
	Mode of action : Meclozine blocks vasopressor response to histamine and has a slight blocking action against acetylcholine. It decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways.
									
									Pyridoxine is a water-soluble vitamin which functions in the metabolism of carbohydrates, proteins and fats. It is essential in Hb formation and GABA synthesis within the CNS. It also aids in the release of glycogen stored in the liver and muscles.
	Interaction : Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
	Therapeutic class : Anti-emetic drugs
	Packsize : 100's pack
Aclo
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Aclobet
	n : Clobetasol Propionate 0.05%
	Indications : Corticosteroid-responsive Dermatoses, Psoriasis, Scalp Psoriasis, Plaque-type Psoriasis, Vitiligo, Eczema, Alopecia areata, Herpes labialis, Lichen sclerosus, Lichen, Mycosis fungoides, Corticosteroid-responsive dermatoses
	Doses and administration : Adults and children over 1 year:
									Apply sparingly to cover the affected area, and gently rub into the skin. Frequency of application is 2 to 3 times daily according to the severity of the condition. The total dose applied should not exceed 50 g weekly.
									
									Treatment should not be continued for more than 7 days without medical supervision. If a longer course is necessary, it is recommended that treatment should not be continued for more than 4 weeks without the patient's condition being reviewed.
									
									Repeated short courses of Clobetasol may be used to control exacerbations
									Children below 1 year: Under 1 year this preparation is not recommended.
									
									Scalp Application
									 It should be applied to the affected scalp areas twice daily, once in morning and once at night.
									Total dosage should not exceed 50 ml per week.
									As with other highly active topical steroid preparations, therapy should be discontinued when control is achieved
									Children: Under 1 year this preparation is not recommended.
									
									Shampoo
									It should be applied to the dry (not wet) scalp once a day to the affected areas only.
									It should be massaged gently into the lesions and left in place for 15 minutes before lathering and rinsing.
									Treatment should be limited to 4 consecutive weeks.
									Total dosage of shampoo should not exceed 50 g per week.
									Under 18 years this preparation is not recommended.
	Contara-indications : Childn <12 yrs. Long-term treatment of ulcerative conditions, rosacea, pruritus; It is contraindicated in rosacea, acne vulgaris, perioral dermatitis, primary cutaneous viral infections (eg. herpes simplex, chickenpox), otitis externa with a perforated eardrum, hypersensitivity to the preparations. Scalp application is contraindicated in infection of the scalp.
	Side effects : Perioral dermatitis, striae esp in flexures. Dermal and epidermal atrophy esp on the face, steroid purpura. Potentially Fatal: Prolonged usage of large amount of clobetasol propionate can lead to sufficient systemic levels to produce adrenal suppression, Cushing's syndrome, diabetes and hypertension.
	Precaution : Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even without occlusion. If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye. If used in psoriasis careful patient supervision is important.
				Scalp Application: Keep away from eye. Flammable. Do not use or dry the hair near a fire or flame.
				Scalp Shampoo: Do not use on areas other than the scalp. Keep away from eye.
	Pregnancy category : 3
	Mode of action : Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; and reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation.
	Interaction : Increased systemic exposure w/ CYP3A4 inhibitors (eg ritonavir & itraconazole).
	Therapeutic class : Clobetasol/Clobetasone & Combined Preparations
	Packsize : 10gm  tube
Aclobet
	n : Clobetasol Propionate 0.05%
	Indications : Corticosteroid-responsive Dermatoses, Psoriasis, Scalp Psoriasis, Plaque-type Psoriasis, Vitiligo, Eczema, Alopecia areata, Herpes labialis, Lichen sclerosus, Lichen, Mycosis fungoides, Corticosteroid-responsive dermatoses
	Doses and administration : Adults and children over 1 year:
									Apply sparingly to cover the affected area, and gently rub into the skin. Frequency of application is 2 to 3 times daily according to the severity of the condition. The total dose applied should not exceed 50 g weekly.
									
									Treatment should not be continued for more than 7 days without medical supervision. If a longer course is necessary, it is recommended that treatment should not be continued for more than 4 weeks without the patient's condition being reviewed.
									
									Repeated short courses of Clobetasol may be used to control exacerbations
									Children below 1 year: Under 1 year this preparation is not recommended.
									
									Scalp Application
									 It should be applied to the affected scalp areas twice daily, once in morning and once at night.
									Total dosage should not exceed 50 ml per week.
									As with other highly active topical steroid preparations, therapy should be discontinued when control is achieved
									Children: Under 1 year this preparation is not recommended.
									
									Shampoo
									It should be applied to the dry (not wet) scalp once a day to the affected areas only.
									It should be massaged gently into the lesions and left in place for 15 minutes before lathering and rinsing.
									Treatment should be limited to 4 consecutive weeks.
									Total dosage of shampoo should not exceed 50 g per week.
									Under 18 years this preparation is not recommended.
	Contara-indications : Childn <12 yrs. Long-term treatment of ulcerative conditions, rosacea, pruritus; It is contraindicated in rosacea, acne vulgaris, perioral dermatitis, primary cutaneous viral infections (eg. herpes simplex, chickenpox), otitis externa with a perforated eardrum, hypersensitivity to the preparations. Scalp application is contraindicated in infection of the scalp.
	Side effects : Perioral dermatitis, striae esp in flexures. Dermal and epidermal atrophy esp on the face, steroid purpura. Potentially Fatal: Prolonged usage of large amount of clobetasol propionate can lead to sufficient systemic levels to produce adrenal suppression, Cushing's syndrome, diabetes and hypertension.
	Precaution : Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even without occlusion. If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye. If used in psoriasis careful patient supervision is important.
				Scalp Application: Keep away from eye. Flammable. Do not use or dry the hair near a fire or flame.
				Scalp Shampoo: Do not use on areas other than the scalp. Keep away from eye.
	Pregnancy category : 3
	Mode of action : Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; and reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation.
	Interaction : Increased systemic exposure w/ CYP3A4 inhibitors (eg ritonavir & itraconazole).
	Therapeutic class : Clobetasol/Clobetasone & Combined Preparations
	Packsize : 10gm  tube
Aclobet-N
	n : Clobetasol Propionate 0.05% + Neomycin Sulphate 0.5% + Nystatin BP 1,00,000 IU.
	Indications : Psoriasis, Eczema, Severe inflammatory skin disorders
	Doses and administration : Adults and children over 2 years:
									Apply sparingly to the affected area once or twice daily until improvement occurs. As with other highly active topical steroid preparations therapy should be discontinued when control is achieved. 
									
									Treatment should not be continued for more than 7 days without medical supervision. If a longer course is necessary, it is recommended that treatment should not be continued for more than 4 weeks without the patient's condition being reviewed. 
									
									Elderly: This preparation is suitable for use in the elderly. Caution should be exercised in cases where a decrease in renal function exists and significant systemic absorption of Neomycin Sulphate may occur.
									
									Children: Under 2 years this preparation is not recommended.
	Contara-indications : Childn <12 yrs. Long-term treatment of ulcerative conditions, rosacea, pruritus; presence of acute infections. Hypersensitivity.
	Side effects : Perioral dermatitis, striae esp in flexures. Dermal and epidermal atrophy esp on the face, steroid purpura.
									Potentially Fatal: Prolonged usage of large amount of clobetasol propionate can lead to sufficient systemic levels to produce adrenal suppression, Cushing's syndrome, diabetes and hypertension.
	Precaution : Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even without occlusion. If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye. If used in psoriasis careful patient supervision is important. Scalp Application: Keep away from eye. Flammable. Do not use or dry the hair near a fire or flame.
	Pregnancy category : 3
	Mode of action : Clobetasol is a highly active corticosteroid that has topical anti-inflammatory action brought about partly by vasoconstriction and reduced collagen synthesis. Neomycin is an aminoglycoside antibiotic that binds to ribosomal 30S and 50S subunits of susceptible bacteria, thus inhibiting protein synthesis; it also causes misreading of the genetic codes on the mRNA template. Nystatin works by binding to ergosterol in the cell membrane of fungus resulting in a change in the cell wall permeability and leakage of cellular components.
	Interaction : If there is substantial systemic absorption, neomycin may prolong and intensify respiratory depressant effects of neuromuscular blockers.
	Therapeutic class : Clobetasol/Clobetasone & Combined Preparations
	Packsize : 10gm  tube
Aclobet-N
	n : Clobetasol Propionate 0.05% + Neomycin Sulphate 0.5% + Nystatin BP 1,00,000 IU.
	Indications : Psoriasis, Eczema, Severe inflammatory skin disorders
	Doses and administration : Adults and children over 2 years:
									Apply sparingly to the affected area once or twice daily until improvement occurs. As with other highly active topical steroid preparations therapy should be discontinued when control is achieved. 
									
									Treatment should not be continued for more than 7 days without medical supervision. If a longer course is necessary, it is recommended that treatment should not be continued for more than 4 weeks without the patient's condition being reviewed. 
									
									Elderly: This preparation is suitable for use in the elderly. Caution should be exercised in cases where a decrease in renal function exists and significant systemic absorption of Neomycin Sulphate may occur.
									
									Children: Under 2 years this preparation is not recommended.
	Contara-indications : Childn <12 yrs. Long-term treatment of ulcerative conditions, rosacea, pruritus; presence of acute infections. Hypersensitivity.
	Side effects : Perioral dermatitis, striae esp in flexures. Dermal and epidermal atrophy esp on the face, steroid purpura.
									Potentially Fatal: Prolonged usage of large amount of clobetasol propionate can lead to sufficient systemic levels to produce adrenal suppression, Cushing's syndrome, diabetes and hypertension.
	Precaution : Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even without occlusion. If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye. If used in psoriasis careful patient supervision is important. Scalp Application: Keep away from eye. Flammable. Do not use or dry the hair near a fire or flame.
	Pregnancy category : 3
	Mode of action : Clobetasol is a highly active corticosteroid that has topical anti-inflammatory action brought about partly by vasoconstriction and reduced collagen synthesis. Neomycin is an aminoglycoside antibiotic that binds to ribosomal 30S and 50S subunits of susceptible bacteria, thus inhibiting protein synthesis; it also causes misreading of the genetic codes on the mRNA template. Nystatin works by binding to ergosterol in the cell membrane of fungus resulting in a change in the cell wall permeability and leakage of cellular components.
	Interaction : If there is substantial systemic absorption, neomycin may prolong and intensify respiratory depressant effects of neuromuscular blockers.
	Therapeutic class : Clobetasol/Clobetasone & Combined Preparations
	Packsize : 15gm  tube
Aclonac
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Aclopain
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Aclovix
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Acmecilin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Acmecilin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Acmecilin IV/IM
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 5's pack
Acmecilin IV/IM
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 5's pack
Acme's Milk of Magnesia Plus
	n : Liquid Paraffin + Magnesium Hydroxide
	Indications : Constipation
	Doses and administration : Adult: PO Constipation Up to 45 mL/day. Max duration: 1 wk.
									
									The recommended oral dose are as follows-
									
									Adults:
									15-30ml before breakfast or at bedtime.
									
									Children:
									Over 7 years: 7.5ml-15ml at bedtime.
									
									3-7 years: 5-10ml at bedtime.
									
									The dose may be mixed with milk or half a glass of water if desired.
	Contara-indications : Abdominal pain, nausea and vomiting is present; children <3 yr.
	Side effects : Anal irritation (excessive dose) and seepage. Foreign-body granulomatous reactions; vasospasm; lipoid pneumonia; interference with absorption of fat-soluble vitamins. 
	Precaution : Oral: not recommended for use in patients with difficulty swallowing or impaired neurodevelopment. Avoid prolonged use as a laxative or faecal softener. 
	Pregnancy category : 0
	Mode of action : Paraffin: When taken orally: penetrates and softens faecal material. Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
	Interaction : May impair absorption of fat-soluble vitamins and possibly other compounds.
	Therapeutic class : Antacid with laxative action
	Packsize : 120ml bot
Acme's Milk Of Magnesia
	n : Magnesium Hydroxide
	Indications : Heartburn, Constipation, Indigestion, Gastrointestinal hyperacidity, Osmotic laxative
	Doses and administration : Adult: PO: 
									Constipation
									Magnesium hydroxide (400 mg/5 mL): 30-60 mL/day PO at bedtime or in divided doses
									
									Magnesium hydroxide (800 mg/5 mL): 15-30 mL/day PO at bedtime or in divided doses
									
									Child: 
									 2-6 years: 5-15 mL/day of regular-strength liquid PO at bedtime or in divided doses
									 6-12 years: 15-30 mL/day (400 mg/5 mL) or 7.5-15 mL/day (800 mg/5 mL) PO at bedtime or in divided doses
									  >12 years: 30-60 mL/day (400 mg/5 mL) or 15-30 mL/day (800 mg/5 mL) PO at bedtime or in divided doses
									
									Adult:
									Acid Indigestion
									Magnesium hydroxide (400 mg/5 mL): 5-15 mL PO q4hr; no more than 4 doses per 24-hour period.
									
									Child: 
									<12 years: Not recommended
									>12 years: 5-15 mL (400 mg/5 mL) PO q4hr; no more than 4 doses per 24-hour period
									
	Contara-indications : Intestinal obstruction, faecal impaction; renal failure; appendicitis.
	Side effects : GI irritation, diarrhoea, abdominal cramps; hypermagnesaemia (in patients with renal impairment). Paralytic ileus.
	Precaution : Colostomy, ileostomy; electrolyte imbalance. Monitor for toxicity in patients with impaired renal function. Pregnancy.
	Pregnancy category : 1
	Mode of action : Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
	Interaction : Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacid with laxative action
	Packsize : 114ml bot
ACN
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
A-Cof
	n : Dextromethorphan + Pseudoephedrine Hydrochloride +Triprolidine Hydrochloride
	Indications : Flu, Colds, Runny nose, Dry coughs, Non-productive cough, Nasal congestion
	Doses and administration : Adult 2 teaspoonful three times a day.
									
									Children
									Over 12 years 2 teaspoonful three times a day
									6-12 years 1 teaspoonful three times a day
									2-6 years 1/2 teaspoonful three times a day or
									as directed by the physician
	Contara-indications : Patients at risk of developing resp failure. During an acute attack. Patients receiving MAOI or for 2 wk after discontinuing them. Persistent or chronic cough.
	Side effects : Dizziness, GI disturbances.
	Precaution : 3rd trimester of pregnancy; atopic childn; child <1 yr; sedated or debilitated patients; patients confined to supine position; history of asthma. Moderate to severe renal impairment; liver disease.
	Pregnancy category : 3
	Mode of action : Triprolidine is a potent competitive histamine H1-receptor antagonist with mild sedating and antimuscarinic properties. Pseudoephedrine, an ?- and ?-adrenergic receptor agonist, mediates vasoconstriction via direct stimulation of ?-adrenergic receptors of the respiratory mucosa. Dextromethorphan is a centrally acting cough suppressant which acts on the cough centre in the medulla.
	Interaction : Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol.
				Potentially Fatal: Memantine, moclobemide.
				
				Triprolidine + Pseudoephedrine: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine.
				Potentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.
	Therapeutic class : Combined cough suppressants
	Packsize : 100ml bot
Acorex
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Acorex
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100's pack
Acos
	n : Azithromycin
	Indications : Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							
									
	Doses and administration : Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. 
									
									Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. 
									Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. 
									Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. 
									
									IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. 
									
									Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
									
									Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. 
	Contara-indications : Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
	Side effects : GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
									Potentially Fatal: Angioedema and cholestatic jaundice.
	Precaution : May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
	Pregnancy category : 2
	Mode of action : Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
	Interaction : Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
				Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
	Therapeutic class : Macrolides
	Packsize : 6's pack
Acryth
	n : Erythromycin
	Indications : Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.						
									
	Doses and administration : Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. 
									
									Upper respiratory tract infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Lower respiratory infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Respiratory tract infections due to Mycoplasma pneumoniae:  500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.
									
									Skin and soft tissue infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.
									Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae:  500 mg 4 times a day for 10 to 14 days.
									Urogenital infection during pregnancy caused by Chlamydia trachomatis:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Urethral, endocervical or rectal infections, uncomplicated:  500 mg 4 times daily for 7 days or
									250 mg 4 times daily for 14 days.
									
									Non-gonococcal urethritis:  500 mg 4 times daily for at least 7 days.
									Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG):  500 mg 4 times a day for 7 days.
									
									Early syphillis (primary, secondary or latent syphillis of < 1 year duration):  500 mg 4 times a day for 14 days.
									Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever:	250 mg 2 times daily.
									
									Bacterial endocarditis:	1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.
									Acne:	500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.
									
									Children:
									The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled. 
	Contara-indications : Hypersensitivity; porphyria; hepatic impairment; pregnancy.
	Side effects : Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
									Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
	Precaution : Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
	Pregnancy category : 2
	Mode of action : Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
	Interaction : May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
	Therapeutic class : Macrolides
	Packsize : 100ml bot
Act
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Act
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 250's pack
Act
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 15 ml bot
Aceta X
	n : Paracetamol + Caffeine
	Indications : Pain,Fever,Headache,Influenza,Migraine,Sore throat,Backache,Toothache,Rheumatic pain,Dysmenorrhea,Colds
	Doses and administration : Adults : 1-2 tablets every 4-6 hours. Maximum dose: 8 tablets daily. Not recommended for children below 12 years.
	Contara-indications : History of hypersensitivity to any of the components.
	Side effects : Skin rash, diarrhoea, anorexia, GI disturbances, epistaxis (rare).
	Precaution : Severe hepatic or renal disorder.
	Pregnancy category : 3
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
									
									Caffeine, a methylxanthine, is a phosphodiesterase inhibitor. It has an antagonistic effect at central adenosine receptors. It is a CNS and resp stimulant. It has bronchodilating and diuretic properties and it facilitates the performance of muscular work.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non opioid analgesics
	Packsize : 100's pack
Actidex
	n : Dexketoprofen
	Indications : Pain, Dysmenorrhea, Rheumatic disorders
	Doses and administration : Adult: PO Rheumatic disorders 100-200 mg/day in 2-4 divided doses. Max: 300 mg/day in divided doses. Pain and inflammation 25-50 mg 6-8 hrly. Max: 300 mg/day. 
									
									IM Pain and inflammation associated w/ musculoskeletal and joint disorders; Pain following orthopaedic surgery 50-100 mg by deep inj into the gluteal muscle 4 hrly. Max: 200 mg/24 hr for up to 3 days. 
	Contara-indications : Dexketoprofen tablets are not recommended to use in patients who are:
									
									- Allergic to this product or any of its components, aspirin or other non-steroidal anti-inflammatory medicines.
									
									- Have suffered attacks of asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria, angioedema (swollen face, eyes, lips, or tongue, or difficulty in breathing), after taking aspirin or other non-steroidal anti-inflammatory medicines.
									
									- Have or have previously suffered from a peptic ulcer or chronic gastro-intestinal disorders.
									
									- Have had previously gastro-intestinal haemorrhage (bleeding).
									
									- Have suffered from bronchial asthma.
									
									- Have severe heart failure, moderate to severe renal dysfunction or severely impaired hepatic function.
									
									- Have a bleeding disorder, a blood clotting disorder or taking an anticoagulant.
									
									- Pregnant or breast-feeding.
	Side effects : As with all medicines, Dexketoprofen may cause some unwanted effects in some patients. These are described below and are characteristic of non steroidal anti-inflammatory drugs:
									
									- Common (1 - 10%): nausea, vomiting, diarrhoea, stomach pain or heartburn.
									
									- Uncommon (0.1 - 1%): sleep disorders, nervousness, headache, dizziness,vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise.
									
									- Rare (0.01-0.1%): stomach ulceration, gastric haemorrhage or perforation, pins and needles, high blood pressure, water retention, slowed breathing rate, increased hepatic enzymes, increased sweating.
									
									- Very rare / isolated cases (<0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis.
									
									- In patients with systemic lupus erythematosus or mixed connective tissue disease, anti-inflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck).
	Precaution : The medicine should be used with caution in conditions mentioned below:
				- Allergic to any other medicines.
				- Kidney disease, liver disease, heart disease or fluid retention conditions.
				- Blood disorder, systemic lupus erythematosus or mixed connective tissue disease.
	Pregnancy category : 4
	Mode of action : Dexketoprofen exhibits anti-inflammatory, analgesic and antipyretic properties. It potently inhibits the enzyme cyclooxygenase resulting in prostaglandin synthesis inhibition.
	Interaction : Increased risk of GI ulcers & bleeding (synergistic effect) w/ other NSAIDs. Increased risk of haemorrhagic effect of oral anticoagulants. Increased risk of haemorrhage w/ heparin. Increased blood lithium levels, which may reach toxic values, w/ lithium. Increased haematological toxicity of methotrexate at high dose of ?15 mg/wk. Increased toxic effects of hydantoins & sulphonamides. Increase risk of bleeding & damage of GI mucosal w/ anticoagulant. Increase hypoglycemic effect of sulfonylurea agents.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Actifed
	n : Guaiphenesin + Pseudoephedrine Hydrochloride + Triprolidine Hydrochloride
	Indications : Pneumonia, Productive cough, Allergic rhinitis, Sneezing, Respiratory tract disorders, Cough & runny nose, Nasal congestion
	Doses and administration : Adult and Children over 12 years: 10 ml (2 teaspoonful) three times a day.
									Children 6-12 years: 5 ml (1 teaspoonful) three times a day.
									Children 2-5 years: 2.5 ml (1/2 teaspoonful) three times a day.
									
	Contara-indications : Patients with a known hypersensitivity to guaiphenesin, psedoephedrine or triprolidine. Contraindicated in persons under treatment with monoamine oxidase inhibitors within 2 weeks of stopping such treatment.
									Patients with severe hypertension or severe coronary artery disease
	Side effects : Central nervous system (CNS) depression or excitation may occur. Sleep disturbance and rarely hallucination have been reported. Skin rashes, tachycardia, dryness of mouth, nose and throat have occasionally been reported. Urinary retention has been reported occasionally in men receiving pseudoephedrine; prostatic enlargement could have been an important predisposing factor.
	Precaution :  It may cause drowsiness and impair performance in tests of auditory vigilance. It may also impair the patients ability to drive and also to use machineries. So, driving and operation of machineries should be avoided during treatment with Aquaphen. Although there are no objective data, Avoid the concomitant use of alcohol or other centrally acting sedatives.
				Although Pseudoephedrine has virtually no pressor effect in patients with normal blood pressure, Aquaphen should be used with caution in patients taking antihypertensive agents, tricyclic antidepressants or other sympathomimetic agents such as decongestant, appetite suppressants and amphetamine-like psychostimulants.  It effects   on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment.
				As with other sympathomimetic agents, caution should be exercised in patients with hypertension, heart disease, diabetes, hyperthyroidism, elevated intraocular pressure and prostatic enlargement.  It should not be used for persistent or chronic cough such as occurs with smoking, asthma or emphysema or where cough is accompanied by excessive secretions unless directed by a physician.
	Pregnancy category : 3
	Mode of action : Triprolidine hydrochloride is a potent competitive histamine H1-receptor antagonist with antimuscarinic and mild sedative properties.
									
									Pseudoephedrine is both an ?-and ?-adrenergic receptor agonist. It causes vasoconstriction via direct stimulation of ?-adrenergic receptors of the respiratory mucosa. It also directly stimulates ?-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility.
									
									Guaifenesin increases the volume and reduce the viscosity of tenacious sputum and is used as an expectorant for productive cough.
	Interaction : Sympathomimetics eg decongestants, TCAs, appetite suppressants, amphetamine-like psychostimulants; may increase BP w/ MAOIs. Bretylium, bethanidine, guanethidine, debrisoquine, methyldopa, ?- & ?-adrenergic blocker; furazolidone, alcohol, sedatives.
	Therapeutic class : Combined cough expectorants
	Packsize : 100ml bot
Actilac
	n : Lactulose 68 %
	Indications : Constipation, Hepatic encephalopathy
	Doses and administration : Constipation:
									Adults: Initially 15 ml twice daily, adjusted according to patient's need.
									Children: Under 1 year: 2.5 ml twice daily
									1-5 years: 5 ml twice daily
									5-10 years: 10 ml twice daily
									
									Hepatic encephalopathy: 30-50 ml 3 times daily, subsequently adjusted to produce 2-3 soft stools daily.
	Contara-indications : Lactulose is contraindicated in patients with galactosaemia and intestinal obstruction.
	Side effects : Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhoea.
	Precaution : It should be used with caution in patients with lactose intolerance and diabetes.
	Pregnancy category : 2
	Mode of action : Lactulose promotes peristalsis by producing an osmotic effect in the colon with resultant distention. In hepatic encephalopathy, it reduces absorption of ammonium ions and toxic nitrogenous compounds, resulting in reduced blood ammonia concentrations.
	Interaction : May prevent release of mesalazine in the colon. Decreased effect with oral neomycin, antacids.
	Therapeutic class : Osmotic purgatives
	Packsize : 100ml bot/200ml bot
Actinase
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 100ml bot
Actinase
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 20's pack
Actine
	n : Glipizide
	Indications : Type 2 DM
	Doses and administration : Adult: PO Initial: 2.5-5 mg/day as a single dose, may increase slowly. Doses >15 mg may be given in 2 divided doses. Max: 40 mg/day.
									
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Hypersensitivity. Type 1 DM; ketoacidosis; severe renal or hepatic insufficiency. Pregnancy, lactation.
	Side effects : GI upsets, diarrhoea, nausea; allergic skin reactions, leucopenia, thrombocytopenia, agranulocytosis, hyponatraemia; jaundice; haemolytic anaemia, pancytopenia.
									Potentially Fatal: Hypoglycaemia in presence of renal or hepatic damage and alcohol.
	Precaution : Hypoglycaemia, stress, elderly. Thyroid impairment; moderate hepatic or renal impairment. Monitor blood glucose concentration.
	Pregnancy category : 3
	Mode of action : Glipizide stimulates insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Increased plasma concentration w/ certain antifungals (e.g. miconazole, fluconazole). Protein-bound drugs (e.g. NSAIDs, other sulfonamides, oral anticoagulants, hydantoins), probenecid, MAOIs, and chloramphenicol may potentiate hypoglycaemic action of glipizide. Diminished therapeutic effect w/ thiazides, other diuretics, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers, rifampicin and isoniazid. Concomitant use w/ ?-blockers may impair glucose tolerance, increase frequency or severity of hypoglycaemia and block hypoglycaemia-induced tachycardia. Decreased serum concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 50's pack
Actisal
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 50ml bot/100ml bot
Actisal
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 100's pack
Actisal
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 100's pack
Activa
	n : Sildenafil
	Indications : Altitude sickness, Pulmonary arterial hypertension, Erectile dysfunction
	Doses and administration : Oral
									Erectile dysfunction
									Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr.
									Elderly: >65 yr: Lower initial dose at 25 mg.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	Initially, 25 mg.
									
									Hepatic impairment: Initially, 25 mg.
	Contara-indications : Hypersensitivity. Patients concurrently or intermittently using organic nitrates in any form.
	Side effects : Headache, flushing, respiratory tract infection, angina pectoris, AV block, migraine, syncope, tachycardia, postural hypotension, MI, cerebral thrombosis, cardiac arrest, paraesthesia, tremor, depression, herpes simplex, skin ulcer, oesophagitis, abnormal LFT, rectal haemorrhage, hypoglycaemic reaction, arthritis, deafness, retinal vascular disease, photosensitivity, accidental fall.
	Precaution : Caution when used in patients with anatomical deformation of penis or conditions that may predispose them to priapism (e.g. sickle cell anaemia, myeloma, or leukaemia). Mild, transient, dose-related impairment of colour discrimination (blue/green) may occur. Hepatic or severe renal impairment, bleeding disorders, active peptic ulceration, hypotension, recent history of stroke, MI, arrhythmias, unstable angina, heart failure or retinal disorders. May cause sudden loss or decrease in hearing.
	Pregnancy category : 2
	Mode of action : Sildenafil inhibits phosphodiesterase type-5 (PDE5) which is responsible for cGMP degradation in the corpus cavernosum. Inhibition of PDE5 increases cGMP levels in the corpus cavernosum which results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
	Interaction : Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.
				Potentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 4's pack
Activa
	n : Sildenafil
	Indications : Altitude sickness, Pulmonary arterial hypertension, Erectile dysfunction
	Doses and administration : Oral
									Erectile dysfunction
									Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr.
									Elderly: >65 yr: Lower initial dose at 25 mg.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	Initially, 25 mg.
									
									Hepatic impairment: Initially, 25 mg.
	Contara-indications : Hypersensitivity. Patients concurrently or intermittently using organic nitrates in any form.
	Side effects : Headache, flushing, respiratory tract infection, angina pectoris, AV block, migraine, syncope, tachycardia, postural hypotension, MI, cerebral thrombosis, cardiac arrest, paraesthesia, tremor, depression, herpes simplex, skin ulcer, oesophagitis, abnormal LFT, rectal haemorrhage, hypoglycaemic reaction, arthritis, deafness, retinal vascular disease, photosensitivity, accidental fall.
	Precaution : Caution when used in patients with anatomical deformation of penis or conditions that may predispose them to priapism (e.g. sickle cell anaemia, myeloma, or leukaemia). Mild, transient, dose-related impairment of colour discrimination (blue/green) may occur. Hepatic or severe renal impairment, bleeding disorders, active peptic ulceration, hypotension, recent history of stroke, MI, arrhythmias, unstable angina, heart failure or retinal disorders. May cause sudden loss or decrease in hearing.
	Pregnancy category : 2
	Mode of action : Sildenafil inhibits phosphodiesterase type-5 (PDE5) which is responsible for cGMP degradation in the corpus cavernosum. Inhibition of PDE5 increases cGMP levels in the corpus cavernosum which results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
	Interaction : Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.
				Potentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 4's pack
Active PLUS
	n : Betacarotene + Vitamin C + Vitamin E  (Anti-Oxidant Vitamins and Minerals)
	Indications : Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair.
									
	Doses and administration : One tablet/capsule daily or as directed by a physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.
	Pregnancy category : 1
	Mode of action : Beta carotene is 1 of a group of red, orange, and yellow pigments called carotenoids; Dietary sources include fruits, vegetables, and whole grains.  Photoprotective effects: Exact mechanism unknown; in vitro studies suggest antioxidant effects and that beta carotene reduces free radicals and singlet oxygen, which are produced when porphyrin is exposed to light and air.
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin preparations
	Packsize : 30's pack
Activit B
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 100ml
Activit GOLD
	n : Multivitamin and Multimineral A-Z Gold preparations
	Indications : Vitamin/mineral deficiency
	Doses and administration : 1 tablet daily or as recommended by the physician.
	Contara-indications :  Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. 
	Precaution : Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.
	Pregnancy category : 0
	Mode of action : Vitamin A: Helps form and maintain healthy skin, eyes, teeth, gums, hair, mucous membranes and glands.
									
									Vitamin C (Ascorbic Acid): Collagen formation: without it, protocollagen does not cross- link properly, resulting in impaired wound healing.
									
									Vitamin D: Vitamin D helps to regulate calcium metabolism and normal calcification of the bones in the body as well as influencing our utilization of the mineral phosphorus
									
									Vitamin E: Necessary for the formation of normal red blood cells, muscle, and tissue and necessary for immune functions
									
									Vitamin K: Necessary for normal blood coagulation
									
									Vitamin B-Complexes
									
									Thiamine (Vitamin B1): Aids in energy utilization from food by promoting proper carbohydrate metabolism.
									
									Riboflavin (Vitamin B2): Aids in energy utilization from food
									
									Niacin (Vitamin B3): Present in all cells in the body helps convert food into energy; involved in fat, protein, and carbohydrate metabolism
									
									Pyridoxine (Vitamin B6): Important in protein and amino acid metabolism
									
									Folic Acid: Adequate amounts of this B vitamin (folic acid) as part of a healthy diet can help reduce the risk of birth defects of the brain and spine
									
									Cyanocobalamin (Vitamin B12): Helps form red blood cells and build vital genetic material (nucleic acids) for the cell nucleus
									
									Biotin: Necessary for formation of fatty acids & for production of
									
									energy from glucose
									
									Pantothenic Acid (Vitamin B5): Involved in converting carbohydrates, fats and proteins into energy
									
									Calcium: Helps build and maintain strong teeth and bones.
									
									Iron: Necessary for proper formation of oxygen-rich red blood cells & plays important role in the transport of oxygen
									
									Phosphorous: Helps build and maintain teeth and bones
									
									Iodine: Essential for formation of thyroid hormone thyroxin which governs metabolism and growth
									
									Magnesium: Maintains proper levels of calcium and potassium
									
									Zinc: The important antioxidant enzyme, superoxide dismutase (SOD), requires zinc, together with copper and manganese, to function. Zinc is also essential for the metabolism of vitamin A, another important antioxidant, enhance wound healing.
									
									Selenium: Role as an antioxidant in the enzyme selenium-glutathione-peroxidase.
									
									Copper: Involved in brain and red cell function, iron metabolism, bone health and protein synthesis
									
									Manganese: Necessary for normal growth and development, reproduction and cell function
									
									Chromium: Necessary for normal carbohydrate, protein and fat metabolism
									
									Molybdenum: Important for normal cell function
									
									Potassium: It is part of a number of metabolic actions, especially those that involve release of energy
									
									Boron: Boron affects calcium, magnesium, and phosphorus balance and the mineral movement and make up of the bones by regulating the hormones, mainly parathyroid that control these functions.
									
									Nickel: Enhances the body's use of iron
									
									Silicon: May be necessary for normal cartilage, collagen and bone formation. Silicon promotes firmness and strength in the tissues.
									
									Tin: Necessary for normal growth & Cell metabolism.
									
									Vanadium: Pharmacological studies in animals suggest that vanadium may be involved in hormone, glucose, fat, bone and tooth metabolism as well as reproduction and growth.
									
									Lutein: Super antioxidant that provides protection against free radicals.
	Interaction : None
	Therapeutic class : Multi-vitamin & Multi-mineral combined preparations
	Packsize : 15's pack / 30's pack
Activit SILVER
	n : Multivitamin and Multimineral A-Z Silver preparations
	Indications : Vitamin/mineral deficiency
	Doses and administration : 1 tablet daily or as recommended by the physician.
	Contara-indications : patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. 
	Precaution : Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.
	Pregnancy category : 0
	Mode of action : Vitamin A: Helps form and maintain healthy skin, eyes, teeth, gums, hair, mucous membranes and glands.
									
									Vitamin C (Ascorbic Acid): Collagen formation: without it, protocollagen does not cross- link properly, resulting in impaired wound healing.
									
									Vitamin D: Vitamin D helps to regulate calcium metabolism and normal calcification of the bones in the body as well as influencing our utilization of the mineral phosphorus
									
									Vitamin E: Necessary for the formation of normal red blood cells, muscle, and tissue and necessary for immune functions
									
									Vitamin K: Necessary for normal blood coagulation
									
									Vitamin B-Complexes
									
									Thiamine (Vitamin B1): Aids in energy utilization from food by promoting proper carbohydrate metabolism.
									
									Riboflavin (Vitamin B2): Aids in energy utilization from food
									
									Niacin (Vitamin B3): Present in all cells in the body helps convert food into energy; involved in fat, protein, and carbohydrate metabolism
									
									Pyridoxine (Vitamin B6): Important in protein and amino acid metabolism
									
									Folic Acid: Adequate amounts of this B vitamin (folic acid) as part of a healthy diet can help reduce the risk of birth defects of the brain and spine
									
									Cyanocobalamin (Vitamin B12): Helps form red blood cells and build vital genetic material (nucleic acids) for the cell nucleus
									
									Biotin: Necessary for formation of fatty acids & for production of
									
									energy from glucose
									
									Pantothenic Acid (Vitamin B5): Involved in converting carbohydrates, fats and proteins into energy
									
									Calcium: Helps build and maintain strong teeth and bones.
									
									Iron: Necessary for proper formation of oxygen-rich red blood cells & plays important role in the transport of oxygen
									
									Phosphorous: Helps build and maintain teeth and bones
									
									Iodine: Essential for formation of thyroid hormone thyroxin which governs metabolism and growth
									
									Magnesium: Maintains proper levels of calcium and potassium
									
									Zinc: The important antioxidant enzyme, superoxide dismutase (SOD), requires zinc, together with copper and manganese, to function. Zinc is also essential for the metabolism of vitamin A, another important antioxidant, enhance wound healing.
									
									Selenium: Role as an antioxidant in the enzyme selenium-glutathione-peroxidase.
									
									Copper: Involved in brain and red cell function, iron metabolism, bone health and protein synthesis
									
									Manganese: Necessary for normal growth and development, reproduction and cell function
									
									Chromium: Necessary for normal carbohydrate, protein and fat metabolism
									
									Molybdenum: Important for normal cell function
									
									Potassium: It is part of a number of metabolic actions, especially those that involve release of energy
									
									Boron: Boron affects calcium, magnesium, and phosphorus balance and the mineral movement and make up of the bones by regulating the hormones, mainly parathyroid that control these functions.
									
									Nickel: Enhances the body's use of iron
									
									Silicon: May be necessary for normal cartilage, collagen and bone formation. Silicon promotes firmness and strength in the tissues.
									
									Tin: Necessary for normal growth & Cell metabolism.
									
									Vanadium: Pharmacological studies in animals suggest that vanadium may be involved in hormone, glucose, fat, bone and tooth metabolism as well as reproduction and growth.
									
									Lutein: Super antioxidant that provides protection against free radicals.
	Interaction : None
	Therapeutic class : Multi-vitamin & Multi-mineral combined preparations
	Packsize : 15's pack
Activit Z
	n : Vitamin B-complex + Zinc
	Indications : Vitamin B and Zinc deficiencies
	Doses and administration : Adults: 10 ml (2 teaspoonful) 2 to 3 times daily or as recommended by the physician.
									Children: 10 ml (2 teaspoonful) 1 to 3 times daily or as recommended by the physician.
									Infants: 5 ml (1 teaspoonful) 1 to 2 times daily or as recommended by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients of this product.
	Side effects : Generally well tolerated.
	Precaution : None
	Pregnancy category : 0
	Mode of action : Zinc: Cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system; helps maintain a sense of smell and taste; may assist in porper function of insulin.
									Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
									
	Interaction : None
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize :  100ml bot / 200 ml bot
Activit ZI
	n : Iron Polymaltose  +  Vitamin B Complex  +  Zinc
	Indications : Iron, Vitamin-B,  Zinc deficiency
	Doses and administration : Adults: 10 ml (2 teaspoonful) twice daily or as recommended by the physician.
									Children: 5 ml (1 teaspoonful) once or twice daily or as recommended by the physician.
									Infants: 0.33 ml/Kg body weight daily or as recommended by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients of this product. Iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, and hemolytic anemias.
	Side effects : A few side-effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur.
	Precaution : Caution should be taken in the conditions where there is a risk of iron overload, such as haemochromatosis, thalassemia, haemosiderosis or haemolytic anaemia.
	Pregnancy category : 0
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Zinc: Cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system; helps maintain a sense of smell and taste; may assist in porper function of insulin.
									Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
									
	Interaction : None
	Therapeutic class : Iron & Vitamin Combined preparations
	Packsize : 100ml bot
Actizen
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Actizen
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Actol
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Actol
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 200's pack
Actolin
	n : Salbutamol
	Indications : Acute severe asthma, Severe bronchospasm
	Doses and administration : Adult: PO Acute bronchospasm 2-4 mg (up to 8 mg) 3-4 times/day. Extended release 8 mg twice daily. 
									
									Children
									2 - 6 years: 2.5 ml syrup, 3-4 times daily
									6-12 years: 5 ml syrup, 3-4 times daily
									Over 12 years: 5-10 ml syrup, 3-4 times daily (2-4 mg tablet, 3-4 times daily) 
									
									Inhalation Capsule: Adults:
									For the relief of acute asthma or before exercise 400 g (2 ConviCaps). The recommended dose for maintenance treatment or prophylactic therapy is 400 g (2 ConviCaps) three to four times a day. Maximum dose is 1600 g/day.
									
									Children:
									In the treatment of episodic asthma or before exercise 200 g (1 ConviCap). The recommended dose for maintenance treatment or prophylactic treatment is 200 g (1 ConviCap) three to four times a day. Maximum dose is 800 g/day.
									
									As aerosol: Inhalation Acute bronchospasm 100 or 200 mcg 3-4 times/day. 2 puffs may be given prior to exertion to prevent exercise-induced bronchospasm. 
									
									Acute severe asthma As MDI: 4-6 inhalations every 10-20 mins. Severe bronchospasm Via nebuliser: 2.5-5 mg up to 4 times/day.
									
									Children For relief of acute bronchospasm in the maintenance of episodic asthma or before exercise: one 1 puff may be administered as a single dose. 
									
									For routine maintenance and prophylaxis therapy: one 1 puff three or four times daily, increasing if necessary to two puffs three or four times daily. 
									Elderly The dosage is the same as that for adults.
									
									Nebuliser Solution
									Nebuliser Solution is for inhalation use only, to be breathed in through the mouth, under the direction of a physician, using a suitable nebuliser. The solution should not be injected or swallowed.
									Adults (including the elderly): 2.5 mg to 5 mg salbutamol up to four times a day. Up to 40 mg per day can be given under strict medical supervision in hospital.
									
									Children 4 years and above: 2.5 mg to 5 mg up to four times a day.
									Children 18 months to 4 years: 2.5 mg up to four times a day.The dose may be increased to 5 mg if necessary.
									Infants under 18 months old: 1.25 mg (0.25 mg/kg) to 2.5 mg up to four times a day.
									
									Respirator Solution
									By Intermittent Administration : Adult : Respirator Solution 0.5-1.0 ml should be diluted to final volume of 2.0-4.0 ml with normal saline for injection. The resulting solution is inhaled from a suitably driven nebulizer until aerosol generation ceases. Should take about 10 minutes. 
									Respirator Solution may be used undiluted for intermittent administration. For this 2.0 ml of the solution is placed in the nebulizer and the patient allowed to inhale until bronchodilatation is achieved. This usually takes 3-5 minutes. 
									
									Children under 12 years age: 0.5 ml of the solution diluted to 2.0-4.0 ml with normal saline. Intermittent treatment may be repeated four times a day. 
									
									By Continuous Administration :  Respirator Solution is diluted with normal saline for injection, 1-2 ml solution made upto 100 ml with diluent. The diluted solution is administered as an aerosol by a suitably driven nebulizer. The usual rate of administration is 1-2 mg/hour.
	Contara-indications : Salbuatmol inhaler is contraindicated in patients with a history of hypersensitivity to any of its components. Although intravenous Salbutamol, and occasionally Salbutamol tablets, is used in the management of premature labour uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage or toxaemia of pregnancy, Salbutamol inhaler preparations are not appropriate for managing premature labour. Salbutamol preparation should not be used for threatened abortion during the first or second trimesters of pregnancy.
	Side effects : Fine skeletal muscle tremor especially hands, tachycardia, palpitations, muscle cramps, headache, paradoxical bronchospasm, angioedema, urticaria, hypotension and collapse.
									Potentially Fatal: Potentially serious hypokalaemia after large doses.
	Precaution : Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. In the event of previously effective dose of Salbuatmol inhaler failing to give relief for at least three hours, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken.
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with beta-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : Diuretics, corticosteroids and xanthines may augment hypokalaemia. CV effects potentiated by MAOIs, TCAs, sympathomimetics. Increases absorption of sulfamethoxazole when used together. May markedly increase heart rate and BP when used with atomoxetine. Reduces serum levels of digoxin. Hypokalaemia induced by salbutamol increases the risk of digitalis toxicity. BP should be closely monitored if linezolid is used concurrently with salbutamol.
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 100ml bot
Actomeg 500
	n : Metformin Hydrochloride + Pioglitazone
	Indications : Type 2 DM
	Doses and administration : Dosage of this preparation must be individualized on the basis of effectiveness and tolerability while not exceeding the maximum recommended daily dose of Pioglitazone 45 mg and Metformin 2550 mg.  
									
									It may be initiated at either the 15 mg/500 mg twice daily or 15 mg/850 mg once daily with meals to reduce the gastrointestinal side effects associated with Metformin and gradually titrated after assessing adequacy of therapeutic response.
									
									The initial and maintenance dose of  it should be carefully selected in patients with advanced age due to the potential for decreased renal function in these populations. 
									
									Monitoring of renal function is necessary to aid in prevention of Metformin associated lactic acidosis, particularly in the elderly.  It should not be initiated if the patients exhibit clinical evidence of active liver disease. Liver enzyme monitoring is recommended in all patients prior to initiation of therapy with combination of Pioglitazone and Metformin and periodically thereafter. 
	Contara-indications : 1. Renal disease or renal dysfunction (e.g. as suggested by serum creatinine levels >1.5 mg/dl in male, >1.4 mg/dl in females or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction and septicemia.
									2. Known hypersensitivity to Pioglitazone, Metformin or any other component of this combination.
									3. Acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma.
	Side effects : Generally this combined preparation is well tolerated. However, the most common side effects are upper respiratory tract infection, diarrhea, peripheral edema and headache, respectively. These are mild in severity.
	Precaution : Pioglitazone exerts its antihyperglycemic effect only in the presence of insulin. Therefore, Pioglitazone should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Pioglitazone should be used with caution in combination especially with insulin, hepatic insufficiency and heart diseases.
				
				Metformin is known to be substantially excreted by the kidney and the risk of Metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus patients with serum creatinine levels above the upper limit of normal for their age should not receive this combination.
	Pregnancy category : 13
	Mode of action : Pioglitazone is as a potent and highly selective agonist for the peroxisome proliferator activated receptor-gamma. Activation of these receptors promotes the production of gene products involved in lipid and glucose metabolism. It also improves insulin response to target cells witho increasing the pancreatic secretion of insulin. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).
	Interaction : Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.
				Potentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
	Therapeutic class : Combination Oral hypoglycemic preparations
	Packsize : 20's pack
Actomeg 850
	n : Metformin Hydrochloride + Pioglitazone
	Indications : Type 2 DM
	Doses and administration : Dosage of this preparation must be individualized on the basis of effectiveness and tolerability while not exceeding the maximum recommended daily dose of Pioglitazone 45 mg and Metformin 2550 mg.  
									
									It may be initiated at either the 15 mg/500 mg twice daily or 15 mg/850 mg once daily with meals to reduce the gastrointestinal side effects associated with Metformin and gradually titrated after assessing adequacy of therapeutic response.
									
									The initial and maintenance dose of  it should be carefully selected in patients with advanced age due to the potential for decreased renal function in these populations. 
									
									Monitoring of renal function is necessary to aid in prevention of Metformin associated lactic acidosis, particularly in the elderly.  It should not be initiated if the patients exhibit clinical evidence of active liver disease. Liver enzyme monitoring is recommended in all patients prior to initiation of therapy with combination of Pioglitazone and Metformin and periodically thereafter. 
	Contara-indications : 1. Renal disease or renal dysfunction (e.g. as suggested by serum creatinine levels >1.5 mg/dl in male, >1.4 mg/dl in females or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction and septicemia.
									2. Known hypersensitivity to Pioglitazone, Metformin or any other component of this combination.
									3. Acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma.
	Side effects : Generally this combined preparation is well tolerated. However, the most common side effects are upper respiratory tract infection, diarrhea, peripheral edema and headache, respectively. These are mild in severity.
	Precaution : Pioglitazone exerts its antihyperglycemic effect only in the presence of insulin. Therefore, Pioglitazone should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Pioglitazone should be used with caution in combination especially with insulin, hepatic insufficiency and heart diseases.
				
				Metformin is known to be substantially excreted by the kidney and the risk of Metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus patients with serum creatinine levels above the upper limit of normal for their age should not receive this combination.
	Pregnancy category : 13
	Mode of action : Pioglitazone is as a potent and highly selective agonist for the peroxisome proliferator activated receptor-gamma. Activation of these receptors promotes the production of gene products involved in lipid and glucose metabolism. It also improves insulin response to target cells witho increasing the pancreatic secretion of insulin. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).
	Interaction : Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.
				Potentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
	Therapeutic class : Combination Oral hypoglycemic preparations
	Packsize : 20's pack
Actrim
	n : Sulphamethoxazole + Trimethoprim
	Indications : Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
	Doses and administration : Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. 
									Suspension : 1-2 teaspoonful twice daily.
									
									GI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. 
									
									Pneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.
									
									Child: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.
									
									Renal impairment: Dosage reduction for adults and children >12 yr:
									CrCl (ml/min)	
									15-30	Half the standard dose.
									<15	        Not recommended.
	Contara-indications : Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.
	Side effects : Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.
									Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.
	Precaution : G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.
	Pregnancy category : 4
	Mode of action : Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
	Interaction : Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
				Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
	Therapeutic class : Sulphonamides & Trimethoprim
	Packsize : 60ml bot
Actrim
	n : Sulphamethoxazole + Trimethoprim
	Indications : Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
	Doses and administration : Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. 
									Suspension : 1-2 teaspoonful twice daily.
									
									GI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. 
									
									Pneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.
									
									Child: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.
									
									Renal impairment: Dosage reduction for adults and children >12 yr:
									CrCl (ml/min)	
									15-30	Half the standard dose.
									<15	        Not recommended.
	Contara-indications : Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.
	Side effects : Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.
									Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.
	Precaution : G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.
	Pregnancy category : 4
	Mode of action : Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
	Interaction : Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
				Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
	Therapeutic class : Sulphonamides & Trimethoprim
	Packsize : 100's pack
Actrim DS
	n : Sulphamethoxazole + Trimethoprim
	Indications : Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
	Doses and administration : Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. 
									Suspension : 1-2 teaspoonful twice daily.
									
									GI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. 
									
									Pneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.
									
									Child: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.
									
									Renal impairment: Dosage reduction for adults and children >12 yr:
									CrCl (ml/min)	
									15-30	Half the standard dose.
									<15	        Not recommended.
	Contara-indications : Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.
	Side effects : Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.
									Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.
	Precaution : G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.
	Pregnancy category : 4
	Mode of action : Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
	Interaction : Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
				Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
	Therapeutic class : Sulphonamides & Trimethoprim
	Packsize : 100's pack
Actulose
	n : Lactulose 68 %
	Indications : Constipation, Hepatic encephalopathy
	Doses and administration : Constipation:
									Adults: Initially 15 ml twice daily, adjusted according to patient's need.
									Children: Under 1 year: 2.5 ml twice daily
									1-5 years: 5 ml twice daily
									5-10 years: 10 ml twice daily
									
									Hepatic encephalopathy: 30-50 ml 3 times daily, subsequently adjusted to produce 2-3 soft stools daily.
	Contara-indications : Lactulose is contraindicated in patients with galactosaemia and intestinal obstruction.
	Side effects : Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhoea.
	Precaution : It should be used with caution in patients with lactose intolerance and diabetes.
	Pregnancy category : 2
	Mode of action : Lactulose promotes peristalsis by producing an osmotic effect in the colon with resultant distention. In hepatic encephalopathy, it reduces absorption of ammonium ions and toxic nitrogenous compounds, resulting in reduced blood ammonia concentrations.
	Interaction : May prevent release of mesalazine in the colon. Decreased effect with oral neomycin, antacids.
	Therapeutic class : Osmotic purgatives
	Packsize : 100ml bot/200ml bot
Acunac
	n : Bromfenac Sodium 0 .09 %  eye prep
	Indications : Postoperative ocular inflammation, Ocular pain
	Doses and administration : One drop should be applied to the affected eye(s) once daily beginning 1 day prior to surgery,continued on the day of surgery and through 2 weeks after surgery.
	Contara-indications : Bromfenac ophthalmic solution is contraindicated in patients with known hypersensitivity to any ingredients of the formulation.
	Side effects : Abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache and iritis.
	Precaution : Bromfenac ophthalmic solution should be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
				Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
	Pregnancy category : 4
	Mode of action : Nonsteroidal anti-inflammatory agent; inhibits COX-1 and COX-2, which results in decreased formation of prostaglandin precursors
	Interaction : None
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5ml drop
Acupain
	n : Ketorolac Tromethamine
	Indications : Moderate to severe pain
	Doses and administration : Oral
									Moderate to severe pain
									Adult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.
									Elderly: 10 mg every 6-8 hr. Max duration: 7 days.
									Parenteral
									Moderate to severe pain
									Adult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.
									Elderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.
									
									Pediatric Patients (2 to 16 years of age):
									IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
									IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
									
	Contara-indications : Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.
	Side effects : GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).
									Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.
	Precaution : Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.
	Pregnancy category : 4
	Mode of action : Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.
	Interaction : May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.
				Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 30's pack
Acupain
	n : Ketorolac Tromethamine
	Indications : Moderate to severe pain
	Doses and administration : Oral
									Moderate to severe pain
									Adult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.
									Elderly: 10 mg every 6-8 hr. Max duration: 7 days.
									Parenteral
									Moderate to severe pain
									Adult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.
									Elderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.
									
									Pediatric Patients (2 to 16 years of age):
									IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
									IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
									
	Contara-indications : Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.
	Side effects : GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).
									Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.
	Precaution : Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.
	Pregnancy category : 4
	Mode of action : Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.
	Interaction : May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.
				Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 30 mg  amp x 5's pack
Acuren
	n : Hydrochlorothiazide
	Indications : Hypertension, Congestive heart failure, Oedema, Diabetes insipidus, Renal tubular acidosis
	Doses and administration : Oral
									Hypertension
									Adult: Initially, 12.5 mg, may increase to 25-50 mg once daily as necessary either alone or w/ other antihypertensives.
									Child: <6>2-12 yr 1-2 mg/kg/day in 1-2 divided doses Max: 100 mg daily.
									Elderly: 12.5-25 mg once daily, titrate as necessary in increments of 12.5 mg.
									Oedema associated w/ heart failure Usual: 25-100 mg/day in the morning, may reduce based on response. Severe: Up to 200 mg/day. 
									Child: <6>2-12 yr 1-2 mg/kg/day in 1-2 divided doses Max: 100 mg daily.
									Elderly: 12.5-25 mg once daily, titrate as necessary in increments of 12.5 mg.
									
									Nephrogenic diabetes insipidus Initial: Up to 100 mg/day.
	Contara-indications : Severe hepatic and renal impairment, Addison's disease, preexisting hypercalcaemia, anuria, sulphonamide allergy. Pregnancy, lactation.
	Side effects : Volume depletion and electrolyte imbalance, dry mouth, thirst, lethargy, drowsiness, muscle pain and cramps, hypotension, hypersensitivity reactions e.g. rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence, hyperglycaemia; anorexia, gastric irritation, nausea, vomiting, constipation, diarrhoea, sialadenitis, dizziness, raised Ca concentration.
									Potentially Fatal: Hypersensitivity reactions.
	Precaution : Existing electrolyte disturbances, hepatic cirrhosis, severe heart failure, oedema, elderly, renal impairment. Monitor for signs of fluid and electrolyte disturbance. Hepatic impairment, DM, gout, hyperlipidaemia, hypercalcaemia, hyperuricaemia; ECG: LVH and/or ventricular ectopics (extrasystoles). May exacerbate or activate SLE in susceptible patients.
	Pregnancy category : 2
	Mode of action : Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions.
	Interaction : Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
	Therapeutic class : Thiazide diuretics & related drugs
	Packsize : 100's pack
Acuren
	n : Hydrochlorothiazide
	Indications : Hypertension, Congestive heart failure, Oedema, Diabetes insipidus, Renal tubular acidosis
	Doses and administration : Oral
									Hypertension
									Adult: Initially, 12.5 mg, may increase to 25-50 mg once daily as necessary either alone or w/ other antihypertensives.
									Child: <6>2-12 yr 1-2 mg/kg/day in 1-2 divided doses Max: 100 mg daily.
									Elderly: 12.5-25 mg once daily, titrate as necessary in increments of 12.5 mg.
									Oedema associated w/ heart failure Usual: 25-100 mg/day in the morning, may reduce based on response. Severe: Up to 200 mg/day. 
									Child: <6>2-12 yr 1-2 mg/kg/day in 1-2 divided doses Max: 100 mg daily.
									Elderly: 12.5-25 mg once daily, titrate as necessary in increments of 12.5 mg.
									
									Nephrogenic diabetes insipidus Initial: Up to 100 mg/day.
	Contara-indications : Severe hepatic and renal impairment, Addison's disease, preexisting hypercalcaemia, anuria, sulphonamide allergy. Pregnancy, lactation.
	Side effects : Volume depletion and electrolyte imbalance, dry mouth, thirst, lethargy, drowsiness, muscle pain and cramps, hypotension, hypersensitivity reactions e.g. rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence, hyperglycaemia; anorexia, gastric irritation, nausea, vomiting, constipation, diarrhoea, sialadenitis, dizziness, raised Ca concentration.
									Potentially Fatal: Hypersensitivity reactions.
	Precaution : Existing electrolyte disturbances, hepatic cirrhosis, severe heart failure, oedema, elderly, renal impairment. Monitor for signs of fluid and electrolyte disturbance. Hepatic impairment, DM, gout, hyperlipidaemia, hypercalcaemia, hyperuricaemia; ECG: LVH and/or ventricular ectopics (extrasystoles). May exacerbate or activate SLE in susceptible patients.
	Pregnancy category : 2
	Mode of action : Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions.
	Interaction : Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
	Therapeutic class : Thiazide diuretics & related drugs
	Packsize : 100's pack
Acusan
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Acusan Plus
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
				
Acuten
	n : Nefopam Hydrochloride
	Indications : Acute and chronic pain
	Doses and administration : Adult: PO Initial: 60 mg 3 times/day. Usual range: 30-90 mg 3 times/day. Max: 300 mg/day. 
									
									IV 20 mg 4 hrly. Max:120 mg/day. IM 20 mg 6 hrly if needed.
									
									Children: Not recommended for children under the age of 12 years. 
	Contara-indications : History of convulsive disorders.
	Side effects : Nausea, vomiting, sweating, drowsiness, insomnia, urinary retention, dizziness, hypotension, tremor, paraesthesia, palpitations, lightheadedness, nervousness, mental confusion, blurred vision, headache, dry mouth, angioedema, tachycardia, euphoria, hallucinations, convulsions, temporary pink discolouration of the urine.
	Precaution : Glaucoma, urinary retention, hepatic or renal impairment. Elderly. Pregnancy.
	Pregnancy category : 0
	Mode of action : Nefopam is a non-opioid analgesic and though it acts centrally, its mechanism is not defined. It also exerts antimuscarinic and sympathomimetic actions.
	Interaction : Adverse effects increased with antimuscarinic or sympathomimetic drugs. Increased risk of seizures with TCAs. Increased CNS depressant effects with other sedatives.
				Potentially Fatal: Additive sympathomimetic effects with MAOIs.
	Therapeutic class : Non opioid analgesics
	Packsize : 60's pack
Acuten
	n : Nefopam Hydrochloride
	Indications : Acute and chronic pain
	Doses and administration : Adult: PO Initial: 60 mg 3 times/day. Usual range: 30-90 mg 3 times/day. Max: 300 mg/day. 
									
									IV 20 mg 4 hrly. Max:120 mg/day. IM 20 mg 6 hrly if needed.
									
									Children: Not recommended for children under the age of 12 years. 
	Contara-indications : History of convulsive disorders.
	Side effects : Nausea, vomiting, sweating, drowsiness, insomnia, urinary retention, dizziness, hypotension, tremor, paraesthesia, palpitations, lightheadedness, nervousness, mental confusion, blurred vision, headache, dry mouth, angioedema, tachycardia, euphoria, hallucinations, convulsions, temporary pink discolouration of the urine.
	Precaution : Glaucoma, urinary retention, hepatic or renal impairment. Elderly. Pregnancy.
	Pregnancy category : 0
	Mode of action : Nefopam is a non-opioid analgesic and though it acts centrally, its mechanism is not defined. It also exerts antimuscarinic and sympathomimetic actions.
	Interaction : Adverse effects increased with antimuscarinic or sympathomimetic drugs. Increased risk of seizures with TCAs. Increased CNS depressant effects with other sedatives.
				Potentially Fatal: Additive sympathomimetic effects with MAOIs.
	Therapeutic class : Non opioid analgesics
	Packsize : 60's pack
Acyvir
	n : Acyclovir 3%
	Indications : Herpes simplex keratitis
	Doses and administration :  As 3% oint: Apply 5 times/day until 3rd day of complete healing.
	Contara-indications : Hypersensitivity.
	Side effects :  Eye application may produce stinging, superficial punctate keratopathy, blepharitis or conjunctivitis.
	Precaution : Renal impairment. Pregnancy, lactation. Neurological abnormalities with significant hypoxia, serious hepatic or electrolyte abnormalities. Maintain adequate hydration.
	Pregnancy category : 2
	Mode of action : Activity against HSV types I and II and varicella-zoster virus is due to intracellular conversion of aciclovir to the monophosphate by viral thymidine kinase with subsequent conversion to the diphosphate and active triphosphate by cellular enzymes. This active form inhibits viral DNA synthesis and replication by interfering with viral DNA polymerase enzyme and being incorporated into viral DNA.
	Interaction : Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).
	Therapeutic class : Ophthalmic Anti-viral Products
	Packsize : 5 gm tube
Ad - All
	n : Iron + Folic acid + B Complex + Vitamin C + Zinc
	Indications : Vitamin/mineral deficiency during pregnancy and lactation
	Doses and administration : Adults (persons over 12 years of age), One (1) capsule daily, between meals, or as prescribed by a physician. Do not exceed recommended dosage. Do not administer to children under the age of 12.
	Contara-indications :  Patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. Pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.
	Side effects :  Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy. Reducing the dose and administering it with meals will minimize these effects in the sensitive patient. Increasing fiber in the diet can relieve constipation. Iron may turn stools black. This is a harmless effect that is a result of unabsorbed iron. Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I. disturbances. Integra FTM is best absorbed when taken at bedtime.
	Precaution : General: Anemia is a manifestation that requires appropriate investigation to determine its cause or causes. No single regimen fits all cases and the status of the patient observed in follow-up is the final criterion for adequacy of therapy. Periodic clinical and laboratory studies are considered essential. Blood examinations including hemoglobin and hematacrit should be done at the usual intervals to make certain that therapy is adequate. Use with care in the presence of peptic ulcer, regional enteritis, and ulcerative colitis. Folic acid, especially in doses above 0.1 mg -0.4 mg daily may obscure pernicious anemia, in that hematological remission can occur while neurological manifestations remain progressive.
	Pregnancy category : 3
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
									Zinc: Cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system; helps maintain a sense of smell and taste; may assist in porper function of insulin.
									Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									
	Interaction : Iron: Antacids may decrease the absorption of carbonyl iron.
				
				Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
				
				Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.
				
				
				
	Therapeutic class : Iron & Vitamin Combined preparations
	Packsize : 100'pack
Adafil
	n : Tadalafil
	Indications : Erectile dysfunction, signs and symptoms of benign prostatic hyperplasia (BPH)
	Doses and administration : Oral
									Erectile dysfunction
									Adult: Initially, 10 mg at least 30 min before sexual activity once daily, up to 20 mg as single dose. Max: Not more than once daily. If used with potent inhibitors of CYP3A4, e.g. azole antifungals or protease inhibitors: max 10 mg once every 72 hr.
									
									Benign Prostatic Hyperplasia
									The recommended dose  is 5 mg, taken at approximately the same time every day.
									
									Renal impairment:
									CrCl (ml/min)	
									31-50	Initial dose at 5 mg/day. Max: 10 mg/48hr
									<30	        Max: 5 mg/24hr.
									
									Hepatic impairment: Mild-moderate hepatic impairment (Child-Pugh category A or B): Max dose 10 mg. Severe hepatic impairment (Child-Pugh category C): Not recommended.
	Contara-indications : Concurrent use of organic nitrates, nitrates and nitric oxide donors. Men with cardiac disease for whom sexual activity is inadvisable. Recent MI (within 90 days) or stroke (within last 6 mth), hypotension (<90/50 mm Hg), unstable angina, heart failure, uncontrolled arrhythmias or hypertension.
	Side effects : Headache, dyspepsia, dizziness, flushing, swelling of eyelids, eye pain, conjunctival hyperemia, back pain, myalgia, visual disturbances, nasal congestion, sudden decrease or loss of hearing, tinnitus.
									Potentially Fatal: Stevens-Johnson syndrome, exfoliative dermatitis, severe cardiovascular events e.g. MI, stroke, sudden cardiac death;
	Precaution : Hepatic or renal impairment; CV diseases; anatomical penile deformation; predisposition to priapism; child <18 yr. Discontinue and seek medical advice if there is sudden vision loss or decreased vision in one or both eyes or tinnitus, dizziness or sudden loss or decrease in hearing, while taking Tadalafil. Seek immediate medical advice if erection last > 4 hr.
	Pregnancy category : 2
	Mode of action : Tadalafil is a phosphodiesterase type-5 inhibitor.
	Interaction : Concurrent use increased risk of hypotension with beta-blockers; increased risk of priapism with other drugs for erectile dysfunction, e.g. alprostadil; increased heart rate with theophylline; decreased tadalafil serum concentration with CYP 3A4 inducers e.g. rifampicin, efavirenz, carbamazepine, nevirapine, barbiturates, phenobarbital, phenytoin, ribabutin; increased tadalafil serum concentration with CYP3A4 inhibitors e.g. azole antifungals, protease inhibitors, cimetidine, macrolides.
				
				Potentially Fatal: Enhanced hypotensive effect with nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 4's pack
Adafil
	n : Tadalafil
	Indications : Erectile dysfunction, signs and symptoms of benign prostatic hyperplasia (BPH)
	Doses and administration : Oral
									Erectile dysfunction
									Adult: Initially, 10 mg at least 30 min before sexual activity once daily, up to 20 mg as single dose. Max: Not more than once daily. If used with potent inhibitors of CYP3A4, e.g. azole antifungals or protease inhibitors: max 10 mg once every 72 hr.
									
									Benign Prostatic Hyperplasia
									The recommended dose  is 5 mg, taken at approximately the same time every day.
									
									Renal impairment:
									CrCl (ml/min)	
									31-50	Initial dose at 5 mg/day. Max: 10 mg/48hr
									<30	        Max: 5 mg/24hr.
									
									Hepatic impairment: Mild-moderate hepatic impairment (Child-Pugh category A or B): Max dose 10 mg. Severe hepatic impairment (Child-Pugh category C): Not recommended.
	Contara-indications : Concurrent use of organic nitrates, nitrates and nitric oxide donors. Men with cardiac disease for whom sexual activity is inadvisable. Recent MI (within 90 days) or stroke (within last 6 mth), hypotension (<90/50 mm Hg), unstable angina, heart failure, uncontrolled arrhythmias or hypertension.
	Side effects : Headache, dyspepsia, dizziness, flushing, swelling of eyelids, eye pain, conjunctival hyperemia, back pain, myalgia, visual disturbances, nasal congestion, sudden decrease or loss of hearing, tinnitus.
									Potentially Fatal: Stevens-Johnson syndrome, exfoliative dermatitis, severe cardiovascular events e.g. MI, stroke, sudden cardiac death;
	Precaution : Hepatic or renal impairment; CV diseases; anatomical penile deformation; predisposition to priapism; child <18 yr. Discontinue and seek medical advice if there is sudden vision loss or decreased vision in one or both eyes or tinnitus, dizziness or sudden loss or decrease in hearing, while taking Tadalafil. Seek immediate medical advice if erection last > 4 hr.
	Pregnancy category : 2
	Mode of action : Tadalafil is a phosphodiesterase type-5 inhibitor.
	Interaction : Concurrent use increased risk of hypotension with beta-blockers; increased risk of priapism with other drugs for erectile dysfunction, e.g. alprostadil; increased heart rate with theophylline; decreased tadalafil serum concentration with CYP 3A4 inducers e.g. rifampicin, efavirenz, carbamazepine, nevirapine, barbiturates, phenobarbital, phenytoin, ribabutin; increased tadalafil serum concentration with CYP3A4 inhibitors e.g. azole antifungals, protease inhibitors, cimetidine, macrolides.
				
				Potentially Fatal: Enhanced hypotensive effect with nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 4's pack
Adam 33
	n : Prednisolone
	Indications : Rheumatoid arthritis, Multiple sclerosis, Allergic and inflammatory disorders, Nephrotic syndrome, Idiopathic thrombocytopenic purpura, Joint inflammations, Moderate to severe asthma, Infantile spasms
	Doses and administration :  Oral
									Allergic and inflammatory disorders
									Adult: 5-60 mg daily in 2-4 divided doses. Maintenance: 2.5-15 mg daily. Withdrawal should be gradual after long-term therapy.
									
									Child: 1 mth-18 yr: Autoimmune inflammatory disorders: Initially, 1-2 mg/kg once daily; may reduce dose gradually after a few days if needed. Max: 60 mg daily. Autoimmune hepatitis: Initially, 2 mg/kg once daily, then reduce to minimum effective dose. Max: 40 mg daily.
									
									Poorly controlled, moderate to severe asthma
									Adult: Patients with at least 2 exacerbations/yr requiring oral corticosteroids: 40-60 mg daily in 1-2 divided doses; usually given as a short course treatment over 3-10 days until symptom resolution and patient achieves a peak expiratory flow (PEF) of at least 80% of his or her personal best. May be used with maintenance dosages of inhaled corticosteroid and a long-acting inhaled ?2-agonist bronchodilator.
									
									Child: Patients with >3 exacerbations/yr in children ?4 yr or at least 2 exacerbations/yr in children 5-11 yr: 1-2 mg/kg daily for 3-5 days may be used with existing asthma treatment; dose may be given in 1-2 divided doses. Max: 60 mg daily.
									
									Nephrotic syndrome
									Child: 1 mth-18 yr: Initially, 60 mg/m2 (max: 80 mg) once daily for 4 wk until urine is protein-free followed by 40 mg/m2 every other day for 4 wk, then withdraw dose gradually. Prevention of relapse: 0.5-1 mg/kg once daily every other day for 3-6 mth.
									
									Rheumatoid arthritis
									Adult: Initially, 5-7.5 mg daily, adjusted as necessary.
									Elderly: 5 mg daily.
									
									Multiple sclerosis
									Adult: 200 mg daily for 1 wk followed by 80 mg every other day for 1 mth.
									
									Infantile spasms
									Child: 1 mth-2 yr: Initially, 10 mg 4 times daily for 14 days; increase to 20 mg 3 times daily for 7 days if seizures are not controlled after 7 days; reduce dose slowly over 15 days until therapy is stopped. For patients taking 40 mg daily, reduce dose in steps of 10 mg every 5 days, then stop; in patients taking 60 mg daily, reduce dose to 40 mg daily for 5 days, then 20 mg daily for 5 days, then 10 mg daily for 5 days, then stop.
									
									Idiopathic thrombocytopenic purpura
									Child: 1-10 yr: 1-2 mg/kg daily (max: 14 days) or 4 mg/kg daily (max: 4 days). 
	Contara-indications : Live vaccines; herpes simplex keratitis, systemic infections.
	Side effects : Cushing's syndrome and growth retardation in childn; osteoporosis, fractures. Peptic ulceration; glaucoma, cataracts; hyperglycaemia, pancreatitis; increased appetite, obesity. 
									
									Potentially Fatal: Acute adrenal insufficiency precipitated by infection, trauma or surgery in patients on long-term therapy or following cessation of such therapy. CV collapse following rapid IV injection.
	Precaution : Patients with hypothyroidism, cirrhosis, ulcerative colitis, CHF, convulsive disorders, thrombophlebitis, peptic ulcer, elderly. DM, hypertension, psychological disturbances, osteoporosis; pregnancy, lactation. Adrenal suppression and infection. May cause irreversible growth retardation, glaucoma, corneal perforation. 
	Pregnancy category : 3
	Mode of action : Prednisolone decreases inflammation by inhibition of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It suppresses the immune system by reducing the activity and production of the lymphocytes and eosinophils.
	Interaction : Efficacy may be reduced by phenytoin, phenobarb, rifampicin. Corticoids may reduce the effects of diuretics, hypoglycaemics, anticholinesterases, salicylates.
	Therapeutic class : Glucocorticoids
	Packsize : 50's pack
Adam 33
	n : Prednisolone
	Indications : Rheumatoid arthritis, Multiple sclerosis, Allergic and inflammatory disorders, Nephrotic syndrome, Idiopathic thrombocytopenic purpura, Joint inflammations, Moderate to severe asthma, Infantile spasms
	Doses and administration :  Oral
									Allergic and inflammatory disorders
									Adult: 5-60 mg daily in 2-4 divided doses. Maintenance: 2.5-15 mg daily. Withdrawal should be gradual after long-term therapy.
									
									Child: 1 mth-18 yr: Autoimmune inflammatory disorders: Initially, 1-2 mg/kg once daily; may reduce dose gradually after a few days if needed. Max: 60 mg daily. Autoimmune hepatitis: Initially, 2 mg/kg once daily, then reduce to minimum effective dose. Max: 40 mg daily.
									
									Poorly controlled, moderate to severe asthma
									Adult: Patients with at least 2 exacerbations/yr requiring oral corticosteroids: 40-60 mg daily in 1-2 divided doses; usually given as a short course treatment over 3-10 days until symptom resolution and patient achieves a peak expiratory flow (PEF) of at least 80% of his or her personal best. May be used with maintenance dosages of inhaled corticosteroid and a long-acting inhaled ?2-agonist bronchodilator.
									
									Child: Patients with >3 exacerbations/yr in children ?4 yr or at least 2 exacerbations/yr in children 5-11 yr: 1-2 mg/kg daily for 3-5 days may be used with existing asthma treatment; dose may be given in 1-2 divided doses. Max: 60 mg daily.
									
									Nephrotic syndrome
									Child: 1 mth-18 yr: Initially, 60 mg/m2 (max: 80 mg) once daily for 4 wk until urine is protein-free followed by 40 mg/m2 every other day for 4 wk, then withdraw dose gradually. Prevention of relapse: 0.5-1 mg/kg once daily every other day for 3-6 mth.
									
									Rheumatoid arthritis
									Adult: Initially, 5-7.5 mg daily, adjusted as necessary.
									Elderly: 5 mg daily.
									
									Multiple sclerosis
									Adult: 200 mg daily for 1 wk followed by 80 mg every other day for 1 mth.
									
									Infantile spasms
									Child: 1 mth-2 yr: Initially, 10 mg 4 times daily for 14 days; increase to 20 mg 3 times daily for 7 days if seizures are not controlled after 7 days; reduce dose slowly over 15 days until therapy is stopped. For patients taking 40 mg daily, reduce dose in steps of 10 mg every 5 days, then stop; in patients taking 60 mg daily, reduce dose to 40 mg daily for 5 days, then 20 mg daily for 5 days, then 10 mg daily for 5 days, then stop.
									
									Idiopathic thrombocytopenic purpura
									Child: 1-10 yr: 1-2 mg/kg daily (max: 14 days) or 4 mg/kg daily (max: 4 days). 
	Contara-indications : Live vaccines; herpes simplex keratitis, systemic infections.
	Side effects : Cushing's syndrome and growth retardation in childn; osteoporosis, fractures. Peptic ulceration; glaucoma, cataracts; hyperglycaemia, pancreatitis; increased appetite, obesity. 
									
									Potentially Fatal: Acute adrenal insufficiency precipitated by infection, trauma or surgery in patients on long-term therapy or following cessation of such therapy. CV collapse following rapid IV injection.
	Precaution : Patients with hypothyroidism, cirrhosis, ulcerative colitis, CHF, convulsive disorders, thrombophlebitis, peptic ulcer, elderly. DM, hypertension, psychological disturbances, osteoporosis; pregnancy, lactation. Adrenal suppression and infection. May cause irreversible growth retardation, glaucoma, corneal perforation. 
	Pregnancy category : 3
	Mode of action : Prednisolone decreases inflammation by inhibition of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It suppresses the immune system by reducing the activity and production of the lymphocytes and eosinophils.
	Interaction : Efficacy may be reduced by phenytoin, phenobarb, rifampicin. Corticoids may reduce the effects of diuretics, hypoglycaemics, anticholinesterases, salicylates.
	Therapeutic class : Glucocorticoids
	Packsize : 300's pack
Adcal D
	n : Calcium + Vitamin D3
	Indications : Postmenopausal osteoporosis, Osteoporosis, Osteomalacia/rickets, Hypoparathyroidism, Latent tetany, Hypocalcaemia, Calcium and vitamin D deficiency
	Doses and administration : Adult: PO Per tab contains Ca carbonate 1,500 mg and vitamin D3 10 mcg: 1 tab twice daily.
	Contara-indications : Patients with hypercalcaemia and/or hypercalciuria. Nephrolithiasis, hypervitaminosis D, hypophosphataemia.
	Side effects : Constipation, flatulence, nausea, abdominal pain and diarrhoea, pruritus, rash and urticaria.
	Precaution : Impaired calcium absorption in achlorhydria which is common in elderly. Increased risk of hypercalcaemia and hypercalciuria in hypoparathyroid patients receiving high doses of vitamin D. Caution when using in patients with history of kidney stones. Renal impairment; frequent monitoring of serum calcium and phosphorus is recommended.
	Pregnancy category : 3
	Mode of action : Calcium /vitamin D3 prevents or treats negative Ca balance. It also helps facilitate nerve and muscle performance as well as normal cardiac function. Bone mineral component; cofoactor in enzymatic reactions, essential for neurotransmission, muscle contraction, and many signal transduction pathways. Vitamin D3 is a fat-soluble sterol. It is necessary for the regulation and regulation of calcium and phosphate homoeostasis and bone mineralisation. Vitamin D is also essential for healthy bones as it aids in Calcium absorption from the GI tract. In addition to this it stimulates bone formation. Clinical studies also show that Calcium and Vitamin D has synergistic effects on bone growth as well as in Osteoporosis and fracture prevention.
	Interaction : May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 15's pack / 30's pack
Adecef
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Adecef
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 24's pack
Adecef DS
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Adecin
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 30's pack
Adegra
	n : Sildenafil
	Indications : Altitude sickness, Pulmonary arterial hypertension, Erectile dysfunction
	Doses and administration : Oral
									Erectile dysfunction
									Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr.
									Elderly: >65 yr: Lower initial dose at 25 mg.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	Initially, 25 mg.
									
									Hepatic impairment: Initially, 25 mg.
	Contara-indications : Hypersensitivity. Patients concurrently or intermittently using organic nitrates in any form.
	Side effects : Headache, flushing, respiratory tract infection, angina pectoris, AV block, migraine, syncope, tachycardia, postural hypotension, MI, cerebral thrombosis, cardiac arrest, paraesthesia, tremor, depression, herpes simplex, skin ulcer, oesophagitis, abnormal LFT, rectal haemorrhage, hypoglycaemic reaction, arthritis, deafness, retinal vascular disease, photosensitivity, accidental fall.
	Precaution : Caution when used in patients with anatomical deformation of penis or conditions that may predispose them to priapism (e.g. sickle cell anaemia, myeloma, or leukaemia). Mild, transient, dose-related impairment of colour discrimination (blue/green) may occur. Hepatic or severe renal impairment, bleeding disorders, active peptic ulceration, hypotension, recent history of stroke, MI, arrhythmias, unstable angina, heart failure or retinal disorders. May cause sudden loss or decrease in hearing.
	Pregnancy category : 2
	Mode of action : Sildenafil inhibits phosphodiesterase type-5 (PDE5) which is responsible for cGMP degradation in the corpus cavernosum. Inhibition of PDE5 increases cGMP levels in the corpus cavernosum which results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
	Interaction : Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.
				Potentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 4's pack
Adegra
	n : Sildenafil
	Indications : Altitude sickness, Pulmonary arterial hypertension, Erectile dysfunction
	Doses and administration : Oral
									Erectile dysfunction
									Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr.
									Elderly: >65 yr: Lower initial dose at 25 mg.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	Initially, 25 mg.
									
									Hepatic impairment: Initially, 25 mg.
	Contara-indications : Hypersensitivity. Patients concurrently or intermittently using organic nitrates in any form.
	Side effects : Headache, flushing, respiratory tract infection, angina pectoris, AV block, migraine, syncope, tachycardia, postural hypotension, MI, cerebral thrombosis, cardiac arrest, paraesthesia, tremor, depression, herpes simplex, skin ulcer, oesophagitis, abnormal LFT, rectal haemorrhage, hypoglycaemic reaction, arthritis, deafness, retinal vascular disease, photosensitivity, accidental fall.
	Precaution : Caution when used in patients with anatomical deformation of penis or conditions that may predispose them to priapism (e.g. sickle cell anaemia, myeloma, or leukaemia). Mild, transient, dose-related impairment of colour discrimination (blue/green) may occur. Hepatic or severe renal impairment, bleeding disorders, active peptic ulceration, hypotension, recent history of stroke, MI, arrhythmias, unstable angina, heart failure or retinal disorders. May cause sudden loss or decrease in hearing.
	Pregnancy category : 2
	Mode of action : Sildenafil inhibits phosphodiesterase type-5 (PDE5) which is responsible for cGMP degradation in the corpus cavernosum. Inhibition of PDE5 increases cGMP levels in the corpus cavernosum which results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
	Interaction : Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.
				Potentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 4's pack
Adegra
	n : Sildenafil
	Indications : Altitude sickness, Pulmonary arterial hypertension, Erectile dysfunction
	Doses and administration : Oral
									Erectile dysfunction
									Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr.
									Elderly: >65 yr: Lower initial dose at 25 mg.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	Initially, 25 mg.
									
									Hepatic impairment: Initially, 25 mg.
	Contara-indications : Hypersensitivity. Patients concurrently or intermittently using organic nitrates in any form.
	Side effects : Headache, flushing, respiratory tract infection, angina pectoris, AV block, migraine, syncope, tachycardia, postural hypotension, MI, cerebral thrombosis, cardiac arrest, paraesthesia, tremor, depression, herpes simplex, skin ulcer, oesophagitis, abnormal LFT, rectal haemorrhage, hypoglycaemic reaction, arthritis, deafness, retinal vascular disease, photosensitivity, accidental fall.
	Precaution : Caution when used in patients with anatomical deformation of penis or conditions that may predispose them to priapism (e.g. sickle cell anaemia, myeloma, or leukaemia). Mild, transient, dose-related impairment of colour discrimination (blue/green) may occur. Hepatic or severe renal impairment, bleeding disorders, active peptic ulceration, hypotension, recent history of stroke, MI, arrhythmias, unstable angina, heart failure or retinal disorders. May cause sudden loss or decrease in hearing.
	Pregnancy category : 2
	Mode of action : Sildenafil inhibits phosphodiesterase type-5 (PDE5) which is responsible for cGMP degradation in the corpus cavernosum. Inhibition of PDE5 increases cGMP levels in the corpus cavernosum which results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
	Interaction : Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.
				Potentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 4's pack
Adegut
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 50's pack
Adegut
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 60ml bot
Adelax
	n : Flupenthixol + Melitracen
	Indications : Depression, Anxiety, Apathy, Dysphoria
	Doses and administration : Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets.
									Elderly: 1 tablet in the morning.
									Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
	Contara-indications : The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
	Side effects : In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
	Precaution : If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.
	Pregnancy category : 3
	Mode of action : Flupentixol is a thioxanthene antipsychotic that inhibits dopamine-mediated effects by blocking postsynaptic dopamine receptors in the CNS.
									Melitracen is a TCA with anxiolytic properties.
	Interaction :  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).
				Potentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.
				 	Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 80's pack
Adetil
	n : Cefuroxime
	Indications : Pharyngitis, Acute otitis media, Lyme disease, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections,Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Urinary tract infections, Acute bacterial exacerbation of chronic bronchitis, Surgical Prophylaxis
	Doses and administration : Adult: PO Uncomplicated UTI 125 mg twice daily. 
									Resp tract infections 250-500 mg twice daily. 
									Uncomplicated gonorrhoea W/ oral probenecid: 1 g as a single dose.
									 IV Meningitis 3 g 8 hrly. 
									IM Gonorrhoea W/ oral probenecid: 1.5 g as a single dose. 
									IV/IM Surgical prophylaxis 1.5 g IV per-op, then 750 mg IM 8 hrly for up to 24-48 hr. 
									Susceptible infections 750 mg 8 hrly, up to 1.5 g 6-8 hrly for severe infections.
									
									Children (above 3 months of age): 30 - 100 mg/kg/day given in 3 or 4 equally divided doses. A dose of 60mg/kg/day is appropriate for most infections.
									
									Neonate: 30 - 100 mg/kg/day given in 2 or 3 equally divided doses.
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional 750-mg dose after each dialysis; those undergoing continuous peritoneal dialysis may be given 750 mg bid.
									CrCl (ml/min)	
									10-20	750 mg bid.
									<10	750 mg once daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Large doses can cause cerebral irritation and convulsions; nausea, vomiting, diarrhoea, GI disturbances; erythema multiforme, Stevens-Johnson syndrome, epidermal necrolysis.
									Potentially Fatal: Anaphylaxis, nephrotoxicity, pseudomembranous colitis.
	Precaution : Severe renal impairment; pregnancy, lactation; hypersensitivity to penicillins.
	Pregnancy category : 2
	Mode of action : Cefuroxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 10's pack
Adetil
	n : Cefuroxime
	Indications : Pharyngitis, Acute otitis media, Lyme disease, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections,Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Urinary tract infections, Acute bacterial exacerbation of chronic bronchitis, Surgical Prophylaxis
	Doses and administration : Adult: PO Uncomplicated UTI 125 mg twice daily. 
									Resp tract infections 250-500 mg twice daily. 
									Uncomplicated gonorrhoea W/ oral probenecid: 1 g as a single dose.
									 IV Meningitis 3 g 8 hrly. 
									IM Gonorrhoea W/ oral probenecid: 1.5 g as a single dose. 
									IV/IM Surgical prophylaxis 1.5 g IV per-op, then 750 mg IM 8 hrly for up to 24-48 hr. 
									Susceptible infections 750 mg 8 hrly, up to 1.5 g 6-8 hrly for severe infections.
									
									Children (above 3 months of age): 30 - 100 mg/kg/day given in 3 or 4 equally divided doses. A dose of 60mg/kg/day is appropriate for most infections.
									
									Neonate: 30 - 100 mg/kg/day given in 2 or 3 equally divided doses.
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional 750-mg dose after each dialysis; those undergoing continuous peritoneal dialysis may be given 750 mg bid.
									CrCl (ml/min)	
									10-20	750 mg bid.
									<10	750 mg once daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Large doses can cause cerebral irritation and convulsions; nausea, vomiting, diarrhoea, GI disturbances; erythema multiforme, Stevens-Johnson syndrome, epidermal necrolysis.
									Potentially Fatal: Anaphylaxis, nephrotoxicity, pseudomembranous colitis.
	Precaution : Severe renal impairment; pregnancy, lactation; hypersensitivity to penicillins.
	Pregnancy category : 2
	Mode of action : Cefuroxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 6's pack
Adexim
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 50ml bot
Adexim
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 6's pack
Adfovir
	n : Adefovir Dipivoxil
	Indications : Herpes simplex virus, Chronic hepatitis B
	Doses and administration : Adult: PO: The recommended dose of Adefovir for the treatment of chronic hepatitis B in adolescent & adults (age > 12 year) with adequate renal function is 10 mg, once daily, taken orally, without regard to food. 
									
									Renal impairment: Haemodialysis patients: 10 mg every 7 days after dialysis.
									CrCl (ml/min)	
									20-49	10 mg every 48 hr.
									10-19	10 mg every 72 hr.
									
									
									Dose Adjustment in Renal Impairment: Significantly increased drug exposures are seen when Adefovir Dipivoxil is administered to patients with renal impairment. Therefore, the dosing interval of Adefovir Dipivoxil should be adjusted in patients with baseline creatinine clearance < 50 mL/min using the following suggested guidelines- Dosing interval adjustment of Adefovir in patients with renal impairment Creatinine clearance (mL/min) > 50 20 to 49 10 to 19 < 10 Hemodialysis or CAPD Recommended dose and dosing interval 10 mg every 24 hours 10 mg every 48 hours 10 mg every 72 hours 10 mg every 7 days.
									
	Contara-indications : Adefovir Dipivoxil is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product.
	Side effects : Nausea, dyspepsia, abdominal pain, flatulence, diarrhoea, asthenia, headache. Pruritus, skin rashes, and respiratory effects e.g. cough, pharyngitis and sinusitis.Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis, hepatotoxicity, nephrotoxicity.
	Precaution : Pregnancy; elderly; child; renal or hepatic impairment. HIV antibody testing to be performed before initiation due to possible resistance development in untreated HIV infection. Increased risk of hepatotoxicity in females, obese patients and with prolonged treatment. Monitor renal function every 3 mth; hepatitis B biochemical, viral and serological markers every 6 mth and LFTs. Discontinue therapy if liver function worsens, severe hepatomegaly, steatosis or unexplained metabolic or lactic acidosis. Monitor hepatic function for several mth in patients whose antihepatitis therapy is discontinued as acute exacerbations of hepatitis may occur.
	Pregnancy category : 3
	Mode of action : Adefovir dipivoxil is an acyclic nucleoside reverse transciptase inhibitor. The diester function is hydrolyzed and subsequently phosphorylated to the active adefovir diphosphate. The active metabolite inhibits HBV DNA polymerase (reverse transcriptase) and hence inhibits viral replication. It can be used in patients with lamivudine-resistant hepatitis B.
	Interaction : Increased risk of nephrotoxicity with nephrotoxic drugs e.g. aminoglycosides, ciclosporin, NSAIDs, vancomycin, tacrolimus. Ibuprofen increases bioavailability of adefovir.
	Therapeutic class : Hepatic viral infections (Hepatitis B)
	Packsize : 10's pack
Adgar 0.1%
	n : Adapalene 0.1%
	Indications : Acne, Keratosis pilaris
	Doses and administration : Adult: Topical As 0.1% soln/cream/gel: Apply once daily at night.
	Contara-indications : Hypersensitivity.
	Side effects : Mild skin irritation, scaling, erythema, cutaneous dryness, sensations of stinging and burning, pruritus.
	Precaution : Patients with sunburn, eczema. Pregnancy, lactation. Avoid excessive exposure to sunlight or UV irradiation. Keep away from the eyes, lips, nostrils and mucous membranes. Do not apply to cuts, abrasions, scaly or flaky skin, or patches of sunburned skin. Use with caution with preparations containing sulfur, resorcinol, or salicylic acid.
	Pregnancy category : 3
	Mode of action : Adapalene binds to specific retinoic acid nuclear receptors which normalises the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.
	Interaction : Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.
	Therapeutic class : Topical antibiotic & retinoid preparations
	Packsize : 10g
Adgar 0.3%
	n : Adapalene 0.3%
	Indications : Acne
	Doses and administration : Adult: Topical As 0.3% soln/cream/gel: Apply once daily at night.
	Contara-indications : Hypersensitivity.
	Side effects : Mild skin irritation, scaling, erythema, cutaneous dryness, sensations of stinging and burning, pruritus.
	Precaution : Patients with sunburn, eczema. Pregnancy, lactation. Avoid excessive exposure to sunlight or UV irradiation. Keep away from the eyes, lips, nostrils and mucous membranes. Do not apply to cuts, abrasions, scaly or flaky skin, or patches of sunburned skin. Use with caution with preparations containing sulfur, resorcinol, or salicylic acid.
	Pregnancy category : 3
	Mode of action : Adapalene binds to specific retinoic acid nuclear receptors which normalises the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.
	Interaction : Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.
	Therapeutic class : Topical retinoid and related preparations
	Packsize : 10g
Adglim
	n : Glimepiride
	Indications : Type 2 DM
	Doses and administration : Oral
									Type 2 diabetes mellitus
									Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
									Elderly: Initially, 1 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Diabetic ketoacidosis with or without coma.
	Side effects : Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.
	Precaution : Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Adglim
	n : Glimepiride
	Indications : Type 2 DM
	Doses and administration : Oral
									Type 2 diabetes mellitus
									Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
									Elderly: Initially, 1 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Diabetic ketoacidosis with or without coma.
	Side effects : Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.
	Precaution : Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Adinir
	n : Cefdinir
	Indications : Community-acquired pneumonia, Susceptible infections, Sinusitis, Otitis media, Sore throat, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Acute Maxillary Sinusitis
	Doses and administration : Adult: PO 600 mg once daily.  Once-daily dosing for 10 days is as effective as BID dosing.
									Child:
									The total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	 300 mg once daily. 
	Contara-indications : Hypersensitivity.
	Side effects : Headache, dizziness, fever; nausea, vomiting, diarrhoea, abdominal pain; rash; leukopaenia, thrombocytopaenia, haemolytic anaemia.
									Potentially Fatal: Anaphylaxis; renal and hepatic failure.
	Precaution : Penicillin-sensitive patients; superinfection; seizure; pseudomembranous colitis; pregnancy, lactation; renal or hepatic insufficiency.
	Pregnancy category : 2
	Mode of action : Cefdinir binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concomitant admin w/ antacids or Fe supplements reduce the rate and extent of absorption. Admin w/ Fe supplements may cause reddish stools. Decreased renal elimination w/ probenecid.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 60ml bot
Adinir
	n : Cefdinir
	Indications : Community-acquired pneumonia, Susceptible infections, Sinusitis, Otitis media, Sore throat, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Acute Maxillary Sinusitis
	Doses and administration : Adult: PO 600 mg once daily.  Once-daily dosing for 10 days is as effective as BID dosing.
									Child:
									The total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	 300 mg once daily. 
	Contara-indications : Hypersensitivity.
	Side effects : Headache, dizziness, fever; nausea, vomiting, diarrhoea, abdominal pain; rash; leukopaenia, thrombocytopaenia, haemolytic anaemia.
									Potentially Fatal: Anaphylaxis; renal and hepatic failure.
	Precaution : Penicillin-sensitive patients; superinfection; seizure; pseudomembranous colitis; pregnancy, lactation; renal or hepatic insufficiency.
	Pregnancy category : 2
	Mode of action : Cefdinir binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concomitant admin w/ antacids or Fe supplements reduce the rate and extent of absorption. Admin w/ Fe supplements may cause reddish stools. Decreased renal elimination w/ probenecid.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 8's pack
Adiponil
	n : Orlistat
	Indications : Obesity
	Doses and administration : Adult: PO 120 mg 3 times/day with each main meal. (Should be taken with food. Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted).
	Contara-indications : Chronic malabsorption syndrome. Cholestasis. Lactation
	Side effects : Faecal urgency and incontinence, flatulence, fatty stools or discharge, increased defecation; headache, anxiety, fatigue, menstrual irregularities; abdominal pain/discomfort.
									Potentially Fatal: Anaphylaxis; angioedema.
	Precaution : Distribute daily intake of fat over 3 main meals. Fat-soluble vitamins supplements may be required during long-term therapy. Discontinue use if 5% body wt loss is not achieved during the first 12 wk. History of hyperoxaluria or calcium oxalate nephrolithiasis. DM. Pregnancy.
	Pregnancy category : 2
	Mode of action : Orlistat is a reversible gastric and pancreatic lipase inhibitor. It exerts antiobesity effects by limiting the absorption of dietary fats through inhibition of triglyceride hydrolysis. It does not exert appetite suppressant effects.
	Interaction : May decrease absorption of oral fat-soluble vitamins, amiodarone, propafenone. May decrease plasma levels of ciclosporin. May alter the effects of warfarin (monitor INR). May elevate plasma levels of pravastatin.
	Therapeutic class : Appetite suppressant drugs/Anti-obesity drugs
	Packsize : 10's pack
Adiva
	n : Efavirenz
	Indications : HIV infection
	Doses and administration : Oral
									HIV infection
									Adult: Combined with other antiretrovirals: 600 mg once daily. Dosing at bedtime recommended during 1st 2-4 wk of therapy to improve tolerability.
									
									Child: Combined with other antiretrovirals: >3 yr, 10-14 kg: 200 mg; 15-19 kg: 250 mg; 20-24 kg: 300 mg; 25-32.4 kg: 350 mg; 32.5-39 kg: 400 mg; ?40 kg: 600 mg. To be taken once daily.
	Contara-indications : Severe hepatic impairment; hypersensitivity; lactation.
	Side effects : Rash including Stevens-Johnson syndrome and erythema multiforme; CNS effects e.g. dizziness, headache, insomnia, somnolence, abnormal dreams, fatigue, impaired concentration. Nausea, less frequently, vomiting, diarrhoea, hepatitis, depression, anxiety, psychosis, amnesia and ataxia, stupor, vertigo, abdominal pain, hepatic failure, pancreatitis, convulsions, gynaecomastia, pruritus, blurred vision.
	Precaution : Mild to moderate liver disease; renal impairment. Monitor liver enzymes and cholesterol. Discontinue if severe skin rash or fever develops; known or suspected hepatitis B or infection. History of mental illness or seizures; elderly. Pregnancy. Children.
	Pregnancy category : 4
	Mode of action : Efavirenz, a non-nucleoside reverse transcriptase inhibitor with activity against HIV, blocks the RNA-dependent and DNA-dependent polymerase activities including HIV replication.
	Interaction : Hormonal contraceptives; antibacterial e.g. rifampicin, rifabutin, clarithromycin; enzyme inducers. St. John's wort may decrease serum level. Ethanol (hepatic and CNS adverse effects).
				Potentially Fatal: Life-threatening adverse effects when used with terfenadine, astemizole, cisapride, midazolam, triazolam and ergot alkaloids.
	Therapeutic class : Drugs for HIV / Anti-retroviral drugs
	Packsize : 10's pack
Adiz
	n : Azithromycin
	Indications : Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							
									
	Doses and administration : Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. 
									
									Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. 
									Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. 
									Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. 
									
									IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. 
									
									Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
									
									Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. 
	Contara-indications : Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
	Side effects : GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
									Potentially Fatal: Angioedema and cholestatic jaundice.
	Precaution : May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
	Pregnancy category : 2
	Mode of action : Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
	Interaction : Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
				Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
	Therapeutic class : Macrolides
	Packsize : 15ml bot/30ml bot
Adiz
	n : Azithromycin
	Indications : Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							
									
	Doses and administration : Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. 
									
									Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. 
									Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. 
									Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. 
									
									IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. 
									
									Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
									
									Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. 
	Contara-indications : Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
	Side effects : GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
									Potentially Fatal: Angioedema and cholestatic jaundice.
	Precaution : May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
	Pregnancy category : 2
	Mode of action : Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
	Interaction : Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
				Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
	Therapeutic class : Macrolides
	Packsize : 8's pack
Adlock
	n : Propranolol Hydrochloride
	Indications : Tuberculosis, Hypertrophic cardiomyopathy, MI, Anxiety, Diabetic nephropathy, HTN, Cardiac arrhythmias, Angina pectoris, Phaeochromocytoma, Migraine prophylaxis, Essential tremor
	Doses and administration : Adults
									Hypertension: As starting dose of 80mg twice a day may increased at weekly intervals according to response. The usual dose range is 160-320mg per day. With concurrentdiuretic or other antihypertensive drugs a further reduction of blood pressure is obtained.
									
									Angina, anxiety,migraine and essential tremor:
									A staring dose of 40mg two or three times daily may be increased by the same amount at weekly intervals according to patients response. An adequate response in anxiety, migraine and essential tremor is usually seen in the range 80-160mg/day and an angina in the range 120-240mg/day.
									
									Situational and generalized anxiety:
									A dose of 40mg daily may provide short term relief of acute situational anxiety.
									Generalized anxiety require long term therapy, usually responds adequately to 40mg twice daily which, which individual cases, may be increased to 40mg three times daily. Treatment should be continued according to responses. Patients shouldreviewed after 6 to12 months treatment.
									
									Dysarhythmias, anxiety tachycardia, hypertrophic obstructive cardiomyopathy and thyrotoxicosis:
									A dosage range of 10-40mg three or four times a day usually achieves the required response.
									
									Post myocardial infarction:Treatment should be started between days 5 and after 21 after myocardial infarction,with an initial dose of 40mg four times a day for 2 or 3 days. In order to improve compliance the total daily doses three after be given as 80mg twice a day.
									
									Phaeochromocytoma (Used only with an alpha receptor blocking drug).
									Pre-operative: 60mg daily for three days. Non-operable malignant cases: 30mg daily.
									
									Children: Sysrhythmias, Phaeochromocytoma,Thyrotoxicisis: Dosage should be individually determined and the following is only a guide.0.25-0.5mg/kg three or four times daily as required.
									
									Migraine Under 12 years: 20mg two or three times daily.
									Over 12 years: The adult dose.
									
									As Extended release Capsule:
									Hypertension
									Dosage Must Be Individualized. The usual initial dosage is 80 mg propranolol hydrochloride extended-release capsules once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks.
									
									Angina Pectoris
									
									Dosage Must Be Individualized. Starting with 80 mg propranolol hydrochloride extended-release capsules once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established.
									
									If treatment is to be discontinued, reduce dosage gradually over a period of a few weeks.
									
									Migraine
									Dosage Must Be Individualized. The initial oral dose is 80 mg propranolol hydrochloride extended-release capsules once daily. The usual effective dose range is 160 to 240 mg once daily. The dosage may be increased gradually to achieve optimal migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximal dose, propranolol hydrochloride extended-release capsules therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks.
									
									Hypertrophic Subaortic Stenosis
									80 mg to 160 mg propranolol hydrochloride extended-release capsules once daily.
									
									
	Contara-indications : Propranolol hydrochloride is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3) bronchial asthma; 4) congestive heart failure (see WARNINGS), unless the failure is secondary to a tachyarrhythmia treatable with propranolol hydrochloride.
	Side effects : Most adverse effects have been mild and transient and have rarely required the withdrawal of therapy.
									
									Cardiovascular: Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.
									
									Central Nervous System: Lightheadedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate formulations, fatigue, lethargy, and vivid dreams appear dose related.
									
									Gastrointestinal: Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, and ischemic colitis.
									
									Allergic: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, pharyngitis and agranulocytosis, erythematous rash, fever combined with aching and sore throat, laryngospasm, and respiratory distress.
									
									Respiratory: Bronchospasm.
									
									Hematologic: Agranulocytosis, nonthrombocytopenic purpura, and thrombocytopenic purpura.
									
									Skin: Stevens-Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria.
	Precaution : Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol is not indicated for the treatment of hypertensive emergencies.
				
				Beta-adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that propranolol may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.
				
				Risk of Anaphylactic Reaction
				
				
				While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
	Pregnancy category : 4
	Mode of action : Propranolol is a non-cardioselective ?-blocker that competitively blocks ?1- and ?2-receptors resulting in decreased heart rate, myocardial contractility, BP and myocardial oxygen demand. It has membrane-stabilising properties.
	Interaction : Antidiabetics, verapamil, diltiazem, lignocaine, ergotamine, dihydroergotamine, indomethacin, chlorpromazine, anaesth, disopyramide, quinidine, amiodarone, digitalis glycosides, cimetidine, hydralazine, adrenaline, alcohol.
	Therapeutic class : Beta-adrenoceptor blocking drugs
	Packsize : 100's pack
Adlock
	n : Propranolol Hydrochloride
	Indications : Tuberculosis, Hypertrophic cardiomyopathy, MI, Anxiety, Diabetic nephropathy, HTN, Cardiac arrhythmias, Angina pectoris, Phaeochromocytoma, Migraine prophylaxis, Essential tremor
	Doses and administration : Adults
									Hypertension: As starting dose of 80mg twice a day may increased at weekly intervals according to response. The usual dose range is 160-320mg per day. With concurrentdiuretic or other antihypertensive drugs a further reduction of blood pressure is obtained.
									
									Angina, anxiety,migraine and essential tremor:
									A staring dose of 40mg two or three times daily may be increased by the same amount at weekly intervals according to patients response. An adequate response in anxiety, migraine and essential tremor is usually seen in the range 80-160mg/day and an angina in the range 120-240mg/day.
									
									Situational and generalized anxiety:
									A dose of 40mg daily may provide short term relief of acute situational anxiety.
									Generalized anxiety require long term therapy, usually responds adequately to 40mg twice daily which, which individual cases, may be increased to 40mg three times daily. Treatment should be continued according to responses. Patients shouldreviewed after 6 to12 months treatment.
									
									Dysarhythmias, anxiety tachycardia, hypertrophic obstructive cardiomyopathy and thyrotoxicosis:
									A dosage range of 10-40mg three or four times a day usually achieves the required response.
									
									Post myocardial infarction:Treatment should be started between days 5 and after 21 after myocardial infarction,with an initial dose of 40mg four times a day for 2 or 3 days. In order to improve compliance the total daily doses three after be given as 80mg twice a day.
									
									Phaeochromocytoma (Used only with an alpha receptor blocking drug).
									Pre-operative: 60mg daily for three days. Non-operable malignant cases: 30mg daily.
									
									Children: Sysrhythmias, Phaeochromocytoma,Thyrotoxicisis: Dosage should be individually determined and the following is only a guide.0.25-0.5mg/kg three or four times daily as required.
									
									Migraine Under 12 years: 20mg two or three times daily.
									Over 12 years: The adult dose.
									
									As Extended release Capsule:
									Hypertension
									Dosage Must Be Individualized. The usual initial dosage is 80 mg propranolol hydrochloride extended-release capsules once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks.
									
									Angina Pectoris
									
									Dosage Must Be Individualized. Starting with 80 mg propranolol hydrochloride extended-release capsules once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established.
									
									If treatment is to be discontinued, reduce dosage gradually over a period of a few weeks.
									
									Migraine
									Dosage Must Be Individualized. The initial oral dose is 80 mg propranolol hydrochloride extended-release capsules once daily. The usual effective dose range is 160 to 240 mg once daily. The dosage may be increased gradually to achieve optimal migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximal dose, propranolol hydrochloride extended-release capsules therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks.
									
									Hypertrophic Subaortic Stenosis
									80 mg to 160 mg propranolol hydrochloride extended-release capsules once daily.
									
									
	Contara-indications : Propranolol hydrochloride is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3) bronchial asthma; 4) congestive heart failure (see WARNINGS), unless the failure is secondary to a tachyarrhythmia treatable with propranolol hydrochloride.
	Side effects : Most adverse effects have been mild and transient and have rarely required the withdrawal of therapy.
									
									Cardiovascular: Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.
									
									Central Nervous System: Lightheadedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate formulations, fatigue, lethargy, and vivid dreams appear dose related.
									
									Gastrointestinal: Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, and ischemic colitis.
									
									Allergic: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, pharyngitis and agranulocytosis, erythematous rash, fever combined with aching and sore throat, laryngospasm, and respiratory distress.
									
									Respiratory: Bronchospasm.
									
									Hematologic: Agranulocytosis, nonthrombocytopenic purpura, and thrombocytopenic purpura.
									
									Skin: Stevens-Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria.
	Precaution : Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol is not indicated for the treatment of hypertensive emergencies.
				
				Beta-adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that propranolol may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.
				
				Risk of Anaphylactic Reaction
				
				
				While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
	Pregnancy category : 4
	Mode of action : Propranolol is a non-cardioselective ?-blocker that competitively blocks ?1- and ?2-receptors resulting in decreased heart rate, myocardial contractility, BP and myocardial oxygen demand. It has membrane-stabilising properties.
	Interaction : Antidiabetics, verapamil, diltiazem, lignocaine, ergotamine, dihydroergotamine, indomethacin, chlorpromazine, anaesth, disopyramide, quinidine, amiodarone, digitalis glycosides, cimetidine, hydralazine, adrenaline, alcohol.
	Therapeutic class : Beta-adrenoceptor blocking drugs
	Packsize : 100's pack
Adlorin
	n : Desloratadine
	Indications : Itching, Sneezing, Watery eyes, Allergic conditions, Runny nose, Hives, Skin rash, Common cold
	Doses and administration : Adults and adolescent of 12 years or over : 5 mg once daily.
									Child 6-11 years : 2.5 mg once daily.
									Child 12 months-5 years : 1.25 mg (2.5 ml syrup) once daily.
									Child 6 months-11 months : 1 mg (2 ml syrup) once daily.
	Contara-indications : Hypersensitivity.
	Side effects : Headache, fatigue, somnolence, dizziness; nausea, dyspepsia; xerostomia, dysmenorrhoea; pharyngitis.
	Precaution : Severe renal or hepatic failure; children <6 mth, elderly, epilepsy, pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Desloratadine is a long-acting, tricyclic, non-sedating, selective peripheral histamine H1-receptor antagonist which inhibits the release of pro-inflammatory mediators from human mast cells and basophils.
	Interaction :  	Potential increase in plasma concentrations w/ drugs affecting hepatic microsomal enzymes (e.g. azithromycin, cimetidine, erythromycin, fluoxetine, ketoconazole).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize :  100's pack
Admira
	n : Gliclazide
	Indications : Type 2 DM
	Doses and administration : Adult: PO Initial: 40-80 mg/day, increase slowly if needed. Doses >160 mg/day may be given in 2 divided doses.
	Contara-indications : Type 1 DM, diabetes complicated with ketoacidosis; hypersensitivity; severe renal and hepatic impairment. Pregnancy and lactation.
	Side effects : GI disturbances, skin reaction, leucopenia, thrombocytopenia, agranulocytosis, haemolytic anaemia, cholestatic jaundice, vomiting, diarrhoea, gastritis, increased transaminases.
	Precaution : Monitor blood glucose concentration. May require insulin during metabolic stress. Care when transferring from combination therapy. Increased risk of severe hypoglycaemia in elderly, debilitated patients, patients with hepatic or renal impairment. Risk of hypogylcaemia when caloric intake is deficient, after strenuous exercise, when taken with ethanol or when >1 antidiabetic drug is used.
	Pregnancy category : 3
	Mode of action : Gliclazide stimulates insulin secretion from pancreatic ?-cells, reduces insulin uptake and glucose output by the liver, and increases insulin sensitivity at peripheral target sites. It decreases microthrombosis by partial inhibition of platelet aggregation and adhesion, and by restoring fibrinolysis w/ an increase in tissue plasminogen activator (t-PA) activity.
	Interaction : May increase hypoglycaemic effect w/ phenylbutazone. Potentiation of blood glucose lowering effect w/ other antidiabetics (e.g. acarbose, insulins, metformin), ?-blockers, ACE inhibitors, H2-receptor antagonists, MAOIs, sulfonamides, clarithromycin and NSAIDs. Chlorpromazine, glucocorticoids, ritodrine, salbutamol and terbutaline may cause increases in blood glucose levels. May diminish hypoglycaemic effect w/ danazol. May increase anticoagulant effect of warfarin.
				Potentially Fatal: Increased hypoglycaemic effect w/ miconazole
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Admira MR
	n : Gliclazide
	Indications : Type 2 DM
	Doses and administration : Adult: PO Initial: 40-80 mg/day, increase slowly if needed. Doses >160 mg/day may be given in 2 divided doses.
	Contara-indications : Type 1 DM, diabetes complicated with ketoacidosis; hypersensitivity; severe renal and hepatic impairment. Pregnancy and lactation.
	Side effects : GI disturbances, skin reaction, leucopenia, thrombocytopenia, agranulocytosis, haemolytic anaemia, cholestatic jaundice, vomiting, diarrhoea, gastritis, increased transaminases.
	Precaution : Monitor blood glucose concentration. May require insulin during metabolic stress. Care when transferring from combination therapy. Increased risk of severe hypoglycaemia in elderly, debilitated patients, patients with hepatic or renal impairment. Risk of hypogylcaemia when caloric intake is deficient, after strenuous exercise, when taken with ethanol or when >1 antidiabetic drug is used.
	Pregnancy category : 3
	Mode of action : Gliclazide stimulates insulin secretion from pancreatic ?-cells, reduces insulin uptake and glucose output by the liver, and increases insulin sensitivity at peripheral target sites. It decreases microthrombosis by partial inhibition of platelet aggregation and adhesion, and by restoring fibrinolysis w/ an increase in tissue plasminogen activator (t-PA) activity.
	Interaction : May increase hypoglycaemic effect w/ phenylbutazone. Potentiation of blood glucose lowering effect w/ other antidiabetics (e.g. acarbose, insulins, metformin), ?-blockers, ACE inhibitors, H2-receptor antagonists, MAOIs, sulfonamides, clarithromycin and NSAIDs. Chlorpromazine, glucocorticoids, ritodrine, salbutamol and terbutaline may cause increases in blood glucose levels. May diminish hypoglycaemic effect w/ danazol. May increase anticoagulant effect of warfarin.
				Potentially Fatal: Increased hypoglycaemic effect w/ miconazole
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Adnix
	n : Nitazoxanide
	Indications : Giardiasis, Cryptosporidiosis
	Doses and administration : Age 1 - 3 years : 5 ml (100 mg) twice daily for 3 days, Age 4 - 11 years : 10 ml (200 mg) twice daily for 3 days, Age >12 years : 25 ml or 1 tablet (500 mg) twice daily for 3 days. 
	Contara-indications : Hypersensitivity.
	Side effects : Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.
	Precaution : Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.
	Pregnancy category : 2
	Mode of action : Nitazoxanide is an antiprotozoal agent. Both nitazoxanide and its active metabolite (tizoxanide) interfere with the pyruvate:ferredoxin 2-oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism in susceptible organisms.
	Interaction : May possibly interact with highly protein-bound drugs e.g. warfarin.
	Therapeutic class : Anti-diarrhoeal Antiprotozoal
	Packsize : 30ml bot
Adnix
	n : Nitazoxanide
	Indications : Giardiasis, Cryptosporidiosis
	Doses and administration : Age 1 - 3 years : 5 ml (100 mg) twice daily for 3 days, Age 4 - 11 years : 10 ml (200 mg) twice daily for 3 days, Age >12 years : 25 ml or 1 tablet (500 mg) twice daily for 3 days. 
	Contara-indications : Hypersensitivity.
	Side effects : Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.
	Precaution : Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.
	Pregnancy category : 2
	Mode of action : Nitazoxanide is an antiprotozoal agent. Both nitazoxanide and its active metabolite (tizoxanide) interfere with the pyruvate:ferredoxin 2-oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism in susceptible organisms.
	Interaction : May possibly interact with highly protein-bound drugs e.g. warfarin.
	Therapeutic class : Anti-diarrhoeal Antiprotozoal
	Packsize : 12's pack
Adnor
	n : Doxepin
	Indications : Anxiety disorders, Depression, Insomnia
	Doses and administration : Adult: PO Initial: 75 mg/day, up to 300 mg/day in severely depressed patients. Total daily dose >100 mg should be given in divided doses
	Contara-indications : Hypersensitivity; mania, glaucoma, neonates (topical); lactation.
	Side effects : Drowsiness, dizziness, confusion, headache, dry mouth, constipation, blurring of vision, hypotension, tachycardia, rashes. Topical: Burning, stinging, scaling, oedema and dryness.
	Precaution : Epilepsy, CV disease, pregnancy, history of urinary retention, glaucoma; gradual withdrawal. May impair ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Doxepin inhibits serotonin and norepinephrine re-uptake by the presynaptic neuronal membrane increasing its synaptic conc in the CNS.
	Interaction : Methylphenidate may increase plasma doxepin levels.
				Potentially Fatal: Potentiates hypertensive action of sympathomimetics. Increased anticholinergic effects with MAOIs. Additive CNS effects with anticholinergics, CNS depressants and alcohol.
	Therapeutic class : Tricyclic & related anti-depressant drugs
	Packsize : 28's pack
Adocil
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Adocil
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack
Adora
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 15ml bot
Adora
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Adora
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack
Adora DS
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml
Adorex
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 100's pack
Adorex
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 60ml bot/100ml bot
Adorex
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 15ml drop
Adovir
	n : Adefovir Dipivoxil
	Indications : Herpes simplex virus, Chronic hepatitis B
	Doses and administration : Adult: PO: The recommended dose of Adefovir for the treatment of chronic hepatitis B in adolescent & adults (age > 12 year) with adequate renal function is 10 mg, once daily, taken orally, without regard to food. 
									
									Renal impairment: Haemodialysis patients: 10 mg every 7 days after dialysis.
									CrCl (ml/min)	
									20-49	10 mg every 48 hr.
									10-19	10 mg every 72 hr.
									
									
									Dose Adjustment in Renal Impairment: Significantly increased drug exposures are seen when Adefovir Dipivoxil is administered to patients with renal impairment. Therefore, the dosing interval of Adefovir Dipivoxil should be adjusted in patients with baseline creatinine clearance < 50 mL/min using the following suggested guidelines- Dosing interval adjustment of Adefovir in patients with renal impairment Creatinine clearance (mL/min) > 50 20 to 49 10 to 19 < 10 Hemodialysis or CAPD Recommended dose and dosing interval 10 mg every 24 hours 10 mg every 48 hours 10 mg every 72 hours 10 mg every 7 days.
									
	Contara-indications : Adefovir Dipivoxil is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product.
	Side effects : Nausea, dyspepsia, abdominal pain, flatulence, diarrhoea, asthenia, headache. Pruritus, skin rashes, and respiratory effects e.g. cough, pharyngitis and sinusitis.Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis, hepatotoxicity, nephrotoxicity.
	Precaution : Pregnancy; elderly; child; renal or hepatic impairment. HIV antibody testing to be performed before initiation due to possible resistance development in untreated HIV infection. Increased risk of hepatotoxicity in females, obese patients and with prolonged treatment. Monitor renal function every 3 mth; hepatitis B biochemical, viral and serological markers every 6 mth and LFTs. Discontinue therapy if liver function worsens, severe hepatomegaly, steatosis or unexplained metabolic or lactic acidosis. Monitor hepatic function for several mth in patients whose antihepatitis therapy is discontinued as acute exacerbations of hepatitis may occur.
	Pregnancy category : 3
	Mode of action : Adefovir dipivoxil is an acyclic nucleoside reverse transciptase inhibitor. The diester function is hydrolyzed and subsequently phosphorylated to the active adefovir diphosphate. The active metabolite inhibits HBV DNA polymerase (reverse transcriptase) and hence inhibits viral replication. It can be used in patients with lamivudine-resistant hepatitis B.
	Interaction : Increased risk of nephrotoxicity with nephrotoxic drugs e.g. aminoglycosides, ciclosporin, NSAIDs, vancomycin, tacrolimus. Ibuprofen increases bioavailability of adefovir.
	Therapeutic class : Hepatic viral infections (Hepatitis B)
	Packsize : 30's pack
Adpas
	n : Pioglitazone
	Indications : Type 2 DM
	Doses and administration : Adult: PO 15 mg once daily. Please see the precaution.
									
									
	Contara-indications : Hypersensitivity. Type 1 diabetes mellitus, symptomatic or history of heart failure, diabetic ketoacidosis, childn <18 yr. Lactation.
	Side effects : Pharyngitis, oedema, headache, upper resp tract infection, sinusitis, anaemia; GI disturbances, wt gain, visual disturbances, dizziness, arthralgia, haematuria, impotence.
	Precaution : I. Liver Enzyme must be monitored regularly 
				II. History of heart failure and MI should be verified 
				III. Incidence of bladder cancer should be verified 
				IV. Not to be used for elderly patients 
				V. Not to be used continuously more than one year 
				VI. Use only by Specialist advice.
				
				Increased risk of hypoglycaemia when used with insulin or oral hypoglycaemics. Oedema, congestive heart failure, hepatic dysfunction, jaundice, anaemia. May cause ovulation in premenopausal, anovulatory women. Monitor liver function before and during treatment. Monitor glycaemic control. Pregnancy. Caution when oral contraceptives or hormonal replacement therapy is used in diabetics due to increased risk of arterial diseases. Stop treatment if ALT increases and remains >3 times above the upper limit of normal or if jaundice develops.
	Pregnancy category : 3
	Mode of action : Pioglitazone is as a potent and highly selective agonist for the peroxisome proliferator activated receptor-? (PPAR-?). Activation of these receptors promotes the production of gene products involved in lipid and glucose metabolism. It also improves insulin response to target cells w/o increasing the pancreatic secretion of insulin.
	Interaction : Increased risk of oedema w/ insulin, metformin and sulfonylureas. Increased plasma levels w/ gemfibrozil and ketoconazole. Decreased plasma levels w/ rifampicin.
	Therapeutic class : Thiazolidinedione Group
	Packsize : 30's pack
Adrenaline
	n : Adrenaline (Epinephrine)
	Indications : Cardiac arrest, Anaphylaxis, Superficial bleeding, Acute asthma
	Doses and administration : Parenteral
									Acute asthma
									Adult: 0.3-0.5 ml (300-500 mcg). Dose may be given via IM or SC inj. 
									Child: 0.01 ml/kg (10 mcg/kg). Max: 0.5 ml (500 mcg). Dose may be given via IM or SC inj. 
									Intravenous
									Advanced cardiac life support (Cardiac Arrest)
									Adult: 
									1. Intravenous injection: 1 mg injection repeated every 2-3 minutes as necessary.
									2. Endotracheal: 2-3 mg via an endotracheal tube, repeated as necessary.
									3. Intracardiac injection: 0.1 to 1 mg, direct into the atrium of the heart.
									4. Intraspinal use: Usual dose is 0.2 to 0.4 mg added to anesthetic spinal fluid mixture (to prolong anesthetic action by limiting absorption).
									
									Child: Initially, 10 mcg/kg, may repeat as often as every 2-3 minutes throughout the resuscitation process. Endotracheal doses: 100 mcg/kg. Intraosseous doses are the same as IV doses. 
									Max Dosage: Intraosseous doses for adults and children are the same as IV doses. 
									
									Anaphylactic shock
									Adult: 0.5 mg (5 mL) given at a slow rate of 100 mcg/minute, stopping when a response is achieved. 
									Child: 10 mcg/kg. If auto injectors are used, doses are based on body wt: 15-30 kg: 150 mcg and >30 kg: 300 mcg. 
									
									Intramuscular
									Anaphylactic shock
									Adult: 500 mcg (0.5 ml), repeat every 5 minutes as needed until improvement occurs. For emergency self-admin (e.g. via autoinjector): A dose of 300 mcg (0.3 ml) may be used.
									Child: Dose depends on age and weight. Usual dose: 10 mcg/kg.
									
	Contara-indications : Preexisting hypertension; occlusive vascular disease; angle-closure glaucoma (eye drops); hypersensitivity; cardiac arrhythmias or tachycardia. When used in addition to local anaesthetics: Procedures involving digits, ears, nose, penis or scrotum.
	Side effects : CNS effects; GI disturbances; epigastric pain; CV disorders; difficulty in micturition with urinary retention; dyspnoea; hyperglycaemia; sweating; hypersalivation; weakness, tremors; coldness of extremities; hypokalaemia. Gangrene, tissue necrosis and sloughing (extravasation) when used in addition to local anaesthetics. Eye drops: Severe smarting, blurred vision, photophobia; naso-lachrymal ducts obstruction. Oedema, hyperaemia and inflammation of the eyes with repeated administration.
	Precaution : CV diseases; hyperthyroidism; DM; Parkinson's disease; elderly; pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Epinephrine, an active principle of the adrenal medulla, is a direct-acting sympathomimetic. It stimulates alpha- and beta-adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation and dilation of skeletal muscle vasculature. It is frequently added to local anaesthetics to retard diffusion and limit absorption, to prolong the duration of effect and to lessen the danger of toxicity.
	Interaction : Halogenated inhalation anaesthetics; alpha- or beta-blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce hypertension and arrhythmia.
	Therapeutic class : Other adrenoceptor stimulants
	Packsize : 10 amps pack
Adrin
	n : Adrenaline (Epinephrine)
	Indications : Cardiac arrest, Anaphylaxis, Superficial bleeding, Acute asthma
	Doses and administration : Parenteral
									Acute asthma
									Adult: 0.3-0.5 ml (300-500 mcg). Dose may be given via IM or SC inj. 
									Child: 0.01 ml/kg (10 mcg/kg). Max: 0.5 ml (500 mcg). Dose may be given via IM or SC inj. 
									Intravenous
									Advanced cardiac life support (Cardiac Arrest)
									Adult: 
									1. Intravenous injection: 1 mg injection repeated every 2-3 minutes as necessary.
									2. Endotracheal: 2-3 mg via an endotracheal tube, repeated as necessary.
									3. Intracardiac injection: 0.1 to 1 mg, direct into the atrium of the heart.
									4. Intraspinal use: Usual dose is 0.2 to 0.4 mg added to anesthetic spinal fluid mixture (to prolong anesthetic action by limiting absorption).
									
									Child: Initially, 10 mcg/kg, may repeat as often as every 2-3 minutes throughout the resuscitation process. Endotracheal doses: 100 mcg/kg. Intraosseous doses are the same as IV doses. 
									Max Dosage: Intraosseous doses for adults and children are the same as IV doses. 
									
									Anaphylactic shock
									Adult: 0.5 mg (5 mL) given at a slow rate of 100 mcg/minute, stopping when a response is achieved. 
									Child: 10 mcg/kg. If auto injectors are used, doses are based on body wt: 15-30 kg: 150 mcg and >30 kg: 300 mcg. 
									
									Intramuscular
									Anaphylactic shock
									Adult: 500 mcg (0.5 ml), repeat every 5 minutes as needed until improvement occurs. For emergency self-admin (e.g. via autoinjector): A dose of 300 mcg (0.3 ml) may be used.
									Child: Dose depends on age and weight. Usual dose: 10 mcg/kg.
									
	Contara-indications : Preexisting hypertension; occlusive vascular disease; angle-closure glaucoma (eye drops); hypersensitivity; cardiac arrhythmias or tachycardia. When used in addition to local anaesthetics: Procedures involving digits, ears, nose, penis or scrotum.
	Side effects : CNS effects; GI disturbances; epigastric pain; CV disorders; difficulty in micturition with urinary retention; dyspnoea; hyperglycaemia; sweating; hypersalivation; weakness, tremors; coldness of extremities; hypokalaemia. Gangrene, tissue necrosis and sloughing (extravasation) when used in addition to local anaesthetics. Eye drops: Severe smarting, blurred vision, photophobia; naso-lachrymal ducts obstruction. Oedema, hyperaemia and inflammation of the eyes with repeated administration.
	Precaution : CV diseases; hyperthyroidism; DM; Parkinson's disease; elderly; pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Epinephrine, an active principle of the adrenal medulla, is a direct-acting sympathomimetic. It stimulates alpha- and beta-adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation and dilation of skeletal muscle vasculature. It is frequently added to local anaesthetics to retard diffusion and limit absorption, to prolong the duration of effect and to lessen the danger of toxicity.
	Interaction : Halogenated inhalation anaesthetics; alpha- or beta-blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce hypertension and arrhythmia.
	Therapeutic class : Other adrenoceptor stimulants
	Packsize : 1 amps pack
Adrinor
	n : Adrenaline (Epinephrine)
	Indications : Cardiac arrest, Anaphylaxis, Superficial bleeding, Acute asthma
	Doses and administration : Parenteral
									Acute asthma
									Adult: 0.3-0.5 ml (300-500 mcg). Dose may be given via IM or SC inj. 
									Child: 0.01 ml/kg (10 mcg/kg). Max: 0.5 ml (500 mcg). Dose may be given via IM or SC inj. 
									Intravenous
									Advanced cardiac life support (Cardiac Arrest)
									Adult: 
									1. Intravenous injection: 1 mg injection repeated every 2-3 minutes as necessary.
									2. Endotracheal: 2-3 mg via an endotracheal tube, repeated as necessary.
									3. Intracardiac injection: 0.1 to 1 mg, direct into the atrium of the heart.
									4. Intraspinal use: Usual dose is 0.2 to 0.4 mg added to anesthetic spinal fluid mixture (to prolong anesthetic action by limiting absorption).
									
									Child: Initially, 10 mcg/kg, may repeat as often as every 2-3 minutes throughout the resuscitation process. Endotracheal doses: 100 mcg/kg. Intraosseous doses are the same as IV doses. 
									Max Dosage: Intraosseous doses for adults and children are the same as IV doses. 
									
									Anaphylactic shock
									Adult: 0.5 mg (5 mL) given at a slow rate of 100 mcg/minute, stopping when a response is achieved. 
									Child: 10 mcg/kg. If auto injectors are used, doses are based on body wt: 15-30 kg: 150 mcg and >30 kg: 300 mcg. 
									
									Intramuscular
									Anaphylactic shock
									Adult: 500 mcg (0.5 ml), repeat every 5 minutes as needed until improvement occurs. For emergency self-admin (e.g. via autoinjector): A dose of 300 mcg (0.3 ml) may be used.
									Child: Dose depends on age and weight. Usual dose: 10 mcg/kg.
									
	Contara-indications : Preexisting hypertension; occlusive vascular disease; angle-closure glaucoma (eye drops); hypersensitivity; cardiac arrhythmias or tachycardia. When used in addition to local anaesthetics: Procedures involving digits, ears, nose, penis or scrotum.
	Side effects : CNS effects; GI disturbances; epigastric pain; CV disorders; difficulty in micturition with urinary retention; dyspnoea; hyperglycaemia; sweating; hypersalivation; weakness, tremors; coldness of extremities; hypokalaemia. Gangrene, tissue necrosis and sloughing (extravasation) when used in addition to local anaesthetics. Eye drops: Severe smarting, blurred vision, photophobia; naso-lachrymal ducts obstruction. Oedema, hyperaemia and inflammation of the eyes with repeated administration.
	Precaution : CV diseases; hyperthyroidism; DM; Parkinson's disease; elderly; pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Epinephrine, an active principle of the adrenal medulla, is a direct-acting sympathomimetic. It stimulates alpha- and beta-adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation and dilation of skeletal muscle vasculature. It is frequently added to local anaesthetics to retard diffusion and limit absorption, to prolong the duration of effect and to lessen the danger of toxicity.
	Interaction : Halogenated inhalation anaesthetics; alpha- or beta-blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce hypertension and arrhythmia.
	Therapeutic class : Other adrenoceptor stimulants
	Packsize : 5 amps pack
Adryl
	n : Diphenhydramine Hydrochloride
	Indications : Allergic rhinitis, Allergic conditions, Motion sickness, Common cold, Insomnia, Extrapyramidal symptoms
	Doses and administration : Oral
									Adult: As hydrochloride: 25-50 mg 3-4 times daily. Max: 300 mg/day. 
									Child: 6.25-25 mg 3-4 times daily, up to 5 mg/kg in divided doses. Max: 300 mg/day. 
									
									Treatment and prophylaxis of motion sickness
									Adult: As diphenhydramine di (acefyllinate): Usual dose: 90-135 mg, may repeat if needed at intervals of at least 6 hr. Max: 540 mg daily. For prevention, dose to be given at least 30 min before travelling. 
									
	Contara-indications : Hypersensitivity ; neonates, lactation.
	Side effects : CNS depression, dizziness, headache, sedation; paradoxical stimulation in children; dryness of mouth, thickened respiratory secretion, blurring of vision, urinary retention; GI disturbances; blood dyscrasias.
	Precaution : Epilepsy; elderly; performing tasks which require mental alertness; angle-closure glaucoma; pyroduodenal obstruction; urinary tract obstruction; hyperthyroidism; raised intraocular pressure; CV disease; acute asthma; pregnancy.
	Pregnancy category : 2
	Mode of action : Diphenhydramine blocks histamine H1-receptors on effector cells of the GI tract, blood vessels and respiratory tract. It also causes sedation and has some anticholinergic action.
	Interaction :  	Masks ototoxicity produced by aminoglycosides. Increases gastric degradation of levodopa and decreases its absorption by reduction of gastric emptying. Antagonises therapeutic effects of cholinergic agents e.g. tacrine, donezepil and neuroleptics. Valerian, St. John's wort, Kava Kava and gotu kola may increase CNS depression.
				Potentially Fatal: Potentiates CNS depression with alcohol, barbiturates, analgesics, sedatives and neuroleptics. Additive antimuscarinic action with MAOIs, atropine and TCAs.
	Therapeutic class : Sedating Anti-histamines
	Packsize : 100ml bot
Aduvit
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 200's pack
Aduvit
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 100ml bot/200ml bot
Advel
	n : Ibuprofen
	Indications : Rheumatoid arthritis, Osteoarthritis, Pain, Fever, Pericarditis, Dysmenorrhea, Patent ductus arteriosus, Inflammation, Musculoskeletal and joint disorders
	Doses and administration : Adult: PO Pain and inflammation 1.2-1.8 g/day in divided doses. Maintenance: 0.6-1.2 g/day. Max: 2.4 g/day. 
									Fever 200-400 mg 4-6 hrly. Max: 1.2 g/day. 
									
									
	Contara-indications : Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).
	Side effects : Oral: Dyspepsia, vomitting, abdominal pain, heart burn, nausea, diarrhoea, epigastric pain, edema, fluid retention, dizziness, rash, tinnitus. Parenteral: Intraventricular hemorrhage, skin irritation, hypocalcemia, hypoglycemia, GI disorders, anemia, apnea, respiratory infection, sepsis.
									Potentially Fatal: Severe CV thrombotic events. Severe GI bleeding, ulceration and perforation.
	Precaution : Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation.
	Pregnancy category : 4
	Mode of action : Ibuprofen inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase-1 and 2. It has anti-inflammatory, analgesic and antipyretic properties.
	Interaction : Increased risk of GI bleeding w/ warfarin, corticosteroids, SSRIs and aspirin. May reduce the natriuretic effects of diuretics. Reduced antihypertensive effect of ACE inhibitors and angiotensin II receptor antagonists. May increase toxicity of lithium and methotrexate. Increased nephrotoxicity w/ ciclosporin and tacrolimus.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100 ml bot
Advel
	n : Ibuprofen
	Indications : Rheumatoid arthritis, Osteoarthritis, Pain, Fever, Pericarditis, Dysmenorrhea, Patent ductus arteriosus, Inflammation, Musculoskeletal and joint disorders
	Doses and administration : Adult: PO Pain and inflammation 1.2-1.8 g/day in divided doses. Maintenance: 0.6-1.2 g/day. Max: 2.4 g/day. 
									Fever 200-400 mg 4-6 hrly. Max: 1.2 g/day. 
									
									
	Contara-indications : Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).
	Side effects : Oral: Dyspepsia, vomitting, abdominal pain, heart burn, nausea, diarrhoea, epigastric pain, edema, fluid retention, dizziness, rash, tinnitus. Parenteral: Intraventricular hemorrhage, skin irritation, hypocalcemia, hypoglycemia, GI disorders, anemia, apnea, respiratory infection, sepsis.
									Potentially Fatal: Severe CV thrombotic events. Severe GI bleeding, ulceration and perforation.
	Precaution : Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation.
	Pregnancy category : 4
	Mode of action : Ibuprofen inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase-1 and 2. It has anti-inflammatory, analgesic and antipyretic properties.
	Interaction : Increased risk of GI bleeding w/ warfarin, corticosteroids, SSRIs and aspirin. May reduce the natriuretic effects of diuretics. Reduced antihypertensive effect of ACE inhibitors and angiotensin II receptor antagonists. May increase toxicity of lithium and methotrexate. Increased nephrotoxicity w/ ciclosporin and tacrolimus.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Advel
	n : Ibuprofen
	Indications : Rheumatoid arthritis, Osteoarthritis, Pain, Fever, Pericarditis, Dysmenorrhea, Patent ductus arteriosus, Inflammation, Musculoskeletal and joint disorders
	Doses and administration : Adult: PO Pain and inflammation 1.2-1.8 g/day in divided doses. Maintenance: 0.6-1.2 g/day. Max: 2.4 g/day. 
									Fever 200-400 mg 4-6 hrly. Max: 1.2 g/day. 
									
									
	Contara-indications : Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).
	Side effects : Oral: Dyspepsia, vomitting, abdominal pain, heart burn, nausea, diarrhoea, epigastric pain, edema, fluid retention, dizziness, rash, tinnitus. Parenteral: Intraventricular hemorrhage, skin irritation, hypocalcemia, hypoglycemia, GI disorders, anemia, apnea, respiratory infection, sepsis.
									Potentially Fatal: Severe CV thrombotic events. Severe GI bleeding, ulceration and perforation.
	Precaution : Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation.
	Pregnancy category : 4
	Mode of action : Ibuprofen inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase-1 and 2. It has anti-inflammatory, analgesic and antipyretic properties.
	Interaction : Increased risk of GI bleeding w/ warfarin, corticosteroids, SSRIs and aspirin. May reduce the natriuretic effects of diuretics. Reduced antihypertensive effect of ACE inhibitors and angiotensin II receptor antagonists. May increase toxicity of lithium and methotrexate. Increased nephrotoxicity w/ ciclosporin and tacrolimus.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Adze
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Aerodyl
	n : Bambuterol Hydrochloride
	Indications : Chronic obstructive pulmonary disease (COPD), Asthma.
	Doses and administration : Adult: PO 10-20 mg/day at bedtime.
									
									Renal impairment:
									CrCl (ml/min)	
									<50	 Initial dose should be halved. 
	Contara-indications : Severe hepatic impairment; cirrhosis.
	Side effects : Fine tremor of skeletal muscle (e.g. hands), palpitations and muscle cramps; tachycardia, tenseness and peripheral vasodilation.
	Precaution : DM, hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation. Pregnancy.
	Pregnancy category : 0
	Mode of action : Bambuterol HCl is a prodrug of terbutaline. It relaxes bronchial smooth muscle by selectively acting on ?2-receptors.
	Interaction : Risk of hypokalaemia increased by co-admin of corticosteroids, diuretics or xanthines. Prolong the action of drugs e.g. suxamethonium.
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 60ml bot
Aerodyl
	n : Bambuterol Hydrochloride
	Indications : Chronic obstructive pulmonary disease (COPD), Asthma.
	Doses and administration : Adult: PO 10-20 mg/day at bedtime.
									
									Renal impairment:
									CrCl (ml/min)	
									<50	 Initial dose should be halved. 
	Contara-indications : Severe hepatic impairment; cirrhosis.
	Side effects : Fine tremor of skeletal muscle (e.g. hands), palpitations and muscle cramps; tachycardia, tenseness and peripheral vasodilation.
	Precaution : DM, hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation. Pregnancy.
	Pregnancy category : 0
	Mode of action : Bambuterol HCl is a prodrug of terbutaline. It relaxes bronchial smooth muscle by selectively acting on ?2-receptors.
	Interaction : Risk of hypokalaemia increased by co-admin of corticosteroids, diuretics or xanthines. Prolong the action of drugs e.g. suxamethonium.
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 100's pack
Aerodyl
	n : Bambuterol Hydrochloride
	Indications : Chronic obstructive pulmonary disease (COPD), Asthma.
	Doses and administration : Adult: PO 10-20 mg/day at bedtime.
									
									Renal impairment:
									CrCl (ml/min)	
									<50	 Initial dose should be halved. 
	Contara-indications : Severe hepatic impairment; cirrhosis.
	Side effects : Fine tremor of skeletal muscle (e.g. hands), palpitations and muscle cramps; tachycardia, tenseness and peripheral vasodilation.
	Precaution : DM, hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation. Pregnancy.
	Pregnancy category : 0
	Mode of action : Bambuterol HCl is a prodrug of terbutaline. It relaxes bronchial smooth muscle by selectively acting on ?2-receptors.
	Interaction : Risk of hypokalaemia increased by co-admin of corticosteroids, diuretics or xanthines. Prolong the action of drugs e.g. suxamethonium.
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 100's pack
Aerofen
	n : Ketotifen
	Indications : Allergic conjunctivitis,  Allergic conditions,  Asthma prophylaxis
	Doses and administration : Adult: PO: Tablet:
									 Asthma prophylaxis; Allergic conditions 1 mg twice daily, up to 2 mg twice daily if needed. 
									
									Syrup:
									6 months to 3 years:
									0.25 ml / kg body weight, twice daily (Once in the morning & once in the evening).
									
	Contara-indications : Acute asthma attack.
	Side effects : Sedation, drowsiness, dizziness, dry mouth, weight gain, increased appetite, CNS stimulation. Rarely, cystitis. Conjunctival injection, headaches and rhinitis (ophthalmic).
	Precaution : May impair tasks requring mental alertness e.g. driving or operating machinery. History of epilepsy. Pregnancy and lactation. Children <3 yr.
	Pregnancy category : 3
	Mode of action : Ketotifen selectively and noncompetitively inhibits the release of mediators from cells involved in hypersensitivity reactions. It is also a mast cell stabiliser.
	Interaction : Reduced platelet count with oral antidiabetics.
				Potentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.
	Therapeutic class : Cromoglycate & related drugs
	Packsize : 50's pack
Aerofen
	n : Ketotifen
	Indications : Allergic conjunctivitis,  Allergic conditions,  Asthma prophylaxis
	Doses and administration : Adult: PO: Tablet:
									 Asthma prophylaxis; Allergic conditions 1 mg twice daily, up to 2 mg twice daily if needed. 
									
									Syrup:
									6 months to 3 years:
									0.25 ml / kg body weight, twice daily (Once in the morning & once in the evening).
									
	Contara-indications : Acute asthma attack.
	Side effects : Sedation, drowsiness, dizziness, dry mouth, weight gain, increased appetite, CNS stimulation. Rarely, cystitis. Conjunctival injection, headaches and rhinitis (ophthalmic).
	Precaution : May impair tasks requring mental alertness e.g. driving or operating machinery. History of epilepsy. Pregnancy and lactation. Children <3 yr.
	Pregnancy category : 3
	Mode of action : Ketotifen selectively and noncompetitively inhibits the release of mediators from cells involved in hypersensitivity reactions. It is also a mast cell stabiliser.
	Interaction : Reduced platelet count with oral antidiabetics.
				Potentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.
	Therapeutic class : Cromoglycate & related drugs
	Packsize : 100ml bot
Aeron
	n : Montelukast
	Indications : Asthma, Allergic rhinitis
	Doses and administration : Adults (15 years of age or over): 10 mg daily to be taken in the evening.
									
									Chronic asthma; Allergic rhinitis 10 mg/day once in the evening. Prophylaxis of exercise-induced asthma 10 mg at least 2 hr before exercise; do not admin additional doses w/in 24 hr.
									
									Children (6-14 years of age): 5 mg daily to be taken in the evening.
									Children (2-5 years of age): 4 mg daily to be taken in the evening
	Contara-indications : Hypersensitivity.
	Side effects : Dizziness, fatigue, fever; rash; abdominal pain, dyspepsia, dental pain, gastroenteritis; increased AST; weakness; cough, nasal congestion. Aggression, agitation, angioedema, arthralgia, bleeding tendency, bruising, cholestasis, diarrhoea, dream abnormalities, drowsiness, oedema, eosinophilia, hallucinations, hepatic eosinophilic infiltration (rare), hepatitis, hypersensitivity, hypoaesthesia, insomnia, irritability, muscle cramps, myalgia, nausea, palpitation, pancreatitis, paraesthesia, pruritus, restlessness, seizure, urticaria, vasculitis, vomiting.
									Potentially Fatal: Anaphylaxis, Churg-Strauss syndrome.
	Precaution : Not for the relief of acute bronchospasm. Not to be used as monotherapy for the prevention of exercise-induced bronchospasm. Patients in whom asthma is precipitated by aspirin or other NSAIDs should continue to avoid aspirin and NSAIDs. Do not abruptly substitute for oral or inhaled corticosteroids. Be alert for any signs of Churg-Strauss syndrome. Pregnancy and lactation. Children <6 mth.
	Pregnancy category : 2
	Mode of action : Montelukast is a selective leukotriene receptor antagonist that blocks the effects of cysteinyl leukotrienes in the airways.
	Interaction : nduced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).
	Therapeutic class : Leukotriene receptor antagonists
	Packsize : 12's pack
Aeron FT
	n : Montelukast
	Indications : Asthma, Allergic rhinitis
	Doses and administration : Adults (15 years of age or over): 10 mg daily to be taken in the evening.
									
									Chronic asthma; Allergic rhinitis 10 mg/day once in the evening. Prophylaxis of exercise-induced asthma 10 mg at least 2 hr before exercise; do not admin additional doses w/in 24 hr.
									
									Children (6-14 years of age): 5 mg daily to be taken in the evening.
									Children (2-5 years of age): 4 mg daily to be taken in the evening
	Contara-indications : Hypersensitivity.
	Side effects : Dizziness, fatigue, fever; rash; abdominal pain, dyspepsia, dental pain, gastroenteritis; increased AST; weakness; cough, nasal congestion. Aggression, agitation, angioedema, arthralgia, bleeding tendency, bruising, cholestasis, diarrhoea, dream abnormalities, drowsiness, oedema, eosinophilia, hallucinations, hepatic eosinophilic infiltration (rare), hepatitis, hypersensitivity, hypoaesthesia, insomnia, irritability, muscle cramps, myalgia, nausea, palpitation, pancreatitis, paraesthesia, pruritus, restlessness, seizure, urticaria, vasculitis, vomiting.
									Potentially Fatal: Anaphylaxis, Churg-Strauss syndrome.
	Precaution : Not for the relief of acute bronchospasm. Not to be used as monotherapy for the prevention of exercise-induced bronchospasm. Patients in whom asthma is precipitated by aspirin or other NSAIDs should continue to avoid aspirin and NSAIDs. Do not abruptly substitute for oral or inhaled corticosteroids. Be alert for any signs of Churg-Strauss syndrome. Pregnancy and lactation. Children <6 mth.
	Pregnancy category : 2
	Mode of action : Montelukast is a selective leukotriene receptor antagonist that blocks the effects of cysteinyl leukotrienes in the airways.
	Interaction : nduced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).
	Therapeutic class : Leukotriene receptor antagonists
	Packsize : 30's pack
Aeron FT
	n : Montelukast
	Indications : Asthma, Allergic rhinitis
	Doses and administration : Adults (15 years of age or over): 10 mg daily to be taken in the evening.
									
									Chronic asthma; Allergic rhinitis 10 mg/day once in the evening. Prophylaxis of exercise-induced asthma 10 mg at least 2 hr before exercise; do not admin additional doses w/in 24 hr.
									
									Children (6-14 years of age): 5 mg daily to be taken in the evening.
									Children (2-5 years of age): 4 mg daily to be taken in the evening
	Contara-indications : Hypersensitivity.
	Side effects : Dizziness, fatigue, fever; rash; abdominal pain, dyspepsia, dental pain, gastroenteritis; increased AST; weakness; cough, nasal congestion. Aggression, agitation, angioedema, arthralgia, bleeding tendency, bruising, cholestasis, diarrhoea, dream abnormalities, drowsiness, oedema, eosinophilia, hallucinations, hepatic eosinophilic infiltration (rare), hepatitis, hypersensitivity, hypoaesthesia, insomnia, irritability, muscle cramps, myalgia, nausea, palpitation, pancreatitis, paraesthesia, pruritus, restlessness, seizure, urticaria, vasculitis, vomiting.
									Potentially Fatal: Anaphylaxis, Churg-Strauss syndrome.
	Precaution : Not for the relief of acute bronchospasm. Not to be used as monotherapy for the prevention of exercise-induced bronchospasm. Patients in whom asthma is precipitated by aspirin or other NSAIDs should continue to avoid aspirin and NSAIDs. Do not abruptly substitute for oral or inhaled corticosteroids. Be alert for any signs of Churg-Strauss syndrome. Pregnancy and lactation. Children <6 mth.
	Pregnancy category : 2
	Mode of action : Montelukast is a selective leukotriene receptor antagonist that blocks the effects of cysteinyl leukotrienes in the airways.
	Interaction : nduced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).
	Therapeutic class : Leukotriene receptor antagonists
	Packsize : 30's pack
Aeronid
	n : Budesonide
	Indications :  Asthma, COPD.				
	Doses and administration : Adult: Inhalation Asthma As metered dose inhaler: 400 mcg/day in 2 divided doses, up to 1.6 mg/day in severe cases. Maintenance: 200-400 mcg/day. As dry powd inhaler: 200-800 mcg/day. As nebulised soln: Inhale. Adults and elderly: 1 - 2 mg twice daily. 
									
									Children 3 months to 12 years of age: 0.5 - 1 mg twice daily.
	Contara-indications : Hypersensitivity to any of the ingredients of this preparation.
	Side effects : Sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects. hoarseness and candidiasis of the mouth or throat.
	Precaution : Active or doubtfully quiescent tuberculosis, paradoxical bronchospasm; untreated fungal, bacterial, or systemic viral infections, or ocular herpes simplex infection. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Budesonide controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes, fibroblasts, reverses capillary permeability and lysosomal stabilisation at the cellular level to prevent or control inflammation.
	Interaction : Increased systemic exposure w/ potent CYP3A4 inhibitors (e.g. ketoconazole). Decreased systemic exposure w/ CYP3A4 inducers (e.g. carbamazepine).
	Therapeutic class : Respiratory corticosteroids
	Packsize : 120 doses unit
Aeronid HFA
	n : Budesonide
	Indications :  Asthma, COPD.				
	Doses and administration : Adult: Inhalation Asthma As metered dose inhaler: 400 mcg/day in 2 divided doses, up to 1.6 mg/day in severe cases. Maintenance: 200-400 mcg/day. As dry powd inhaler: 200-800 mcg/day. As nebulised soln: Inhale. Adults and elderly: 1 - 2 mg twice daily. 
									
									Children 3 months to 12 years of age: 0.5 - 1 mg twice daily.
	Contara-indications : Hypersensitivity to any of the ingredients of this preparation.
	Side effects : Sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects. hoarseness and candidiasis of the mouth or throat.
	Precaution : Active or doubtfully quiescent tuberculosis, paradoxical bronchospasm; untreated fungal, bacterial, or systemic viral infections, or ocular herpes simplex infection. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Budesonide controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes, fibroblasts, reverses capillary permeability and lysosomal stabilisation at the cellular level to prevent or control inflammation.
	Interaction : Increased systemic exposure w/ potent CYP3A4 inhibitors (e.g. ketoconazole). Decreased systemic exposure w/ CYP3A4 inducers (e.g. carbamazepine).
	Therapeutic class : Respiratory corticosteroids
	Packsize : 30's pack
Aeropac
	n : Simethicone
	Indications : Peptic ulcer, Infantile colic, Upper GI bloating, Functional dyspepsia, Spastic or irritable colon
	Doses and administration : Simethicone drops should be taken after meals and at bedtime or as directed by the physician. 
									
									Children younger than 2 years of age: 20 mg (0.3 ml drops) 4 times daily up to 240 mg/day (3.6 ml drops).
									Children 2 to12 years of age: 40 mg (0.6 ml drops) 4 times daily.
									
									Adults and children older than 12 years of age: 40 to 80 mg (0.6 to 1.2 ml drops) 4 times daily up to 500 mg/day (7.5 ml drops).
	Contara-indications : There is no information about the contraindication of Simethicone.
	Side effects : Simethicone is physiologically inert and no adverse effect has been reported after oral ingestion.
	Precaution : More than 12 doses per day should not be used, except under the advice and supervision of a physician. Keep the medicine out of the reach of children.
	Pregnancy category : 1
	Mode of action : Changes surface tension of gas bubbles and causes collapse of foam bubbles, thus allowing easier passage of gas and preventing gas pockets in gastrointestinal tract.
	Interaction : None
	Therapeutic class : Anti-dyspeptic/Carminatives
	Packsize : 15ml drop
Aerovil
	n : Pheniramine Maleate
	Indications : Allergic conjunctivitis, Allergic conditions, Motion sickness
	Doses and administration :  Adult: PO Allergic conditions; Prevention of motion sickness As maleate: 
									Syr: 15-30 mg 2-3 times/day. 
									Tab: Up to 45 mg 3 times/day. Max: 3 mg/kg/day. 
									For motion sickness prevention: Take 1st dose at least 30 mins before travelling. 
									
									Children aged 1-3 years:  Half a measuring spoonful 2 or 3 times daily.
									Children aged 4-12 years: 1 measuring spoonful 2 or 3 times daily.
									
	Contara-indications : Symptomatic prostatic hypertrophy; neonates and premature infants.
	Side effects : Oral: Sedation. Hypersensitivity reactions. Lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. Nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. Urinary retention. Palpitations, headache. Blurred vision, increased intraocular pressure. Muscular weakness. Rarely, blood dyscrasias e.g. agranulocytosis, haemolytic anaemia. Ophthalmic: Temporarily enlarged pupils, eye redness (overuse).
	Precaution :  	May impair ability to drive or operate machinery. Has potential for abuse. Narrow angle glaucoma, asthma or severe CV disease. Antiemetic effect may mask signs of other conditions. Pregnancy and lactation. Elderly.
	Pregnancy category : 3
	Mode of action : Pheniramine is an alkylamine derivative with histamine H1-receptor antagonist effects. It also has anticholinergic and moderate sedative effects.
	Interaction : May mask ototoxicity produced by aminoglycoside antibiotics.
				
				Potentially Fatal: Potentiation of CNS depression by alcohol, sedatives, opioids, barbiturates, hypnotics, narcoleptics. May increase antimuscarinic effect of MAOIs, atropine and TCAs.
	Therapeutic class : Sedating Anti-histamines
	Packsize : 100ml bot
Afix
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 30ml bot/ 50ml bot
Afix
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 10's pack
Afix
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 10's pack
Afix
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 6's pack
Afix
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 6's pack
Afix DS
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 30ml bot/ 50ml bot
Afixime
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 50ml bot
Afixime
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 8's pack
Afm
	n : Fluorometholone 0.1 % Eye prep
	Indications : Allergic and inflammatory conditions of the eye
	Doses and administration : Adults and children (above 2 years of age):
									Instill 1-2 drops into conjunctivalsac 2-3 times daily. Dose may be increased to 1 drop hourly during first 24-48 hr.
	Contara-indications : This medication is contraindicated in following cases-
									 Viral infection of cornea & conjunctiva caused by Herpes simplex etc
									 Fungal infection of the cornea & conjunctiva
									 Tuberculous infections
									 Ulcerous processes of the cornea
									 Hypersensitivity to any ingredients of this formulation.
	Side effects : Mild burning sensation, reversible increase in intra ocular pressure (IOP), reactive hyperemia/rebound effect, cataract & corneal defects, glaucoma, systemic effects (chronic use).
	Precaution :  Prolonged use in pregnant women and infants should be avoided
				 This medication should be used with caution in patients under treatment with MAO inhibitors
				 Do not apply while wearing soft contact lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.
				 Shake well before use.
	Pregnancy category : 3
	Mode of action : Fluorometholone suppresses the migration of polymorphonuclear leukocytes and reversal of increased capillary permeability thus decreasing inflammation.
	Interaction : None
	Therapeutic class : Ophthalmic Steroid preparations
	Packsize : 5  ml drop
AFM plus
	n : Fluorometholone 0.1% + Gentamicin 0.3% Eye prep
	Indications : Allergic and inflammatory conditions of the eye
	Doses and administration : Sterile Ophthalmic Suspension:
									Bacterial infection: The dosage depends on the severity of the disease. The application of 1 drop 5 times daily into the conjunctival sac of the affected eye is recommended. In severe cases the dosage can be increased up to 1 drop per hour for 1 to 2 days.
									Ocular postoperative infection: 1 drop 4 times daily into the conjunctival sac for 1 week. Then a reduced application frequency is recommended for the remaining part of the treatment.
									Sterile Eye Ointment:
									Bacterial infection: Apply 3-4 times daily into the affected eye.
									Ocular postoperative infection: To support the therapy with Ophthalmic Suspension during the night apply ointment before retiring.
	Contara-indications : Hypersensitivity to any of the components. Injuries and ulceration of the cornea. Viral infections (e.g. Herpes simplex, Vaccinia) or mycosis.
									
									Eye tuberculosis.
									
									Glaucoma.
	Side effects : A transient burning sensation may occur after instillation. Rare: Hypersensitivity reactions including eczema of the eyelid and puncture keratitis. Prolonged use of topical steroids may delay wound healing, increase of IOP, develop cataract and cause thinning of cornea & sclera.
	Precaution : Steroids can mask, activate or aggravate ocular infections.
				
				Long term treatment with steroid may enhance thinning of cornea and sclera and rarely perforation of the cornea has been reported.
				
				In case no improvement is observed after 7-8 days of treatment, other therapeutical means should be considered.
				
				Patients experiencing blurred vision after application of the product, particularly the ointment, should refrain from driving vehicles or operating machinery.
				
				Contact lenses should be removed before each application.
	Pregnancy category : 3
	Mode of action : Fluorometholone suppresses the migration of polymorphonuclear leukocytes and reversal of increased capillary permeability thus decreasing inflammation.
									
									Gentamicin is an aminoglycoside that binds to 30s and 50s ribosomal subunits of susceptible bacteria disrupting protein synthesis, thus rendering the bacterial cell membrane defective.
	Interaction : None
	Therapeutic class : Ophthalmic Steroid- antibiotic combined preparations
	Packsize : 3 gm tube
AFM PLUS
	n : Fluorometholone 0.1% + Gentamicin 0.3% Eye prep
	Indications : Allergic and inflammatory conditions of the eye
	Doses and administration : Sterile Ophthalmic Suspension:
									Bacterial infection: The dosage depends on the severity of the disease. The application of 1 drop 5 times daily into the conjunctival sac of the affected eye is recommended. In severe cases the dosage can be increased up to 1 drop per hour for 1 to 2 days.
									Ocular postoperative infection: 1 drop 4 times daily into the conjunctival sac for 1 week. Then a reduced application frequency is recommended for the remaining part of the treatment.
									Sterile Eye Ointment:
									Bacterial infection: Apply 3-4 times daily into the affected eye.
									Ocular postoperative infection: To support the therapy with Ophthalmic Suspension during the night apply ointment before retiring.
	Contara-indications : Hypersensitivity to any of the components. Injuries and ulceration of the cornea. Viral infections (e.g. Herpes simplex, Vaccinia) or mycosis.
									
									Eye tuberculosis.
									
									Glaucoma.
	Side effects : A transient burning sensation may occur after instillation. Rare: Hypersensitivity reactions including eczema of the eyelid and puncture keratitis. Prolonged use of topical steroids may delay wound healing, increase of IOP, develop cataract and cause thinning of cornea & sclera.
	Precaution : Steroids can mask, activate or aggravate ocular infections.
				
				Long term treatment with steroid may enhance thinning of cornea and sclera and rarely perforation of the cornea has been reported.
				
				In case no improvement is observed after 7-8 days of treatment, other therapeutical means should be considered.
				
				Patients experiencing blurred vision after application of the product, particularly the ointment, should refrain from driving vehicles or operating machinery.
				
				Contact lenses should be removed before each application.
	Pregnancy category : 3
	Mode of action : Fluorometholone suppresses the migration of polymorphonuclear leukocytes and reversal of increased capillary permeability thus decreasing inflammation.
									
									Gentamicin is an aminoglycoside that binds to 30s and 50s ribosomal subunits of susceptible bacteria disrupting protein synthesis, thus rendering the bacterial cell membrane defective.
	Interaction : None
	Therapeutic class : Ophthalmic Steroid- antibiotic combined preparations
	Packsize : 5  ml drop
AFM-T
	n : Fluorometholone 0.1% + Tetrahydrozoline Hydrochloride 0.025% Eye prep
	Indications : Keratitis, Allergic and inflammatory conditions of the eye, Iridocyclitis, Iritis, Acute & chronic conjunctivitis, Scleritis, Episcleritis, Myositis. Post-op conditions after strabotomy, Cataract & glaucoma operations
	Doses and administration : Adults and children (above 2 years of age):
									Instill 1-2 drops into conjunctivalsac 2-3 times daily. Dose may be increased to 1 drop hourly during first 24-48 hr.
	Contara-indications : This medication is contraindicated in following cases-
									 Viral infection of cornea & conjunctiva caused by Herpes simplex etc
									 Fungal infection of the cornea & conjunctiva
									 Tuberculous infections
									 Ulcerous processes of the cornea
									 Hypersensitivity to any ingredients of this formulation.
	Side effects : Mild burning sensation, reversible increase in intra ocular pressure (IOP), reactive hyperemia/rebound effect, cataract & corneal defects, glaucoma, systemic effects (chronic use).
	Precaution :  Prolonged use in pregnant women and infants should be avoided
				 This medication should be used with caution in patients under treatment with MAO inhibitors
				 Do not apply while wearing soft contact lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.
				 Shake well before use.
	Pregnancy category : 3
	Mode of action : Fluorometholone suppresses the migration of polymorphonuclear leukocytes and reversal of increased capillary permeability thus decreasing inflammation.
									
									May stimulate alpha-adrenergic receptors in the arterioles of the conjunctiva; produces vasoconstriction. May produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants.
	Interaction : None
	Therapeutic class : Ophthalmic Steroid preparations
	Packsize : 5  ml drop
Afrin 0.025%
	n : Oxymetazoline Hydrochloride .025 % Nasal prep
	Indications : Sinusitis, Hay fever, Common cold, Conjunctival decongestant, Acute or chronic rhinitis, Nasal congestion
	Doses and administration : Adults and children 6 yrs of age and older : 2-3 drops or sprays in each nostril twice daily for 3-5 days.
									Children of age 2-6 : 2-3 drops in each nostril twice daily for 3-5 days. Sprays are generally unsuitable for young children because of the small size of their nostrils. The drug is not recommended in children under the age of 2.
	Contara-indications : Contraindicated in patients hypersensitive to Oxymetazoine Hydrochloride.
	Side effects : * Transient burning, dryness of the nasal mucosa, sneezing.
									* Nervousness, dizziness, headache.
									* Hypertension, palpitation or reflex bradycardia.
	Precaution : * Prolonged use may result in rebound congestion.
				* Since oxymetazoline has systemic adverse effects, it should be used with caution in patients with
				* hypertension, cardiovascular disease or hyperthyroidism or in those receiving MAO inhibitors.
	Pregnancy category : 3
	Mode of action : Oxymetazoline is a direct-acting sympathomimetic which has vasoconstrictor effect on mucosal blood vessels when applied topically and in turn reduces oedema of the nasal mucosa.
	Interaction : Potentially Fatal: Hypertensive crisis with MAOIs.
	Therapeutic class : Nasal Anti-histamine preparations
	Packsize : 10 ml drop
Afrin 0.05%
	n : Oxymetazoline Hydrochloride .05 % Nasal prep
	Indications : Sinusitis, Hay fever, Common cold, Acute or chronic rhinitis, Nasal congestion
	Doses and administration : Adults and children 6 yrs of age and older : 2-3 drops or sprays in each nostril twice daily for 3-5 days.
									Children of age 2-6 : 2-3 drops in each nostril twice daily for 3-5 days. Sprays are generally unsuitable for young children because of the small size of their nostrils. The drug is not recommended in children under the age of 2.
	Contara-indications : Contraindicated in patients hypersensitive to Oxymetazoine Hydrochloride.
	Side effects : * Transient burning, dryness of the nasal mucosa, sneezing.
									* Nervousness, dizziness, headache.
									* Hypertension, palpitation or reflex bradycardia.
	Precaution : * Prolonged use may result in rebound congestion.
				* Since oxymetazoline has systemic adverse effects, it should be used with caution in patients with
				* hypertension, cardiovascular disease or hyperthyroidism or in those receiving MAO inhibitors.
	Pregnancy category : 3
	Mode of action : Oxymetazoline is a direct-acting sympathomimetic which has vasoconstrictor effect on mucosal blood vessels when applied topically and in turn reduces oedema of the nasal mucosa.
	Interaction : Potentially Fatal: Hypertensive crisis with MAOIs.
	Therapeutic class : Nasal Anti-histamine preparations
	Packsize : 10 ml drop
Afun
	n : Clotrimazole 1%  Topical
	Indications : Skin and nail fungal infections, Tinea pedis, Tinea cruris, Tinea corporis, Candidiasis, Pityriasis versicolor 
	Doses and administration : Topical/Cutaneous Skin  and nail fungal infections: Adult: Apply 2 or 3 times daily. Onychomycosis: for 6 months.Tinea pedis & Dermatomycoses: for 4 weeks.
	Contara-indications : Hypersensitivity.
	Side effects : Topical: Erythema, stinging, irritation; hypersensitivity reactions; contact dermatitis. 
	Precaution : Avoid contact with eyes upon topical application. Childn <3 yrs. Pregnancy, lactation.If local intolerance develops, consider withdrawal of the medicine and institution of appropriate therapy. 
	Pregnancy category : 2
	Mode of action : Clotrimazole is a broad-spectrum antifungal which binds to phospholipids in the cell membrane altering cell wall permeability causing a loss in essential intracellular elements.
	Interaction : Antagonism with polyene antibiotics.
	Therapeutic class : Drugs for subcutaneous and systemic mycoses
	Packsize : 10gm  tube
Afun VT
	n : Clotrimazole VT
	Indications : Vaginal itching, burning and discharge associated with recurrent vaginal yeast infections Vulvovaginal candidiasis (Vagonal thrush).
	Doses and administration : Adult: Vaginal Vulvovaginal candidiasis:
									Clotrimazole VT 100 & 200- First infections: In general, a 3-day treatment is sufficient for Candida vaginitis. On 3 consecutive nights, Clotrimazole VT 100  or 1  Clotrimazole VT 200 are inserted as deeply as possible into the vagina. This is best achieved when lying on ones back with the knees slightly bent. 
									
									Re-infections: In general, a 6-day treatment is sufficient. This applies also to mixed infections with the above-mentioned causative organisms. On six consecutive nights, 1 Clotrimazole VT 100 is inserted as deeply as possible into the vagina. If necessary, 2 Clotrimazole VT 100 (1 in the morning and 1 in the evening) or 1 Clotrimazole VT 200 daily can be used for 6-12 days. 
									
									Treatment should be timed so as to avoid the menstrual period and be finished before the onset of menstruation. To avoid re-infection, the partner should undergo local treatment with Clotrimazole Cream at the same time. 
									
									Clotrimazole VT 500- Single dose, complete treatment with one vaginal tablet. The tablet should be inserted as deeply as possible in to the vagina. This is best achieved when lying on ones back with the knees slightly bent. It is recommended that the treatment should be timed so as to avoid the menstrual period. 
									For prevention of re-infection the partner should be treated locally with Clotrimazole Cream at the same time.
	Contara-indications : Hypersensitivity.
	Side effects : Topical: Erythema, stinging, irritation; hypersensitivity reactions; contact dermatitis. 
	Precaution : Avoid contact with eyes upon topical application. Childn <3 yrs. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Clotrimazole is a broad-spectrum antifungal which binds to phospholipids in the cell membrane altering cell wall permeability causing a loss in essential intracellular elements.
	Interaction : Antagonism with polyene antibiotics.
	Therapeutic class : Drugs used in Vaginal and Vulval conditions
	Packsize : 6's pack
Afun VT
	n : Clotrimazole VT
	Indications : Vaginal itching, burning and discharge associated with recurrent vaginal yeast infections Vulvovaginal candidiasis (Vagonal thrush).
	Doses and administration : Adult: Vaginal Vulvovaginal candidiasis:
									Clotrimazole VT 100 & 200- First infections: In general, a 3-day treatment is sufficient for Candida vaginitis. On 3 consecutive nights, Clotrimazole VT 100  or 1  Clotrimazole VT 200 are inserted as deeply as possible into the vagina. This is best achieved when lying on ones back with the knees slightly bent. 
									
									Re-infections: In general, a 6-day treatment is sufficient. This applies also to mixed infections with the above-mentioned causative organisms. On six consecutive nights, 1 Clotrimazole VT 100 is inserted as deeply as possible into the vagina. If necessary, 2 Clotrimazole VT 100 (1 in the morning and 1 in the evening) or 1 Clotrimazole VT 200 daily can be used for 6-12 days. 
									
									Treatment should be timed so as to avoid the menstrual period and be finished before the onset of menstruation. To avoid re-infection, the partner should undergo local treatment with Clotrimazole Cream at the same time. 
									
									Clotrimazole VT 500- Single dose, complete treatment with one vaginal tablet. The tablet should be inserted as deeply as possible in to the vagina. This is best achieved when lying on ones back with the knees slightly bent. It is recommended that the treatment should be timed so as to avoid the menstrual period. 
									For prevention of re-infection the partner should be treated locally with Clotrimazole Cream at the same time.
	Contara-indications : Hypersensitivity.
	Side effects : Topical: Erythema, stinging, irritation; hypersensitivity reactions; contact dermatitis. 
	Precaution : Avoid contact with eyes upon topical application. Childn <3 yrs. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Clotrimazole is a broad-spectrum antifungal which binds to phospholipids in the cell membrane altering cell wall permeability causing a loss in essential intracellular elements.
	Interaction : Antagonism with polyene antibiotics.
	Therapeutic class : Drugs used in Vaginal and Vulval conditions
	Packsize : 1's pack
Afuvin
	n : Griseofulvin
	Indications : Dermatophytosis
	Doses and administration : Adult: PO 0.5-1 g/day. Hair and skin infecions: 2-8 wk. Fingernail infections: 6 mth. Toenail infections: 12 mth or more.
									
									Child: 10 mg/kg daily.
	Contara-indications : Severe liver disease; porphyria; monilial infection; SLE; pregnancy.
	Side effects : Oral thrush; GI distress, taste perversion; dizziness, confusion, headache, depression, insomnia, fatigue; peripheral neuritis, photosensitivity; skin rashes, urticaria, erythema multiforme; leucopenia, proteinuria.
									Potentially Fatal: Hepatotoxicity; angioedema.
	Precaution : Lactation; may impair ability to drive or operate machinery; avoid exposure to intense sunlight or artificial light. Regular monitoring of the renal, hepatic and blood tests should be done.
	Pregnancy category : 3
	Mode of action : Griseofulvin is a fungistatic antibiotic that inhibits fungal cell division at metaphase and binds to human keratin making it resistant to fungal infections. It has activity against common dermatophytes including epidermophyton, Microsporum, or Trichophyton spp.
	Interaction : Antagonises oral anticoagulants and oral contraceptives. Decreased GI absorption with phenobarbital. Reduced plasma concentrations with enzyme inducers e.g. phenylbutazone and hypnotics.
				Potentially Fatal: Enhances effects of alcohol and causes disulfiram-like reaction.
	Therapeutic class : Drugs for subcutaneous and systemic mycoses
	Packsize : 100's pack
Age M
	n : Betacarotene + Vitamin C + Vitamin E  (Anti-Oxidant Vitamins and Minerals)
	Indications : Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair.
									
	Doses and administration : One tablet/capsule daily or as directed by a physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.
	Pregnancy category : 1
	Mode of action : Beta carotene is 1 of a group of red, orange, and yellow pigments called carotenoids; Dietary sources include fruits, vegetables, and whole grains.  Photoprotective effects: Exact mechanism unknown; in vitro studies suggest antioxidant effects and that beta carotene reduces free radicals and singlet oxygen, which are produced when porphyrin is exposed to light and air.
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin preparations
	Packsize : 20's pack
AGE PLUS
	n : Super Antioxidant Vitamins & Multimineral (Vitamin A + C + E + K ) + Copper  + Zinc + Manganese + Selenium
	Indications : To develop immune system.To prevent aging.Prevent certain types of cancer. Vitamin/mineral deficiency
	Doses and administration : One tablet daily or as recommended by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis, Should not use in over dosage or use continiously.
	Pregnancy category : 0
	Mode of action : Vitamin A plays an essential role in the function of retina and is essential for growh and differentiation of epithelial tissue.
									Vitamin C: Necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									Vitamins and minerals are essential for normal metabolic functions including hematopoiesis.
									Zinc is a cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system. Copper cofactor in many enzymes, including ceruloplasmin; involved in formation of iron carrier protein, transferrin. Helps maintain normal rates of red and white blood cell formation and helps prevent development of deficiency symptoms. 
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin Multimineral preparations
	Packsize : 20's pack
Agedefy
	n : Betacarotene + Vitamin C + Vitamin E  (Anti-Oxidant Vitamins and Minerals)
	Indications : Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair.
									
	Doses and administration : One tablet/capsule daily or as directed by a physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.
	Pregnancy category : 1
	Mode of action : Beta carotene is 1 of a group of red, orange, and yellow pigments called carotenoids; Dietary sources include fruits, vegetables, and whole grains.  Photoprotective effects: Exact mechanism unknown; in vitro studies suggest antioxidant effects and that beta carotene reduces free radicals and singlet oxygen, which are produced when porphyrin is exposed to light and air.
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin preparations
	Packsize : 20's pack
Aggra
	n : Sildenafil
	Indications : Altitude sickness, Pulmonary arterial hypertension, Erectile dysfunction
	Doses and administration : Oral
									Erectile dysfunction
									Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr.
									Elderly: >65 yr: Lower initial dose at 25 mg.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	Initially, 25 mg.
									
									Hepatic impairment: Initially, 25 mg.
	Contara-indications : Hypersensitivity. Patients concurrently or intermittently using organic nitrates in any form.
	Side effects : Headache, flushing, respiratory tract infection, angina pectoris, AV block, migraine, syncope, tachycardia, postural hypotension, MI, cerebral thrombosis, cardiac arrest, paraesthesia, tremor, depression, herpes simplex, skin ulcer, oesophagitis, abnormal LFT, rectal haemorrhage, hypoglycaemic reaction, arthritis, deafness, retinal vascular disease, photosensitivity, accidental fall.
	Precaution : Caution when used in patients with anatomical deformation of penis or conditions that may predispose them to priapism (e.g. sickle cell anaemia, myeloma, or leukaemia). Mild, transient, dose-related impairment of colour discrimination (blue/green) may occur. Hepatic or severe renal impairment, bleeding disorders, active peptic ulceration, hypotension, recent history of stroke, MI, arrhythmias, unstable angina, heart failure or retinal disorders. May cause sudden loss or decrease in hearing.
	Pregnancy category : 2
	Mode of action : Sildenafil inhibits phosphodiesterase type-5 (PDE5) which is responsible for cGMP degradation in the corpus cavernosum. Inhibition of PDE5 increases cGMP levels in the corpus cavernosum which results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
	Interaction : Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.
				Potentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 100ml
Aggra
	n : Sildenafil
	Indications : Altitude sickness, Pulmonary arterial hypertension, Erectile dysfunction
	Doses and administration : Oral
									Erectile dysfunction
									Adult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr.
									Elderly: >65 yr: Lower initial dose at 25 mg.
									
									Renal impairment:
									CrCl (ml/min)	
									<30	Initially, 25 mg.
									
									Hepatic impairment: Initially, 25 mg.
	Contara-indications : Hypersensitivity. Patients concurrently or intermittently using organic nitrates in any form.
	Side effects : Headache, flushing, respiratory tract infection, angina pectoris, AV block, migraine, syncope, tachycardia, postural hypotension, MI, cerebral thrombosis, cardiac arrest, paraesthesia, tremor, depression, herpes simplex, skin ulcer, oesophagitis, abnormal LFT, rectal haemorrhage, hypoglycaemic reaction, arthritis, deafness, retinal vascular disease, photosensitivity, accidental fall.
	Precaution : Caution when used in patients with anatomical deformation of penis or conditions that may predispose them to priapism (e.g. sickle cell anaemia, myeloma, or leukaemia). Mild, transient, dose-related impairment of colour discrimination (blue/green) may occur. Hepatic or severe renal impairment, bleeding disorders, active peptic ulceration, hypotension, recent history of stroke, MI, arrhythmias, unstable angina, heart failure or retinal disorders. May cause sudden loss or decrease in hearing.
	Pregnancy category : 2
	Mode of action : Sildenafil inhibits phosphodiesterase type-5 (PDE5) which is responsible for cGMP degradation in the corpus cavernosum. Inhibition of PDE5 increases cGMP levels in the corpus cavernosum which results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
	Interaction : Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.
				Potentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.
	Therapeutic class : Drugs for Erectile Dysfunction
	Packsize : 4's pack
Agoxin
	n : Digoxin
	Indications : Heart failure, Supraventricular arrhythmias, Atrial fibrillation and Atrial flutter
	Doses and administration : Adult: PO Heart failure; Supraventricular arrhythmias Rapid digitalisation: Loading dose: 0.75-1.5 mg in the 1st 24 hr. Slow digitilisation: 250 mcg 1-2 times/day. Uusal maintenance: 125-250 mcg/day. 
									
									Child: Neonate <1.5 kg: Initial: 25 mcg/kg/day in 3 divided doses for 24 hr, then 4-6 mcg/kg/day in 1-2 divided doses; neonate 1.5-2.5 kg: Initial: 30 mcg/kg/day in 3 divided doses for 24 hr, then 4-6 mcg/kg/day in 1-2 divided doses; Neonate >2.5 kg and child 1 mth-2 yr: Initial: 45 mcg/kg/day in 3 divided doses for 24 hr, then 10 mcg/kg/day in 1-2 divided doses. 2-5 yr: Initial: 35 mcg/kg/day in 3 divided doses for 24 hr, then 10 mcg/kg/day in 1-2 divided doses. 5-10 yr: Initial: 25 mcg/kg/day (max: 750 mcg/day) in 3 divided doses for 24 hr, then 6 mcg/kg/day (max: 250 mcg/day) in 1-2 divided doses. 10-18 yr: Initial: 0.75-1.5 mg/day in 3 divided doses for 24 hr, then 62.5-750 mcg/day in 1-2 divided doses. Reduce doses if patient has been given cardiac glycoside in the preceding 2 wk. 
									
									Adult: IV Emergency heart failure For patients who have not received cardiac glycosides in the previous 2 wk: 0.5-1 mg via infusion as a single dose or in divided doses. Maintenance: Usually via oral admin.
	Contara-indications : Digitalis toxicity, ventricular tachycardia/fibrillation, obstructive cardiomyopathy. Arrhythmias due to accessory pathways (e.g. Wolff-Parkinson-White syndrome).
	Side effects : Extra beats, anorexia, nausea and vomiting. Diarrhoea in elderly, confusion, dizziness, drowsiness, restlessness, nervousness, agitation and amnesia, visual disturbances, gynaecomastia, local irritation (IM/SC inj), rapid IV admin may lead to vasocostriction and transient hypertension.
									Potentially Fatal: Cardiac arrhythmias in combination with heart block.
	Precaution : Cardiac dysrhythmias, hypokalaemia, hypertension, IHD, hypercalcaemia, hypomagnesaemia, electroconversion, chronic cor pulmonale, aortic valve disease, acute myocarditis, congestive cardiomyopathies, constrictive pericarditis, heart block, elderly, renal impairment, abnormalities in thyroid function; pregnancy. IV digoxin can only be given to patients who have not received cardiac glycosides in the preceding 2 wk.
	Pregnancy category : 3
	Mode of action : Digoxin is a cardiac glycoside which has positive inotropic activity characterized by an increase in the force of myocardial contraction. It also reduces the conductivity of the heart through the atrioventricular (AV) node. Digoxin also exerts direct action on vascular smooth muscle and indirect effects mediated primarily by the autonomic nervous system and an increase in vagal activity.
	Interaction : Effectiveness reduced by phenytoin, neomycin, sulphasalazine, kaolin, pectin, antacids and in patients receiving radiotherapy. Metoclopramide may alter the absorption of solid dosage forms of digoxin. Blood levels increased by calcium channel blockers, spironolactone, quinidine and calcium salts.
				Potentially Fatal: Electrolyte imbalances such as hypokalaemia and hypomagnesemia (e.g. admin of potassium-losing diuretics, corticosteroids) can increase the risk of cardiac toxicity.
	Therapeutic class : Positive Inotropic drugs
	Packsize : 100's pack
Aire
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 50ml bot
Aire
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 50's pack
Aire
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 50's pack
AL
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 10 ml bot
Al
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 30's pack
Al DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 40's pack
Alaclov
	n : Valacyclovir
	Indications : Genital herpes, Herpes zoster, Herpes labialis, CMV infections
	Doses and administration : Oral
									Herpes zoster (shingles)
									Adult: 1 g tid for 7 days; commence within 72 hr of rash.
									Renal impairment: Patients on haemodialysis: 1 g daily after haemodialysis.
									CrCl (ml/min)	
									15-30	1 g bid.
									<15 	1 g daily.
									
									
									Genital herpes
									Adult: Initial episode: 1 g bid for up to 10 days, begin course within 72 hr of symptom onset.
									Renal impairment:
									CrCl (ml/min)	
									10-29	1 g once daily.
									<10	        500 mg once daily.
									
									
									Prophylaxis of herpes simplex infections
									Adult: Immunocompetent patients: 500 mg daily in 1-2 divided doses. Immunocompromised patients: 500 mg bid.
									Renal impairment: Patients on haemodialysis: immunocompetent patients: 250 mg once daily after haemodialysis; immunocompromised patients: 500 mg once daily after haemodialysis
									CrCl (ml/min)	
									<15 	Immunocompetent patients: 250 mg once daily; immunocompromised patients: 500 mg once daily .
									
									
									Herpes simplex infections of skin and mucous membranes
									Adult: Initial episode: 500 mg bid for up to 10 days, start treatment as early as possible. For recurrent episodes, 500 mg bid for 5 days, begin during prodromal period or as soon as symptoms appear.
									Renal impairment: Patients on haemodialysis: 500 mg daily after haemodialysis.
									CrCl (ml/min)	
									<15	           500 mg once daily.
									
									Recurrent genital herpes
									Adult: 500 mg bid for 3 days within 24 hr of first sign or symptom.
									Renal impairment:
									CrCl (ml/min)	
									<29 	500 mg once daily.
									
									Suppression of recurrent episodes of genital herpes
									Adult: Immunocompetent patients: 1 g once daily or 500 mg once daily for patients with ?9 recurrences per year; HIV infected patients with CD4 cells count ?100 cells/mm3: 500 mg bid up to 6 mth.
									Renal impairment:
									CrCl (ml/min)	
									<29	500 mg once daily if normal dose is 1 g once daily or HIV infected patients; 500 mg every 48 hr if normal dose is 500 mg once daily.
									
									Reduction of transmission of genital herpes
									Adult: In combination with safer sex practices and abstinence when lesions are present, 500 mg once daily for infected partner with history of ?9 recurrences per yr.
									Renal impairment:
									CrCl (ml/min)	
									<15	         250 mg once daily.
									
									Prophylaxis of cytomegaloviral infections in immunocompromised patients
									Adult: 2 g 4 times daily for 90 days, started within 72 hr after transplant.
									Child: >12 yr: 2 g 4 times daily for 90 days, started within 72 hr after transplant.
									Renal impairment: Patients on haemodialysis: 1.5 g once daily after haemodialysis.
									CrCl (ml/min)	
									50 to <75	1.5 g four times daily
									25 to <50	1.5 g tid
									10 to <25	1.5 g bid
									<10           	1.5 g once daily.
									
									Herpes labialis
									Adult: 2 g 12 hrly for 1 day, admin at earliest symptom of cold sore (e.g. tingling, itching or burning).
									Renal impairment:
									CrCl (ml/min)	
									30-49	1 g 12 hrly for 1 day.
									10-29	500 mg 12 hrly for 1 day.
									<10	        500 mg as a single dose.
									Hepatic impairment: Use with caution.
	Contara-indications : Hypersensitvity to valaciclovir, aciclovir.
	Side effects : Headache, nausea, vomiting, diarrhoea, rash, photosensitivity, LFT abnormalities, psychiatric reactions (e.g. confusion, hallucinations and thinking disorders) especially at high doses.
									Potentially Fatal: Hepatitis; renal failure; blood dyscrasias; thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
	Precaution : Dehydration; renal or hepatic impairment, pregnancy, lactation. Maintain adequate hydration. Monitor renal function daily especially during first 10 days post transplant.
	Pregnancy category : 2
	Mode of action : Valaciclovir is the L-valine ester of aciclovir. A prodrug, it is rapidly converted to aciclovir by intestinal and hepatic metabolism. Aciclovir inhibits DNA synthesis and viral replication and has antiviral activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella-zoster virus.
	Interaction : Increased risk of renal failure w/ nephrotoxic drugs (e.g. aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, tacrolimus). Probenecid and cimetidine may increase peak plasma concentrations and AUC of aciclovir.
	Therapeutic class : Herpes simplex & Varicella-zoster virus infections
	Packsize : 10's pack
Alacot 0.1%
	n : Olopatadine 0.1% Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration : Adults and children (above 3 years of age). One drop   in the conjunctival sac of the affected eye(s) twice daily.
									 
	Contara-indications : It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
	Side effects : Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
									Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.
	Precaution : To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.
	Pregnancy category : 3
	Mode of action : Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
	Interaction : May result in additive CNS depression w/ CNS depressants.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5  ml drop
Alacot DS
	n : Olopatadine 0.2% Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration :  Adults and children (above 2 years of age). One drop in each affected eye once a day.
	Contara-indications : It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
	Side effects : Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
									Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.
	Precaution : To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.
	Pregnancy category : 3
	Mode of action : Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
	Interaction : May result in additive CNS depression w/ CNS depressants.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5ml bot
Aladay
	n : Olopatadine 0.1% Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration : Adults and children (above 3 years of age). One drop   in the conjunctival sac of the affected eye(s) twice daily.
									 
	Contara-indications : It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
	Side effects : Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
									Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.
	Precaution : To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.
	Pregnancy category : 3
	Mode of action : Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
	Interaction : May result in additive CNS depression w/ CNS depressants.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5ml
Aladay DS
	n : Olopatadine 0.2% Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration :  Adults and children (above 2 years of age). One drop in each affected eye once a day.
	Contara-indications : It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
	Side effects : Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
									Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.
	Precaution : To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.
	Pregnancy category : 3
	Mode of action : Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
	Interaction : May result in additive CNS depression w/ CNS depressants.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 30's pack
Alafree
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50's pack
Alafree
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 30's pack
Alagra
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50ml bot
Alagra
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 30's pack
Alagra
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 30's pack
Alagra
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 30's pack
Alagra
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 30's pack
Alanil
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50ml bot
Alanil
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 3x10's pake
Alanil
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 3x10's pack
Alarex
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Alarid
	n : Ketotifen
	Indications : Allergic conjunctivitis,  Allergic conditions,  Asthma prophylaxis
	Doses and administration : Adult: PO: Tablet:
									 Asthma prophylaxis; Allergic conditions 1 mg twice daily, up to 2 mg twice daily if needed. 
									
									Syrup:
									6 months to 3 years:
									0.25 ml / kg body weight, twice daily (Once in the morning & once in the evening).
									
	Contara-indications : Acute asthma attack.
	Side effects : Sedation, drowsiness, dizziness, dry mouth, weight gain, increased appetite, CNS stimulation. Rarely, cystitis. Conjunctival injection, headaches and rhinitis (ophthalmic).
	Precaution : May impair tasks requring mental alertness e.g. driving or operating machinery. History of epilepsy. Pregnancy and lactation. Children <3 yr.
	Pregnancy category : 3
	Mode of action : Ketotifen selectively and noncompetitively inhibits the release of mediators from cells involved in hypersensitivity reactions. It is also a mast cell stabiliser.
	Interaction : Reduced platelet count with oral antidiabetics.
				Potentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.
	Therapeutic class : Cromoglycate & related drugs
	Packsize : 100's pack
Alarid
	n : Ketotifen
	Indications : Allergic conjunctivitis,  Allergic conditions,  Asthma prophylaxis
	Doses and administration : Adult: PO: Tablet:
									 Asthma prophylaxis; Allergic conditions 1 mg twice daily, up to 2 mg twice daily if needed. 
									
									Syrup:
									6 months to 3 years:
									0.25 ml / kg body weight, twice daily (Once in the morning & once in the evening).
									
	Contara-indications : Acute asthma attack.
	Side effects : Sedation, drowsiness, dizziness, dry mouth, weight gain, increased appetite, CNS stimulation. Rarely, cystitis. Conjunctival injection, headaches and rhinitis (ophthalmic).
	Precaution : May impair tasks requring mental alertness e.g. driving or operating machinery. History of epilepsy. Pregnancy and lactation. Children <3 yr.
	Pregnancy category : 3
	Mode of action : Ketotifen selectively and noncompetitively inhibits the release of mediators from cells involved in hypersensitivity reactions. It is also a mast cell stabiliser.
	Interaction : Reduced platelet count with oral antidiabetics.
				Potentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.
	Therapeutic class : Cromoglycate & related drugs
	Packsize : 100ml bot
Alarid 0.025%
	n : Ketotifen 0.25 % Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration : Adults and children over 3 years of age: 1 drop Ketotifen eye drop into the conjunctival sac of the affected eye(s) twice a day or as directed by the physician.
									
									Children below 3 years of age: Not recommended.
	Contara-indications : Patients with known hypersensitivity to ketotifen or to any of the excipients of the preparation.
	Side effects : Generally side effects of Ketotifen are localized ocular toxicity and hypersensitivity such as burning or stinging, punctate corneal epithelial erosion, dry eyes, eyelid disorder, photophobia, keratitis, lacrimation etc. Systemic side effects are very rare, there may be headache, urticaria, dry mouth and allergic reaction.
	Precaution : Eye drops contains benzalkonium chloride as a preservative, which may be deposited in soft contact lenses; thereforeKetotifen eye drops should not be instilled while the patient is wearing contact lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.
	Pregnancy category : 3
	Mode of action : Ketotifen selectively and noncompetitively inhibits the release of mediators from cells involved in hypersensitivity reactions. It is also a mast cell stabiliser.
	Interaction : Reduced platelet count with oral antidiabetics.
				Potentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5  ml drop
Alarm
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 30's pack
Alaron
	n : Loratadine
	Indications : Pneumonia, Allergic rhinitis, Pruritus, Urticaria, Sneezing, Allergic conditions, Rhinorrhea, Lacrimation
	Doses and administration : Adult and child over 6 years: One 10 mg tablet or two teaspoonful (10 ml) suspension once daily. or 5 mg 12 hrly.
									Children aged 2-5 years: 5 ml or 1 teaspoonful (5 mg) suspension once daily. 
									Loratadine is not recommended for children under 2 years of age.
	Contara-indications : Pregnancy, lactation, children <2 yr.
	Side effects : Fatigue, giddiness, dizziness, dry mouth, headache, nausea, somnolence.
	Precaution : Severe hepatic damage, epilepsy, renal insufficiency.
	Pregnancy category : 2
	Mode of action : Loratadine is a non-sedating antihistamine. It works by selectively binding to peripheral histamine H1-receptors on effector cells.
	Interaction : May increase plasma concentrations w/ inhibitors of CYP3A4 and/or CYP2D6 (e.g. cimetidine, erythromycin, ketoconazole, clarithromycin, quinidine, fluconazole, fluoxetine).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Alaron
	n : Loratadine
	Indications : Pneumonia, Allergic rhinitis, Pruritus, Urticaria, Sneezing, Allergic conditions, Rhinorrhea, Lacrimation
	Doses and administration : Adult and child over 6 years: One 10 mg tablet or two teaspoonful (10 ml) suspension once daily. or 5 mg 12 hrly.
									Children aged 2-5 years: 5 ml or 1 teaspoonful (5 mg) suspension once daily. 
									Loratadine is not recommended for children under 2 years of age.
	Contara-indications : Pregnancy, lactation, children <2 yr.
	Side effects : Fatigue, giddiness, dizziness, dry mouth, headache, nausea, somnolence.
	Precaution : Severe hepatic damage, epilepsy, renal insufficiency.
	Pregnancy category : 2
	Mode of action : Loratadine is a non-sedating antihistamine. It works by selectively binding to peripheral histamine H1-receptors on effector cells.
	Interaction : May increase plasma concentrations w/ inhibitors of CYP3A4 and/or CYP2D6 (e.g. cimetidine, erythromycin, ketoconazole, clarithromycin, quinidine, fluconazole, fluoxetine).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Alatin
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50's pack
Alatrol
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 15 ml bot
Alatrol
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Alatrol
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Alba
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Albamax DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 100's pack
Albaplex
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 100ml bot/200ml bot
Albasine
	n : Almitrine Bismesylate + Raubasine
	Indications : Cerebrovascular insufficiency, Functional rehabilitation after cerebrovascular accidents, Auditory, Vestibular and visual disorders of ischaemic aetiology, Stroke
	Doses and administration : Adult: PO Auditory, vestibular and visual disorders of ischaemic aetiology; Cerebrovascular insufficiency; Functional rehabilitation after cerebrovascular accidents Per tab contains almitrine 30 mg and raubasine 10 mg: 1 tab twice daily.
	Contara-indications : Concurrent usage with MAOIs.
	Side effects : Mild GI disorders, sleep disturbances, palpitations, anxiety, dizziness. Rarely, wt loss, peripheral neuropathy with abnormal sensations in the lower limbs.
	Precaution : Pregnancy. Long term treatment may result in numbness, prickling or formication effects in the lower limbs which may, in rare cases, lead to treatment withdrawal.
	Pregnancy category : 0
	Mode of action : Almitrine and raubasine work together to increase the amount of oxygen brought to the brain and neurosensory tissue, by increasing the oxygen content of arterial blood.
	Interaction : Not to be used concurrently with other almitrine-containing preparations.
				Potentially Fatal: MAOIs.
	Therapeutic class : Cerebral vasodilator & Neurosensory oxygenator drugs
	Packsize : 30's pack
Albatab
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 100'pack
Albazol DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Alben
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 10ml
Alben DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 100's pack
Albenda DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 20's pack
Albendox
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Albezen
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 60's pack
Albicon DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 100's pack
Albrex
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Alcet
	n : Levocetirizine Hydrochloride
	Indications : Allergic rhinitis,  Allergic conditions, Chronic idiopathic urticaria
	Doses and administration :  Adult and children 12 years of age and older: 5mg once daily
									 Children 6 to 11 years of age: 2.5mg (1/2 tablet or 1 teaspoon oral solution) once daily
									 Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) once daily
									
									Renal impairment:
									CrCl (ml/min)	
									<10 and patients undergoing dialysis	Contraindicated.
									10-29	5 mg once every 3 days.
									30-49	5 mg every other day.
									50-79	5 mg once daily.
									Hepatic impairment: No dosage adjustment needed.
	Contara-indications : Patients who are hypersensitive to this medication or to any of its ingredients.
	Side effects : Generally Levocetirizine is well tolerated. However, a few side effects like headache, dry mouth, fatigue and skin rash have been reported rarely.
	Precaution : N/A
	Pregnancy category : 2
	Mode of action : Levocetirizine is an active isomer of cetirizine which selectively competes w/ histamine for H1-receptor sites on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Possible additive adverse CNS effects w/ CNS depressants (e.g. sedatives, tranquilizers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize :  100's pack
Alcet
	n : Levocetrizine Dihydrochloride 0.1%
	Indications : Allergic rhinitis, Chronic idiopathic urticaria
	Doses and administration :  Adult and children 12 years of age and older: 5mg once daily
									 Children 6 to 11 years of age: 2.5mg (1/2 tablet or 1 teaspoon oral solution) once daily
									 Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) once daily
	Contara-indications : Lactation. End-stage renal disease (CrCl <10 ml/min) or haemodialysis patients. Child 6-11 yr with renal impairment.
	Side effects : Fatigue, somnolence, dry mouth, nasopharyngitis, pyrexia, cough, epistaxis.
	Precaution : Renal impairment. May impair ability to drive or operate machinery.
	Pregnancy category : 2
	Mode of action : Levocetirizine is an active isomer of cetirizine which selectively competes w/ histamine for H1-receptor sites on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Possible additive adverse CNS effects w/ CNS depressants (e.g. sedatives, tranquilizers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Alchek
	n : Olopatadine 0.1% Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration : Adults and children (above 3 years of age). One drop   in the conjunctival sac of the affected eye(s) twice daily.
									 
	Contara-indications : It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
	Side effects : Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
									Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.
	Precaution : To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.
	Pregnancy category : 3
	Mode of action : Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
	Interaction : May result in additive CNS depression w/ CNS depressants.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5  ml drop
Alclor
	n : Cefaclor
	Indications : Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis and Tonsillitis
	Doses and administration :  	Oral
									Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media
									Adult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.
									Child: >1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid.
									
									Suspension  & Paediatric Drops:
									1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
									1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d
									over 5 years 10 ml t.i.d 2.5 ml t.i.d
	Contara-indications : Known hypersensitivity to cephalosporins.
	Side effects : Allergic reactions; diarrhoea, nausea, vomiting; candidiasis, eosinophilia; elevated transaminases.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Severe renal impairment; history of allergy to penicillin; pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
	Interaction : May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 1's pack
Alclor
	n : Cefaclor
	Indications : Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis and Tonsillitis
	Doses and administration :  	Oral
									Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media
									Adult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.
									Child: >1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid.
									
									Suspension  & Paediatric Drops:
									1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
									1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d
									over 5 years 10 ml t.i.d 2.5 ml t.i.d
	Contara-indications : Known hypersensitivity to cephalosporins.
	Side effects : Allergic reactions; diarrhoea, nausea, vomiting; candidiasis, eosinophilia; elevated transaminases.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Severe renal impairment; history of allergy to penicillin; pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
	Interaction : May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 1's pack
Alclor
	n : Cefaclor
	Indications : Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis and Tonsillitis
	Doses and administration :  	Oral
									Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media
									Adult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.
									Child: >1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid.
									
									Suspension  & Paediatric Drops:
									1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
									1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d
									over 5 years 10 ml t.i.d 2.5 ml t.i.d
	Contara-indications : Known hypersensitivity to cephalosporins.
	Side effects : Allergic reactions; diarrhoea, nausea, vomiting; candidiasis, eosinophilia; elevated transaminases.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Severe renal impairment; history of allergy to penicillin; pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
	Interaction : May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 20's pack
Alcofen
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Alcot
	n : Sulphamethoxazole + Trimethoprim
	Indications : Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
	Doses and administration : Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. 
									Suspension : 1-2 teaspoonful twice daily.
									
									GI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. 
									
									Pneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.
									
									Child: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.
									
									Renal impairment: Dosage reduction for adults and children >12 yr:
									CrCl (ml/min)	
									15-30	Half the standard dose.
									<15	        Not recommended.
	Contara-indications : Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.
	Side effects : Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.
									Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.
	Precaution : G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.
	Pregnancy category : 4
	Mode of action : Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
	Interaction : Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
				Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
	Therapeutic class : Sulphonamides & Trimethoprim
	Packsize : 60ml bot
Alcot
	n : Sulphamethoxazole + Trimethoprim
	Indications : Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
	Doses and administration : Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. 
									Suspension : 1-2 teaspoonful twice daily.
									
									GI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. 
									
									Pneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.
									
									Child: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.
									
									Renal impairment: Dosage reduction for adults and children >12 yr:
									CrCl (ml/min)	
									15-30	Half the standard dose.
									<15	        Not recommended.
	Contara-indications : Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.
	Side effects : Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.
									Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.
	Precaution : G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.
	Pregnancy category : 4
	Mode of action : Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
	Interaction : Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
				Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
	Therapeutic class : Sulphonamides & Trimethoprim
	Packsize : 100's pack
Alcot DS
	n : Sulphamethoxazole + Trimethoprim
	Indications : Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
	Doses and administration : Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. 
									Suspension : 1-2 teaspoonful twice daily.
									
									GI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. 
									
									Pneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.
									
									Child: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.
									
									Renal impairment: Dosage reduction for adults and children >12 yr:
									CrCl (ml/min)	
									15-30	Half the standard dose.
									<15	        Not recommended.
	Contara-indications : Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.
	Side effects : Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.
									Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.
	Precaution : G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.
	Pregnancy category : 4
	Mode of action : Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
	Interaction : Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
				Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
	Therapeutic class : Sulphonamides & Trimethoprim
	Packsize : 100's pack
Alda
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 10ml bot
Alda DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 25's pack
Aldaben
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 10ml bot
Aldaben DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 25's pack
Aldes
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 10ml bot
Aldes-DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack/100's pack
Aldew
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Aldex
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 10 ml bot
Aldex DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 20's pack
Aldin DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 60's pack
Aldonist
	n : Eplerenone
	Indications : Hypertension, Heart failure, Congestive heart failure, Left ventricular dysfunction, Acute myocardial infarction
	Doses and administration : Adult: PO CHF Post-MI Initial: 25 mg once daily; titrate to recommended dose of 50 mg once daily w/in 4 wk as tolerated. Adjust dose based on serum potassium level; reduce or w/draw therapy if hyperkalaemia develops. 
									
									HTN Initial: 50 mg once daily; may increase to 50 mg twice daily based on response. Initiate at lower dose of 25 mg once daily if used concurrently w/ moderate CYP3A4 inhibitors.
	Contara-indications : For all patients: Serum potassium >5.5 mEq/L at initiation; CrCl ?30 mL/min; concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir). For patients treated for hypertension: Patients with type 2 DM with microalbuminuria; serum creatinine >2 mg/dL (male), or >1.8 mg/dL (female); CrCl <50 mL/min; concomitant use of potassium supplements or potassium-sparing diuretics (e.g. amiloride, spironolactone, or triamterene).
	Side effects : Hyperkalaemia, hyponatraemia, dizziness, headache, abdominal pain, diarrhoea, cough, fatigue, influenza-like symptoms, abnormal vaginal bleeding, gynaecomastia, mastodynia, myocardial infarction, angina pectoris, hypercholesterolaemia, hypertriglyceridaemia, albuminuria, increased creatinine, elevated liver enzymes, increased uric acid, rash and angioneurotic oedema.
	Precaution : Measure serum potassium levels before starting therapy, within the first wk, and periodically thereafter. Increased risk of hyperkalaemia in patients with impaired renal functions; diabetic patients with CHF post-MI (especially those with proteinuria); or concurrent use of agents affecting the rennin-angiotensin-aldosterone system. Safety and efficacy not established in patients with severe hepatic impairment; or paediatric patients <18 yr. Elderly. Pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g. kidney, GI tract) and nonepithelial (e.g. heart, blood vessels, brain) tissues; causing increases in blood pressure by inducing sodium reabsorption, vascular remodeling, water retention and possibly other mechanisms. Eplerenone is a relatively selective mineralocorticoid receptor antagonist, blocking binding of aldosterone and reducing blood pressure. Eplerenone also appears to have cardioprotective effect in patients with congestive heart failure (CHF) after myocardial infarction (MI).
	Interaction : Concomitant use with CYP3A4 Inhibitors (e.g. ketoconazole, voriconazole, itraconazole, fluconazole, clarithromycin, diltiazem saquinavir, verpamil, ritonavir) may increase serum concentrations of Eplerenone. CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital) may decrease Eplerenone efficacy. Eplerenone may enhance hyperkalaemic effect of ACE inhibitors, angiotensin II receptor blockers, potassium-sparing diuretics or potassium salts. Concomitant use with diazoxide, MAOIs, pentoxifylline, prostacyclin analogues may enhance hypotensive effect of antihypertensives. NSAIDs may possibly reduce the antihypertensive and/or diuretic effects of potassium-sparing diuretics and may increase risk of hyperkalaemia. Lithium toxicity has been reported when used with ACE inhibitors or diuretics; monitor lithium levels when used with Eplerenone.
	Therapeutic class : Potassium-sparing diuretics & Aldosterone antagonists
	Packsize : 28's pack
Aldorin
	n : Epalrestat
	Indications : Diabetic neuropathy
	Doses and administration :     In general, for adults, take 1 tablet (50mg of the active ingredient) at a time, three times daily, before meal. The dosage may be adjusted according to the age or symptoms. Strictly follow the instructions.
									
									  
	Contara-indications :     If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
									
									    If you are pregnant or breastfeeding.
									
									    If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
	Side effects :  The most commonly reported adverse reactions include abdominal pain, nausea, rash, itch, erythema and blister. If any of these symptoms occur, consult with your doctor or pharmacist.
	Precaution : If you find your urine yellowish brown or reddish after taking the medicine, take it as usual, because the yellowish brown or reddish color is attributed to components of this medicine.
	Pregnancy category : 0
	Mode of action : Epalrestat is aldose reductase inhibitor. The aldose reductase inhibitors have a distinct mechanism of action, affecting the underlying disease process in diabetic neuropathy, although the extent of the polyol pathway involvement is yet to be determined. Epalrestat reduces sorbitol accumulation in the sciatic nerve, erythrocytes. Epalrestat may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms.
	Interaction : None
	Therapeutic class : Aldose reductase inhibitor
	Packsize : 24's pack
Alendon
	n : Alendronic Acid
	Indications : Osteopetrosis, postmenopausal osteoporosis, Paget's disease of bone.
	Doses and administration : Adult: PO Osteoporosis 10 mg/day or 70 mg once wkly. Prevention of postmenopausal osteoporosis 5 mg/day or 35 mg once wkly. Corticosteroid-induced osteoporosis 5 mg/day; up to 10 mg/day in women not on HRT treatment. Paget's disease of bone 40 mg/day for 6 mth. May repeat after an interval of 6 mth if needed.
									
									Renal impairment:
									CrCl (ml/min)	
									<35	        Not recommended.
									
	Contara-indications : Hypocalcaemia; oesophageal abnormalities and factors which delay oesophageal emptying; severe renal impairment; hypersensitivity; inability to stand or sit upright for ?30 min. Pregnancy, lactation.
	Side effects : Oesophagitis, oesophageal ulcers and erosions, dysphagia, heartburn, retrosternal pain, abdominal pain, distension, diarrhoea, constipation, flatulence, headache, rash, erythema, musculoskeletal pain, transient decreases in serum phosphate.
	Precaution : Upper GI disorders (discontinue if symptoms worsen); history of ulcers, active GI bleeding. Correct vitamin D and calcium deficiency before starting therapy. To be taken half an hr before breakfast and remain upright for at least 30 minutes after admin. Not recommended for use in patients with CrCl <35 ml/min.
	Pregnancy category : 3
	Mode of action : Alendronic acid reduces bone resorption by inhibiting the action of osteoclasts.
	Interaction : Concomitant iron, calcium supplements and antacids hinder alendronate absorption. Concomitant aspirin or NSAIDs may increase the incidence of adverse GI effects.
	Therapeutic class : Bisphosphonate preparations
	Packsize : 30's pack
Alendon
	n : Alendronic Acid
	Indications : Osteopetrosis, postmenopausal osteoporosis, Paget's disease of bone.
	Doses and administration : Adult: PO Osteoporosis 10 mg/day or 70 mg once wkly. Prevention of postmenopausal osteoporosis 5 mg/day or 35 mg once wkly. Corticosteroid-induced osteoporosis 5 mg/day; up to 10 mg/day in women not on HRT treatment. Paget's disease of bone 40 mg/day for 6 mth. May repeat after an interval of 6 mth if needed.
									
									Renal impairment:
									CrCl (ml/min)	
									<35	        Not recommended.
									
	Contara-indications : Hypocalcaemia; oesophageal abnormalities and factors which delay oesophageal emptying; severe renal impairment; hypersensitivity; inability to stand or sit upright for ?30 min. Pregnancy, lactation.
	Side effects : Oesophagitis, oesophageal ulcers and erosions, dysphagia, heartburn, retrosternal pain, abdominal pain, distension, diarrhoea, constipation, flatulence, headache, rash, erythema, musculoskeletal pain, transient decreases in serum phosphate.
	Precaution : Upper GI disorders (discontinue if symptoms worsen); history of ulcers, active GI bleeding. Correct vitamin D and calcium deficiency before starting therapy. To be taken half an hr before breakfast and remain upright for at least 30 minutes after admin. Not recommended for use in patients with CrCl <35 ml/min.
	Pregnancy category : 3
	Mode of action : Alendronic acid reduces bone resorption by inhibiting the action of osteoclasts.
	Interaction : Concomitant iron, calcium supplements and antacids hinder alendronate absorption. Concomitant aspirin or NSAIDs may increase the incidence of adverse GI effects.
	Therapeutic class : Bisphosphonate preparations
	Packsize : 30's pack
Alenia
	n : Esomeprazole Magnesium Trihydrate BP
	Indications : Heartburn, Acid Related Dyspepsia, Peptic ulcer disease, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Helicobacter pylori infection, Erosive Esophagitis, Gouty arthritis, Duodenal and Gastric Ulcer.
	Doses and administration : Adult: PO: Erosive oesophagitis: 40 mg once daily for 4 wk, up to 8 wk if needed. Maintenance: 20 mg/day.  
									
									Peptic ulcer: 20 mg twice daily for 7 days. NSAID-associated ulceration 20 mg once daily for 4-8 wk.  
									
									Zollinger-Ellison syndrome Initial: 40 mg twice daily. Usual range: 80-160 mg/day.  
									
									Gastro-oesophageal reflux disease: 20 mg once daily for 4 wk.  The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered.  Delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating. 
	Contara-indications : Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.
	Side effects : The most frequently occurring adverse events ( >1%) are headache, diarrhoea, abdominal pain, nausea, flatulence, dry mouth, constipation.
	Precaution : Paediatric; pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia. For patients with severe liver impairment, a dose of 20 mg should not be exceeded.
	Pregnancy category : 3
	Mode of action : Esomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
	Interaction : Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.
				
				Potentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 64's pack
Alenia
	n : Esomeprazole Magnesium Trihydrate BP
	Indications : Heartburn, Acid Related Dyspepsia, Peptic ulcer disease, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Helicobacter pylori infection, Erosive Esophagitis, Gouty arthritis, Duodenal and Gastric Ulcer.
	Doses and administration : Adult: PO: Erosive oesophagitis: 40 mg once daily for 4 wk, up to 8 wk if needed. Maintenance: 20 mg/day.  
									
									Peptic ulcer: 20 mg twice daily for 7 days. NSAID-associated ulceration 20 mg once daily for 4-8 wk.  
									
									Zollinger-Ellison syndrome Initial: 40 mg twice daily. Usual range: 80-160 mg/day.  
									
									Gastro-oesophageal reflux disease: 20 mg once daily for 4 wk.  The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered.  Delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating. 
	Contara-indications : Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.
	Side effects : The most frequently occurring adverse events ( >1%) are headache, diarrhoea, abdominal pain, nausea, flatulence, dry mouth, constipation.
	Precaution : Paediatric; pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia. For patients with severe liver impairment, a dose of 20 mg should not be exceeded.
	Pregnancy category : 3
	Mode of action : Esomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
	Interaction : Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.
				
				Potentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 30's pack
Alenia-40
	n : Esomeprazole Magnesium Trihydrate BP
	Indications : Heartburn, Acid Related Dyspepsia, Peptic ulcer disease, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Helicobacter pylori infection, Erosive Esophagitis, Gouty arthritis, Duodenal and Gastric Ulcer.
	Doses and administration : Adult: PO: Erosive oesophagitis: 40 mg once daily for 4 wk, up to 8 wk if needed. Maintenance: 20 mg/day.  
									
									Peptic ulcer: 20 mg twice daily for 7 days. NSAID-associated ulceration 20 mg once daily for 4-8 wk.  
									
									Zollinger-Ellison syndrome Initial: 40 mg twice daily. Usual range: 80-160 mg/day.  
									
									Gastro-oesophageal reflux disease: 20 mg once daily for 4 wk.  The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered.  Delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating. 
	Contara-indications : Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.
	Side effects : The most frequently occurring adverse events ( >1%) are headache, diarrhoea, abdominal pain, nausea, flatulence, dry mouth, constipation.
	Precaution : Paediatric; pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia. For patients with severe liver impairment, a dose of 20 mg should not be exceeded.
	Pregnancy category : 3
	Mode of action : Esomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
	Interaction : Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.
				
				Potentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 30's pack
Alentin
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 80's pack
Alentin DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 25's pack
Alercon
	n : Olopatadine 0.1% Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration : Adults and children (above 3 years of age). One drop   in the conjunctival sac of the affected eye(s) twice daily.
									 
	Contara-indications : It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
	Side effects : Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
									Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.
	Precaution : To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.
	Pregnancy category : 3
	Mode of action : Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
	Interaction : May result in additive CNS depression w/ CNS depressants.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5  ml drop
Alercon
	n : Olopatadine 0.6% Nasal prep
	Indications : Allergic rhinitis
	Doses and administration : Adults and Adolescents 12 years of age and older: Two sprays per nostril twice daily.
									Children 6 to 11 years of age: One spray per nostril twice daily.
	Contara-indications : It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
	Side effects : Side Effects
									A bitter taste in the mouth, nosebleeds, or irritation/soreness in the nose may occur. Drowsiness may rarely occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
	Precaution : Priming: Before initial use, prime   Nasal Spray by releasing 5 sprays or until a fine mist appears. When  Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays. Avoid spraying   Nasal Spray into the eyes.
				Patients should be informed to avoid spraying  Nasal Spray in their eyes.
	Pregnancy category : 3
	Mode of action : Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
	Interaction : May result in additive CNS depression w/ CNS depressants.
	Therapeutic class : Nasal Anti-histamine preparations
	Packsize : None
Alerfast
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 30's pack
Alerfex
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50ml bot
Alerfex
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize :  30's pack
Alerfex
	n : Fexofenadine Hydrochloride
	Indications : Allergic rhinitis, Hay fever, Urticaria, Allergy
	Doses and administration : Adults:
									Allergic rhinitis: 120 mg once daily or 60 mg twice daily
									Urticaria: 180 mg once daily
									
									Children:
									2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
									6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily
	Contara-indications : Hypersensitivity.
	Side effects : Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.
	Precaution : Renal impairment. Pregnancy, lactation; children <6 yr.
	Pregnancy category : 3
	Mode of action : Fexofenadine, an active metabolite of terfenadine, is a competitive peripheral histamine H1-receptor antagonist on effector cells in the GI tract, blood vessels and respiratory tract.
	Interaction :  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 20's pack
Alerjess
	n : Chlorpheniramine Maleate
	Indications : Urticaria, Sneezing, Watery eyes,  Allergic conditions, Anaphylactic shock, Rhinitis, Itching
	Doses and administration : Adult: 4 mg every 4-6 hr. Max: 24 mg daily. 
									Child: 1-2 yr: 1 mg bid, 2-5 yr: 1 mg every 4-6 hr, 6-12 yr: 2 mg every 4-6 hr. Max: 6 mg daily (1-5 yr); 12 mg daily (6-12 yr). 
									
									Parenteral
									Adjunct in the emergency treatment of anaphylactic shock
									Adult: 10-20 mg IM, SC, or slow IV inj over 1 min. Max dose: 40 mg daily.
									Child: 87.5 mcg/kg SC 4 times daily
									
									
	Contara-indications : Hypersensitivity, Neonates.
	Side effects : CNS depression, sedation, drowsiness, lassitude, dizziness. GI upsets, anorexia, or increased appetite, epigastric pain, blurring of vision, dysuria, dryness of mouth, tightness in chest, hypotension, muscular weakness, tinnitus, euphoria, headache, paradoxical CNS stimulation.
									Potentially Fatal: CV collapse and respiratory failure.
	Precaution : Elderly, pylori duodenal obstruction, angle-closure glaucoma, urinary retention, prostatic hyperplasia, epilepsy, renal and hepatic impairment. May affect performance of skilled tasks. BPH, bladder neck obstruction, hypertension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Chlorphenamine is an H1-receptor antagonist which competetively blocks H1-receptor sites on tissues.
	Interaction : Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).
	Therapeutic class : Sedating Anti-histamines
	Packsize : 100ml bot
Alerjess
	n : Chlorpheniramine Maleate
	Indications : Urticaria, Sneezing, Watery eyes,  Allergic conditions, Anaphylactic shock, Rhinitis, Itching
	Doses and administration : Adult: 4 mg every 4-6 hr. Max: 24 mg daily. 
									Child: 1-2 yr: 1 mg bid, 2-5 yr: 1 mg every 4-6 hr, 6-12 yr: 2 mg every 4-6 hr. Max: 6 mg daily (1-5 yr); 12 mg daily (6-12 yr). 
									
									Parenteral
									Adjunct in the emergency treatment of anaphylactic shock
									Adult: 10-20 mg IM, SC, or slow IV inj over 1 min. Max dose: 40 mg daily.
									Child: 87.5 mcg/kg SC 4 times daily
									
									
	Contara-indications : Hypersensitivity, Neonates.
	Side effects : CNS depression, sedation, drowsiness, lassitude, dizziness. GI upsets, anorexia, or increased appetite, epigastric pain, blurring of vision, dysuria, dryness of mouth, tightness in chest, hypotension, muscular weakness, tinnitus, euphoria, headache, paradoxical CNS stimulation.
									Potentially Fatal: CV collapse and respiratory failure.
	Precaution : Elderly, pylori duodenal obstruction, angle-closure glaucoma, urinary retention, prostatic hyperplasia, epilepsy, renal and hepatic impairment. May affect performance of skilled tasks. BPH, bladder neck obstruction, hypertension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Chlorphenamine is an H1-receptor antagonist which competetively blocks H1-receptor sites on tissues.
	Interaction : Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).
	Therapeutic class : Sedating Anti-histamines
	Packsize : 200's pack
Alert
	n : Loratadine
	Indications : Pneumonia, Allergic rhinitis, Pruritus, Urticaria, Sneezing, Allergic conditions, Rhinorrhea, Lacrimation
	Doses and administration : Adult and child over 6 years: One 10 mg tablet or two teaspoonful (10 ml) suspension once daily. or 5 mg 12 hrly.
									Children aged 2-5 years: 5 ml or 1 teaspoonful (5 mg) suspension once daily. 
									Loratadine is not recommended for children under 2 years of age.
	Contara-indications : Pregnancy, lactation, children <2 yr.
	Side effects : Fatigue, giddiness, dizziness, dry mouth, headache, nausea, somnolence.
	Precaution : Severe hepatic damage, epilepsy, renal insufficiency.
	Pregnancy category : 2
	Mode of action : Loratadine is a non-sedating antihistamine. It works by selectively binding to peripheral histamine H1-receptors on effector cells.
	Interaction : May increase plasma concentrations w/ inhibitors of CYP3A4 and/or CYP2D6 (e.g. cimetidine, erythromycin, ketoconazole, clarithromycin, quinidine, fluconazole, fluoxetine).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Alertadin
	n : Desloratadine
	Indications : Itching, Sneezing, Watery eyes, Allergic conditions, Runny nose, Hives, Skin rash, Common cold
	Doses and administration : Adults and adolescent of 12 years or over : 5 mg once daily.
									Child 6-11 years : 2.5 mg once daily.
									Child 12 months-5 years : 1.25 mg (2.5 ml syrup) once daily.
									Child 6 months-11 months : 1 mg (2 ml syrup) once daily.
	Contara-indications : Hypersensitivity.
	Side effects : Headache, fatigue, somnolence, dizziness; nausea, dyspepsia; xerostomia, dysmenorrhoea; pharyngitis.
	Precaution : Severe renal or hepatic failure; children <6 mth, elderly, epilepsy, pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Desloratadine is a long-acting, tricyclic, non-sedating, selective peripheral histamine H1-receptor antagonist which inhibits the release of pro-inflammatory mediators from human mast cells and basophils.
	Interaction :  	Potential increase in plasma concentrations w/ drugs affecting hepatic microsomal enzymes (e.g. azithromycin, cimetidine, erythromycin, fluoxetine, ketoconazole).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Alervil
	n : Pheniramine Maleate
	Indications : Allergic conjunctivitis, Allergic conditions, Motion sickness
	Doses and administration :  Adult: PO Allergic conditions; Prevention of motion sickness As maleate: 
									Syr: 15-30 mg 2-3 times/day. 
									Tab: Up to 45 mg 3 times/day. Max: 3 mg/kg/day. 
									For motion sickness prevention: Take 1st dose at least 30 mins before travelling. 
									
									Children aged 1-3 years:  Half a measuring spoonful 2 or 3 times daily.
									Children aged 4-12 years: 1 measuring spoonful 2 or 3 times daily.
									
	Contara-indications : Symptomatic prostatic hypertrophy; neonates and premature infants.
	Side effects : Oral: Sedation. Hypersensitivity reactions. Lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. Nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. Urinary retention. Palpitations, headache. Blurred vision, increased intraocular pressure. Muscular weakness. Rarely, blood dyscrasias e.g. agranulocytosis, haemolytic anaemia. Ophthalmic: Temporarily enlarged pupils, eye redness (overuse).
	Precaution :  	May impair ability to drive or operate machinery. Has potential for abuse. Narrow angle glaucoma, asthma or severe CV disease. Antiemetic effect may mask signs of other conditions. Pregnancy and lactation. Elderly.
	Pregnancy category : 3
	Mode of action : Pheniramine is an alkylamine derivative with histamine H1-receptor antagonist effects. It also has anticholinergic and moderate sedative effects.
	Interaction : May mask ototoxicity produced by aminoglycoside antibiotics.
				
				Potentially Fatal: Potentiation of CNS depression by alcohol, sedatives, opioids, barbiturates, hypnotics, narcoleptics. May increase antimuscarinic effect of MAOIs, atropine and TCAs.
	Therapeutic class : Sedating Anti-histamines
	Packsize : 75ml bot
Alestin
	n : Ebastine
	Indications : Allergic rhinitis, Allergic conditions, Chronic idiopathic urticaria
	Doses and administration : Adult: PO 10-20 mg once daily.
									Child: >6 yr: 5 mg once daily.
	Contara-indications : Hypersensitivity, cardiac arrhythmias.
	Side effects : Headache, dry mouth, drowsiness, pharyngitis, abdominal pain, dyspepsia, asthenia, epistaxis, rhinitis, sinusitis, nausea, insomnia.
	Precaution : Caution is advised when used in hepatic impairment, renal insufficiency, QTc interval prolongation. Pregnancy, lactation.
	Pregnancy category : 0
	Mode of action : Ebastine, a piperidine derivative, is a long-acting, nonsedating, second-generation histamine receptor antagonist that binds preferentially to peripheral H1 receptors. It is metabolised to active metabolite, carebastine. It has antihistaminic, antiallergic activity and prevents histamine-induced bronchoconstriction. It does not have significant sedative or antimuscarinic actions.
	Interaction : Concomitant use of ketoconazole, itraconazole, clarithromycin or erythromycin may increase plasma levels of ebastine and cause QTc interval prolongation.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50's pack
Alestin
	n : Ebastine
	Indications : Allergic rhinitis, Allergic conditions, Chronic idiopathic urticaria
	Doses and administration : Adult: PO 10-20 mg once daily.
									Child: >6 yr: 5 mg once daily.
	Contara-indications : Hypersensitivity, cardiac arrhythmias.
	Side effects : Headache, dry mouth, drowsiness, pharyngitis, abdominal pain, dyspepsia, asthenia, epistaxis, rhinitis, sinusitis, nausea, insomnia.
	Precaution : Caution is advised when used in hepatic impairment, renal insufficiency, QTc interval prolongation. Pregnancy, lactation.
	Pregnancy category : 0
	Mode of action : Ebastine, a piperidine derivative, is a long-acting, nonsedating, second-generation histamine receptor antagonist that binds preferentially to peripheral H1 receptors. It is metabolised to active metabolite, carebastine. It has antihistaminic, antiallergic activity and prevents histamine-induced bronchoconstriction. It does not have significant sedative or antimuscarinic actions.
	Interaction : Concomitant use of ketoconazole, itraconazole, clarithromycin or erythromycin may increase plasma levels of ebastine and cause QTc interval prolongation.
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50ml bot
Aletrin
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Alexid
	n : Pivmecillinam
	Indications : Acute uncomplicated cystitis, Chronic or recurrent bacteriuria
	Doses and administration : Oral
									Acute uncomplicated cystitis
									Adult: Initially 400 mg followed by 200 mg tid for 8 doses.
									Child: <40 kg with UTI: 20-40 mg/kg/day in 3-4 divided doses.
									
									Chronic or recurrent bacteriuria
									Adult: 400 mg 3-4 times daily.
									Child: <40 kg with UTI: 20-40 mg/kg/day in 3-4 divided doses.
	Contara-indications : Hypersensitivity, porphyria.
	Side effects : Hypersensitivity reactions including uticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropaenia; thrombocytopaenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis. Induction of carnitine deficiency.
									Potentially Fatal: Anaphylaxis.
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum K concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route. May cause oesophageal injury.
	Pregnancy category : 2
	Mode of action : Pivmecillinam has the antimicrobial activity of mecillinam to which it is hydrolysed in vivo. It interferes with the synthesis of bacterial cell wall. It is active against many gm-ve bacteria, esp Enterobacteriaceae including Escherichia coli, Enterobacter, Klebsiella, Salmonella and Shigella spp; indole-positive Proteus and Serratia marcescens are resistant. It is inactivated by ?-lactamases, but is more stable than ampicillin.
	Interaction : Probenecid prolongs T1/2 of pivmecillinam. May cause prolonged bleeding when taken with anticoagulants. May decrease the efficacy of oral contraceptives. Increased risk of carnitine deficiency when used with valproate.
	Therapeutic class : Mecillinams
	Packsize : 50's pack
Alexin
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 50's pack
Alexin
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 50's pack
Alexin
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Aleze
	n : Loratadine
	Indications : Pneumonia, Allergic rhinitis, Pruritus, Urticaria, Sneezing, Allergic conditions, Rhinorrhea, Lacrimation
	Doses and administration : Adult and child over 6 years: One 10 mg tablet or two teaspoonful (10 ml) suspension once daily. or 5 mg 12 hrly.
									Children aged 2-5 years: 5 ml or 1 teaspoonful (5 mg) suspension once daily. 
									Loratadine is not recommended for children under 2 years of age.
	Contara-indications : Pregnancy, lactation, children <2 yr.
	Side effects : Fatigue, giddiness, dizziness, dry mouth, headache, nausea, somnolence.
	Precaution : Severe hepatic damage, epilepsy, renal insufficiency.
	Pregnancy category : 2
	Mode of action : Loratadine is a non-sedating antihistamine. It works by selectively binding to peripheral histamine H1-receptors on effector cells.
	Interaction : May increase plasma concentrations w/ inhibitors of CYP3A4 and/or CYP2D6 (e.g. cimetidine, erythromycin, ketoconazole, clarithromycin, quinidine, fluconazole, fluoxetine).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50's pack
Aleze
	n : Loratadine
	Indications : Pneumonia, Allergic rhinitis, Pruritus, Urticaria, Sneezing, Allergic conditions, Rhinorrhea, Lacrimation
	Doses and administration : Adult and child over 6 years: One 10 mg tablet or two teaspoonful (10 ml) suspension once daily. or 5 mg 12 hrly.
									Children aged 2-5 years: 5 ml or 1 teaspoonful (5 mg) suspension once daily. 
									Loratadine is not recommended for children under 2 years of age.
	Contara-indications : Pregnancy, lactation, children <2 yr.
	Side effects : Fatigue, giddiness, dizziness, dry mouth, headache, nausea, somnolence.
	Precaution : Severe hepatic damage, epilepsy, renal insufficiency.
	Pregnancy category : 2
	Mode of action : Loratadine is a non-sedating antihistamine. It works by selectively binding to peripheral histamine H1-receptors on effector cells.
	Interaction : May increase plasma concentrations w/ inhibitors of CYP3A4 and/or CYP2D6 (e.g. cimetidine, erythromycin, ketoconazole, clarithromycin, quinidine, fluconazole, fluoxetine).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Alfa E
	n : Vitamin E  (Alpha-tocopherol)
	Indications : Cardiovascular disease,Male infertility,Diabetes,Obesity,Vitamin E deficiency and peripheral neuropathy,Macular Degeneration
	Doses and administration : Adult: Betterment of Cardiovascular health: 400 mg - 800 mg / day Deficiency syndrome in adults: 200 mg - 400 mg / day Deficiency syndrome in children: 200 mg / day Thalassemia: 800 mg / day Sickle-cell anemia: 400 mg / day Betterment of Skin & Hair: 200 mg - 400 mg / day. Chronic cold in adults: 200 mg / day 
	Contara-indications : There is no absolute contraindication except known hypersensitivity to vitamin E.
	Side effects : Vitamin E is usually well tolerated. Large doses (more than 400 mg/day) for prolonged period have been associated with a variety of less serious side effects including fatigue, weakness, headache, nausea, blurred vision, flatulence or diarrhoea.
	Precaution : Vitamin E may enhance the anticoagulant activity of anticoagulant drugs.
	Pregnancy category : 1
	Mode of action : Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
	Interaction : Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.
	Therapeutic class : Vitamin-E Preparations
	Packsize : 15's pack
Alfasin XR
	n : Alfuzosin
	Indications : Benign prostatic hyperplasia (BPH)
	Doses and administration : Oral
									Benign prostatic hyperplasia
									Adult: 2.5 mg tid. Max: 10 mg/day. 1st dose should be given before bedtime. Extended-release: 10 mg once daily.
									
									Elderly: Initially, 2.5 mg bid. Acute urinary retention: Extended-release: 10 mg once daily to be taken from 1st day of catheterisation. Duration: 3-4 days.
									
									Hepatic impairment: Mild to moderate: Initially, 2.5 mg daily, may increase to 2.5 mg bid according to response. Severe: Contraindicated.
	Contara-indications : Severe hepatic impairment; history of postural hypotension and micturition syncope; intestinal occlusion; severe renal insufficiency; lactation.
	Side effects : Drowsiness, postural hypotension, syncope, asthenia, depression, headache, dry mouth, GI disturbances, edema, blurred vision, rhinitis, erectile disorders, tachycardia, palpitation, hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy.
	Precaution : Elderly; hypertension; coronary insufficiency; angina (discontinue); renal or hepatic impairment. Monitor BP regularly. May affect ability to drive or operate machinery.
	Pregnancy category : 2
	Mode of action : Alfuzosin is a quinazoline derivative which exhibits selectivity for ?1-adrenergic receptors in the lower urinary tract. Blockade of these adrenoreceptors causes relaxation of smooth muscle in the bladder neck and prostate, resulting in improvement in urine flow and a reduction in symptoms of benign prostatic hyperplasia (BPH).
	Interaction : Additive effect on QT interval prolongation when used w/ QT-prolonging drugs. Concomitant admin w/ other ?1-adrenergic blocking agents, atenolol or diltiazem may result in additive CV effects. Increased plasma alfuzosin concentrations w/ cimetidine.
				Potentially Fatal: Concurrent use w/ potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir) increase plasma alfuzosin levels.
	Therapeutic class : Alpha adrenoceptor blocking drugs
	Packsize :  24's pack
Alfil
	n : Iron +  Folic Acid  +   Vitamin B  +  Vitamin C
	Indications : Nutritional deficiency in pregnancy & lactation.
	Doses and administration : 1 capsule daily or in more severe cases 2 capsules daily or as directed by the physician.
									
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients, haemolytic anemia.
	Side effects : Allergic sensitization has been reported following oral administration. May cause constipation.
	Precaution : Iron chelates with antacid and tetracycline and absorption of all these may be impaired. 
	Pregnancy category : 0
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
									Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. 
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
	Interaction : Iron: Antacids may decrease the absorption of carbonyl iron.
				
				Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
				
				Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.
				
				
				
	Therapeutic class : Iron & Vitamin Combined preparations
	Packsize : 30's pack
Algex
	n : Aluminium Hydroxide + Magnesium Hydroxide
	Indications : Heartburn, Reflux oesophagitis, Hyperacidity, Peptic ulcer, Constipation, Indigestion
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200's pack
Algex
	n : Aluminium Oxide + Magnesium Hydroxide
	Indications : Hyperacidity, Flatulence, Gastric ulcer, Duodenal ulcer, Gastritis, Stomach distension
	Doses and administration : Chew 1-2 tablets after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. For best results, drink a half glass of water or other liquid after each dose. Do not take more than 16 tablets in 24 hours
	Contara-indications : Hypophosphataemia.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200ml bot
Algicid
	n : Potassium Bicarbonate + Sodium Alginate
	Indications : Heartburn, Indigestion, Gastro-oesophageal reflux, Acid regurgitation, Reflux esophagitis
	Doses and administration : Daily 4 times, after meals & before bedtime.
									Tablet
									Adult and child over 12 years: 1-2 tablets.
									Child 6-12 years: 1 tablet.
									
									Suspension
									Adult and child over 12 years: 5-10 ml.
									Child 2-12 years: 2.5-5 ml.
									It is not recommended for children under 2 years of age.
	Contara-indications : Sodium alginate and potassium bicarbonate is contraindicated in patients with known hypersensitivity to these.
	Side effects : In addition to the desired effect of the drug, some side effects may appear such as: nausea, constipation, diarrhea or headache. In these cases consult a physician In case too big dosage has been taken, there might appear a sensation of swelling. In this case it is advisable to consult a physician.
	Precaution : This should be prescribed with caution in patients with renal impairment and congestive cardiac failure.
	Pregnancy category : 0
	Mode of action : Potassium depletion occurs when rate of loss through renal excretion and/or GI tract exceeds intake. Supplementation with potassium-containing products may alleviate depletion. Potassium plays essential role in the conduction of nerve impulses in the heart, brain, and skeletal muscle; plays a role in contraction of cardiac, skeletal, and smooth muscles.
									
									Alginic acid is used in combination with an antacid or histamine H2-antagonist in the management of gastro-esophageal reflux disease. It reacts with gastric acid to form a viscous gel which acts as a mechanical barrier to reduce reflux.
	Interaction : None
	Therapeutic class : Antacids
	Packsize : 100's pack
Algicid
	n : Potassium Bicarbonate + Sodium Alginate
	Indications : Heartburn, Indigestion, Gastro-oesophageal reflux, Acid regurgitation, Reflux esophagitis
	Doses and administration : Daily 4 times, after meals & before bedtime.
									Tablet
									Adult and child over 12 years: 1-2 tablets.
									Child 6-12 years: 1 tablet.
									
									Suspension
									Adult and child over 12 years: 5-10 ml.
									Child 2-12 years: 2.5-5 ml.
									It is not recommended for children under 2 years of age.
	Contara-indications : Sodium alginate and potassium bicarbonate is contraindicated in patients with known hypersensitivity to these.
	Side effects : In addition to the desired effect of the drug, some side effects may appear such as: nausea, constipation, diarrhea or headache. In these cases consult a physician In case too big dosage has been taken, there might appear a sensation of swelling. In this case it is advisable to consult a physician.
	Precaution : This should be prescribed with caution in patients with renal impairment and congestive cardiac failure.
	Pregnancy category : 0
	Mode of action : Potassium depletion occurs when rate of loss through renal excretion and/or GI tract exceeds intake. Supplementation with potassium-containing products may alleviate depletion. Potassium plays essential role in the conduction of nerve impulses in the heart, brain, and skeletal muscle; plays a role in contraction of cardiac, skeletal, and smooth muscles.
									
									Alginic acid is used in combination with an antacid or histamine H2-antagonist in the management of gastro-esophageal reflux disease. It reacts with gastric acid to form a viscous gel which acts as a mechanical barrier to reduce reflux.
	Interaction : None
	Therapeutic class : Antacids
	Packsize : 200ml bot
Algin
	n : Tiemonium Methylsulphate
	Indications : Dysentery, Diarrhoea, Gastroenteritis, Biliary colic, Enterocolitis, Cholecystitis, Colonopathies, Mild cystitis and spasmodic dysmenorrhoea, Visceral muscle spasm
	Doses and administration : Tablet: The usual dosages of Timozin are 2 to 6 tablets (100-300 mg) daily in divided doses as required.
									Injection: 1 ampoule by slow IV/IM injection 3 times daily.
	Contara-indications : This drug must not be used in glaucoma (acute pain in the eyeball with disorders of vision), difficulties in urinating (disorders of the prostate or bladder).
	Side effects : Tiemonium Methylsulfate INN may have some undesirable effects in certain individuals like risk of hypotension and tachycardia especially in case of injection.
	Precaution : Precautions should be exercised for treatment of patients with disorders of the prostate, serious diseases of the kidney or liver, cardiac disorders, thyroid disorders, chronic bronchitis and certain gastrointestinal diseases. The risks of visual disturbances can make it dangerous to drive or use machines.
	Pregnancy category : 0
	Mode of action : Tiemonium Methylsulfate) is a synthetic anticholinergic-antispasmodic drug. Tiemonium are quaternary ammonium antimuscarinic agent with peripheral effect similar to those of atropine. Tiemonium strengthens calcium bonding with phospho lipids and proteins thus stabilizing the cell membrane of the GI tract.
	Interaction : None
	Therapeutic class : Anticholinergics(others)
	Packsize : 100ml bot
Algin
	n : Tiemonium Methylsulphate
	Indications : Dysentery, Diarrhoea, Gastroenteritis, Biliary colic, Enterocolitis, Cholecystitis, Colonopathies, Mild cystitis and spasmodic dysmenorrhoea, Visceral muscle spasm
	Doses and administration : Tablet: The usual dosages of Timozin are 2 to 6 tablets (100-300 mg) daily in divided doses as required.
									Injection: 1 ampoule by slow IV/IM injection 3 times daily.
	Contara-indications : This drug must not be used in glaucoma (acute pain in the eyeball with disorders of vision), difficulties in urinating (disorders of the prostate or bladder).
	Side effects : Tiemonium Methylsulfate INN may have some undesirable effects in certain individuals like risk of hypotension and tachycardia especially in case of injection.
	Precaution : Precautions should be exercised for treatment of patients with disorders of the prostate, serious diseases of the kidney or liver, cardiac disorders, thyroid disorders, chronic bronchitis and certain gastrointestinal diseases. The risks of visual disturbances can make it dangerous to drive or use machines.
	Pregnancy category : 0
	Mode of action : Tiemonium Methylsulfate) is a synthetic anticholinergic-antispasmodic drug. Tiemonium are quaternary ammonium antimuscarinic agent with peripheral effect similar to those of atropine. Tiemonium strengthens calcium bonding with phospho lipids and proteins thus stabilizing the cell membrane of the GI tract.
	Interaction : None
	Therapeutic class : Anticholinergics(others)
	Packsize : 5 amps pack
Algin
	n : Tiemonium Methylsulphate
	Indications : Dysentery, Diarrhoea, Gastroenteritis, Biliary colic, Enterocolitis, Cholecystitis, Colonopathies, Mild cystitis and spasmodic dysmenorrhoea, Visceral muscle spasm
	Doses and administration : Tablet: The usual dosages of Timozin are 2 to 6 tablets (100-300 mg) daily in divided doses as required.
									Injection: 1 ampoule by slow IV/IM injection 3 times daily.
	Contara-indications : This drug must not be used in glaucoma (acute pain in the eyeball with disorders of vision), difficulties in urinating (disorders of the prostate or bladder).
	Side effects : Tiemonium Methylsulfate INN may have some undesirable effects in certain individuals like risk of hypotension and tachycardia especially in case of injection.
	Precaution : Precautions should be exercised for treatment of patients with disorders of the prostate, serious diseases of the kidney or liver, cardiac disorders, thyroid disorders, chronic bronchitis and certain gastrointestinal diseases. The risks of visual disturbances can make it dangerous to drive or use machines.
	Pregnancy category : 0
	Mode of action : Tiemonium Methylsulfate) is a synthetic anticholinergic-antispasmodic drug. Tiemonium are quaternary ammonium antimuscarinic agent with peripheral effect similar to those of atropine. Tiemonium strengthens calcium bonding with phospho lipids and proteins thus stabilizing the cell membrane of the GI tract.
	Interaction : None
	Therapeutic class : Anticholinergics(others)
	Packsize : 50's pack
Algirex
	n : Etoricoxib
	Indications : Rheumatoid arthritis, Osteoarthritis, Gout
	Doses and administration : Adult: PO Osteoarthritis 60 mg once daily. Rheumatoid arthritis 90 mg once daily. Acute gout 120 mg once daily. Max duration: 8 days.
									
									Child: <16 yr Contraindicated.
									Hepatic impairment: Mild (Child-Pugh score of 5-6): 60 mg once daily. Moderate (Child-Pugh 7-9): Max 60 mg every other day or 30 mg once daily. Severe (Child-Pugh >10): Avoid.
	Contara-indications : Inflammatory bowel disease, severe congestive heart failure, active peptic ulceration, cerebrovascular disease, CrCL <30 ml/min; lactation. Children and adolescent < 16 yr.
	Side effects : GI disorders; ischemic cardiac events; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity; blood disorders, fluid retention, hypertension; dry mouth, taste disturbance, mouth ulcers; appetite and wt changes; chest pain, fatigue, paraesthesia, influenza-like syndrome, myalgia. Renal toxicity.
	Precaution : Allergic disorders, coagulation defects; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, renal, cardiac or hepatic impairment. Withdraw treatment if GI lesions develop; caution when admin to dehydrated patients. Regular BP monitoring is advisable. May mask fever and other signs of infection. Pregnancy.
	Pregnancy category : 0
	Mode of action : Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor primarily responsible to reduce mediators of pain and inflammation. Its action is due to inhibition of prostaglandin synthesis via inhibition of COX-2.
	Interaction : May increase INR w/ oral anticoagulants. May decrease effects of ACE inhibitors, angiotensin II antagonist and diuretics. May increase lithium plasma concentrations. May reduce plasma levels w/ rifampicin. Increased serum concentrations of ethinylestradiol.
	Therapeutic class : Non-steroidal Anti-inflammatory Drugs (NSAIDs)
	Packsize : 20's pack
Algirex
	n : Etoricoxib
	Indications : Rheumatoid arthritis, Osteoarthritis, Gout
	Doses and administration : Adult: PO Osteoarthritis 60 mg once daily. Rheumatoid arthritis 90 mg once daily. Acute gout 120 mg once daily. Max duration: 8 days.
									
									Child: <16 yr Contraindicated.
									Hepatic impairment: Mild (Child-Pugh score of 5-6): 60 mg once daily. Moderate (Child-Pugh 7-9): Max 60 mg every other day or 30 mg once daily. Severe (Child-Pugh >10): Avoid.
	Contara-indications : Inflammatory bowel disease, severe congestive heart failure, active peptic ulceration, cerebrovascular disease, CrCL <30 ml/min; lactation. Children and adolescent < 16 yr.
	Side effects : GI disorders; ischemic cardiac events; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity; blood disorders, fluid retention, hypertension; dry mouth, taste disturbance, mouth ulcers; appetite and wt changes; chest pain, fatigue, paraesthesia, influenza-like syndrome, myalgia. Renal toxicity.
	Precaution : Allergic disorders, coagulation defects; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, renal, cardiac or hepatic impairment. Withdraw treatment if GI lesions develop; caution when admin to dehydrated patients. Regular BP monitoring is advisable. May mask fever and other signs of infection. Pregnancy.
	Pregnancy category : 0
	Mode of action : Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor primarily responsible to reduce mediators of pain and inflammation. Its action is due to inhibition of prostaglandin synthesis via inhibition of COX-2.
	Interaction : May increase INR w/ oral anticoagulants. May decrease effects of ACE inhibitors, angiotensin II antagonist and diuretics. May increase lithium plasma concentrations. May reduce plasma levels w/ rifampicin. Increased serum concentrations of ethinylestradiol.
	Therapeutic class : Non-steroidal Anti-inflammatory Drugs (NSAIDs)
	Packsize : 30's pack
Algirex
	n : Etoricoxib
	Indications : Rheumatoid arthritis, Osteoarthritis, Gout
	Doses and administration : Adult: PO Osteoarthritis 60 mg once daily. Rheumatoid arthritis 90 mg once daily. Acute gout 120 mg once daily. Max duration: 8 days.
									
									Child: <16 yr Contraindicated.
									Hepatic impairment: Mild (Child-Pugh score of 5-6): 60 mg once daily. Moderate (Child-Pugh 7-9): Max 60 mg every other day or 30 mg once daily. Severe (Child-Pugh >10): Avoid.
	Contara-indications : Inflammatory bowel disease, severe congestive heart failure, active peptic ulceration, cerebrovascular disease, CrCL <30 ml/min; lactation. Children and adolescent < 16 yr.
	Side effects : GI disorders; ischemic cardiac events; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity; blood disorders, fluid retention, hypertension; dry mouth, taste disturbance, mouth ulcers; appetite and wt changes; chest pain, fatigue, paraesthesia, influenza-like syndrome, myalgia. Renal toxicity.
	Precaution : Allergic disorders, coagulation defects; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, renal, cardiac or hepatic impairment. Withdraw treatment if GI lesions develop; caution when admin to dehydrated patients. Regular BP monitoring is advisable. May mask fever and other signs of infection. Pregnancy.
	Pregnancy category : 0
	Mode of action : Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor primarily responsible to reduce mediators of pain and inflammation. Its action is due to inhibition of prostaglandin synthesis via inhibition of COX-2.
	Interaction : May increase INR w/ oral anticoagulants. May decrease effects of ACE inhibitors, angiotensin II antagonist and diuretics. May increase lithium plasma concentrations. May reduce plasma levels w/ rifampicin. Increased serum concentrations of ethinylestradiol.
	Therapeutic class : Non-steroidal Anti-inflammatory Drugs (NSAIDs)
	Packsize : 20's pack
Alic
	n : Ferrous Fumarate + Folic Acid
	Indications : Iron deficiency anemia, Iron supplement, Iron deficiency in pregnancy
	Doses and administration : Adult: PO Each tab contains ferrous fumurate 322 mg and folic acid 0.35 mg: 1 tab/day starting from the 13th wk of gestation.
	Contara-indications : Paroxysmal nocturnal haemoglobinuria, haemosiderosis, haemochromatosis.
	Side effects : GI discomfort, anorexia, nausea, vomiting, constipation, diarrhoea. Stool darkening may occur.
	Precaution : Avoid use in patients with active peptic ulcer, repeated blood transfusion, regional enteritis and ulcerative colitis. Caution when used in patients with folate-dependent tumours. Not recommended for use during 1st trimester of pregnancy.
	Pregnancy category : 0
	Mode of action : Ferrous fumarate is an iron preparation that is used in the prevention and treatment of iron deficiency. The amount of elemental iron is 330 mg/g of ferrous fumarate.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
	Interaction : Ferrous Fumarate:  Oral absorption of iron may be increased when taken with ascorbic acid. May reduce the absorption of quinolones and tetracyclines when taken concurrently via the oral route. Concurrent admin with antacids may reduce the absorption of ferrous fumarate from the GI tract. May reduce the absorption of penicillamine in the gut when taken concurrently.
				
				Folic Acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
	Therapeutic class : Iron & Vitamin Combined preparations
	Packsize : 100's pack
Alin
	n : Ranitidine
	Indications : Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
	Doses and administration : Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. 
									For prevention of NSAID-associated ulceration: 150 mg bid. 
									Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. 
									GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.
									 Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. 
									Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. 
									Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. 
									Prophylaxis during NSAID treatment 150 mg twice daily. 
									
									IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. 
									
									IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
	Contara-indications : Porphyria.
	Side effects : Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
									Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
	Precaution : Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
	Interaction : Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
	Therapeutic class : H2 antagonists
	Packsize : 100's pack
Alinix
	n : Nitazoxanide
	Indications : Giardiasis, Cryptosporidiosis
	Doses and administration : Age 1 - 3 years : 5 ml (100 mg) twice daily for 3 days, Age 4 - 11 years : 10 ml (200 mg) twice daily for 3 days, Age >12 years : 25 ml or 1 tablet (500 mg) twice daily for 3 days. 
	Contara-indications : Hypersensitivity.
	Side effects : Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.
	Precaution : Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.
	Pregnancy category : 2
	Mode of action : Nitazoxanide is an antiprotozoal agent. Both nitazoxanide and its active metabolite (tizoxanide) interfere with the pyruvate:ferredoxin 2-oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism in susceptible organisms.
	Interaction : May possibly interact with highly protein-bound drugs e.g. warfarin.
	Therapeutic class : Anti-diarrhoeal Antiprotozoal
	Packsize : 30ml bot/60ml bot
Alinix
	n : Nitazoxanide
	Indications : Giardiasis, Cryptosporidiosis
	Doses and administration : Age 1 - 3 years : 5 ml (100 mg) twice daily for 3 days, Age 4 - 11 years : 10 ml (200 mg) twice daily for 3 days, Age >12 years : 25 ml or 1 tablet (500 mg) twice daily for 3 days. 
	Contara-indications : Hypersensitivity.
	Side effects : Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.
	Precaution : Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.
	Pregnancy category : 2
	Mode of action : Nitazoxanide is an antiprotozoal agent. Both nitazoxanide and its active metabolite (tizoxanide) interfere with the pyruvate:ferredoxin 2-oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism in susceptible organisms.
	Interaction : May possibly interact with highly protein-bound drugs e.g. warfarin.
	Therapeutic class : Anti-diarrhoeal Antiprotozoal
	Packsize : 30's pack
Allion
	n : Multivitamin and Multimineral A-Z Gold preparations
	Indications : Vitamin/mineral deficiency
	Doses and administration : 1 tablet daily or as recommended by the physician.
	Contara-indications :  Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. 
	Precaution : Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.
	Pregnancy category : 0
	Mode of action : Vitamin A: Helps form and maintain healthy skin, eyes, teeth, gums, hair, mucous membranes and glands.
									
									Vitamin C (Ascorbic Acid): Collagen formation: without it, protocollagen does not cross- link properly, resulting in impaired wound healing.
									
									Vitamin D: Vitamin D helps to regulate calcium metabolism and normal calcification of the bones in the body as well as influencing our utilization of the mineral phosphorus
									
									Vitamin E: Necessary for the formation of normal red blood cells, muscle, and tissue and necessary for immune functions
									
									Vitamin K: Necessary for normal blood coagulation
									
									Vitamin B-Complexes
									
									Thiamine (Vitamin B1): Aids in energy utilization from food by promoting proper carbohydrate metabolism.
									
									Riboflavin (Vitamin B2): Aids in energy utilization from food
									
									Niacin (Vitamin B3): Present in all cells in the body helps convert food into energy; involved in fat, protein, and carbohydrate metabolism
									
									Pyridoxine (Vitamin B6): Important in protein and amino acid metabolism
									
									Folic Acid: Adequate amounts of this B vitamin (folic acid) as part of a healthy diet can help reduce the risk of birth defects of the brain and spine
									
									Cyanocobalamin (Vitamin B12): Helps form red blood cells and build vital genetic material (nucleic acids) for the cell nucleus
									
									Biotin: Necessary for formation of fatty acids & for production of
									
									energy from glucose
									
									Pantothenic Acid (Vitamin B5): Involved in converting carbohydrates, fats and proteins into energy
									
									Calcium: Helps build and maintain strong teeth and bones.
									
									Iron: Necessary for proper formation of oxygen-rich red blood cells & plays important role in the transport of oxygen
									
									Phosphorous: Helps build and maintain teeth and bones
									
									Iodine: Essential for formation of thyroid hormone thyroxin which governs metabolism and growth
									
									Magnesium: Maintains proper levels of calcium and potassium
									
									Zinc: The important antioxidant enzyme, superoxide dismutase (SOD), requires zinc, together with copper and manganese, to function. Zinc is also essential for the metabolism of vitamin A, another important antioxidant, enhance wound healing.
									
									Selenium: Role as an antioxidant in the enzyme selenium-glutathione-peroxidase.
									
									Copper: Involved in brain and red cell function, iron metabolism, bone health and protein synthesis
									
									Manganese: Necessary for normal growth and development, reproduction and cell function
									
									Chromium: Necessary for normal carbohydrate, protein and fat metabolism
									
									Molybdenum: Important for normal cell function
									
									Potassium: It is part of a number of metabolic actions, especially those that involve release of energy
									
									Boron: Boron affects calcium, magnesium, and phosphorus balance and the mineral movement and make up of the bones by regulating the hormones, mainly parathyroid that control these functions.
									
									Nickel: Enhances the body's use of iron
									
									Silicon: May be necessary for normal cartilage, collagen and bone formation. Silicon promotes firmness and strength in the tissues.
									
									Tin: Necessary for normal growth & Cell metabolism.
									
									Vanadium: Pharmacological studies in animals suggest that vanadium may be involved in hormone, glucose, fat, bone and tooth metabolism as well as reproduction and growth.
									
									Lutein: Super antioxidant that provides protection against free radicals.
	Interaction : None
	Therapeutic class : Multi-vitamin & Multi-mineral combined preparations
	Packsize :   30's pack
Aljen
	n : Ketotifen 0.25 % Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration : Adults and children over 3 years of age: 1 drop Ketotifen eye drop into the conjunctival sac of the affected eye(s) twice a day or as directed by the physician.
									
									Children below 3 years of age: Not recommended.
	Contara-indications : Patients with known hypersensitivity to ketotifen or to any of the excipients of the preparation.
	Side effects : Generally side effects of Ketotifen are localized ocular toxicity and hypersensitivity such as burning or stinging, punctate corneal epithelial erosion, dry eyes, eyelid disorder, photophobia, keratitis, lacrimation etc. Systemic side effects are very rare, there may be headache, urticaria, dry mouth and allergic reaction.
	Precaution : Eye drops contains benzalkonium chloride as a preservative, which may be deposited in soft contact lenses; thereforeKetotifen eye drops should not be instilled while the patient is wearing contact lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.
	Pregnancy category : 3
	Mode of action : Ketotifen selectively and noncompetitively inhibits the release of mediators from cells involved in hypersensitivity reactions. It is also a mast cell stabiliser.
	Interaction : Reduced platelet count with oral antidiabetics.
				Potentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5  ml drop
Alkafen
	n : Paracetamol + Tramadol Hydrochloride
	Indications : Moderate to severe pain
	Doses and administration : Adult: PO >12 yr: Per tab contains tramadol HCl 37.5 mg and paracetamol 325 mg: 2 tab 6 hrly. Max: 8 tab/day.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Increase dosing interva to 12 hr.ly
									<10	        Not recommended.
	Contara-indications : Hypersensitivity to tramadol, paracetamol or opioids. Situations where opioid use may be contra-indicated (e.g. acute intoxication with alcohol, hypnotic drugs, centrally-acting analgesics, opioids or psychotropic drugs). Severe hepatic impairment, uncontrolled epilepsy. Concurrent use or within 2 wk of discontinuation from MAOIs.
	Side effects : Nausea, vomiting, constipation, diarrhoea, abdominal pain, dry mouth, dyspepsia, flatulence, dizziness, somnolence, headache, confusion, mood changes, nightmares, amnesia, sweating, pruritus.
									Potentially Fatal: Severe anaphylactic reactions.
	Precaution : Not recommended in severe renal impairment (CrCl <10 ml/min), severe respiratory insufficiency, liver disease or opioid dependent patients. Increased intracranial pressure or head injury, patients at risk of seizures or on drugs that may lower the seizure threshold (e.g. SSRI, TCA, antipsychotics, centrally acting analgesics or local anaesthesia), biliary tract disorders, in a state of shock or unconsciousness. May impair ability to drive or operate machinery. Avoid abrupt withdrawal. May cause withdrawal symptoms, dependence and abuse. Elderly. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Tramadol is a centrally acting opioid analgesic which binds to mu-opioid receptors and weakly inhibits the reuptake of norepinephrine and serotonin. Paracetamol, a para-aminophenol derivative, has analgesic, antipyretic and weak anti-inflammatory activity. Together, tramadol and paracetamol has faster onset of action compared to tramadol alone and longer duration of action compared to paracetamol alone.
	Interaction : Concomitant use is contraindicated w/ non-selective MAOIs, selective-A & B MAOIs; not recommend w/ alcohol, carbamazepine & other enzyme inducers, opioid agonists-antagonists; needs consideration w/ selective serotonin re-uptake inhibitors, triptans, other opioid derivatives & anxiolytics, barbiturates, benzodiazepines, hypnotics, sedative antidepressants & antihistamines, neuroleptics, centrally-acting antihypertensives, TCAs, thalidomide, baclofen, warfarin-like compd, ketoconazole, erythromycin, bupropion, ondansetron.
	Therapeutic class : Combined analgesics
	Packsize : 20's pack
Allbeevit
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 100'pack
Allbeevit
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 100'pack/200's pack
Allbeevit
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize :  100ml bot/200ml bot
Allbeevit-M
	n : Multivitamins + Multiminerals
	Indications : Vitamin/mineral deficiency
	Doses and administration : One tablet/capsule daily or as directed by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated.
	Precaution : Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.
	Pregnancy category : 0
	Mode of action : Vitamins and minerals are essential for normal metabolic functions including hematopoiesis. The members of Vitamin B-group are components of enzyme system that regulates various stages of carbohydrate, fat and protein metabolism, each of the components playing a specific biological role. Vitamin C is involved in tissue repair and collagen formation. Vitamin A plays an essential role in the function of retina and is essential for growh and differentiation of epithelial tissue. Vitamin E is an antioxidant which preserves essential cellular constituents. Vitamin D is supplemented for prevention and cure of nutritional and metabolic rickets and for treatment of hypoparathyroidism. Iron, copper, manganese and zinc serve as catalysts in enzyme systems which perform vital cellular functions. Potassium and calcium are essential for normal excitability of muscle tissue, specially cardiac muscle. Iodine is essential in the development and functioning of the thyroid gland and for formation of thyroxine hormone.
									
									
	Interaction : None
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 100's pack
Allbeevit-M
	n : Multivitamins + Multiminerals
	Indications : Vitamin/mineral deficiency
	Doses and administration : One tablet/capsule daily or as directed by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated.
	Precaution : Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.
	Pregnancy category : 0
	Mode of action : Vitamins and minerals are essential for normal metabolic functions including hematopoiesis. The members of Vitamin B-group are components of enzyme system that regulates various stages of carbohydrate, fat and protein metabolism, each of the components playing a specific biological role. Vitamin C is involved in tissue repair and collagen formation. Vitamin A plays an essential role in the function of retina and is essential for growh and differentiation of epithelial tissue. Vitamin E is an antioxidant which preserves essential cellular constituents. Vitamin D is supplemented for prevention and cure of nutritional and metabolic rickets and for treatment of hypoparathyroidism. Iron, copper, manganese and zinc serve as catalysts in enzyme systems which perform vital cellular functions. Potassium and calcium are essential for normal excitability of muscle tissue, specially cardiac muscle. Iodine is essential in the development and functioning of the thyroid gland and for formation of thyroxine hormone.
									
									
	Interaction : None
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 24' pack
Alleloc
	n : Olopatadine 0.1% Eye prep
	Indications : Allergic conjunctivitis
	Doses and administration : Adults and children (above 3 years of age). One drop   in the conjunctival sac of the affected eye(s) twice daily.
									 
	Contara-indications : It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
	Side effects : Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
									Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.
	Precaution : To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.
	Pregnancy category : 3
	Mode of action : Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
	Interaction : May result in additive CNS depression w/ CNS depressants.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5ml drop
Allercet
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Allercet
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Allermine
	n : Chlorpheniramine Maleate
	Indications : Urticaria, Sneezing, Watery eyes,  Allergic conditions, Anaphylactic shock, Rhinitis, Itching
	Doses and administration : Adult: 4 mg every 4-6 hr. Max: 24 mg daily. 
									Child: 1-2 yr: 1 mg bid, 2-5 yr: 1 mg every 4-6 hr, 6-12 yr: 2 mg every 4-6 hr. Max: 6 mg daily (1-5 yr); 12 mg daily (6-12 yr). 
									
									Parenteral
									Adjunct in the emergency treatment of anaphylactic shock
									Adult: 10-20 mg IM, SC, or slow IV inj over 1 min. Max dose: 40 mg daily.
									Child: 87.5 mcg/kg SC 4 times daily
									
									
	Contara-indications : Hypersensitivity, Neonates.
	Side effects : CNS depression, sedation, drowsiness, lassitude, dizziness. GI upsets, anorexia, or increased appetite, epigastric pain, blurring of vision, dysuria, dryness of mouth, tightness in chest, hypotension, muscular weakness, tinnitus, euphoria, headache, paradoxical CNS stimulation.
									Potentially Fatal: CV collapse and respiratory failure.
	Precaution : Elderly, pylori duodenal obstruction, angle-closure glaucoma, urinary retention, prostatic hyperplasia, epilepsy, renal and hepatic impairment. May affect performance of skilled tasks. BPH, bladder neck obstruction, hypertension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Chlorphenamine is an H1-receptor antagonist which competetively blocks H1-receptor sites on tissues.
	Interaction : Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).
	Therapeutic class : Sedating Anti-histamines
	Packsize :  100ml bot
Allernil
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Allernil
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Allphen
	n : Promethazine Hydrochloride
	Indications : Allergic conditions, Nausea and vomiting, Motion sickness, Insomnia
	Doses and administration : Oral
									Allergic conditions
									Adult: As hydrochloride: 25 mg at night inreased to 25 mg bid, if needed; alternatively, 10-20 mg bid or tid.
									Child: As hydrochloride: 5-10 yr: 10-25 mg daily; 2-5 yr: 5-15 mg daily. Doses are given in 1 or 2 divided doses.
									Renal impairment: Dose reduction may be required.
									
									Prophylaxis of motion sickness
									Adult: As hydrochloride: 20 or 25 mg the night before travelling followed by a similar dose in the morning if needed. 
									
									Child: As hydrochoride: 5-10 yr: 10 mg; 2-5 yr: 5 mg; doses are given at night before travelling, repeated the following morning if needed. As teoclate: 5-10 yr: 12.5 mg daily starting either on the night before long journeys or 1-2 hr before short journeys. 
									
									Renal impairment: Dose reduction may be required.
									
									Short-term management of insomnia
									Adult: As hydrochloride: 20-50 mg at night.
									Child: As hydrochloride: 5-10 yr: 20-25 mg; 2-5 yr; 15-20 mg. Doses are taken at night. May also be given as suppository.
									
									Renal impairment: Dose reduction may be required.
									
									Parenteral
									Allergic conditions
									Adult: As hydrochloride: 25-50 mg, given via IM or slow IV inj or injected into the tubing of a freely running infusion at a concentration of not >25 mg/ml and infused at a rate of not >25 mg/min. Max dose: 100 mg.
									
									Child: As hydrochloride: 5-10 yr: 6.25-12.5 mg by deep IM inj.
									Renal impairment: Dose reduction may be required. 
	Contara-indications : Hypersensitivity, coma, porphyria, cardiac disease, hypokalaemia, intra-arterial or SC inj, neonates and young children, pregnancy, lactation.
	Side effects : CNS depression, paradoxical excitation in childn, dryness of mouth, blurring of vision, retention of urine, constipation, glaucoma, tachycardia, headache, hypotension, tinnitus.
	Precaution : Elderly, glaucoma, epilepsy, CVS disease, impaired liver function, asthma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction. May cause drowsiness. For parenteral admin: Drug must be administered carefully and slowly; incorrect admin can lead to severe tissue injury.
	Pregnancy category : 3
	Mode of action : Promethazine, a phenothiazine derivative, blocks postsynaptic dopaminergic receptors in the brain and has a strong ?-adrenergic blocking effect. It competitively binds to H1-receptors.
	Interaction : Masks ototoxicity of aminoglycoside antibiotics. May enhance the sedative effects of CNS depressants like alcohol, hypnotics, barbiturates and opioids.
				Potentially Fatal: Ventricular arrhythmias when used with drugs that prolong QT interval.
	Therapeutic class : Anti-emetic drugs
	Packsize :  50ml bot / 100 ml bot
Allygest
	n : Allystrenol
	Indications : Threatened miscarriage, Premature labor
	Doses and administration : Adult: PO 5 mg 3 times/day for 5-7 days.
	Contara-indications : Hypersensitivity; thrombophleobitis; undiagnosed vag bleeding, incomplete abortion, hormone-dependent carcinoma, cerebral apoplexy, as a diagnostic test for pregnancy; severe hepatic impairment; pregnancy.
	Side effects : GI disturbances, appetite/weight change; fluid retention, oedema; acnes, skin rash, urticaria; depression, headache, fever, fatigue; breast changes, hirsutism, changes in libido, altered menstrual cycles or irregular menstrual bleeding (rare).
	Precaution : Discontinue medications if there is sudden partial or complete loss of vision, proptosis or diplopia; migraine and embolic disorders; epilepsy, migraine, asthma, cardiac or renal dysfunction. History of depression, glucose tolerance and diabetic patients. My impair ability to drive operate machinery. Sudden withdrawal of allyloestrenol should be avoided as it leads to intermittent breakthrough bleeding; lactation.
	Pregnancy category : 0
	Mode of action : Allylestrenol is similar to that of natural progesterone. It prepares the uterus for receiving the fertilised ovum and suppresses uterine motility.
	Interaction : Enhanced clearance with enzyme-inducing drugs eg, carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Ketoconazole may increase bioavailability of progesterone.
				Potentially Fatal: Increased ciclosporin concentration.
	Therapeutic class : Female Sex hormones
	Packsize : 30's pack
Allynol
	n : Allystrenol
	Indications : Threatened miscarriage, Premature labor
	Doses and administration : Adult: PO 5 mg 3 times/day for 5-7 days.
	Contara-indications : Hypersensitivity; thrombophleobitis; undiagnosed vag bleeding, incomplete abortion, hormone-dependent carcinoma, cerebral apoplexy, as a diagnostic test for pregnancy; severe hepatic impairment; pregnancy.
	Side effects : GI disturbances, appetite/weight change; fluid retention, oedema; acnes, skin rash, urticaria; depression, headache, fever, fatigue; breast changes, hirsutism, changes in libido, altered menstrual cycles or irregular menstrual bleeding (rare).
	Precaution : Discontinue medications if there is sudden partial or complete loss of vision, proptosis or diplopia; migraine and embolic disorders; epilepsy, migraine, asthma, cardiac or renal dysfunction. History of depression, glucose tolerance and diabetic patients. My impair ability to drive operate machinery. Sudden withdrawal of allyloestrenol should be avoided as it leads to intermittent breakthrough bleeding; lactation.
	Pregnancy category : 0
	Mode of action : Allylestrenol is similar to that of natural progesterone. It prepares the uterus for receiving the fertilised ovum and suppresses uterine motility.
	Interaction : Enhanced clearance with enzyme-inducing drugs eg, carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Ketoconazole may increase bioavailability of progesterone.
				Potentially Fatal: Increased ciclosporin concentration.
	Therapeutic class : Female Sex hormones
	Packsize : 45's pack
Almex
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 10 ml bot
Almex
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 100's pack / 48's pack
Almin
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 10 ml bot
Almin
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Almoxil
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Almoxil
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Almoxil
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Alneed
	n : Iron +  Folic Acid  +   Vitamin B  +  Vitamin C
	Indications : Nutritional deficiency in pregnancy & lactation.
	Doses and administration : 1 capsule daily or in more severe cases 2 capsules daily or as directed by the physician.
									
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients, haemolytic anemia.
	Side effects : Allergic sensitization has been reported following oral administration. May cause constipation.
	Precaution : Iron chelates with antacid and tetracycline and absorption of all these may be impaired. 
	Pregnancy category : 0
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
									Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. 
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
	Interaction : Iron: Antacids may decrease the absorption of carbonyl iron.
				
				Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
				
				Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.
				
				
				
	Therapeutic class : Iron & Vitamin Combined preparations
	Packsize : 100's pack
Alneed Gold
	n : Elemental Iron (Iron Polymaltose Complex) + Folic Acid + Zinc + Vitamin B-Complex
	Indications : Dietary supplement, Iron, Folic Acid and Zinc deficiency, Vitamin-B Deficiency especially during pregnancy and lactation.
	Doses and administration : One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.
	Contara-indications : This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. However, a few allergic reactions may be seen.
	Precaution : Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.
	Pregnancy category : 0
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
									Zinc: Cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system; helps maintain a sense of smell and taste; may assist in porper function of insulin.
									Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
									
	Interaction : Iron: Absorption decreased w/ antacids. May reduce effects of penicillamine. Concurrent use with psychotropic drugs may worsen constipation. Increased systemic side effects with concomitant ACE inhibitors and parenteral iron admin.
				
				Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
	Therapeutic class : Iron & Vitamin Combined preparations
	Packsize : 30's pack
Alneed PLUS
	n : Iron + Folic acid + B Complex + Vitamin C + Zinc
	Indications : Vitamin/mineral deficiency during pregnancy and lactation
	Doses and administration : Adults (persons over 12 years of age), One (1) capsule daily, between meals, or as prescribed by a physician. Do not exceed recommended dosage. Do not administer to children under the age of 12.
	Contara-indications :  Patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. Pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.
	Side effects :  Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy. Reducing the dose and administering it with meals will minimize these effects in the sensitive patient. Increasing fiber in the diet can relieve constipation. Iron may turn stools black. This is a harmless effect that is a result of unabsorbed iron. Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I. disturbances. Integra FTM is best absorbed when taken at bedtime.
	Precaution : General: Anemia is a manifestation that requires appropriate investigation to determine its cause or causes. No single regimen fits all cases and the status of the patient observed in follow-up is the final criterion for adequacy of therapy. Periodic clinical and laboratory studies are considered essential. Blood examinations including hemoglobin and hematacrit should be done at the usual intervals to make certain that therapy is adequate. Use with care in the presence of peptic ulcer, regional enteritis, and ulcerative colitis. Folic acid, especially in doses above 0.1 mg -0.4 mg daily may obscure pernicious anemia, in that hematological remission can occur while neurological manifestations remain progressive.
	Pregnancy category : 3
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
									Zinc: Cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system; helps maintain a sense of smell and taste; may assist in porper function of insulin.
									Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									
	Interaction : Iron: Antacids may decrease the absorption of carbonyl iron.
				
				Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
				
				Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.
				
				
				
	Therapeutic class : Iron & Vitamin Combined preparations
	Packsize : 100'pack
Alona
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Alopec
	n : Finasteride
	Indications : Male pattern baldness, Benign prostatic hyperplasia
	Doses and administration : Adult: PO Benign prostatic hyperplasia 5 mg once daily. Male pattern baldness 1 mg once daily
	Contara-indications : Children, exposure of pregnant women to finasteride either via direct contact with crushed tab or through semen of male sexual partners who are taking finasteride; pregnancy, lactation.
	Side effects : Gynaecomastia, decreased libido, impotence, reduction in the volume of ejaculate, testicular pain. Hypersensitivity reactions e.g. swelling of lips and face, urticaria, rashes.
	Precaution : Undiagnosed prostate cancer, liver dysfunction, obstructive uropathy.
	Pregnancy category : 5
	Mode of action : Finasteride is a competitive inhibitor of the enzyme 5-alpha reductase which converts testosterone to dihydrotestosterone (DHT), thus resulting in decreased serum levels of DHT.
	Interaction : No drug interactions of clinical importance have been identified. Proscar does not appear to affect significantly the cytochrome P-450-linked drug metabolizing enzyme system. Compounds which have been tested in man have included propranolol, digoxin, glyburide, warfarin, theophylline and antipyrine, and no clinically meaningful interactions were found.
				
				Other Concomitant Therapy: Although specific interaction studies were not performed, in clinical studies Proscar was used concomitantly with angiotensin converting-enzyme (ACE) inhibitors, acetaminophen, acetylsalicylic acid, ?-blockers, ?-blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2-antagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), quinolones and benzodiazepines without evidence of clinically significant adverse interactions.
	Therapeutic class : BPH/Urinary retention/Urinary incontinence
	Packsize : 100
Alor
	n : Fluocinolone Acetonide 0.025% Topical
	Indications : Psoriasis, Eczema, Tularaemia, Dermatitis,
	Doses and administration : Adult: Topical  cream/gel/lotion/oint/scalp lotion: Apply 3-4 times/day.
	Contara-indications : Primary infectious (bacterial, viral, fungal) ulcers, hypersensitivity, acne vulgaris. Neonates.
	Side effects : Prolonged admin causes epidermal thinning, telangiectasia and striae (especially face and flexures). Application on eyelid and surrounding skin can cause raised intraocular pressure, cataracts, glaucoma, corneal ulcers and raised intracranial pressure. Systemic absorption with adrenal suppression may be seen when applied over large areas, when skin is broken or under occlusive dressing. Contact dermatitis, perioral dermatitis, papular disorder, mild depigmentation.
	Precaution : Children, elderly, hepatic failure. Prolonged use on the face; contact with eyes. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Fluocinolone acetonide is a synthetic fluorinated corticosteroid that is used topically for its anti-inflammatory, anti-pruritic and vasoconstrictive properties. 
									
	Interaction : None
	Therapeutic class : Fluocinolone & Combined Preparations
	Packsize : 5gm  tube
Aloran
	n : Desloratadine
	Indications : Itching, Sneezing, Watery eyes, Allergic conditions, Runny nose, Hives, Skin rash, Common cold
	Doses and administration : Adults and adolescent of 12 years or over : 5 mg once daily.
									Child 6-11 years : 2.5 mg once daily.
									Child 12 months-5 years : 1.25 mg (2.5 ml syrup) once daily.
									Child 6 months-11 months : 1 mg (2 ml syrup) once daily.
	Contara-indications : Hypersensitivity.
	Side effects : Headache, fatigue, somnolence, dizziness; nausea, dyspepsia; xerostomia, dysmenorrhoea; pharyngitis.
	Precaution : Severe renal or hepatic failure; children <6 mth, elderly, epilepsy, pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Desloratadine is a long-acting, tricyclic, non-sedating, selective peripheral histamine H1-receptor antagonist which inhibits the release of pro-inflammatory mediators from human mast cells and basophils.
	Interaction :  	Potential increase in plasma concentrations w/ drugs affecting hepatic microsomal enzymes (e.g. azithromycin, cimetidine, erythromycin, fluoxetine, ketoconazole).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 50's pack
Aloton
	n : Esomeprazole Magnesium Trihydrate BP
	Indications : Heartburn, Acid Related Dyspepsia, Peptic ulcer disease, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Helicobacter pylori infection, Erosive Esophagitis, Gouty arthritis, Duodenal and Gastric Ulcer.
	Doses and administration : Adult: PO: Erosive oesophagitis: 40 mg once daily for 4 wk, up to 8 wk if needed. Maintenance: 20 mg/day.  
									
									Peptic ulcer: 20 mg twice daily for 7 days. NSAID-associated ulceration 20 mg once daily for 4-8 wk.  
									
									Zollinger-Ellison syndrome Initial: 40 mg twice daily. Usual range: 80-160 mg/day.  
									
									Gastro-oesophageal reflux disease: 20 mg once daily for 4 wk.  The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered.  Delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating. 
	Contara-indications : Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.
	Side effects : The most frequently occurring adverse events ( >1%) are headache, diarrhoea, abdominal pain, nausea, flatulence, dry mouth, constipation.
	Precaution : Paediatric; pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia. For patients with severe liver impairment, a dose of 20 mg should not be exceeded.
	Pregnancy category : 3
	Mode of action : Esomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
	Interaction : Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.
				
				Potentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 30's pack
Aloten 5/25
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Aloten Forte
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Aloxif
	n : Raloxifene Hydrochloride
	Indications : Post-menopausal osteoporosis, Malignant gastrointestinal stromal tumours
	Doses and administration : One tablet (60 mg) once daily orally. It can be taken without regard to meal. High fat meal increases the absorption of Raloxifene.
	Contara-indications : Hepatic & renal impairment.In active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis.Hypersensitivity to Raloxifene or any other constituents of the tablet.
	Side effects : Raloxifene is generally well tolerated. However, a few side effects like hot flushes, leg cramps, and influenza like symptoms, gastro-intestinal disturbances etc may be seen usually during first 6 months of treatment and were not different from placebo.
	Precaution : Concurrent Estrogen Therapy: Concomitant use of Raloxifene with systemic estrogens is not recommended.Lipid Metabolism: Concurrent use of Raloxifene and lipid-lowering agents has not been studied.
	Pregnancy category : 5
	Mode of action : Raloxifene is a selective oestrogen receptor modulator that has both selective agonist or antagonist activities on oestrogen receptors. It acts as an agonist on bone by preventing bone loss and partially on cholesterol metabolism by decreasing total and LDL cholesterol levels but antagonises oestrogen effects leading to development of breast and uterine cancer.
	Interaction : Cholestyramine reduces the absorption of raloxifene. Raloxifene with warfarin may reduce the prothrombin response and time. Caution when used in hghly protein-bound drugs such as diazepam, lidocaine and diazoxide.
	Therapeutic class : Other preparations: Inhibiting bone resorption
	Packsize : 30's pack
Alpam
	n : Alprazolam
	Indications : Anxiety disorders, Panic disorders, Nausea due to chemotherapy
	Doses and administration : Oral
									Short-term management of anxiety
									Adult: 0.25-0.5 mg tid, increased to 3-4 mg daily if necessary.
									Elderly: Initially, 0.25 mg bid/tid.
									Hepatic impairment: Avoid in severe impairment.
									
									Panic attacks
									Adult: Up to 10 mg daily.
	Contara-indications : Acute narrow-angle glaucoma, preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; pregnancy, lactation.
	Side effects : Psychological and physical dependence, withdrawal syndrome; drowsiness, sedation, vertigo, headache, visual disturbances, GI disturbances, jaundice; fatigue, muscle weakness, ataxia, dizziness, confusion and depression.
									Potentially Fatal: Blood dyscrasias.
	Precaution : Dosage reduction or gradual withdrawal. Dependence. Geriatric or debilitated patients. Muscle weakness, impaired hepatic or renal function; arteriosclerosis; obesity; depression particularly suicidal tendency; chronic pulmonary insufficiency. May impair ability to drive or operate machinery. Children <18 yr.
	Pregnancy category : 4
	Mode of action : Alprazolam has anxiolytic, muscle-relaxant, anticonvulsant, antidepressant and sleep-modifying effects. It binds to the ? aminobutyric acid (GABA)-specific sites throughout the CNS, leading to an increase in the inhibitory effect of GABA on neuronal excitability. Increased neuronal permeability to chloride ions thus results in hyperpolarisation and stabilisation.
	Interaction : Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.
				Potentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. 
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 100's pack
Alpam
	n : Alprazolam
	Indications : Anxiety disorders, Panic disorders, Nausea due to chemotherapy
	Doses and administration : Oral
									Short-term management of anxiety
									Adult: 0.25-0.5 mg tid, increased to 3-4 mg daily if necessary.
									Elderly: Initially, 0.25 mg bid/tid.
									Hepatic impairment: Avoid in severe impairment.
									
									Panic attacks
									Adult: Up to 10 mg daily.
	Contara-indications : Acute narrow-angle glaucoma, preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; pregnancy, lactation.
	Side effects : Psychological and physical dependence, withdrawal syndrome; drowsiness, sedation, vertigo, headache, visual disturbances, GI disturbances, jaundice; fatigue, muscle weakness, ataxia, dizziness, confusion and depression.
									Potentially Fatal: Blood dyscrasias.
	Precaution : Dosage reduction or gradual withdrawal. Dependence. Geriatric or debilitated patients. Muscle weakness, impaired hepatic or renal function; arteriosclerosis; obesity; depression particularly suicidal tendency; chronic pulmonary insufficiency. May impair ability to drive or operate machinery. Children <18 yr.
	Pregnancy category : 4
	Mode of action : Alprazolam has anxiolytic, muscle-relaxant, anticonvulsant, antidepressant and sleep-modifying effects. It binds to the ? aminobutyric acid (GABA)-specific sites throughout the CNS, leading to an increase in the inhibitory effect of GABA on neuronal excitability. Increased neuronal permeability to chloride ions thus results in hyperpolarisation and stabilisation.
	Interaction : Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.
				Potentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. 
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 50's pack
Alphapress
	n : Prazosin
	Indications : Hypertension, Heart failure, Benign prostatic hyperplasia; Raynaud's syndrome
	Doses and administration : Adult: PO HTN Initial: 500 mcg 2-3 times/day for 3-7 days, increase to 1 mg 2-3 times/day for the next 3-7 days if tolerated. May further increase if needed. Max: 20 mg/day. 
									Heart failure Initial: 500 mcg 2-4 times/day, increase gradually when needed. Maintenance: 4-20 mg/day. 
									Benign prostatic hyperplasia; Raynaud's syndrome Initial: 500 mcg twice daily. Maintenance: <2 mg twice daily.
	Contara-indications : Congestive heart failure due to mechanical obstruction. Hypersensitivity. Pregnancy.
	Side effects : Postural hypotension, syncope, palpitations, lack of energy, nausea, oedema, chest pain, dyspnoea, constipation, diarrhoea, vomiting, depression, nervousness, sleep disturbances, headache, lassitude, drowsiness, loss of consciousness, dizziness, vertigo, hallucinations, paraesthesia, nasal congestion, epistaxis, dry mouth, urinary frequency and incontinence, pruritus, rash.
									Potentially Fatal: Rarely, hypotension may be life-threatening.
	Precaution : Angina pectoris. Ability to drive or operate machinery may be impaired. Phaeochromocytoma, abrupt withdrawal, impaired renal and liver function. child <12 yr. Lactation. May develop tolerance in prolonged treatment. Intiate treatment with low doses.
	Pregnancy category : 3
	Mode of action : Prazosin competitively blocks postsynaptic ?1-adrenoceptors of veins and arterioles causing vasodilation, reduction in BP and total peripheral resistance usually w/o reflex tachycardia.
	Interaction : Hypotensive effects may be enhanced w/ diuretics and other antihypertensives. Increased risk of 1st dose hypotension w/ ?-blockers or Ca channel blockers. Concomitant admin w/ phosphodiesterase type 5 (PDE5) inhibitors (e.g. sildenafil) may result in additive hypotensive effects and symptomatic hypotension.
	Therapeutic class : Alpha adrenoceptor blocking drugs
	Packsize : 100's pack
Alphapress
	n : Prazosin
	Indications : Hypertension, Heart failure, Benign prostatic hyperplasia; Raynaud's syndrome
	Doses and administration : Adult: PO HTN Initial: 500 mcg 2-3 times/day for 3-7 days, increase to 1 mg 2-3 times/day for the next 3-7 days if tolerated. May further increase if needed. Max: 20 mg/day. 
									Heart failure Initial: 500 mcg 2-4 times/day, increase gradually when needed. Maintenance: 4-20 mg/day. 
									Benign prostatic hyperplasia; Raynaud's syndrome Initial: 500 mcg twice daily. Maintenance: <2 mg twice daily.
	Contara-indications : Congestive heart failure due to mechanical obstruction. Hypersensitivity. Pregnancy.
	Side effects : Postural hypotension, syncope, palpitations, lack of energy, nausea, oedema, chest pain, dyspnoea, constipation, diarrhoea, vomiting, depression, nervousness, sleep disturbances, headache, lassitude, drowsiness, loss of consciousness, dizziness, vertigo, hallucinations, paraesthesia, nasal congestion, epistaxis, dry mouth, urinary frequency and incontinence, pruritus, rash.
									Potentially Fatal: Rarely, hypotension may be life-threatening.
	Precaution : Angina pectoris. Ability to drive or operate machinery may be impaired. Phaeochromocytoma, abrupt withdrawal, impaired renal and liver function. child <12 yr. Lactation. May develop tolerance in prolonged treatment. Intiate treatment with low doses.
	Pregnancy category : 3
	Mode of action : Prazosin competitively blocks postsynaptic ?1-adrenoceptors of veins and arterioles causing vasodilation, reduction in BP and total peripheral resistance usually w/o reflex tachycardia.
	Interaction : Hypotensive effects may be enhanced w/ diuretics and other antihypertensives. Increased risk of 1st dose hypotension w/ ?-blockers or Ca channel blockers. Concomitant admin w/ phosphodiesterase type 5 (PDE5) inhibitors (e.g. sildenafil) may result in additive hypotensive effects and symptomatic hypotension.
	Therapeutic class : Alpha adrenoceptor blocking drugs
	Packsize : 100's pack
Alphin DS
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Alprax
	n : Alprazolam
	Indications : Anxiety disorders, Panic disorders, Nausea due to chemotherapy
	Doses and administration : Oral
									Short-term management of anxiety
									Adult: 0.25-0.5 mg tid, increased to 3-4 mg daily if necessary.
									Elderly: Initially, 0.25 mg bid/tid.
									Hepatic impairment: Avoid in severe impairment.
									
									Panic attacks
									Adult: Up to 10 mg daily.
	Contara-indications : Acute narrow-angle glaucoma, preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; pregnancy, lactation.
	Side effects : Psychological and physical dependence, withdrawal syndrome; drowsiness, sedation, vertigo, headache, visual disturbances, GI disturbances, jaundice; fatigue, muscle weakness, ataxia, dizziness, confusion and depression.
									Potentially Fatal: Blood dyscrasias.
	Precaution : Dosage reduction or gradual withdrawal. Dependence. Geriatric or debilitated patients. Muscle weakness, impaired hepatic or renal function; arteriosclerosis; obesity; depression particularly suicidal tendency; chronic pulmonary insufficiency. May impair ability to drive or operate machinery. Children <18 yr.
	Pregnancy category : 4
	Mode of action : Alprazolam has anxiolytic, muscle-relaxant, anticonvulsant, antidepressant and sleep-modifying effects. It binds to the ? aminobutyric acid (GABA)-specific sites throughout the CNS, leading to an increase in the inhibitory effect of GABA on neuronal excitability. Increased neuronal permeability to chloride ions thus results in hyperpolarisation and stabilisation.
	Interaction : Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.
				Potentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. 
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 50's pack
Alprax
	n : Alprazolam
	Indications : Anxiety disorders, Panic disorders, Nausea due to chemotherapy
	Doses and administration : Oral
									Short-term management of anxiety
									Adult: 0.25-0.5 mg tid, increased to 3-4 mg daily if necessary.
									Elderly: Initially, 0.25 mg bid/tid.
									Hepatic impairment: Avoid in severe impairment.
									
									Panic attacks
									Adult: Up to 10 mg daily.
	Contara-indications : Acute narrow-angle glaucoma, preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; pregnancy, lactation.
	Side effects : Psychological and physical dependence, withdrawal syndrome; drowsiness, sedation, vertigo, headache, visual disturbances, GI disturbances, jaundice; fatigue, muscle weakness, ataxia, dizziness, confusion and depression.
									Potentially Fatal: Blood dyscrasias.
	Precaution : Dosage reduction or gradual withdrawal. Dependence. Geriatric or debilitated patients. Muscle weakness, impaired hepatic or renal function; arteriosclerosis; obesity; depression particularly suicidal tendency; chronic pulmonary insufficiency. May impair ability to drive or operate machinery. Children <18 yr.
	Pregnancy category : 4
	Mode of action : Alprazolam has anxiolytic, muscle-relaxant, anticonvulsant, antidepressant and sleep-modifying effects. It binds to the ? aminobutyric acid (GABA)-specific sites throughout the CNS, leading to an increase in the inhibitory effect of GABA on neuronal excitability. Increased neuronal permeability to chloride ions thus results in hyperpolarisation and stabilisation.
	Interaction : Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.
				Potentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. 
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 50's pack
Alpro
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 30's pack
Alsporin
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Alsporin
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100's pack
Alsporin
	n : Cephalexin
	Indications : Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adults
									1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.
									Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.
									
									Children
									25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.
									Otitis media: 75 to 100 mg/kg/day in 4 divided doses.
									beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
									
									Renal impairment:
									CrCl (ml/min)	
									40-50	Max: 3 g daily.
									10-40	Max: 1.5 g daily.
									<10	        Max: 750 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.
									Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
	Precaution : Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
	Therapeutic class : First generation Cephalosporins
	Packsize : 50's pack
Alterin
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Alterin TR
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Alton
	n : Esomeprazole Magnesium Trihydrate BP
	Indications : Heartburn, Acid Related Dyspepsia, Peptic ulcer disease, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Helicobacter pylori infection, Erosive Esophagitis, Gouty arthritis, Duodenal and Gastric Ulcer.
	Doses and administration : Adult: PO: Erosive oesophagitis: 40 mg once daily for 4 wk, up to 8 wk if needed. Maintenance: 20 mg/day.  
									
									Peptic ulcer: 20 mg twice daily for 7 days. NSAID-associated ulceration 20 mg once daily for 4-8 wk.  
									
									Zollinger-Ellison syndrome Initial: 40 mg twice daily. Usual range: 80-160 mg/day.  
									
									Gastro-oesophageal reflux disease: 20 mg once daily for 4 wk.  The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered.  Delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating. 
	Contara-indications : Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.
	Side effects : The most frequently occurring adverse events ( >1%) are headache, diarrhoea, abdominal pain, nausea, flatulence, dry mouth, constipation.
	Precaution : Paediatric; pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia. For patients with severe liver impairment, a dose of 20 mg should not be exceeded.
	Pregnancy category : 3
	Mode of action : Esomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
	Interaction : Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.
				
				Potentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 30's pack
Altrip
	n : Almotriptan
	Indications : Migraine headache, Acute migraine attacks
	Doses and administration : Oral
									Acute migraine attacks
									Adult: Initially, 6.25-12.5 mg. May repeat 2 hr later if needed. Max: 2 doses/24 hr.
									Hepatic impairment: Initially, 6.25 mg as a single dose. Max: 12.5 mg/24 hr. Avoid in severe impairment.
	Contara-indications : Underlying CV disease e.g. ischaemic heart disease or coronary artery vasospasm. Uncontrolled hypertension. Severe hepatic or renal impairment. Prophylaxis of migraine, hemiplegic or basilar migraine; cluster headache. Use within 24 hr of another 5-HT1 agonist; use within 24 hr of ergotamine derivative; concurrent use or within 2 wk of discontinuing an MAOI.
	Side effects : Nausea, somnolence, headache, flushing, fatigue, paresthesia and dry mouth. Hypotension, bradycardia or tachycardia, palpitations, Raynaud's syndrome, ischaemic colitis and visual disturbances.
									Potentially Fatal: Serious cardiac events.
	Precaution : Hypersensitivity to sulfonamides. Hepatic or moderate-severe renal impairment. Caution when used in patients with a history of seizures. May significantly increase BP. May cause drowsiness. Children <18 yr. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Almotriptan is a selective serotonin agonist which acts mainly on the 5-HT1 receptors and produces cranial vasodilation. It is used for the acute treatment of migraine.
	Interaction : Increased risk of serotonin syndrome when used with SSRIs or serotonin norepinephrine reuptake inhibitors. Increased plasma concentrations when used with verapamil, ketoconazole or other potent CYP450 inhibitors.
				Potentially Fatal: Severe vasospastic reactions may occur when given within 24 hr of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-like medication. Avoid usage with or within 2 wk of stopping treatment with a MAOI.
	Therapeutic class : 5-HT Agonists
	Packsize : 10's pack
Alucil
	n : Aluminium Hydroxide + Magnesium Hydroxide
	Indications : Heartburn, Reflux oesophagitis, Hyperacidity, Peptic ulcer, Constipation, Indigestion
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200ml bot
Alucil S
	n : Aluminium Hydroxide + Magnesium Hydroxide + Simethicon
	Indications : Dyspepsia, Flatulence
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Aluminum hydroxide: Neutralizes stomach hydrocloride to form AlCl3 salt plus water; increases gastric pH.
									Magnesium hydroxide: Promotes bowel evacuation by causing osmotic retention of fluid, which causes the colon to distend with increased peristaltic activity; forms magnesium chloride when reacts with hydrochloric acid.
									Simethicone: Disperses and prevents gas pockets in the GI system by decreasing surface tension of gas bubles.
									
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
				
				Simethicon: None well documented.
	Therapeutic class : Antacids
	Packsize : 10x10's pack
Alucil S
	n : Aluminium Oxide + Magnesium Hydroxide + Simethicon
	Indications : Hyperacidity, Gastric ulcer duodenal ulcer and gastritis
	Doses and administration : Chew1-2 tablets or 2-4 tsf after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. 
	Contara-indications : Hypophosphataemia. Simethicon is contrindicated in renal failure, severely debiliated patients, 1st trimester of pregnancy.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Aluminum hydroxide: Neutralizes stomach hydrocloride to form AlCl3 salt plus water; increases gastric pH.
									Magnesium hydroxide: Promotes bowel evacuation by causing osmotic retention of fluid, which causes the colon to distend with increased peristaltic activity; forms magnesium chloride when reacts with hydrochloric acid.
									Simethicone: Disperses and prevents gas pockets in the GI system by decreasing surface tension of gas bubles.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
				
				Simethicon: None well documented.
				
	Therapeutic class : Antacids
	Packsize : 200ml bot
Aluctin
	n : Flurazepam
	Indications : Insomnia
	Doses and administration : Oral
									Short-term management of insomnia
									Adult: 15-30 mg at night.
									Child: >15 yr 15 mg at night.
									Elderly: Max: 15 mg at night.
	Contara-indications : Hypersensitivity; porphyria. Pregnancy (3rd trimester); neonates.
	Side effects : Drowsiness and lightheadedness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia.
	Precaution : Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; personality disorders or organic brain changes; history of alcohol or drug addiction. Respiratory depression and hypotension with parenteral admin. Dependence; lactation. Safety and efficacy are not proven in children <15 yr.
	Pregnancy category : 5
	Mode of action : Flurazepam is a long-acting benzodiazepine which binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron w/in the CNS, including the limbic system, reticular formation. It enhances the inhibitory effect of GABA on neuronal excitability by increasing neuronal membrane permeability to Cl ions, thus resulting in hyperpolarisation and stabilisation.
	Interaction : May enhance CNS depressant effect w/ antidepressants, antipsychotics, general anaesth, hypnotics or sedatives, opioid analgesics. Flurazepam clearance may be reduced by cimetidine, and may be increased by rifampicin.
	Therapeutic class : Benzodiazepine hypnotics
	Packsize : 100's pack
Alugel
	n : Aluminium Hydroxide + Magnesium Hydroxide
	Indications : Heartburn, Reflux oesophagitis, Hyperacidity, Peptic ulcer, Constipation, Indigestion
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200's pack
Aluric
	n : Allopurinol
	Indications : Hyperuricaemia, Uric acid nephropathy, Cancer therapy-induced hyperuricaemia, Gout, Recurrent renal stones
	Doses and administration : Adult: PO Gout; Hyperuricaemia Initial: 100 mg/day, may adjust dose according to response. Max: 800 mg/day. 
									
									Prevention of hyperuricaemia associated w/ chemotherapy treatment or enzyme disorders 600-800 mg/day, starting 2-3 days before cancer treatment. 
									
									Renal impairment: Haemodialysis: Administer dose after session or administer 50% supplemental dose.
									
									CrCl (ml/min)	
									10-20	200 mg daily.
									<3	100 mg daily at extended intervals.
									3-10	 100 mg daily.
									
									Hepatic impairment: Dose reduction may be needed. Monitor liver function regularly.
									
	Contara-indications : Hypersensitivity; acute attack of gout.
	Side effects : Rash; alopoecia; GI disorders, taste disturbances, nausea, vomiting, abdominal pain, diarrhoea; paraesthesia, peripheral neuropathy, vertigo, headache, hepatic necrosis, drowsiness, neuritis, arthralgia; hypertension.
									Potentially Fatal: Stevens-Jonhson and/or Lyell's Syndrome (urticaria, fever, lymphadenopathy, arthralgia). Occasionally, thrombocytopaenia, agranulocytosis and aplastic anaemia.
	Precaution : Ensure adequate fluid intake. Prophylactically with an anti-inflammatory or colchicine for at least 1 mth. Withdraw immediately when sensitivity (skin rash, etc) appears. Pregnancy, lactation. Hepatic and renal impairment.
	Pregnancy category : 3
	Mode of action : Allopurinol is an inhibitor of the enzyme xanthine oxidase which converts hypoxanthine to xanthine then uric acid. The reduced production of uric acid relieves all symptoms associated with hyperuricaemia and gout. Inhibition of xanthine oxidase leads to accumulation of its substrates hypoxanthine and xanthine but since their renal clearance is more than 10 times that of uric acid, there is no risk of nephrolithiasis.
	Interaction : May inhibit the metabolism of mercaptopurine and azathioprine; reduce dose of mercaptopurine and azathioprine when given w/ allopurinol. May increase effect of warfarin and other coumarin anticoagulants. Increased excretion of the oxipurinol (metabolite) w/ salicylates or uricosuric agents. Increased toxicity w/ thiazide diuretics, some antibacterials, other antineoplastics, ciclosporin, some sulfonylurea antidiabetics, theophylline and vidarabine.
	Therapeutic class : Drugs used in Gout
	Packsize : 100's pack
Alurol
	n : Allopurinol
	Indications : Hyperuricaemia, Uric acid nephropathy, Cancer therapy-induced hyperuricaemia, Gout, Recurrent renal stones
	Doses and administration : Adult: PO Gout; Hyperuricaemia Initial: 100 mg/day, may adjust dose according to response. Max: 800 mg/day. 
									
									Prevention of hyperuricaemia associated w/ chemotherapy treatment or enzyme disorders 600-800 mg/day, starting 2-3 days before cancer treatment. 
									
									Renal impairment: Haemodialysis: Administer dose after session or administer 50% supplemental dose.
									
									CrCl (ml/min)	
									10-20	200 mg daily.
									<3	100 mg daily at extended intervals.
									3-10	 100 mg daily.
									
									Hepatic impairment: Dose reduction may be needed. Monitor liver function regularly.
									
	Contara-indications : Hypersensitivity; acute attack of gout.
	Side effects : Rash; alopoecia; GI disorders, taste disturbances, nausea, vomiting, abdominal pain, diarrhoea; paraesthesia, peripheral neuropathy, vertigo, headache, hepatic necrosis, drowsiness, neuritis, arthralgia; hypertension.
									Potentially Fatal: Stevens-Jonhson and/or Lyell's Syndrome (urticaria, fever, lymphadenopathy, arthralgia). Occasionally, thrombocytopaenia, agranulocytosis and aplastic anaemia.
	Precaution : Ensure adequate fluid intake. Prophylactically with an anti-inflammatory or colchicine for at least 1 mth. Withdraw immediately when sensitivity (skin rash, etc) appears. Pregnancy, lactation. Hepatic and renal impairment.
	Pregnancy category : 3
	Mode of action : Allopurinol is an inhibitor of the enzyme xanthine oxidase which converts hypoxanthine to xanthine then uric acid. The reduced production of uric acid relieves all symptoms associated with hyperuricaemia and gout. Inhibition of xanthine oxidase leads to accumulation of its substrates hypoxanthine and xanthine but since their renal clearance is more than 10 times that of uric acid, there is no risk of nephrolithiasis.
	Interaction : May inhibit the metabolism of mercaptopurine and azathioprine; reduce dose of mercaptopurine and azathioprine when given w/ allopurinol. May increase effect of warfarin and other coumarin anticoagulants. Increased excretion of the oxipurinol (metabolite) w/ salicylates or uricosuric agents. Increased toxicity w/ thiazide diuretics, some antibacterials, other antineoplastics, ciclosporin, some sulfonylurea antidiabetics, theophylline and vidarabine.
	Therapeutic class : Drugs used in Gout
	Packsize : 100's pack
Alve
	n : Alverine Citrate
	Indications : Dysmenorrhoea, Gastrointestinal tract spasm, Irritable bowel syndrome, Diverticular disease
	Doses and administration : Oral
									Dysmenorrhoea, Gastrointestinal tract spasm
									Adult: 60-120 mg 1-3 times daily.
									Child: >12 yr: 60-120 mg 1-3 times daily.
	Contara-indications : Hypersensitivity, intestinal obstruction, paralytic ileus; children <12 yr.
	Side effects : Nausea, headache; pruritus, rash; dizziness; allergic reactions.
									Potentially Fatal: Anaphylaxis.
	Precaution : Pregnancy, lactation.
	Pregnancy category : 0
	Mode of action : Alverine is a synthetic, non-narcotic, nonhabit-forming spasmolytic agent, which acts directly on intestinal and uterine smooth muscle.
	Interaction : None
	Therapeutic class : Anticholinergics(others)
	Packsize : 50's pack
Alverin
	n : Alverine Citrate
	Indications : Dysmenorrhoea, Gastrointestinal tract spasm, Irritable bowel syndrome, Diverticular disease
	Doses and administration : Oral
									Dysmenorrhoea, Gastrointestinal tract spasm
									Adult: 60-120 mg 1-3 times daily.
									Child: >12 yr: 60-120 mg 1-3 times daily.
	Contara-indications : Hypersensitivity, intestinal obstruction, paralytic ileus; children <12 yr.
	Side effects : Nausea, headache; pruritus, rash; dizziness; allergic reactions.
									Potentially Fatal: Anaphylaxis.
	Precaution : Pregnancy, lactation.
	Pregnancy category : 0
	Mode of action : Alverine is a synthetic, non-narcotic, nonhabit-forming spasmolytic agent, which acts directly on intestinal and uterine smooth muscle.
	Interaction : None
	Therapeutic class : Anticholinergics(others)
	Packsize : 30's pack
Alvolex
	n : Salbutamol
	Indications : Acute severe asthma, Severe bronchospasm
	Doses and administration : Adult: PO Acute bronchospasm 2-4 mg (up to 8 mg) 3-4 times/day. Extended release 8 mg twice daily. 
									
									Children
									2 - 6 years: 2.5 ml syrup, 3-4 times daily
									6-12 years: 5 ml syrup, 3-4 times daily
									Over 12 years: 5-10 ml syrup, 3-4 times daily (2-4 mg tablet, 3-4 times daily) 
									
									Inhalation Capsule: Adults:
									For the relief of acute asthma or before exercise 400 g (2 ConviCaps). The recommended dose for maintenance treatment or prophylactic therapy is 400 g (2 ConviCaps) three to four times a day. Maximum dose is 1600 g/day.
									
									Children:
									In the treatment of episodic asthma or before exercise 200 g (1 ConviCap). The recommended dose for maintenance treatment or prophylactic treatment is 200 g (1 ConviCap) three to four times a day. Maximum dose is 800 g/day.
									
									As aerosol: Inhalation Acute bronchospasm 100 or 200 mcg 3-4 times/day. 2 puffs may be given prior to exertion to prevent exercise-induced bronchospasm. 
									
									Acute severe asthma As MDI: 4-6 inhalations every 10-20 mins. Severe bronchospasm Via nebuliser: 2.5-5 mg up to 4 times/day.
									
									Children For relief of acute bronchospasm in the maintenance of episodic asthma or before exercise: one 1 puff may be administered as a single dose. 
									
									For routine maintenance and prophylaxis therapy: one 1 puff three or four times daily, increasing if necessary to two puffs three or four times daily. 
									Elderly The dosage is the same as that for adults.
									
									Nebuliser Solution
									Nebuliser Solution is for inhalation use only, to be breathed in through the mouth, under the direction of a physician, using a suitable nebuliser. The solution should not be injected or swallowed.
									Adults (including the elderly): 2.5 mg to 5 mg salbutamol up to four times a day. Up to 40 mg per day can be given under strict medical supervision in hospital.
									
									Children 4 years and above: 2.5 mg to 5 mg up to four times a day.
									Children 18 months to 4 years: 2.5 mg up to four times a day.The dose may be increased to 5 mg if necessary.
									Infants under 18 months old: 1.25 mg (0.25 mg/kg) to 2.5 mg up to four times a day.
									
									Respirator Solution
									By Intermittent Administration : Adult : Respirator Solution 0.5-1.0 ml should be diluted to final volume of 2.0-4.0 ml with normal saline for injection. The resulting solution is inhaled from a suitably driven nebulizer until aerosol generation ceases. Should take about 10 minutes. 
									Respirator Solution may be used undiluted for intermittent administration. For this 2.0 ml of the solution is placed in the nebulizer and the patient allowed to inhale until bronchodilatation is achieved. This usually takes 3-5 minutes. 
									
									Children under 12 years age: 0.5 ml of the solution diluted to 2.0-4.0 ml with normal saline. Intermittent treatment may be repeated four times a day. 
									
									By Continuous Administration :  Respirator Solution is diluted with normal saline for injection, 1-2 ml solution made upto 100 ml with diluent. The diluted solution is administered as an aerosol by a suitably driven nebulizer. The usual rate of administration is 1-2 mg/hour.
	Contara-indications : Salbuatmol inhaler is contraindicated in patients with a history of hypersensitivity to any of its components. Although intravenous Salbutamol, and occasionally Salbutamol tablets, is used in the management of premature labour uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage or toxaemia of pregnancy, Salbutamol inhaler preparations are not appropriate for managing premature labour. Salbutamol preparation should not be used for threatened abortion during the first or second trimesters of pregnancy.
	Side effects : Fine skeletal muscle tremor especially hands, tachycardia, palpitations, muscle cramps, headache, paradoxical bronchospasm, angioedema, urticaria, hypotension and collapse.
									Potentially Fatal: Potentially serious hypokalaemia after large doses.
	Precaution : Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. In the event of previously effective dose of Salbuatmol inhaler failing to give relief for at least three hours, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken.
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with beta-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : Diuretics, corticosteroids and xanthines may augment hypokalaemia. CV effects potentiated by MAOIs, TCAs, sympathomimetics. Increases absorption of sulfamethoxazole when used together. May markedly increase heart rate and BP when used with atomoxetine. Reduces serum levels of digoxin. Hypokalaemia induced by salbutamol increases the risk of digitalis toxicity. BP should be closely monitored if linezolid is used concurrently with salbutamol.
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 100ml bot
Alzed
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 20's pack
Alzolam 0.25
	n : Alprazolam
	Indications : Anxiety disorders, Panic disorders, Nausea due to chemotherapy
	Doses and administration : Oral
									Short-term management of anxiety
									Adult: 0.25-0.5 mg tid, increased to 3-4 mg daily if necessary.
									Elderly: Initially, 0.25 mg bid/tid.
									Hepatic impairment: Avoid in severe impairment.
									
									Panic attacks
									Adult: Up to 10 mg daily.
	Contara-indications : Acute narrow-angle glaucoma, preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; pregnancy, lactation.
	Side effects : Psychological and physical dependence, withdrawal syndrome; drowsiness, sedation, vertigo, headache, visual disturbances, GI disturbances, jaundice; fatigue, muscle weakness, ataxia, dizziness, confusion and depression.
									Potentially Fatal: Blood dyscrasias.
	Precaution : Dosage reduction or gradual withdrawal. Dependence. Geriatric or debilitated patients. Muscle weakness, impaired hepatic or renal function; arteriosclerosis; obesity; depression particularly suicidal tendency; chronic pulmonary insufficiency. May impair ability to drive or operate machinery. Children <18 yr.
	Pregnancy category : 4
	Mode of action : Alprazolam has anxiolytic, muscle-relaxant, anticonvulsant, antidepressant and sleep-modifying effects. It binds to the ? aminobutyric acid (GABA)-specific sites throughout the CNS, leading to an increase in the inhibitory effect of GABA on neuronal excitability. Increased neuronal permeability to chloride ions thus results in hyperpolarisation and stabilisation.
	Interaction : Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.
				Potentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. 
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 100's pack
Alzolam 0.5
	n : Alprazolam
	Indications : Anxiety disorders, Panic disorders, Nausea due to chemotherapy
	Doses and administration : Oral
									Short-term management of anxiety
									Adult: 0.25-0.5 mg tid, increased to 3-4 mg daily if necessary.
									Elderly: Initially, 0.25 mg bid/tid.
									Hepatic impairment: Avoid in severe impairment.
									
									Panic attacks
									Adult: Up to 10 mg daily.
	Contara-indications : Acute narrow-angle glaucoma, preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; pregnancy, lactation.
	Side effects : Psychological and physical dependence, withdrawal syndrome; drowsiness, sedation, vertigo, headache, visual disturbances, GI disturbances, jaundice; fatigue, muscle weakness, ataxia, dizziness, confusion and depression.
									Potentially Fatal: Blood dyscrasias.
	Precaution : Dosage reduction or gradual withdrawal. Dependence. Geriatric or debilitated patients. Muscle weakness, impaired hepatic or renal function; arteriosclerosis; obesity; depression particularly suicidal tendency; chronic pulmonary insufficiency. May impair ability to drive or operate machinery. Children <18 yr.
	Pregnancy category : 4
	Mode of action : Alprazolam has anxiolytic, muscle-relaxant, anticonvulsant, antidepressant and sleep-modifying effects. It binds to the ? aminobutyric acid (GABA)-specific sites throughout the CNS, leading to an increase in the inhibitory effect of GABA on neuronal excitability. Increased neuronal permeability to chloride ions thus results in hyperpolarisation and stabilisation.
	Interaction : Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.
				Potentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. 
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 100's pack
Alzolam SR 1
	n : Alprazolam
	Indications : Anxiety disorders, Panic disorders, Nausea due to chemotherapy
	Doses and administration : Oral
									Short-term management of anxiety
									Adult: 0.25-0.5 mg tid, increased to 3-4 mg daily if necessary.
									Elderly: Initially, 0.25 mg bid/tid.
									Hepatic impairment: Avoid in severe impairment.
									
									Panic attacks
									Adult: Up to 10 mg daily.
	Contara-indications : Acute narrow-angle glaucoma, preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; pregnancy, lactation.
	Side effects : Psychological and physical dependence, withdrawal syndrome; drowsiness, sedation, vertigo, headache, visual disturbances, GI disturbances, jaundice; fatigue, muscle weakness, ataxia, dizziness, confusion and depression.
									Potentially Fatal: Blood dyscrasias.
	Precaution : Dosage reduction or gradual withdrawal. Dependence. Geriatric or debilitated patients. Muscle weakness, impaired hepatic or renal function; arteriosclerosis; obesity; depression particularly suicidal tendency; chronic pulmonary insufficiency. May impair ability to drive or operate machinery. Children <18 yr.
	Pregnancy category : 4
	Mode of action : Alprazolam has anxiolytic, muscle-relaxant, anticonvulsant, antidepressant and sleep-modifying effects. It binds to the ? aminobutyric acid (GABA)-specific sites throughout the CNS, leading to an increase in the inhibitory effect of GABA on neuronal excitability. Increased neuronal permeability to chloride ions thus results in hyperpolarisation and stabilisation.
	Interaction : Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.
				Potentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. 
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 100's pack
AM
	n : Azithromycin
	Indications : Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							
									
	Doses and administration : Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. 
									
									Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. 
									Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. 
									Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. 
									
									IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. 
									
									Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
									
									Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. 
	Contara-indications : Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
	Side effects : GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
									Potentially Fatal: Angioedema and cholestatic jaundice.
	Precaution : May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
	Pregnancy category : 2
	Mode of action : Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
	Interaction : Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
				Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
	Therapeutic class : Macrolides
	Packsize : 30ml bot
AM
	n : Azithromycin
	Indications : Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							
									
	Doses and administration : Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. 
									
									Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. 
									Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. 
									Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. 
									
									IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. 
									
									Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
									
									Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. 
	Contara-indications : Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
	Side effects : GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
									Potentially Fatal: Angioedema and cholestatic jaundice.
	Precaution : May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
	Pregnancy category : 2
	Mode of action : Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
	Interaction : Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
				Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
	Therapeutic class : Macrolides
	Packsize : 10's pack
Amacid Plus
	n : Aluminium Hydroxide + Magnesium Hydroxide + Simethicon
	Indications : Dyspepsia, Flatulence
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Aluminum hydroxide: Neutralizes stomach hydrocloride to form AlCl3 salt plus water; increases gastric pH.
									Magnesium hydroxide: Promotes bowel evacuation by causing osmotic retention of fluid, which causes the colon to distend with increased peristaltic activity; forms magnesium chloride when reacts with hydrochloric acid.
									Simethicone: Disperses and prevents gas pockets in the GI system by decreasing surface tension of gas bubles.
									
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
				
				Simethicon: None well documented.
	Therapeutic class : Antacids
	Packsize : 200's pack
Amacid Plus Susp
	n : Aluminium Oxide + Magnesium Hydroxide + Simethicon
	Indications : Hyperacidity, Gastric ulcer duodenal ulcer and gastritis
	Doses and administration : Chew1-2 tablets or 2-4 tsf after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. 
	Contara-indications : Hypophosphataemia. Simethicon is contrindicated in renal failure, severely debiliated patients, 1st trimester of pregnancy.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Aluminum hydroxide: Neutralizes stomach hydrocloride to form AlCl3 salt plus water; increases gastric pH.
									Magnesium hydroxide: Promotes bowel evacuation by causing osmotic retention of fluid, which causes the colon to distend with increased peristaltic activity; forms magnesium chloride when reacts with hydrochloric acid.
									Simethicone: Disperses and prevents gas pockets in the GI system by decreasing surface tension of gas bubles.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
				
				Simethicon: None well documented.
				
	Therapeutic class : Antacids
	Packsize : 200ml
Amarin
	n : Pheniramine Maleate
	Indications : Allergic conjunctivitis, Allergic conditions, Motion sickness
	Doses and administration :  Adult: PO Allergic conditions; Prevention of motion sickness As maleate: 
									Syr: 15-30 mg 2-3 times/day. 
									Tab: Up to 45 mg 3 times/day. Max: 3 mg/kg/day. 
									For motion sickness prevention: Take 1st dose at least 30 mins before travelling. 
									
									Children aged 1-3 years:  Half a measuring spoonful 2 or 3 times daily.
									Children aged 4-12 years: 1 measuring spoonful 2 or 3 times daily.
									
	Contara-indications : Symptomatic prostatic hypertrophy; neonates and premature infants.
	Side effects : Oral: Sedation. Hypersensitivity reactions. Lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. Nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. Urinary retention. Palpitations, headache. Blurred vision, increased intraocular pressure. Muscular weakness. Rarely, blood dyscrasias e.g. agranulocytosis, haemolytic anaemia. Ophthalmic: Temporarily enlarged pupils, eye redness (overuse).
	Precaution :  	May impair ability to drive or operate machinery. Has potential for abuse. Narrow angle glaucoma, asthma or severe CV disease. Antiemetic effect may mask signs of other conditions. Pregnancy and lactation. Elderly.
	Pregnancy category : 3
	Mode of action : Pheniramine is an alkylamine derivative with histamine H1-receptor antagonist effects. It also has anticholinergic and moderate sedative effects.
	Interaction : May mask ototoxicity produced by aminoglycoside antibiotics.
				
				Potentially Fatal: Potentiation of CNS depression by alcohol, sedatives, opioids, barbiturates, hypnotics, narcoleptics. May increase antimuscarinic effect of MAOIs, atropine and TCAs.
	Therapeutic class : Sedating Anti-histamines
	Packsize : 100ml bot
Amarin
	n : Pheniramine Maleate
	Indications : Allergic conjunctivitis, Allergic conditions, Motion sickness
	Doses and administration :  Adult: PO Allergic conditions; Prevention of motion sickness As maleate: 
									Syr: 15-30 mg 2-3 times/day. 
									Tab: Up to 45 mg 3 times/day. Max: 3 mg/kg/day. 
									For motion sickness prevention: Take 1st dose at least 30 mins before travelling. 
									
									Children aged 1-3 years:  Half a measuring spoonful 2 or 3 times daily.
									Children aged 4-12 years: 1 measuring spoonful 2 or 3 times daily.
									
	Contara-indications : Symptomatic prostatic hypertrophy; neonates and premature infants.
	Side effects : Oral: Sedation. Hypersensitivity reactions. Lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. Nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. Urinary retention. Palpitations, headache. Blurred vision, increased intraocular pressure. Muscular weakness. Rarely, blood dyscrasias e.g. agranulocytosis, haemolytic anaemia. Ophthalmic: Temporarily enlarged pupils, eye redness (overuse).
	Precaution :  	May impair ability to drive or operate machinery. Has potential for abuse. Narrow angle glaucoma, asthma or severe CV disease. Antiemetic effect may mask signs of other conditions. Pregnancy and lactation. Elderly.
	Pregnancy category : 3
	Mode of action : Pheniramine is an alkylamine derivative with histamine H1-receptor antagonist effects. It also has anticholinergic and moderate sedative effects.
	Interaction : May mask ototoxicity produced by aminoglycoside antibiotics.
				
				Potentially Fatal: Potentiation of CNS depression by alcohol, sedatives, opioids, barbiturates, hypnotics, narcoleptics. May increase antimuscarinic effect of MAOIs, atropine and TCAs.
	Therapeutic class : Sedating Anti-histamines
	Packsize : 100's pack
Amaryl
	n : Glimepiride
	Indications : Type 2 DM
	Doses and administration : Oral
									Type 2 diabetes mellitus
									Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
									Elderly: Initially, 1 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Diabetic ketoacidosis with or without coma.
	Side effects : Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.
	Precaution : Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Amaryl
	n : Glimepiride
	Indications : Type 2 DM
	Doses and administration : Oral
									Type 2 diabetes mellitus
									Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
									Elderly: Initially, 1 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Diabetic ketoacidosis with or without coma.
	Side effects : Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.
	Precaution : Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Amaryl
	n : Glimepiride
	Indications : Type 2 DM
	Doses and administration : Oral
									Type 2 diabetes mellitus
									Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
									Elderly: Initially, 1 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Diabetic ketoacidosis with or without coma.
	Side effects : Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.
	Precaution : Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Amaryl
	n : Glimepiride
	Indications : Type 2 DM
	Doses and administration : Oral
									Type 2 diabetes mellitus
									Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
									Elderly: Initially, 1 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Diabetic ketoacidosis with or without coma.
	Side effects : Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.
	Precaution : Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Ambeeclox
	n : Cloxacillin
	Indications : Bacterial infections, Staphylococcal infections resistant to benzylpenicillin, Bacterial Meningitis caused by Staphylococcus, Bacterial Pneumonia caused by Staphylococcus, Lower Respiratory Tract Infection, Urinary Tract Infection caused by Staphylococcus Aureus
	Doses and administration : Adult: PO 250-500 mg 4 times/day. 
									Child: 50-100 mg/kg in divided doses every 6 hr.
	Contara-indications : Hypersensitivity to penicillins.
	Side effects : Neutropenia, agranulocytosis; GI upsets; rash. Sore mouth or tongue. Black hairy tongue.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis; anaphylaxis.
	Precaution : Renal impairment; pregnancy and lactation. Porphyria.
	Pregnancy category : 2
	Mode of action : Cloxacillin is resistant to degradation by penicillinases. It is particularly useful against penicillinase-producing staphylococci. Highly active against S aureus, S pyogenes, S viridans and S pneumoniae.
	Interaction :  	May diminish the effect of BCG and typhoid vaccine. May increase risk of methotrexate toxicity. May diminish the therapeutic effect of Na picosulfate. May decrease serum concentrations of mycophenolate. May prolong bleeding time w/ anticoagulants. Increased serum concentrations w/ probenecid. Tetracycline may antagonise the bactericidal effect of cloxacillin.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 100's pack
Ambeexin
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 15ml bot
Ambeexin
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Ambeexin
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Ambix
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambokof
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambolos
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambolyt
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambolyt
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 15ml bot
Amboral
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Amboral
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 15ml bot
Ambosil
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambosil
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 15ml bot
Amboten
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Amboten PD
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 15ml bot
Amboxol
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambozin
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambozin SR
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 3x10's pack
Ambronil
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 12ml bot
Ambrosol
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambrotil
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambrox
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambrox
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 15ml bot
Ambrox SR 75
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 30's pack
Ambroxol
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambroxol
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 15ml bot
Ambroxol SR
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 30's pack
Ambryl
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Ambryl SF
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Amdin
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amdin
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 50's pack
Amdin PLUS 5/50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Amdocal
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 60's pack
Amdocal
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 100's pack
Amdocal PLUS 5/25
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amdocal PLUS 5/50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 60's pack
Amdoper
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amdopril 10/20
	n : Amlodipine + Benazepril Hydrochloride
	Indications : Hypertension
	Doses and administration : Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.
	Contara-indications : Patients with history of angioedema; pregnancy, lactation.
	Side effects : Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.
									Potentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.
	Precaution : Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.
	Pregnancy category : 17
	Mode of action : Amlodipine is a dihydropyridine calcium antagonist. It lowers BP by relaxing the coronary vascular smooth muscles and producing coronary vasodilation; through inhibition of transmembrane Ca ion influx into vascular smooth muscle and cardiac muscle. It is also a peripheral vascular vasodilator. Benazepril and its active metabolite benazeprilat inhibit ACE, which results in decreased plasma angiotensin II and thus leading to decreased aldosterone secretion.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amdopril 2.5/10
	n : Amlodipine + Benazepril Hydrochloride
	Indications : Hypertension
	Doses and administration : Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.
	Contara-indications : Patients with history of angioedema; pregnancy, lactation.
	Side effects : Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.
									Potentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.
	Precaution : Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.
	Pregnancy category : 17
	Mode of action : Amlodipine is a dihydropyridine calcium antagonist. It lowers BP by relaxing the coronary vascular smooth muscles and producing coronary vasodilation; through inhibition of transmembrane Ca ion influx into vascular smooth muscle and cardiac muscle. It is also a peripheral vascular vasodilator. Benazepril and its active metabolite benazeprilat inhibit ACE, which results in decreased plasma angiotensin II and thus leading to decreased aldosterone secretion.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 60's pack
Amdopril 5/10
	n : Amlodipine + Benazepril Hydrochloride
	Indications : Hypertension
	Doses and administration : Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.
	Contara-indications : Patients with history of angioedema; pregnancy, lactation.
	Side effects : Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.
									Potentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.
	Precaution : Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.
	Pregnancy category : 17
	Mode of action : Amlodipine is a dihydropyridine calcium antagonist. It lowers BP by relaxing the coronary vascular smooth muscles and producing coronary vasodilation; through inhibition of transmembrane Ca ion influx into vascular smooth muscle and cardiac muscle. It is also a peripheral vascular vasodilator. Benazepril and its active metabolite benazeprilat inhibit ACE, which results in decreased plasma angiotensin II and thus leading to decreased aldosterone secretion.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 60's pack
Amdopril 5/20
	n : Amlodipine + Benazepril Hydrochloride
	Indications : Hypertension
	Doses and administration : Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.
	Contara-indications : Patients with history of angioedema; pregnancy, lactation.
	Side effects : Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.
									Potentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.
	Precaution : Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.
	Pregnancy category : 17
	Mode of action : Amlodipine is a dihydropyridine calcium antagonist. It lowers BP by relaxing the coronary vascular smooth muscles and producing coronary vasodilation; through inhibition of transmembrane Ca ion influx into vascular smooth muscle and cardiac muscle. It is also a peripheral vascular vasodilator. Benazepril and its active metabolite benazeprilat inhibit ACE, which results in decreased plasma angiotensin II and thus leading to decreased aldosterone secretion.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amdova
	n : Amlodipine 5mg + Atorvastatin 10mg
	Indications : Angina, Hyperlipidaemia, Hypertension, Stroke prevention
	Doses and administration : Adult: PO HTN or angina and hyperlipidaemia: 
									
									 Amlodipine: Initially 5 mg once daily, titrate over 1-2 wk; max: 10 mg/day. Atorvastatin: Initially 10-20 mg once daily (anytime of the day), patients who require >45 % reduction in LDL cholesterol may be initiated at 40 mg once daily. Titrate dose at intervals of at least 4 week; max: 80 mg/day.
	Contara-indications : Active liver disease or unexplained persistent elevated hepatic transaminases. Pregnancy and lactation.
	Side effects : Amlodipine: Headache, dizziness, fatigue, somnolence, peripheral oedema, flushing, palpitations, nausea, abdominal pain; rarely pruritus, rash, dyspnoea, asthenia and muscle cramps. Atorvastatin: Nasopharyngitis, arthralgia, diarrhoea, pain in extremity, UTI, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, increased transaminases, abnormal liver function test, increased creatinine phosphokinase, thrombocytopenia, malaise, hepatitis, cholestasis, bullous rashes.
									Potentially Fatal: Rhabdomyolysis with acute renal failure.
	Precaution : Atorvastatin may cause myopathy, and rarely rhabdomyolysis with acute renal failure secondary to myoglobinuria especially at high doses or in patients with history of renal impairment. Caution when used with CYP3A4 inhibitors which may increase plasma concentrations of Atorvastatin. Withhold/discontinue Atorvastatin if symptoms suggestive of myopathy or rhabdomyolysis are observed. Atorvastatin has been associated with biochemical abnormalities of liver; LFT should be monitored prior to and at 12 wk following treatment initiation and dosage increment; caution in patients who consume large amounts of alcohol or with history of liver disease. Worsening of angina and/or myocardial infarction has been reported with use of dihydrophyridine calcium channel blockers, especially in patients with severe obstructive coronary artery disease. Amlodipine may cause dose-dependent peripheral oedema. Caution in patients with severe aortic stenosis, symptomatic hypotension may occur. Elderly.
	Pregnancy category : 5
	Mode of action : Amlodipine is a dihydropyridine calcium channel blocker which relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It reduces peripheral vascular resistance and hence resulting in a reduction of blood pressure. In vasospastic angina, Amlodipine also inhibits coronary spasm in patients with vasopastic angina. Atorvastatin selectively and competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate which is a rate-limiting step in cholesterol biosynthesis.
	Interaction : Rifamycins may increase the metabolism of both Amlodipine and Atorvastatin. Atorvastatin may increase AUC of norethindrone and ethinyl estradiol.
				Potentially Fatal: Atorvastatin: Increased risk of myopathy when used concurrently with fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYP3A4 inhibitors (e.g. clarithromycin, HIV protease inhibitors, itraconazole). Cyclosporine (OATP1B1 inhibitor) may significantly increase bioavailability of Atorvastatin.
	Therapeutic class : Anti-anginal & lipid lowering drugs
	Packsize : 30's pack
Ameloss 5
	n : Donepezil Hydrochloride
	Indications : Mild to moderately severe dementia in Alzheimer's disease.
	Doses and administration : Adult: PO Initial: 5 mg/day in the evening, up to 10 mg/day after 4-6 wk. The 5 mg (1 tab)/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. 
									
									Following a one-month clinical assessment of treatment at 5 mg/day, the dose can be increased to 10 mg/day (once-a-day dosing). Since food does not affect the rate or extent of absorption of donepezil, it can be administered with or without food. 
									
									In case of renal & hepatic impairment: A similar dose schedule can be followed for patients with renal or mild to moderate hepatic impairment as clearance of donepezil hydrochloride is not affected by these conditions. 
									
									In case of children: There are no adequate and well controlled trials in document to safety and efficacy of donepezil hydrochloride in any illness occurring in children. Donepezil is not recommended for use in children.
									
	Contara-indications : Donepezil is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.
	Side effects : Nausea, vomiting, anorexia, wt loss, diarrhoea, insomnia, fatigue, muscle cramps; headache and dizziness; syncope, bradycardia; convulsions; increased liver transaminases; sinoatrial and atrioventricular block; hallucinations, agitation and aggressive behavior; minor increases in plasma creatine kinase; potentially bladder outflow obstruction.
	Precaution : Caution when used in patients with sick sinus syndrome or cardiac conduction abnormalities. May increase secretion of gastric acid; caution when used in patients at risk of ulcer disease. Patients with COPD, asthma, history of epilepsy, bladder obstruction, prostatic hypertrophy. May cause dose-related diarrhoea, nausea and/or vomiting which usually resolves after 1-3 wk. Safety and efficacy have not been established in children. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Donepezil reversibly and noncompetitively inhibits centrally-active acetylcholinesterase. It is used for the symptomatic treatment of Alzheimer's disease.
	Interaction : May increase the neurotoxic effect of antipsychotics. Concurrent use with systemic corticosteroids may increase the adverse effects of donepezil. May increase the neuromuscular-blocking effect of succinylcholine. May increase the adverse effects of cholinergic agonists. May increase the bradycardic effect of ?-blockers.
	Therapeutic class : Drugs for Dementia
	Packsize : 30's pack
Ametil
	n : Prochlorperazine Maleate
	Indications : Vertigo, Psychoses, Nausea and vomiting, Severe anxiety disorders
	Doses and administration : Oral
									Prophylaxis of nausea and vomitting
									Adult: As maleate : 5-10 mg bid/tid. 
									
									Nausea and vomiting
									Adult: As maleate : 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid.
									
									Psychoses
									Adult: As maleate : 12.5 mg bid for 7 days, adjusted gradually to 75-100 mg daily according to response. Usual maintenance dose: 25-50 mg daily.
									
									Child: 1-5 yr: 1.25-2.5 mg; 5-12 yr: 2.5-5 mg. May be given up to tid, if necessary.
									
									Adjunct in severe anxiety disorders
									Adult: As maleate: 5-10 mg, up to 3-4 times daily.
									
									Vertigo
									Adult: As maleate : 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid.
									
									
	Contara-indications : CNS depression, comatose patients. Bone marrow depression, phaechromocytoma, prolactin-dependent tumours, hypersensitivity. Childn <2 yr. Pregnancy and lactation.
	Side effects : Cholestatic jaundice, cardiac arrhythmias, orthostatic hypotension, leucopaenia, thrombocytopaenia, dry mouth, blurring of vision, glaucoma, urinary retention, constipation, galactorrhoea, gynaecomastia, amenorrhoea and impotence. Buccal: Transient numbness of gum and tongue.
									Potentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration.
	Precaution : Extrapyramidal syndrome, hypotension, epilepsy, impaired hepatic, renal, CV, cerebrovascular or respiratory function, glaucoma. May impair ability to drive or perform tasks requiring mental alertness or physical coordination. Parenteral use in children is not recommended. History of jaundice, parkinsonism, diabetes mellitus, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia or urinary retention. Regular eye examinations are recommended in patients on long-term treatment.
	Pregnancy category : 3
	Mode of action : Prochlorperazine blocks both postsynaptic dopamine receptors as well as the medullary chemo receptor trigger zone. It depresses hypothalamic and hypophyseal hormone release and posssesses ?-adrenergic and anticholinergic inhibitory activity.
	Interaction :  	Alcohol, antacids.
	Therapeutic class : Anti-emetic drugs
	Packsize : 500's pack
Ametrol VT
	n : Metronidazole + Miconazole Nitrate Vag prep
	Indications : Vaginal candidiasis, Bacterial and trichomonal vaginitis
	Doses and administration : Adult: Vag candidiasis As pessary: 100 mg every night for 7-14 days. As 2% cream: 5 g every night for 7-14 days. 
	Contara-indications : Hypersensitivity; hepatic impairment (oral gel). Porphyria.
	Side effects : Nausea, vomiting, febrile reactions, rash, drowsiness, diarrhoea, anorexia and flushing, hepatitis. Local irritation and sensitisation, contact dermatitis.
									Potentially Fatal: IV: Anaphylactic reaction and cardiac arrest.
	Precaution : For external use only; discontinue if sensitization or irritation occurs. Pregnancy and lactation
	Pregnancy category : 13
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
									
									Miconazole inhibits ergosterol synthesis thus damaging fungal cell wall membrane and increases its permeability, allowing leakage of nutrients.
	Interaction : Metronidazole: Disulfiram-like reaction w/ alcohol. Increased oral anticoagulant effect, blood levels of phenytoin, lithium toxicity, plasma conc of astemizole & terfenadine; blood conc of carbamazepine. Decreased blood levels w/ phenobarb. Risk of CNS-related effects (eg psychotic reactions) w/ disulfiram. Increased blood levels & neurologic effects w/ cimetidine. May increase blood levels & toxicity of fluorouracil; toxicity of cyclosporine. Increased cardiotoxicity w/ amiodarone. Interference w/ blood levels of liver enzymes, glucose (hexokinase method), theophylline & procainamide. Decreased levels w/ phenytoin. 
				
				Miconazole: Increased risk of bleeding w/ acenocoumarol, anisindione, dicumarol, phenindione, phenprocoumon, warfarin; plasma conc & exposure to oxybutinin. May increase risk of phenytoin, phosphenytoin, cyclosporine, trimetrexate toxicity & cardiotoxicity w/ pimozide. May inhibit metabolism of astemizole, cisapride & terfenadine. Reduced carbamazepine metabolism. Increased or prolonged effects of opioid (fentanyl). May cause hypoglycemia w/ glimepiride. Reduced clearance & increased plasma conc of oxycodone. May increase bioavailability of tolterodine (in patients w/ deficient CYP2D6 activity).
	Therapeutic class : Drugs used in Vaginal and Vulval conditions
	Packsize : 10's pack
Amezol
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Amezol
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Amibac
	n : Amikacin
	Indications : Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
	Doses and administration : Parenteral
									Uncomplicated urinary tract infections
									Adult: 250 mg bid, given via IM, IV inj over 2-3 minutes or as IV infusion.
									
									Severe Gram-negative infections resistant to gentamicin and tobramycin
									Adult: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Max: Up to 500 mg every 8 hr in life-threatening infections. Max cumulative dose: 15 g. Doses may be given via IM, slow IV inj over 2-3 minutes or IV infusion.
									
									Child: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Neonates: 10 mg/kg daily in 2 divided doses.
									
									Impaired renal function: In patient with impaired renal function the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug. Simple doses schedule for renal impairment is given below:
									Renal function Dosage schedule
									Mild impairment 500 mg every 18 hours
									Moderate impairment 500 mg every 24 hours
									Severe impairment 250 mg every 24 hours. 
	Contara-indications : Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
	Side effects : Tinnitus, vertigo; ataxia and overt deafness.
									Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
	Precaution : Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment.
	Pregnancy category : 4
	Mode of action : Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
	Interaction : Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.
				Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
	Therapeutic class : Aminoglycosides
	Packsize : 10 amps pack
Amibac
	n : Amikacin
	Indications : Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
	Doses and administration : Parenteral
									Uncomplicated urinary tract infections
									Adult: 250 mg bid, given via IM, IV inj over 2-3 minutes or as IV infusion.
									
									Severe Gram-negative infections resistant to gentamicin and tobramycin
									Adult: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Max: Up to 500 mg every 8 hr in life-threatening infections. Max cumulative dose: 15 g. Doses may be given via IM, slow IV inj over 2-3 minutes or IV infusion.
									
									Child: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Neonates: 10 mg/kg daily in 2 divided doses.
									
									Impaired renal function: In patient with impaired renal function the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug. Simple doses schedule for renal impairment is given below:
									Renal function Dosage schedule
									Mild impairment 500 mg every 18 hours
									Moderate impairment 500 mg every 24 hours
									Severe impairment 250 mg every 24 hours. 
	Contara-indications : Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
	Side effects : Tinnitus, vertigo; ataxia and overt deafness.
									Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
	Precaution : Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment.
	Pregnancy category : 4
	Mode of action : Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
	Interaction : Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.
				Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
	Therapeutic class : Aminoglycosides
	Packsize : 10 amps pack
Amicard PLUS 5/50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Amidol 300
	n : Iopamidol
	Indications : Radiographic contrast medium for diagnostic procedures
	Doses and administration : Adult: Inj As soln containing 41-76% of iopamidol. Dose and strength used depends on the procedure and route of administration used.
	Contara-indications : Not for intrathecal use.
	Side effects : Arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.
									Potentially Fatal: Severe anaphylactoid reactions.
	Precaution : May inhibit blood coagulation. Multiple myeloma or other paraproteinaemia. Sickle-cell disease. Known or suspected phaeochromocytoma (monitor closely). Hyperthyroidism. Ensure adequate hydration. History of a previous sensitivity to a contrast medium, sensitivity to iodine, bronchial asthma, hay fever and food allergy. Monitor patients with CHF. Avoid angiography in patients with homocystinuria. Severe arterial or venous disease. Severe renal impairment, combined renal and hepatic disease or anuria, especially when large doses are used. Pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Iopamidol is a nonionic iodinated radiographic contrast medium. It allows visualisation of internal body structures by opacifying the path of its flow.
	Interaction : Arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.
				Potentially Fatal: Severe anaphylactoid reactions.
	Therapeutic class : Contrast medium for diagnostic procedures
	Packsize : 1's pack
Amidol 370
	n : Iopamidol
	Indications : Radiographic contrast medium for diagnostic procedures
	Doses and administration : Adult: Inj As soln containing 41-76% of iopamidol. Dose and strength used depends on the procedure and route of administration used.
	Contara-indications : Not for intrathecal use.
	Side effects : Arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.
									Potentially Fatal: Severe anaphylactoid reactions.
	Precaution : May inhibit blood coagulation. Multiple myeloma or other paraproteinaemia. Sickle-cell disease. Known or suspected phaeochromocytoma (monitor closely). Hyperthyroidism. Ensure adequate hydration. History of a previous sensitivity to a contrast medium, sensitivity to iodine, bronchial asthma, hay fever and food allergy. Monitor patients with CHF. Avoid angiography in patients with homocystinuria. Severe arterial or venous disease. Severe renal impairment, combined renal and hepatic disease or anuria, especially when large doses are used. Pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Iopamidol is a nonionic iodinated radiographic contrast medium. It allows visualisation of internal body structures by opacifying the path of its flow.
	Interaction : Arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.
				Potentially Fatal: Severe anaphylactoid reactions.
	Therapeutic class : Contrast medium for diagnostic procedures
	Packsize : 100ml
Amifen
	n : Mefenamic Acid
	Indications : Rheumatoid arthritis, Osteoarthritis, Dysmenorrhoea, Menorrhagia, Dental pain, Pain and inflammation, Mild to moderate pain, Postoperative pain
	Doses and administration : Oral
									Rheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia
									Adult: 500 mg tid.
									Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
	Contara-indications : Inflammatory bowel disease; peptic ulcer; neonates; pregnancy (3rd trimester), lactation. Coronary artery bypass graft surgery, severe renal impairment, severe heart failure.
	Side effects : Abdominal pain, dyspepsia, constipation, diarrhoea, nausea, GI ulcers; oedema; bronchospasm; headache, drowsiness, insomnia, visual disturbances; CHF, hypertension, tachycardia, syncope; urticaria, rash; thrombocytopenia, aplastic anaemia, agranulocytosis; tinnitus; elevated liver enzymes; abnormal renal function.
									Potentially Fatal: Autoimmune haemolytic anaemia; convulsions (overdosage).
	Precaution :  	Renal and hepatic impairment, asthma. Monitor blood counts and liver function during long-term therapy. Drowsiness may affect ability to perform skilled tasks. Elderly.
	Pregnancy category : 4
	Mode of action : Oral
									Rheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia
									Adult: 500 mg tid.
									Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
	Interaction : Concomitant use w/ CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events w/ aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 60ml bot
Amifen
	n : Mefenamic Acid
	Indications : Rheumatoid arthritis, Osteoarthritis, Dysmenorrhoea, Menorrhagia, Dental pain, Pain and inflammation, Mild to moderate pain, Postoperative pain
	Doses and administration : Oral
									Rheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia
									Adult: 500 mg tid.
									Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
	Contara-indications : Inflammatory bowel disease; peptic ulcer; neonates; pregnancy (3rd trimester), lactation. Coronary artery bypass graft surgery, severe renal impairment, severe heart failure.
	Side effects : Abdominal pain, dyspepsia, constipation, diarrhoea, nausea, GI ulcers; oedema; bronchospasm; headache, drowsiness, insomnia, visual disturbances; CHF, hypertension, tachycardia, syncope; urticaria, rash; thrombocytopenia, aplastic anaemia, agranulocytosis; tinnitus; elevated liver enzymes; abnormal renal function.
									Potentially Fatal: Autoimmune haemolytic anaemia; convulsions (overdosage).
	Precaution :  	Renal and hepatic impairment, asthma. Monitor blood counts and liver function during long-term therapy. Drowsiness may affect ability to perform skilled tasks. Elderly.
	Pregnancy category : 4
	Mode of action : Oral
									Rheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia
									Adult: 500 mg tid.
									Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
	Interaction : Concomitant use w/ CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events w/ aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Amifen
	n : Mefenamic Acid
	Indications : Rheumatoid arthritis, Osteoarthritis, Dysmenorrhoea, Menorrhagia, Dental pain, Pain and inflammation, Mild to moderate pain, Postoperative pain
	Doses and administration : Oral
									Rheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia
									Adult: 500 mg tid.
									Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
	Contara-indications : Inflammatory bowel disease; peptic ulcer; neonates; pregnancy (3rd trimester), lactation. Coronary artery bypass graft surgery, severe renal impairment, severe heart failure.
	Side effects : Abdominal pain, dyspepsia, constipation, diarrhoea, nausea, GI ulcers; oedema; bronchospasm; headache, drowsiness, insomnia, visual disturbances; CHF, hypertension, tachycardia, syncope; urticaria, rash; thrombocytopenia, aplastic anaemia, agranulocytosis; tinnitus; elevated liver enzymes; abnormal renal function.
									Potentially Fatal: Autoimmune haemolytic anaemia; convulsions (overdosage).
	Precaution :  	Renal and hepatic impairment, asthma. Monitor blood counts and liver function during long-term therapy. Drowsiness may affect ability to perform skilled tasks. Elderly.
	Pregnancy category : 4
	Mode of action : Oral
									Rheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia
									Adult: 500 mg tid.
									Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
	Interaction : Concomitant use w/ CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events w/ aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Amiflox
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 30's pack
Amiflox
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 30's pack
Amiflox
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 10's pack
Amiflox DS
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 60ml bot
A-Migel
	n : Miconazole 2% Oral
	Indications : Oropharyngeal candidiasis, Oral thrush, Denture stomatitis, Fungal infections of the mouth, Throat and gut, Angular cheilitis, Dermatomycoses, Tinea pedis, Tinea corporis, Tinea cruris, Tinea versicolor
	Doses and administration : For oral administration: The usual dose is 15 mg/kg/day in divided doses. 
									
									Adults : 1-2 tea-spoonfuls of gel 4 times daily. 
									
									Children aged 6 years and over : 1 tea-spoonful of gel 4 times daily. 
									
									Children aged 2-6 years : 1 tea-spoonful of gel twice daily1 month - 2 years : 1/2 tea-spoonful of gel twice daily. Localised lesions of mouth:Smear small amount on affected area with clean finger 4 times daily for 5-7 days.
	Contara-indications : Miconazole Oral Gel is contraindicated in patients with known hypersensitivity to any of its components and in patients with liver dysfunction.
	Side effects : Nausea, vomiting, diarrhoea (with long-term treatment); rarely allergic reactions; isolated reports of hepatitis.
	Precaution : Caution is required particularly in infants & young children to ensure that the gel does not obstruct the throat.
	Pregnancy category : 2
	Mode of action : Miconazole inhibits ergosterol synthesis thus damaging fungal cell wall membrane and increases its permeability, allowing leakage of nutrients.
	Interaction : May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.
				Potentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.
	Therapeutic class : Mouth & Throat preparations
	Packsize : 15 gm tube
Amikacin IV/IM
	n : Amikacin
	Indications : Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
	Doses and administration : Parenteral
									Uncomplicated urinary tract infections
									Adult: 250 mg bid, given via IM, IV inj over 2-3 minutes or as IV infusion.
									
									Severe Gram-negative infections resistant to gentamicin and tobramycin
									Adult: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Max: Up to 500 mg every 8 hr in life-threatening infections. Max cumulative dose: 15 g. Doses may be given via IM, slow IV inj over 2-3 minutes or IV infusion.
									
									Child: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Neonates: 10 mg/kg daily in 2 divided doses.
									
									Impaired renal function: In patient with impaired renal function the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug. Simple doses schedule for renal impairment is given below:
									Renal function Dosage schedule
									Mild impairment 500 mg every 18 hours
									Moderate impairment 500 mg every 24 hours
									Severe impairment 250 mg every 24 hours. 
	Contara-indications : Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
	Side effects : Tinnitus, vertigo; ataxia and overt deafness.
									Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
	Precaution : Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment.
	Pregnancy category : 4
	Mode of action : Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
	Interaction : Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.
				Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
	Therapeutic class : Aminoglycosides
	Packsize : 5's pack
Amikin
	n : Amikacin
	Indications : Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
	Doses and administration : Parenteral
									Uncomplicated urinary tract infections
									Adult: 250 mg bid, given via IM, IV inj over 2-3 minutes or as IV infusion.
									
									Severe Gram-negative infections resistant to gentamicin and tobramycin
									Adult: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Max: Up to 500 mg every 8 hr in life-threatening infections. Max cumulative dose: 15 g. Doses may be given via IM, slow IV inj over 2-3 minutes or IV infusion.
									
									Child: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Neonates: 10 mg/kg daily in 2 divided doses.
									
									Impaired renal function: In patient with impaired renal function the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug. Simple doses schedule for renal impairment is given below:
									Renal function Dosage schedule
									Mild impairment 500 mg every 18 hours
									Moderate impairment 500 mg every 24 hours
									Severe impairment 250 mg every 24 hours. 
	Contara-indications : Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
	Side effects : Tinnitus, vertigo; ataxia and overt deafness.
									Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
	Precaution : Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment.
	Pregnancy category : 4
	Mode of action : Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
	Interaction : Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.
				Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
	Therapeutic class : Aminoglycosides
	Packsize : 10 amps pack
Amikin
	n : Amikacin
	Indications : Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
	Doses and administration : Parenteral
									Uncomplicated urinary tract infections
									Adult: 250 mg bid, given via IM, IV inj over 2-3 minutes or as IV infusion.
									
									Severe Gram-negative infections resistant to gentamicin and tobramycin
									Adult: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Max: Up to 500 mg every 8 hr in life-threatening infections. Max cumulative dose: 15 g. Doses may be given via IM, slow IV inj over 2-3 minutes or IV infusion.
									
									Child: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Neonates: 10 mg/kg daily in 2 divided doses.
									
									Impaired renal function: In patient with impaired renal function the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug. Simple doses schedule for renal impairment is given below:
									Renal function Dosage schedule
									Mild impairment 500 mg every 18 hours
									Moderate impairment 500 mg every 24 hours
									Severe impairment 250 mg every 24 hours. 
	Contara-indications : Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
	Side effects : Tinnitus, vertigo; ataxia and overt deafness.
									Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
	Precaution : Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment.
	Pregnancy category : 4
	Mode of action : Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
	Interaction : Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.
				Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
	Therapeutic class : Aminoglycosides
	Packsize : 10 amps pack
Amilac IV
	n : Amino Acids 5 % & 10%
	Indications : Protein supply for parenteral nutrition. Prophylaxis & therapy of protein deficiency resulting from increased protein losses &/or increased protein requirements.
	Doses and administration : Adults:
									
									The nitrogen requirement for maintenance of body protein mass depends on the patient's condition (nutritional state and degree of metabolic stress).
									No or minor metabolic stress and normal nutritional state: 0.10-0.15 g nitrogen/kg/day,
									Moderate metabolic stress with or without malnutrition: 0.15-0.20 g nitrogen/kg/day,
									Severe catabolism as in burns, sepsis and trauma: up to 0.20-0.25 g nitrogen/kg/day.
									
									The dosage range 0.10-0.25 g nitrogen/kg/day corresponds to 15-35 ml amino acid IV/kg/day.
									In obese patients, the dose should be based on the estimated ideal weight. Depending upon patients requirements, 1000-2000 ml amino acid may be infused intravenously per 24 hours. It should be infused slowly, at rates 1.4-2.8 ml (30-60 drops) per minute.
									
									Infants and Children:
									In children and infants, the rate of infusion is 28-35 ml/kg body wt/day is recommended, with a stepwise increment in the rate of administration during the first week of treatment.
	Contara-indications : Contraindicated in patients with inborn errors of amino acids metabolism. Moreover, amino acid should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.
	Side effects : It is usually well tolerated. Yet nausea, vomiting, flushing and sweating have been observed during infusion of amino acid IV at rates exceeding the recommended maximal rate. Hypersensitivity reactions have been reported. Like all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. The incidence may be reduced by the simultaneous infusion of 10% fat emulsion. If it is infused to severely ill patients, premature infants, hyperphenylalaninemia may occur.
	Precaution : Hyperphenylalaninemia has been noted in severely ill, premature infants. In these patients, monitoring of the phenylalanine levels is recommended and the infusion rate adjusted as needed.
				Do not use if the solution is turbid or contains particles. Discard any unused portion.
	Pregnancy category : 3
	Mode of action : A crystalline amino acid solution provides crystalline amino acids to promote protein synthesis and wound healing, and to reduce the rate of endogenous protein catabolism. Amino Acids , given by central venous infusion in combination with concentrated dextrose, electrolytes, vitamins, trace metals, and ancillary fat supplements, constitutes total parenteral nutrition (TPN). Amino Acids  can also be administered by peripheral vein with dextrose and maintenance electrolytes.
	Interaction : None
	Therapeutic class : Parenteral Nutritional preparations
	Packsize : 500 ml bot
Amilin
	n : Amitriptyline Hydrochloride
	Indications : Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
	Doses and administration : Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. 
									Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.
									Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. 
									
									Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. 
									Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.
									Nocturnal enuresis
									Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
	Contara-indications : Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
	Side effects : Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.
									Potentially Fatal: Cardiac arrhythmias.
	Precaution : Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
	Therapeutic class : Tricyclic Anti-depressants
	Packsize : 100's pack
Amilin
	n : Amitriptyline Hydrochloride
	Indications : Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
	Doses and administration : Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. 
									Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.
									Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. 
									
									Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. 
									Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.
									Nocturnal enuresis
									Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
	Contara-indications : Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
	Side effects : Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.
									Potentially Fatal: Cardiac arrhythmias.
	Precaution : Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
	Therapeutic class : Tricyclic Anti-depressants
	Packsize : 100's pack
Amimax
	n : Amikacin
	Indications : Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
	Doses and administration : Parenteral
									Uncomplicated urinary tract infections
									Adult: 250 mg bid, given via IM, IV inj over 2-3 minutes or as IV infusion.
									
									Severe Gram-negative infections resistant to gentamicin and tobramycin
									Adult: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Max: Up to 500 mg every 8 hr in life-threatening infections. Max cumulative dose: 15 g. Doses may be given via IM, slow IV inj over 2-3 minutes or IV infusion.
									
									Child: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Neonates: 10 mg/kg daily in 2 divided doses.
									
									Impaired renal function: In patient with impaired renal function the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug. Simple doses schedule for renal impairment is given below:
									Renal function Dosage schedule
									Mild impairment 500 mg every 18 hours
									Moderate impairment 500 mg every 24 hours
									Severe impairment 250 mg every 24 hours. 
	Contara-indications : Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
	Side effects : Tinnitus, vertigo; ataxia and overt deafness.
									Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
	Precaution : Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment.
	Pregnancy category : 4
	Mode of action : Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
	Interaction : Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.
				Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
	Therapeutic class : Aminoglycosides
	Packsize : 10 amps pack
Amimax
	n : Amikacin
	Indications : Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
	Doses and administration : Parenteral
									Uncomplicated urinary tract infections
									Adult: 250 mg bid, given via IM, IV inj over 2-3 minutes or as IV infusion.
									
									Severe Gram-negative infections resistant to gentamicin and tobramycin
									Adult: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Max: Up to 500 mg every 8 hr in life-threatening infections. Max cumulative dose: 15 g. Doses may be given via IM, slow IV inj over 2-3 minutes or IV infusion.
									
									Child: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Neonates: 10 mg/kg daily in 2 divided doses.
									
									Impaired renal function: In patient with impaired renal function the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug. Simple doses schedule for renal impairment is given below:
									Renal function Dosage schedule
									Mild impairment 500 mg every 18 hours
									Moderate impairment 500 mg every 24 hours
									Severe impairment 250 mg every 24 hours. 
	Contara-indications : Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
	Side effects : Tinnitus, vertigo; ataxia and overt deafness.
									Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
	Precaution : Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment.
	Pregnancy category : 4
	Mode of action : Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
	Interaction : Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.
				Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
	Therapeutic class : Aminoglycosides
	Packsize : 10 amps pack
Aminomax Gold IV
	n : Amino Acids 5 % & 10%
	Indications : Protein supply for parenteral nutrition. Prophylaxis & therapy of protein deficiency resulting from increased protein losses &/or increased protein requirements.
	Doses and administration : Adults:
									
									The nitrogen requirement for maintenance of body protein mass depends on the patient's condition (nutritional state and degree of metabolic stress).
									No or minor metabolic stress and normal nutritional state: 0.10-0.15 g nitrogen/kg/day,
									Moderate metabolic stress with or without malnutrition: 0.15-0.20 g nitrogen/kg/day,
									Severe catabolism as in burns, sepsis and trauma: up to 0.20-0.25 g nitrogen/kg/day.
									
									The dosage range 0.10-0.25 g nitrogen/kg/day corresponds to 15-35 ml amino acid IV/kg/day.
									In obese patients, the dose should be based on the estimated ideal weight. Depending upon patients requirements, 1000-2000 ml amino acid may be infused intravenously per 24 hours. It should be infused slowly, at rates 1.4-2.8 ml (30-60 drops) per minute.
									
									Infants and Children:
									In children and infants, the rate of infusion is 28-35 ml/kg body wt/day is recommended, with a stepwise increment in the rate of administration during the first week of treatment.
	Contara-indications : Contraindicated in patients with inborn errors of amino acids metabolism. Moreover, amino acid should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.
	Side effects : It is usually well tolerated. Yet nausea, vomiting, flushing and sweating have been observed during infusion of amino acid IV at rates exceeding the recommended maximal rate. Hypersensitivity reactions have been reported. Like all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. The incidence may be reduced by the simultaneous infusion of 10% fat emulsion. If it is infused to severely ill patients, premature infants, hyperphenylalaninemia may occur.
	Precaution : Hyperphenylalaninemia has been noted in severely ill, premature infants. In these patients, monitoring of the phenylalanine levels is recommended and the infusion rate adjusted as needed.
				Do not use if the solution is turbid or contains particles. Discard any unused portion.
	Pregnancy category : 3
	Mode of action : A crystalline amino acid solution provides crystalline amino acids to promote protein synthesis and wound healing, and to reduce the rate of endogenous protein catabolism. Amino Acids , given by central venous infusion in combination with concentrated dextrose, electrolytes, vitamins, trace metals, and ancillary fat supplements, constitutes total parenteral nutrition (TPN). Amino Acids  can also be administered by peripheral vein with dextrose and maintenance electrolytes.
	Interaction : None
	Therapeutic class : Parenteral Nutritional preparations
	Packsize : 500ml bot
Aminophylline
	n : Aminophylline
	Indications : Asthma, Acute bronchospasm, Chronic bronchitis, Emphysema, COPD
	Doses and administration : Oral
									Chronic bronchospasm
									Adult: As hydrate: Initially, 225-450 mg bid, increased if necessary.
									Child: >3 yr: As modified-release hydrate: 12 mg/kg daily increased to 24 mg/kg daily in 2 divided doses after 1 wk.
									
									Intravenous
									Acute severe bronchospasm
									Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min.
									Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
									
									Elderly: Dose reduction may be ncessary.
									Hepatic impairment: Dose reduction may be ncessary.
	Contara-indications : Hypersensitivity.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness; tremor, palpitations.
									Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV injection.
	Precaution : Neonates, elderly, lactation, pregnancy, cardiac/hepatic diseases, peptic ulceration, hyperthyroidism, hypertension, epilepsy, heart failure, chronic alcoholism, acute febrile illness.
	Pregnancy category : 3
	Mode of action : Aminophylline is a combination of theophylline and ethylenediamine. Ethylenediamine is inactive; it increases the solubility of theophylline in water. Theophylline relaxes bronchial smooth muscle. Suggested mechanisms are an increase in intracellular cAMP through inhibition of phosphodiesterase; adenosine receptor antagonism, prostaglandin antagonism and effects on intracellular calcium.
	Interaction : Other xanthines. Clearance reduced by allopurinol, some antiarrhythmics, cimetidine, disulfiram, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, cigarette smoking. Corticosteroids, diuretics, ?2-agonists.
				Potentially Fatal: Increased risk of cardiac arrhythmias with sympathomimetics and halothane. Tachycardia with pancuronium. ?-blockers inhibit metabolism. Increased risk of convulsion with quinolones, ketamine.
	Therapeutic class : Respiratory stimulants: analeptics
	Packsize : 500's pack
Aminophylline
	n : Aminophylline
	Indications : Asthma, Acute bronchospasm, Chronic bronchitis, Emphysema, COPD
	Doses and administration : Oral
									Chronic bronchospasm
									Adult: As hydrate: Initially, 225-450 mg bid, increased if necessary.
									Child: >3 yr: As modified-release hydrate: 12 mg/kg daily increased to 24 mg/kg daily in 2 divided doses after 1 wk.
									
									Intravenous
									Acute severe bronchospasm
									Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min.
									Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
									
									Elderly: Dose reduction may be ncessary.
									Hepatic impairment: Dose reduction may be ncessary.
	Contara-indications : Hypersensitivity.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness; tremor, palpitations.
									Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV injection.
	Precaution : Neonates, elderly, lactation, pregnancy, cardiac/hepatic diseases, peptic ulceration, hyperthyroidism, hypertension, epilepsy, heart failure, chronic alcoholism, acute febrile illness.
	Pregnancy category : 3
	Mode of action : Aminophylline is a combination of theophylline and ethylenediamine. Ethylenediamine is inactive; it increases the solubility of theophylline in water. Theophylline relaxes bronchial smooth muscle. Suggested mechanisms are an increase in intracellular cAMP through inhibition of phosphodiesterase; adenosine receptor antagonism, prostaglandin antagonism and effects on intracellular calcium.
	Interaction : Other xanthines. Clearance reduced by allopurinol, some antiarrhythmics, cimetidine, disulfiram, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, cigarette smoking. Corticosteroids, diuretics, ?2-agonists.
				Potentially Fatal: Increased risk of cardiac arrhythmias with sympathomimetics and halothane. Tachycardia with pancuronium. ?-blockers inhibit metabolism. Increased risk of convulsion with quinolones, ketamine.
	Therapeutic class : Respiratory stimulants: analeptics
	Packsize : 5 amps pack
Aminophylline
	n : Aminophylline
	Indications : Asthma, Acute bronchospasm, Chronic bronchitis, Emphysema, COPD
	Doses and administration : Oral
									Chronic bronchospasm
									Adult: As hydrate: Initially, 225-450 mg bid, increased if necessary.
									Child: >3 yr: As modified-release hydrate: 12 mg/kg daily increased to 24 mg/kg daily in 2 divided doses after 1 wk.
									
									Intravenous
									Acute severe bronchospasm
									Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min.
									Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
									
									Elderly: Dose reduction may be ncessary.
									Hepatic impairment: Dose reduction may be ncessary.
	Contara-indications : Hypersensitivity.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness; tremor, palpitations.
									Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV injection.
	Precaution : Neonates, elderly, lactation, pregnancy, cardiac/hepatic diseases, peptic ulceration, hyperthyroidism, hypertension, epilepsy, heart failure, chronic alcoholism, acute febrile illness.
	Pregnancy category : 3
	Mode of action : Aminophylline is a combination of theophylline and ethylenediamine. Ethylenediamine is inactive; it increases the solubility of theophylline in water. Theophylline relaxes bronchial smooth muscle. Suggested mechanisms are an increase in intracellular cAMP through inhibition of phosphodiesterase; adenosine receptor antagonism, prostaglandin antagonism and effects on intracellular calcium.
	Interaction : Other xanthines. Clearance reduced by allopurinol, some antiarrhythmics, cimetidine, disulfiram, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, cigarette smoking. Corticosteroids, diuretics, ?2-agonists.
				Potentially Fatal: Increased risk of cardiac arrhythmias with sympathomimetics and halothane. Tachycardia with pancuronium. ?-blockers inhibit metabolism. Increased risk of convulsion with quinolones, ketamine.
	Therapeutic class : Respiratory stimulants: analeptics
	Packsize : 200's pack
Aminophylline
	n : Aminophylline
	Indications : Asthma, Acute bronchospasm, Chronic bronchitis, Emphysema, COPD
	Doses and administration : Oral
									Chronic bronchospasm
									Adult: As hydrate: Initially, 225-450 mg bid, increased if necessary.
									Child: >3 yr: As modified-release hydrate: 12 mg/kg daily increased to 24 mg/kg daily in 2 divided doses after 1 wk.
									
									Intravenous
									Acute severe bronchospasm
									Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min.
									Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
									
									Elderly: Dose reduction may be ncessary.
									Hepatic impairment: Dose reduction may be ncessary.
	Contara-indications : Hypersensitivity.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness; tremor, palpitations.
									Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV injection.
	Precaution : Neonates, elderly, lactation, pregnancy, cardiac/hepatic diseases, peptic ulceration, hyperthyroidism, hypertension, epilepsy, heart failure, chronic alcoholism, acute febrile illness.
	Pregnancy category : 3
	Mode of action : Aminophylline is a combination of theophylline and ethylenediamine. Ethylenediamine is inactive; it increases the solubility of theophylline in water. Theophylline relaxes bronchial smooth muscle. Suggested mechanisms are an increase in intracellular cAMP through inhibition of phosphodiesterase; adenosine receptor antagonism, prostaglandin antagonism and effects on intracellular calcium.
	Interaction : Other xanthines. Clearance reduced by allopurinol, some antiarrhythmics, cimetidine, disulfiram, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, cigarette smoking. Corticosteroids, diuretics, ?2-agonists.
				Potentially Fatal: Increased risk of cardiac arrhythmias with sympathomimetics and halothane. Tachycardia with pancuronium. ?-blockers inhibit metabolism. Increased risk of convulsion with quinolones, ketamine.
	Therapeutic class : Respiratory stimulants: analeptics
	Packsize : 500's pack
Aminophyllinum Retard
	n : Aminophylline
	Indications : Asthma, Acute bronchospasm, Chronic bronchitis, Emphysema, COPD
	Doses and administration : Oral
									Chronic bronchospasm
									Adult: As hydrate: Initially, 225-450 mg bid, increased if necessary.
									Child: >3 yr: As modified-release hydrate: 12 mg/kg daily increased to 24 mg/kg daily in 2 divided doses after 1 wk.
									
									Intravenous
									Acute severe bronchospasm
									Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min.
									Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
									
									Elderly: Dose reduction may be ncessary.
									Hepatic impairment: Dose reduction may be ncessary.
	Contara-indications : Hypersensitivity.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness; tremor, palpitations.
									Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV injection.
	Precaution : Neonates, elderly, lactation, pregnancy, cardiac/hepatic diseases, peptic ulceration, hyperthyroidism, hypertension, epilepsy, heart failure, chronic alcoholism, acute febrile illness.
	Pregnancy category : 3
	Mode of action : Aminophylline is a combination of theophylline and ethylenediamine. Ethylenediamine is inactive; it increases the solubility of theophylline in water. Theophylline relaxes bronchial smooth muscle. Suggested mechanisms are an increase in intracellular cAMP through inhibition of phosphodiesterase; adenosine receptor antagonism, prostaglandin antagonism and effects on intracellular calcium.
	Interaction : Other xanthines. Clearance reduced by allopurinol, some antiarrhythmics, cimetidine, disulfiram, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, cigarette smoking. Corticosteroids, diuretics, ?2-agonists.
				Potentially Fatal: Increased risk of cardiac arrhythmias with sympathomimetics and halothane. Tachycardia with pancuronium. ?-blockers inhibit metabolism. Increased risk of convulsion with quinolones, ketamine.
	Therapeutic class : Respiratory stimulants: analeptics
	Packsize : 50's pack
Aminosol 5 IV
	n : Amino Acids 5 % & 10%
	Indications : Protein supply for parenteral nutrition. Prophylaxis & therapy of protein deficiency resulting from increased protein losses &/or increased protein requirements.
	Doses and administration : Adults:
									
									The nitrogen requirement for maintenance of body protein mass depends on the patient's condition (nutritional state and degree of metabolic stress).
									No or minor metabolic stress and normal nutritional state: 0.10-0.15 g nitrogen/kg/day,
									Moderate metabolic stress with or without malnutrition: 0.15-0.20 g nitrogen/kg/day,
									Severe catabolism as in burns, sepsis and trauma: up to 0.20-0.25 g nitrogen/kg/day.
									
									The dosage range 0.10-0.25 g nitrogen/kg/day corresponds to 15-35 ml amino acid IV/kg/day.
									In obese patients, the dose should be based on the estimated ideal weight. Depending upon patients requirements, 1000-2000 ml amino acid may be infused intravenously per 24 hours. It should be infused slowly, at rates 1.4-2.8 ml (30-60 drops) per minute.
									
									Infants and Children:
									In children and infants, the rate of infusion is 28-35 ml/kg body wt/day is recommended, with a stepwise increment in the rate of administration during the first week of treatment.
	Contara-indications : Contraindicated in patients with inborn errors of amino acids metabolism. Moreover, amino acid should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.
	Side effects : It is usually well tolerated. Yet nausea, vomiting, flushing and sweating have been observed during infusion of amino acid IV at rates exceeding the recommended maximal rate. Hypersensitivity reactions have been reported. Like all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. The incidence may be reduced by the simultaneous infusion of 10% fat emulsion. If it is infused to severely ill patients, premature infants, hyperphenylalaninemia may occur.
	Precaution : Hyperphenylalaninemia has been noted in severely ill, premature infants. In these patients, monitoring of the phenylalanine levels is recommended and the infusion rate adjusted as needed.
				Do not use if the solution is turbid or contains particles. Discard any unused portion.
	Pregnancy category : 3
	Mode of action : A crystalline amino acid solution provides crystalline amino acids to promote protein synthesis and wound healing, and to reduce the rate of endogenous protein catabolism. Amino Acids , given by central venous infusion in combination with concentrated dextrose, electrolytes, vitamins, trace metals, and ancillary fat supplements, constitutes total parenteral nutrition (TPN). Amino Acids  can also be administered by peripheral vein with dextrose and maintenance electrolytes.
	Interaction : None
	Therapeutic class : Parenteral Nutritional preparations
	Packsize : 500 ml bot
Amisol IV
	n : Amino Acids 5 % & 10%
	Indications : Protein supply for parenteral nutrition. Prophylaxis & therapy of protein deficiency resulting from increased protein losses &/or increased protein requirements.
	Doses and administration : Adults:
									
									The nitrogen requirement for maintenance of body protein mass depends on the patient's condition (nutritional state and degree of metabolic stress).
									No or minor metabolic stress and normal nutritional state: 0.10-0.15 g nitrogen/kg/day,
									Moderate metabolic stress with or without malnutrition: 0.15-0.20 g nitrogen/kg/day,
									Severe catabolism as in burns, sepsis and trauma: up to 0.20-0.25 g nitrogen/kg/day.
									
									The dosage range 0.10-0.25 g nitrogen/kg/day corresponds to 15-35 ml amino acid IV/kg/day.
									In obese patients, the dose should be based on the estimated ideal weight. Depending upon patients requirements, 1000-2000 ml amino acid may be infused intravenously per 24 hours. It should be infused slowly, at rates 1.4-2.8 ml (30-60 drops) per minute.
									
									Infants and Children:
									In children and infants, the rate of infusion is 28-35 ml/kg body wt/day is recommended, with a stepwise increment in the rate of administration during the first week of treatment.
	Contara-indications : Contraindicated in patients with inborn errors of amino acids metabolism. Moreover, amino acid should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.
	Side effects : It is usually well tolerated. Yet nausea, vomiting, flushing and sweating have been observed during infusion of amino acid IV at rates exceeding the recommended maximal rate. Hypersensitivity reactions have been reported. Like all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. The incidence may be reduced by the simultaneous infusion of 10% fat emulsion. If it is infused to severely ill patients, premature infants, hyperphenylalaninemia may occur.
	Precaution : Hyperphenylalaninemia has been noted in severely ill, premature infants. In these patients, monitoring of the phenylalanine levels is recommended and the infusion rate adjusted as needed.
				Do not use if the solution is turbid or contains particles. Discard any unused portion.
	Pregnancy category : 3
	Mode of action : A crystalline amino acid solution provides crystalline amino acids to promote protein synthesis and wound healing, and to reduce the rate of endogenous protein catabolism. Amino Acids , given by central venous infusion in combination with concentrated dextrose, electrolytes, vitamins, trace metals, and ancillary fat supplements, constitutes total parenteral nutrition (TPN). Amino Acids  can also be administered by peripheral vein with dextrose and maintenance electrolytes.
	Interaction : None
	Therapeutic class : Parenteral Nutritional preparations
	Packsize : 250 ml bot/500 ml bot
Amit
	n : Amitriptyline Hydrochloride
	Indications : Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
	Doses and administration : Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. 
									Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.
									Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. 
									
									Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. 
									Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.
									Nocturnal enuresis
									Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
	Contara-indications : Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
	Side effects : Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.
									Potentially Fatal: Cardiac arrhythmias.
	Precaution : Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
	Therapeutic class : Tricyclic Anti-depressants
	Packsize : 100's pack
Amit
	n : Amitriptyline Hydrochloride
	Indications : Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
	Doses and administration : Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. 
									Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.
									Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. 
									
									Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. 
									Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.
									Nocturnal enuresis
									Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
	Contara-indications : Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
	Side effects : Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.
									Potentially Fatal: Cardiac arrhythmias.
	Precaution : Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
	Therapeutic class : Tricyclic Anti-depressants
	Packsize : 100's pack
Amitor 5/10
	n : Amlodipine 5mg + Atorvastatin 10mg
	Indications : Angina, Hyperlipidaemia, Hypertension, Stroke prevention
	Doses and administration : Adult: PO HTN or angina and hyperlipidaemia: 
									
									 Amlodipine: Initially 5 mg once daily, titrate over 1-2 wk; max: 10 mg/day. Atorvastatin: Initially 10-20 mg once daily (anytime of the day), patients who require >45 % reduction in LDL cholesterol may be initiated at 40 mg once daily. Titrate dose at intervals of at least 4 week; max: 80 mg/day.
	Contara-indications : Active liver disease or unexplained persistent elevated hepatic transaminases. Pregnancy and lactation.
	Side effects : Amlodipine: Headache, dizziness, fatigue, somnolence, peripheral oedema, flushing, palpitations, nausea, abdominal pain; rarely pruritus, rash, dyspnoea, asthenia and muscle cramps. Atorvastatin: Nasopharyngitis, arthralgia, diarrhoea, pain in extremity, UTI, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, increased transaminases, abnormal liver function test, increased creatinine phosphokinase, thrombocytopenia, malaise, hepatitis, cholestasis, bullous rashes.
									Potentially Fatal: Rhabdomyolysis with acute renal failure.
	Precaution : Atorvastatin may cause myopathy, and rarely rhabdomyolysis with acute renal failure secondary to myoglobinuria especially at high doses or in patients with history of renal impairment. Caution when used with CYP3A4 inhibitors which may increase plasma concentrations of Atorvastatin. Withhold/discontinue Atorvastatin if symptoms suggestive of myopathy or rhabdomyolysis are observed. Atorvastatin has been associated with biochemical abnormalities of liver; LFT should be monitored prior to and at 12 wk following treatment initiation and dosage increment; caution in patients who consume large amounts of alcohol or with history of liver disease. Worsening of angina and/or myocardial infarction has been reported with use of dihydrophyridine calcium channel blockers, especially in patients with severe obstructive coronary artery disease. Amlodipine may cause dose-dependent peripheral oedema. Caution in patients with severe aortic stenosis, symptomatic hypotension may occur. Elderly.
	Pregnancy category : 5
	Mode of action : Amlodipine is a dihydropyridine calcium channel blocker which relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It reduces peripheral vascular resistance and hence resulting in a reduction of blood pressure. In vasospastic angina, Amlodipine also inhibits coronary spasm in patients with vasopastic angina. Atorvastatin selectively and competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate which is a rate-limiting step in cholesterol biosynthesis.
	Interaction : Rifamycins may increase the metabolism of both Amlodipine and Atorvastatin. Atorvastatin may increase AUC of norethindrone and ethinyl estradiol.
				Potentially Fatal: Atorvastatin: Increased risk of myopathy when used concurrently with fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYP3A4 inhibitors (e.g. clarithromycin, HIV protease inhibitors, itraconazole). Cyclosporine (OATP1B1 inhibitor) may significantly increase bioavailability of Atorvastatin.
	Therapeutic class : Anti-anginal & lipid lowering drugs
	Packsize : 30's pack
Amitriptyline
	n : Amitriptyline Hydrochloride
	Indications : Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
	Doses and administration : Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. 
									Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.
									Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. 
									
									Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. 
									Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.
									Nocturnal enuresis
									Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
	Contara-indications : Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
	Side effects : Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.
									Potentially Fatal: Cardiac arrhythmias.
	Precaution : Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
	Therapeutic class : Tricyclic Anti-depressants
	Packsize : 200's pack
Amitriptyline
	n : Amitriptyline Hydrochloride
	Indications : Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
	Doses and administration : Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. 
									Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.
									Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. 
									
									Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. 
									Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.
									Nocturnal enuresis
									Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
	Contara-indications : Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
	Side effects : Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.
									Potentially Fatal: Cardiac arrhythmias.
	Precaution : Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
	Therapeutic class : Tricyclic Anti-depressants
	Packsize : 500's bot
Amival
	n : Fluphenazine Hydrochloride + Nortriptyline
	Indications : Headache, Depression, Anxiety, Emotional disturbance, Tension, Fatigue, Sleep disorder, Bodyache, Gastric problems
	Doses and administration : Adult: 1 tablet 2 to 3 times daily.
									Child: Not recommended.
	Contara-indications : Patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. The presence of blood dyscrasia or liver damage precludes the use of fluphenazine hydrochloride. Fluphenazine hydrochloride is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross sensitivity to phenothiazine derivatives may occur.
	Side effects : Dryness of mouth, drowsiness, constipation, tachycardia, nasal congestion, blurred vision and excitement.
	Precaution : Patients with glaucoma, prostate enlargement, cardiac failure and myocardial infarction. The drug may impair alertness and abilities to drive a car or operating machinery.
				
				Because of the possibility of cross-sensitivity, fluphenazine hydrochloride should be used cautiously in patients who have developed cholestatic jaundice, dermatoses or other allergic reactions to phenothiazine derivatives.
				
				Psychotic patients on large doses of a phenothiazine drug who are undergoing surgery should be watched carefully for possible hypotensive phenomena. Moreover, it should be remembered that reduced amounts of anesthetics or central nervous system depressants may be necessary.
				
				The effects of atropine may be potentiated in some patients receiving fluphenazine because of added anticholinergic effects.
	Pregnancy category : 3
	Mode of action : Fluphenazine blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system and decreases the release of hypothalamic and hypophyseal hormones. It reduces aggressiveness with disappearance of hallucinations and delusions.
									
									Nortriptyline, a dibenzocycloheptadiene tricyclic antidepressant, is the primary active metabolite of amitriptyline. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics.
				Potentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 100's pack
Amival F
	n : Fluphenazine Hydrochloride + Nortriptyline
	Indications : Headache, Depression, Anxiety, Emotional disturbance, Tension, Fatigue, Sleep disorder, Bodyache, Gastric problems
	Doses and administration : Adult: 1 tablet 2 to 3 times daily.
									Child: Not recommended.
	Contara-indications : Patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. The presence of blood dyscrasia or liver damage precludes the use of fluphenazine hydrochloride. Fluphenazine hydrochloride is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross sensitivity to phenothiazine derivatives may occur.
	Side effects : Dryness of mouth, drowsiness, constipation, tachycardia, nasal congestion, blurred vision and excitement.
	Precaution : Patients with glaucoma, prostate enlargement, cardiac failure and myocardial infarction. The drug may impair alertness and abilities to drive a car or operating machinery.
				
				Because of the possibility of cross-sensitivity, fluphenazine hydrochloride should be used cautiously in patients who have developed cholestatic jaundice, dermatoses or other allergic reactions to phenothiazine derivatives.
				
				Psychotic patients on large doses of a phenothiazine drug who are undergoing surgery should be watched carefully for possible hypotensive phenomena. Moreover, it should be remembered that reduced amounts of anesthetics or central nervous system depressants may be necessary.
				
				The effects of atropine may be potentiated in some patients receiving fluphenazine because of added anticholinergic effects.
	Pregnancy category : 3
	Mode of action : Fluphenazine blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system and decreases the release of hypothalamic and hypophyseal hormones. It reduces aggressiveness with disappearance of hallucinations and delusions.
									
									Nortriptyline, a dibenzocycloheptadiene tricyclic antidepressant, is the primary active metabolite of amitriptyline. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics.
				Potentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 100's pack
Amizide
	n : Amiloride Hydrochloride + Hydrochlorothiazide
	Indications : Hypertension, Congestive heart failure, Hepatic cirrhosis with ascites and oedema
	Doses and administration : Adult: PO: 
									Hypertension Per tab contains amiloride 5 mg and hydrochlorothiazide 50 mg: 1/2  to 1 tab/day. 
									
									Congestive heart failure Per tab contains amiloride 5 mg and hydrochlorothiazide 50 mg: 1/2  to 2 tabs/day. 
									
									Hepatic cirrhosis with ascites and oedema Per tab contains amiloride 5 mg and hydrochlorothiazide 50 mg: 1-2 tabs/day.
	Contara-indications : Hyperkalaemia; anuria; acute renal failure, severe progressive renal disease; severe hepatic failure, precoma associated with hepatic cirrhosis; Addison's disease; hypercalcaemia; diabetic neuropathy; DM. Child <18 yr. Lactation.
	Side effects : Electrolyte imbalance e.g. hyponatraemia, hypochloraemic alkalosis, hypokalaemia and hypomagnesaemia. Anaphylaxis, back pain, chest pain, fatigue, fever, headache, malaise, neck/shoulder ache, pain in extremities, syncope, weakness; angina, arrhythmias, digitalis toxicity, orthostatic hypotension, necrotising angiitis, palpitation and tachycardia; 
									GI disturbances; agranulocytosis, aplastic anaemia, haemolytic anaemia, leucopenia, neutropenia, purpura and thrombocytopenia; alopecia, diaphoresis, dry mouth, flushing, photosensitivity, pruritis, rash, sialadenitis and urticaria; glycosuria, gout, hyperglycaemia and hyperuricaemia; joint pain, leg ache and muscle cramps; dizziness, encephalopathy, paraesthesia, stupor, tremors, vertigo; decreased libido, depression, insomnia, mental confusion, nervousness, restlessness, sleepiness and somnolence; cough, dyspnoea and respiratory distress; bad taste, increased intraocular pressure, nasal congestion, tinnitus, visual disturbance and xanthopsia; bladder spasm, dysuria, impotence, incontinence, interstitial nephritis, nocturia, polyuria, renal dysfunction.
	Precaution : Renal impairment; BUN >10 mmol/L, serum creatinine >130 mmol/L. Monitor serum electrolytes and blood urea levels in seriously ill patients e.g. those with hepatic cirrhosis with ascites and metabolic alkalosis, or those with resistant oedema. Pre-existing severe liver disease. May affect parathyroid function. Hyperuricaemia or gout may occur. Cholesterol and triglyceride levels may be increased. Thiazides may impair glucose tolerance. DM may be precipitated or aggravated. May activate or exacerbate SLE. Elderly. Hyponatraemia. Pregnancy.
	Pregnancy category : 2
	Mode of action : Amiloride is an antikaliuretic with weak natriuretic, diuretic and antihypertensive effects. Some clinical studies found these effects to be partially additive to the effects of thiazide diuretics. Amiloride exerts its potassium-sparing effect by inhibiting Na reabsorption at the distal renal tubules; this decreases the net -ve potential of the tubular lumen and reduces both K and hydrogen secretion and their subsequent excretion. Hydrochlorothiazide is a diuretic and antihypertensive. It reduces electrolyte reabsorption from the renal tubules. Hydrochlorothiazide increases excretion of Na and chloride in approx equiv amounts. Natriuresis may be accompanied by some loss of K and bicarbonate. It exerts its hypotensive effect partly by reducing peripheral resistance.
	Interaction :  	Additive effects with other antihypertensives. May increase the responsiveness to tubocurarine. May reduce arterial responsiveness to pressor amines e.g. norepinephrine. Orthostatic hypotension may occur with alcohol, barbiturates and narcotics. Discontinue diuretics 2-3 days before initiation of an ACE inhibitor to reduce the likelihood of 1st dose hypotension. Increased hypokalaemia with corticosteroids or ACTH. Attenuation of diuretic, natriuretic and antihypertensive effects of diuretics with NSAIDs. Increased hyponatraemia with chlorpropamide. Increased hyperkalaemia with ciclosporin, tacrolimus, indometacin and angiotensin II receptor antagonists.
				Potentially Fatal: Increases risk of hyperkalaemia with other potassium-sparing diuretics (spironolactone or triamterene). Increases risk of lithium toxicity.
	Therapeutic class : Potassium-sparing diuretics with other diuretics
	Packsize : 200's pack
Amlex
	n : Amlexanox
	Indications : Aphthous ulcer
	Doses and administration : Adult: Topical As a 5% oral paste: Apply approx 0.5 cm of oral paste directly on to each ulcer 4 times/day; following oral hygiene after meals and at bedtime. 
									
									Initiate treatment at earliest symptom of an aphthous ulcer. Continue treatment until mouth ulcer is healed, not exceeding 10 days. 
									
									Child: Not to be used in children below age 12.
	Contara-indications : Known hypersensitivity to any of the ingredients.
	Side effects : Application site reactions e.g. transient pain, stinging, burning, irritation, contact mucositis, nausea and diarrhoea.
	Precaution : For topical use on mouth ulcers only. Avoid contact with the eyes; rinse immediately if ocular contact occurs. Wash hands before and after every application. Discontinue treatment if rash or contact mucositis develops. Seek medical advice if mouth ulcers have not healed after 10 days of treatment. Effects have not been evaluated in immune-compromised patients. Use lower initial dose for elderly patients. Not recommended for use in children below <12 yr. Pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Amlexanox accelerates healing of aphthous ulcers. The exact mechanism of action is not known. In vitro studies have shown that Amlexanox is a potent inhibitor of the formation and/or release of inflammatory mediators (histamine and leukotrienes) from mast cells, neutrophils, and mononuclear cells.
	Interaction : None
	Therapeutic class : Drugs for Aphthous ulcer
	Packsize : 5g
Amlip
	n : Amlodipine 5mg + Atorvastatin 10mg
	Indications : Angina, Hyperlipidaemia, Hypertension, Stroke prevention
	Doses and administration : Adult: PO HTN or angina and hyperlipidaemia: 
									
									 Amlodipine: Initially 5 mg once daily, titrate over 1-2 wk; max: 10 mg/day. Atorvastatin: Initially 10-20 mg once daily (anytime of the day), patients who require >45 % reduction in LDL cholesterol may be initiated at 40 mg once daily. Titrate dose at intervals of at least 4 week; max: 80 mg/day.
	Contara-indications : Active liver disease or unexplained persistent elevated hepatic transaminases. Pregnancy and lactation.
	Side effects : Amlodipine: Headache, dizziness, fatigue, somnolence, peripheral oedema, flushing, palpitations, nausea, abdominal pain; rarely pruritus, rash, dyspnoea, asthenia and muscle cramps. Atorvastatin: Nasopharyngitis, arthralgia, diarrhoea, pain in extremity, UTI, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, increased transaminases, abnormal liver function test, increased creatinine phosphokinase, thrombocytopenia, malaise, hepatitis, cholestasis, bullous rashes.
									Potentially Fatal: Rhabdomyolysis with acute renal failure.
	Precaution : Atorvastatin may cause myopathy, and rarely rhabdomyolysis with acute renal failure secondary to myoglobinuria especially at high doses or in patients with history of renal impairment. Caution when used with CYP3A4 inhibitors which may increase plasma concentrations of Atorvastatin. Withhold/discontinue Atorvastatin if symptoms suggestive of myopathy or rhabdomyolysis are observed. Atorvastatin has been associated with biochemical abnormalities of liver; LFT should be monitored prior to and at 12 wk following treatment initiation and dosage increment; caution in patients who consume large amounts of alcohol or with history of liver disease. Worsening of angina and/or myocardial infarction has been reported with use of dihydrophyridine calcium channel blockers, especially in patients with severe obstructive coronary artery disease. Amlodipine may cause dose-dependent peripheral oedema. Caution in patients with severe aortic stenosis, symptomatic hypotension may occur. Elderly.
	Pregnancy category : 5
	Mode of action : Amlodipine is a dihydropyridine calcium channel blocker which relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It reduces peripheral vascular resistance and hence resulting in a reduction of blood pressure. In vasospastic angina, Amlodipine also inhibits coronary spasm in patients with vasopastic angina. Atorvastatin selectively and competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate which is a rate-limiting step in cholesterol biosynthesis.
	Interaction : Rifamycins may increase the metabolism of both Amlodipine and Atorvastatin. Atorvastatin may increase AUC of norethindrone and ethinyl estradiol.
				Potentially Fatal: Atorvastatin: Increased risk of myopathy when used concurrently with fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYP3A4 inhibitors (e.g. clarithromycin, HIV protease inhibitors, itraconazole). Cyclosporine (OATP1B1 inhibitor) may significantly increase bioavailability of Atorvastatin.
	Therapeutic class : Anti-anginal & lipid lowering drugs
	Packsize : 30's pack
Amlo
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 50's pack
Amlobet 5/50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Amlocard
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 50's pack
Amlocard
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 100's pack
Amlocard PLUS 5/25
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Amlocard PLUS 5/50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Amlopin
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amlopin
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amlosart 5/20
	n : Amlodipine + Olmesartan Medoxomil
	Indications : Hypertension
	Doses and administration : Adult: Initial: 10-20 mg once daily. Antihypertensive effect is substantially present within 2 wk of therapy initiation. Dose may be increased up to 40 mg once daily if needed. May consider a lower starting dose in patients with possible depletion of intravascular volume (e.g. patients receiving concomitant diuretics, especially those with renal impairment).
									 
									Child: 6 to 16 yr: 20-35 kg: 10 mg once daily, may increase to maximum of 20 mg once daily. >35 kg: 20 mg once daily, may increase to maximum of 40 mg once daily.
									
									Elderly: May consider lower starting dose of 5-10 mg daily.
	Contara-indications : Pregnancy (2nd and 3rd trimesters); biliary obstruction.
	Side effects : Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.
									Potentially Fatal: Acute renal failure.
	Precaution : Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.
	Pregnancy category : 17
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
									Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
					Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amlosartan 10/160
	n : Amlodipine + Valsartan
	Indications : Hypertension
	Doses and administration : Adult: PO Initiate with 5 mg/160 mg once daily.
									
									May increase dose after at least 2 weeks, not to exceed 10 mg/day amlodipine and 320 mg/day valsartan once daily if needed.
	Contara-indications : Known hypersensitivity to dihydropyridines.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.
									Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.
	Pregnancy category : 17
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
									
									Valsartan, an angiotensin II type 1 (AT1) receptor antagonist, produces its BP lowering effects by inhibiting angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of Na.
									
	Interaction : Amlodipine : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
				
				Valsartan : May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.
				Potentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amlosartan 5/160
	n : Amlodipine + Valsartan
	Indications : Hypertension
	Doses and administration : Adult: PO Initiate with 5 mg/160 mg once daily.
									
									May increase dose after at least 2 weeks, not to exceed 10 mg/day amlodipine and 320 mg/day valsartan once daily if needed.
	Contara-indications : Known hypersensitivity to dihydropyridines.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.
									Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.
	Pregnancy category : 17
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
									
									Valsartan, an angiotensin II type 1 (AT1) receptor antagonist, produces its BP lowering effects by inhibiting angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of Na.
									
	Interaction : Amlodipine : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
				
				Valsartan : May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.
				Potentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amlosartan 5/80
	n : Amlodipine + Valsartan
	Indications : Hypertension
	Doses and administration : Adult: PO Initiate with 5 mg/160 mg once daily.
									
									May increase dose after at least 2 weeks, not to exceed 10 mg/day amlodipine and 320 mg/day valsartan once daily if needed.
	Contara-indications : Known hypersensitivity to dihydropyridines.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.
									Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.
	Pregnancy category : 17
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
									
									Valsartan, an angiotensin II type 1 (AT1) receptor antagonist, produces its BP lowering effects by inhibiting angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of Na.
									
	Interaction : Amlodipine : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
				
				Valsartan : May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.
				Potentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amlosin
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amlosin PLUS
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amlosun
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 50's pack
Amlotab 5
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 50's pack
Amloten 5/25
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amloten 5/50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amlovas
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amlovas
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 50's pack
Amlovas PLUS 5/50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Amlovas VS 160/5
	n : Amlodipine + Valsartan
	Indications : Hypertension
	Doses and administration : Adult: PO Initiate with 5 mg/160 mg once daily.
									
									May increase dose after at least 2 weeks, not to exceed 10 mg/day amlodipine and 320 mg/day valsartan once daily if needed.
	Contara-indications : Known hypersensitivity to dihydropyridines.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.
									Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.
	Pregnancy category : 17
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
									
									Valsartan, an angiotensin II type 1 (AT1) receptor antagonist, produces its BP lowering effects by inhibiting angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of Na.
									
	Interaction : Amlodipine : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
				
				Valsartan : May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.
				Potentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amlovas VS 5/80
	n : Amlodipine + Valsartan
	Indications : Hypertension
	Doses and administration : Adult: PO Initiate with 5 mg/160 mg once daily.
									
									May increase dose after at least 2 weeks, not to exceed 10 mg/day amlodipine and 320 mg/day valsartan once daily if needed.
	Contara-indications : Known hypersensitivity to dihydropyridines.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.
									Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.
	Pregnancy category : 17
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
									
									Valsartan, an angiotensin II type 1 (AT1) receptor antagonist, produces its BP lowering effects by inhibiting angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of Na.
									
	Interaction : Amlodipine : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
				
				Valsartan : May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.
				Potentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amlowide
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 50's pack
Amlozep 5/10
	n : Amlodipine + Benazepril Hydrochloride
	Indications : Hypertension
	Doses and administration : Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.
	Contara-indications : Patients with history of angioedema; pregnancy, lactation.
	Side effects : Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.
									Potentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.
	Precaution : Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.
	Pregnancy category : 17
	Mode of action : Amlodipine is a dihydropyridine calcium antagonist. It lowers BP by relaxing the coronary vascular smooth muscles and producing coronary vasodilation; through inhibition of transmembrane Ca ion influx into vascular smooth muscle and cardiac muscle. It is also a peripheral vascular vasodilator. Benazepril and its active metabolite benazeprilat inhibit ACE, which results in decreased plasma angiotensin II and thus leading to decreased aldosterone secretion.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amo
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amo
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 50's pack
Amobet
	n : Clobetasone butyrate 0.05% Topical
	Indications : Eczema, Inflammatory skin disorders, Dermatitis
	Doses and administration : Topical/Cutaneous
									Corticosteroid-responsive dermatoses
									Adult: Use as 0.05% cream or ointment to be applied thinly once or bid on affected areas.
	Contara-indications : Pregnancy (in high doses). Presence of acute infections. Treatment of rosacea; leg ulcers; acne vulgaris; widespread plaque psoriasis. Child <1 yr.
	Side effects :  Increased liability to infection. Infections may be masked. Acute adrenal insufficiency. Growth retardation in child. Cushingoid symptoms. Amenorrhoea, hyperhidrosis, skin thinning,
	Precaution : May be absorbed in sufficient amounts to cause systemic effects when applied topically to large areas, broken skin or under occlusive dressings. Peptic ulcer, osteoporosis, psychoses or severe psychoneuroses. Not to be used indiscriminately for pruritus. CHF or hypertension. Diabetes mellitus, epilepsy, glaucoma, infectious diseases, ocular herpes simplex, chronic renal failure and uraemia. Active or doubtfully quiescent tuberculosis. Local treatment of eye disorders. Elderly. Prolonged use on the face.
	Pregnancy category : 3
	Mode of action : Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; and reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation.
	Interaction : None
	Therapeutic class : Clobetasol/Clobetasone & Combined Preparations
	Packsize : 10gm  tube
Amobin
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Amobin
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Amobin
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Amocal
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amocal
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amocal AT 5/25
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amocal AT 5/50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amocal BZ 2.5/10
	n : Amlodipine + Benazepril Hydrochloride
	Indications : Hypertension
	Doses and administration : Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.
	Contara-indications : Patients with history of angioedema; pregnancy, lactation.
	Side effects : Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.
									Potentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.
	Precaution : Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.
	Pregnancy category : 17
	Mode of action : Amlodipine is a dihydropyridine calcium antagonist. It lowers BP by relaxing the coronary vascular smooth muscles and producing coronary vasodilation; through inhibition of transmembrane Ca ion influx into vascular smooth muscle and cardiac muscle. It is also a peripheral vascular vasodilator. Benazepril and its active metabolite benazeprilat inhibit ACE, which results in decreased plasma angiotensin II and thus leading to decreased aldosterone secretion.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amocal BZ 5/10
	n : Amlodipine + Benazepril Hydrochloride
	Indications : Hypertension
	Doses and administration : Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.
	Contara-indications : Patients with history of angioedema; pregnancy, lactation.
	Side effects : Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.
									Potentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.
	Precaution : Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.
	Pregnancy category : 17
	Mode of action : Amlodipine is a dihydropyridine calcium antagonist. It lowers BP by relaxing the coronary vascular smooth muscles and producing coronary vasodilation; through inhibition of transmembrane Ca ion influx into vascular smooth muscle and cardiac muscle. It is also a peripheral vascular vasodilator. Benazepril and its active metabolite benazeprilat inhibit ACE, which results in decreased plasma angiotensin II and thus leading to decreased aldosterone secretion.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amocal BZ 5/20
	n : Amlodipine + Benazepril Hydrochloride
	Indications : Hypertension
	Doses and administration : Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.
	Contara-indications : Patients with history of angioedema; pregnancy, lactation.
	Side effects : Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.
									Potentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.
	Precaution : Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.
	Pregnancy category : 17
	Mode of action : Amlodipine is a dihydropyridine calcium antagonist. It lowers BP by relaxing the coronary vascular smooth muscles and producing coronary vasodilation; through inhibition of transmembrane Ca ion influx into vascular smooth muscle and cardiac muscle. It is also a peripheral vascular vasodilator. Benazepril and its active metabolite benazeprilat inhibit ACE, which results in decreased plasma angiotensin II and thus leading to decreased aldosterone secretion.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 20's pack
Amocap
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amocap
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 40's pack
Amocil
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amocil
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amocil
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Amocin
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amocin
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amocin
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Amoclav 125/31
	n : Amoxicillin + Clavulanic Acid
	Indications : Bacterial infections, Acute otitis media, Acute bacterial sinusitis, Endocarditis, Dental abscess, H. pylori infection, Community-acquired pneumonia, Acute uncomplicated UTI, Uncomplicated gonorrhea, Severe or recurrent resp tract infections
	Doses and administration : Adults and children over 12 years: One 375 mg tablet 3 times a day. In severe infection one 625mg tablet 3 times a day or one 1gm tablet two times a day. 
									
									Children of 6-12 years:  2 teaspoonful Powder for Suspension every 8 hours. 
									Children of 1-6 years: 1 teaspoonful Powder for Suspension every 8 hours. 
									Children below 1 year: 25 mg/kg/day in divided doses every 8 hours. 
									
									Adults and children over 12 years: IV Injection: 1.2 g every 6-8 hours, 
									Children up to 3 months: 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants); 
									child 3 months-12 years, 30 mg/kg every 6-8 hours.
									
	Contara-indications : Penicillin allergy.
	Side effects : Nausea, vomiting, diarrhoea, indigestion, rash and urticaria, candida superinfection.
									Potentially Fatal: Anaphylactic reaction with CV collapse esp with parenteral use.
	Precaution : History of allergy especially to cephalosporins, infectious mononucleosis, severe renal impairment.
	Pregnancy category : 2
	Mode of action : Clavulanic acid has a high affinity for and binds to certain ?-lactamases that generally inactivate amoxicillin by hydrolyzing its ?-lactam ring. Combining clavulanate potassium with amoxicillin extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins.
	Interaction : Allopurinol may reduce renal tubular secretion of amoxicillin thus increasing the serum levels of amoxicillin. Concurrent use may reduce the efficacy of oral contraceptives.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 60ml bot/ 100ml bot
Amoclav 375
	n : Amoxicillin + Clavulanic Acid
	Indications : Bacterial infections, Acute otitis media, Acute bacterial sinusitis, Endocarditis, Dental abscess, H. pylori infection, Community-acquired pneumonia, Acute uncomplicated UTI, Uncomplicated gonorrhea, Severe or recurrent resp tract infections
	Doses and administration : Adults and children over 12 years: One 375 mg tablet 3 times a day. In severe infection one 625mg tablet 3 times a day or one 1gm tablet two times a day. 
									
									Children of 6-12 years:  2 teaspoonful Powder for Suspension every 8 hours. 
									Children of 1-6 years: 1 teaspoonful Powder for Suspension every 8 hours. 
									Children below 1 year: 25 mg/kg/day in divided doses every 8 hours. 
									
									Adults and children over 12 years: IV Injection: 1.2 g every 6-8 hours, 
									Children up to 3 months: 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants); 
									child 3 months-12 years, 30 mg/kg every 6-8 hours.
									
	Contara-indications : Penicillin allergy.
	Side effects : Nausea, vomiting, diarrhoea, indigestion, rash and urticaria, candida superinfection.
									Potentially Fatal: Anaphylactic reaction with CV collapse esp with parenteral use.
	Precaution : History of allergy especially to cephalosporins, infectious mononucleosis, severe renal impairment.
	Pregnancy category : 2
	Mode of action : Clavulanic acid has a high affinity for and binds to certain ?-lactamases that generally inactivate amoxicillin by hydrolyzing its ?-lactam ring. Combining clavulanate potassium with amoxicillin extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins.
	Interaction : Allopurinol may reduce renal tubular secretion of amoxicillin thus increasing the serum levels of amoxicillin. Concurrent use may reduce the efficacy of oral contraceptives.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 20's pack
Amoclav 0.6 IV
	n : Amoxicillin + Clavulanic Acid
	Indications : Bacterial infections, Acute otitis media, Acute bacterial sinusitis, Endocarditis, Dental abscess, H. pylori infection, Community-acquired pneumonia, Acute uncomplicated UTI, Uncomplicated gonorrhea, Severe or recurrent resp tract infections
	Doses and administration : Adults and children over 12 years: One 375 mg tablet 3 times a day. In severe infection one 625mg tablet 3 times a day or one 1gm tablet two times a day. 
									
									Children of 6-12 years:  2 teaspoonful Powder for Suspension every 8 hours. 
									Children of 1-6 years: 1 teaspoonful Powder for Suspension every 8 hours. 
									Children below 1 year: 25 mg/kg/day in divided doses every 8 hours. 
									
									Adults and children over 12 years: IV Injection: 1.2 g every 6-8 hours, 
									Children up to 3 months: 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants); 
									child 3 months-12 years, 30 mg/kg every 6-8 hours.
									
	Contara-indications : Penicillin allergy.
	Side effects : Nausea, vomiting, diarrhoea, indigestion, rash and urticaria, candida superinfection.
									Potentially Fatal: Anaphylactic reaction with CV collapse esp with parenteral use.
	Precaution : History of allergy especially to cephalosporins, infectious mononucleosis, severe renal impairment.
	Pregnancy category : 2
	Mode of action : Clavulanic acid has a high affinity for and binds to certain ?-lactamases that generally inactivate amoxicillin by hydrolyzing its ?-lactam ring. Combining clavulanate potassium with amoxicillin extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins.
	Interaction : Allopurinol may reduce renal tubular secretion of amoxicillin thus increasing the serum levels of amoxicillin. Concurrent use may reduce the efficacy of oral contraceptives.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 1's pack
Amoclav 625
	n : Amoxicillin + Clavulanic Acid
	Indications : Bacterial infections, Acute otitis media, Acute bacterial sinusitis, Endocarditis, Dental abscess, H. pylori infection, Community-acquired pneumonia, Acute uncomplicated UTI, Uncomplicated gonorrhea, Severe or recurrent resp tract infections
	Doses and administration : Adults and children over 12 years: One 375 mg tablet 3 times a day. In severe infection one 625mg tablet 3 times a day or one 1gm tablet two times a day. 
									
									Children of 6-12 years:  2 teaspoonful Powder for Suspension every 8 hours. 
									Children of 1-6 years: 1 teaspoonful Powder for Suspension every 8 hours. 
									Children below 1 year: 25 mg/kg/day in divided doses every 8 hours. 
									
									Adults and children over 12 years: IV Injection: 1.2 g every 6-8 hours, 
									Children up to 3 months: 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants); 
									child 3 months-12 years, 30 mg/kg every 6-8 hours.
									
	Contara-indications : Penicillin allergy.
	Side effects : Nausea, vomiting, diarrhoea, indigestion, rash and urticaria, candida superinfection.
									Potentially Fatal: Anaphylactic reaction with CV collapse esp with parenteral use.
	Precaution : History of allergy especially to cephalosporins, infectious mononucleosis, severe renal impairment.
	Pregnancy category : 2
	Mode of action : Clavulanic acid has a high affinity for and binds to certain ?-lactamases that generally inactivate amoxicillin by hydrolyzing its ?-lactam ring. Combining clavulanate potassium with amoxicillin extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins.
	Interaction : Allopurinol may reduce renal tubular secretion of amoxicillin thus increasing the serum levels of amoxicillin. Concurrent use may reduce the efficacy of oral contraceptives.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 18's pack
Amoclav FORTE
	n : Amoxicillin + Clavulanic Acid
	Indications : Bacterial infections, Acute otitis media, Acute bacterial sinusitis, Endocarditis, Dental abscess, H. pylori infection, Community-acquired pneumonia, Acute uncomplicated UTI, Uncomplicated gonorrhea, Severe or recurrent resp tract infections
	Doses and administration : Adults and children over 12 years: One 375 mg tablet 3 times a day. In severe infection one 625mg tablet 3 times a day or one 1gm tablet two times a day. 
									
									Children of 6-12 years:  2 teaspoonful Powder for Suspension every 8 hours. 
									Children of 1-6 years: 1 teaspoonful Powder for Suspension every 8 hours. 
									Children below 1 year: 25 mg/kg/day in divided doses every 8 hours. 
									
									Adults and children over 12 years: IV Injection: 1.2 g every 6-8 hours, 
									Children up to 3 months: 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants); 
									child 3 months-12 years, 30 mg/kg every 6-8 hours.
									
	Contara-indications : Penicillin allergy.
	Side effects : Nausea, vomiting, diarrhoea, indigestion, rash and urticaria, candida superinfection.
									Potentially Fatal: Anaphylactic reaction with CV collapse esp with parenteral use.
	Precaution : History of allergy especially to cephalosporins, infectious mononucleosis, severe renal impairment.
	Pregnancy category : 2
	Mode of action : Clavulanic acid has a high affinity for and binds to certain ?-lactamases that generally inactivate amoxicillin by hydrolyzing its ?-lactam ring. Combining clavulanate potassium with amoxicillin extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins.
	Interaction : Allopurinol may reduce renal tubular secretion of amoxicillin thus increasing the serum levels of amoxicillin. Concurrent use may reduce the efficacy of oral contraceptives.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 35ml bot
Amodis
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Amodis
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 200's pack
Amodis
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Amodis IV
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100ml bot
Amogit
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Amotid
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 15ml bot
Amotid
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amotid
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amotid
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amotid F
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amotrex
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Amotrex
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Amotrex
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Amotrex DS
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Amovast
	n : Amlodipine 5mg + Atorvastatin 10mg
	Indications : Angina, Hyperlipidaemia, Hypertension, Stroke prevention
	Doses and administration : Adult: PO HTN or angina and hyperlipidaemia: 
									
									 Amlodipine: Initially 5 mg once daily, titrate over 1-2 wk; max: 10 mg/day. Atorvastatin: Initially 10-20 mg once daily (anytime of the day), patients who require >45 % reduction in LDL cholesterol may be initiated at 40 mg once daily. Titrate dose at intervals of at least 4 week; max: 80 mg/day.
	Contara-indications : Active liver disease or unexplained persistent elevated hepatic transaminases. Pregnancy and lactation.
	Side effects : Amlodipine: Headache, dizziness, fatigue, somnolence, peripheral oedema, flushing, palpitations, nausea, abdominal pain; rarely pruritus, rash, dyspnoea, asthenia and muscle cramps. Atorvastatin: Nasopharyngitis, arthralgia, diarrhoea, pain in extremity, UTI, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, increased transaminases, abnormal liver function test, increased creatinine phosphokinase, thrombocytopenia, malaise, hepatitis, cholestasis, bullous rashes.
									Potentially Fatal: Rhabdomyolysis with acute renal failure.
	Precaution : Atorvastatin may cause myopathy, and rarely rhabdomyolysis with acute renal failure secondary to myoglobinuria especially at high doses or in patients with history of renal impairment. Caution when used with CYP3A4 inhibitors which may increase plasma concentrations of Atorvastatin. Withhold/discontinue Atorvastatin if symptoms suggestive of myopathy or rhabdomyolysis are observed. Atorvastatin has been associated with biochemical abnormalities of liver; LFT should be monitored prior to and at 12 wk following treatment initiation and dosage increment; caution in patients who consume large amounts of alcohol or with history of liver disease. Worsening of angina and/or myocardial infarction has been reported with use of dihydrophyridine calcium channel blockers, especially in patients with severe obstructive coronary artery disease. Amlodipine may cause dose-dependent peripheral oedema. Caution in patients with severe aortic stenosis, symptomatic hypotension may occur. Elderly.
	Pregnancy category : 5
	Mode of action : Amlodipine is a dihydropyridine calcium channel blocker which relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It reduces peripheral vascular resistance and hence resulting in a reduction of blood pressure. In vasospastic angina, Amlodipine also inhibits coronary spasm in patients with vasopastic angina. Atorvastatin selectively and competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate which is a rate-limiting step in cholesterol biosynthesis.
	Interaction : Rifamycins may increase the metabolism of both Amlodipine and Atorvastatin. Atorvastatin may increase AUC of norethindrone and ethinyl estradiol.
				Potentially Fatal: Atorvastatin: Increased risk of myopathy when used concurrently with fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYP3A4 inhibitors (e.g. clarithromycin, HIV protease inhibitors, itraconazole). Cyclosporine (OATP1B1 inhibitor) may significantly increase bioavailability of Atorvastatin.
	Therapeutic class : Anti-anginal & lipid lowering drugs
	Packsize : 20's pack
Amox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 15ml bot
Amox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 40's pack
Amoxic
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amoxic
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amoxic
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amoxicap
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amoxicon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amoxicon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amoxicon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Amoxima
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 15ml bot
Amoxima
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Amoxipan
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amoxipan
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Amoxirak
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Amoxizen
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amoxizen
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amoxizen DS
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Amoxon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 15ml bot
Amoxon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Amoxon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amoxon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 5 Vial
Amoxon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Amoxon
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 5 Vial
Ampexin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 15ml bot
Ampexin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Ampexin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Ampexin IV/IM
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 4 Vial
Ampexin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Ampexin IV/IM
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 4 Vial
Ampicin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 15ml bot
Ampicin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Ampicin
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Ampicin IV/IM
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 5's pack
Ampil Plus 5/25
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 50's pack
Ampimet
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Ampimet
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Ampimet DS
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Ampirex
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Ampirex IV/IM
	n : Ampicillin
	Indications : Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections
	Doses and administration : Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. 
									
									IV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.
									
									Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. 
									
									Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
									CrCl (ml/min)
									<10	  Dose reduction or increase in dose interval.
	Contara-indications : Hypersensitivity; infectious mononucleosis.
	Side effects : GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.
									Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.
	Precaution : Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall.
	Interaction : May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 5 Vial
Amsiv
	n : Ambroxol
	Indications : Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
	Doses and administration : Paediatric Drops : 
									0 - 6 months old - 0.5 ml, 2 times a day, 
									6 - 12 months old - 1 ml, 2 times a day, 
									1 - 2 years old -1.25 ml, 2 times a day. 
									
									Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 
									5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 
									10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. 
									
									SR Capsule : Adults and children over 12 years old - 1 capsule, once daily 
	Contara-indications : Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
	Side effects : Mild GI effects and allergic reactions.
	Precaution : Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
	Pregnancy category : 0
	Mode of action : Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
	Interaction : None
	Therapeutic class : Cough expectorants & mucolytics
	Packsize : 100ml bot
Amtinol Plus
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Amtinol
	n : Amlodipine
	Indications : Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention
	Doses and administration : Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. 
									
									Child: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.
									Elderly: Initially, 2.5 mg once daily.
									Hepatic impairment: Initially, 2.5 mg once daily.
	Contara-indications : Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.
	Side effects : Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.
	Precaution : Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.
	Pregnancy category : 3
	Mode of action : Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
	Interaction : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
	Therapeutic class : Calcium-channel blockers
	Packsize : 30's pack
Amtylin
	n : Amitriptyline Hydrochloride
	Indications : Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
	Doses and administration : Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. 
									Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.
									Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. 
									
									Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. 
									Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.
									Nocturnal enuresis
									Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
	Contara-indications : Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
	Side effects : Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.
									Potentially Fatal: Cardiac arrhythmias.
	Precaution : Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
	Therapeutic class : Tricyclic Anti-depressants
	Packsize : 100's pack
Amtylin
	n : Amitriptyline Hydrochloride
	Indications : Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
	Doses and administration : Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. 
									Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.
									Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. 
									
									Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. 
									Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.
									Nocturnal enuresis
									Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
	Contara-indications : Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
	Side effects : Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.
									Potentially Fatal: Cardiac arrhythmias.
	Precaution : Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
	Pregnancy category : 3
	Mode of action : Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
	Therapeutic class : Tricyclic Anti-depressants
	Packsize : 100's pack
Amuran
	n : Ranitidine
	Indications : Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
	Doses and administration : Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. 
									For prevention of NSAID-associated ulceration: 150 mg bid. 
									Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. 
									GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.
									 Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. 
									Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. 
									Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. 
									Prophylaxis during NSAID treatment 150 mg twice daily. 
									
									IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. 
									
									IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
	Contara-indications : Porphyria.
	Side effects : Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
									Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
	Precaution : Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
	Interaction : Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
	Therapeutic class : H2 antagonists
	Packsize : 100's pack
AMX
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
AMX
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
AMX
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Amynil
	n : Glimepiride
	Indications : Type 2 DM
	Doses and administration : Oral
									Type 2 diabetes mellitus
									Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
									Elderly: Initially, 1 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Diabetic ketoacidosis with or without coma.
	Side effects : Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.
	Precaution : Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Amynil
	n : Glimepiride
	Indications : Type 2 DM
	Doses and administration : Oral
									Type 2 diabetes mellitus
									Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
									Elderly: Initially, 1 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Diabetic ketoacidosis with or without coma.
	Side effects : Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.
	Precaution : Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
	Interaction : Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
	Therapeutic class : Sulfonylureas
	Packsize : 30's pack
Amzith
	n : Azithromycin
	Indications : Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							
									
	Doses and administration : Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. 
									
									Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. 
									Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. 
									Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. 
									
									IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. 
									
									Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
									
									Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. 
	Contara-indications : Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
	Side effects : GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
									Potentially Fatal: Angioedema and cholestatic jaundice.
	Precaution : May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
	Pregnancy category : 2
	Mode of action : Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
	Interaction : Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
				Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
	Therapeutic class : Macrolides
	Packsize : 30ml bot
				
Amzith
	n : Azithromycin
	Indications : Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							
									
	Doses and administration : Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. 
									
									Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. 
									Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. 
									Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. 
									
									IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. 
									
									Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
									
									Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. 
	Contara-indications : Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
	Side effects : GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
									Potentially Fatal: Angioedema and cholestatic jaundice.
	Precaution : May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
	Pregnancy category : 2
	Mode of action : Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
	Interaction : Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
				Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
	Therapeutic class : Macrolides
	Packsize : 12's pack
Anabolin
	n : Nandrolone
	Indications : Postmenopausal osteoporosis, Metastatic breast cancer, Anaemia of chronic renal failure, Anaemia in chemotherapy patients
	Doses and administration : Adult: IM Anabolic after debilitating illness; Metastatic breast carcinoma; Postmenopausal osteoporosis As decanoate: 25-100 mg 3-4 wkly. Anaemia of chronic renal failure As decanoate: 50-200 mg/wk. Aplastic anaemia As decanoate: 50-150 mg/wk.
	Contara-indications : Prostatic or breast carcinoma (male); nephrosis, porphyria; infants, pregnancy and lactation.
	Side effects : Male: Postpubertal: Acne, gynaecomastia, bladder irritability, priapism, insomnia, chills, decreased libido, hepatic dysfunction, nausea, diarrhoea, prostatic hyperplasia. Prepubertal: Acne, virilism, chills, insomnia, hyperpigmentation, diarrhoea, nausea. Female: Virilism, hypercalcaemia, nausea, diarrhoea, chills, insomnia, iron deficiency anaemia, hepatic dysfunction.
	Precaution : Monitor diabetic patients carefully. Conditions influenced by oedema (e.g. CV disease, migraine, seizure disorder, renal impairment). Hepatic impairment. Elderly. Discontinue if signs of virilisation in women occur. Monitor skeletal maturation in children.
	Pregnancy category : 5
	Mode of action : Nandrolone is an anabolic steroid. It promotes tissue-building processes and protein anabolism. It also stimulates erythropoeitin production, causing an increase in haemoglobin and RBC volume.
	Interaction : May increase effects of oral anticoagulants, insulin, oral antidiabetic agents, adrenal steroid, adrenocorticotropic hormone (ACTH).
	Therapeutic class : Hormone in bone formation by stimulation
	Packsize : 5 amps pack
Anacort
	n : Hydrocortisone
	Indications : Corticosteroid-responsive dermatoses, hypersensitivity reactions such as angioedema, status asthmaticus,  Soft tissue inflammation, Joint inflammations, Primary or secondary adrenocortical insufficiency, Acute adrenocortical insufficiency, Shock unresponsive to conventional therapy, Congenital adrenal hyperplasia, Hypercalcemia associated with cancer, Nonsuppurative thyroiditis, Rheumatic Disorders, Dermatologic Diseases (Allergic States, Severe seborrheic dermatitis, Severe psoriasis, Pemphigus, Severe erythema multiforme), Control of severe or incapacitating allergic conditions (Bronchial asthma, Contact dermatitis, Atopic dermatitis, Serum sickness, Seasonal or perennial allergic rhinitis, Drug hypersensitivity reactions, Urticarial transfusion reactions, Acute noninfectious laryngeal edema), Ophthalmic Diseases (Herpes zoster ophthalmicus, Iritis, iridocyclitis, Chorioretinitis, Diffuse posterior uveitis and choroiditis, Optic neuritis), Gastrointestinal Diseases, Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, Loeffler's syndrome, Aspiration pneumonitis, Hematologic Disorders (Acquired, autoimmune hemolytic anemia, Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia, Erythroblastopenia), Neoplastic Diseases (Leukemias and lymphomas in adults, Acute leukemia of childhood), Edematous States, Acute exacerbations of multiple sclerosis
	Doses and administration : Adult: By IM injection or slow IV injection or infusion, 100-500 mg, 3-4 times in 24 hours or as required; 
									Child: by slow IV Injection, up to 1 year: 25 mg, 1-5 years: 50 mg, 6-12 years: 100 mg.
									
									PO Adrenocortical insufficiency 20-30 mg/day in 2 divided doses. 
									
									IV Supplement in adrenal insufficiency during surgery under general anesth Patients taking >10 mg/day prednisolone or its equivalent by mouth: 25-50 mg at induction. 
									
									Acute adrenocortical insufficiency 100-500 mg 3-4 times/24 hr depending on severity and response. 
									
									Inj Soft-tissue inflammation As Na phosphate or Na succinate esters: 100-200 mg as local inj. 
									
									Intra-articular Joint inflammations As acetate: 5-50 mg depending on size of affected joint.
									
									Children: By slow IV injection, up to 1 year 25 mg, 1-5 years 50 mg, 6-12 years 100 mg.
	Contara-indications : Viral/fungal infections, tubercular or syphilitic lesions, bacterial infections unless used in conjunction with appropriate chemotherapy.
	Side effects : Sodium and fluid retention. Potassium and calcium depletion. Muscle wasting, weakness, osteoporosis. GI disturbances and bleeding. Increased appetite and delayed wound healing. Bruising, striae, hirsutism, acne, flushing. Raised intracranial pressure, headache, depression, psychosis, menstrual irregularities. Hyperglycaemia, glycosuria, DM, obesity, moon-face, buffalo hump. Suppression of pituitary-adrenocortical system. Growth retardation in childn (prolonged therapy). Increased susceptibility for infection. Topical use: Dermal atrophy, local irritation, folliculitis, hypertrichosis. Inhaled corticosteroids: May cause hoarseness, candidiasis of mouth and throat. Topical application to the eye: Can produce corneal ulcers, raised IOP and reduced visual function. Intralesional injection: Local hypopigmentation of deeply pigmented skin. Intra-articular injection: Joint damage, fibrosis esp in load bearing joints.
									Potentially Fatal: Abrupt withdrawal leading to acute adrenal insufficiency. Rapid IV Inj may cause CV collapse.
	Precaution : CHF, hypertension, DM, epilepsy, elderly, patients on prolonged therapy. Gradual withdrawal, pregnancy and lactation.
	Pregnancy category : 4
	Mode of action : Hydrocortisone is a corticosteroid used for its anti-inflammatory and immunosuppressive effects. Its anti-inflammatory action is due to the suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It may also be used as replacement therapy in adrenocortical insufficiency.
	Interaction : Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. 
				
				Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.
	Therapeutic class : Glucocorticoids
	Packsize : 5's pack
Anadol
	n : Tramadol Hydrochloride
	Indications : Moderate to severe pain, Postoperative pain
	Doses and administration :  Adult: PO Moderate to severe pain 50-100 mg 4-6 hrly. Max: 400 mg/day. 
									
									Extended-release 50-100 mg 1-2 times/day. Max: 300 mg/day. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	                 Contraindicated.
									10 to <30	Increase dosing interval to 12hrly. Max: 200 mg/day; Contraindicated (extended-release tab).
									Hepatic impairment: Severe: Increase dosing interval to 12 hrly; Contraindicated (extended-release). 
									
									IV/IM Moderate to severe pain 50-100 mg 4-6 hrly. 
									
									Post-op pain Initial: 100 mg, then 50 mg every 10-20 mins if needed, up to 250 mg for the 1st hr. Maintenance: 50-100 mg 4-6 hrly. Max: 600 mg/day. 
									
									Rectal Moderate to severe pain As 100 mg supp: 1 supp up to 4 times/day.
									
									Elderly: >75 yr Increase dosing interval.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Increase dosing interval to 12 hrly.
									<10 	Contraindicated.
									
									Hepatic impairment: Severe: increase dosing interval to 12 hrly.
	Contara-indications : Suicidal patients, acute alcoholism; head injuries; raised intracranial pressure; severe renal impairment; lactation.
	Side effects : Sweating, dizziness, nausea, vomiting, dry mouth, fatigue, asthenia, somnolence, confusion, constipation, flushing, headache, vertigo, tachycardia, palpitations, miosis, insomnia, orthostatic hypotension, seizures, CNS stimulation e.g. hallucinations.
									Potentially Fatal: Respiratory depression.
	Precaution : Hypothyroidism; adrenocortical insufficiency; renal or hepatic impairment; history of epilepsy or increased risk of seizures; inflammatory or obstructive bowel disease; myasthaenia gravis; respiratory depression; prostatic hyperplasia. Pregnancy.
	Pregnancy category : 3
	Mode of action : Tramadol inhibits reuptake of norepinephrine, serotonin and enhances serotonin release. It alters perception and response to pain by binding to mu-opiate receptors in the CNS.
	Interaction : Increased risk of convulsions or serotonin syndrome w/ SSRI, serotonin-norepinephrine reuptake inhibitors (SNRI), TCA and other seizure threshold lowering drugs (e.g. bupropion, mirtazapine, tetrahydrocannabinol). Decreased serum concentrations w/ carbamazepine. May potentiate the anti-depressant effect of norepinephrine, 5-HT agonists or lithium. Increased INR and ecchymoses w/ coumarin derivatives (e.g. warfarin).
				
				Potentially Fatal: Increased risk of seizure and serotonin syndrome w/ MAOIs. 
	Therapeutic class : Opioid analgesics
	Packsize :  20's pack
Anadol
	n : Tramadol Hydrochloride
	Indications : Moderate to severe pain, Postoperative pain
	Doses and administration :  Adult: PO Moderate to severe pain 50-100 mg 4-6 hrly. Max: 400 mg/day. 
									
									Extended-release 50-100 mg 1-2 times/day. Max: 300 mg/day. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	                 Contraindicated.
									10 to <30	Increase dosing interval to 12hrly. Max: 200 mg/day; Contraindicated (extended-release tab).
									Hepatic impairment: Severe: Increase dosing interval to 12 hrly; Contraindicated (extended-release). 
									
									IV/IM Moderate to severe pain 50-100 mg 4-6 hrly. 
									
									Post-op pain Initial: 100 mg, then 50 mg every 10-20 mins if needed, up to 250 mg for the 1st hr. Maintenance: 50-100 mg 4-6 hrly. Max: 600 mg/day. 
									
									Rectal Moderate to severe pain As 100 mg supp: 1 supp up to 4 times/day.
									
									Elderly: >75 yr Increase dosing interval.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Increase dosing interval to 12 hrly.
									<10 	Contraindicated.
									
									Hepatic impairment: Severe: increase dosing interval to 12 hrly.
	Contara-indications : Suicidal patients, acute alcoholism; head injuries; raised intracranial pressure; severe renal impairment; lactation.
	Side effects : Sweating, dizziness, nausea, vomiting, dry mouth, fatigue, asthenia, somnolence, confusion, constipation, flushing, headache, vertigo, tachycardia, palpitations, miosis, insomnia, orthostatic hypotension, seizures, CNS stimulation e.g. hallucinations.
									Potentially Fatal: Respiratory depression.
	Precaution : Hypothyroidism; adrenocortical insufficiency; renal or hepatic impairment; history of epilepsy or increased risk of seizures; inflammatory or obstructive bowel disease; myasthaenia gravis; respiratory depression; prostatic hyperplasia. Pregnancy.
	Pregnancy category : 3
	Mode of action : Tramadol inhibits reuptake of norepinephrine, serotonin and enhances serotonin release. It alters perception and response to pain by binding to mu-opiate receptors in the CNS.
	Interaction : Increased risk of convulsions or serotonin syndrome w/ SSRI, serotonin-norepinephrine reuptake inhibitors (SNRI), TCA and other seizure threshold lowering drugs (e.g. bupropion, mirtazapine, tetrahydrocannabinol). Decreased serum concentrations w/ carbamazepine. May potentiate the anti-depressant effect of norepinephrine, 5-HT agonists or lithium. Increased INR and ecchymoses w/ coumarin derivatives (e.g. warfarin).
				
				Potentially Fatal: Increased risk of seizure and serotonin syndrome w/ MAOIs. 
	Therapeutic class : Opioid analgesics
	Packsize : 10 amps  pack
Anadol SR
	n : Tramadol Hydrochloride
	Indications : Moderate to severe pain, Postoperative pain
	Doses and administration :  Adult: PO Moderate to severe pain 50-100 mg 4-6 hrly. Max: 400 mg/day. 
									
									Extended-release 50-100 mg 1-2 times/day. Max: 300 mg/day. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	                 Contraindicated.
									10 to <30	Increase dosing interval to 12hrly. Max: 200 mg/day; Contraindicated (extended-release tab).
									Hepatic impairment: Severe: Increase dosing interval to 12 hrly; Contraindicated (extended-release). 
									
									IV/IM Moderate to severe pain 50-100 mg 4-6 hrly. 
									
									Post-op pain Initial: 100 mg, then 50 mg every 10-20 mins if needed, up to 250 mg for the 1st hr. Maintenance: 50-100 mg 4-6 hrly. Max: 600 mg/day. 
									
									Rectal Moderate to severe pain As 100 mg supp: 1 supp up to 4 times/day.
									
									Elderly: >75 yr Increase dosing interval.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Increase dosing interval to 12 hrly.
									<10 	Contraindicated.
									
									Hepatic impairment: Severe: increase dosing interval to 12 hrly.
	Contara-indications : Suicidal patients, acute alcoholism; head injuries; raised intracranial pressure; severe renal impairment; lactation.
	Side effects : Sweating, dizziness, nausea, vomiting, dry mouth, fatigue, asthenia, somnolence, confusion, constipation, flushing, headache, vertigo, tachycardia, palpitations, miosis, insomnia, orthostatic hypotension, seizures, CNS stimulation e.g. hallucinations.
									Potentially Fatal: Respiratory depression.
	Precaution : Hypothyroidism; adrenocortical insufficiency; renal or hepatic impairment; history of epilepsy or increased risk of seizures; inflammatory or obstructive bowel disease; myasthaenia gravis; respiratory depression; prostatic hyperplasia. Pregnancy.
	Pregnancy category : 3
	Mode of action : Tramadol inhibits reuptake of norepinephrine, serotonin and enhances serotonin release. It alters perception and response to pain by binding to mu-opiate receptors in the CNS.
	Interaction : Increased risk of convulsions or serotonin syndrome w/ SSRI, serotonin-norepinephrine reuptake inhibitors (SNRI), TCA and other seizure threshold lowering drugs (e.g. bupropion, mirtazapine, tetrahydrocannabinol). Decreased serum concentrations w/ carbamazepine. May potentiate the anti-depressant effect of norepinephrine, 5-HT agonists or lithium. Increased INR and ecchymoses w/ coumarin derivatives (e.g. warfarin).
				
				Potentially Fatal: Increased risk of seizure and serotonin syndrome w/ MAOIs. 
	Therapeutic class : Opioid analgesics
	Packsize : 30's pack
Anadol
	n : Tramadol Hydrochloride
	Indications : Moderate to severe pain, Postoperative pain
	Doses and administration :  Adult: PO Moderate to severe pain 50-100 mg 4-6 hrly. Max: 400 mg/day. 
									
									Extended-release 50-100 mg 1-2 times/day. Max: 300 mg/day. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	                 Contraindicated.
									10 to <30	Increase dosing interval to 12hrly. Max: 200 mg/day; Contraindicated (extended-release tab).
									Hepatic impairment: Severe: Increase dosing interval to 12 hrly; Contraindicated (extended-release). 
									
									IV/IM Moderate to severe pain 50-100 mg 4-6 hrly. 
									
									Post-op pain Initial: 100 mg, then 50 mg every 10-20 mins if needed, up to 250 mg for the 1st hr. Maintenance: 50-100 mg 4-6 hrly. Max: 600 mg/day. 
									
									Rectal Moderate to severe pain As 100 mg supp: 1 supp up to 4 times/day.
									
									Elderly: >75 yr Increase dosing interval.
									
									Renal impairment:
									CrCl (ml/min)	
									10-30	Increase dosing interval to 12 hrly.
									<10 	Contraindicated.
									
									Hepatic impairment: Severe: increase dosing interval to 12 hrly.
	Contara-indications : Suicidal patients, acute alcoholism; head injuries; raised intracranial pressure; severe renal impairment; lactation.
	Side effects : Sweating, dizziness, nausea, vomiting, dry mouth, fatigue, asthenia, somnolence, confusion, constipation, flushing, headache, vertigo, tachycardia, palpitations, miosis, insomnia, orthostatic hypotension, seizures, CNS stimulation e.g. hallucinations.
									Potentially Fatal: Respiratory depression.
	Precaution : Hypothyroidism; adrenocortical insufficiency; renal or hepatic impairment; history of epilepsy or increased risk of seizures; inflammatory or obstructive bowel disease; myasthaenia gravis; respiratory depression; prostatic hyperplasia. Pregnancy.
	Pregnancy category : 3
	Mode of action : Tramadol inhibits reuptake of norepinephrine, serotonin and enhances serotonin release. It alters perception and response to pain by binding to mu-opiate receptors in the CNS.
	Interaction : Increased risk of convulsions or serotonin syndrome w/ SSRI, serotonin-norepinephrine reuptake inhibitors (SNRI), TCA and other seizure threshold lowering drugs (e.g. bupropion, mirtazapine, tetrahydrocannabinol). Decreased serum concentrations w/ carbamazepine. May potentiate the anti-depressant effect of norepinephrine, 5-HT agonists or lithium. Increased INR and ecchymoses w/ coumarin derivatives (e.g. warfarin).
				
				Potentially Fatal: Increased risk of seizure and serotonin syndrome w/ MAOIs. 
	Therapeutic class : Opioid analgesics
	Packsize : 50's pack
Anafen
	n : Ibuprofen
	Indications : Rheumatoid arthritis, Osteoarthritis, Pain, Fever, Pericarditis, Dysmenorrhea, Patent ductus arteriosus, Inflammation, Musculoskeletal and joint disorders
	Doses and administration : Adult: PO Pain and inflammation 1.2-1.8 g/day in divided doses. Maintenance: 0.6-1.2 g/day. Max: 2.4 g/day. 
									Fever 200-400 mg 4-6 hrly. Max: 1.2 g/day. 
									
									
	Contara-indications : Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).
	Side effects : Oral: Dyspepsia, vomitting, abdominal pain, heart burn, nausea, diarrhoea, epigastric pain, edema, fluid retention, dizziness, rash, tinnitus. Parenteral: Intraventricular hemorrhage, skin irritation, hypocalcemia, hypoglycemia, GI disorders, anemia, apnea, respiratory infection, sepsis.
									Potentially Fatal: Severe CV thrombotic events. Severe GI bleeding, ulceration and perforation.
	Precaution : Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation.
	Pregnancy category : 4
	Mode of action : Ibuprofen inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase-1 and 2. It has anti-inflammatory, analgesic and antipyretic properties.
	Interaction : Increased risk of GI bleeding w/ warfarin, corticosteroids, SSRIs and aspirin. May reduce the natriuretic effects of diuretics. Reduced antihypertensive effect of ACE inhibitors and angiotensin II receptor antagonists. May increase toxicity of lithium and methotrexate. Increased nephrotoxicity w/ ciclosporin and tacrolimus.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize :  100's pack
Anaflex
	n : Naproxen 10%
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Renal colic, Mild to moderate pain, Tendonitis, Acute musculoskeletal disorders, Bursitis
	Doses and administration : Adult: Apply Naproxen gel 2-6 times a day as required.
	Contara-indications : Hypersensitivity. Aspirin or NSAID allergy. Perioperative pain in the setting of CABG surgery. Pregnancy (3rd trimester)
	Side effects : Oedema, palpitation, dizziness, drowsiness, headache, light headedness, vertigo, pruritus, skin eruption, ecchymosis, purpura, rash, fluid retention, abdominal pain, constipation, nausea, heartburn, diarrhoea, dyspepsia, stomatitis, flatulence, gross bleeding/perforation, indigestion, ulcers, vomiting, abnormal renal function, haemolysis, anaemia, increased bleeding time, elevated LFTs, visual disturbances, tinnitus, hearing disturbances, dyspnoea, diaphoresis, thirst. Potentially Fatal: Anaphylactic/anaphylactoid reactions. Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
	Precaution : Pre-existing CV risk factors or disease e.g. fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment. Elderly. Lactation.
	Pregnancy category : 4
	Mode of action : Naproxen, a propionic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It can inhibit platelet aggregation, has anti-inflammatory, analgesic and antipyretic actions.
	Interaction : May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. Delayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.
	Therapeutic class : Topical Analgesics
	Packsize : 15gm tube/ 30gm tube
Anaflex
	n : Naproxen
	Indications : Rheumatoid arthritis, Ankylosing spondylitis, Post-operative pain, Dysmenorrhea, Acute gout, Acute migraine attacks, Renal colic, Cutaneous candidiasis, Mild to moderate pain, Tendonitis, Osteoarthritis (degenerative arthritis), Acute musculoskeletal disorders, Bursitis
	Doses and administration : Adults
									Oral:
									For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis
									The usual dose is 500-1000 mg per day taken in 2 doses at 12 hours intervals after meals.
									For acute gout
									750 mg should be given initially, followed in 8 hours with 500 mg, and thereafter 250 mg at 12 hours intervals until the attack has passed.
									For dysmennorhoea
									500 mg should be given initially, followed by 250 mg at 6-8 hour intervals for up to 5 days.
									For analgesia and acute muscular skeletal disorders
									500 mg should be given initially, followed by 250 mg at 6-8 hour intervals.
									
									Children over 5 years
									For juvenile rheumatoid arthritis
									10mg/kg/day given as 2 divided doses at 12 hour intervals.
									SR tablet: For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis
									500mg or 1000mg (500mg  2) SR tablet once daily (morning or evening) after meals.
									SR tablet is also indicated after the acute condition is subsided for long term use.
									
									Naproxen suspension
									Adults
									Dosage is the same as Naproxen tablet.
									Children over 5 years
									10 mg/kg/day given as 2 divided doses at 12 hours intervals.
									
									
	Contara-indications : Hypersensitivity. Aspirin or NSAID allergy. Perioperative pain in the setting of CABG surgery. Pregnancy (3rd trimester).
	Side effects : Oedema, palpitation, dizziness, drowsiness, headache, light headedness, vertigo, pruritus, skin eruption, ecchymosis, purpura, rash, fluid retention, abdominal pain, constipation, nausea, heartburn, diarrhoea, dyspepsia, stomatitis, flatulence, gross bleeding/perforation, indigestion, ulcers, vomiting, abnormal renal function, haemolysis, anaemia, increased bleeding time, elevated LFTs, visual disturbances, tinnitus, hearing disturbances, dyspnoea, diaphoresis, thirst.
									Potentially Fatal: Anaphylactic/anaphylactoid reactions. Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
	Precaution : Pre-existing CV risk factors or disease e.g. fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment. Elderly. Lactation.
	Pregnancy category : 4
	Mode of action : Naproxen, a propionic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It can inhibit platelet aggregation, has anti-inflammatory, analgesic and antipyretic actions.
	Interaction : May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. 
				
				Delayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Anaflex
	n : Naproxen
	Indications : Rheumatoid arthritis, Ankylosing spondylitis, Post-operative pain, Dysmenorrhea, Acute gout, Acute migraine attacks, Renal colic, Cutaneous candidiasis, Mild to moderate pain, Tendonitis, Osteoarthritis (degenerative arthritis), Acute musculoskeletal disorders, Bursitis
	Doses and administration : Adults
									Oral:
									For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis
									The usual dose is 500-1000 mg per day taken in 2 doses at 12 hours intervals after meals.
									For acute gout
									750 mg should be given initially, followed in 8 hours with 500 mg, and thereafter 250 mg at 12 hours intervals until the attack has passed.
									For dysmennorhoea
									500 mg should be given initially, followed by 250 mg at 6-8 hour intervals for up to 5 days.
									For analgesia and acute muscular skeletal disorders
									500 mg should be given initially, followed by 250 mg at 6-8 hour intervals.
									
									Children over 5 years
									For juvenile rheumatoid arthritis
									10mg/kg/day given as 2 divided doses at 12 hour intervals.
									SR tablet: For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis
									500mg or 1000mg (500mg  2) SR tablet once daily (morning or evening) after meals.
									SR tablet is also indicated after the acute condition is subsided for long term use.
									
									Naproxen suspension
									Adults
									Dosage is the same as Naproxen tablet.
									Children over 5 years
									10 mg/kg/day given as 2 divided doses at 12 hours intervals.
									
									
	Contara-indications : Hypersensitivity. Aspirin or NSAID allergy. Perioperative pain in the setting of CABG surgery. Pregnancy (3rd trimester).
	Side effects : Oedema, palpitation, dizziness, drowsiness, headache, light headedness, vertigo, pruritus, skin eruption, ecchymosis, purpura, rash, fluid retention, abdominal pain, constipation, nausea, heartburn, diarrhoea, dyspepsia, stomatitis, flatulence, gross bleeding/perforation, indigestion, ulcers, vomiting, abnormal renal function, haemolysis, anaemia, increased bleeding time, elevated LFTs, visual disturbances, tinnitus, hearing disturbances, dyspnoea, diaphoresis, thirst.
									Potentially Fatal: Anaphylactic/anaphylactoid reactions. Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
	Precaution : Pre-existing CV risk factors or disease e.g. fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment. Elderly. Lactation.
	Pregnancy category : 4
	Mode of action : Naproxen, a propionic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It can inhibit platelet aggregation, has anti-inflammatory, analgesic and antipyretic actions.
	Interaction : May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. 
				
				Delayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 30's pack
Anaflex Max 375
	n : Esomeprazole + Naproxen
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Joint stiffness
	Doses and administration : Rheumatoid Arthritis, Osteoarthritis, Alkylosing Spondylitis, and dysmenorrhoea: 375 or 500 mg, one tablet twice daily.
									
									
	Contara-indications :  Known hypersensitivity to any component of Progesic or substituted benzimidazoles
									 History of asthma, urticaria or other allergic-type reactions after taking aspirin or other NSAIDs
									 Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery
									 Late pregnancy
	Side effects : In general,The most common adverse reactions in clinical trials (>5%): erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea etc.
	Precaution : Patients with known CV disease/risk factors may be at greater risk. Progesic should be used with caution in patients with fluid retention or heart failure.
	Pregnancy category : 4
	Mode of action : Naproxen, a propionic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It can inhibit platelet aggregation, has anti-inflammatory, analgesic and antipyretic actions.
									
									Esomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
	Interaction : Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.
				Potentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Anaflex 500
	n : Esomeprazole + Naproxen
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Joint stiffness
	Doses and administration : Rheumatoid Arthritis, Osteoarthritis, Alkylosing Spondylitis, and dysmenorrhoea: 375 or 500 mg, one tablet twice daily.
									
									
	Contara-indications :  Known hypersensitivity to any component of Progesic or substituted benzimidazoles
									 History of asthma, urticaria or other allergic-type reactions after taking aspirin or other NSAIDs
									 Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery
									 Late pregnancy
	Side effects : In general,The most common adverse reactions in clinical trials (>5%): erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea etc.
	Precaution : Patients with known CV disease/risk factors may be at greater risk. Progesic should be used with caution in patients with fluid retention or heart failure.
	Pregnancy category : 4
	Mode of action : Naproxen, a propionic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It can inhibit platelet aggregation, has anti-inflammatory, analgesic and antipyretic actions.
									
									Esomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
	Interaction : Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.
				Potentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 30's pack
Anaflex SR
	n : Naproxen
	Indications : Rheumatoid arthritis, Ankylosing spondylitis, Post-operative pain, Dysmenorrhea, Acute gout, Acute migraine attacks, Renal colic, Cutaneous candidiasis, Mild to moderate pain, Tendonitis, Osteoarthritis (degenerative arthritis), Acute musculoskeletal disorders, Bursitis
	Doses and administration : Adults
									Oral:
									For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis
									The usual dose is 500-1000 mg per day taken in 2 doses at 12 hours intervals after meals.
									For acute gout
									750 mg should be given initially, followed in 8 hours with 500 mg, and thereafter 250 mg at 12 hours intervals until the attack has passed.
									For dysmennorhoea
									500 mg should be given initially, followed by 250 mg at 6-8 hour intervals for up to 5 days.
									For analgesia and acute muscular skeletal disorders
									500 mg should be given initially, followed by 250 mg at 6-8 hour intervals.
									
									Children over 5 years
									For juvenile rheumatoid arthritis
									10mg/kg/day given as 2 divided doses at 12 hour intervals.
									SR tablet: For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis
									500mg or 1000mg (500mg  2) SR tablet once daily (morning or evening) after meals.
									SR tablet is also indicated after the acute condition is subsided for long term use.
									
									Naproxen suspension
									Adults
									Dosage is the same as Naproxen tablet.
									Children over 5 years
									10 mg/kg/day given as 2 divided doses at 12 hours intervals.
									
									
	Contara-indications : Hypersensitivity. Aspirin or NSAID allergy. Perioperative pain in the setting of CABG surgery. Pregnancy (3rd trimester).
	Side effects : Oedema, palpitation, dizziness, drowsiness, headache, light headedness, vertigo, pruritus, skin eruption, ecchymosis, purpura, rash, fluid retention, abdominal pain, constipation, nausea, heartburn, diarrhoea, dyspepsia, stomatitis, flatulence, gross bleeding/perforation, indigestion, ulcers, vomiting, abnormal renal function, haemolysis, anaemia, increased bleeding time, elevated LFTs, visual disturbances, tinnitus, hearing disturbances, dyspnoea, diaphoresis, thirst.
									Potentially Fatal: Anaphylactic/anaphylactoid reactions. Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
	Precaution : Pre-existing CV risk factors or disease e.g. fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment. Elderly. Lactation.
	Pregnancy category : 4
	Mode of action : Naproxen, a propionic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It can inhibit platelet aggregation, has anti-inflammatory, analgesic and antipyretic actions.
	Interaction : May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. 
				
				Delayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 20's pack
Anafranil
	n : Clomipramine Hydrochloride
	Indications : Depression, Panic disorder, Obsessive compulsive disorder, Cataplexy, Narcolepsy, Phobias, Premature ejaculation, Enuresis, Trichotillomania
	Doses and administration :  Adult: PO Adjunct in cataplexy associated w/ narcolepsy Initial: 10 mg/day, up to 75 mg/day. 
									Obsessive-compulsive disorder; Panic disorder; Phobias Initial: 25 mg/day, gradually increase up to 100-150 mg/day if needed. Max: 250 mg/day. 
									Depression Initial: 10 mg/day, up to 30-150 mg/day if needed. >250 mg/day may be needed in severe cases. 
	Contara-indications :  Hypersensitivity. Concomitant use of MAOIs; recovery phase following MI, heartblock or other arrhythmias; mania; childn.
	Side effects :  Dryness of mouth; disturbances in micturition; drowsiness, increased sweating; sexual dysfunction; confusion, paraesthesia, ataxia, tremors; extrapyramidal symptoms; tinnitus, dizziness, fatigue, headache; wt gain esp in women; gynaecomastia and galactorrhoea.
									Potentially Fatal: Death, rare (except in patients with preexisting significant heart block and patients on MAOI therapy). Induction of mania in individuals with underlying manic-depressive illness or worsening of psychoses in already psychotic individuals.
	Precaution :  Cardiovascular insufficiency; narrow-angle glaucoma; urinary retention; history of epilepsy; renal or hepatic dysfunction; electroconvulsive therapy; hypotension; hyperthyroidism or concomitant treatment with thyroid preparations; suicidal tendencies; surgery; pregnancy and lactation; tasks requiring mental alertness; elderly; avoid abrupt withdrawal.
	Pregnancy category : 3
	Mode of action : Clomipramine is a potent inhibitor of serotonin re-uptake in the brain. Significant antagonism at cholinergic and ?1-receptors. Weak antagonism at dopamine receptors. It has also antidepressant, sedative and anticholinergic effects.
	Interaction : Barbiturates increase metabolism of tricyclic antidepressants; conversely cimetidine, guanethidine, haloperidol and phenothiazines block the tricyclic metabolism. CNS effects of alcohol enhanced.
				Potentially Fatal: If clomipramine is to be substituted for MAOIs, at least 3 wk should elapse after discontinuing MAOIs. Risk of hypertension and arrhythmias if co-administered with adrenaline and noradrenaline.
	Therapeutic class : Tricyclic & related anti-depressant drugs
	Packsize : 50's pack
Analac
	n : Ketorolac Tromethamine
	Indications : Moderate to severe pain
	Doses and administration : Oral
									Moderate to severe pain
									Adult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.
									Elderly: 10 mg every 6-8 hr. Max duration: 7 days.
									Parenteral
									Moderate to severe pain
									Adult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.
									Elderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.
									
									Pediatric Patients (2 to 16 years of age):
									IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
									IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
									
	Contara-indications : Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.
	Side effects : GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).
									Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.
	Precaution : Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.
	Pregnancy category : 4
	Mode of action : Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.
	Interaction : May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.
				Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 20's pack
Analac
	n : Ketorolac Tromethamine
	Indications : Moderate to severe pain
	Doses and administration : Oral
									Moderate to severe pain
									Adult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.
									Elderly: 10 mg every 6-8 hr. Max duration: 7 days.
									Parenteral
									Moderate to severe pain
									Adult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.
									Elderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.
									
									Pediatric Patients (2 to 16 years of age):
									IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
									IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
									
	Contara-indications : Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.
	Side effects : GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).
									Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.
	Precaution : Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.
	Pregnancy category : 4
	Mode of action : Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.
	Interaction : May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.
				Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 5's pack
Analac
	n : Ketorolac Tromethamine
	Indications : Moderate to severe pain
	Doses and administration : Oral
									Moderate to severe pain
									Adult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.
									Elderly: 10 mg every 6-8 hr. Max duration: 7 days.
									Parenteral
									Moderate to severe pain
									Adult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.
									Elderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.
									
									Pediatric Patients (2 to 16 years of age):
									IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
									IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
									
	Contara-indications : Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.
	Side effects : GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).
									Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.
	Precaution : Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.
	Pregnancy category : 4
	Mode of action : Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.
	Interaction : May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.
				Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 2ml amp x 1's pack
Analgen
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Analor
	n : Loratadine
	Indications : Pneumonia, Allergic rhinitis, Pruritus, Urticaria, Sneezing, Allergic conditions, Rhinorrhea, Lacrimation
	Doses and administration : Adult and child over 6 years: One 10 mg tablet or two teaspoonful (10 ml) suspension once daily. or 5 mg 12 hrly.
									Children aged 2-5 years: 5 ml or 1 teaspoonful (5 mg) suspension once daily. 
									Loratadine is not recommended for children under 2 years of age.
	Contara-indications : Pregnancy, lactation, children <2 yr.
	Side effects : Fatigue, giddiness, dizziness, dry mouth, headache, nausea, somnolence.
	Precaution : Severe hepatic damage, epilepsy, renal insufficiency.
	Pregnancy category : 2
	Mode of action : Loratadine is a non-sedating antihistamine. It works by selectively binding to peripheral histamine H1-receptors on effector cells.
	Interaction : May increase plasma concentrations w/ inhibitors of CYP3A4 and/or CYP2D6 (e.g. cimetidine, erythromycin, ketoconazole, clarithromycin, quinidine, fluconazole, fluoxetine).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Analpain
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Analpain
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 15ml bot
Analpain
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 500's pack
Anamet
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Anamet
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Anapril
	n : Enalapril Maleate
	Indications : Hypertension, Heart failure
	Doses and administration : Adult: PO HTN Initial: 5 mg/day at bedtime. Maintenance: 10-20 mg once daily. Severe: Up to 40 mg/day in divided doses. Max: 40 mg/day. 
									
									Heart failure Initial: 2.5 mg/day. Maintenance: 20 mg once daily, up to 40 mg/day in 2 divided doses. 
	Contara-indications : Hypersensitivity. History of angioedema due to previous treatment with ACE inhibitors; bilateral renal artery stenosis. Pregnancy.
	Side effects : Initial hypotension may be severe and prolonged. Dizziness, headache, fatigue, persistent dry cough, abnormal taste, lassitude, rash, neutropenia, renal impairment or failure.
									Potentially Fatal: Angioedema.
	Precaution : Impaired renal function. Hyperkalaemia, hypovolaemia, collagen vascular disease, valvular stenosis, during or immediately before or after anaesthesia, unilateral renal artery stenosis. Hypotension due to volume depletion, diuretic therapy. Monitor WBC count. Lactation, children.
	Pregnancy category : 4
	Mode of action : Enalapril, a prodrug of enalaprilat, competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.
	Interaction : May potentiate hypotensive action w/ diuretics, other antihypertensives, TCAs, nitrates or anaesth. Concomitant admin w/ lithium carbonate may cause lithium toxicity. Increased risk of renal impairment w/ NSAIDs. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 100's pack
Anapril
	n : Enalapril Maleate
	Indications : Hypertension, Heart failure
	Doses and administration : Adult: PO HTN Initial: 5 mg/day at bedtime. Maintenance: 10-20 mg once daily. Severe: Up to 40 mg/day in divided doses. Max: 40 mg/day. 
									
									Heart failure Initial: 2.5 mg/day. Maintenance: 20 mg once daily, up to 40 mg/day in 2 divided doses. 
	Contara-indications : Hypersensitivity. History of angioedema due to previous treatment with ACE inhibitors; bilateral renal artery stenosis. Pregnancy.
	Side effects : Initial hypotension may be severe and prolonged. Dizziness, headache, fatigue, persistent dry cough, abnormal taste, lassitude, rash, neutropenia, renal impairment or failure.
									Potentially Fatal: Angioedema.
	Precaution : Impaired renal function. Hyperkalaemia, hypovolaemia, collagen vascular disease, valvular stenosis, during or immediately before or after anaesthesia, unilateral renal artery stenosis. Hypotension due to volume depletion, diuretic therapy. Monitor WBC count. Lactation, children.
	Pregnancy category : 4
	Mode of action : Enalapril, a prodrug of enalaprilat, competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.
	Interaction : May potentiate hypotensive action w/ diuretics, other antihypertensives, TCAs, nitrates or anaesth. Concomitant admin w/ lithium carbonate may cause lithium toxicity. Increased risk of renal impairment w/ NSAIDs. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 100's pack
Anaroxyl
	n : Adrenochrome Monosemicarbazone
	Indications : Capillary bleeding, Haemoptysis, Haematuria, Retinal hemorrhage,Secondary hemorrhage, Menorrhagia.
	Doses and administration : Oral As a haemostatic 
									Adult: 10-30 mg tid. 
									Injection As a haemostatic Adult: 10 mg daily by SC/IM inj. Alternatively, 25-100 mg daily by IV Inj or drip infusion.
									Pre-operative: 2-6ml at suitable intervals. Post-operative: 1-2ml every 2hrs. Non-surgical: 2-4ml tid. Child <6yrs: 1-2ml tid.
	Contara-indications : Should not be administered to patients with hypersensitivity.
	Side effects : Allergic reactions may occur like dyspnoea, bronchospasm, skin reaction etc
	Precaution : Because of the content of diprophylline (90 mg/ml), the dosage to premature babies, infants and young children should not exceed 0.3 ml.
	Pregnancy category : 0
	Mode of action : Carbazochrome is an oxidation product of adrenaline (epinephrine). It has been used as a haemostatic agent.
	Interaction : No specific drug interaction has been demonstrated.
	Therapeutic class : Anti-fibrinolytic drugs
	Packsize : 30's pack
Anaroxyl
	n : Adrenochrome Monosemicarbazone
	Indications : Capillary bleeding, Haemoptysis, Haematuria, Retinal hemorrhage,Secondary hemorrhage, Menorrhagia.
	Doses and administration : Oral As a haemostatic 
									Adult: 10-30 mg tid. 
									Injection As a haemostatic Adult: 10 mg daily by SC/IM inj. Alternatively, 25-100 mg daily by IV Inj or drip infusion.
									Pre-operative: 2-6ml at suitable intervals. Post-operative: 1-2ml every 2hrs. Non-surgical: 2-4ml tid. Child <6yrs: 1-2ml tid.
	Contara-indications : Should not be administered to patients with hypersensitivity.
	Side effects : Allergic reactions may occur like dyspnoea, bronchospasm, skin reaction etc
	Precaution : Because of the content of diprophylline (90 mg/ml), the dosage to premature babies, infants and young children should not exceed 0.3 ml.
	Pregnancy category : 0
	Mode of action : Carbazochrome is an oxidation product of adrenaline (epinephrine). It has been used as a haemostatic agent.
	Interaction : No specific drug interaction has been demonstrated.
	Therapeutic class : Anti-fibrinolytic drugs
	Packsize : 5 amp's pack
Anasec
	n : Omeprazole
	Indications : Peptic ulcer, H. pylori infection, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Oesophagitis, Acid-related dyspepsia, NSAID-associated ulceration
	Doses and administration : Adult: PO Peptic ulcer 20 mg once daily. Severe: 40 mg/day. Duration: Duodenal ulcers: 4 wk; Gastric ulcers: 8 wk. Maintenance: 10-20 mg once daily. NSAID-associated ulceration 20 mg/day. 
									
									Eradication of H. pylori infection Dose varies w/ regimen: 20 mg once daily or 40 mg/day in 1-2 divided doses. To use w/ antibiotics. GERD 20 mg once daily for 4 wk, may continue for another 8 wk if needed. Maintenance: 10 mg/day. Zollinger-Ellison syndrome Initial: 60 mg once daily. Maintenance: 20-120 mg/day. Give doses >80 mg in 2 divided doses. 
									
									Prophylaxis of acid aspiration during general anesth Initial: 40 mg the evening before surgery and another 40 mg 2-6 hr pre-op. Acid-related dyspepsia 10 or 20 mg/day 2-4 wkly. Erosive oesophagitis 20 mg/day for 4-8 wk. Maintenance: 20 mg/day for up to 12 mth of total therapy inclusive of treatment period. 
									
									IV Gastric and duodenal ulcers; Reflux oesophagitis 40 mg once daily. Prophylaxis of acid aspiration during general anesth 40 mg, to be completed 1 hr before the surgery.
	Contara-indications : Known hypersensitivity to any of its component.
	Side effects : Diarrhoea, nausea, fatigue, constipation, vomiting, flatulence, acid regurgitation, taste perversion, arthralgia, myalgia, urticaria, dry mouth, dizziness, headache, paraesthesia, abdominal pain, skin rashes, weakness, back pain, upper respiratory infection, cough.
									Potentially Fatal: Anaphylaxis.
	Precaution : Exclude malignancy, prolonged use, hepatic impairment. Pregnancy, lactation, children <1 yr. Elderly and Asians (increased bioavailability).
	Pregnancy category : 3
	Mode of action : Omeprazole is a substituted benzimidazole gastric antisecretory agent and is also known as PPI. It blocks the final step in gastric acid secretion by specific inhibition of H+/K+ ATPase enzyme system present on the secretory surface of the gastric parietal cell. Both basal and stimulated acid are inhibited.
	Interaction : Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.
				Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 60's pack
Anasec
	n : Omeprazole
	Indications : Peptic ulcer, H. pylori infection, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Oesophagitis, Acid-related dyspepsia, NSAID-associated ulceration
	Doses and administration : Adult: PO Peptic ulcer 20 mg once daily. Severe: 40 mg/day. Duration: Duodenal ulcers: 4 wk; Gastric ulcers: 8 wk. Maintenance: 10-20 mg once daily. NSAID-associated ulceration 20 mg/day. 
									
									Eradication of H. pylori infection Dose varies w/ regimen: 20 mg once daily or 40 mg/day in 1-2 divided doses. To use w/ antibiotics. GERD 20 mg once daily for 4 wk, may continue for another 8 wk if needed. Maintenance: 10 mg/day. Zollinger-Ellison syndrome Initial: 60 mg once daily. Maintenance: 20-120 mg/day. Give doses >80 mg in 2 divided doses. 
									
									Prophylaxis of acid aspiration during general anesth Initial: 40 mg the evening before surgery and another 40 mg 2-6 hr pre-op. Acid-related dyspepsia 10 or 20 mg/day 2-4 wkly. Erosive oesophagitis 20 mg/day for 4-8 wk. Maintenance: 20 mg/day for up to 12 mth of total therapy inclusive of treatment period. 
									
									IV Gastric and duodenal ulcers; Reflux oesophagitis 40 mg once daily. Prophylaxis of acid aspiration during general anesth 40 mg, to be completed 1 hr before the surgery.
	Contara-indications : Known hypersensitivity to any of its component.
	Side effects : Diarrhoea, nausea, fatigue, constipation, vomiting, flatulence, acid regurgitation, taste perversion, arthralgia, myalgia, urticaria, dry mouth, dizziness, headache, paraesthesia, abdominal pain, skin rashes, weakness, back pain, upper respiratory infection, cough.
									Potentially Fatal: Anaphylaxis.
	Precaution : Exclude malignancy, prolonged use, hepatic impairment. Pregnancy, lactation, children <1 yr. Elderly and Asians (increased bioavailability).
	Pregnancy category : 3
	Mode of action : Omeprazole is a substituted benzimidazole gastric antisecretory agent and is also known as PPI. It blocks the final step in gastric acid secretion by specific inhibition of H+/K+ ATPase enzyme system present on the secretory surface of the gastric parietal cell. Both basal and stimulated acid are inhibited.
	Interaction : Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.
				Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 60's pack
Anasec
	n : Omeprazole
	Indications : Peptic ulcer, H. pylori infection, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Oesophagitis, Acid-related dyspepsia, NSAID-associated ulceration
	Doses and administration : Adult: PO Peptic ulcer 20 mg once daily. Severe: 40 mg/day. Duration: Duodenal ulcers: 4 wk; Gastric ulcers: 8 wk. Maintenance: 10-20 mg once daily. NSAID-associated ulceration 20 mg/day. 
									
									Eradication of H. pylori infection Dose varies w/ regimen: 20 mg once daily or 40 mg/day in 1-2 divided doses. To use w/ antibiotics. GERD 20 mg once daily for 4 wk, may continue for another 8 wk if needed. Maintenance: 10 mg/day. Zollinger-Ellison syndrome Initial: 60 mg once daily. Maintenance: 20-120 mg/day. Give doses >80 mg in 2 divided doses. 
									
									Prophylaxis of acid aspiration during general anesth Initial: 40 mg the evening before surgery and another 40 mg 2-6 hr pre-op. Acid-related dyspepsia 10 or 20 mg/day 2-4 wkly. Erosive oesophagitis 20 mg/day for 4-8 wk. Maintenance: 20 mg/day for up to 12 mth of total therapy inclusive of treatment period. 
									
									IV Gastric and duodenal ulcers; Reflux oesophagitis 40 mg once daily. Prophylaxis of acid aspiration during general anesth 40 mg, to be completed 1 hr before the surgery.
	Contara-indications : Known hypersensitivity to any of its component.
	Side effects : Diarrhoea, nausea, fatigue, constipation, vomiting, flatulence, acid regurgitation, taste perversion, arthralgia, myalgia, urticaria, dry mouth, dizziness, headache, paraesthesia, abdominal pain, skin rashes, weakness, back pain, upper respiratory infection, cough.
									Potentially Fatal: Anaphylaxis.
	Precaution : Exclude malignancy, prolonged use, hepatic impairment. Pregnancy, lactation, children <1 yr. Elderly and Asians (increased bioavailability).
	Pregnancy category : 3
	Mode of action : Omeprazole is a substituted benzimidazole gastric antisecretory agent and is also known as PPI. It blocks the final step in gastric acid secretion by specific inhibition of H+/K+ ATPase enzyme system present on the secretory surface of the gastric parietal cell. Both basal and stimulated acid are inhibited.
	Interaction : Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.
				Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.
	Therapeutic class : Proton Pump Inhibitor
	Packsize : 1 amp's pack
Anaxyl
	n : Tranexamic Acid
	Indications : Haemorrhage, Hereditary angioedema
	Doses and administration : Adult: PO Short-term management of haemorrhage 1-1.5 g 2-3 times/day. Long-term management of hereditary angioedema 1-1.5 g 2-3 times/day. 
									Child: 25 mg/kg bid or tid.
									
									IV Short-term management of haemorrhage 0.5-1 g 3 times/day.
									Child: 10 mg/kg bid or tid.
	Contara-indications : Severe renal failure, active intravascular clotting, thromboembolic disease, colour vision disorders, subarachnoid bleeding.
	Side effects : Diarrhoea, nausea, vomiting, disturbances in colour vision, giddiness, hypotension (after rapid IV inj), thromboembolic events.
	Precaution : Mild to moderate renal impairment, irregular menstrual bleeding, previous history of thromboembolic disease, haematuria. Monitor closely in disseminated intravascular coagulation. Monitor LFT and eye examination regularly during long-term use. Discontinue if disturbance in colour vision occurs. Avoid IV inj rate >1 ml/minute due to risk of hypotension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Tranexamic acid is an antifibrinolytic agent that competitively inhibits breakdown of fibrin clots. It blocks binding of plasminogen and plasmin to fibrin, thereby preventing haemostatic plug dissolution.
	Interaction : Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocytic leukaemia. 
	Therapeutic class : Anti-fibrinolytic drugs
	Packsize : 20's pack
Anaxyl
	n : Tranexamic Acid
	Indications : Haemorrhage, Hereditary angioedema
	Doses and administration : Adult: PO Short-term management of haemorrhage 1-1.5 g 2-3 times/day. Long-term management of hereditary angioedema 1-1.5 g 2-3 times/day. 
									Child: 25 mg/kg bid or tid.
									
									IV Short-term management of haemorrhage 0.5-1 g 3 times/day.
									Child: 10 mg/kg bid or tid.
	Contara-indications : Severe renal failure, active intravascular clotting, thromboembolic disease, colour vision disorders, subarachnoid bleeding.
	Side effects : Diarrhoea, nausea, vomiting, disturbances in colour vision, giddiness, hypotension (after rapid IV inj), thromboembolic events.
	Precaution : Mild to moderate renal impairment, irregular menstrual bleeding, previous history of thromboembolic disease, haematuria. Monitor closely in disseminated intravascular coagulation. Monitor LFT and eye examination regularly during long-term use. Discontinue if disturbance in colour vision occurs. Avoid IV inj rate >1 ml/minute due to risk of hypotension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Tranexamic acid is an antifibrinolytic agent that competitively inhibits breakdown of fibrin clots. It blocks binding of plasminogen and plasmin to fibrin, thereby preventing haemostatic plug dissolution.
	Interaction : Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocytic leukaemia. 
	Therapeutic class : Anti-fibrinolytic drugs
	Packsize : 5 amps pack
Anca
	n : Cefprozil
	Indications : Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections, Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Acute bacterial exacerbation of chronic bronchitis
	Doses and administration : Oral
									Skin and soft tissue infections, Susceptible infections
									Adult: 500 mg/day as a single dose or in 2 divided doses, increased to 500 mg bid if necessary.
									Child: 20 mg/kg/day once or twice daily, up to a max dose of 500 mg once daily, if necessary, bid for otitis media.
									Renal impairment:
									CrCl (ml/min)	
									<30	  Half normal dose. 
	Contara-indications : Hypersensitivity.
	Side effects : Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefprozil inhibits cell wall synthesis and has activity against a broad range of gram-positive and gram-negative bacteria.
	Interaction : Renal excretion delayed by probenecid. Decreases contraceptive effect of oestrogen-containing oral contraceptives.
	Therapeutic class : Second generation Cephalosporins
	Packsize : 50ml bot
Anca
	n : Cefprozil
	Indications : Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections, Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Acute bacterial exacerbation of chronic bronchitis
	Doses and administration : Oral
									Skin and soft tissue infections, Susceptible infections
									Adult: 500 mg/day as a single dose or in 2 divided doses, increased to 500 mg bid if necessary.
									Child: 20 mg/kg/day once or twice daily, up to a max dose of 500 mg once daily, if necessary, bid for otitis media.
									Renal impairment:
									CrCl (ml/min)	
									<30	  Half normal dose. 
	Contara-indications : Hypersensitivity.
	Side effects : Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefprozil inhibits cell wall synthesis and has activity against a broad range of gram-positive and gram-negative bacteria.
	Interaction : Renal excretion delayed by probenecid. Decreases contraceptive effect of oestrogen-containing oral contraceptives.
	Therapeutic class : Second generation Cephalosporins
	Packsize : None
Anca
	n : Cefprozil
	Indications : Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections, Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Acute bacterial exacerbation of chronic bronchitis
	Doses and administration : Oral
									Skin and soft tissue infections, Susceptible infections
									Adult: 500 mg/day as a single dose or in 2 divided doses, increased to 500 mg bid if necessary.
									Child: 20 mg/kg/day once or twice daily, up to a max dose of 500 mg once daily, if necessary, bid for otitis media.
									Renal impairment:
									CrCl (ml/min)	
									<30	  Half normal dose. 
	Contara-indications : Hypersensitivity.
	Side effects : Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Cefprozil inhibits cell wall synthesis and has activity against a broad range of gram-positive and gram-negative bacteria.
	Interaction : Renal excretion delayed by probenecid. Decreases contraceptive effect of oestrogen-containing oral contraceptives.
	Therapeutic class : Second generation Cephalosporins
	Packsize : None
Ancef
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 15ml bot
Ancef
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Ancef
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack
Ancef
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack
Ancef Forte
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Ancid Plus
	n : Aluminium Hydroxide + Magnesium Hydroxide
	Indications : Heartburn, Reflux oesophagitis, Hyperacidity, Peptic ulcer, Constipation, Indigestion
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200ml bot
Ancid DS Plus
	n : Aluminium Oxide + Magnesium Hydroxide + Simethicon
	Indications : Hyperacidity, Gastric ulcer duodenal ulcer and gastritis
	Doses and administration : Chew1-2 tablets or 2-4 tsf after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. 
	Contara-indications : Hypophosphataemia. Simethicon is contrindicated in renal failure, severely debiliated patients, 1st trimester of pregnancy.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Aluminum hydroxide: Neutralizes stomach hydrocloride to form AlCl3 salt plus water; increases gastric pH.
									Magnesium hydroxide: Promotes bowel evacuation by causing osmotic retention of fluid, which causes the colon to distend with increased peristaltic activity; forms magnesium chloride when reacts with hydrochloric acid.
									Simethicone: Disperses and prevents gas pockets in the GI system by decreasing surface tension of gas bubles.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
				
				Simethicon: None well documented.
				
	Therapeutic class : Antacids
	Packsize : 200ml bot
Ancipro
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 20's pack
Ancipro
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 20's pack
Ancipro
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 20's pack
Anclog
	n : Clopidogrel
	Indications : Coronary Artery Disease, Acute coronary syndrome, Myocardial infarction, Peripheral vascular disease, Cerebrovascular disease, Atherosclerosis, Thromboembolic disorders, Unstable angina, Stroke
	Doses and administration : Adult: PO Prophylaxis of thromboembolic events 75 mg once daily. 
									
									Acute coronary syndrome For ST-elevation myocardial infarction: W/ aspirin: 75 mg once daily. Continue treatment for up to 28 days. 
									
									For unstable angina, non-ST-elevation myocardial infarction: Initial: 300 mg loading dose, followed by 75 mg once daily (w/ aspirin 75-325 mg once daily).
	Contara-indications : Hypersensitivity. Active pathological bleeding. admin within 7 days after MI and ischaemic stroke, coagulation disorders. Lactation.
	Side effects : Dyspepsia, abdominal pain, nausea, vomiting, flatulence, constipation, gastritis, gastric and duodenal ulcers. GI upset, diarrhoea, paraesthesia, vertigo, headache, dizziness, pruritus and rashes.
									Potentially Fatal: Bleeding disorders including GI and intracranial haemorrhage. Blood dyscrasias.
	Precaution : Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions; ulcer; renal and hepatic impairment; history of bleeding or haemostatic disorders. Pregnancy.
	Pregnancy category : 2
	Mode of action : Clopidogrel inhibits adenosine diphosphate (ADP) from binding to its receptor sites on the platelets and subsequent activation of glycoprotein GP IIb/IIIa complex thus preventing fibrinogen binding, platelet adhesion and aggregation.
	Interaction :  	Co-admin with NSAIDs may increase the risk of stomach and intestinal bleeding. High-dose clopidogrel may lead to increased warfarin levels thus increasing the risk of bleeding. High-dose clopidogrel may also inhibit P450 (2C9), thus interfering with the metabolism of phenytoin, tamoxifen, torasemide, fluvastatin and some NSAIDs. Avoid concurrent use of drugs that inhibit CYP2C19, including omeprazole, esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine and ticlopidine.
	Therapeutic class : Anti-platelet drugs
	Packsize : 30's pack
Anclog PLUS
	n : Aspirin + Clopidogrel
	Indications : Acute coronary syndrome, TIA, Ischaemic events, MI, Stroke
	Doses and administration : Adult: PO Prevention of ischaemic events Per tab contains clopidogrel 75 mg and aspirin 75 mg: 1 tab once daily. Acute coronary syndrome Per tab contains clopidogrel 75 mg and aspirin 75 mg: Loading dose: 4 tab; maintenance: 1 tab/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	   Avoid use.
									Hepatic impairment: Severe hepatic impairment: Avoid use.
	Contara-indications : Hypersensitivity to aspirin, NSAIDs or clopidogrel; active peptic ulceration; children <12 yr; patients with haemophilia or haemorrhagic disorders; gout; severe renal or hepatic impairment; lactation.
	Side effects : Aspirin: GI disturbances, epigastric discomfort, prolonged bleeding time, rhinitis, urticaria; angioedema, salicylism, tinnitus. Clopidogrel: Dyspepsia, abdominal pain, nausea, vomiting, flatulence, constipation, gastritis, gastric and duodenal ulcers. Serious events include bleeding and GI haemorrhage. GI upset, diarrhoea, paraesthesia, vertigo, headache, dizziness, leucopaenia, eosinophilia, rash and pruritus.
									Potentially Fatal: Aspirin: Gastric erosion, ulceration and bleeding; severe, occasionally fatal exacerbation of airway obstruction in asthma; Reye's syndrome (childn <12 yrs). Hepatotoxicity; CNS depression, which may lead to coma; CV collapse, resp failure; paroxysmal bronchospasm and dyspnoea. Clopidogrel: Bleeding disorders including GI intracranial haemorrhage and thrombotic thrombocytopenic purpura.
	Precaution : History of peptic ulcer or those prone to dyspepsia and those with gastric mucosal lesion or heavy ethanol consumption; asthma or allergic disorders; tinnitus; dehydrated patients; uncontrolled hypertension; impaired renal or hepatic function; children and elderly; pregnancy. Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions. Increased risk of Reye's syndrome when used in patients with chicken pox, influenza or flu symptoms. Caution when used in patients with nasal allergies or nasal polyps. For patients undergoing elective surgery and an antiplatelet effect is not needed, clopidogrel should be discontinued 7-10 days before surgery.
	Pregnancy category : 19
	Mode of action : Aspirin inhibits the formation of thromboxane A2 in the platelets. This inhibits platelet aggregation and coagulation. This action lasts until the enzyme cyclo-oxygenase is regenerated in the platelets. Clopidogrel is a prodrug and is metabolised an active thiol metabolite. The active metabolite selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GP IIb/IIIa complex, thereby inhibiting platelet aggregation.
	Interaction : Aspirin: Corticosteroids, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Use with coumarins, anagrelide, agatroban, LMWH, bivalirudin, dasatinib, iloprost, lepirudin and tenecteplase may increase the risk of bleeding. Clopidogrel: Co-administration of clopidogrel with NSAIDs may increase the risk of stomach and intestinal bleeding. There is an increased risk of bleeding with coumarins, agatroban, dasatinib, heparin, LMWH, gingko biloba and iloprost. Increased risk of bleeding if clopidogrel and drotrecogin alfa are given within 7 days. May increase bupropion level and side effects (lightheadedness , GI discomfort).
				Potentially Fatal: Aspirin and clopidogrel: Increased risk of bleeding with dabigatran.
	Therapeutic class : Anti-platelet drugs
	Packsize : 30's pack
Ancoc
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 30's pack
Ancoc
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 20's pack
Ancoc PFS
	n : Flucloxacillin
	Indications : Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne
	Doses and administration : Adults (including elderly patients):
									Oral:
									250-500mg three to four times a day. Oral doses should be administered 1 hour before meal
									
									Children
									2-10 years: Half of adult dose
									Under 2 years: One fourth of adult dose
									
									Children have been given doses of 12.5-25 mg/kg body weight four times a day.
									
									IV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Dosage adjustment may be necessary.
	Contara-indications : Hypersensitivity to penicillins. Porphyria.
	Side effects : Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).
									Potentially Fatal: Anaphylaxis. Stevens-Johnson syndrome
	Precaution : Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.
	Pregnancy category : 2
	Mode of action : Flucloxacillin inhibits the 3rd and last step of bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. It is active against penicillinase-producing and non-penicillinase-producing staphylococci.
	Interaction : May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
	Therapeutic class : Penicillinase-resistant penicillins
	Packsize : 100ml bot
Ancopan
	n : Hyoscine Butyl Bromide
	Indications : Gastrointestinal tract spasm, Abdominal pain, Genitourinary spasm
	Doses and administration : Adult: PO Genito-urinary spasm; GI tract spasm As butylbromide: 20 mg 4 times/day.
									
									IV/IM Genito-urinary spasm; GI tract spasm As butylbromide: 20 mg, repeat 30 mins later if needed. Max: 100 mg/day. 
									
									
	Contara-indications : Narrow-angle glaucoma, acute haemorrhage, paralytic ileus, tachycardia due to cardiac insufficiency, myasthenia gravis.
	Side effects : Flushing, postural hypotension, tachycardia, fibrillation. Rarely psychotic reactions. Dizziness, drowsiness, fatigue, headache, memory loss. Dry skin, erythema, increased sensitivity to light, rash. Bloatedness, constipation, dry throat, dysphagia, nausea, vomiting, xerostomia. Dysuria, urinary retention. Tremor, weakness. Impaired accommodation, blurred vision, cycloplegia, dryness, narrow-angle glaucoma, increased intraocular pain, itching, photophobia, pupil dilation. Dry nose. Decreased diaphoresis, heat intolerance. Ophthalmic: Somnolence, dermatitis, oedema, exudate, follicular conjunctivitis, increased IOP, local irritation, photophobia, vascular and respiratory congestion.
									Potentially Fatal: CNS depression, coma, circulatory and respiratory failure.
	Precaution : Hepatic/renal disease, pyloric stenosis, urinary retention, prostatic hyperplasia, psychosis, seizure disorders, ulcerative colitis, coronary artery disease, tachyarrhythmias, heart failure, hypertension. Elderly, children, pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Hyoscine competitively blocks muscarinic receptors and has central and peripheral actions. It relaxes smooth muscle and reduces gastric and intestinal motility.
	Interaction : Additive sedative effects with alcohol or other CNS depressants. Reduced effects with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine).
				Potentially Fatal: Effect potentiated by other anticholinergic drugs and TCAs.
	Therapeutic class : Anticholinergics(antimuscarinics)/Anti-spasmodics
	Packsize : 50's pack
Ancor F/C
	n : Bisoprolol
	Indications : Hypertension, Angina pectoris;  Congestive heart failure					
									
	Doses and administration : The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
									
									For heart failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max. 10 mg daily. 
									
									Renal impairment:
									CrCl (ml/min)	
									<40	Initial: 2.5 mg/day.
									
									Hepatic impairment: Severe: Initially, 2.5 mg/day. Max: 10 mg/day.
	Contara-indications : Patients with cardiogenic shock, overt cardiac failure, second or third degree AV block and marked sinus bradycardia.
	Side effects : Diarrhoea, dizziness, drowsiness, fatigue, headache, lightheadedness, nausea, sleeplessness, unusual tiredness, weakness, Severe allergic reactions (rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue), chest pain, difficulty breathing, lightheadedness or dizziness when rising from a lying or sitting position, very slow heartbeat.
	Precaution : Impaired Renal or Hepatic Function.
	Pregnancy category : 4
	Mode of action : Bisoprolol selectively and competitively blocks ?1-receptors but has little or no effect on ?2-receptors except at high doses.
	Interaction : May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.
	Therapeutic class : Beta-blockers
	Packsize : 30's pack
Ancor F/C
	n : Bisoprolol
	Indications : Hypertension, Angina pectoris;  Congestive heart failure					
									
	Doses and administration : The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
									
									For heart failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max. 10 mg daily. 
									
									Renal impairment:
									CrCl (ml/min)	
									<40	Initial: 2.5 mg/day.
									
									Hepatic impairment: Severe: Initially, 2.5 mg/day. Max: 10 mg/day.
	Contara-indications : Patients with cardiogenic shock, overt cardiac failure, second or third degree AV block and marked sinus bradycardia.
	Side effects : Diarrhoea, dizziness, drowsiness, fatigue, headache, lightheadedness, nausea, sleeplessness, unusual tiredness, weakness, Severe allergic reactions (rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue), chest pain, difficulty breathing, lightheadedness or dizziness when rising from a lying or sitting position, very slow heartbeat.
	Precaution : Impaired Renal or Hepatic Function.
	Pregnancy category : 4
	Mode of action : Bisoprolol selectively and competitively blocks ?1-receptors but has little or no effect on ?2-receptors except at high doses.
	Interaction : May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.
	Therapeutic class : Beta-blockers
	Packsize : 30's pack
Ancor Plus 2.5
	n : Bisoprolol  + Hydrochlorothiazide
	Indications : Hypertension, Congestive heart failure, HTN, Angina pectoris
	Doses and administration : Adult: PO Initial: 2.5 mg/6.25 mg tablet once daily.
									
									Increase based on clinical response in 2 weeks, Maximum: bisoprolol 20 mg/hydrochlorothiazide 12.5 mg once daily.
	Contara-indications : Low cardiac output and uncompensated cardiac failure; sinus bradycardia, 1st  heart block, cardiogenic shock, bronchospasm; severe haemorrhage. Pregnancy.
	Side effects : Giddiness, headache, fatigue, bradycardia. Nausea, vomiting, diarrhoea or constipation, stomach discomfort, mild ocular stinging, photophobia, keratitis, decreased sexual ability. GI disturbances, dyspnoea, cold extremities, insomnia, hallucination, drowsiness and mood alterations.
									Potentially Fatal: AV block, bradycardia. Rare but may occur in patients with preexisting cardiac disease. Includes severe bronchospasm, hypoglycaemia, hypotension, orthostatic hypotension, bradyarrhythmias. 'Rebound phenomenon' leading to unstable angina or MI on sudden withdrawal.
	Precaution : Bronchospastic disease, hyperthyroidism, peripheral vascular disease, undergoing anaesthesia. Monitor blood glucose regularly. May mask symptoms of hypoglycaemia. Elderly. Gradual withdrawal is advised. Lactation.
	Pregnancy category : 19
	Mode of action : Bisoprolol fumarate/hydrochlorothiazide is a fixed-combination tablet that combines a Beta adrenergic receptor blocker, bisoprolol fumarate, and a thiazide diuretic, hydrochlorothiazide.
									
									Bisoprolol fumarate, a cardioselective inhibitor of beta(1)-adrenoceptor, has no significant intrinsic sympathomimetic activity or membrane stabilizing activity in its therapeutic dosage; exhibits beta(2)-adrenoceptors inhibition and negative chronotropic effect.
									
									Hydrochlorothiazide is a thiazide diuretic that inhibits Na reabsorption in distal renal tubules resulting in increased excretion of Na+ and water, also K+ and H+ ions.
	Interaction : Bisoprolol : May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.
				
				Hydrochlorothiazide: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Ancor Plus 5
	n : Bisoprolol  + Hydrochlorothiazide
	Indications : Hypertension, Congestive heart failure, HTN, Angina pectoris
	Doses and administration : Adult: PO Initial: 2.5 mg/6.25 mg tablet once daily.
									
									Increase based on clinical response in 2 weeks, Maximum: bisoprolol 20 mg/hydrochlorothiazide 12.5 mg once daily.
	Contara-indications : Low cardiac output and uncompensated cardiac failure; sinus bradycardia, 1st  heart block, cardiogenic shock, bronchospasm; severe haemorrhage. Pregnancy.
	Side effects : Giddiness, headache, fatigue, bradycardia. Nausea, vomiting, diarrhoea or constipation, stomach discomfort, mild ocular stinging, photophobia, keratitis, decreased sexual ability. GI disturbances, dyspnoea, cold extremities, insomnia, hallucination, drowsiness and mood alterations.
									Potentially Fatal: AV block, bradycardia. Rare but may occur in patients with preexisting cardiac disease. Includes severe bronchospasm, hypoglycaemia, hypotension, orthostatic hypotension, bradyarrhythmias. 'Rebound phenomenon' leading to unstable angina or MI on sudden withdrawal.
	Precaution : Bronchospastic disease, hyperthyroidism, peripheral vascular disease, undergoing anaesthesia. Monitor blood glucose regularly. May mask symptoms of hypoglycaemia. Elderly. Gradual withdrawal is advised. Lactation.
	Pregnancy category : 19
	Mode of action : Bisoprolol fumarate/hydrochlorothiazide is a fixed-combination tablet that combines a Beta adrenergic receptor blocker, bisoprolol fumarate, and a thiazide diuretic, hydrochlorothiazide.
									
									Bisoprolol fumarate, a cardioselective inhibitor of beta(1)-adrenoceptor, has no significant intrinsic sympathomimetic activity or membrane stabilizing activity in its therapeutic dosage; exhibits beta(2)-adrenoceptors inhibition and negative chronotropic effect.
									
									Hydrochlorothiazide is a thiazide diuretic that inhibits Na reabsorption in distal renal tubules resulting in increased excretion of Na+ and water, also K+ and H+ ions.
	Interaction : Bisoprolol : May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.
				
				Hydrochlorothiazide: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Ancor
	n : Bisoprolol
	Indications : Hypertension, Angina pectoris;  Congestive heart failure					
									
	Doses and administration : The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
									
									For heart failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max. 10 mg daily. 
									
									Renal impairment:
									CrCl (ml/min)	
									<40	Initial: 2.5 mg/day.
									
									Hepatic impairment: Severe: Initially, 2.5 mg/day. Max: 10 mg/day.
	Contara-indications : Patients with cardiogenic shock, overt cardiac failure, second or third degree AV block and marked sinus bradycardia.
	Side effects : Diarrhoea, dizziness, drowsiness, fatigue, headache, lightheadedness, nausea, sleeplessness, unusual tiredness, weakness, Severe allergic reactions (rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue), chest pain, difficulty breathing, lightheadedness or dizziness when rising from a lying or sitting position, very slow heartbeat.
	Precaution : Impaired Renal or Hepatic Function.
	Pregnancy category : 4
	Mode of action : Bisoprolol selectively and competitively blocks ?1-receptors but has little or no effect on ?2-receptors except at high doses.
	Interaction : May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.
	Therapeutic class : Beta-blockers
	Packsize : 10's pack
Ancotil
	n : Bromazepam
	Indications : Anxiety, Panic attacks
	Doses and administration : Adult: PO Initial: 6-18 mg/day in divided doses. Higher doses  have occasionally been given to hospitalized patients. Dose should be reduced at least half in elderly patients and those with hepatic and renal impairment.
	Contara-indications : Preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnea; severe hepatic impairment; not indicated for chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behavior, not used alone to treat depression or anxiety associated with depression; glaucoma.
	Side effects : Drowsiness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia; rarely, jaundice, blood disorders and hypersensitivity reactions; pain and thrombophlebitis; raised liver enzyme values; paradoxical excitation.
	Precaution : Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; patients with personality disorders or organic brain changes; pregnancy and lactation; history of alcohol or drug addiction due to risk of dependence. resp depression and hypotension with parenteral administration, therefore this route should only be used when facilities for reversing resp depression are available.
	Pregnancy category : 0
	Mode of action : Bromazepam is a benzodiazepine with general properties similar to diazepam. It is used in the treatment of anxiety occuring alone or associated with insomnia.
	Interaction : May enhance the activity w/ CYP450 inhibitor (e.g. azole antifungals, macrolides, HIV protease inhibitors, Ca channel blockers). Elevated plasma levels w/ disulfiram or cimetidine. Additive CNS depressant effects w/ barbiturates, sedatives, anaeasth, anxiolytics, hypnotics, phenothiazines, other antipsychotics, skeletal muscle relaxants. May potentiate anticholinergic effects of atropine, antihistamines and antidepressants. Increased psychic drug dependence w/ narcotic analgesics.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 50's pack
Andep
	n : Sertraline Hydrochloride
	Indications : Depressive illness, Panic disorder, Premenstrual dysphoric disorder, Post-traumatic stress disorder, Obsessive-compulsive disorder, Social anxiety disorder
	Doses and administration : Depressive illness :Initially 50 mg daily, increased if necessary by increments of 50 mg over several weeks to maximum 200 mg daily. Usual maintenance dose is 50 mg daily. 
									
									Child and adolescent less than 18 years are not recommended.
									
									Obsessive-compulsive disorder :Adult and adolescent over 13 years- Initially 50 mg daily, increased if necessary in steps of 50 mg over several weeks. Usual dose range is 50-200 mg daily. 
									
									Child (6-12 years) - Initially 25 mg daily, increased to 50 mg daily after 1 week, further increased if necessary in steps of 50 mg at intervals of at least 1 week (maximum 200 mg daily).
									
									Post-traumatic stress disorder: Initially 25 mg daily, increased after 1 week to 50 mg daily; if response is partial and if drug is tolerated, dose can be increased in steps of 50 mg over several weeks to maximum 200 mg daily. 
									
									Child and adolescent less than 18 years are not recommended. 
	Contara-indications : Sertraline is contraindicated in patients with a known hypersensitivity to Sertraline or any of the excipients of drug.
	Side effects : Sertraline may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc.
	Precaution : Precaution should be taken in case of liver problems, kidney diseases, seizures, heart problems and any allergies. This drug may cause dizziness or drowsiness. Caution should be taken in activities requiring alertness such as driving or using machinery. Caution is advised while using this product in the elderly because they may be more sensitive to the effects of the drug. Do not take this drug if you have taken monoamine oxidase inhibitor in the last five weeks.
	Pregnancy category : 3
	Mode of action : Sertraline has a potent and selective inhibitory action on CNS neuronal reuptake of 5-HT resulting in increased 5-HT concentrations at the synaptic clefts, leading to sustained activity at the postsynaptic receptor sites and improvement of depression. Reduction of serotonin turnover (in brain) also contributes to its action. Its long half-life allows once daily admin.
	Interaction : May increase risk of delirium when used with antimuscarinics. Increased risk of extrapyramidal symptoms and neuroleptic malignant syndrome when used with aripiprazole. Serum levels may be reduced by carbamazepine. Concurrent use with dihydroergotamine or linezolid may lead to serotonin syndrome. May increase serum levels of lamotrigine and risk of toxicity. May increase serum levels of olanzapine, pimozide, risperidone, methadone, clozapine and amiodarone. Plasma levels may be increased by cimetidine and ritonavir. May increase the anticoagulant activity of warfarin and acenocoumarol.
				
				Potentially Fatal: Concomitant admin with MAOIs can result in serious serotonin syndrome.
	Therapeutic class : SSRIs & related anti-depressant drugs
	Packsize : 50's pack
Anefer
	n : Elemental Iron (Iron sucrose)
	Indications : Iron deficiency anemia in pregnancy and in non-dialysis dependent chronic kidney disease (CKD) patients, hemodialysis dependent CKD patients  or peritoneal dialysis CKD patients.
	Doses and administration : Adults and the Elderly: 
									As injection: Iron Sucrose can also be administered undiluted by slow IV injection at a rate of 1 ml Iron Sucrose (20 mg Iron) in at least 1 minute a maximum of 10 ml Iron Sucrose (200 mg Iron) can be administered per injection in at least 10 minutes.
									
									Iron-deficiency Anemia in Chronic Kidney Disease
									Hemodialysis-dependent CKD: 100 mg elemental iron IV (injection or infusion over 2-5 min) per dialysis session not to exceed total cumulative dose of 1000 mg divided in 3 doses/week.
									
									Non-dialysis-dependent CKD: 200 mg IV injection for 5 doses in over 14 days (cumulative 1000 mg in 14-day period).
									
									Peritoneal dialysis-dependent CKD: 300 mg IV infusion (1.5 hr) for 2 doses 14 days apart, THEN 400 mg IV infusion (2.5 hr) 14 days later (cumulative 1000 mg divided in 3 doses/week).
									
									As infusion: Iron Sucrose should preferably be administered by drip infusion ( in order to reduce hypotensive episodes) in a dilution of 1 ml Iron Sucrose in maximum 20 ml 0.9% NaCl etc up to 25 ml Iron Sucrose in maximum 500 ml 0.9% NaCl. Dilution must take place immediately prior to infusion and solution must be administered as follows: 100 mg Iron in at least 15 minutes; 200 mg Iron in at least 30 minutes ete. Normal posology is to use 5-10 ml Iron Sucrose 1-3 times a week depending on the Hemoglobin level. For the administration of the maximum tolerable dose of 7 mg Iron/kg body weight an infusion time of at least 3.5 hours has to be respected, independently of the total dose.
									
									Children: There is limited data on children under study conditions. If there is a clinical need, it is recommended not to exceed 0.15 ml Iron Sucrose (3 mg Iron) per kg body weight 1-3 times a week depending on the hemoglobin level.
									
									Iron-deficiency Anemia in Chronic Kidney Disease
									Indicated for maintenance treatment of iron-deficient anemia associated with chronic kidney disease
									<2 years: Safety and efficacy not established.
									
									Hemodialysis-dependent: 0.5 mg/kg IV q2weeks for 12 weeks; not to exceed 100 mg/dose.
									
									Non-dialysis dependent or peritoneal-dependent (on erythropoietin): 0.5 mg/kg IV q4weeks for 12 weeks; not to exceed 100 mg/dose.
									
									Before administering a slow intravenous injection, a test dose of 1 ml (20 mg of iron) should be injected slowly over a period of 1 to 2 minutes. If no adverse events occur within 15 minutes of completing the test dose, then the remaining portion of the injection may be given.
									
	Contara-indications : The use of Iron Sucrose is contraindicated in patients with evidence of Iron overload e.g. Haemochromatosis, thalassemia or haemosiderosis and in patients with known hypersensitivity to Iron preparations or any components preparation, in patients with anemia not caused by Iron deficiency.
	Side effects : Iron Sucrose is generally well tolerated. However, occasionally metallic taste, headache, nausea, vomiting and hypotension may occur. Less frequently side-effects are paresthesia, abdominal disorders, muscular pain, fever, urticaria, flushing, edema of the extremities, anaphylactic (pseudoallergic) reactions and in the region of the punctured vein, phlebitis and venous spasm have been observed.
	Precaution : Iron Sucrose should be administered with caution in patients with asthma, eczema, other atopic allergies or allergic reaction to other parenteral Iron preparations, low binding capacity and/or folic acid deficiency, liver dysfunction, acute or chronic infection.
				
				Baseline tests: Ensure Hgb, Hct, serum ferritin and transferrin saturation is determined before starting therapy and periodically during treatment. Note that serum Iron levels may be reliably obtained 48 hours after IV dosing.
				
				Blood Pressure: Monitor Blood Pressure during infusion. If hypotension occurs, slow the rate of infusion. If hypotension continues, discontinue infusion and be prepared to treat appropriately.
				
				Discontinue oral Iron preparations before administering parenteral Iron products. Co-administration of parenteral Iron preparations may reduce absorption of oral Iron.The dose will be in terms of elemental Iron. For IV administration only. Not for intradermal, subcutaneous, IM, or intra-arterial administration. Medication is administered 1 to 3 times/ week. Do not administer more than 3 times/week. Discard any unused diluted solution. Do not save unused solution for future use. Do not administer if particulate matter or discoloration noted.
	Pregnancy category : 2
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
	Interaction : May reduce the serum levels of cefdinir; stools may appear red due to the formation of an insoluble iron-cefdinir complex. May reduce the serum levels of eltrombopag. May decrease absorption of phosphate supplements. Concurrent use with trientine may result in reduction of serum levels of iron sucrose and/or trientine.
				Potentially Fatal: Dimercaprol may increase the nephrotoxic effect of iron salts when used concurrently.
	Therapeutic class : Parenteral Iron Preparations
	Packsize : 1x1's pack
Aneron
	n : Iron Hydroxide Polymaltose
	Indications : Iron-deficiency anemia
	Doses and administration : Dosage and duration of therapy are dependent upon the extent of iron deficiency and should be taken as directed by the physician.
									
									Adults: 10 ml once or twice daily
									Children (6 - 12 years): 10 ml daily
									Children (2 - 6 years): 5 ml daily
									Premature infants & Infants: 3.33 mg of elemental iron/kg body weight (0.06 ml  drops/kg body weight) daily.
	Contara-indications : * In conditions where there is a risk of iron overload e.g. Haemochromatosis, thalassemia or haemosiderosis.
									* In case of hypersensitivity to iron or any other ingredients of the syrup.
	Side effects : This preparation is well tolerated. However, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur.
	Precaution : Avoid concomitant parenteral and oral iron admin, oral iron therapy should start at least 1 wk after last iron inj. Parenteral: Pregnancy (2nd and 3rd trimester), allergies, hepatic and liver insufficiency, low iron binding capacity and or folic acid deficiency. Facilities for CPR should be available during admin. Excessive IV infusion rate may cause nausea and epigastric upset. IV infusion route should be used only if IM route is unacceptable and when there is no stored iron in the bone marrow.
	Pregnancy category : 0
	Mode of action : Iron polymaltose is a water soluble, macro-molecular complex of iron (III) hydroxide and isomaltose. It is used in the treatment of iron-deficiency anaemia.
	Interaction : Concurrent use with psychotropic drugs may worsen constipation. Increased systemic side effects with concomitant ACE inhibitors and parenteral iron admin.
	Therapeutic class : Oral Iron preparations
	Packsize : 200ml bot / 100ml bot
Anespine
	n : Bupivacaine + Dextrose
	Indications : Intrathecal anesthesia, Spinal anesthesia, Epidural anesthesia, Subarachnoid anesthesia
	Doses and administration : Adult: Inj Percutaneous infiltration anesth For prolonged action: 9 mg w/ adrenaline (1 in 200,000), may repeat 2-10 mins later if needed. Max: 90 mg per dental sitting. 
									Peripheral nerve block 12.5 mg (as 0.25% soln) or 25 mg (as 0.5% soln) . Max: 150 mg/dose. 
									Sympathetic nerve block As 0.25% soln: 50-125 mg. 
									Retrobulbar block As 0.75% soln: 15-30 mg. 
									Caudal block In surgery: 37.5-75 mg (as 0.25% soln) or 75-150 mg (as 0.5% soln). 
									Lumbar epidural block In surgery: 25-50 mg (as 0.25% soln) and 50-100 mg (as 0.5% soln).
	Contara-indications : Hypersensitivity to local anaesthetics of amide type. IV regional anaesthesia; paracervical block in obstetrics; spinal anaesthesia <18 yr. Lactation. Solutions containing preservatives for caudal or epidural block.
	Side effects : CNS excitation may be followed by depression. Hypotension, bradycardia, arrhythmias and cardiac arrest; methaemoglobinaemia; seizures, restlessness, dizziness. Hypersensitivity. Prolonged block.
									Potentially Fatal: Cardiac and sudden respiratory arrest.
	Precaution : Hepatic disease; CV disease; children <12 yr; pregnancy. Elderly and debilitated patients.
	Pregnancy category : 3
	Mode of action : Bupivacaine blocks both the initiation and conduction of nerve impulses reducing the permeability of neuronal membranes to Na ions resulting in inhibition of depolarization w/ resultant blockade of conduction.  	Dextrose is a monosaccharide that is used as a source of calories and water for hydration. It helps to reduce loss of body protein and nitrogen. It also promotes glycogen deposition in the liver.
	Interaction : Additive systemic toxic effect w/ other local anaesth or agents structurally related to amide-type local anaesth (e.g. lidocaine and mexiletine). Increased risk of myocardial depression w/ antiarrhythmics. Enhanced adverse effects w/ hyaluronidase. Decreased clearance resulting to increased plasma concentrations w/ cimetidine and ranitidine. Increased risk of adverse effects w/ ?-blockers and Ca channel blockers.
	Therapeutic class : Regional anesthesia
	Packsize : 4 ml amps x 10's pack
Anestho IV 0.5gm
	n : Thiopental Sodium
	Indications : Status epilepticus, Induction of anesthesia, Reduction of raised intracranial pressure
	Doses and administration : Intravenous
									Induction of anaesthesia
									Adult: 100-150 mg of a 2.5 or 5% solution injected over 10-15 sec repeated every 30-60 sec according to response or as a continuous infusion of a 0.2 or 0.4% solution. Max: 500mg. Max in pregnancy: 250mg.
									Child: 2-7 mg/kg over 10-15 seconds; repeated after 1 minute if needed..
									
									Status epilepticus
									Adult: In conjunction with assisted ventilation: 75-125 mg as a 2.5% solution.
									Child: 5 mg/kg by slow IV inj followed by, neonates: continuous iv infusion of 2.5 mg/kg/hr; >1 month: 2-8 mg/kg/hr. Adjust infusion dose according to response.
									
									Reduction of raised intracranial pressure
									Adult: Intermittent bolus inj of 1.5-3.5 mg/kg, if adequate ventilation is provided.
									Child: 3 mth-15 yr: initial 5-10-mg/kg IV followed by a continuous IV infusion at 1-4 mg/kg/hr.
									Elderly: Dose reduction may be needed.
									Hepatic impairment: Dose reduction may be needed.
	Contara-indications : Thiopental Sodium for Injection is contraindicated in patients with severe respiratory embarrassment, hypersensitivity to barbiturates, status asthmaticus, variegate or acute intermittent porphyria, and inflammatory conditions of the mouth, jaw, and neck and in the absence of suitable veins for intravenous administration. Thiopental Sodium for Injection is also relatively contraindicated in severe cardiovascular disease, hypotension or shock, and conditions in which the hypnotic effect may be prolonged or potentiated, i.e. excessive premedication, Addison's disease, hepatic or renal dysfunction, myxedema, increased blood urea, severe anemia and myasthenia gravis.
	Side effects : Hypersensitivity reactions have been reported. Other adverse reactions to thiopental sodium include the followings: respiratory depression, myocardial depression, cardiac arrhythmias, prolonged somnolence and recovery, hypotension, tachycardia, sneezing, coughing, bronchospasm, laryngospasm and shivering. Anaphylactic reactions have been reported. Symptoms, e.g., urticaria, bronchospasm, vasodilation and edema.
	Precaution : A person competent in anesthesia management should be in constant attendance and adequate facilities for support of respiration and circulation should be available when Thiopental Sodium for injection is being used. Thiopental Sodium for Injection should be administered with caution to patients with preexisting hypotension or in conditions where the hypnotic effect may be prolonged or intensified, such as in the presence of liver disease and renal disease.
				
				Warnings
				This product may be habit forming. Keep resuscitative and endotracheal intubation equipment and oxygen readily available. Maintain patency of the airway at all times. Only persons qualified in the use of anesthetics should administer this drug. Avoid extravasations or intra-arterial injection.
	Pregnancy category : 3
	Mode of action : Thiopental sodium, a short-acting barbiturate anaesthetic, is a CNS depressant inducing hypnosis and anaesthesia but not analgesia. It has also been used in the control of refractory tonic-clonic status epilepticus and to reduce increased intracranial pressure in neurosurgical patients.
	Interaction : Possible increase in difficulty in producing anaesthesia in patients taking alcohol or CNS depressants. Additive action with other CNS depressants including sedatives, hypnotics, nitrous oxide or alcohol. Increased hypotension and excitatory effects with phenothiazine antipsychotics. Increased hypnotic effect with antipsychotic. Decreased requirement of thiopental sodium with metoclopramide, sulfisoxazole, aspirin, meprobamate, probenecid and other highly protein bound drugs.
				Potentially Fatal: Increased resp depression with opioids.
	Therapeutic class : General (Intravenous) anesthetics
	Packsize : 1's pack
Anestho IV 1gm
	n : Thiopental Sodium
	Indications : Status epilepticus, Induction of anesthesia, Reduction of raised intracranial pressure
	Doses and administration : Intravenous
									Induction of anaesthesia
									Adult: 100-150 mg of a 2.5 or 5% solution injected over 10-15 sec repeated every 30-60 sec according to response or as a continuous infusion of a 0.2 or 0.4% solution. Max: 500mg. Max in pregnancy: 250mg.
									Child: 2-7 mg/kg over 10-15 seconds; repeated after 1 minute if needed..
									
									Status epilepticus
									Adult: In conjunction with assisted ventilation: 75-125 mg as a 2.5% solution.
									Child: 5 mg/kg by slow IV inj followed by, neonates: continuous iv infusion of 2.5 mg/kg/hr; >1 month: 2-8 mg/kg/hr. Adjust infusion dose according to response.
									
									Reduction of raised intracranial pressure
									Adult: Intermittent bolus inj of 1.5-3.5 mg/kg, if adequate ventilation is provided.
									Child: 3 mth-15 yr: initial 5-10-mg/kg IV followed by a continuous IV infusion at 1-4 mg/kg/hr.
									Elderly: Dose reduction may be needed.
									Hepatic impairment: Dose reduction may be needed.
	Contara-indications : Thiopental Sodium for Injection is contraindicated in patients with severe respiratory embarrassment, hypersensitivity to barbiturates, status asthmaticus, variegate or acute intermittent porphyria, and inflammatory conditions of the mouth, jaw, and neck and in the absence of suitable veins for intravenous administration. Thiopental Sodium for Injection is also relatively contraindicated in severe cardiovascular disease, hypotension or shock, and conditions in which the hypnotic effect may be prolonged or potentiated, i.e. excessive premedication, Addison's disease, hepatic or renal dysfunction, myxedema, increased blood urea, severe anemia and myasthenia gravis.
	Side effects : Hypersensitivity reactions have been reported. Other adverse reactions to thiopental sodium include the followings: respiratory depression, myocardial depression, cardiac arrhythmias, prolonged somnolence and recovery, hypotension, tachycardia, sneezing, coughing, bronchospasm, laryngospasm and shivering. Anaphylactic reactions have been reported. Symptoms, e.g., urticaria, bronchospasm, vasodilation and edema.
	Precaution : A person competent in anesthesia management should be in constant attendance and adequate facilities for support of respiration and circulation should be available when Thiopental Sodium for injection is being used. Thiopental Sodium for Injection should be administered with caution to patients with preexisting hypotension or in conditions where the hypnotic effect may be prolonged or intensified, such as in the presence of liver disease and renal disease.
				
				Warnings
				This product may be habit forming. Keep resuscitative and endotracheal intubation equipment and oxygen readily available. Maintain patency of the airway at all times. Only persons qualified in the use of anesthetics should administer this drug. Avoid extravasations or intra-arterial injection.
	Pregnancy category : 3
	Mode of action : Thiopental sodium, a short-acting barbiturate anaesthetic, is a CNS depressant inducing hypnosis and anaesthesia but not analgesia. It has also been used in the control of refractory tonic-clonic status epilepticus and to reduce increased intracranial pressure in neurosurgical patients.
	Interaction : Possible increase in difficulty in producing anaesthesia in patients taking alcohol or CNS depressants. Additive action with other CNS depressants including sedatives, hypnotics, nitrous oxide or alcohol. Increased hypotension and excitatory effects with phenothiazine antipsychotics. Increased hypnotic effect with antipsychotic. Decreased requirement of thiopental sodium with metoclopramide, sulfisoxazole, aspirin, meprobamate, probenecid and other highly protein bound drugs.
				Potentially Fatal: Increased resp depression with opioids.
	Therapeutic class : General (Intravenous) anesthetics
	Packsize : 1's pack
Anet
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 100's pack
Anet
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 60ml bot
Anetol
	n : Atenolol
	Indications : Hypertension, Migraine, Arrhythmias, MI, Angina pectoris
	Doses and administration : Adult: PO HTN 25-100 mg/day. 
									Angina pectoris; Migraine prophylaxis 50-100 mg/day. Max for angina pectoris: 200 mg/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<15	  25 mg or 50 mg on alternate days.
									15-35	50 mg/day.
									Dialysis patients	25-50 mg after each dialysis.
	Contara-indications : Hypersensitivity. Sinus bradycardia, sinus node dysfunction, heart block >1st degree, compensated cardiac failure, cardiogenic shock, bronchospastic diseases, peripheral vascular diseases. Pregnancy.
	Side effects : Bronchospasm; cold extremities, fatigue, dizziness, insomnia, lethargy, confusion, headache, depression, nightmares, nausea, diarrhoea, constipation, impotence and paraesthesia.
									Potentially Fatal: Heart failure, 2nd or 3rd degree AV block.
	Precaution : Compensated heart failure. Variant angina, acute MI, DM; peripheral vascular disorders; hepatic and renal dysfunction; elderly patients, children. Lactation. If atenolol and clonidine are co-admin, then gradual withdrawal of clonidine should take place a few days after withdrawal of atenolol.
	Pregnancy category : 4
	Mode of action : Atenolol is a competitive cardioselective beta1-blocker and does not have effect on ?beta2-receptors except in high doses. It reduces resting and exercise-induced heart rate as well as myocardial contractility.
	Interaction : Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment.
				
	Therapeutic class : Beta-blockers
	Packsize : 100's pack
Anfasil
	n : Fluconazole
	Indications : Cryptococcal meningitis, Candidiasis, Tinea pedis, Tinea cruris, Tinea corporis, Vaginal candidiasis, Onychomycosis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Mucosal candidiasis, Candidal balanitis, Dermatophytosis
	Doses and administration : Adult: PO Superficial mucosal candidiasis 50 mg/day, up to 100 mg/day. Treatment duration: 7-30 days depending on condition. 
									Candidal balanitis; Vag candidiasis 150 mg as a single dose. 
									Dermatophytosis; Pityriasis versicolor; Cutaneous candidiasis 50 mg/day, for up to 6 wk. 
									Systemic candidiasis; Cryptococcal infections Initial: 400 mg, then 200-400 mg/day. Max: 800 mg/day in severe cases. 
									Prevention of relapse after a primary course of antifungal treatment for acute cryptococcal infections in AIDS patients 100-200 mg/day. 
									Prophylaxis of fungal infections in immunocompromised patients 50-400 mg/day.
									
									Child over 1 year - superficial candidal infections, 1-2 mg/kg daily; systemic candidiasis and cryptococcal infections (including meningitis) - 3-6 mg/kg daily (in serious life threatening infections up to 12 mg/kg daily has been given to children aged 5-13 years - max. 400 mg daily).
									
									Renal impairment: Haemodialysis patients: Usual dose given after each session.
									CrCl (ml/min)	
									<50  and not receiving dialysis	50% of the usual dose.
									>50	     Usual dose.
									
	Contara-indications : Hypersensitivity.
	Side effects : Nausea, abdominal pain, vomiting, diarrhoea, flatulence; elevated liver function values; headache; rash, exfoliative dermatitis. Rarely, angioedema, anaphylactic reactions and thrombocytopenia.
									Potentially Fatal: Hepatotoxicity; rarely anaphylaxis; Stevens-Johnson syndrome.
	Precaution : Renal or hepatic impairment. May prolong QT interval. Pregnancy, lactation.
	Pregnancy category : 4
	Mode of action : Fluconazole decreases ergosterol synthesis by interfering w/ cytochrome P450 activity, thus inhibiting cell membrane formation of susceptible fungi including B. dermatitidis, Candida spp., C. immitis, C. neoformans, Epidermophyton spp., H. capsulatum, Micosporum spp., Trichophyton spp.
	Interaction : May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).
				Potentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.
	Therapeutic class : Drugs for subcutaneous and systemic mycoses
	Packsize : 35ml bot
Anfasil
	n : Fluconazole
	Indications : Cryptococcal meningitis, Candidiasis, Tinea pedis, Tinea cruris, Tinea corporis, Vaginal candidiasis, Onychomycosis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Mucosal candidiasis, Candidal balanitis, Dermatophytosis
	Doses and administration : Adult: PO Superficial mucosal candidiasis 50 mg/day, up to 100 mg/day. Treatment duration: 7-30 days depending on condition. 
									Candidal balanitis; Vag candidiasis 150 mg as a single dose. 
									Dermatophytosis; Pityriasis versicolor; Cutaneous candidiasis 50 mg/day, for up to 6 wk. 
									Systemic candidiasis; Cryptococcal infections Initial: 400 mg, then 200-400 mg/day. Max: 800 mg/day in severe cases. 
									Prevention of relapse after a primary course of antifungal treatment for acute cryptococcal infections in AIDS patients 100-200 mg/day. 
									Prophylaxis of fungal infections in immunocompromised patients 50-400 mg/day.
									
									Child over 1 year - superficial candidal infections, 1-2 mg/kg daily; systemic candidiasis and cryptococcal infections (including meningitis) - 3-6 mg/kg daily (in serious life threatening infections up to 12 mg/kg daily has been given to children aged 5-13 years - max. 400 mg daily).
									
									Renal impairment: Haemodialysis patients: Usual dose given after each session.
									CrCl (ml/min)	
									<50  and not receiving dialysis	50% of the usual dose.
									>50	     Usual dose.
									
	Contara-indications : Hypersensitivity.
	Side effects : Nausea, abdominal pain, vomiting, diarrhoea, flatulence; elevated liver function values; headache; rash, exfoliative dermatitis. Rarely, angioedema, anaphylactic reactions and thrombocytopenia.
									Potentially Fatal: Hepatotoxicity; rarely anaphylaxis; Stevens-Johnson syndrome.
	Precaution : Renal or hepatic impairment. May prolong QT interval. Pregnancy, lactation.
	Pregnancy category : 4
	Mode of action : Fluconazole decreases ergosterol synthesis by interfering w/ cytochrome P450 activity, thus inhibiting cell membrane formation of susceptible fungi including B. dermatitidis, Candida spp., C. immitis, C. neoformans, Epidermophyton spp., H. capsulatum, Micosporum spp., Trichophyton spp.
	Interaction : May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).
				Potentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.
	Therapeutic class : Drugs for subcutaneous and systemic mycoses
	Packsize : 12's pack
Anfasil
	n : Fluconazole
	Indications : Cryptococcal meningitis, Candidiasis, Tinea pedis, Tinea cruris, Tinea corporis, Vaginal candidiasis, Onychomycosis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Mucosal candidiasis, Candidal balanitis, Dermatophytosis
	Doses and administration : Adult: PO Superficial mucosal candidiasis 50 mg/day, up to 100 mg/day. Treatment duration: 7-30 days depending on condition. 
									Candidal balanitis; Vag candidiasis 150 mg as a single dose. 
									Dermatophytosis; Pityriasis versicolor; Cutaneous candidiasis 50 mg/day, for up to 6 wk. 
									Systemic candidiasis; Cryptococcal infections Initial: 400 mg, then 200-400 mg/day. Max: 800 mg/day in severe cases. 
									Prevention of relapse after a primary course of antifungal treatment for acute cryptococcal infections in AIDS patients 100-200 mg/day. 
									Prophylaxis of fungal infections in immunocompromised patients 50-400 mg/day.
									
									Child over 1 year - superficial candidal infections, 1-2 mg/kg daily; systemic candidiasis and cryptococcal infections (including meningitis) - 3-6 mg/kg daily (in serious life threatening infections up to 12 mg/kg daily has been given to children aged 5-13 years - max. 400 mg daily).
									
									Renal impairment: Haemodialysis patients: Usual dose given after each session.
									CrCl (ml/min)	
									<50  and not receiving dialysis	50% of the usual dose.
									>50	     Usual dose.
									
	Contara-indications : Hypersensitivity.
	Side effects : Nausea, abdominal pain, vomiting, diarrhoea, flatulence; elevated liver function values; headache; rash, exfoliative dermatitis. Rarely, angioedema, anaphylactic reactions and thrombocytopenia.
									Potentially Fatal: Hepatotoxicity; rarely anaphylaxis; Stevens-Johnson syndrome.
	Precaution : Renal or hepatic impairment. May prolong QT interval. Pregnancy, lactation.
	Pregnancy category : 4
	Mode of action : Fluconazole decreases ergosterol synthesis by interfering w/ cytochrome P450 activity, thus inhibiting cell membrane formation of susceptible fungi including B. dermatitidis, Candida spp., C. immitis, C. neoformans, Epidermophyton spp., H. capsulatum, Micosporum spp., Trichophyton spp.
	Interaction : May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).
				Potentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.
	Therapeutic class : Drugs for subcutaneous and systemic mycoses
	Packsize : 30's pack
Anfenac
	n : Diclofenac Sodium 0.1% Eye prep
	Indications : Allergic conjunctivitis, Ocular inflammation, Miosis
	Doses and administration : Adults
									Pre-operatively: Instill 1 drop in the conjunctival sac up to 5 times over the 3 hours preceding surgery
									
									Post-operatively: Instill 1 drop in the conjunctival sac after 15, 30 & 45 minutes following surgery; then 3-5 times daily for as long as required.
									
									Inflammatory conditions: Instill 1 drop in the conjunctival sac 4-5 times daily depending upon the severity of the diseases.
	Contara-indications : Contraindicated to patients hypersensitive to Diclofenac Sodium or any other of its ingredients. Diclofenac sodium is also contraindicated in patients who may have NSAID induced asthma, urticaria, or acute rhinitis.
	Side effects : Mild to moderate burning sensation in 5-15% patients which is transient in nature and almost never necessitated discontinuation of treatment. Other less common side-effects are sensitivity to light, bad taste, feeling of pressure, allergic reactions etc. 
	Precaution : Diclofenac eye drops may mask the signs of infection. So physicians should be alert to the development of infections in patients receiving the drug. During prolonged use, it is recommended that physicians conduct periodic examinations of the eye, including measurement of the intraocular pressure. Contact lenses should not be worn during treatment.
	Pregnancy category : 3
	Mode of action : Inhibits cyclooxygenase (COX)-1 and COX-2, thereby inhibiting prostaglandin synthesis.May also inhibit neutrophil aggregation/activation, inhibit chemotaxis, decrease proinflammatory cytokine level, and alter lymphocyte activity.
	Interaction : May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5  ml drop
Anflu
	n : Fluphenazine Hydrochloride + Nortriptyline
	Indications : Headache, Depression, Anxiety, Emotional disturbance, Tension, Fatigue, Sleep disorder, Bodyache, Gastric problems
	Doses and administration : Adult: 1 tablet 2 to 3 times daily.
									Child: Not recommended.
	Contara-indications : Patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. The presence of blood dyscrasia or liver damage precludes the use of fluphenazine hydrochloride. Fluphenazine hydrochloride is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross sensitivity to phenothiazine derivatives may occur.
	Side effects : Dryness of mouth, drowsiness, constipation, tachycardia, nasal congestion, blurred vision and excitement.
	Precaution : Patients with glaucoma, prostate enlargement, cardiac failure and myocardial infarction. The drug may impair alertness and abilities to drive a car or operating machinery.
				
				Because of the possibility of cross-sensitivity, fluphenazine hydrochloride should be used cautiously in patients who have developed cholestatic jaundice, dermatoses or other allergic reactions to phenothiazine derivatives.
				
				Psychotic patients on large doses of a phenothiazine drug who are undergoing surgery should be watched carefully for possible hypotensive phenomena. Moreover, it should be remembered that reduced amounts of anesthetics or central nervous system depressants may be necessary.
				
				The effects of atropine may be potentiated in some patients receiving fluphenazine because of added anticholinergic effects.
	Pregnancy category : 3
	Mode of action : Fluphenazine blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system and decreases the release of hypothalamic and hypophyseal hormones. It reduces aggressiveness with disappearance of hallucinations and delusions.
									
									Nortriptyline, a dibenzocycloheptadiene tricyclic antidepressant, is the primary active metabolite of amitriptyline. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics.
				Potentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 100's pack
Anfree
	n : Flupenthixol + Melitracen
	Indications : Depression, Anxiety, Apathy, Dysphoria
	Doses and administration : Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets.
									Elderly: 1 tablet in the morning.
									Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
	Contara-indications : The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
	Side effects : In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
	Precaution : If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.
	Pregnancy category : 3
	Mode of action : Flupentixol is a thioxanthene antipsychotic that inhibits dopamine-mediated effects by blocking postsynaptic dopamine receptors in the CNS.
									Melitracen is a TCA with anxiolytic properties.
	Interaction :  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).
				Potentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.
				 	Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 100's pack
Angenta
	n : Flupenthixol + Melitracen
	Indications : Depression, Anxiety, Apathy, Dysphoria
	Doses and administration : Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets.
									Elderly: 1 tablet in the morning.
									Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
	Contara-indications : The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
	Side effects : In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
	Precaution : If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.
	Pregnancy category : 3
	Mode of action : Flupentixol is a thioxanthene antipsychotic that inhibits dopamine-mediated effects by blocking postsynaptic dopamine receptors in the CNS.
									Melitracen is a TCA with anxiolytic properties.
	Interaction :  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).
				Potentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.
				 	Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 100's pack
Angesic
	n : Ketorolac Tromethamine
	Indications : Moderate to severe pain
	Doses and administration : Oral
									Moderate to severe pain
									Adult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.
									Elderly: 10 mg every 6-8 hr. Max duration: 7 days.
									Parenteral
									Moderate to severe pain
									Adult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.
									Elderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.
									
									Pediatric Patients (2 to 16 years of age):
									IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
									IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
									
	Contara-indications : Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.
	Side effects : GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).
									Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.
	Precaution : Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.
	Pregnancy category : 4
	Mode of action : Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.
	Interaction : May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.
				Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 30's pack
Angical 25
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Angical 50
	n : Amlodipine  +  Atenolol
	Indications : Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.
	Doses and administration : Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.
	Contara-indications : Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.
	Side effects : Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.
	Precaution : Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.
	Pregnancy category : 17
	Mode of action : Atenolol is a cardioselective beta blocker. Amlodipine is a dihydropyridine calcium-channel blocker that blocks the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Combination of the two drugs results in additive antihypertensive action.
	Interaction : Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Angicard
	n : Glyceryl Trinitrate (nitroglycerine)
	Indications : Angina pectoris, Acute myocardial infarction, Severe hypertension, Pulmonary edema.
	Doses and administration : Usual dosage for adults and elderly patients:  PO: 1 capsule/tablet: 2 times a day before meal (e.g. at 8 AM & 2 PM, with a daily nitrate-free interval of 10-12 hours). If necessary the dosage may be raised gradually to 2 or 3 capsules/tablets: 2 times daily. But dosage should be individualized depending on the Nitroglycerin sensitivity of the patient, the severity of illness and the occurrence of side-effects. Use in Children: Not recommended for children. Spray: In case of attack 1 or 2 doses should be administered under the tongue to a sitting patient. If necessary, more doses can be given but not more than 3 doses within 15 minutes.  For prevention 1 dose should be applied 5-10 minutes before physical exercise.         Use in Children: Nitroglycerin Spray is not recommended for children.
	Contara-indications : Hypersensitivity. Severe hypotension, heart failure, marked anaemia, hypertrophic obstructive cardiomyopathy, cerebral haemorrhage or head trauma, low cardiac output secondary to hypovolaemia, inferior MI with right ventricular involvement, raised intracranial pressure. Concomitant use with phosphodiesterase type-5 inhibitors.
	Side effects :  Headache, facial flashing, dizziness, nausea, vomiting, sweating, palpitation, sensation of heat, postural hypotension and reflex tachycardia. Large doses can cause vomiting, restlessness, hypotension, syncope, rarely cyanosis and methaemoglobinaemia, impaired respiration, bradycardia. Sublingual Tabs/Spray: Dry mouth, localised burning sensation. Buccal tablets: Delayed dissolution, may be swallowed by mistake. Potentially Fatal: Hypotension, paradoxical bradycardia, impaired respiration, syncope and collapse.
	Precaution : Severe hepatic or renal impairment, hypothyroidism, malnutrition, hypothermia. Cerebrovascular disease, lung disease or cor pulmonale. Pregnancy, lactation, glaucoma, mitral valve prolapse, cardiac tamponade, syncope. Gradual withdrawal in patients who have received prolonged high dose infusions. Avoid prolonged excessive hypotension. Nitrate-free interval is recommended in patients on continuous treatment with nitrates to reduce risk of tolerance.
	Pregnancy category : 3
	Mode of action : Glyceryl trinitrate acts on the enzyme nitric oxide stimulating guanylate cyclase in the vascular smooth muscle cells resulting in the relaxation of smooth muscles. It reduces venous return (preload) and facilitates subendocardial blood flow with redistribution into ischaemic areas. It relieves coronary vasospasm and dilates arterioles reducing afterload. It is useful for relief and prevention of anginal attacks.
	Interaction : Enhances bioavailability of dihydroergotamine. Glyceryl trinitrate infusion may prolong pancuronium-induced neuromuscular blockade. May reduce the efficacy of heparin, alteplase and noradrenaline when used together. Efficacy of buccal and sublingual preparations may be reduced by drugs that can cause dry mouth due to decreased dissolution. Aspirin and other NSAIDs may reduce the therapeutic response to glyceryl trinitrate.
				Potentially Fatal: Orthostatic hypotension may be produced by combined use of calcium channel blockers, antihypertensives, phenothiazines and TCAs. Alcohol may cause severe hypotension and collapse.
	Therapeutic class : Nitrates: Coronary vasodilators
	Packsize : 100's pack
Angifix
	n : Isosorbide Mononitrate
	Indications : Heart failure,  Angina pectoris
	Doses and administration : Adult: PO 20 mg 2-3 times/day. Usual range: 20-120 mg/day.
									As LA form: One capsule once daily.
	Contara-indications : Severe hypotension or anaemia, hypovolaemia, heart failure due to obstruction, or raised intracranial pressure due to head trauma or cerebral haemorrhage.
	Side effects : Hypotension, tachycardia, flushing, headache, dizziness, palpitation, syncope, confusion. Nausea, vomiting, abdominal pain. Restlessness, weakness and vertigo. Dry mouth, chest pain, back pain, oedema, fatigue, abdominal pain, constipation, diarrhoea, dyspepsia and flatulence.
									Potentially Fatal: Severe hypotension and cardiac failure.
	Precaution : Severe renal or severe hepatic impairment, hypothyroidism, malnutrition, or hypothermia. Caution in patients who are already hypotensive. May aggravate angina caused by hypertrophic cardiomyopathy. Tolerance may develop after long-term treatment. Lactation.
	Pregnancy category : 3
	Mode of action : Isosorbide mononitrate relaxes vascular smooth muscles by stimulating cyclic-GMP. It decreases left ventricular pressure (preload) and arterial resistance (afterload).
	Interaction : Hypotensive effects may be increased when used with alcohol or vasodilators. Concurrent use with calcium channel blockers may lead to marked orthostatic hypotension.
				Potentially Fatal: Significant hypotension may occur when used with phosphodiesterase-5 inhibitors.
	Therapeutic class : Nitrates: Coronary vasodilators
	Packsize : 50's pack
Angilat
	n : Metoprolol Tartrate
	Indications : Heart failure, Migraine, Acute MI, Diabetic nephropathy, Hypertension, Cardiac arrhythmias, Angina pectoris
	Doses and administration : Hypertension: initially 100mg daily, maintenance 100-200mg daily in 1-2 divided doses
									Angina Pectoris: 50-100mg 2-3 times daily.
									Myocardial Infarction: After early intravenous treatment for 48 hours, patients should receive a maintenance dose of 100mg twice daily.
									Arrhythmias: usually 50mg 2-3 times daily; up to 300mg daily in divided doses if necessary.
									Hyperthyroidism: (adjunct), 50mg 4 times daily
									Migraine Prophylaxis: 100-200mg daily in divided doses.
	Contara-indications : Hypertension and Angina: Metoprolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure.
									
									Myocardial Infarction: Metoprolol is contraindicated in patients with a heart rate<45 beats/min; second and third-degree heart block; significant first-degree heart block; systolic blood pressure <100 mmHg; or moderate-to-severe cardiac failure.
	Side effects : Bradycardia, Heart failure, hypotension, Conduction disorder, Bronchospasm, Peripheral vasoconstriction, Gastrointestinal disturbances, Fatigue, Sleep disturbance, Rare reports of rashes and dry eyes, Sexual dysfunction, and Exacerbation of psoriasis.
	Precaution : Gereral: Metoprolol should be used with caution in patients with impaired hepatic function.
				Information for Patients: Patients should be advised to take Metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose missed, the patient should take only the next scheduled dose (without doubling it). Patient should not discontinue Metoprolol without consulting the physician. Patients should be advised to
				avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the
				patient's response to therapy with Metoprolol has been determined.
				contact the physician if any difficulty in breathing occurs.
				inform the physician or dentist before any type of surgery that he or she is taking Metoprolol.
	Pregnancy category : 4
	Mode of action : Metoprolol selectively inhibits ?1-adrenergic receptors but has little or no effect on ?2-receptors except in high doses. It does not exhibit membrane stabilising or intrinsic sympathomimetic activity.
	Interaction : Additive effect w/ catecholamine-depleting drugs (e.g. reserpine) and MAOIs. May antagonise ?1-adrenergic stimulating effects of sympathomimetics. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. Paradoxical response to epinephrine may occur. Increased plasma concentrations w/ CYP2D6 inhibitors (e.g. bupropion, cimetidine). Increased risk of hypotension and heart failure w/ myocardial depressant general anaesth (e.g. diethyl ether). Risk of pulmonary HTN w/ vasodilators (e.g. hydralazine) in uraemic patients. Reduced plasma levels w/ rifampicin. May increase negative inotropic and negative dromotropic effect of antiarrhythmic drugs (e.g. quinidine, amiodarone). May reduce antihypertensive efficacy w/ indometacin. May increase effects of hypoglycaemics.
	Therapeutic class : Beta-blockers
	Packsize : 5 mg (ml) amp X 5's pack
Angilat
	n : Metoprolol Tartrate
	Indications : Heart failure, Migraine, Acute MI, Diabetic nephropathy, Hypertension, Cardiac arrhythmias, Angina pectoris
	Doses and administration : Hypertension: initially 100mg daily, maintenance 100-200mg daily in 1-2 divided doses
									Angina Pectoris: 50-100mg 2-3 times daily.
									Myocardial Infarction: After early intravenous treatment for 48 hours, patients should receive a maintenance dose of 100mg twice daily.
									Arrhythmias: usually 50mg 2-3 times daily; up to 300mg daily in divided doses if necessary.
									Hyperthyroidism: (adjunct), 50mg 4 times daily
									Migraine Prophylaxis: 100-200mg daily in divided doses.
	Contara-indications : Hypertension and Angina: Metoprolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure.
									
									Myocardial Infarction: Metoprolol is contraindicated in patients with a heart rate<45 beats/min; second and third-degree heart block; significant first-degree heart block; systolic blood pressure <100 mmHg; or moderate-to-severe cardiac failure.
	Side effects : Bradycardia, Heart failure, hypotension, Conduction disorder, Bronchospasm, Peripheral vasoconstriction, Gastrointestinal disturbances, Fatigue, Sleep disturbance, Rare reports of rashes and dry eyes, Sexual dysfunction, and Exacerbation of psoriasis.
	Precaution : Gereral: Metoprolol should be used with caution in patients with impaired hepatic function.
				Information for Patients: Patients should be advised to take Metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose missed, the patient should take only the next scheduled dose (without doubling it). Patient should not discontinue Metoprolol without consulting the physician. Patients should be advised to
				avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the
				patient's response to therapy with Metoprolol has been determined.
				contact the physician if any difficulty in breathing occurs.
				inform the physician or dentist before any type of surgery that he or she is taking Metoprolol.
	Pregnancy category : 4
	Mode of action : Metoprolol selectively inhibits ?1-adrenergic receptors but has little or no effect on ?2-receptors except in high doses. It does not exhibit membrane stabilising or intrinsic sympathomimetic activity.
	Interaction : Additive effect w/ catecholamine-depleting drugs (e.g. reserpine) and MAOIs. May antagonise ?1-adrenergic stimulating effects of sympathomimetics. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. Paradoxical response to epinephrine may occur. Increased plasma concentrations w/ CYP2D6 inhibitors (e.g. bupropion, cimetidine). Increased risk of hypotension and heart failure w/ myocardial depressant general anaesth (e.g. diethyl ether). Risk of pulmonary HTN w/ vasodilators (e.g. hydralazine) in uraemic patients. Reduced plasma levels w/ rifampicin. May increase negative inotropic and negative dromotropic effect of antiarrhythmic drugs (e.g. quinidine, amiodarone). May reduce antihypertensive efficacy w/ indometacin. May increase effects of hypoglycaemics.
	Therapeutic class : Beta-blockers
	Packsize : 100's pack
Angilat
	n : Metoprolol Tartrate
	Indications : Heart failure, Migraine, Acute MI, Diabetic nephropathy, Hypertension, Cardiac arrhythmias, Angina pectoris
	Doses and administration : Hypertension: initially 100mg daily, maintenance 100-200mg daily in 1-2 divided doses
									Angina Pectoris: 50-100mg 2-3 times daily.
									Myocardial Infarction: After early intravenous treatment for 48 hours, patients should receive a maintenance dose of 100mg twice daily.
									Arrhythmias: usually 50mg 2-3 times daily; up to 300mg daily in divided doses if necessary.
									Hyperthyroidism: (adjunct), 50mg 4 times daily
									Migraine Prophylaxis: 100-200mg daily in divided doses.
	Contara-indications : Hypertension and Angina: Metoprolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure.
									
									Myocardial Infarction: Metoprolol is contraindicated in patients with a heart rate<45 beats/min; second and third-degree heart block; significant first-degree heart block; systolic blood pressure <100 mmHg; or moderate-to-severe cardiac failure.
	Side effects : Bradycardia, Heart failure, hypotension, Conduction disorder, Bronchospasm, Peripheral vasoconstriction, Gastrointestinal disturbances, Fatigue, Sleep disturbance, Rare reports of rashes and dry eyes, Sexual dysfunction, and Exacerbation of psoriasis.
	Precaution : Gereral: Metoprolol should be used with caution in patients with impaired hepatic function.
				Information for Patients: Patients should be advised to take Metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose missed, the patient should take only the next scheduled dose (without doubling it). Patient should not discontinue Metoprolol without consulting the physician. Patients should be advised to
				avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the
				patient's response to therapy with Metoprolol has been determined.
				contact the physician if any difficulty in breathing occurs.
				inform the physician or dentist before any type of surgery that he or she is taking Metoprolol.
	Pregnancy category : 4
	Mode of action : Metoprolol selectively inhibits ?1-adrenergic receptors but has little or no effect on ?2-receptors except in high doses. It does not exhibit membrane stabilising or intrinsic sympathomimetic activity.
	Interaction : Additive effect w/ catecholamine-depleting drugs (e.g. reserpine) and MAOIs. May antagonise ?1-adrenergic stimulating effects of sympathomimetics. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. Paradoxical response to epinephrine may occur. Increased plasma concentrations w/ CYP2D6 inhibitors (e.g. bupropion, cimetidine). Increased risk of hypotension and heart failure w/ myocardial depressant general anaesth (e.g. diethyl ether). Risk of pulmonary HTN w/ vasodilators (e.g. hydralazine) in uraemic patients. Reduced plasma levels w/ rifampicin. May increase negative inotropic and negative dromotropic effect of antiarrhythmic drugs (e.g. quinidine, amiodarone). May reduce antihypertensive efficacy w/ indometacin. May increase effects of hypoglycaemics.
	Therapeutic class : Beta-blockers
	Packsize : 100's pack
Angilock
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Angilock PLUS 100/12.5
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Angilock
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 50's pack
Angilock 25/100
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Angilock
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 50's pack
Angilock PLUS 100/25
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Angimet
	n : Trimetazidine Dihydrochloride
	Indications : Ischaemic heart disease, Angina pectoris; Meniere's disease, Coronary heart disease
	Doses and administration : One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.
									
									One 35 mg MR tablet twice daily at mealtimes in the morning and evening.
	Contara-indications : Hypersensitivity to Trimetazidine Dihydrochloride.
	Side effects : (Trimetazidine) is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.
	Precaution : Although teratological studies have not shown any drug related adverse effects on the course and outcome of pregnancy, the use  in pregnant women is not recommended.It is not known whetherTrimetazidine passes into breast milk or not. This medication should be used while breast feeding only if the potential benefits outweigh risks to the nursing infants.
	Pregnancy category : 0
	Mode of action : Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance.
	Interaction : MAOIs, nifedipine. May potentiate the effects of other antianginals.
	Therapeutic class : Other Anti-anginal & Anti-ischaemic drugs
	Packsize : 50's pack
Angimet MR
	n : Trimetazidine Dihydrochloride
	Indications : Ischaemic heart disease, Angina pectoris; Meniere's disease, Coronary heart disease
	Doses and administration : One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.
									
									One 35 mg MR tablet twice daily at mealtimes in the morning and evening.
	Contara-indications : Hypersensitivity to Trimetazidine Dihydrochloride.
	Side effects : (Trimetazidine) is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.
	Precaution : Although teratological studies have not shown any drug related adverse effects on the course and outcome of pregnancy, the use  in pregnant women is not recommended.It is not known whetherTrimetazidine passes into breast milk or not. This medication should be used while breast feeding only if the potential benefits outweigh risks to the nursing infants.
	Pregnancy category : 0
	Mode of action : Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance.
	Interaction : MAOIs, nifedipine. May potentiate the effects of other antianginals.
	Therapeutic class : Other Anti-anginal & Anti-ischaemic drugs
	Packsize : 30's pack
Angimil
	n : Verapamil Hydrochloride
	Indications : Essential hypertension, Angina pectoris and prevention of re-infarction, Supraventricular arrhythmias. Paroxysmal supraventricular tachycardias, Atrial fibrillation with rapid ventricular response (except WPWS) , Atrial flutter with rapid conduction,  Extrasystoles, Acute hypertension, Acute coronary insufficiency, For the prophylaxis and / or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia respectively.
	Doses and administration : Oral: The dose of Verapamil should be individualized by titration and the drug should be administered with food.
									
									For essential hypertension the initial dose should be given 180 mg in the morning. If adequate response is not obtained with 180 mg of Verapamil then the dose may be titrated by following manner:
									240 mg each morning.
									180 mg each morning plus 180 mg each evening.
									240 mg every 12 hourly.
									
									For angina the usual dose is 80 mg to 120 mg three times a day.
									
									For arrythmias in digitalized patients, Verapamil should be given 240 mg to 360 mg in divided doses, depending on the severity of the condition. Divided doses up to 180 mg/day may occasionally be needed.
									
									Intravenous: Adults: 5mg slowly intravenously, in tachycardias and hypertensive crises, if necessary repeat after 5 to 10 minutes. 
									
									Drip infusion to maintain the therapeutic effect: 5-10 mg/hour in physiological saline, glucose, laevulose or similar solutions, on average up to a total dose of 100mg/day.   
									
									Children: Newborn 0.75-1mg (= 0.3-0.4ml) 
									Infants 0.75-2mg (= 0.3-0.8ml) 
									Children age 1-5 years: 2-3mg (= 0.8-1.2ml) 
									age 6-14 years: 2.5-5mg (= 1-2ml) of Verapamil, given intravenously, depending on age and action. 
									
									The injection should be made slowly under electrocardiographic control and only until onset of the effect. 
									
									Intravenous infusion in hypertensive crises: initially 0.05-0.1mg/kg/hour; if the effect proves to be insufficient, the dose is increased at 30-60 minute intervals until twice the dose or more is reached. Average total dose up to 1.5mg/kg/day.
	Contara-indications : Severe left ventricular dysfunction, hypotension or cardiogenic shockSick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker)Second or third-degree atrioventricular (AV) block (except in patients with a functioning artificial pacemaker)Patients with atrial flutter or atrial fibrillation and an accessory by pass tract(eg. Wolff-Parkinson-White, Lown-Ganong-Levine syndrome)Patients with known hypersensitivity to verapamil hydrochlorideVerapamil injection should not be administered intravenously to patients on beta-blockers (except in an intensive care setting) and known hypersensitivity to Verapamil hydrochloride.
	Side effects : Verapamil is generally well tolerated. The following reaction to orally administered Verapamil appeared clearly drug related or occurred at rates greater than 1% in clinical trials with approximately 5000 patients.Digestive system: Constipation, nausea;Cardiovascular system: Hypotension, edema, CHF, pulmonary edema, bradycardia, AV block;Respiratory system: Upper respiratory tract infections;Nervous system: Dizziness, headache, fatigue;Skin: Rash, flashing;Hepatic: Elevated liver enzyme.
	Precaution : Care should be taken in 1st degree AV block, bradycardia <50 beats/minutes, hypotension <90 mm Hg systolic pressure, atrial fibrillation/flutter and simultaneous pre-excitation syndrome e.g. WPW syndrome, heart failure (previous compensation with cardiac glycosides/diuretics required).Verapamil may impair ability to drive or operate machinery, particularly in the initial stages of treatment and with concomitant consumption of alcohol. 
				
				Verapamil markedly slows down the elimination of alcohol and prolongs the duration of the effects of alcohol.Verapamil should be given as a slow intravenous injection over at least 2 minutes under continuous ECG and blood pressure monitoring. Intravenous injection should only be given by the physician.In atrial fibrillation and simultaneous WPW syndrome there is a risk of inducing ventricular fibrillation
	Pregnancy category : 3
	Mode of action : Verapamil inhibits entry of calcium ions into arterial smooth muscle cells as well as the myocytes and conducting tissue. These actions lead to reversal and preventions of coronary artery spasm, reduction in afterload through peripheral vasodilatation and reduction in ventricular rate in patients with chronic atrial flutter or fibrillation and reduction in the occurrence of paroxysmal supraventricular tachycardia. Verapamil reduces BP, relieves angina and slows AV conduction.
	Interaction : Increased cardiac depressant effects with ?-blockers and flecainide. Increased risk of additive bradycardia, conduction disturbances and digoxin toxicity with digoxin. Increased risk of bradycardia and hypotension with remifentanil and sufentanil. Increased levels of both everolimus and verapamil on concurrent use. May increase doxorubicin, buspirone, carbamazepine, ciclosporin, epirubicin, eplerenone, quinidine, statins, sirolimus, tacrolimus, quinupristin/dalfopristin levels. Verapamil increase blood alcohol levels. Unpredictable interactions with lithium. Decreased verapamil concentrations with phenobarbital, sulfinpyrazone, rifampicin, rifabutin and rifapentine. Increased verapamil concentrations with protease inhibitors and cimetidine.
				
				Potentially Fatal: Increased cardiac depressant effects with amiodarone. Increased risk of QT prolongation with dofetilide, ranolazine, sertindole. Additive bradycardia with ivabradine. Increased risk of heart block with clonidine. Increased risk of acute hyperkalaemia and CV collapse with dantrolene.
	Therapeutic class : Calcium-channel blockers
	Packsize : 100's pack
Angimil
	n : Verapamil Hydrochloride
	Indications : Essential hypertension, Angina pectoris and prevention of re-infarction, Supraventricular arrhythmias. Paroxysmal supraventricular tachycardias, Atrial fibrillation with rapid ventricular response (except WPWS) , Atrial flutter with rapid conduction,  Extrasystoles, Acute hypertension, Acute coronary insufficiency, For the prophylaxis and / or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia respectively.
	Doses and administration : Oral: The dose of Verapamil should be individualized by titration and the drug should be administered with food.
									
									For essential hypertension the initial dose should be given 180 mg in the morning. If adequate response is not obtained with 180 mg of Verapamil then the dose may be titrated by following manner:
									240 mg each morning.
									180 mg each morning plus 180 mg each evening.
									240 mg every 12 hourly.
									
									For angina the usual dose is 80 mg to 120 mg three times a day.
									
									For arrythmias in digitalized patients, Verapamil should be given 240 mg to 360 mg in divided doses, depending on the severity of the condition. Divided doses up to 180 mg/day may occasionally be needed.
									
									Intravenous: Adults: 5mg slowly intravenously, in tachycardias and hypertensive crises, if necessary repeat after 5 to 10 minutes. 
									
									Drip infusion to maintain the therapeutic effect: 5-10 mg/hour in physiological saline, glucose, laevulose or similar solutions, on average up to a total dose of 100mg/day.   
									
									Children: Newborn 0.75-1mg (= 0.3-0.4ml) 
									Infants 0.75-2mg (= 0.3-0.8ml) 
									Children age 1-5 years: 2-3mg (= 0.8-1.2ml) 
									age 6-14 years: 2.5-5mg (= 1-2ml) of Verapamil, given intravenously, depending on age and action. 
									
									The injection should be made slowly under electrocardiographic control and only until onset of the effect. 
									
									Intravenous infusion in hypertensive crises: initially 0.05-0.1mg/kg/hour; if the effect proves to be insufficient, the dose is increased at 30-60 minute intervals until twice the dose or more is reached. Average total dose up to 1.5mg/kg/day.
	Contara-indications : Severe left ventricular dysfunction, hypotension or cardiogenic shockSick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker)Second or third-degree atrioventricular (AV) block (except in patients with a functioning artificial pacemaker)Patients with atrial flutter or atrial fibrillation and an accessory by pass tract(eg. Wolff-Parkinson-White, Lown-Ganong-Levine syndrome)Patients with known hypersensitivity to verapamil hydrochlorideVerapamil injection should not be administered intravenously to patients on beta-blockers (except in an intensive care setting) and known hypersensitivity to Verapamil hydrochloride.
	Side effects : Verapamil is generally well tolerated. The following reaction to orally administered Verapamil appeared clearly drug related or occurred at rates greater than 1% in clinical trials with approximately 5000 patients.Digestive system: Constipation, nausea;Cardiovascular system: Hypotension, edema, CHF, pulmonary edema, bradycardia, AV block;Respiratory system: Upper respiratory tract infections;Nervous system: Dizziness, headache, fatigue;Skin: Rash, flashing;Hepatic: Elevated liver enzyme.
	Precaution : Care should be taken in 1st degree AV block, bradycardia <50 beats/minutes, hypotension <90 mm Hg systolic pressure, atrial fibrillation/flutter and simultaneous pre-excitation syndrome e.g. WPW syndrome, heart failure (previous compensation with cardiac glycosides/diuretics required).Verapamil may impair ability to drive or operate machinery, particularly in the initial stages of treatment and with concomitant consumption of alcohol. 
				
				Verapamil markedly slows down the elimination of alcohol and prolongs the duration of the effects of alcohol.Verapamil should be given as a slow intravenous injection over at least 2 minutes under continuous ECG and blood pressure monitoring. Intravenous injection should only be given by the physician.In atrial fibrillation and simultaneous WPW syndrome there is a risk of inducing ventricular fibrillation
	Pregnancy category : 3
	Mode of action : Verapamil inhibits entry of calcium ions into arterial smooth muscle cells as well as the myocytes and conducting tissue. These actions lead to reversal and preventions of coronary artery spasm, reduction in afterload through peripheral vasodilatation and reduction in ventricular rate in patients with chronic atrial flutter or fibrillation and reduction in the occurrence of paroxysmal supraventricular tachycardia. Verapamil reduces BP, relieves angina and slows AV conduction.
	Interaction : Increased cardiac depressant effects with ?-blockers and flecainide. Increased risk of additive bradycardia, conduction disturbances and digoxin toxicity with digoxin. Increased risk of bradycardia and hypotension with remifentanil and sufentanil. Increased levels of both everolimus and verapamil on concurrent use. May increase doxorubicin, buspirone, carbamazepine, ciclosporin, epirubicin, eplerenone, quinidine, statins, sirolimus, tacrolimus, quinupristin/dalfopristin levels. Verapamil increase blood alcohol levels. Unpredictable interactions with lithium. Decreased verapamil concentrations with phenobarbital, sulfinpyrazone, rifampicin, rifabutin and rifapentine. Increased verapamil concentrations with protease inhibitors and cimetidine.
				
				Potentially Fatal: Increased cardiac depressant effects with amiodarone. Increased risk of QT prolongation with dofetilide, ranolazine, sertindole. Additive bradycardia with ivabradine. Increased risk of heart block with clonidine. Increased risk of acute hyperkalaemia and CV collapse with dantrolene.
	Therapeutic class : Calcium-channel blockers
	Packsize : 100's pack
Angimil SR
	n : Verapamil Hydrochloride
	Indications : Essential hypertension, Angina pectoris and prevention of re-infarction, Supraventricular arrhythmias. Paroxysmal supraventricular tachycardias, Atrial fibrillation with rapid ventricular response (except WPWS) , Atrial flutter with rapid conduction,  Extrasystoles, Acute hypertension, Acute coronary insufficiency, For the prophylaxis and / or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia respectively.
	Doses and administration : Oral: The dose of Verapamil should be individualized by titration and the drug should be administered with food.
									
									For essential hypertension the initial dose should be given 180 mg in the morning. If adequate response is not obtained with 180 mg of Verapamil then the dose may be titrated by following manner:
									240 mg each morning.
									180 mg each morning plus 180 mg each evening.
									240 mg every 12 hourly.
									
									For angina the usual dose is 80 mg to 120 mg three times a day.
									
									For arrythmias in digitalized patients, Verapamil should be given 240 mg to 360 mg in divided doses, depending on the severity of the condition. Divided doses up to 180 mg/day may occasionally be needed.
									
									Intravenous: Adults: 5mg slowly intravenously, in tachycardias and hypertensive crises, if necessary repeat after 5 to 10 minutes. 
									
									Drip infusion to maintain the therapeutic effect: 5-10 mg/hour in physiological saline, glucose, laevulose or similar solutions, on average up to a total dose of 100mg/day.   
									
									Children: Newborn 0.75-1mg (= 0.3-0.4ml) 
									Infants 0.75-2mg (= 0.3-0.8ml) 
									Children age 1-5 years: 2-3mg (= 0.8-1.2ml) 
									age 6-14 years: 2.5-5mg (= 1-2ml) of Verapamil, given intravenously, depending on age and action. 
									
									The injection should be made slowly under electrocardiographic control and only until onset of the effect. 
									
									Intravenous infusion in hypertensive crises: initially 0.05-0.1mg/kg/hour; if the effect proves to be insufficient, the dose is increased at 30-60 minute intervals until twice the dose or more is reached. Average total dose up to 1.5mg/kg/day.
	Contara-indications : Severe left ventricular dysfunction, hypotension or cardiogenic shockSick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker)Second or third-degree atrioventricular (AV) block (except in patients with a functioning artificial pacemaker)Patients with atrial flutter or atrial fibrillation and an accessory by pass tract(eg. Wolff-Parkinson-White, Lown-Ganong-Levine syndrome)Patients with known hypersensitivity to verapamil hydrochlorideVerapamil injection should not be administered intravenously to patients on beta-blockers (except in an intensive care setting) and known hypersensitivity to Verapamil hydrochloride.
	Side effects : Verapamil is generally well tolerated. The following reaction to orally administered Verapamil appeared clearly drug related or occurred at rates greater than 1% in clinical trials with approximately 5000 patients.Digestive system: Constipation, nausea;Cardiovascular system: Hypotension, edema, CHF, pulmonary edema, bradycardia, AV block;Respiratory system: Upper respiratory tract infections;Nervous system: Dizziness, headache, fatigue;Skin: Rash, flashing;Hepatic: Elevated liver enzyme.
	Precaution : Care should be taken in 1st degree AV block, bradycardia <50 beats/minutes, hypotension <90 mm Hg systolic pressure, atrial fibrillation/flutter and simultaneous pre-excitation syndrome e.g. WPW syndrome, heart failure (previous compensation with cardiac glycosides/diuretics required).Verapamil may impair ability to drive or operate machinery, particularly in the initial stages of treatment and with concomitant consumption of alcohol. 
				
				Verapamil markedly slows down the elimination of alcohol and prolongs the duration of the effects of alcohol.Verapamil should be given as a slow intravenous injection over at least 2 minutes under continuous ECG and blood pressure monitoring. Intravenous injection should only be given by the physician.In atrial fibrillation and simultaneous WPW syndrome there is a risk of inducing ventricular fibrillation
	Pregnancy category : 3
	Mode of action : Verapamil inhibits entry of calcium ions into arterial smooth muscle cells as well as the myocytes and conducting tissue. These actions lead to reversal and preventions of coronary artery spasm, reduction in afterload through peripheral vasodilatation and reduction in ventricular rate in patients with chronic atrial flutter or fibrillation and reduction in the occurrence of paroxysmal supraventricular tachycardia. Verapamil reduces BP, relieves angina and slows AV conduction.
	Interaction : Increased cardiac depressant effects with ?-blockers and flecainide. Increased risk of additive bradycardia, conduction disturbances and digoxin toxicity with digoxin. Increased risk of bradycardia and hypotension with remifentanil and sufentanil. Increased levels of both everolimus and verapamil on concurrent use. May increase doxorubicin, buspirone, carbamazepine, ciclosporin, epirubicin, eplerenone, quinidine, statins, sirolimus, tacrolimus, quinupristin/dalfopristin levels. Verapamil increase blood alcohol levels. Unpredictable interactions with lithium. Decreased verapamil concentrations with phenobarbital, sulfinpyrazone, rifampicin, rifabutin and rifapentine. Increased verapamil concentrations with protease inhibitors and cimetidine.
				
				Potentially Fatal: Increased cardiac depressant effects with amiodarone. Increased risk of QT prolongation with dofetilide, ranolazine, sertindole. Additive bradycardia with ivabradine. Increased risk of heart block with clonidine. Increased risk of acute hyperkalaemia and CV collapse with dantrolene.
	Therapeutic class : Calcium-channel blockers
	Packsize : 15's pack
Angin
	n : Aspirin
	Indications : Fever, Headache, Pain/inflammation, Acute coronary syndrome, TIA,  MI, Stroke
	Doses and administration : Oral
									Acute symptoms 
									150-300 mg PO; (within minutes of symptoms)
									Prophylaxis of myocardial infarction
									Adult: 75-300 mg once daily. Lower doses should be used in patients receiving ACE inhibitors.
									Stent implantation
									Adult: 300 mg 2 hr before procedure followed by 150-300 mg/day thereafter.
									Juvenile rheumatoid arthritis
									Child: 80-100 mg/kg daily in 5 or 6 divided doses. Up to 130 mg/kg daily in acute exacerbations if necessary.
									Mild to moderate pain and fever
									Adult: 150-300 mg repeated every 4-6 hr according to response. Max: 4 g/day. 
									Pain and inflammation associated with musculoskeletal and joint disorders
									Adult: Initial: 2.4-3.6 g/day in divided doses. Usual maintenance: 3.6-5.4 g/day. Monitor serum concentrations.
									
	Contara-indications : Hypersensitivity (attacks of asthma, angioedema, urticaria or rhinitis), active peptic ulceration; pregnancy (3rd trimester), children <12 yr, patients with haemophilia or haemorrhagic disorders, gout, severe renal or hepatic impairment, lactation.
	Side effects : GI disturbances; prolonged bleeding time, rhinitis, urticaria and epigastric discomfort; angioedema, salicylism, tinnitus; bronchospasm.
									Potentially Fatal: Gastric erosion, ulceration and bleeding; severe, occasionally fatal exacerbation of airway obstruction in asthma; Reye's syndrome (children <12 yr). Hepatotoxicity; CNS depression which may lead to coma; CV collapse and resp failure; paroxysmal bronchospasm and dyspnoea.
	Precaution : Patients with history  of asthma, angioedema, urticaria or rhinitis, nasal polyp, severe renal or hepatic impairment, lactation.
	Pregnancy category : 4
	Mode of action : Aspirin is an analgesic, anti-inflammatory and antipyretic. It inhibits cyclooxygenase, which is responsible for the synthesis of prostaglandin and thromboxane. It also inhibits platelet aggregation.
	Interaction : Alcohol, corticosteroids, analgin, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Aspirin increases phenytoin levels. May antagonize actions of uricosurics and spironolactone.
				Potentially Fatal: May potentiate effects of anticoagulants, methotrexate and oral hypoglycaemics.
	Therapeutic class : Anti-platelet drugs
	Packsize : 100's pack
Anginox
	n : Trimetazidine Dihydrochloride
	Indications : Ischaemic heart disease, Angina pectoris; Meniere's disease, Coronary heart disease
	Doses and administration : One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.
									
									One 35 mg MR tablet twice daily at mealtimes in the morning and evening.
	Contara-indications : Hypersensitivity to Trimetazidine Dihydrochloride.
	Side effects : (Trimetazidine) is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.
	Precaution : Although teratological studies have not shown any drug related adverse effects on the course and outcome of pregnancy, the use  in pregnant women is not recommended.It is not known whetherTrimetazidine passes into breast milk or not. This medication should be used while breast feeding only if the potential benefits outweigh risks to the nursing infants.
	Pregnancy category : 0
	Mode of action : Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance.
	Interaction : MAOIs, nifedipine. May potentiate the effects of other antianginals.
	Therapeutic class : Other Anti-anginal & Anti-ischaemic drugs
	Packsize : 30's pack
Angipro
	n : Metoprolol Tartrate
	Indications : Heart failure, Migraine, Acute MI, Diabetic nephropathy, Hypertension, Cardiac arrhythmias, Angina pectoris
	Doses and administration : Hypertension: initially 100mg daily, maintenance 100-200mg daily in 1-2 divided doses
									Angina Pectoris: 50-100mg 2-3 times daily.
									Myocardial Infarction: After early intravenous treatment for 48 hours, patients should receive a maintenance dose of 100mg twice daily.
									Arrhythmias: usually 50mg 2-3 times daily; up to 300mg daily in divided doses if necessary.
									Hyperthyroidism: (adjunct), 50mg 4 times daily
									Migraine Prophylaxis: 100-200mg daily in divided doses.
	Contara-indications : Hypertension and Angina: Metoprolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure.
									
									Myocardial Infarction: Metoprolol is contraindicated in patients with a heart rate<45 beats/min; second and third-degree heart block; significant first-degree heart block; systolic blood pressure <100 mmHg; or moderate-to-severe cardiac failure.
	Side effects : Bradycardia, Heart failure, hypotension, Conduction disorder, Bronchospasm, Peripheral vasoconstriction, Gastrointestinal disturbances, Fatigue, Sleep disturbance, Rare reports of rashes and dry eyes, Sexual dysfunction, and Exacerbation of psoriasis.
	Precaution : Gereral: Metoprolol should be used with caution in patients with impaired hepatic function.
				Information for Patients: Patients should be advised to take Metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose missed, the patient should take only the next scheduled dose (without doubling it). Patient should not discontinue Metoprolol without consulting the physician. Patients should be advised to
				avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the
				patient's response to therapy with Metoprolol has been determined.
				contact the physician if any difficulty in breathing occurs.
				inform the physician or dentist before any type of surgery that he or she is taking Metoprolol.
	Pregnancy category : 4
	Mode of action : Metoprolol selectively inhibits ?1-adrenergic receptors but has little or no effect on ?2-receptors except in high doses. It does not exhibit membrane stabilising or intrinsic sympathomimetic activity.
	Interaction : Additive effect w/ catecholamine-depleting drugs (e.g. reserpine) and MAOIs. May antagonise ?1-adrenergic stimulating effects of sympathomimetics. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. Paradoxical response to epinephrine may occur. Increased plasma concentrations w/ CYP2D6 inhibitors (e.g. bupropion, cimetidine). Increased risk of hypotension and heart failure w/ myocardial depressant general anaesth (e.g. diethyl ether). Risk of pulmonary HTN w/ vasodilators (e.g. hydralazine) in uraemic patients. Reduced plasma levels w/ rifampicin. May increase negative inotropic and negative dromotropic effect of antiarrhythmic drugs (e.g. quinidine, amiodarone). May reduce antihypertensive efficacy w/ indometacin. May increase effects of hypoglycaemics.
	Therapeutic class : Beta-blockers
	Packsize : 50's pack
Angirid MR
	n : Trimetazidine Dihydrochloride
	Indications : Ischaemic heart disease, Angina pectoris; Meniere's disease, Coronary heart disease
	Doses and administration : One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.
									
									One 35 mg MR tablet twice daily at mealtimes in the morning and evening.
	Contara-indications : Hypersensitivity to Trimetazidine Dihydrochloride.
	Side effects : (Trimetazidine) is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.
	Precaution : Although teratological studies have not shown any drug related adverse effects on the course and outcome of pregnancy, the use  in pregnant women is not recommended.It is not known whetherTrimetazidine passes into breast milk or not. This medication should be used while breast feeding only if the potential benefits outweigh risks to the nursing infants.
	Pregnancy category : 0
	Mode of action : Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance.
	Interaction : MAOIs, nifedipine. May potentiate the effects of other antianginals.
	Therapeutic class : Other Anti-anginal & Anti-ischaemic drugs
	Packsize : 30's pack
Angist SR
	n : Glyceryl Trinitrate (nitroglycerine)
	Indications : Angina pectoris, Acute myocardial infarction, Severe hypertension, Pulmonary edema.
	Doses and administration : Usual dosage for adults and elderly patients:  PO: 1 capsule/tablet: 2 times a day before meal (e.g. at 8 AM & 2 PM, with a daily nitrate-free interval of 10-12 hours). If necessary the dosage may be raised gradually to 2 or 3 capsules/tablets: 2 times daily. But dosage should be individualized depending on the Nitroglycerin sensitivity of the patient, the severity of illness and the occurrence of side-effects. Use in Children: Not recommended for children. Spray: In case of attack 1 or 2 doses should be administered under the tongue to a sitting patient. If necessary, more doses can be given but not more than 3 doses within 15 minutes.  For prevention 1 dose should be applied 5-10 minutes before physical exercise.         Use in Children: Nitroglycerin Spray is not recommended for children.
	Contara-indications : Hypersensitivity. Severe hypotension, heart failure, marked anaemia, hypertrophic obstructive cardiomyopathy, cerebral haemorrhage or head trauma, low cardiac output secondary to hypovolaemia, inferior MI with right ventricular involvement, raised intracranial pressure. Concomitant use with phosphodiesterase type-5 inhibitors.
	Side effects :  Headache, facial flashing, dizziness, nausea, vomiting, sweating, palpitation, sensation of heat, postural hypotension and reflex tachycardia. Large doses can cause vomiting, restlessness, hypotension, syncope, rarely cyanosis and methaemoglobinaemia, impaired respiration, bradycardia. Sublingual Tabs/Spray: Dry mouth, localised burning sensation. Buccal tablets: Delayed dissolution, may be swallowed by mistake. Potentially Fatal: Hypotension, paradoxical bradycardia, impaired respiration, syncope and collapse.
	Precaution : Severe hepatic or renal impairment, hypothyroidism, malnutrition, hypothermia. Cerebrovascular disease, lung disease or cor pulmonale. Pregnancy, lactation, glaucoma, mitral valve prolapse, cardiac tamponade, syncope. Gradual withdrawal in patients who have received prolonged high dose infusions. Avoid prolonged excessive hypotension. Nitrate-free interval is recommended in patients on continuous treatment with nitrates to reduce risk of tolerance.
	Pregnancy category : 3
	Mode of action : Glyceryl trinitrate acts on the enzyme nitric oxide stimulating guanylate cyclase in the vascular smooth muscle cells resulting in the relaxation of smooth muscles. It reduces venous return (preload) and facilitates subendocardial blood flow with redistribution into ischaemic areas. It relieves coronary vasospasm and dilates arterioles reducing afterload. It is useful for relief and prevention of anginal attacks.
	Interaction : Enhances bioavailability of dihydroergotamine. Glyceryl trinitrate infusion may prolong pancuronium-induced neuromuscular blockade. May reduce the efficacy of heparin, alteplase and noradrenaline when used together. Efficacy of buccal and sublingual preparations may be reduced by drugs that can cause dry mouth due to decreased dissolution. Aspirin and other NSAIDs may reduce the therapeutic response to glyceryl trinitrate.
				Potentially Fatal: Orthostatic hypotension may be produced by combined use of calcium channel blockers, antihypertensives, phenothiazines and TCAs. Alcohol may cause severe hypotension and collapse.
	Therapeutic class : Nitrates: Coronary vasodilators
	Packsize : 30's pack
Angiten
	n : Captopril
	Indications : Hypertension, Congestive heart failure, Post Myocardial infarction, Diabetic nephropathy
	Doses and administration : Adult: PO HTN Initial: 12.5 mg twice daily. Maintenance: 25-50 mg twice daily. Max: 50 mg 3 times/day. 
									
									Heart failure Initial: 6.25-12.5 mg 2-3 times/day. Max: 50 mg 3 times/day. 
									
									Post MI Start 3 days after MI. Initial: 6.25 mg/day, may increase after several wk to 150 mg/day in divided doses if needed and tolerated. 
									
									Diabetic nephropathy 25 mg 3 times/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	Initially, 6.25 mg/day. Max: 37.5 mg/day.
									10-20	Initially, 12.5 mg/day. Max: 75 mg/day.
									21-40	Initially, 25 mg/day. Max: 100 mg/day.
	Contara-indications : Known hypersensitivity to the drug. Bilateral renal artery stenosis, hereditary angioedema; renal impairment; pregnancy.
	Side effects : Hypotension, tachycardia, chest pain, palpitations, pruritus, hyperkalaemia. Proteinuria; angioedema, skin rashes; taste disturbance, nonproductive cough, headache.
									Potentially Fatal: Neutropenia, usually occurs within 3 mth of starting therapy especially in patients with renal dysfunction or collagen diseases. Hyperkalaemia. Anaphylactic reactions.
	Precaution : Patients on diuretics or with sodium depletion should discontinue diuretics or increase sodium intake prior to initiation of therapy. Renal impairment, SLE and other autoimmune collagen disorders and during concurrent use of immunosuppressant or leucopenic drugs, monitor WBC count and urinary protein before and during therapy. Lactation. Porphyria. Severe CHF.
	Pregnancy category : 4
	Mode of action : Captopril competitively inhibits the conversion of angiotensin I (ATI) to angiotensin II (ATII), thus resulting in reduced ATII levels and aldosterone secretion. It also increases plasma renin activity and bradykinin levels. Reduction of ATII leads to decreased Na and water retention. This promotes vasodilation and BP reduction.
	Interaction : Concurrent treatment w/ NSAIDs reduces hypotensive action and increases the risk of nephrotoxicity. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. heparin). May increase risk of leucopenia w/ procainamide, allopurinol, cytostatic or immunosuppressants. May increase risk of lithium toxicity. Increased risk of nitritoid reactions w/ gold (Na aurothiomalate).
				Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) w/ aliskiren in diabetic patients.
	Therapeutic class : Angiotensin-converting enzyme (ACE) inhibitors
	Packsize : 100's pack
Angivent MR
	n : Trimetazidine Dihydrochloride
	Indications : Ischaemic heart disease, Angina pectoris; Meniere's disease, Coronary heart disease
	Doses and administration : One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.
									
									One 35 mg MR tablet twice daily at mealtimes in the morning and evening.
	Contara-indications : Hypersensitivity to Trimetazidine Dihydrochloride.
	Side effects : (Trimetazidine) is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.
	Precaution : Although teratological studies have not shown any drug related adverse effects on the course and outcome of pregnancy, the use  in pregnant women is not recommended.It is not known whetherTrimetazidine passes into breast milk or not. This medication should be used while breast feeding only if the potential benefits outweigh risks to the nursing infants.
	Pregnancy category : 0
	Mode of action : Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance.
	Interaction : MAOIs, nifedipine. May potentiate the effects of other antianginals.
	Therapeutic class : Other Anti-anginal & Anti-ischaemic drugs
	Packsize : 30's pack
Animet
	n : Carbonyl Iron + Folic Acid + Zinc
	Indications : Iron,Folic acid and zinc deficiency during pregnancy and lactation
	Doses and administration : One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.
	Contara-indications : This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. However, a few allergic reactions may be seen.
	Precaution : Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.
	Pregnancy category : 0
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
									Zinc: Cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system; helps maintain a sense of smell and taste; may assist in porper function of insulin.
									
	Interaction : Carbonyl iron: Antacids may decrease the absorption of carbonyl iron.
				
				Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
				
				
	Therapeutic class : Iron Vitamin & Mineral Combined preparation
	Packsize : 30's pack
Anin
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Anin Plus
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 20's pack
Anin 50 Plus
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 20's pack
Ankof
	n : Dextromethorphan + Pseudoephedrine Hydrochloride +Triprolidine Hydrochloride
	Indications : Flu, Colds, Runny nose, Dry coughs, Non-productive cough, Nasal congestion
	Doses and administration : Adult 2 teaspoonful three times a day.
									
									Children
									Over 12 years 2 teaspoonful three times a day
									6-12 years 1 teaspoonful three times a day
									2-6 years 1/2 teaspoonful three times a day or
									as directed by the physician
	Contara-indications : Patients at risk of developing resp failure. During an acute attack. Patients receiving MAOI or for 2 wk after discontinuing them. Persistent or chronic cough.
	Side effects : Dizziness, GI disturbances.
	Precaution : 3rd trimester of pregnancy; atopic childn; child <1 yr; sedated or debilitated patients; patients confined to supine position; history of asthma. Moderate to severe renal impairment; liver disease.
	Pregnancy category : 3
	Mode of action : Triprolidine is a potent competitive histamine H1-receptor antagonist with mild sedating and antimuscarinic properties. Pseudoephedrine, an ?- and ?-adrenergic receptor agonist, mediates vasoconstriction via direct stimulation of ?-adrenergic receptors of the respiratory mucosa. Dextromethorphan is a centrally acting cough suppressant which acts on the cough centre in the medulla.
	Interaction : Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol.
				Potentially Fatal: Memantine, moclobemide.
				
				Triprolidine + Pseudoephedrine: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine.
				Potentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.
	Therapeutic class : Combined cough suppressants
	Packsize : 100ml bot
Anleptic
	n : Carbamazepine
	Indications : Epilepsy,Schizophrenia,Bipolar disorder,Trigeminal neuralgia
	Doses and administration : Epilepsy: Adults and children over 12 years of age - Initial: Either 200 mg b.i.d. for tablets and XR tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. 
									
									Dosage generally should not exceed 1000 mg daily in children 12-15 years of age, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. 
									
									Maintenance: usually 800-1200 mg daily. Children 6-12 years of age - Initial: Either 100 mg b.i.d. for tablets or XR tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance: usually 400-800 mg daily. 
									
									Children under 6 years of age - Initial: 10-20 mg/kg/day b.i.d. or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of Carbamazepine for use at doses above 35 mg/kg/24 hours can be made. 
									
									Combination therapy: Carbamazepine may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased. 
									
									Trigeminal Neuralgia: Initial: On the first day, either 100 mg b.i.d. for tablets or XR tablets, or 1/2 teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or XR tablets, or 50 mg (1/2 teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. A total dose of 1200 mg daily shouldn't be exceeded. 
									Maintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug. The tablets or syrup can be taken without regards to meal.
									
	Contara-indications : Hypersensitivity; bone marrow depression; porphyria, pregnancy.
	Side effects : Dizziness, drowsiness, ataxia; dry mouth, abdominal pain, nausea, vomiting, anorexia; leucopenia, proteinuria, renal failure, heart failure and hyponatraemia.
									Potentially Fatal: Agranulocytosis, aplastic anaemia, hepatic failure, severe exfoliative dermatitis and Stevens-Johnson syndrome.
	Precaution : Lactation; CV disease, hepatic or renal disorders, history of blood disorders or haematological reactions to other drugs; glaucoma; skin disorders; elderly, patients on MAO inhibitors; abrupt withdrawal of treatment.
	Pregnancy category : 4
	Mode of action : Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation. It is effective in partial and generalised convulsions as well as in mixed types but not in petit mal seizures. It reduces or abolishes pain in trigeminal and glossopharyngeal neuralgia.
	Interaction : Increased plasma levels w/ CYP3A4 inhibitors (e.g. cimetidine). Decreased plasma levels w/ CYP3A4 inducers (e.g. cisplatin). Increased risk of neurotoxic side effects w/ lithium. May decrease the effect of hormonal contraceptives. Increased plasma levels of active metabolite carbamazepine-10, 11-epoxide w/ loxapine, quetiapine, primidone, progabide, valproic acid and valpromide. May increase cyclophosphamide levels. May reduce exposure of aripiprazole. May reduce plasma levels of tacrolimus, temsirolimus and lapatinib. May increase risk of isoniazid-induced hepatotoxicity. Risk of symptomatic hyponatraemia w/ diuretics (e.g. hydrochlorothiazide, furosemide).
				Potentially Fatal: May decrease serum concentrations of nefazodone and its active metabolites. Toxic reactions may develop when taken concurrently w/ MAOIs.
	Therapeutic class : Primary anti-epileptic drugs
	Packsize : 100ml bot
Anleptic
	n : Carbamazepine
	Indications : Epilepsy,Schizophrenia,Bipolar disorder,Trigeminal neuralgia
	Doses and administration : Epilepsy: Adults and children over 12 years of age - Initial: Either 200 mg b.i.d. for tablets and XR tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. 
									
									Dosage generally should not exceed 1000 mg daily in children 12-15 years of age, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. 
									
									Maintenance: usually 800-1200 mg daily. Children 6-12 years of age - Initial: Either 100 mg b.i.d. for tablets or XR tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance: usually 400-800 mg daily. 
									
									Children under 6 years of age - Initial: 10-20 mg/kg/day b.i.d. or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of Carbamazepine for use at doses above 35 mg/kg/24 hours can be made. 
									
									Combination therapy: Carbamazepine may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased. 
									
									Trigeminal Neuralgia: Initial: On the first day, either 100 mg b.i.d. for tablets or XR tablets, or 1/2 teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or XR tablets, or 50 mg (1/2 teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. A total dose of 1200 mg daily shouldn't be exceeded. 
									Maintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug. The tablets or syrup can be taken without regards to meal.
									
	Contara-indications : Hypersensitivity; bone marrow depression; porphyria, pregnancy.
	Side effects : Dizziness, drowsiness, ataxia; dry mouth, abdominal pain, nausea, vomiting, anorexia; leucopenia, proteinuria, renal failure, heart failure and hyponatraemia.
									Potentially Fatal: Agranulocytosis, aplastic anaemia, hepatic failure, severe exfoliative dermatitis and Stevens-Johnson syndrome.
	Precaution : Lactation; CV disease, hepatic or renal disorders, history of blood disorders or haematological reactions to other drugs; glaucoma; skin disorders; elderly, patients on MAO inhibitors; abrupt withdrawal of treatment.
	Pregnancy category : 4
	Mode of action : Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation. It is effective in partial and generalised convulsions as well as in mixed types but not in petit mal seizures. It reduces or abolishes pain in trigeminal and glossopharyngeal neuralgia.
	Interaction : Increased plasma levels w/ CYP3A4 inhibitors (e.g. cimetidine). Decreased plasma levels w/ CYP3A4 inducers (e.g. cisplatin). Increased risk of neurotoxic side effects w/ lithium. May decrease the effect of hormonal contraceptives. Increased plasma levels of active metabolite carbamazepine-10, 11-epoxide w/ loxapine, quetiapine, primidone, progabide, valproic acid and valpromide. May increase cyclophosphamide levels. May reduce exposure of aripiprazole. May reduce plasma levels of tacrolimus, temsirolimus and lapatinib. May increase risk of isoniazid-induced hepatotoxicity. Risk of symptomatic hyponatraemia w/ diuretics (e.g. hydrochlorothiazide, furosemide).
				Potentially Fatal: May decrease serum concentrations of nefazodone and its active metabolites. Toxic reactions may develop when taken concurrently w/ MAOIs.
	Therapeutic class : Primary anti-epileptic drugs
	Packsize : 50's pack
Anlet
	n : Clopidogrel
	Indications : Coronary Artery Disease, Acute coronary syndrome, Myocardial infarction, Peripheral vascular disease, Cerebrovascular disease, Atherosclerosis, Thromboembolic disorders, Unstable angina, Stroke
	Doses and administration : Adult: PO Prophylaxis of thromboembolic events 75 mg once daily. 
									
									Acute coronary syndrome For ST-elevation myocardial infarction: W/ aspirin: 75 mg once daily. Continue treatment for up to 28 days. 
									
									For unstable angina, non-ST-elevation myocardial infarction: Initial: 300 mg loading dose, followed by 75 mg once daily (w/ aspirin 75-325 mg once daily).
	Contara-indications : Hypersensitivity. Active pathological bleeding. admin within 7 days after MI and ischaemic stroke, coagulation disorders. Lactation.
	Side effects : Dyspepsia, abdominal pain, nausea, vomiting, flatulence, constipation, gastritis, gastric and duodenal ulcers. GI upset, diarrhoea, paraesthesia, vertigo, headache, dizziness, pruritus and rashes.
									Potentially Fatal: Bleeding disorders including GI and intracranial haemorrhage. Blood dyscrasias.
	Precaution : Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions; ulcer; renal and hepatic impairment; history of bleeding or haemostatic disorders. Pregnancy.
	Pregnancy category : 2
	Mode of action : Clopidogrel inhibits adenosine diphosphate (ADP) from binding to its receptor sites on the platelets and subsequent activation of glycoprotein GP IIb/IIIa complex thus preventing fibrinogen binding, platelet adhesion and aggregation.
	Interaction :  	Co-admin with NSAIDs may increase the risk of stomach and intestinal bleeding. High-dose clopidogrel may lead to increased warfarin levels thus increasing the risk of bleeding. High-dose clopidogrel may also inhibit P450 (2C9), thus interfering with the metabolism of phenytoin, tamoxifen, torasemide, fluvastatin and some NSAIDs. Avoid concurrent use of drugs that inhibit CYP2C19, including omeprazole, esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine and ticlopidine.
	Therapeutic class : Anti-platelet drugs
	Packsize : 30's pack
Anlet PLUS
	n : Aspirin + Clopidogrel
	Indications : Acute coronary syndrome, TIA, Ischaemic events, MI, Stroke
	Doses and administration : Adult: PO Prevention of ischaemic events Per tab contains clopidogrel 75 mg and aspirin 75 mg: 1 tab once daily. Acute coronary syndrome Per tab contains clopidogrel 75 mg and aspirin 75 mg: Loading dose: 4 tab; maintenance: 1 tab/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<10	   Avoid use.
									Hepatic impairment: Severe hepatic impairment: Avoid use.
	Contara-indications : Hypersensitivity to aspirin, NSAIDs or clopidogrel; active peptic ulceration; children <12 yr; patients with haemophilia or haemorrhagic disorders; gout; severe renal or hepatic impairment; lactation.
	Side effects : Aspirin: GI disturbances, epigastric discomfort, prolonged bleeding time, rhinitis, urticaria; angioedema, salicylism, tinnitus. Clopidogrel: Dyspepsia, abdominal pain, nausea, vomiting, flatulence, constipation, gastritis, gastric and duodenal ulcers. Serious events include bleeding and GI haemorrhage. GI upset, diarrhoea, paraesthesia, vertigo, headache, dizziness, leucopaenia, eosinophilia, rash and pruritus.
									Potentially Fatal: Aspirin: Gastric erosion, ulceration and bleeding; severe, occasionally fatal exacerbation of airway obstruction in asthma; Reye's syndrome (childn <12 yrs). Hepatotoxicity; CNS depression, which may lead to coma; CV collapse, resp failure; paroxysmal bronchospasm and dyspnoea. Clopidogrel: Bleeding disorders including GI intracranial haemorrhage and thrombotic thrombocytopenic purpura.
	Precaution : History of peptic ulcer or those prone to dyspepsia and those with gastric mucosal lesion or heavy ethanol consumption; asthma or allergic disorders; tinnitus; dehydrated patients; uncontrolled hypertension; impaired renal or hepatic function; children and elderly; pregnancy. Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions. Increased risk of Reye's syndrome when used in patients with chicken pox, influenza or flu symptoms. Caution when used in patients with nasal allergies or nasal polyps. For patients undergoing elective surgery and an antiplatelet effect is not needed, clopidogrel should be discontinued 7-10 days before surgery.
	Pregnancy category : 19
	Mode of action : Aspirin inhibits the formation of thromboxane A2 in the platelets. This inhibits platelet aggregation and coagulation. This action lasts until the enzyme cyclo-oxygenase is regenerated in the platelets. Clopidogrel is a prodrug and is metabolised an active thiol metabolite. The active metabolite selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GP IIb/IIIa complex, thereby inhibiting platelet aggregation.
	Interaction : Aspirin: Corticosteroids, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Use with coumarins, anagrelide, agatroban, LMWH, bivalirudin, dasatinib, iloprost, lepirudin and tenecteplase may increase the risk of bleeding. Clopidogrel: Co-administration of clopidogrel with NSAIDs may increase the risk of stomach and intestinal bleeding. There is an increased risk of bleeding with coumarins, agatroban, dasatinib, heparin, LMWH, gingko biloba and iloprost. Increased risk of bleeding if clopidogrel and drotrecogin alfa are given within 7 days. May increase bupropion level and side effects (lightheadedness , GI discomfort).
				Potentially Fatal: Aspirin and clopidogrel: Increased risk of bleeding with dabigatran.
	Therapeutic class : Anti-platelet drugs
	Packsize : 30's pack
Anodyne IM
	n : Diclofenac + Lidocaine Hydrochloride
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Acute gout, Inflammation, Tendinitis, Actinic keratoses, Bursitis
	Doses and administration : Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
	Contara-indications : In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									
									Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide-type.
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									The adverse effects due to Lidocaine mainly involve the CNS, are usually of short duration, and are dose related. The CNS reaction may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadness, etc. Incase of eye drops ocular burning sensation or allergic reaction may occur in 5-10% patients. 
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued.
	Pregnancy category : 19
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
									
									Lidocaine is an amide type local anaesth. It stabilises the neuronal membrane and inhibits Na ion movements, which are necessary for conduction of impulses. In the heart, lidocaine reduces depolarisation of the ventricles during diastole and automaticity in the His-Purkinje system. Duration of action potential and effective refractory period are also reduced.
	Interaction :  	May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
				May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 10's pack
Anodyne
	n : Diclofenac Sodium 0.1% Eye prep
	Indications : Allergic conjunctivitis, Ocular inflammation, Miosis
	Doses and administration : Adults
									Pre-operatively: Instill 1 drop in the conjunctival sac up to 5 times over the 3 hours preceding surgery
									
									Post-operatively: Instill 1 drop in the conjunctival sac after 15, 30 & 45 minutes following surgery; then 3-5 times daily for as long as required.
									
									Inflammatory conditions: Instill 1 drop in the conjunctival sac 4-5 times daily depending upon the severity of the diseases.
	Contara-indications : Contraindicated to patients hypersensitive to Diclofenac Sodium or any other of its ingredients. Diclofenac sodium is also contraindicated in patients who may have NSAID induced asthma, urticaria, or acute rhinitis.
	Side effects : Mild to moderate burning sensation in 5-15% patients which is transient in nature and almost never necessitated discontinuation of treatment. Other less common side-effects are sensitivity to light, bad taste, feeling of pressure, allergic reactions etc. 
	Precaution : Diclofenac eye drops may mask the signs of infection. So physicians should be alert to the development of infections in patients receiving the drug. During prolonged use, it is recommended that physicians conduct periodic examinations of the eye, including measurement of the intraocular pressure. Contact lenses should not be worn during treatment.
	Pregnancy category : 3
	Mode of action : Inhibits cyclooxygenase (COX)-1 and COX-2, thereby inhibiting prostaglandin synthesis.May also inhibit neutrophil aggregation/activation, inhibit chemotaxis, decrease proinflammatory cytokine level, and alter lymphocyte activity.
	Interaction : May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 5  ml drop
Anodyne 1%
	n : Diclofenac Sodium 1% Topical
	Indications : Rheumatoid arthritis, Osteoarthritis, Joint and muscular pains
	Doses and administration : Gel: For external use only. Depending on the size of area to be treated, 2-4 g of  Gel should be applied to the skin 3-4 times daily. To the affected area gel should be rubbed in lightly.  
									Gel may also be given in addition to further treatment with other dosage forms of Diclofenac.
									
									
	Contara-indications : Contraindicated to the patients hypersensitive to any ingredient of the products. Peptic ulcer, hypersensitivity to Diclofenac like other non-steroid anti-inflammatory agents, Diclofenac is also contra-indicated in asthmatic patient in whom attack with asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or by other drugs with prostaglandin synthetase inhibitor.  Gel should not be used under occlusive airtight dressings.
	Side effects : Generally well tolerated. Adverse effects are mild, rare and transient. At the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. These effects are usually mild in nature. Peripheral edema and skin reactions, such as rash and eczema have also been encountered. Gel may cause local irritation and reddening of the skin and skin rash.
	Precaution : In rare instances where peptic ulceration or gastro-intestinal bleeding occurs in patients under treatment with Diclofenac. In patients with advanced age should be kept under close observation.Gel should not be allowed to come in contact with the eyes or mucus membranes, after application the hands should be washed properly and not to be taken by mouth.
	Pregnancy category : 3
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. Inhibits cyclooxygenase (COX)-1 and COX-2, thereby inhibiting prostaglandin synthesis. May also inhibit neutrophil aggregation/activation, inhibit chemotaxis, decrease proinflammatory cytokine level, and alter lymphocyte activity.
	Interaction : May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Topical Analgesics
	Packsize : 10 gm tube
Anodyne
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Anodyne SR
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Anol
	n : Atenolol
	Indications : Hypertension, Migraine, Arrhythmias, MI, Angina pectoris
	Doses and administration : Adult: PO HTN 25-100 mg/day. 
									Angina pectoris; Migraine prophylaxis 50-100 mg/day. Max for angina pectoris: 200 mg/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<15	  25 mg or 50 mg on alternate days.
									15-35	50 mg/day.
									Dialysis patients	25-50 mg after each dialysis.
	Contara-indications : Hypersensitivity. Sinus bradycardia, sinus node dysfunction, heart block >1st degree, compensated cardiac failure, cardiogenic shock, bronchospastic diseases, peripheral vascular diseases. Pregnancy.
	Side effects : Bronchospasm; cold extremities, fatigue, dizziness, insomnia, lethargy, confusion, headache, depression, nightmares, nausea, diarrhoea, constipation, impotence and paraesthesia.
									Potentially Fatal: Heart failure, 2nd or 3rd degree AV block.
	Precaution : Compensated heart failure. Variant angina, acute MI, DM; peripheral vascular disorders; hepatic and renal dysfunction; elderly patients, children. Lactation. If atenolol and clonidine are co-admin, then gradual withdrawal of clonidine should take place a few days after withdrawal of atenolol.
	Pregnancy category : 4
	Mode of action : Atenolol is a competitive cardioselective beta1-blocker and does not have effect on ?beta2-receptors except in high doses. It reduces resting and exercise-induced heart rate as well as myocardial contractility.
	Interaction : Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment.
				
	Therapeutic class : Beta-blockers
	Packsize : 100's pack
Anolol
	n : Atenolol
	Indications : Hypertension, Migraine, Arrhythmias, MI, Angina pectoris
	Doses and administration : Adult: PO HTN 25-100 mg/day. 
									Angina pectoris; Migraine prophylaxis 50-100 mg/day. Max for angina pectoris: 200 mg/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<15	  25 mg or 50 mg on alternate days.
									15-35	50 mg/day.
									Dialysis patients	25-50 mg after each dialysis.
	Contara-indications : Hypersensitivity. Sinus bradycardia, sinus node dysfunction, heart block >1st degree, compensated cardiac failure, cardiogenic shock, bronchospastic diseases, peripheral vascular diseases. Pregnancy.
	Side effects : Bronchospasm; cold extremities, fatigue, dizziness, insomnia, lethargy, confusion, headache, depression, nightmares, nausea, diarrhoea, constipation, impotence and paraesthesia.
									Potentially Fatal: Heart failure, 2nd or 3rd degree AV block.
	Precaution : Compensated heart failure. Variant angina, acute MI, DM; peripheral vascular disorders; hepatic and renal dysfunction; elderly patients, children. Lactation. If atenolol and clonidine are co-admin, then gradual withdrawal of clonidine should take place a few days after withdrawal of atenolol.
	Pregnancy category : 4
	Mode of action : Atenolol is a competitive cardioselective beta1-blocker and does not have effect on ?beta2-receptors except in high doses. It reduces resting and exercise-induced heart rate as well as myocardial contractility.
	Interaction : Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment.
				
	Therapeutic class : Beta-blockers
	Packsize : 100's pack
Anolol
	n : Atenolol
	Indications : Hypertension, Migraine, Arrhythmias, MI, Angina pectoris
	Doses and administration : Adult: PO HTN 25-100 mg/day. 
									Angina pectoris; Migraine prophylaxis 50-100 mg/day. Max for angina pectoris: 200 mg/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<15	  25 mg or 50 mg on alternate days.
									15-35	50 mg/day.
									Dialysis patients	25-50 mg after each dialysis.
	Contara-indications : Hypersensitivity. Sinus bradycardia, sinus node dysfunction, heart block >1st degree, compensated cardiac failure, cardiogenic shock, bronchospastic diseases, peripheral vascular diseases. Pregnancy.
	Side effects : Bronchospasm; cold extremities, fatigue, dizziness, insomnia, lethargy, confusion, headache, depression, nightmares, nausea, diarrhoea, constipation, impotence and paraesthesia.
									Potentially Fatal: Heart failure, 2nd or 3rd degree AV block.
	Precaution : Compensated heart failure. Variant angina, acute MI, DM; peripheral vascular disorders; hepatic and renal dysfunction; elderly patients, children. Lactation. If atenolol and clonidine are co-admin, then gradual withdrawal of clonidine should take place a few days after withdrawal of atenolol.
	Pregnancy category : 4
	Mode of action : Atenolol is a competitive cardioselective beta1-blocker and does not have effect on ?beta2-receptors except in high doses. It reduces resting and exercise-induced heart rate as well as myocardial contractility.
	Interaction : Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment.
				
	Therapeutic class : Beta-blockers
	Packsize : 100's pack
Anorel
	n : Cinchocaine Hydrochloride 0.5% + Esculin 1% + Hydrocortisone + Neomycin Sulphate (Rectal prep)
	Indications : Pruritus ani, Haemorrhoids, Anal fissure, Proctitis
	Doses and administration : Adult: Up to 1% in cream and ointment.Adult: As 0.05% w/w ointment (in combination with hydrocortisone): Apply onto the affected area in the morning and evening and after each stool. 
									
									As suppository containing 5 mg/unit (in combination with hydrocortisone): Insert 1 suppository in the morning and evening and after each stool.
	Contara-indications : Complete heart block; pyogenic infection at or near the skin. Application to inflamed or infected tissues or to damaged skin mucosa; instillation into the middle ear.
	Side effects : Restlessness; excitement; nervousness; paraesthesias; dizziness; tinnitus; blurred vision; nausea; vomiting; muscle twitching; tremors; convulsions; hypotension; bradycardia; arrhythmias; cardiac arrest.
	Precaution : Elderly; debilitated patients; child; epilepsy; impaired cardiac conduction or respiratory function; shock; hepatic impairment; myasthenia gravis. Do not to rub or touch the eye while anaesthesia persists. Avoid application for prolonged periods and to extensive areas. Pregnancy, lactation.
	Pregnancy category : 0
	Mode of action : Cinchocaine prevents or diminishes nerve impulse conduction near to the site of admin. It also has membrane-stabilising effect owing to decrease of permeability of the nerve cell to sodium ions.
									Hydrocortisone is a corticosteroid used for its anti-inflammatory and immunosuppressive effects. Its anti-inflammatory action is due to the suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It may also be used as replacement therapy in adrenocortical insufficiency.
									Neomycin is an aminoglycoside antibiotic. It binds to 30S ribosomal subunits of bacterial ribosome thus inhibiting protein synthesis and generating errors in genetic code transcription causing cell death. It acts against many gram-negative aerobes and some gram-positive aerobes. It lacks activity against fungi, viruses and most anaerobic bacteria.
	Interaction : None
	Therapeutic class : Compound steroidal preparations
	Packsize : 1 tube
Anosea
	n : Meclizine Hydrochloride
	Indications : Motion sickness, Vertigo and Vestibular disorders
	Doses and administration : Adult and Children 12 years of age & over: Nausea and vomiting: 25-50 mg daily or as directed by a physician.
									Motion sickness: Take an initial dose of 25-50 mg, 1 hour prior to travel. May repeat the dose every 24 hours for the duration of the journey.
									Radiation sickness: 50 mg administered 2-12 hours prior to radiation treatment.
									Vertigo: 25-100 mg daily in divided doses.
									Prevention of nausea and vomiting associated with emergency contraceptive pill (ECP) : 25-50 mg, 1 hour before first ECP dose; repeat if needed in 24 hours.
									The safety and efficacy for use in children less than 12 years of age have not been established. 
	Contara-indications : Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.
	Side effects : Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.
	Precaution : Patients should be warned that Meclizine Hydrochloride may impair their ability to perform hazardous activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle). Patients should avoid alcoholic beverages while taking this drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.
	Pregnancy category : 2
	Mode of action : Meclozine blocks vasopressor response to histamine and has a slight blocking action against acetylcholine. It decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways.
	Interaction : Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
	Therapeutic class : Anti-emetic drugs
	Packsize : 50's pack
Anosea Plus
	n : Meclizine Hydrochloride + Pyridoxine Hydrochloride
	Indications : Nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of vestibular motion sickness, radiation sickness and vertigo associated with diseases of vestibular system, morning sickness during pregnancy, drug induced nausea, vomiting induced by oral contraceptives or Estrogen preparations. 
	Doses and administration : Adult: PO: As combination preparation containing meclozine 25 mg and pyridoxine 50 mg per tablet: 1 tablet at night.
	Contara-indications : Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.
	Side effects : Drowsiness, thickening of bronchial secretions, dry mouth, fatigue, blurred vision.
	Precaution : Prostate hypertrophy, obstruction of bladder neck, narrow angle glaucoma, pyloric stenosis. May impair ability to drive or operate machinery. Pregnancy.
	Pregnancy category : 12
	Mode of action : Meclozine blocks vasopressor response to histamine and has a slight blocking action against acetylcholine. It decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways.
									
									Pyridoxine is a water-soluble vitamin which functions in the metabolism of carbohydrates, proteins and fats. It is essential in Hb formation and GABA synthesis within the CNS. It also aids in the release of glycogen stored in the liver and muscles.
	Interaction : Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
	Therapeutic class : Anti-emetic drugs
	Packsize : 50's pack
Anotic
	n : Flupenthixol + Melitracen
	Indications : Depression, Anxiety, Apathy, Dysphoria
	Doses and administration : Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets.
									Elderly: 1 tablet in the morning.
									Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
	Contara-indications : The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
	Side effects : In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
	Precaution : If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.
	Pregnancy category : 3
	Mode of action : Flupentixol is a thioxanthene antipsychotic that inhibits dopamine-mediated effects by blocking postsynaptic dopamine receptors in the CNS.
									Melitracen is a TCA with anxiolytic properties.
	Interaction :  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).
				Potentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.
				 	Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 50's pack
Anoxa
	n : Oxazepam
	Indications : Anxiety, Insomnia, Alcohol withdrawal syndrome
	Doses and administration : Adult: PO Alcohol withdrawal syndrome; Anxiety 15-30 mg 3-4 times/day. Insomnia associated w/ anxiety 15-25 mg 1 hr before bedtime. Up to 50 mg may be used.
	Contara-indications : Not for the treatment of psychoses. Pregnancy and lactation.
	Side effects : Syncope (rare), oedema; drowsiness, ataxia, dizziness, vertigo, memory impairment, headache, paradoxical reactions (excitement, stimulation of effect), lethargy, amnesia, euphoria; rash; decreased libido, menstrual irregularities; incontinence; leukopenia, blood dyscrasias; jaundice; dysarthria, tremor, reflex slowing; blurred vision, diplopia; drug dependence.
	Precaution : Cross-sensitivity with other benzodiazepines may occur. Hepatic and renal impairment. Respiratory disease. Debilitated patients, elderly, patients at risk of falls. Withdraw gradually. Porphyria; impaired gag reflex. History of drug abuse or acute alcoholism. May impair ability to drive or operate machinery. CV or cerebrovascular disease, intolerance to transient decreases in BP. Depression or if suicidal risk is present.
	Pregnancy category : 4
	Mode of action : Oxazepam is a short-acting benzodiazepine. It increases neuronal membrane permeability to Cl ions by binding to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron w/in the CNS (including the limbic system, reticular formation) and enhancing the GABA inhibitory effects resulting in hyperpolarisation and stabilisation.
	Interaction : Additive CNS depressant effects w/ barbiturates, antipsychotics, sedatives/hypnotics, anxiolytics, antidepressants, sedative antihistamines, anticonvulsants, and anaesth. Increased psychic dependence w/ narcotic analgesics. CYP450 inhibitors may enhance benzodiazepine activity.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 30's pack
Anoxiv
	n : Betacarotene + Vitamin C + Vitamin E  (Anti-Oxidant Vitamins and Minerals)
	Indications : Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair.
									
	Doses and administration : One tablet/capsule daily or as directed by a physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.
	Pregnancy category : 1
	Mode of action : Beta carotene is 1 of a group of red, orange, and yellow pigments called carotenoids; Dietary sources include fruits, vegetables, and whole grains.  Photoprotective effects: Exact mechanism unknown; in vitro studies suggest antioxidant effects and that beta carotene reduces free radicals and singlet oxygen, which are produced when porphyrin is exposed to light and air.
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin preparations
	Packsize : 30's pack
Anpar
	n : Terbinafine Topical
	Indications : Tinea pedis, Tinea cruris, Tinea corporis, Dermatophytosis, Nail infections, Cutaneous candidiasis and Pityriasis versicolor
	Doses and administration : Dermatophytosis
									Adult: Apply  cream/solution/spray once or bid. 1-2 wk to treat tinea corporis and tinea cruris; 1-wk course is for tinea pedis; 2-wk course in cutaneous candidiasis and pityriasis versicolor
	Contara-indications : Hypersensitivity, active or chronic liver disease, lactation.
	Side effects : Anorexia, nausea, abdominal pain, taste disturbances, diarrhoea, rash, urticaria.
									Potentially Fatal: Liver failure, Stevens-Johnson syndrome, neutropaenia.
	Precaution : Preexisting liver or renal impairment, pregnancy. Perform liver function tests prior to oral therapy.
	Pregnancy category : 2
	Mode of action : Terbinafine causes fungal cell death by inhibiting squalene epoxidase, the main enzyme in sterol biosynthesis, resulting in ergosterol deficiency within fungal cell walls. It has fungicidal activity against dermatophytes and some yeast.
	Interaction : Possible increase in levels in drugs metabolised by CYP450 2D6. Decreased terbinafine concentration with rifampicin; increased terbinafine concentration with cimetidine.
	Therapeutic class : Topical Anti-fungal preparations
	Packsize : 5gm  tube
Anplat
	n : Clopidogrel
	Indications : Coronary Artery Disease, Acute coronary syndrome, Myocardial infarction, Peripheral vascular disease, Cerebrovascular disease, Atherosclerosis, Thromboembolic disorders, Unstable angina, Stroke
	Doses and administration : Adult: PO Prophylaxis of thromboembolic events 75 mg once daily. 
									
									Acute coronary syndrome For ST-elevation myocardial infarction: W/ aspirin: 75 mg once daily. Continue treatment for up to 28 days. 
									
									For unstable angina, non-ST-elevation myocardial infarction: Initial: 300 mg loading dose, followed by 75 mg once daily (w/ aspirin 75-325 mg once daily).
	Contara-indications : Hypersensitivity. Active pathological bleeding. admin within 7 days after MI and ischaemic stroke, coagulation disorders. Lactation.
	Side effects : Dyspepsia, abdominal pain, nausea, vomiting, flatulence, constipation, gastritis, gastric and duodenal ulcers. GI upset, diarrhoea, paraesthesia, vertigo, headache, dizziness, pruritus and rashes.
									Potentially Fatal: Bleeding disorders including GI and intracranial haemorrhage. Blood dyscrasias.
	Precaution : Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions; ulcer; renal and hepatic impairment; history of bleeding or haemostatic disorders. Pregnancy.
	Pregnancy category : 2
	Mode of action : Clopidogrel inhibits adenosine diphosphate (ADP) from binding to its receptor sites on the platelets and subsequent activation of glycoprotein GP IIb/IIIa complex thus preventing fibrinogen binding, platelet adhesion and aggregation.
	Interaction :  	Co-admin with NSAIDs may increase the risk of stomach and intestinal bleeding. High-dose clopidogrel may lead to increased warfarin levels thus increasing the risk of bleeding. High-dose clopidogrel may also inhibit P450 (2C9), thus interfering with the metabolism of phenytoin, tamoxifen, torasemide, fluvastatin and some NSAIDs. Avoid concurrent use of drugs that inhibit CYP2C19, including omeprazole, esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine and ticlopidine.
	Therapeutic class : Anti-platelet drugs
	Packsize : 30's pack
Anquil
	n : Midazolam
	Indications : Insomnia, Sedation, Induction of anesthesia
	Doses and administration : Oral dosage: For adults 7.5-15 mg daily. In elderly and debilitated patients, the recommended dose is 7.5 mg. In premedication, 15 mg of Midazolam should be given 30-60 minutes before the procedure.
									
									Intravenous administration:
									Endoscopic or Cardiovascular Procedures
									In healthy adults the initial dose is approximately 2.5 mg. In cases of severe illness and in elderly patients, the initial dose must be reduced to 1 to 1.5 mg.
									
									Induction of Anesthesia
									The dose is 10-15 mg I. V.
									
									Intramuscular administration:
									Adult: 0.07-0.1 mg/kg bodyweight i. m. Usual dose is about 5 mg.
									Children: 0.15-0.20 mg/kg.
									Elderly and debilitated patients: 0.025-0.05 mg/kg
									
									Rectal administration in children:
									For preoperative sedation, rectal administration of the ampoule solution (0.35-0.45 mg/kg) 20-30 min before induction of general anesthesia. 
	Contara-indications : Midazolam must not be given to patients with severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis, sleep apnea syndrome and with known hypersensitivity to benzodiazepines or to any component of the product.
	Side effects : At the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. Following parenteral (IV or IM) administration of Midazolam, fluctuations in vital signs have been noted including respiratory depression, apnoea, variations in blood pressure and pulse rate.
	Precaution : Midazolam IV should be administered very slowly.
	Pregnancy category : 4
	Mode of action : Midazolam is a short-acting benzodiazepine. It exerts sedative and hypnotic, muscle relaxant, anxiolytic and anticonvulsant actions. While the probable anxiolytic action might be as a result of the drug's ability to increase glycine inhibitory neurotransmitter level, the hypnotic/anaesthetic action may be due to the occupation of the benzodiazepine and GABA receptors leading to membrane hyperpolarisation and neuronal inhibition, and further interfering with the re-uptake of GABA at the synapses.
	Interaction : Increased CNS depression with alcohol, opioids, barbiturates, other sedatives and anaesthetics. Increased respiratory depression with opiates, phenobarbital, other benzodiazepines. Plasma concentrations increased by CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, diltiazem, verapamil, ketoconazole and itraconazole, antiretroviral agents, quinupristin with dalfopristin. Midazolam concentration decreased by phenytoin, carbamazepine, phenobarbital, rifampicin. Halothane, thiopental requirements may be reduced during concurrent use.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 10's pack
Anquil IV/IM
	n : Midazolam
	Indications : Insomnia, Sedation, Induction of anesthesia
	Doses and administration : Oral dosage: For adults 7.5-15 mg daily. In elderly and debilitated patients, the recommended dose is 7.5 mg. In premedication, 15 mg of Midazolam should be given 30-60 minutes before the procedure.
									
									Intravenous administration:
									Endoscopic or Cardiovascular Procedures
									In healthy adults the initial dose is approximately 2.5 mg. In cases of severe illness and in elderly patients, the initial dose must be reduced to 1 to 1.5 mg.
									
									Induction of Anesthesia
									The dose is 10-15 mg I. V.
									
									Intramuscular administration:
									Adult: 0.07-0.1 mg/kg bodyweight i. m. Usual dose is about 5 mg.
									Children: 0.15-0.20 mg/kg.
									Elderly and debilitated patients: 0.025-0.05 mg/kg
									
									Rectal administration in children:
									For preoperative sedation, rectal administration of the ampoule solution (0.35-0.45 mg/kg) 20-30 min before induction of general anesthesia. 
	Contara-indications : Midazolam must not be given to patients with severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis, sleep apnea syndrome and with known hypersensitivity to benzodiazepines or to any component of the product.
	Side effects : At the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. Following parenteral (IV or IM) administration of Midazolam, fluctuations in vital signs have been noted including respiratory depression, apnoea, variations in blood pressure and pulse rate.
	Precaution : Midazolam IV should be administered very slowly.
	Pregnancy category : 4
	Mode of action : Midazolam is a short-acting benzodiazepine. It exerts sedative and hypnotic, muscle relaxant, anxiolytic and anticonvulsant actions. While the probable anxiolytic action might be as a result of the drug's ability to increase glycine inhibitory neurotransmitter level, the hypnotic/anaesthetic action may be due to the occupation of the benzodiazepine and GABA receptors leading to membrane hyperpolarisation and neuronal inhibition, and further interfering with the re-uptake of GABA at the synapses.
	Interaction : Increased CNS depression with alcohol, opioids, barbiturates, other sedatives and anaesthetics. Increased respiratory depression with opiates, phenobarbital, other benzodiazepines. Plasma concentrations increased by CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, diltiazem, verapamil, ketoconazole and itraconazole, antiretroviral agents, quinupristin with dalfopristin. Midazolam concentration decreased by phenytoin, carbamazepine, phenobarbital, rifampicin. Halothane, thiopental requirements may be reduced during concurrent use.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 30's pack
Anquil
	n : Midazolam
	Indications : Insomnia, Sedation, Induction of anesthesia
	Doses and administration : Oral dosage: For adults 7.5-15 mg daily. In elderly and debilitated patients, the recommended dose is 7.5 mg. In premedication, 15 mg of Midazolam should be given 30-60 minutes before the procedure.
									
									Intravenous administration:
									Endoscopic or Cardiovascular Procedures
									In healthy adults the initial dose is approximately 2.5 mg. In cases of severe illness and in elderly patients, the initial dose must be reduced to 1 to 1.5 mg.
									
									Induction of Anesthesia
									The dose is 10-15 mg I. V.
									
									Intramuscular administration:
									Adult: 0.07-0.1 mg/kg bodyweight i. m. Usual dose is about 5 mg.
									Children: 0.15-0.20 mg/kg.
									Elderly and debilitated patients: 0.025-0.05 mg/kg
									
									Rectal administration in children:
									For preoperative sedation, rectal administration of the ampoule solution (0.35-0.45 mg/kg) 20-30 min before induction of general anesthesia. 
	Contara-indications : Midazolam must not be given to patients with severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis, sleep apnea syndrome and with known hypersensitivity to benzodiazepines or to any component of the product.
	Side effects : At the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. Following parenteral (IV or IM) administration of Midazolam, fluctuations in vital signs have been noted including respiratory depression, apnoea, variations in blood pressure and pulse rate.
	Precaution : Midazolam IV should be administered very slowly.
	Pregnancy category : 4
	Mode of action : Midazolam is a short-acting benzodiazepine. It exerts sedative and hypnotic, muscle relaxant, anxiolytic and anticonvulsant actions. While the probable anxiolytic action might be as a result of the drug's ability to increase glycine inhibitory neurotransmitter level, the hypnotic/anaesthetic action may be due to the occupation of the benzodiazepine and GABA receptors leading to membrane hyperpolarisation and neuronal inhibition, and further interfering with the re-uptake of GABA at the synapses.
	Interaction : Increased CNS depression with alcohol, opioids, barbiturates, other sedatives and anaesthetics. Increased respiratory depression with opiates, phenobarbital, other benzodiazepines. Plasma concentrations increased by CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, diltiazem, verapamil, ketoconazole and itraconazole, antiretroviral agents, quinupristin with dalfopristin. Midazolam concentration decreased by phenytoin, carbamazepine, phenobarbital, rifampicin. Halothane, thiopental requirements may be reduced during concurrent use.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 30's pack
Anreb
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 50's pack
Anreb
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Anreb PLUS 12.5/50
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Anril
	n : Glyceryl Trinitrate (nitroglycerine)
	Indications : Angina pectoris, Acute myocardial infarction, Severe hypertension, Pulmonary edema.
	Doses and administration : Usual dosage for adults and elderly patients:  PO: 1 capsule/tablet: 2 times a day before meal (e.g. at 8 AM & 2 PM, with a daily nitrate-free interval of 10-12 hours). If necessary the dosage may be raised gradually to 2 or 3 capsules/tablets: 2 times daily. But dosage should be individualized depending on the Nitroglycerin sensitivity of the patient, the severity of illness and the occurrence of side-effects. Use in Children: Not recommended for children. Spray: In case of attack 1 or 2 doses should be administered under the tongue to a sitting patient. If necessary, more doses can be given but not more than 3 doses within 15 minutes.  For prevention 1 dose should be applied 5-10 minutes before physical exercise.         Use in Children: Nitroglycerin Spray is not recommended for children.
	Contara-indications : Hypersensitivity. Severe hypotension, heart failure, marked anaemia, hypertrophic obstructive cardiomyopathy, cerebral haemorrhage or head trauma, low cardiac output secondary to hypovolaemia, inferior MI with right ventricular involvement, raised intracranial pressure. Concomitant use with phosphodiesterase type-5 inhibitors.
	Side effects :  Headache, facial flashing, dizziness, nausea, vomiting, sweating, palpitation, sensation of heat, postural hypotension and reflex tachycardia. Large doses can cause vomiting, restlessness, hypotension, syncope, rarely cyanosis and methaemoglobinaemia, impaired respiration, bradycardia. Sublingual Tabs/Spray: Dry mouth, localised burning sensation. Buccal tablets: Delayed dissolution, may be swallowed by mistake. Potentially Fatal: Hypotension, paradoxical bradycardia, impaired respiration, syncope and collapse.
	Precaution : Severe hepatic or renal impairment, hypothyroidism, malnutrition, hypothermia. Cerebrovascular disease, lung disease or cor pulmonale. Pregnancy, lactation, glaucoma, mitral valve prolapse, cardiac tamponade, syncope. Gradual withdrawal in patients who have received prolonged high dose infusions. Avoid prolonged excessive hypotension. Nitrate-free interval is recommended in patients on continuous treatment with nitrates to reduce risk of tolerance.
	Pregnancy category : 3
	Mode of action : Glyceryl trinitrate acts on the enzyme nitric oxide stimulating guanylate cyclase in the vascular smooth muscle cells resulting in the relaxation of smooth muscles. It reduces venous return (preload) and facilitates subendocardial blood flow with redistribution into ischaemic areas. It relieves coronary vasospasm and dilates arterioles reducing afterload. It is useful for relief and prevention of anginal attacks.
	Interaction : Enhances bioavailability of dihydroergotamine. Glyceryl trinitrate infusion may prolong pancuronium-induced neuromuscular blockade. May reduce the efficacy of heparin, alteplase and noradrenaline when used together. Efficacy of buccal and sublingual preparations may be reduced by drugs that can cause dry mouth due to decreased dissolution. Aspirin and other NSAIDs may reduce the therapeutic response to glyceryl trinitrate.
				Potentially Fatal: Orthostatic hypotension may be produced by combined use of calcium channel blockers, antihypertensives, phenothiazines and TCAs. Alcohol may cause severe hypotension and collapse.
	Therapeutic class : Nitrates: Coronary vasodilators
	Packsize : 30's pack
Anril SR
	n : Glyceryl Trinitrate (nitroglycerine)
	Indications : Angina pectoris, Acute myocardial infarction, Severe hypertension, Pulmonary edema.
	Doses and administration : Usual dosage for adults and elderly patients:  PO: 1 capsule/tablet: 2 times a day before meal (e.g. at 8 AM & 2 PM, with a daily nitrate-free interval of 10-12 hours). If necessary the dosage may be raised gradually to 2 or 3 capsules/tablets: 2 times daily. But dosage should be individualized depending on the Nitroglycerin sensitivity of the patient, the severity of illness and the occurrence of side-effects. Use in Children: Not recommended for children. Spray: In case of attack 1 or 2 doses should be administered under the tongue to a sitting patient. If necessary, more doses can be given but not more than 3 doses within 15 minutes.  For prevention 1 dose should be applied 5-10 minutes before physical exercise.         Use in Children: Nitroglycerin Spray is not recommended for children.
	Contara-indications : Hypersensitivity. Severe hypotension, heart failure, marked anaemia, hypertrophic obstructive cardiomyopathy, cerebral haemorrhage or head trauma, low cardiac output secondary to hypovolaemia, inferior MI with right ventricular involvement, raised intracranial pressure. Concomitant use with phosphodiesterase type-5 inhibitors.
	Side effects :  Headache, facial flashing, dizziness, nausea, vomiting, sweating, palpitation, sensation of heat, postural hypotension and reflex tachycardia. Large doses can cause vomiting, restlessness, hypotension, syncope, rarely cyanosis and methaemoglobinaemia, impaired respiration, bradycardia. Sublingual Tabs/Spray: Dry mouth, localised burning sensation. Buccal tablets: Delayed dissolution, may be swallowed by mistake. Potentially Fatal: Hypotension, paradoxical bradycardia, impaired respiration, syncope and collapse.
	Precaution : Severe hepatic or renal impairment, hypothyroidism, malnutrition, hypothermia. Cerebrovascular disease, lung disease or cor pulmonale. Pregnancy, lactation, glaucoma, mitral valve prolapse, cardiac tamponade, syncope. Gradual withdrawal in patients who have received prolonged high dose infusions. Avoid prolonged excessive hypotension. Nitrate-free interval is recommended in patients on continuous treatment with nitrates to reduce risk of tolerance.
	Pregnancy category : 3
	Mode of action : Glyceryl trinitrate acts on the enzyme nitric oxide stimulating guanylate cyclase in the vascular smooth muscle cells resulting in the relaxation of smooth muscles. It reduces venous return (preload) and facilitates subendocardial blood flow with redistribution into ischaemic areas. It relieves coronary vasospasm and dilates arterioles reducing afterload. It is useful for relief and prevention of anginal attacks.
	Interaction : Enhances bioavailability of dihydroergotamine. Glyceryl trinitrate infusion may prolong pancuronium-induced neuromuscular blockade. May reduce the efficacy of heparin, alteplase and noradrenaline when used together. Efficacy of buccal and sublingual preparations may be reduced by drugs that can cause dry mouth due to decreased dissolution. Aspirin and other NSAIDs may reduce the therapeutic response to glyceryl trinitrate.
				Potentially Fatal: Orthostatic hypotension may be produced by combined use of calcium channel blockers, antihypertensives, phenothiazines and TCAs. Alcohol may cause severe hypotension and collapse.
	Therapeutic class : Nitrates: Coronary vasodilators
	Packsize : 50's pack
Anset
	n : Ondansetron
	Indications : Post-op nausea and vomiting, Nausea and vomiting associated w/ cancer chemotherapy
	Doses and administration : 1. Prevention of nausea-vomiting associated with chemotherapy
									
									1 a. Adult
									
									Parenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy
									
									Moderate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet/oral film should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
									
									
									1 b. Pediatric
									
									Parenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral (4-11 years): 4 mg tablet/oral film should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet/oral film should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.
									
									
									2. Prevention of nausea-vomiting associated with radiotherapy
									
									Adults/ Geriatric/ Child of 12 years or over
									The recommended dose is 8 mg tablet/oral film 3 times a day.
									
									For total body irradiation: One 8 mg tablet/oral film should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
									
									For single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
									
									For daily fractionated radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.
									
									
									3. Prevention of post-operative nausea-vomiting
									
									3 a. Adults/ Geriatric/ Child of 12 years or over
									
									Parenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery
									
									Oral: 16 mg (two 8 mg tablets/oral film) 1 hour before induction of anesthesia.
									
									
									3 b. Pediatric (1 months to12 years)
									
									Parenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.
									
									Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.
									
									4. Nausea-vomiting in gastroenteritis
									
									4 a. Adult: 8 mg three times daily.
									
									4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.
									
									
									5. Nausea vomiting in pregnancy
									8 mg (1 tablet) 2-3 times daily
									
	Contara-indications : Use with apomorphine (profound hypotension).
	Side effects : Headache, malaise/fatigue, constipation; drowsiness, fever, dizziness, anxiety, cold sensation; pruritus, rash; diarrhoea; gynaecological disorder, urinary retention; elevated transaminase; local inj site reaction (pain, redness, burning); paresthesia; hypoxia. Rarely: Anaphylaxis, angina, bronchospasm, ECG changes, extrapyramidal symptoms, grand mal seizure, hypokalaemia, tachycardia, vascular occlusive events.
	Precaution : May cause QT prolongation; caution when used in cardiac diseases, patients who are on medications that can prolong QT or patients with electrolyte abnormalities. Severe hepatic impairment. May mask progressive ileus and/or gastric distension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Ondansetron antagonises selective 5-HT3-receptor, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. This action of ondansetron gives it its antiemetic property to prevent emesis due to acute chemotherapy mediated by serotonin.
	Interaction : May reduce analgesic effect of tramadol. Rifampicin and other CYP3A4 inducers may reduce levels/effects of ondansetron. Concomitant use of QT-prolonging agents (e.g. antiarrhythmics) may cause additive prolongation of QT interval. May increase the risk of arrhythmias w/ cardiotoxic drugs (e.g. anthracyclines).
				Potentially Fatal: May increase the hypotensive effect of apomorphine.
	Therapeutic class : Anti-emetic drugs
	Packsize : 50ml bot
Anset
	n : Ondansetron
	Indications : Post-op nausea and vomiting, Nausea and vomiting associated w/ cancer chemotherapy
	Doses and administration : 1. Prevention of nausea-vomiting associated with chemotherapy
									
									1 a. Adult
									
									Parenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy
									
									Moderate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet/oral film should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
									
									
									1 b. Pediatric
									
									Parenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral (4-11 years): 4 mg tablet/oral film should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet/oral film should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.
									
									
									2. Prevention of nausea-vomiting associated with radiotherapy
									
									Adults/ Geriatric/ Child of 12 years or over
									The recommended dose is 8 mg tablet/oral film 3 times a day.
									
									For total body irradiation: One 8 mg tablet/oral film should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
									
									For single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
									
									For daily fractionated radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.
									
									
									3. Prevention of post-operative nausea-vomiting
									
									3 a. Adults/ Geriatric/ Child of 12 years or over
									
									Parenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery
									
									Oral: 16 mg (two 8 mg tablets/oral film) 1 hour before induction of anesthesia.
									
									
									3 b. Pediatric (1 months to12 years)
									
									Parenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.
									
									Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.
									
									4. Nausea-vomiting in gastroenteritis
									
									4 a. Adult: 8 mg three times daily.
									
									4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.
									
									
									5. Nausea vomiting in pregnancy
									8 mg (1 tablet) 2-3 times daily
									
	Contara-indications : Use with apomorphine (profound hypotension).
	Side effects : Headache, malaise/fatigue, constipation; drowsiness, fever, dizziness, anxiety, cold sensation; pruritus, rash; diarrhoea; gynaecological disorder, urinary retention; elevated transaminase; local inj site reaction (pain, redness, burning); paresthesia; hypoxia. Rarely: Anaphylaxis, angina, bronchospasm, ECG changes, extrapyramidal symptoms, grand mal seizure, hypokalaemia, tachycardia, vascular occlusive events.
	Precaution : May cause QT prolongation; caution when used in cardiac diseases, patients who are on medications that can prolong QT or patients with electrolyte abnormalities. Severe hepatic impairment. May mask progressive ileus and/or gastric distension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Ondansetron antagonises selective 5-HT3-receptor, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. This action of ondansetron gives it its antiemetic property to prevent emesis due to acute chemotherapy mediated by serotonin.
	Interaction : May reduce analgesic effect of tramadol. Rifampicin and other CYP3A4 inducers may reduce levels/effects of ondansetron. Concomitant use of QT-prolonging agents (e.g. antiarrhythmics) may cause additive prolongation of QT interval. May increase the risk of arrhythmias w/ cardiotoxic drugs (e.g. anthracyclines).
				Potentially Fatal: May increase the hypotensive effect of apomorphine.
	Therapeutic class : Anti-emetic drugs
	Packsize : 30's pack
Anset
	n : Ondansetron
	Indications : Post-op nausea and vomiting, Nausea and vomiting associated w/ cancer chemotherapy
	Doses and administration : 1. Prevention of nausea-vomiting associated with chemotherapy
									
									1 a. Adult
									
									Parenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy
									
									Moderate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet/oral film should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
									
									
									1 b. Pediatric
									
									Parenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral (4-11 years): 4 mg tablet/oral film should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet/oral film should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.
									
									
									2. Prevention of nausea-vomiting associated with radiotherapy
									
									Adults/ Geriatric/ Child of 12 years or over
									The recommended dose is 8 mg tablet/oral film 3 times a day.
									
									For total body irradiation: One 8 mg tablet/oral film should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
									
									For single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
									
									For daily fractionated radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.
									
									
									3. Prevention of post-operative nausea-vomiting
									
									3 a. Adults/ Geriatric/ Child of 12 years or over
									
									Parenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery
									
									Oral: 16 mg (two 8 mg tablets/oral film) 1 hour before induction of anesthesia.
									
									
									3 b. Pediatric (1 months to12 years)
									
									Parenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.
									
									Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.
									
									4. Nausea-vomiting in gastroenteritis
									
									4 a. Adult: 8 mg three times daily.
									
									4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.
									
									
									5. Nausea vomiting in pregnancy
									8 mg (1 tablet) 2-3 times daily
									
	Contara-indications : Use with apomorphine (profound hypotension).
	Side effects : Headache, malaise/fatigue, constipation; drowsiness, fever, dizziness, anxiety, cold sensation; pruritus, rash; diarrhoea; gynaecological disorder, urinary retention; elevated transaminase; local inj site reaction (pain, redness, burning); paresthesia; hypoxia. Rarely: Anaphylaxis, angina, bronchospasm, ECG changes, extrapyramidal symptoms, grand mal seizure, hypokalaemia, tachycardia, vascular occlusive events.
	Precaution : May cause QT prolongation; caution when used in cardiac diseases, patients who are on medications that can prolong QT or patients with electrolyte abnormalities. Severe hepatic impairment. May mask progressive ileus and/or gastric distension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Ondansetron antagonises selective 5-HT3-receptor, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. This action of ondansetron gives it its antiemetic property to prevent emesis due to acute chemotherapy mediated by serotonin.
	Interaction : May reduce analgesic effect of tramadol. Rifampicin and other CYP3A4 inducers may reduce levels/effects of ondansetron. Concomitant use of QT-prolonging agents (e.g. antiarrhythmics) may cause additive prolongation of QT interval. May increase the risk of arrhythmias w/ cardiotoxic drugs (e.g. anthracyclines).
				Potentially Fatal: May increase the hypotensive effect of apomorphine.
	Therapeutic class : Anti-emetic drugs
	Packsize : 10's pack
Anset ODT
	n : Ondansetron
	Indications : Post-op nausea and vomiting, Nausea and vomiting associated w/ cancer chemotherapy
	Doses and administration : 1. Prevention of nausea-vomiting associated with chemotherapy
									
									1 a. Adult
									
									Parenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy
									
									Moderate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet/oral film should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
									
									
									1 b. Pediatric
									
									Parenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral (4-11 years): 4 mg tablet/oral film should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet/oral film should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.
									
									
									2. Prevention of nausea-vomiting associated with radiotherapy
									
									Adults/ Geriatric/ Child of 12 years or over
									The recommended dose is 8 mg tablet/oral film 3 times a day.
									
									For total body irradiation: One 8 mg tablet/oral film should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
									
									For single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
									
									For daily fractionated radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.
									
									
									3. Prevention of post-operative nausea-vomiting
									
									3 a. Adults/ Geriatric/ Child of 12 years or over
									
									Parenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery
									
									Oral: 16 mg (two 8 mg tablets/oral film) 1 hour before induction of anesthesia.
									
									
									3 b. Pediatric (1 months to12 years)
									
									Parenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.
									
									Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.
									
									4. Nausea-vomiting in gastroenteritis
									
									4 a. Adult: 8 mg three times daily.
									
									4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.
									
									
									5. Nausea vomiting in pregnancy
									8 mg (1 tablet) 2-3 times daily
									
	Contara-indications : Use with apomorphine (profound hypotension).
	Side effects : Headache, malaise/fatigue, constipation; drowsiness, fever, dizziness, anxiety, cold sensation; pruritus, rash; diarrhoea; gynaecological disorder, urinary retention; elevated transaminase; local inj site reaction (pain, redness, burning); paresthesia; hypoxia. Rarely: Anaphylaxis, angina, bronchospasm, ECG changes, extrapyramidal symptoms, grand mal seizure, hypokalaemia, tachycardia, vascular occlusive events.
	Precaution : May cause QT prolongation; caution when used in cardiac diseases, patients who are on medications that can prolong QT or patients with electrolyte abnormalities. Severe hepatic impairment. May mask progressive ileus and/or gastric distension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Ondansetron antagonises selective 5-HT3-receptor, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. This action of ondansetron gives it its antiemetic property to prevent emesis due to acute chemotherapy mediated by serotonin.
	Interaction : May reduce analgesic effect of tramadol. Rifampicin and other CYP3A4 inducers may reduce levels/effects of ondansetron. Concomitant use of QT-prolonging agents (e.g. antiarrhythmics) may cause additive prolongation of QT interval. May increase the risk of arrhythmias w/ cardiotoxic drugs (e.g. anthracyclines).
				Potentially Fatal: May increase the hypotensive effect of apomorphine.
	Therapeutic class : Anti-emetic drugs
	Packsize : 30's pack
Anset ODT
	n : Ondansetron
	Indications : Post-op nausea and vomiting, Nausea and vomiting associated w/ cancer chemotherapy
	Doses and administration : 1. Prevention of nausea-vomiting associated with chemotherapy
									
									1 a. Adult
									
									Parenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy
									
									Moderate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet/oral film should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
									
									
									1 b. Pediatric
									
									Parenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.
									
									Oral (4-11 years): 4 mg tablet/oral film should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet/oral film should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.
									
									
									2. Prevention of nausea-vomiting associated with radiotherapy
									
									Adults/ Geriatric/ Child of 12 years or over
									The recommended dose is 8 mg tablet/oral film 3 times a day.
									
									For total body irradiation: One 8 mg tablet/oral film should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
									
									For single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
									
									For daily fractionated radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.
									
									
									3. Prevention of post-operative nausea-vomiting
									
									3 a. Adults/ Geriatric/ Child of 12 years or over
									
									Parenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery
									
									Oral: 16 mg (two 8 mg tablets/oral film) 1 hour before induction of anesthesia.
									
									
									3 b. Pediatric (1 months to12 years)
									
									Parenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.
									
									Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.
									
									4. Nausea-vomiting in gastroenteritis
									
									4 a. Adult: 8 mg three times daily.
									
									4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.
									
									
									5. Nausea vomiting in pregnancy
									8 mg (1 tablet) 2-3 times daily
									
	Contara-indications : Use with apomorphine (profound hypotension).
	Side effects : Headache, malaise/fatigue, constipation; drowsiness, fever, dizziness, anxiety, cold sensation; pruritus, rash; diarrhoea; gynaecological disorder, urinary retention; elevated transaminase; local inj site reaction (pain, redness, burning); paresthesia; hypoxia. Rarely: Anaphylaxis, angina, bronchospasm, ECG changes, extrapyramidal symptoms, grand mal seizure, hypokalaemia, tachycardia, vascular occlusive events.
	Precaution : May cause QT prolongation; caution when used in cardiac diseases, patients who are on medications that can prolong QT or patients with electrolyte abnormalities. Severe hepatic impairment. May mask progressive ileus and/or gastric distension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Ondansetron antagonises selective 5-HT3-receptor, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. This action of ondansetron gives it its antiemetic property to prevent emesis due to acute chemotherapy mediated by serotonin.
	Interaction : May reduce analgesic effect of tramadol. Rifampicin and other CYP3A4 inducers may reduce levels/effects of ondansetron. Concomitant use of QT-prolonging agents (e.g. antiarrhythmics) may cause additive prolongation of QT interval. May increase the risk of arrhythmias w/ cardiotoxic drugs (e.g. anthracyclines).
				Potentially Fatal: May increase the hypotensive effect of apomorphine.
	Therapeutic class : Anti-emetic drugs
	Packsize : 5 amps pack
Anspar
	n : Sparfloxacin
	Indications : Chronic bronchitis, Community-acquired pneumonia
	Doses and administration : Adult: PO Acute bacterial exacerbation of chronic bronchitis; Community-acquired pneumonia 100-300 mg/day in 1-2 divided doses.
	Contara-indications : Hypersensitivity; pregnancy and lactation; children <18 yr.
	Side effects : Diarrhoea, abdominal pain, nausea, vomiting; jaundice, renal failure, elevation of liver enzymes, BUN and creatinine; anaphylactoid reaction, headache, dizziness, convulsions; tremors, myalgia; rhabdomyolysis, thrombocytopenia and eosinophilia.
									Potentially Fatal: AV block; anaphylaxis.
	Precaution : History of CNS disorders, pseudomembranous colitis, superinfection, severe renal dysfunction, epilepsy, G6PD deficiency, myasthenia gravis, patients with QT prolongation, uncorrected electrolyte disturbances, bradycardia, or pre-existing cardiac disease. Avoid exposure to strong sunlight or sunlamps during treatment. Discontinue treatment if patients experience tendon pain, inflammation or rupture; subsequent use of fluoroquinolones in these patients is not recommended. Avoid in MRSA infections due to high risk of resistance. Ensure adequate fluid intake to reduce risk of crystalluria.
	Pregnancy category : 3
	Mode of action : Sparfloxacin inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp.
	Interaction : Cations such as aluminum, magnesium, zinc and iron may reduce the bioavailability of sparfloxacin. May increase the plasma concentrations of theophylline and tizanidine. May enhance the effect of warfarin and glibenclamide. May decrease the renal clearance of methotrexate. Excretion may be reduced by probenecid. May alter serum levels of phenytoin.
				Potentially Fatal: Corticosteroids may increase risk of tendon rupture. Increased risk of seizures with NSAIDs. Risk of additive QT prolongation effect when used with class Ia or III antiarrhythmic drugs, astemizole, terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs.
	Therapeutic class : 4-Quinolone preparations
	Packsize : 10's pack
Ansulin N
	n : Insulin (Human) N
	Indications : Diabetes mellitus
	Doses and administration : Adult:  SC DM Dosage should be individualised and adjusted based on patient's glycaemic response. Usual range: 0.5-1 u/kg/day.
	Contara-indications : Hypoglycaemia. Hypersensitivity to any of the components. 
	Side effects : Adverse events commonly associated with human insulin therapy include the following:  Allergic reactions.  Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance
	Precaution : Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. During infection.
	Pregnancy category : 2
	Mode of action : Insulin lowers blood glucose levels. It regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal. The various insulin formulations are classified according to their durations of action after SC Inj. They are divided into short-, intermediate-, or long-acting insulin. Soluble insulin (also known as 'neutral insulin' or 'regular insulin') is a short-acting preparation. 
									
									To extend the duration of action of insulin, preparations are formulated as suspensions in 2 methods. The 1st method involves complexing insulin with a protein so that it is slowly released, e.g. protamine zinc insulin (contains an excess of protamine) and isophane insulin (or NPH insulin which contains equal amounts of protamine and insulin). An alternative method is particle size modification e.g. insulin zinc suspensions. While all the formulations can be admin by SC inj, most by IM inj, only soluble insulin can be admin by IV. Compared to SC inj, IM admin usually has a faster onset of action, with a shorter duration of action.
	Interaction : Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
	Therapeutic class : Medium Acting Insulin
	Packsize : 10 ml vial
Ansulin N
	n : Insulin (Human) N
	Indications : Diabetes mellitus
	Doses and administration : Adult:  SC DM Dosage should be individualised and adjusted based on patient's glycaemic response. Usual range: 0.5-1 u/kg/day.
	Contara-indications : Hypoglycaemia. Hypersensitivity to any of the components. 
	Side effects : Adverse events commonly associated with human insulin therapy include the following:  Allergic reactions.  Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance
	Precaution : Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. During infection.
	Pregnancy category : 2
	Mode of action : Insulin lowers blood glucose levels. It regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal. The various insulin formulations are classified according to their durations of action after SC Inj. They are divided into short-, intermediate-, or long-acting insulin. Soluble insulin (also known as 'neutral insulin' or 'regular insulin') is a short-acting preparation. 
									
									To extend the duration of action of insulin, preparations are formulated as suspensions in 2 methods. The 1st method involves complexing insulin with a protein so that it is slowly released, e.g. protamine zinc insulin (contains an excess of protamine) and isophane insulin (or NPH insulin which contains equal amounts of protamine and insulin). An alternative method is particle size modification e.g. insulin zinc suspensions. While all the formulations can be admin by SC inj, most by IM inj, only soluble insulin can be admin by IV. Compared to SC inj, IM admin usually has a faster onset of action, with a shorter duration of action.
	Interaction : Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
	Therapeutic class : Medium Acting Insulin
	Packsize : 10 ml vial
Ansulin R
	n : Insulin (Human) R
	Indications : Diabetic ketoacidosis, Diabetes mellitus
	Doses and administration : Adult: SC DM Dosage should be individualised and adjusted based on patient's glycaemic response. Usual range: 0.5-1 u/kg/day.
									
									IV Diabetic ketoacidosis As soluble insulin at a concentration of 1 u/mL via an infusion pump: Initial: Infuse at a rate of 6 u/hr, double or quadruple the rate if blood glucose concentration do not decrease by about 5 mmol/L/hr. If blood glucose concentrations have decreased to 10 mmol/L, reduce infusion rate to 3 u/hr and continue w/ 5% glucose until the patient can eat orally. 
									
									IM Diabetic ketoacidosis As soluble insulin: Loading dose: 20 u, then 6 u/hr until blood glucose drops to 10 mmol/L, when the dose is given 2 hrly. SC DM Dosage should be individualised and adjusted based on patient's glycaemic response.
	Contara-indications : Hypoglycaemia.Hypersensitivity to any of the components. 
	Side effects : Adverse events commonly associated with human insulin therapy include the following: Allergic reactions. Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance
	Precaution : Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. Regular monitoring of HbA1c and blood glucose concentrations.
	Pregnancy category : 2
	Mode of action : Insulin lowers blood glucose levels. It regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal. The various insulin formulations are classified according to their durations of action after SC Inj. They are divided into short-, intermediate-, or long-acting insulin. Soluble insulin (also known as 'neutral insulin' or 'regular insulin') is a short-acting preparation. 
									
									To extend the duration of action of insulin, preparations are formulated as suspensions in 2 methods. The 1st method involves complexing insulin with a protein so that it is slowly released, e.g. protamine zinc insulin (contains an excess of protamine) and isophane insulin (or NPH insulin which contains equal amounts of protamine and insulin). An alternative method is particle size modification e.g. insulin zinc suspensions. While all the formulations can be admin by SC inj, most by IM inj, only soluble insulin can be admin by IV. Compared to SC inj, IM admin usually has a faster onset of action, with a shorter duration of action.
	Interaction : Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
	Therapeutic class : Short Acting Insulin
	Packsize : 100 i.u X 10ml vial
Ansulin R
	n : Insulin (Human) R
	Indications : Diabetic ketoacidosis, Diabetes mellitus
	Doses and administration : Adult: SC DM Dosage should be individualised and adjusted based on patient's glycaemic response. Usual range: 0.5-1 u/kg/day.
									
									IV Diabetic ketoacidosis As soluble insulin at a concentration of 1 u/mL via an infusion pump: Initial: Infuse at a rate of 6 u/hr, double or quadruple the rate if blood glucose concentration do not decrease by about 5 mmol/L/hr. If blood glucose concentrations have decreased to 10 mmol/L, reduce infusion rate to 3 u/hr and continue w/ 5% glucose until the patient can eat orally. 
									
									IM Diabetic ketoacidosis As soluble insulin: Loading dose: 20 u, then 6 u/hr until blood glucose drops to 10 mmol/L, when the dose is given 2 hrly. SC DM Dosage should be individualised and adjusted based on patient's glycaemic response.
	Contara-indications : Hypoglycaemia.Hypersensitivity to any of the components. 
	Side effects : Adverse events commonly associated with human insulin therapy include the following: Allergic reactions. Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance
	Precaution : Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. Regular monitoring of HbA1c and blood glucose concentrations.
	Pregnancy category : 2
	Mode of action : Insulin lowers blood glucose levels. It regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal. The various insulin formulations are classified according to their durations of action after SC Inj. They are divided into short-, intermediate-, or long-acting insulin. Soluble insulin (also known as 'neutral insulin' or 'regular insulin') is a short-acting preparation. 
									
									To extend the duration of action of insulin, preparations are formulated as suspensions in 2 methods. The 1st method involves complexing insulin with a protein so that it is slowly released, e.g. protamine zinc insulin (contains an excess of protamine) and isophane insulin (or NPH insulin which contains equal amounts of protamine and insulin). An alternative method is particle size modification e.g. insulin zinc suspensions. While all the formulations can be admin by SC inj, most by IM inj, only soluble insulin can be admin by IV. Compared to SC inj, IM admin usually has a faster onset of action, with a shorter duration of action.
	Interaction : Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
	Therapeutic class : Short Acting Insulin
	Packsize : 40 i.u X 10ml vial
Antac
	n : Ranitidine
	Indications : Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
	Doses and administration : Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. 
									For prevention of NSAID-associated ulceration: 150 mg bid. 
									Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. 
									GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.
									 Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. 
									Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. 
									Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. 
									Prophylaxis during NSAID treatment 150 mg twice daily. 
									
									IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. 
									
									IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
	Contara-indications : Porphyria.
	Side effects : Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
									Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
	Precaution : Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
	Interaction : Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
	Therapeutic class : H2 antagonists
	Packsize : 10 amps pack
Antac
	n : Ranitidine
	Indications : Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
	Doses and administration : Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. 
									For prevention of NSAID-associated ulceration: 150 mg bid. 
									Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. 
									GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.
									 Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. 
									Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. 
									Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. 
									Prophylaxis during NSAID treatment 150 mg twice daily. 
									
									IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. 
									
									IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
	Contara-indications : Porphyria.
	Side effects : Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
									Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
	Precaution : Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
	Interaction : Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
	Therapeutic class : H2 antagonists
	Packsize : 100ml bot
Antac
	n : Ranitidine
	Indications : Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
	Doses and administration : Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. 
									For prevention of NSAID-associated ulceration: 150 mg bid. 
									Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. 
									GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.
									 Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. 
									Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. 
									Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. 
									Prophylaxis during NSAID treatment 150 mg twice daily. 
									
									IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. 
									
									IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
	Contara-indications : Porphyria.
	Side effects : Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
									Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
	Precaution : Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
	Interaction : Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
	Therapeutic class : H2 antagonists
	Packsize : 100's pack
Antacid Max
	n : Aluminium Hydroxide + Magnesium Hydroxide + Simethicon
	Indications : Dyspepsia, Flatulence
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Aluminum hydroxide: Neutralizes stomach hydrocloride to form AlCl3 salt plus water; increases gastric pH.
									Magnesium hydroxide: Promotes bowel evacuation by causing osmotic retention of fluid, which causes the colon to distend with increased peristaltic activity; forms magnesium chloride when reacts with hydrochloric acid.
									Simethicone: Disperses and prevents gas pockets in the GI system by decreasing surface tension of gas bubles.
									
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
				
				Simethicon: None well documented.
	Therapeutic class : Antacids
	Packsize : 200's pack
Antage
	n : Vitamin C + Vitamin E
	Indications : Keratosis, Rough skin,Wrinkles associated with aging, Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair. 
	Doses and administration : One tablet/capsule daily or as directed by a physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.
	Pregnancy category : 1
	Mode of action : Vitamin C: Necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									
	Interaction : Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.
				
				Vit E: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.
	Therapeutic class : Anti-oxidant Multivitamin preparations
	Packsize : 15's pack/30's pack
Antameal
	n : Aluminium Hydroxide + Magnesium Hydroxide
	Indications : Heartburn, Reflux oesophagitis, Hyperacidity, Peptic ulcer, Constipation, Indigestion
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200's pack
Antanil
	n : Aluminium Hydroxide + Magnesium Hydroxide
	Indications : Heartburn, Reflux oesophagitis, Hyperacidity, Peptic ulcer, Constipation, Indigestion
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200's pack
Antanil
	n : Aluminium Oxide + Magnesium Hydroxide
	Indications : Hyperacidity, Flatulence, Gastric ulcer, Duodenal ulcer, Gastritis, Stomach distension
	Doses and administration : Chew 1-2 tablets after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. For best results, drink a half glass of water or other liquid after each dose. Do not take more than 16 tablets in 24 hours
	Contara-indications : Hypophosphataemia.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200ml bot
Antanil PLUS
	n : Aluminium Hydroxide + Magnesium Hydroxide + Simethicon
	Indications : Dyspepsia, Flatulence
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Aluminum hydroxide: Neutralizes stomach hydrocloride to form AlCl3 salt plus water; increases gastric pH.
									Magnesium hydroxide: Promotes bowel evacuation by causing osmotic retention of fluid, which causes the colon to distend with increased peristaltic activity; forms magnesium chloride when reacts with hydrochloric acid.
									Simethicone: Disperses and prevents gas pockets in the GI system by decreasing surface tension of gas bubles.
									
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
				
				Simethicon: None well documented.
	Therapeutic class : Antacids
	Packsize : 100's pack
Antazol 0.05%
	n : Xylometazoline Hydrochloride 0.05% Nasal prep
	Indications : Sinusitis, Nasal congestion, Seasonal & perennial allergic rhinitis
	Doses and administration : Adults (including the elderly) and children: One spray each nostril four times daily.
	Contara-indications : Contraindicated in patients with a known hypersensitivity to any ingredients of the preparation.
	Side effects : No serious side effects have been reported. Occasional irritation of the nasal mucosa may occur during the first day of use. In rare cases with Sodium Cromoglicate solutions alone wheezing and tightness of the chest has been reported. Because a lower dose of Xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations.
	Precaution : The prolonged use or abuse of decongestants in general may lead to rebound congestion or drug induced rhinitis.
	Pregnancy category : 3
	Mode of action : Xylometazoline is a direct-acting sympathomimetic which has a vasoconstrictor effect by reducing swelling and congestion when applied to mucous membranes.
	Interaction : Increased heart rate or BP with sibutramine.
				Potentially Fatal: Hypertensive crisis with MAOIs.
	Therapeutic class : Nasal Anti-histamine preparations
	Packsize : 12's pack
Antazol 0.05%
	n : Xylometazoline Hydrochloride 0.05% Nasal prep
	Indications : Sinusitis, Nasal congestion, Seasonal & perennial allergic rhinitis
	Doses and administration : Adults (including the elderly) and children: One spray each nostril four times daily.
	Contara-indications : Contraindicated in patients with a known hypersensitivity to any ingredients of the preparation.
	Side effects : No serious side effects have been reported. Occasional irritation of the nasal mucosa may occur during the first day of use. In rare cases with Sodium Cromoglicate solutions alone wheezing and tightness of the chest has been reported. Because a lower dose of Xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations.
	Precaution : The prolonged use or abuse of decongestants in general may lead to rebound congestion or drug induced rhinitis.
	Pregnancy category : 3
	Mode of action : Xylometazoline is a direct-acting sympathomimetic which has a vasoconstrictor effect by reducing swelling and congestion when applied to mucous membranes.
	Interaction : Increased heart rate or BP with sibutramine.
				Potentially Fatal: Hypertensive crisis with MAOIs.
	Therapeutic class : Nasal Anti-histamine preparations
	Packsize : 120 sprays
Antazol
	n : Xylometazoline Hydrochloride 0.1% Nasal prep
	Indications : Sinusitis, Nasal congestion, Seasonal & perennial allergic rhinitis
	Doses and administration : Adults (including the elderly) and children: One spray each nostril four times daily.
	Contara-indications : Contraindicated in patients with a known hypersensitivity to any ingredients of the preparation.
	Side effects : No serious side effects have been reported. Occasional irritation of the nasal mucosa may occur during the first day of use. In rare cases with Sodium Cromoglicate solutions alone wheezing and tightness of the chest has been reported. Because a lower dose of Xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations.
	Precaution : The prolonged use or abuse of decongestants in general may lead to rebound congestion or drug induced rhinitis.
	Pregnancy category : 3
	Mode of action : Xylometazoline is a direct-acting sympathomimetic which has a vasoconstrictor effect by reducing swelling and congestion when applied to mucous membranes.
	Interaction : Increased heart rate or BP with sibutramine.
				Potentially Fatal: Hypertensive crisis with MAOIs.
	Therapeutic class : Nasal Anti-histamine preparations
	Packsize : 15 ml drop x 12's pack
Antazol 0.1%
	n : Xylometazoline Hydrochloride 0.1% Nasal prep
	Indications : Sinusitis, Nasal congestion, Seasonal & perennial allergic rhinitis
	Doses and administration : Adults (including the elderly) and children: One spray each nostril four times daily.
	Contara-indications : Contraindicated in patients with a known hypersensitivity to any ingredients of the preparation.
	Side effects : No serious side effects have been reported. Occasional irritation of the nasal mucosa may occur during the first day of use. In rare cases with Sodium Cromoglicate solutions alone wheezing and tightness of the chest has been reported. Because a lower dose of Xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations.
	Precaution : The prolonged use or abuse of decongestants in general may lead to rebound congestion or drug induced rhinitis.
	Pregnancy category : 3
	Mode of action : Xylometazoline is a direct-acting sympathomimetic which has a vasoconstrictor effect by reducing swelling and congestion when applied to mucous membranes.
	Interaction : Increased heart rate or BP with sibutramine.
				Potentially Fatal: Hypertensive crisis with MAOIs.
	Therapeutic class : Nasal Anti-histamine preparations
	Packsize : 12's pack
Antazol PLUS
	n : Sodium Cromoglycate +  Xylometazoline Hydrochloride
	Indications : Allergic rhinitis accompanied by nasal congestion
	Doses and administration : Adults (including the elderly) and children: One spray each nostril four times daily.
	Contara-indications : Contraindicated in patients with a known hypersensitivity to any ingredients of the preparation.
	Side effects : No serious side effects have been reported. Occasional irritation of the nasal mucosa may occur during the first day of use. In rare cases with Sodium Cromoglicate solutions alone wheezing and tightness of the chest has been reported. Because a lower dose of Xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations.
	Precaution : The prolonged use or abuse of decongestants in general may lead to rebound congestion or drug induced rhinitis.
	Pregnancy category : 0
	Mode of action : Sodium Cromoglycate inhibits degranulation of mast cells and therefore suppresses the release of histamine, leukotrienes and slow-reacting substance of anaphylaxis.
									
									Xylometazoline is a direct-acting sympathomimetic which has a vasoconstrictor effect by reducing swelling and congestion when applied to mucous membranes.
	Interaction : xylometazoline hydrochloride....Increased heart rate or BP with sibutramine.
				Potentially Fatal: Hypertensive crisis with MAOIs.
	Therapeutic class : Mast Cell Stabiliser
	Packsize : 120 spray unit
Antepsin
	n : Sucralfate
	Indications : Peptic ulcer, Chronic gastritis, GI haemorrhage from stress ulceration
	Doses and administration : Oral
									Chronic gastritis
									Adult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Maintenance dose of 1 g bid may be given to prevent the recurrence of duodenal ulcers. Max: 8 g daily.
									Child: 1 mth-2 yr: 250 mg 4-6 times daily; 2-12 yr: 500 mg 4-6 times daily and 12-18 yr: 1 g 4-6 times daily.
									
									Peptic ulcer
									Adult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Maintenance dose of 1 g bid may be given to prevent the recurrence of duodenal ulcers. Max: 8 g daily.
									Child: 1 mth-2 yr: 250 mg 4-6 times daily; 2-12 yr: 500 mg 4-6 times daily and 12-18 yr: 1 g 4-6 times daily.
									
									Prophylaxis of gastrointestinal haemorrhage from stress ulceration
									Adult: 1 g 6 times daily. Not to exceed 8 g daily.
									Child: 1 mth-2 yr: 250 mg 4-6 times daily; 2-12 yr: 500 mg 4-6 times daily and 12-18 yr: 1 g 4-6 times daily.
	Contara-indications : Hypersensitivity.
	Side effects : Constipation, diarrhoea, nausea, dizziness, dry mouth. GI disturbances, rash, pruritus, headache, vertigo, back pain, drowsiness.
	Precaution : Systemic aluminum toxicity may occur in patients with chronic renal failure. Neonates, children; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Sucralfate protects GI lining against peptic acid, pepsin and bile salts by binding with positively-charged proteins in exudates forming a viscous paste-like adhesive substance thus forming a protective coating.
	Interaction : Avoid antacids within 30 min of sucralfate admin. May reduce absorption of tetracyclines, ranitidine, ketoconazole, theophylline, phenytoin, cimetidine and digoxin (ensure a dosing interval of at least 2 hr between admin of sucralfate and other non-antacid medications).
	Therapeutic class : Chelating complex
	Packsize : 100's pack
Anthel
	n : Albendazole
	Indications : Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis
	Doses and administration : Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.
									
									Child: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.
	Contara-indications : Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.
	Side effects : GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.
									Potentially Fatal: Bone marrow depression.
	Precaution : Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.
	Pregnancy category : 3
	Mode of action : Albendazole sulfoxide (active metabolite), causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired and desecratory substances accumulate intracellulary. ATP production decreases, causing energy depletion, immobilisation and worm death.
	Interaction : Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
	Therapeutic class : Anti-helminthic
	Packsize : 50's pack
Anthisan
	n : Mepyramine Maleate 2% Topical
	Indications : Pruritic skin disorders
	Doses and administration : Adult: Apply 2% cream on affected areas.
	Contara-indications : Severe liver disease; premature infants or full-term neonates; eczema (topical).
	Side effects : Sedation; antimuscarinic effects, CNS depression and disturbances; occasionally, paradoxical CNS stimulation; psychomotor impairment; headache; palpitations and arrhythmias; convulsions, sweating, myalgia, paraesthesias, extrapyramidal symptoms, tremor, sleep and GI disturbances, hypersensitivity reactions and blood dyscrasias; hypotension; hair loss; tinnitus.
	Precaution : Pregnancy; lactation; severe CV disorders; asthma; drowsiness; angle-closure glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction; renal and hepatic impairment; elderly; epilepsy. May affect ability to drive and operate machinery. Broken skin (topical).
	Pregnancy category : 0
	Mode of action : Mepyramine is an ethylenediamine derived antihistamine with antimuscarinic and sedating properties.
	Interaction : increased effects with CNS depressants (e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and neuroleptics). Additive effects with other antimuscarinics (e.g. TCAs, atropine).
	Therapeutic class : Topical Anti-histamines
	Packsize : 15gm  tube
Antial
	n : Galantamine
	Indications : Dementia in Alzheimer's disease.
	Doses and administration : Adult: PO Initial: 4 mg twice daily for 4 wk, then increase to 8 mg twice daily for at least 4 wk. Up to 12 mg twice daily based on response and tolerance.
									
									Renal impairment: Moderate: Max: 16 mg daily.
									CrCl (ml/min)	
									<9	Avoid.
									
									Hepatic impairment: Child-Pugh category C: Avoid.
	Contara-indications : Hypersensitivity; severe liver or kidney dysfunction; lactation; disorders of galactose metabolism; urinary retention or GI obstruction. Lactation.
	Side effects : GI disturbances; bradycardia, CNS disturbances; tremor, anorexia, wt loss; urinary tract infection; anaemia; rhinitis.
									Potentially Fatal: CV effects; convulsion; delirium; rectal haemorrhage; thrombocytopenia.
	Precaution : Mild-moderate hepatic impairment; supraventricular conduction abnormalities; asthma; COPD; pregnancy; peptic ulcers. May increase gastric acid production.
	Pregnancy category : 2
	Mode of action : Galantamine is a centrally-acting cholinesterase inhibitor, elevating acetylcholine in the cerebral cortex. Glutamine and serotonin levels may also be increase. It has nicotinic receptor agonist properties.
	Interaction : ncreased serum concentrations when used with drugs that inhibit CYP2D6 (e.g. quinidine, fluoxetine, fluvoxamine, and paroxetine) and CYP3A4 (e.g. ketoconazole and ritonavir). Cimetidine may increase the bioavailability of galantamine. Increased risk of gastric ulcer when used with NSAIDs.
				Potentially Fatal: Amiodarone, ?-blockers, diltiazem or verapamil; NSAIDs; digoxin.
	Therapeutic class : Drugs for Dementia
	Packsize : 10's pack
Antif
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 15ml bot
Antif
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Antif
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Antif
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Antigrain
	n : Pizotifen
	Indications : Headache, Migraine
	Doses and administration : Oral
									Prophylaxis of migraine, Prophylaxis of cluster headache
									Adult: 1.5 mg/day either in 3 divided doses or as a single dose at night. Gradual increase of 0.5 mg helps to avoid drowsiness. Max dose: 4.5 mg/day and 3 mg/dose.
									
									Child: >2 yr: Up to 1.5 mg daily in divided doses. Max dose: 1 mg/dose.
	Contara-indications : Premature infants or neonates. Postural giddiness.
	Side effects : CNS depression; headache, psychomotor impairment, antimuscarinic effects; GI disturbances; increased appetite; wt gain; drowsiness; palpitations, arrhythmias; hypersensitivity reactions; blood disorders; convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, sleep disturbances, confusion, tinnitus, tremor, depression, hypotension, hair loss.
	Precaution : Angle-closure glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction, epilepsy; hepatic impairment; elderly; young child. May affect ability to drive or operate machinery. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Pizotifen is a sedating antihistamine with strong serotonin antagonist and weak antimuscarinic properties. It also antagonises the action of tryptamine.
	Interaction : Enhances sedative effects of CNS depressants. Additive antimuscarinic action with other antimuscarinic drugs. May mask warning signs of damage caused by ototoxic drugs eg, aminoglycosides.
	Therapeutic class : Other drugs for migraine
	Packsize : 50's pack
Antigrain TS
	n : Pizotifen
	Indications : Headache, Migraine
	Doses and administration : Oral
									Prophylaxis of migraine, Prophylaxis of cluster headache
									Adult: 1.5 mg/day either in 3 divided doses or as a single dose at night. Gradual increase of 0.5 mg helps to avoid drowsiness. Max dose: 4.5 mg/day and 3 mg/dose.
									
									Child: >2 yr: Up to 1.5 mg daily in divided doses. Max dose: 1 mg/dose.
	Contara-indications : Premature infants or neonates. Postural giddiness.
	Side effects : CNS depression; headache, psychomotor impairment, antimuscarinic effects; GI disturbances; increased appetite; wt gain; drowsiness; palpitations, arrhythmias; hypersensitivity reactions; blood disorders; convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, sleep disturbances, confusion, tinnitus, tremor, depression, hypotension, hair loss.
	Precaution : Angle-closure glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction, epilepsy; hepatic impairment; elderly; young child. May affect ability to drive or operate machinery. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Pizotifen is a sedating antihistamine with strong serotonin antagonist and weak antimuscarinic properties. It also antagonises the action of tryptamine.
	Interaction : Enhances sedative effects of CNS depressants. Additive antimuscarinic action with other antimuscarinic drugs. May mask warning signs of damage caused by ototoxic drugs eg, aminoglycosides.
	Therapeutic class : Other drugs for migraine
	Packsize : 30's pack
Antima
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 50ml bot
Antima
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 4's pack
Antima
	n : Cefixime
	Indications : Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis
	Doses and administration : Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
									Gonorrhea: 400 mg as a single dose.
									Powder for Suspension & DS Powder for Suspension:
									Children above 6 months: 8 mg/kg daily in 1-2 divided doses or
									6 months-1year: 75 mg daily
									1-4 years: 100 mg daily
									5-10 years: 200 mg daily
									Typhoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.
									The usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.
									
									Renal impairment: Dose reduction is necessary.
									CrCl (ml/min)	
									<20	     Max: 200 mg daily. 
	Contara-indications : Hypersensitivity to cephalosporin.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.
	Pregnancy category : 2
	Mode of action : Cefixime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : Increased concentrations with probenecid.
				Potentially Fatal: May increase prothrombin time with anticoagulants.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1x4's pack
Antinos
	n : Meclizine Hydrochloride + Pyridoxine Hydrochloride
	Indications : Nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of vestibular motion sickness, radiation sickness and vertigo associated with diseases of vestibular system, morning sickness during pregnancy, drug induced nausea, vomiting induced by oral contraceptives or Estrogen preparations. 
	Doses and administration : Adult: PO: As combination preparation containing meclozine 25 mg and pyridoxine 50 mg per tablet: 1 tablet at night.
	Contara-indications : Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.
	Side effects : Drowsiness, thickening of bronchial secretions, dry mouth, fatigue, blurred vision.
	Precaution : Prostate hypertrophy, obstruction of bladder neck, narrow angle glaucoma, pyloric stenosis. May impair ability to drive or operate machinery. Pregnancy.
	Pregnancy category : 12
	Mode of action : Meclozine blocks vasopressor response to histamine and has a slight blocking action against acetylcholine. It decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways.
									
									Pyridoxine is a water-soluble vitamin which functions in the metabolism of carbohydrates, proteins and fats. It is essential in Hb formation and GABA synthesis within the CNS. It also aids in the release of glycogen stored in the liver and muscles.
	Interaction : Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
	Therapeutic class : Anti-emetic drugs
	Packsize : 50's pack
Antipen
	n : Hyoscine Butyl Bromide
	Indications : Gastrointestinal tract spasm, Abdominal pain, Genitourinary spasm
	Doses and administration : Adult: PO Genito-urinary spasm; GI tract spasm As butylbromide: 20 mg 4 times/day.
									
									IV/IM Genito-urinary spasm; GI tract spasm As butylbromide: 20 mg, repeat 30 mins later if needed. Max: 100 mg/day. 
									
									
	Contara-indications : Narrow-angle glaucoma, acute haemorrhage, paralytic ileus, tachycardia due to cardiac insufficiency, myasthenia gravis.
	Side effects : Flushing, postural hypotension, tachycardia, fibrillation. Rarely psychotic reactions. Dizziness, drowsiness, fatigue, headache, memory loss. Dry skin, erythema, increased sensitivity to light, rash. Bloatedness, constipation, dry throat, dysphagia, nausea, vomiting, xerostomia. Dysuria, urinary retention. Tremor, weakness. Impaired accommodation, blurred vision, cycloplegia, dryness, narrow-angle glaucoma, increased intraocular pain, itching, photophobia, pupil dilation. Dry nose. Decreased diaphoresis, heat intolerance. Ophthalmic: Somnolence, dermatitis, oedema, exudate, follicular conjunctivitis, increased IOP, local irritation, photophobia, vascular and respiratory congestion.
									Potentially Fatal: CNS depression, coma, circulatory and respiratory failure.
	Precaution : Hepatic/renal disease, pyloric stenosis, urinary retention, prostatic hyperplasia, psychosis, seizure disorders, ulcerative colitis, coronary artery disease, tachyarrhythmias, heart failure, hypertension. Elderly, children, pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Hyoscine competitively blocks muscarinic receptors and has central and peripheral actions. It relaxes smooth muscle and reduces gastric and intestinal motility.
	Interaction : Additive sedative effects with alcohol or other CNS depressants. Reduced effects with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine).
				Potentially Fatal: Effect potentiated by other anticholinergic drugs and TCAs.
	Therapeutic class : Anticholinergics(antimuscarinics)/Anti-spasmodics
	Packsize : 100's pack
Antipro
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Antipro
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Antison
	n : Flupenthixol + Melitracen
	Indications : Depression, Anxiety, Apathy, Dysphoria
	Doses and administration : Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets.
									Elderly: 1 tablet in the morning.
									Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
	Contara-indications : The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
	Side effects : In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
	Precaution : If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.
	Pregnancy category : 3
	Mode of action : Flupentixol is a thioxanthene antipsychotic that inhibits dopamine-mediated effects by blocking postsynaptic dopamine receptors in the CNS.
									Melitracen is a TCA with anxiolytic properties.
	Interaction :  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).
				Potentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.
				 	Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 30's pack
Antista
	n : Chlorpheniramine Maleate
	Indications : Urticaria, Sneezing, Watery eyes,  Allergic conditions, Anaphylactic shock, Rhinitis, Itching
	Doses and administration : Adult: 4 mg every 4-6 hr. Max: 24 mg daily. 
									Child: 1-2 yr: 1 mg bid, 2-5 yr: 1 mg every 4-6 hr, 6-12 yr: 2 mg every 4-6 hr. Max: 6 mg daily (1-5 yr); 12 mg daily (6-12 yr). 
									
									Parenteral
									Adjunct in the emergency treatment of anaphylactic shock
									Adult: 10-20 mg IM, SC, or slow IV inj over 1 min. Max dose: 40 mg daily.
									Child: 87.5 mcg/kg SC 4 times daily
									
									
	Contara-indications : Hypersensitivity, Neonates.
	Side effects : CNS depression, sedation, drowsiness, lassitude, dizziness. GI upsets, anorexia, or increased appetite, epigastric pain, blurring of vision, dysuria, dryness of mouth, tightness in chest, hypotension, muscular weakness, tinnitus, euphoria, headache, paradoxical CNS stimulation.
									Potentially Fatal: CV collapse and respiratory failure.
	Precaution : Elderly, pylori duodenal obstruction, angle-closure glaucoma, urinary retention, prostatic hyperplasia, epilepsy, renal and hepatic impairment. May affect performance of skilled tasks. BPH, bladder neck obstruction, hypertension. Pregnancy, lactation.
	Pregnancy category : 2
	Mode of action : Chlorphenamine is an H1-receptor antagonist which competetively blocks H1-receptor sites on tissues.
	Interaction : Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).
	Therapeutic class : Sedating Anti-histamines
	Packsize : 100ml bot
Antiva
	n : Adefovir Dipivoxil
	Indications : Herpes simplex virus, Chronic hepatitis B
	Doses and administration : Adult: PO: The recommended dose of Adefovir for the treatment of chronic hepatitis B in adolescent & adults (age > 12 year) with adequate renal function is 10 mg, once daily, taken orally, without regard to food. 
									
									Renal impairment: Haemodialysis patients: 10 mg every 7 days after dialysis.
									CrCl (ml/min)	
									20-49	10 mg every 48 hr.
									10-19	10 mg every 72 hr.
									
									
									Dose Adjustment in Renal Impairment: Significantly increased drug exposures are seen when Adefovir Dipivoxil is administered to patients with renal impairment. Therefore, the dosing interval of Adefovir Dipivoxil should be adjusted in patients with baseline creatinine clearance < 50 mL/min using the following suggested guidelines- Dosing interval adjustment of Adefovir in patients with renal impairment Creatinine clearance (mL/min) > 50 20 to 49 10 to 19 < 10 Hemodialysis or CAPD Recommended dose and dosing interval 10 mg every 24 hours 10 mg every 48 hours 10 mg every 72 hours 10 mg every 7 days.
									
	Contara-indications : Adefovir Dipivoxil is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product.
	Side effects : Nausea, dyspepsia, abdominal pain, flatulence, diarrhoea, asthenia, headache. Pruritus, skin rashes, and respiratory effects e.g. cough, pharyngitis and sinusitis.Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis, hepatotoxicity, nephrotoxicity.
	Precaution : Pregnancy; elderly; child; renal or hepatic impairment. HIV antibody testing to be performed before initiation due to possible resistance development in untreated HIV infection. Increased risk of hepatotoxicity in females, obese patients and with prolonged treatment. Monitor renal function every 3 mth; hepatitis B biochemical, viral and serological markers every 6 mth and LFTs. Discontinue therapy if liver function worsens, severe hepatomegaly, steatosis or unexplained metabolic or lactic acidosis. Monitor hepatic function for several mth in patients whose antihepatitis therapy is discontinued as acute exacerbations of hepatitis may occur.
	Pregnancy category : 3
	Mode of action : Adefovir dipivoxil is an acyclic nucleoside reverse transciptase inhibitor. The diester function is hydrolyzed and subsequently phosphorylated to the active adefovir diphosphate. The active metabolite inhibits HBV DNA polymerase (reverse transcriptase) and hence inhibits viral replication. It can be used in patients with lamivudine-resistant hepatitis B.
	Interaction : Increased risk of nephrotoxicity with nephrotoxic drugs e.g. aminoglycosides, ciclosporin, NSAIDs, vancomycin, tacrolimus. Ibuprofen increases bioavailability of adefovir.
	Therapeutic class : Hepatic viral infections (Hepatitis B)
	Packsize : 10's pack
Antivert
	n : Meclizine Hydrochloride
	Indications : Motion sickness, Vertigo and Vestibular disorders
	Doses and administration : Adult and Children 12 years of age & over: Nausea and vomiting: 25-50 mg daily or as directed by a physician.
									Motion sickness: Take an initial dose of 25-50 mg, 1 hour prior to travel. May repeat the dose every 24 hours for the duration of the journey.
									Radiation sickness: 50 mg administered 2-12 hours prior to radiation treatment.
									Vertigo: 25-100 mg daily in divided doses.
									Prevention of nausea and vomiting associated with emergency contraceptive pill (ECP) : 25-50 mg, 1 hour before first ECP dose; repeat if needed in 24 hours.
									The safety and efficacy for use in children less than 12 years of age have not been established. 
	Contara-indications : Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.
	Side effects : Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.
	Precaution : Patients should be warned that Meclizine Hydrochloride may impair their ability to perform hazardous activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle). Patients should avoid alcoholic beverages while taking this drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.
	Pregnancy category : 2
	Mode of action : Meclozine blocks vasopressor response to histamine and has a slight blocking action against acetylcholine. It decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways.
	Interaction : Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
	Therapeutic class : Anti-emetic drugs
	Packsize : 100's pack
Antizoa
	n : Nitazoxanide
	Indications : Giardiasis, Cryptosporidiosis
	Doses and administration : Age 1 - 3 years : 5 ml (100 mg) twice daily for 3 days, Age 4 - 11 years : 10 ml (200 mg) twice daily for 3 days, Age >12 years : 25 ml or 1 tablet (500 mg) twice daily for 3 days. 
	Contara-indications : Hypersensitivity.
	Side effects : Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.
	Precaution : Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.
	Pregnancy category : 2
	Mode of action : Nitazoxanide is an antiprotozoal agent. Both nitazoxanide and its active metabolite (tizoxanide) interfere with the pyruvate:ferredoxin 2-oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism in susceptible organisms.
	Interaction : May possibly interact with highly protein-bound drugs e.g. warfarin.
	Therapeutic class : Anti-diarrhoeal Antiprotozoal
	Packsize : 30ml bot
Antizoa
	n : Nitazoxanide
	Indications : Giardiasis, Cryptosporidiosis
	Doses and administration : Age 1 - 3 years : 5 ml (100 mg) twice daily for 3 days, Age 4 - 11 years : 10 ml (200 mg) twice daily for 3 days, Age >12 years : 25 ml or 1 tablet (500 mg) twice daily for 3 days. 
	Contara-indications : Hypersensitivity.
	Side effects : Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.
	Precaution : Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.
	Pregnancy category : 2
	Mode of action : Nitazoxanide is an antiprotozoal agent. Both nitazoxanide and its active metabolite (tizoxanide) interfere with the pyruvate:ferredoxin 2-oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism in susceptible organisms.
	Interaction : May possibly interact with highly protein-bound drugs e.g. warfarin.
	Therapeutic class : Anti-diarrhoeal Antiprotozoal
	Packsize : 30's pack
Antoris MR
	n : Trimetazidine Dihydrochloride
	Indications : Ischaemic heart disease, Angina pectoris; Meniere's disease, Coronary heart disease
	Doses and administration : One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.
									
									One 35 mg MR tablet twice daily at mealtimes in the morning and evening.
	Contara-indications : Hypersensitivity to Trimetazidine Dihydrochloride.
	Side effects : (Trimetazidine) is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.
	Precaution : Although teratological studies have not shown any drug related adverse effects on the course and outcome of pregnancy, the use  in pregnant women is not recommended.It is not known whetherTrimetazidine passes into breast milk or not. This medication should be used while breast feeding only if the potential benefits outweigh risks to the nursing infants.
	Pregnancy category : 0
	Mode of action : Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance.
	Interaction : MAOIs, nifedipine. May potentiate the effects of other antianginals.
	Therapeutic class : Other Anti-anginal & Anti-ischaemic drugs
	Packsize : 30's pack
Antox
	n : Betacarotene + Vitamin C + Vitamin E  (Anti-Oxidant Vitamins and Minerals)
	Indications : Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair.
									
	Doses and administration : One tablet/capsule daily or as directed by a physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.
	Pregnancy category : 1
	Mode of action : Beta carotene is 1 of a group of red, orange, and yellow pigments called carotenoids; Dietary sources include fruits, vegetables, and whole grains.  Photoprotective effects: Exact mechanism unknown; in vitro studies suggest antioxidant effects and that beta carotene reduces free radicals and singlet oxygen, which are produced when porphyrin is exposed to light and air.
									Vitamin C is necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin preparations
	Packsize : 20's pack/100'pack
Antrenex
	n : Oxyphenonium Bromide
	Indications : Peptic ulcer, Gastrointestinal tract spasm, Visceral spasms
	Doses and administration : Adults: 1-2  tablets 3-4 times daily.
									Children: 1/2-1 tablet 1-3 times daily.
	Contara-indications : Intestinal obstruction, renal function impairment , appendicitis, chronic diarrhea, sensitivity to aluminium, magnesium and simethicone.
	Side effects : Constipation , diarrhea, intestinal pain.
	Precaution : Should be caution , if allergic to any ingredient to  magaldrate and simethicone suspension, with a history of kidney problem or taking citrate salts ( found in some calcium supplements, antacids and laxative ) 
	Pregnancy category : 0
	Mode of action : Oxyphenonium is an anticholinergic drug. It exerts its action by inhibiting muscarinic (cholinergic) receptors on smooth muscles, cardiac muscles and prevents the effect of Acetylcholine. Inhibition of Acetylcholine produces relaxation of smooth muscles and prevents the muscle spasm in irritable bowel syndrome. 
									
									Oxyphenonium also has a direct relaxant effect on smooth muscle. It also inhibits gastrointestinal propulsive movement and decreases gastric acid secretion and control bronchial, pharyngeal and tracheal secretions. It also possesses nicotinic blocking activity and interferes with ganglionic or neuromuscular transmission. It cross the BBB poorly and does not produce CNS effect.
									
	Interaction : None
	Therapeutic class : Anticholinergics(antimuscarinics)/Anti-spasmodics
	Packsize : 100's pack
Antrenyl
	n : Oxyphenonium Bromide
	Indications : Peptic ulcer, Gastrointestinal tract spasm, Visceral spasms
	Doses and administration : Adults: 1-2  tablets 3-4 times daily.
									Children: 1/2-1 tablet 1-3 times daily.
	Contara-indications : Intestinal obstruction, renal function impairment , appendicitis, chronic diarrhea, sensitivity to aluminium, magnesium and simethicone.
	Side effects : Constipation , diarrhea, intestinal pain.
	Precaution : Should be caution , if allergic to any ingredient to  magaldrate and simethicone suspension, with a history of kidney problem or taking citrate salts ( found in some calcium supplements, antacids and laxative ) 
	Pregnancy category : 0
	Mode of action : Oxyphenonium is an anticholinergic drug. It exerts its action by inhibiting muscarinic (cholinergic) receptors on smooth muscles, cardiac muscles and prevents the effect of Acetylcholine. Inhibition of Acetylcholine produces relaxation of smooth muscles and prevents the muscle spasm in irritable bowel syndrome. 
									
									Oxyphenonium also has a direct relaxant effect on smooth muscle. It also inhibits gastrointestinal propulsive movement and decreases gastric acid secretion and control bronchial, pharyngeal and tracheal secretions. It also possesses nicotinic blocking activity and interferes with ganglionic or neuromuscular transmission. It cross the BBB poorly and does not produce CNS effect.
									
	Interaction : None
	Therapeutic class : Anticholinergics(antimuscarinics)/Anti-spasmodics
	Packsize : 100's pack
Antrin
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Antuss
	n : Guaiphenesin + Pseudoephedrine Hydrochloride + Triprolidine Hydrochloride
	Indications : Pneumonia, Productive cough, Allergic rhinitis, Sneezing, Respiratory tract disorders, Cough & runny nose, Nasal congestion
	Doses and administration : Adult and Children over 12 years: 10 ml (2 teaspoonful) three times a day.
									Children 6-12 years: 5 ml (1 teaspoonful) three times a day.
									Children 2-5 years: 2.5 ml (1/2 teaspoonful) three times a day.
									
	Contara-indications : Patients with a known hypersensitivity to guaiphenesin, psedoephedrine or triprolidine. Contraindicated in persons under treatment with monoamine oxidase inhibitors within 2 weeks of stopping such treatment.
									Patients with severe hypertension or severe coronary artery disease
	Side effects : Central nervous system (CNS) depression or excitation may occur. Sleep disturbance and rarely hallucination have been reported. Skin rashes, tachycardia, dryness of mouth, nose and throat have occasionally been reported. Urinary retention has been reported occasionally in men receiving pseudoephedrine; prostatic enlargement could have been an important predisposing factor.
	Precaution :  It may cause drowsiness and impair performance in tests of auditory vigilance. It may also impair the patients ability to drive and also to use machineries. So, driving and operation of machineries should be avoided during treatment with Aquaphen. Although there are no objective data, Avoid the concomitant use of alcohol or other centrally acting sedatives.
				Although Pseudoephedrine has virtually no pressor effect in patients with normal blood pressure, Aquaphen should be used with caution in patients taking antihypertensive agents, tricyclic antidepressants or other sympathomimetic agents such as decongestant, appetite suppressants and amphetamine-like psychostimulants.  It effects   on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment.
				As with other sympathomimetic agents, caution should be exercised in patients with hypertension, heart disease, diabetes, hyperthyroidism, elevated intraocular pressure and prostatic enlargement.  It should not be used for persistent or chronic cough such as occurs with smoking, asthma or emphysema or where cough is accompanied by excessive secretions unless directed by a physician.
	Pregnancy category : 3
	Mode of action : Triprolidine hydrochloride is a potent competitive histamine H1-receptor antagonist with antimuscarinic and mild sedative properties.
									
									Pseudoephedrine is both an ?-and ?-adrenergic receptor agonist. It causes vasoconstriction via direct stimulation of ?-adrenergic receptors of the respiratory mucosa. It also directly stimulates ?-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility.
									
									Guaifenesin increases the volume and reduce the viscosity of tenacious sputum and is used as an expectorant for productive cough.
	Interaction : Sympathomimetics eg decongestants, TCAs, appetite suppressants, amphetamine-like psychostimulants; may increase BP w/ MAOIs. Bretylium, bethanidine, guanethidine, debrisoquine, methyldopa, ?- & ?-adrenergic blocker; furazolidone, alcohol, sedatives.
	Therapeutic class : Combined cough expectorants
	Packsize : 100ml bot
Anustat
	n : Cinchocaine Hydrochloride 0.5% + Esculin 1% + Hydrocortisone + Neomycin Sulphate (Rectal prep)
	Indications : Pruritus ani, Haemorrhoids, Anal fissure, Proctitis
	Doses and administration : Adult: Up to 1% in cream and ointment.Adult: As 0.05% w/w ointment (in combination with hydrocortisone): Apply onto the affected area in the morning and evening and after each stool. 
									
									As suppository containing 5 mg/unit (in combination with hydrocortisone): Insert 1 suppository in the morning and evening and after each stool.
	Contara-indications : Complete heart block; pyogenic infection at or near the skin. Application to inflamed or infected tissues or to damaged skin mucosa; instillation into the middle ear.
	Side effects : Restlessness; excitement; nervousness; paraesthesias; dizziness; tinnitus; blurred vision; nausea; vomiting; muscle twitching; tremors; convulsions; hypotension; bradycardia; arrhythmias; cardiac arrest.
	Precaution : Elderly; debilitated patients; child; epilepsy; impaired cardiac conduction or respiratory function; shock; hepatic impairment; myasthenia gravis. Do not to rub or touch the eye while anaesthesia persists. Avoid application for prolonged periods and to extensive areas. Pregnancy, lactation.
	Pregnancy category : 0
	Mode of action : Cinchocaine prevents or diminishes nerve impulse conduction near to the site of admin. It also has membrane-stabilising effect owing to decrease of permeability of the nerve cell to sodium ions.
									Hydrocortisone is a corticosteroid used for its anti-inflammatory and immunosuppressive effects. Its anti-inflammatory action is due to the suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It may also be used as replacement therapy in adrenocortical insufficiency.
									Neomycin is an aminoglycoside antibiotic. It binds to 30S ribosomal subunits of bacterial ribosome thus inhibiting protein synthesis and generating errors in genetic code transcription causing cell death. It acts against many gram-negative aerobes and some gram-positive aerobes. It lacks activity against fungi, viruses and most anaerobic bacteria.
	Interaction : None
	Therapeutic class : Compound steroidal preparations
	Packsize : 15gm tube
Anxio
	n : Bromazepam
	Indications : Anxiety, Panic attacks
	Doses and administration : Adult: PO Initial: 6-18 mg/day in divided doses. Higher doses  have occasionally been given to hospitalized patients. Dose should be reduced at least half in elderly patients and those with hepatic and renal impairment.
	Contara-indications : Preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnea; severe hepatic impairment; not indicated for chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behavior, not used alone to treat depression or anxiety associated with depression; glaucoma.
	Side effects : Drowsiness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia; rarely, jaundice, blood disorders and hypersensitivity reactions; pain and thrombophlebitis; raised liver enzyme values; paradoxical excitation.
	Precaution : Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; patients with personality disorders or organic brain changes; pregnancy and lactation; history of alcohol or drug addiction due to risk of dependence. resp depression and hypotension with parenteral administration, therefore this route should only be used when facilities for reversing resp depression are available.
	Pregnancy category : 0
	Mode of action : Bromazepam is a benzodiazepine with general properties similar to diazepam. It is used in the treatment of anxiety occuring alone or associated with insomnia.
	Interaction : May enhance the activity w/ CYP450 inhibitor (e.g. azole antifungals, macrolides, HIV protease inhibitors, Ca channel blockers). Elevated plasma levels w/ disulfiram or cimetidine. Additive CNS depressant effects w/ barbiturates, sedatives, anaeasth, anxiolytics, hypnotics, phenothiazines, other antipsychotics, skeletal muscle relaxants. May potentiate anticholinergic effects of atropine, antihistamines and antidepressants. Increased psychic drug dependence w/ narcotic analgesics.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 30's pack
Anxionil
	n : Bromazepam
	Indications : Anxiety, Panic attacks
	Doses and administration : Adult: PO Initial: 6-18 mg/day in divided doses. Higher doses  have occasionally been given to hospitalized patients. Dose should be reduced at least half in elderly patients and those with hepatic and renal impairment.
	Contara-indications : Preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnea; severe hepatic impairment; not indicated for chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behavior, not used alone to treat depression or anxiety associated with depression; glaucoma.
	Side effects : Drowsiness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia; rarely, jaundice, blood disorders and hypersensitivity reactions; pain and thrombophlebitis; raised liver enzyme values; paradoxical excitation.
	Precaution : Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; patients with personality disorders or organic brain changes; pregnancy and lactation; history of alcohol or drug addiction due to risk of dependence. resp depression and hypotension with parenteral administration, therefore this route should only be used when facilities for reversing resp depression are available.
	Pregnancy category : 0
	Mode of action : Bromazepam is a benzodiazepine with general properties similar to diazepam. It is used in the treatment of anxiety occuring alone or associated with insomnia.
	Interaction : May enhance the activity w/ CYP450 inhibitor (e.g. azole antifungals, macrolides, HIV protease inhibitors, Ca channel blockers). Elevated plasma levels w/ disulfiram or cimetidine. Additive CNS depressant effects w/ barbiturates, sedatives, anaeasth, anxiolytics, hypnotics, phenothiazines, other antipsychotics, skeletal muscle relaxants. May potentiate anticholinergic effects of atropine, antihistamines and antidepressants. Increased psychic drug dependence w/ narcotic analgesics.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 50's pack
Anxirel
	n : Bromazepam
	Indications : Anxiety, Panic attacks
	Doses and administration : Adult: PO Initial: 6-18 mg/day in divided doses. Higher doses  have occasionally been given to hospitalized patients. Dose should be reduced at least half in elderly patients and those with hepatic and renal impairment.
	Contara-indications : Preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnea; severe hepatic impairment; not indicated for chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behavior, not used alone to treat depression or anxiety associated with depression; glaucoma.
	Side effects : Drowsiness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia; rarely, jaundice, blood disorders and hypersensitivity reactions; pain and thrombophlebitis; raised liver enzyme values; paradoxical excitation.
	Precaution : Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; patients with personality disorders or organic brain changes; pregnancy and lactation; history of alcohol or drug addiction due to risk of dependence. resp depression and hypotension with parenteral administration, therefore this route should only be used when facilities for reversing resp depression are available.
	Pregnancy category : 0
	Mode of action : Bromazepam is a benzodiazepine with general properties similar to diazepam. It is used in the treatment of anxiety occuring alone or associated with insomnia.
	Interaction : May enhance the activity w/ CYP450 inhibitor (e.g. azole antifungals, macrolides, HIV protease inhibitors, Ca channel blockers). Elevated plasma levels w/ disulfiram or cimetidine. Additive CNS depressant effects w/ barbiturates, sedatives, anaeasth, anxiolytics, hypnotics, phenothiazines, other antipsychotics, skeletal muscle relaxants. May potentiate anticholinergic effects of atropine, antihistamines and antidepressants. Increased psychic drug dependence w/ narcotic analgesics.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 30's pack
Anxopam
	n : Bromazepam
	Indications : Anxiety, Panic attacks
	Doses and administration : Adult: PO Initial: 6-18 mg/day in divided doses. Higher doses  have occasionally been given to hospitalized patients. Dose should be reduced at least half in elderly patients and those with hepatic and renal impairment.
	Contara-indications : Preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnea; severe hepatic impairment; not indicated for chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behavior, not used alone to treat depression or anxiety associated with depression; glaucoma.
	Side effects : Drowsiness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia; rarely, jaundice, blood disorders and hypersensitivity reactions; pain and thrombophlebitis; raised liver enzyme values; paradoxical excitation.
	Precaution : Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; patients with personality disorders or organic brain changes; pregnancy and lactation; history of alcohol or drug addiction due to risk of dependence. resp depression and hypotension with parenteral administration, therefore this route should only be used when facilities for reversing resp depression are available.
	Pregnancy category : 0
	Mode of action : Bromazepam is a benzodiazepine with general properties similar to diazepam. It is used in the treatment of anxiety occuring alone or associated with insomnia.
	Interaction : May enhance the activity w/ CYP450 inhibitor (e.g. azole antifungals, macrolides, HIV protease inhibitors, Ca channel blockers). Elevated plasma levels w/ disulfiram or cimetidine. Additive CNS depressant effects w/ barbiturates, sedatives, anaeasth, anxiolytics, hypnotics, phenothiazines, other antipsychotics, skeletal muscle relaxants. May potentiate anticholinergic effects of atropine, antihistamines and antidepressants. Increased psychic drug dependence w/ narcotic analgesics.
	Therapeutic class : Benzodiazepine sedatives
	Packsize : 30's pack
Anzet FC
	n : Flupenthixol + Melitracen
	Indications : Depression, Anxiety, Apathy, Dysphoria
	Doses and administration : Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets.
									Elderly: 1 tablet in the morning.
									Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
	Contara-indications : The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
	Side effects : In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
	Precaution : If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.
	Pregnancy category : 3
	Mode of action : Flupentixol is a thioxanthene antipsychotic that inhibits dopamine-mediated effects by blocking postsynaptic dopamine receptors in the CNS.
									Melitracen is a TCA with anxiolytic properties.
	Interaction :  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).
				Potentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.
				 	Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 50's pack
Anzitor
	n : Atorvastatin
	Indications :  Primary hypercholesterolemia (heterozygous familial and nonfamilial), Mixed Dyslipidemia, Homozygous familial hypercholesterolemia, Hypertriglyceridemia, Familial hypercholesterolemia, Cardiovascular event prevention, Primary dysbetalipoproteinemia
	Doses and administration : Oral
									Mixed dyslipidaemia, Heterozygous familial hypercholesterolaemia, Nonfamilial hypercholesterolaemia
									Adult: Initially, 10 or 20 mg once daily, may be adjusted at 4-wk interval. May initiate 40 mg once daily in patients who require >45% reduction in LDL-cholesterol. Max: 80 mg/day.
									
									Child: Heterozygous familial hypercholesterolaemia: 10-17 yr 10 mg once daily, may increase at intervals of at least 4 wk to max 20 mg/day.
									Elderly: No dosage adjustment needed.
									
									Atorvastatin can be administered as a single dose at any time of the day, with or without food. Therapy should be individualized according to goal of therapy and response. After initiation and/or upon titration of Atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. Since the goal of treatment is to lower LDL-C, the LDL-C levels should be used to initiate and assess treatment response. Only if LDL-C levels are not available, should total-C be used to monitor therapy. 
									
									Homozygous Familial Hypercholesterolemia: The dosage of Atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) in these patients or if such treatments are unavailable. 
									
									Dosage in Patients with Renal Insufficiency: Renal disease does not affect the plasma concentrations or LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary. 
									
									Pediatric Use: Treatment experience in a pediatric population is limited to doses of Atorvastatin up to 80 mg/day for 1 year in 8 patients with homozygous FH. No clinical or biochemical abnormalities were reported in these patients. None of these patients was below 9 years of age. 
									
									Geriatric Use: Treatment experience in adults age 70 years with doses of Atorvastatin up to 80 mg/day has been evaluated. The safety and efficacy of Atorvastatin in this population were similar to those of patients <70 years of age.
									
	Contara-indications : Hypersensitivity, active liver disease or unexplained persistent elevations of serum transaminase, porphyria, pregnancy, lactation.
	Side effects : Headache, flatulence, diarrhoea, nausea, vomiting, anorexia, xerostomia, angioedema, myalgia, rash/pruritus, alopecia, allergy, infection, chest pain.Potentially Fatal: Thrombocytopenia. Rhabdomyolysis with acute renal failure.
	Precaution : Patients who consume substantial quantities of alcohol. History of liver disease. Patients with risk factors for myopathy or rhabdomyolysis. Hypothyroidism should be properly managed prior to starting statin therapy. Children <10 yr. Premenarcheal females.
	Pregnancy category : 5
	Mode of action : Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate. This results in the induction of the LDL receptors and stimulation of LDL catabolism, leading to lowered LDL-cholesterol levels.
	Interaction : May increase risk of myopathy and rhabdomyolysis w/ CYP3A4 potent inhibitor (e.g. HIV or HCV protease inhibitors, itraconazole, clarithromycin), fenofibrate, colchicines, fixed combination of lopinavir/ritonavir. May decrease plasma concentration w/ CYP3A4 inducer (e.g. rifampicin, efavirenz). May significantly increase AUC and peak plasma concentration of digoxin. Increased AUC for norethindrone and ethinyl estradiol.
				Potentially Fatal: Increased risk of myopathy or rhabdomyolysis w/ ciclosporin, gemfibrozil, telaprevir, tipranavir.
	Therapeutic class : Statins
	Packsize : 50's pack
Anzitor
	n : Atorvastatin
	Indications :  Primary hypercholesterolemia (heterozygous familial and nonfamilial), Mixed Dyslipidemia, Homozygous familial hypercholesterolemia, Hypertriglyceridemia, Familial hypercholesterolemia, Cardiovascular event prevention, Primary dysbetalipoproteinemia
	Doses and administration : Oral
									Mixed dyslipidaemia, Heterozygous familial hypercholesterolaemia, Nonfamilial hypercholesterolaemia
									Adult: Initially, 10 or 20 mg once daily, may be adjusted at 4-wk interval. May initiate 40 mg once daily in patients who require >45% reduction in LDL-cholesterol. Max: 80 mg/day.
									
									Child: Heterozygous familial hypercholesterolaemia: 10-17 yr 10 mg once daily, may increase at intervals of at least 4 wk to max 20 mg/day.
									Elderly: No dosage adjustment needed.
									
									Atorvastatin can be administered as a single dose at any time of the day, with or without food. Therapy should be individualized according to goal of therapy and response. After initiation and/or upon titration of Atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. Since the goal of treatment is to lower LDL-C, the LDL-C levels should be used to initiate and assess treatment response. Only if LDL-C levels are not available, should total-C be used to monitor therapy. 
									
									Homozygous Familial Hypercholesterolemia: The dosage of Atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) in these patients or if such treatments are unavailable. 
									
									Dosage in Patients with Renal Insufficiency: Renal disease does not affect the plasma concentrations or LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary. 
									
									Pediatric Use: Treatment experience in a pediatric population is limited to doses of Atorvastatin up to 80 mg/day for 1 year in 8 patients with homozygous FH. No clinical or biochemical abnormalities were reported in these patients. None of these patients was below 9 years of age. 
									
									Geriatric Use: Treatment experience in adults age 70 years with doses of Atorvastatin up to 80 mg/day has been evaluated. The safety and efficacy of Atorvastatin in this population were similar to those of patients <70 years of age.
									
	Contara-indications : Hypersensitivity, active liver disease or unexplained persistent elevations of serum transaminase, porphyria, pregnancy, lactation.
	Side effects : Headache, flatulence, diarrhoea, nausea, vomiting, anorexia, xerostomia, angioedema, myalgia, rash/pruritus, alopecia, allergy, infection, chest pain.Potentially Fatal: Thrombocytopenia. Rhabdomyolysis with acute renal failure.
	Precaution : Patients who consume substantial quantities of alcohol. History of liver disease. Patients with risk factors for myopathy or rhabdomyolysis. Hypothyroidism should be properly managed prior to starting statin therapy. Children <10 yr. Premenarcheal females.
	Pregnancy category : 5
	Mode of action : Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate. This results in the induction of the LDL receptors and stimulation of LDL catabolism, leading to lowered LDL-cholesterol levels.
	Interaction : May increase risk of myopathy and rhabdomyolysis w/ CYP3A4 potent inhibitor (e.g. HIV or HCV protease inhibitors, itraconazole, clarithromycin), fenofibrate, colchicines, fixed combination of lopinavir/ritonavir. May decrease plasma concentration w/ CYP3A4 inducer (e.g. rifampicin, efavirenz). May significantly increase AUC and peak plasma concentration of digoxin. Increased AUC for norethindrone and ethinyl estradiol.
				Potentially Fatal: Increased risk of myopathy or rhabdomyolysis w/ ciclosporin, gemfibrozil, telaprevir, tipranavir.
	Therapeutic class : Statins
	Packsize : 30's pack
Anzitor
	n : Atorvastatin
	Indications :  Primary hypercholesterolemia (heterozygous familial and nonfamilial), Mixed Dyslipidemia, Homozygous familial hypercholesterolemia, Hypertriglyceridemia, Familial hypercholesterolemia, Cardiovascular event prevention, Primary dysbetalipoproteinemia
	Doses and administration : Oral
									Mixed dyslipidaemia, Heterozygous familial hypercholesterolaemia, Nonfamilial hypercholesterolaemia
									Adult: Initially, 10 or 20 mg once daily, may be adjusted at 4-wk interval. May initiate 40 mg once daily in patients who require >45% reduction in LDL-cholesterol. Max: 80 mg/day.
									
									Child: Heterozygous familial hypercholesterolaemia: 10-17 yr 10 mg once daily, may increase at intervals of at least 4 wk to max 20 mg/day.
									Elderly: No dosage adjustment needed.
									
									Atorvastatin can be administered as a single dose at any time of the day, with or without food. Therapy should be individualized according to goal of therapy and response. After initiation and/or upon titration of Atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. Since the goal of treatment is to lower LDL-C, the LDL-C levels should be used to initiate and assess treatment response. Only if LDL-C levels are not available, should total-C be used to monitor therapy. 
									
									Homozygous Familial Hypercholesterolemia: The dosage of Atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) in these patients or if such treatments are unavailable. 
									
									Dosage in Patients with Renal Insufficiency: Renal disease does not affect the plasma concentrations or LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary. 
									
									Pediatric Use: Treatment experience in a pediatric population is limited to doses of Atorvastatin up to 80 mg/day for 1 year in 8 patients with homozygous FH. No clinical or biochemical abnormalities were reported in these patients. None of these patients was below 9 years of age. 
									
									Geriatric Use: Treatment experience in adults age 70 years with doses of Atorvastatin up to 80 mg/day has been evaluated. The safety and efficacy of Atorvastatin in this population were similar to those of patients <70 years of age.
									
	Contara-indications : Hypersensitivity, active liver disease or unexplained persistent elevations of serum transaminase, porphyria, pregnancy, lactation.
	Side effects : Headache, flatulence, diarrhoea, nausea, vomiting, anorexia, xerostomia, angioedema, myalgia, rash/pruritus, alopecia, allergy, infection, chest pain.Potentially Fatal: Thrombocytopenia. Rhabdomyolysis with acute renal failure.
	Precaution : Patients who consume substantial quantities of alcohol. History of liver disease. Patients with risk factors for myopathy or rhabdomyolysis. Hypothyroidism should be properly managed prior to starting statin therapy. Children <10 yr. Premenarcheal females.
	Pregnancy category : 5
	Mode of action : Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate. This results in the induction of the LDL receptors and stimulation of LDL catabolism, leading to lowered LDL-cholesterol levels.
	Interaction : May increase risk of myopathy and rhabdomyolysis w/ CYP3A4 potent inhibitor (e.g. HIV or HCV protease inhibitors, itraconazole, clarithromycin), fenofibrate, colchicines, fixed combination of lopinavir/ritonavir. May decrease plasma concentration w/ CYP3A4 inducer (e.g. rifampicin, efavirenz). May significantly increase AUC and peak plasma concentration of digoxin. Increased AUC for norethindrone and ethinyl estradiol.
				Potentially Fatal: Increased risk of myopathy or rhabdomyolysis w/ ciclosporin, gemfibrozil, telaprevir, tipranavir.
	Therapeutic class : Statins
	Packsize : 10's pack
Anzole
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Anzole
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Apagrel
	n : Prasugrel
	Indications : Acute coronary syndromes, thrombotic cardiovascular (CV) events, stent thrombosis, unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), Stroke
	Doses and administration : Treatment should be initiated with a single 60 mg oral loading dose.
									Continue at 10 mg once daily with or without food. Consider 5 mg once daily for patients < 60 kg. Patients should also take aspirin (75 mg to 325 mg) daily.
									
									Pediatric Use: Safety and effectiveness in pediatric patients have not been established
									Geriatric Use: Patients > 75 years of age who received Prasugrel had an increased risk of fatal bleeding events (1.0%) compared to patients who received clopidogrel (0.1%).
									
									Renal Impairment: No dosage adjustment is necessary for patients with renal impairment. There is limited experience in patients with end-stage renal disease.
									
									Hepatic Impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.
	Contara-indications : Active pathological bleeding such as peptic ulcer or intracranial hamorrhage. Patient with a history of prior transient ischemic attack or stroke 
	Side effects : - Bleeding
									- Thrombotic thrombocytopenic purpura
									- Other side effects ( Headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash etc)
	Precaution : CABG-related bleeding: Risk increases in patients receiving Prasurel who undergo CABG.
				
				Discontinuation of Prasugrel: Premature discontinuation increases risk of stent thrombosis, MI, and death 
	Pregnancy category : 2
	Mode of action : Prasugrel is a prodrug that inhibits platelet activation and aggregation. The active metabolite irreversibly blocks the P2Y12 component of adenosine diphosphate (ADP) receptors on the platelet, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet activation and aggregation.
	Interaction : Increased risk of bleeding w/ oral anticoagulants (e.g. warfain), clopidogrel, NSAIDs and fibrinolytics.
	Therapeutic class : Anti-platelet drugs
	Packsize : 30's pack
Apagrel
	n : Prasugrel
	Indications : Acute coronary syndromes, thrombotic cardiovascular (CV) events, stent thrombosis, unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), Stroke
	Doses and administration : Treatment should be initiated with a single 60 mg oral loading dose.
									Continue at 10 mg once daily with or without food. Consider 5 mg once daily for patients < 60 kg. Patients should also take aspirin (75 mg to 325 mg) daily.
									
									Pediatric Use: Safety and effectiveness in pediatric patients have not been established
									Geriatric Use: Patients > 75 years of age who received Prasugrel had an increased risk of fatal bleeding events (1.0%) compared to patients who received clopidogrel (0.1%).
									
									Renal Impairment: No dosage adjustment is necessary for patients with renal impairment. There is limited experience in patients with end-stage renal disease.
									
									Hepatic Impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.
	Contara-indications : Active pathological bleeding such as peptic ulcer or intracranial hamorrhage. Patient with a history of prior transient ischemic attack or stroke 
	Side effects : - Bleeding
									- Thrombotic thrombocytopenic purpura
									- Other side effects ( Headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash etc)
	Precaution : CABG-related bleeding: Risk increases in patients receiving Prasurel who undergo CABG.
				
				Discontinuation of Prasugrel: Premature discontinuation increases risk of stent thrombosis, MI, and death 
	Pregnancy category : 2
	Mode of action : Prasugrel is a prodrug that inhibits platelet activation and aggregation. The active metabolite irreversibly blocks the P2Y12 component of adenosine diphosphate (ADP) receptors on the platelet, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet activation and aggregation.
	Interaction : Increased risk of bleeding w/ oral anticoagulants (e.g. warfain), clopidogrel, NSAIDs and fibrinolytics.
	Therapeutic class : Anti-platelet drugs
	Packsize : 30's pack
Apain
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Apain IM
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 10 amps pack
Apain MS
	n : Diclofenac Sodium + Misoprostol
	Indications : Rheumatoid arthritis, Osteoarthritis, Joint and muscular pains
	Doses and administration : Osteoarthritis: 50 mg tablet thrice daily. For patients who experience intolerance, 75 mg tablet or 50 mg tablet twice daily.
									Rheumatoid arthritis:50 mg tablet hrice or four times daily. For patients who experience intolerance, 75 mg tablet or 50 mg tablet twice daily.
	Contara-indications :  Diclofenac Sodium and Misoprostol combination is contraindicated in women who are pregnant because of the abortive property of the Misoprostol component.
	Side effects : The most common reported side effects are abdominal pain, diarrhoea and other GI symptoms. Diarrhoea and abdominal pain developed early in the course of therapy and were usually self-limited (resolved after 2-7 days).
	Precaution : Patients with an underlying condition such as inflammatory bowel disease or those in whom dehydration should be monitored carefully if Diclofenac Sodium 50 mg plus Misoprostol 200 mcg is prescribed. 
				
				The pharmacological activity   in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
	Pregnancy category : 22
	Mode of action : Diclofenac: Inhibits cyclooxygenase-1 (COX-1) & -2 (COX-2), thereby inhibiting prostaglandin synthesis; has anti-inflammatory, antipyresis, and analgesic properties.
									
									Misoprostol: Replaces protective prostaglandins consumed by prostaglandin-inhibiting therapies (NSAID-induced ulcers).
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
				May increase effects of oxytocin. Increased risk of misoprostol-induced diarrhoea with magnesium-containing antacids.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 30's pack
Apain Plus IM
	n : Diclofenac + Lidocaine Hydrochloride
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Acute gout, Inflammation, Tendinitis, Actinic keratoses, Bursitis
	Doses and administration : Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
	Contara-indications : In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									
									Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide-type.
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									The adverse effects due to Lidocaine mainly involve the CNS, are usually of short duration, and are dose related. The CNS reaction may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadness, etc. Incase of eye drops ocular burning sensation or allergic reaction may occur in 5-10% patients. 
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued.
	Pregnancy category : 19
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
									
									Lidocaine is an amide type local anaesth. It stabilises the neuronal membrane and inhibits Na ion movements, which are necessary for conduction of impulses. In the heart, lidocaine reduces depolarisation of the ventricles during diastole and automaticity in the His-Purkinje system. Duration of action potential and effective refractory period are also reduced.
	Interaction :  	May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
				May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 10 amps pack
Apain TR
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Apalene 0.1%
	n : Adapalene 0.1%
	Indications : Acne, Keratosis pilaris
	Doses and administration : Adult: Topical As 0.1% soln/cream/gel: Apply once daily at night.
	Contara-indications : Hypersensitivity.
	Side effects : Mild skin irritation, scaling, erythema, cutaneous dryness, sensations of stinging and burning, pruritus.
	Precaution : Patients with sunburn, eczema. Pregnancy, lactation. Avoid excessive exposure to sunlight or UV irradiation. Keep away from the eyes, lips, nostrils and mucous membranes. Do not apply to cuts, abrasions, scaly or flaky skin, or patches of sunburned skin. Use with caution with preparations containing sulfur, resorcinol, or salicylic acid.
	Pregnancy category : 3
	Mode of action : Adapalene binds to specific retinoic acid nuclear receptors which normalises the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.
	Interaction : Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.
	Therapeutic class : Topical antibiotic & retinoid preparations
	Packsize : 1's pack
Apcard
	n : Atenolol
	Indications : Hypertension, Migraine, Arrhythmias, MI, Angina pectoris
	Doses and administration : Adult: PO HTN 25-100 mg/day. 
									Angina pectoris; Migraine prophylaxis 50-100 mg/day. Max for angina pectoris: 200 mg/day.
									
									Renal impairment:
									CrCl (ml/min)	
									<15	  25 mg or 50 mg on alternate days.
									15-35	50 mg/day.
									Dialysis patients	25-50 mg after each dialysis.
	Contara-indications : Hypersensitivity. Sinus bradycardia, sinus node dysfunction, heart block >1st degree, compensated cardiac failure, cardiogenic shock, bronchospastic diseases, peripheral vascular diseases. Pregnancy.
	Side effects : Bronchospasm; cold extremities, fatigue, dizziness, insomnia, lethargy, confusion, headache, depression, nightmares, nausea, diarrhoea, constipation, impotence and paraesthesia.
									Potentially Fatal: Heart failure, 2nd or 3rd degree AV block.
	Precaution : Compensated heart failure. Variant angina, acute MI, DM; peripheral vascular disorders; hepatic and renal dysfunction; elderly patients, children. Lactation. If atenolol and clonidine are co-admin, then gradual withdrawal of clonidine should take place a few days after withdrawal of atenolol.
	Pregnancy category : 4
	Mode of action : Atenolol is a competitive cardioselective beta1-blocker and does not have effect on ?beta2-receptors except in high doses. It reduces resting and exercise-induced heart rate as well as myocardial contractility.
	Interaction : Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment.
				
	Therapeutic class : Beta-blockers
	Packsize : 100's pack
				
Apcetrim
	n : Sulphamethoxazole + Trimethoprim
	Indications : Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
	Doses and administration : Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. 
									Suspension : 1-2 teaspoonful twice daily.
									
									GI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. 
									
									Pneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.
									
									Child: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.
									
									Renal impairment: Dosage reduction for adults and children >12 yr:
									CrCl (ml/min)	
									15-30	Half the standard dose.
									<15	        Not recommended.
	Contara-indications : Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.
	Side effects : Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.
									Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.
	Precaution : G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.
	Pregnancy category : 4
	Mode of action : Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
	Interaction : Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
				Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
	Therapeutic class : Sulphonamides & Trimethoprim
	Packsize : 60ml bot
Apcocid
	n : Aluminium Hydroxide + Magnesium Hydroxide
	Indications : Heartburn, Reflux oesophagitis, Hyperacidity, Peptic ulcer, Constipation, Indigestion
	Doses and administration : Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.
	Contara-indications : Hypersensitivity to aluminium salts.
	Side effects : Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.
	Precaution : Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
									
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 100's pack
Apdox
	n : Doxycycline
	Indications : Acne, Susceptible infections, Syphilis, Uncomplicated gonorrhoea, Relapsing fever and louse-borne typhus, Scrub typhus
	Doses and administration : Adults: Two capsules at a time or one capsule every 12 hours for the first day followed by one capsule per day.
									
									Children: Over 8 years or weighing 45 Kg or less: 4.4 mg/Kg on the first day followed by 2.2 mg/Kg daily.
									
									Acute gonococcal urethritis: 1 capsule twice daily for 2 to 4 days in male and until a cure has been obtained in female.
									Chlamydial infections: 1 capsule twice daily for 7 days.
									Syphilis: 3 capsules in divided doses for 10 days.
	Contara-indications : It is contraindicated to patients with known hypersensitivity to any of the tetracyclines. It is also contraindicated in severe hepatic disorder and patients with systemic lupas erythematosus. Concomitant intake of alkalis, antacids and iron may interfere with the absorption of Doxycycline. It is advisable to avoid giving doxycycline in conjunction with penicillin. Doxycycline should not be used in pregnant women unless, in the judgment of the physician, it is essential for the welfare of the patient.
									 
	Side effects : Epigastric distress, abdominal discomfort, nausea, and vomiting may occur. Long term therapy with Doxacil may produce changes in the peripheral blood. Various skin reactions including rashes, urticaria,
									exfoliative dermatitis.
	Precaution : The use of drugs of tetracycline group during tooth development (last half of pregnancy, infancy and childhood to the age of 12 years) may cause permanent discoloration of the teeth. Tetracyclines, therefore, should not be used in this age group unless other drugs are not likely to be effective or are contraindicated.
	Pregnancy category : 4
	Mode of action : Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It has bacteriostatic activity against a broad range of gm+ve and gm-ve bacteria.
	Interaction : Concomitant use w/ isotretinoin is known to cause pseudotumour cerebri. Prolonged prothrombin time w/ anticoagulants (e.g. warfarin). May interfere w/ the bactericidal action of penicillin. Impaired absorption w/ antacids containing Al, Ca, or Mg, oral Zn, Fe salts, and bismuth preparations. Increased metabolism w/ phenobarbital, carbamazepine, primidone and phenytoin. Risk of breakthrough bleeding w/ oral contraceptives. Increased plasma concentration of ciclosporin. Decreased half-life w/ hepatic enzymes inducers (e.g. rifampicin).
				Potentially Fatal: Concurrent use w/ methoxyflurane may result to fatal renal toxicity.
	Therapeutic class : Tetracycline Group of drugs
	Packsize : 100's pack
Apeclo
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Apedrox
	n : Aluminium Oxide + Magnesium Hydroxide
	Indications : Hyperacidity, Flatulence, Gastric ulcer, Duodenal ulcer, Gastritis, Stomach distension
	Doses and administration : Chew 1-2 tablets after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. For best results, drink a half glass of water or other liquid after each dose. Do not take more than 16 tablets in 24 hours
	Contara-indications : Hypophosphataemia.
	Side effects : Diarrhoea, constipation, nausea, vomiting.
	Precaution : Renal dysfunction, low phosphate diet, prolonged use.
	Pregnancy category : 0
	Mode of action : Alumunium hydroxide acts on the HCl in the stomach by neutralization, forming aluminium chloride salt and water.
									Magnesium hydroxide increases peristaltic activity causing osmotic retention of fluids, thus resulting in bowel evacuation. It also reduces stomach acid by reacting with hydrochloric acid to form Mg chloride.
	Interaction : Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
				
				Magnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
	Therapeutic class : Antacids
	Packsize : 200ml bot
Apefol TR
	n : Ferrous Sulphate + Folic Acid + Zinc
	Indications : Iron, Zinc & Folic acid deficiency
	Doses and administration : One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.
									
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients
	Side effects : Generally well tolerated. However, a few allergic reactions may be seen.
	Precaution : Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.
	Pregnancy category : 0
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
									Zinc: Cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system; helps maintain a sense of smell and taste; may assist in porper function of insulin.
									
	Interaction : None
	Therapeutic class : Iron Vitamin & Mineral Combined preparation
	Packsize : 50's pack
Apetryl
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Apetryl
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 100's pack
Apevit
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 100ml bot/200ml bot
Apevit B
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 45's pot/100's box
Apevit M
	n : Multivitamin Paediatric preparations
	Indications : Vitamin deficiencies
	Doses and administration : Below 1 year : 9-10 drops (0.3 ml), 1 year and above : 23-25 drops (1.0 ml) once daily or as advised by the physicians. 
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients. Supplemental vitamins should not be prescribed for patients with haemochromatosis or Wilsons disease.
	Side effects :  Generally well tolerated. 
	Precaution : Multivitamin preparation with ordinary doses of component are usually nontoxic.
	Pregnancy category : 0
	Mode of action : Vitamins and minerals are essential for normal metabolic functions including hematopoiesis. Depending on ingredients in the formulaiton may support metabolic functions as well as protein and DNA synthesis.
	Interaction : None
	Therapeutic class : Nonspecific multivitamin preparations
	Packsize : 15 ml bot
Apevit Z
	n : Vitamin B-complex + Zinc
	Indications : Vitamin B and Zinc deficiencies
	Doses and administration : Adults: 10 ml (2 teaspoonful) 2 to 3 times daily or as recommended by the physician.
									Children: 10 ml (2 teaspoonful) 1 to 3 times daily or as recommended by the physician.
									Infants: 5 ml (1 teaspoonful) 1 to 2 times daily or as recommended by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients of this product.
	Side effects : Generally well tolerated.
	Precaution : None
	Pregnancy category : 0
	Mode of action : Zinc: Cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system; helps maintain a sense of smell and taste; may assist in porper function of insulin.
									Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
									
	Interaction : None
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 100ml bot
A-Phenicol-D
	n : Chloramphenicol 0.5% + Dexamethasone 0.1%  Eye/Ear drop
	Indications : Allergic conjunctivitis, Acute purulent conjunctivitis, Corneal ulceration, Keratitis disciformis, Post-herpetic keratitis, Allergic blepharitis, Acute and chronic iritis, Iridocyclitis, Otitis externa, infective and inflammatory ear infections.
	Doses and administration : Ocular infections Adult: Instill 1 drop of asolution every 2 hr. Increase dosage interval upon improvement. To continue treatment for at least 48 hr after complete healing. 
									
									 Otic/Aural Otitis externa Adult: Instill 2-3 drops into the ear bid-tid. 
	Contara-indications : History of hypersensitivity or toxic reaction to the drug; Perforated ear drum. Herpes simplex and other virul conditions of the eye or ear, mycosis.
	Side effects : Ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. Ear drops: Ototoxicity.
	Precaution : Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. 
	Pregnancy category : 3
	Mode of action : Dexamethasone is a synthetic glucocorticoid which decreases inflammation by inhibiting the migration of leukocytes and reversal of increased capillary permeability. It suppresses normal immune response.
									
									Chloramphenicol inhibits bacterial protein synthesis by binding to 50s subunit of the bacterial ribosome, thus preventing peptide bond formation by peptidyl transferase. It has both bacteriostatic and bactericidal action against H. influenzae, N. meningitidis and S. pneumoniae.
	Interaction : Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.
				Potentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
	Therapeutic class : Ophthalmic Steroid- antibiotic combined preparations
	Packsize : 5  ml drop
Aphrin
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 15ml bot
Aphrin
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 20's pack
Aphrin DS
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Aphrin IV/IM
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 1's pack
Aphrin IV/IM
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 1's pack
Aphrin PFS
	n : Cephradine
	Indications : Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis
	Doses and administration : Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. 
									
									IV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. 
									
									Surgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. 
									Skin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. 
									
									Lobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. 
									Urinary tract infection: Usual dose is 500 mg every 12 hours. 
									Gastro-intestinal tract infection: 500 mg three to four times daily. 
									
									Children: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. 
									
									Injection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. 
									Perioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. 
									
									Renal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
									
									CrCl (ml/min)	
									>20	        500 mg every 6 hr.
									5-20        250 mg every 6 hr.
									<5	        250 mg every 12 hr. 
	Contara-indications : Hypersensitivity to cefradine or other cephalosporins; porphyria.
	Side effects : Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.
									Potentially Fatal: Pseudomembranous colitis.
	Precaution : Renal impairment; history of penicillin sensitivity; pregnancy; lactation.
	Pregnancy category : 2
	Mode of action : Cefradine is a 1st generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
	Interaction : Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Apidex
	n : Dexamethasone 0.1%   Eye prep
	Indications : Allergic conjunctivitis, Ocular inflammation, Superficial punctate keratitis , Herpes zoster keratitis, Iritis , Cyclitis. 
	Doses and administration : Eye: 1 or 2 drops in conjunctival sac. Severe or acute inflammation: Every 30 to 60 minutes as initial therapy, reducing the dosage when favourable response is observed to every two to four hours. Further reduction may be made to one drop three or four times daily if sufficient to control inflammation. Chronic inflammation: Every three to six hours, or as necessary. Allergic inflammation: Every three to four hours until the desired response is obtained. 
	Contara-indications : Hypersensitivity; Contraindicated in epithelial herpes simplex, vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; tuberculosis of the eye; fungal disease of ocular structures; other diseases caused by micro-organisms, may be enhanced by the presence of the steroid. It is contraindicated in patients with perforated ear drum membrane.
	Side effects : Topical application to eye: Corneal ulcers, glaucoma and reduced visual ability. The following side effects are common for patients taking Dexamethasone  Increased appetite  Insomnia  Fluid retention  Heartburn  Muscle weakness.
	Precaution : Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity, and posterior subcapsular cataract formation.Elderly, children and adolescent; pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Dexamethasone is a synthetic glucocorticoid which decreases inflammation by inhibiting the migration of leukocytes and reversal of increased capillary permeability. It suppresses normal immune response.
	Interaction :  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.
				Potentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.
	Therapeutic class : Ophthalmic Steroid preparations
	Packsize : 5 ml bot
Apilac
	n : Ketorolac Tromethamine
	Indications : Moderate to severe pain
	Doses and administration : Oral
									Moderate to severe pain
									Adult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.
									Elderly: 10 mg every 6-8 hr. Max duration: 7 days.
									Parenteral
									Moderate to severe pain
									Adult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.
									Elderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.
									
									Pediatric Patients (2 to 16 years of age):
									IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
									IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
									
	Contara-indications : Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.
	Side effects : GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).
									Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.
	Precaution : Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.
	Pregnancy category : 4
	Mode of action : Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.
	Interaction : May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.
				Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 30's pack
Apimox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Apimox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Apimox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Apitac
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
APN IV
	n : Dextrose 10% + Sodium Chloride 0.225%
	Indications : Dehydration, Fluid and Electrolytes imbalance
	Doses and administration : The dose is dependent upon the age, weight and clinical condition of the patient.
									
									As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.
									
									Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
	Contara-indications : Hypersensitivity.
	Side effects : Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
									
									If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
	Precaution : Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
				
				Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
				
				Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions to patients receiving corticosteroids or corticotropin.
				
				Do not administer unless solution is clear and container is undamaged. Discard unused portion.
	Pregnancy category : 3
	Mode of action : Dextrose and sodium chloride solutions are used as sources of electrolytes, calories and water for hydration. Sodium and chloride ions are responsible for regulating the acid-base balance of the body. Dextrose is a source of calories. It is readily metabolised and helps to decrease losses of body protein and nitrogen. It also promotes glycogen deposition and decreases or prevents ketosis.
	Interaction : None
	Therapeutic class : Intravenous fluid preparations
	Packsize : 500ml bot / 1000 ml bot
Apnac
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize :  100's pack
Apnac SR
	n : Diclofenac Sodium
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis
	Doses and administration : Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.
									
									Children: 1- 3 mg/kg body weight per day in divided doses.
									
									 Injections are intended for intramuscular injection.
									
									Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.
									
									In migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.
									
									Children: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.
									
									Elderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.
									
									Suppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. 
	Contara-indications : It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
									Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. 
	Side effects : Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.
									
	Precaution : History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.
	Pregnancy category : 4
	Mode of action : Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. It reversibly inhibits the enzyme, cyclooxygenase, thus resulting in reduced synthesis of prostaglandin precursors.
	Interaction :  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Apocal 500
	n : Calcium Carbonate
	Indications : Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset
	Doses and administration : Adult: PO Hyperacidity: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets. 
									
									Hyperphosphataemia in chronic renal failure Initial: 2.5 g/day, up to 17 g/day in divided doses.
									
									Renal impairment:
									CrCl (ml/min)	
									<25	Dosage adjustments may be needed depending on serum calcium levels. 
	Contara-indications : Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.
	Side effects : Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).
	Precaution : Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.
	Pregnancy category : 3
	Mode of action : Calcium carbonate can neutralise gastric acid rapidly and effectively. However, it may adversely activate Ca dependent processes, leading to secretion of gastric and hydrochloric acid. It can induce rebound acid secretion and, prolonged high doses may cause hypercalcemia, alkalosis and milk-alkali syndrome.
	Interaction : Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
	Therapeutic class : Specific mineral preparations
	Packsize : 50's pack
Apocal Chewable 250
	n : Calcium Carbonate
	Indications : Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset
	Doses and administration : Adult: PO Hyperacidity: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets. 
									
									Hyperphosphataemia in chronic renal failure Initial: 2.5 g/day, up to 17 g/day in divided doses.
									
									Renal impairment:
									CrCl (ml/min)	
									<25	Dosage adjustments may be needed depending on serum calcium levels. 
	Contara-indications : Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.
	Side effects : Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).
	Precaution : Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.
	Pregnancy category : 3
	Mode of action : Calcium carbonate can neutralise gastric acid rapidly and effectively. However, it may adversely activate Ca dependent processes, leading to secretion of gastric and hydrochloric acid. It can induce rebound acid secretion and, prolonged high doses may cause hypercalcemia, alkalosis and milk-alkali syndrome.
	Interaction : Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
	Therapeutic class : Specific mineral preparations
	Packsize : 50's pack
Apocal-D
	n : Calcium + Vitamin D3
	Indications : Postmenopausal osteoporosis, Osteoporosis, Osteomalacia/rickets, Hypoparathyroidism, Latent tetany, Hypocalcaemia, Calcium and vitamin D deficiency
	Doses and administration : Adult: PO Per tab contains Ca carbonate 1,500 mg and vitamin D3 10 mcg: 1 tab twice daily.
	Contara-indications : Patients with hypercalcaemia and/or hypercalciuria. Nephrolithiasis, hypervitaminosis D, hypophosphataemia.
	Side effects : Constipation, flatulence, nausea, abdominal pain and diarrhoea, pruritus, rash and urticaria.
	Precaution : Impaired calcium absorption in achlorhydria which is common in elderly. Increased risk of hypercalcaemia and hypercalciuria in hypoparathyroid patients receiving high doses of vitamin D. Caution when using in patients with history of kidney stones. Renal impairment; frequent monitoring of serum calcium and phosphorus is recommended.
	Pregnancy category : 3
	Mode of action : Calcium /vitamin D3 prevents or treats negative Ca balance. It also helps facilitate nerve and muscle performance as well as normal cardiac function. Bone mineral component; cofoactor in enzymatic reactions, essential for neurotransmission, muscle contraction, and many signal transduction pathways. Vitamin D3 is a fat-soluble sterol. It is necessary for the regulation and regulation of calcium and phosphate homoeostasis and bone mineralisation. Vitamin D is also essential for healthy bones as it aids in Calcium absorption from the GI tract. In addition to this it stimulates bone formation. Clinical studies also show that Calcium and Vitamin D has synergistic effects on bone growth as well as in Osteoporosis and fracture prevention.
	Interaction : May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 15's pack/30's pack
Apodin
	n : Povidone Iodine 5% Topical
	Indications : Primary or secondary topical infections, infected surgical incisions, infected decubitus or stasis ulcers, pyodermas, secondarily infected dermatoses, and infected traumatic lesions. Prevention of infections in cuts and abrasions, wounds.
									
									
	Doses and administration : Adult: As Oinement: For the treatment of infection: Apply once or twice daily or at dressing changes for a maximum of 14 days.
									For the prevention of infection: Apply once or twice a week for as long as necessary. Apply ointment directly to the affected area after being cleaned and dried. May be covered with a dressing or bandage.
									
									
									As powd: Apply as often as required directed.May be covered with a dressing or bandage.
									
									
	Contara-indications :  Regular use is contraindicated in patients or users with thyroid disorders (in particular nodular colloid goitre, endemic goiter and Hashimotos thyroiditis). Not for use in infants under 2 years. Special caution is needed when regular applications to broken skin are made to patients with pre-existing renal insufficiency. Regular use should be avoided in patients on concurrent lithium therapy.
	Side effects :  Local skin irritation and sensitivity. Application to large areas of denuded skin may produce systemic effects due to iodine absorption.The application of povidone iodine to large wounds or severe burns may producesystemic adverse effectssuch as metabolic acidosis, hypernatraemia and impairment of renal function.
									
									Occasionally mild-transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions are reported. 
									
	Precaution : Pregnancy, lactation; neonates.
	Pregnancy category : 4
	Mode of action : Povidone-iodine is an iodophore with a powerful broad-spectrum germicidal activity against a wide range of bacteria, viruses, fungi, protozoa and spores. Microbicidal; oxidizes cell constituents; iodinates proteins and inactivates them. 
	Interaction : None
	Therapeutic class : Iodine compounds (Anti-septic Preparations)
	Packsize : 10gm tube
Apoket
	n : Ketorolac Tromethamine
	Indications : Moderate to severe pain
	Doses and administration : Oral
									Moderate to severe pain
									Adult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.
									Elderly: 10 mg every 6-8 hr. Max duration: 7 days.
									Parenteral
									Moderate to severe pain
									Adult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.
									Elderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.
									
									Pediatric Patients (2 to 16 years of age):
									IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
									IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
									
	Contara-indications : Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.
	Side effects : GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).
									Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.
	Precaution : Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.
	Pregnancy category : 4
	Mode of action : Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.
	Interaction : May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.
				Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 30's pack
Apoxy
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Apoxy
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Apoxy
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Apoxy DS
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Apozyth
	n : Azithromycin
	Indications : Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							
									
	Doses and administration : Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. 
									
									Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. 
									Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. 
									Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. 
									
									IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. 
									
									Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
									
									Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. 
	Contara-indications : Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
	Side effects : GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
									Potentially Fatal: Angioedema and cholestatic jaundice.
	Precaution : May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
	Pregnancy category : 2
	Mode of action : Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
	Interaction : Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
				Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
	Therapeutic class : Macrolides
	Packsize : 12's pack
Apresin
	n : Fluphenazine Hydrochloride + Nortriptyline
	Indications : Headache, Depression, Anxiety, Emotional disturbance, Tension, Fatigue, Sleep disorder, Bodyache, Gastric problems
	Doses and administration : Adult: 1 tablet 2 to 3 times daily.
									Child: Not recommended.
	Contara-indications : Patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. The presence of blood dyscrasia or liver damage precludes the use of fluphenazine hydrochloride. Fluphenazine hydrochloride is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross sensitivity to phenothiazine derivatives may occur.
	Side effects : Dryness of mouth, drowsiness, constipation, tachycardia, nasal congestion, blurred vision and excitement.
	Precaution : Patients with glaucoma, prostate enlargement, cardiac failure and myocardial infarction. The drug may impair alertness and abilities to drive a car or operating machinery.
				
				Because of the possibility of cross-sensitivity, fluphenazine hydrochloride should be used cautiously in patients who have developed cholestatic jaundice, dermatoses or other allergic reactions to phenothiazine derivatives.
				
				Psychotic patients on large doses of a phenothiazine drug who are undergoing surgery should be watched carefully for possible hypotensive phenomena. Moreover, it should be remembered that reduced amounts of anesthetics or central nervous system depressants may be necessary.
				
				The effects of atropine may be potentiated in some patients receiving fluphenazine because of added anticholinergic effects.
	Pregnancy category : 3
	Mode of action : Fluphenazine blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system and decreases the release of hypothalamic and hypophyseal hormones. It reduces aggressiveness with disappearance of hallucinations and delusions.
									
									Nortriptyline, a dibenzocycloheptadiene tricyclic antidepressant, is the primary active metabolite of amitriptyline. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
	Interaction : Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics.
				Potentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.
	Therapeutic class : Combined anti-depressant drugs
	Packsize : 100's pack
Aprocin
	n : Ciprofloxacin 0.3% E/E prep
	Indications : Otitis media, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Eye drops: 
									Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is 2 drops into the affected eye every 15 minutes for the first 6 hours and then 2 drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill 2 drops in the affected eye hourly. On the third through the fourteenth day, place 2 drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.
									Conjunctivitis: The recommended dosage regimen for the treatment of bacterial conjunctivitis is 1 or 2 drops instilled into the conjunctival sac(s) every 2 hours while awake for 2 days and one or 2 drops every 4 hours while awake for the next 5 days.
									
									Eye ointment: A thin film of Aprocin Sterile Eye Ointment should evenly be applied either directly to the affected part or inside the lower conjunctival sac at night (if eye drops used during the day) or 3-4 times daily depending on the severity of the condition (if eye ointment used alone).
									
									Ear drops: 
									For all infections, 2-3 drops every 2-3 hours initially, reducing the frequency of the instillation with control of infection. Treatment should be continued at least 7 days. 
	Contara-indications : Ciprofloxacin is contraindicated in patients who have hypersensitivity to Ciprofloxacin or other quinolones.
	Side effects : Local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. Photophobia and nausea may be reported.
	Precaution : Prolonged use of Ciprofloxacin may result in overgrowth of nonsusceptible organisms including fungi. Ciprofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction. Not for injection into the eye.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Aural Anti-bacterial preparations
	Packsize : 10 ml bot
Aprocin
	n : Ciprofloxacin 0.3% E/E prep
	Indications : Otitis media, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Eye drops: 
									Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is 2 drops into the affected eye every 15 minutes for the first 6 hours and then 2 drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill 2 drops in the affected eye hourly. On the third through the fourteenth day, place 2 drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.
									Conjunctivitis: The recommended dosage regimen for the treatment of bacterial conjunctivitis is 1 or 2 drops instilled into the conjunctival sac(s) every 2 hours while awake for 2 days and one or 2 drops every 4 hours while awake for the next 5 days.
									
									Eye ointment: A thin film of Aprocin Sterile Eye Ointment should evenly be applied either directly to the affected part or inside the lower conjunctival sac at night (if eye drops used during the day) or 3-4 times daily depending on the severity of the condition (if eye ointment used alone).
									
									Ear drops: 
									For all infections, 2-3 drops every 2-3 hours initially, reducing the frequency of the instillation with control of infection. Treatment should be continued at least 7 days. 
	Contara-indications : Ciprofloxacin is contraindicated in patients who have hypersensitivity to Ciprofloxacin or other quinolones.
	Side effects : Local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. Photophobia and nausea may be reported.
	Precaution : Prolonged use of Ciprofloxacin may result in overgrowth of nonsusceptible organisms including fungi. Ciprofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction. Not for injection into the eye.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Aural Anti-bacterial preparations
	Packsize : 3gm tube
Aprocin
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 60ml bot
Aprocin
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 30's pack
Aprocin
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 30's pack
Aprocin
	n : Ciprofloxacin
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa
	Doses and administration : Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; 
									
									Chronic Bacterial Prostitis : 500 mg twice daily for 28 days; 
									
									Lower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; 
									
									Acute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, 
									
									Bone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, 
									
									Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, 
									
									Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. 
									
									For IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; 
									
									Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; 
									
									Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; 
									
									Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: 
									Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. 
									
									Children and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; 
									UTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; 
									
									Pseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.
	Contara-indications : Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.
	Side effects : GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.
									Potentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.
	Precaution : Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Anti-diarrhoeal Antimicrobial drugs
	Packsize : 20's pack
Aprocin HC
	n : Ciprofloxacin 0.3% + Hydrocortisone Acetate 1% E/E prep
	Indications : Steroid responsive inflammatory ocular conditions, Otitis media, Otitis externa, Ocular inflammation associated with infection, Post-operative inflammation of ear and eye, Corneal Ulcers, Bacterial Conjunctivitis
	Doses and administration : Eye:
									Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcer is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.
									Bacterial Conjunctivitis:
									The recommended dosage regimen for the treatment of bacterial conjunctivitis is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.
									
									Ear:
									Four drops instilled into the affected ear twice daily for seven days. The suspension should be warmed by holding the bottle in the hand for one or two minutes to avoid dizziness, which may result from the instillation of a cold suspension. The patient should lie with the affected ear upward, and then the suspension should be instilled. This position should be maintained for 60 seconds. Repeat, if necessary, for the opposite ear.
									
									Paediatric Use:
									Ear: Safety and effectiveness of this suspension in pediatric (6 months of age and older) patients for ear application have been established.
									Eye:
									Safety and effectiveness of this suspension in pediatric patients for eye application have not been established.
									
									
	Contara-indications : Known hypersensitivity to any ingredient of the product. Herpes simplex and other viral conditions, mycosis, glaucoma, newborn babies, fungal diseases of ocular or auricular structures.
	Side effects : The most frequently reported drug-related adverse reactions seen with Ciprofloxacin are transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness and eye pain. Rare reports of dizziness have been received.
									
									The reactions due to the steroid component are elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior sub-capsular cataract formation and delayed wound healing.
	Precaution : Prolonged use may result in overgrowth of nonsusceptible organisms including fungi; in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision and posterior sub capsular cataract formation. Patients wearing contact lenses must not use the drops during the time the lenses are worn.
	Pregnancy category : 17
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
									Hydrocortisone is a corticosteroid used for its anti-inflammatory and immunosuppressive effects. Its anti-inflammatory action is due to the suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It may also be used as replacement therapy in adrenocortical insufficiency.
									
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
				 	Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.
	Therapeutic class : Aural Steroid & Steroid/Antibiotic combined preparations
	Packsize : 10ml bot
Aprodex
	n : Ciprofloxacin 0.3% + Dexamethasone 0.1% E/E prep
	Indications : Steroid responsive inflammatory ocular conditions, Otitis media, Otitis externa, Ocular inflammation associated with infection, Post-operative inflammation of ear and eye.
	Doses and administration : For Eye: 1 drop to be instilled into conjunctival sac(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to 1 drop every two hours.
									
									For Ear: Acute otitis media in pediatric patients with typanastomy tube: 4 drops instilled into the affected ear 2 times daily for 7 days. Acute otitis externa: 4 drops instilled into the affected ear 2 times daily for 7 days.
									Frequency should be decreased gradually or warranted in clinical signs. Care should be taken not to discontinue therapy prematurely.
	Contara-indications : Known hypersensitivity to any ingredient of the product. Herpes simplex and other viral conditions, mycosis, glaucoma, newborn babies, fungal diseases of ocular or auricular structures.
	Side effects : The most frequently reported drug-related adverse reactions seen with Ciprofloxacin are transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, conjunctivitis/keratitis, periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain. Rare reports of dizziness have been received.
									
									The reactions due to the steroid component are elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage, posterior sub capsular cataract formation, and delayed wound healing.
	Precaution : Prolonged use may result in overgrowth of nonsusceptible organisms including fungi; in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision and posterior sub capsular cataract formation.
				
				Patients wearing contact lenses must not use the drops during the time the lenses are worn.
	Pregnancy category : 3
	Mode of action : Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
									Dexamethasone is a synthetic glucocorticoid which decreases inflammation by inhibiting the migration of leukocytes and reversal of increased capillary permeability. It suppresses normal immune response.
									
	Interaction : May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.
				Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
	Therapeutic class : Aural Steroid & Steroid/Antibiotic combined preparations
	Packsize : 5  ml drop
Apsol
	n : Amlexanox
	Indications : Aphthous ulcer
	Doses and administration : Adult: Topical As a 5% oral paste: Apply approx 0.5 cm of oral paste directly on to each ulcer 4 times/day; following oral hygiene after meals and at bedtime. 
									
									Initiate treatment at earliest symptom of an aphthous ulcer. Continue treatment until mouth ulcer is healed, not exceeding 10 days. 
									
									Child: Not to be used in children below age 12.
	Contara-indications : Known hypersensitivity to any of the ingredients.
	Side effects : Application site reactions e.g. transient pain, stinging, burning, irritation, contact mucositis, nausea and diarrhoea.
	Precaution : For topical use on mouth ulcers only. Avoid contact with the eyes; rinse immediately if ocular contact occurs. Wash hands before and after every application. Discontinue treatment if rash or contact mucositis develops. Seek medical advice if mouth ulcers have not healed after 10 days of treatment. Effects have not been evaluated in immune-compromised patients. Use lower initial dose for elderly patients. Not recommended for use in children below <12 yr. Pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Amlexanox accelerates healing of aphthous ulcers. The exact mechanism of action is not known. In vitro studies have shown that Amlexanox is a potent inhibitor of the formation and/or release of inflammatory mediators (histamine and leukotrienes) from mast cells, neutrophils, and mononuclear cells.
	Interaction : None
	Therapeutic class : Drugs for Aphthous ulcer
	Packsize : 5gm tube
APT
	n : Clopidogrel
	Indications : Coronary Artery Disease, Acute coronary syndrome, Myocardial infarction, Peripheral vascular disease, Cerebrovascular disease, Atherosclerosis, Thromboembolic disorders, Unstable angina, Stroke
	Doses and administration : Adult: PO Prophylaxis of thromboembolic events 75 mg once daily. 
									
									Acute coronary syndrome For ST-elevation myocardial infarction: W/ aspirin: 75 mg once daily. Continue treatment for up to 28 days. 
									
									For unstable angina, non-ST-elevation myocardial infarction: Initial: 300 mg loading dose, followed by 75 mg once daily (w/ aspirin 75-325 mg once daily).
	Contara-indications : Hypersensitivity. Active pathological bleeding. admin within 7 days after MI and ischaemic stroke, coagulation disorders. Lactation.
	Side effects : Dyspepsia, abdominal pain, nausea, vomiting, flatulence, constipation, gastritis, gastric and duodenal ulcers. GI upset, diarrhoea, paraesthesia, vertigo, headache, dizziness, pruritus and rashes.
									Potentially Fatal: Bleeding disorders including GI and intracranial haemorrhage. Blood dyscrasias.
	Precaution : Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions; ulcer; renal and hepatic impairment; history of bleeding or haemostatic disorders. Pregnancy.
	Pregnancy category : 2
	Mode of action : Clopidogrel inhibits adenosine diphosphate (ADP) from binding to its receptor sites on the platelets and subsequent activation of glycoprotein GP IIb/IIIa complex thus preventing fibrinogen binding, platelet adhesion and aggregation.
	Interaction :  	Co-admin with NSAIDs may increase the risk of stomach and intestinal bleeding. High-dose clopidogrel may lead to increased warfarin levels thus increasing the risk of bleeding. High-dose clopidogrel may also inhibit P450 (2C9), thus interfering with the metabolism of phenytoin, tamoxifen, torasemide, fluvastatin and some NSAIDs. Avoid concurrent use of drugs that inhibit CYP2C19, including omeprazole, esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine and ticlopidine.
	Therapeutic class : Anti-platelet drugs
	Packsize : 20's pack
Aptrim
	n : Sulphamethoxazole + Trimethoprim
	Indications : Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
	Doses and administration : Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. 
									Suspension : 1-2 teaspoonful twice daily.
									
									GI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. 
									
									Pneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.
									
									Child: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.
									
									Renal impairment: Dosage reduction for adults and children >12 yr:
									CrCl (ml/min)	
									15-30	Half the standard dose.
									<15	        Not recommended.
	Contara-indications : Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.
	Side effects : Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.
									Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.
	Precaution : G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.
	Pregnancy category : 4
	Mode of action : Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
	Interaction : Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
				Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
	Therapeutic class : Sulphonamides & Trimethoprim
	Packsize : 60ml bot
Apuldon
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 100's pack
Apuldon
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 60ml bot
Apuldon
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 15ml drop
Apuldon
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 10's pack
Apuldon
	n : Domperidone
	Indications : Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
	Doses and administration : Adults : 10 - 20 mg every 4 - 8 hours daily
									Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
									
									Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. 
									Non ulcer dyspepsia 10-20 mg 3 times/day and at night. 
									Migraine 20 mg 4 hrly. Max: 4 doses/24 hr. 
									
									Rectal: Nausea and vomiting 60 mg twice daily.
	Contara-indications : Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
	Side effects : Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
									Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
	Precaution : Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
	Pregnancy category : 3
	Mode of action : Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
	Interaction : May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
				Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
	Therapeutic class : Motility stimulants/Dopamine antagonist
	Packsize : 10's pack
Apzyl
	n : Metronidazole
	Indications : Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
	Doses and administration : Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.
									
									Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. 
									
									Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.
									
									 Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. 
									
									IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. 
									
									Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. 
									
	Contara-indications : History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
	Side effects : GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).
									Potentially Fatal: Anaphylaxis.
	Precaution : Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
	Pregnancy category : 2
	Mode of action : Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
	Interaction : Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
	Therapeutic class : Amoebicides
	Packsize : 60ml bot
Aqualax
	n : Polyethylene Glycol
	Indications : Constipation, faecal impaction.
	Doses and administration : The usual dose  is 17 gm of powder per day (or as directed by physician) in a glass of water, juice, coke, coffee or tea. 
									Each bottle  is supplied with a cup that is used to measure 17 gm or 8.5 gm of laxative powder when filled upto the marked line. 
	Contara-indications : Polyethylene glycol is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.
	Side effects : Nausea, abdominal bloating, cramping and flatulence may occur. High doses may produce diarrhea and excessive stool frequency, particularly in elderly nursing home patients. Patients taking other medications containing polyethylene glycol have occasionally developed urticaria suggestive of an allergic reaction.
	Precaution : Patients with symptoms suggestive of bowel obstruction (nausea, vomiting, abdominal pain or distention) should be evaluated to rule out this condition before initiating therapy.It should be administered after being dissolved in water, juice, coke, coffee or tea.
	Pregnancy category : 0
	Mode of action : Poly ethylene Glycol is an osmotic agent that causes water to be retained with the stool.It appears to have no effect on the active absorption or secretion of glucose or electrolytes.
	Interaction : None
	Therapeutic class : Osmotic purgatives
	Packsize : 85gm bot
Aquaphen
	n : Guaiphenesin + Pseudoephedrine Hydrochloride + Triprolidine Hydrochloride
	Indications : Pneumonia, Productive cough, Allergic rhinitis, Sneezing, Respiratory tract disorders, Cough & runny nose, Nasal congestion
	Doses and administration : Adult and Children over 12 years: 10 ml (2 teaspoonful) three times a day.
									Children 6-12 years: 5 ml (1 teaspoonful) three times a day.
									Children 2-5 years: 2.5 ml (1/2 teaspoonful) three times a day.
									
	Contara-indications : Patients with a known hypersensitivity to guaiphenesin, psedoephedrine or triprolidine. Contraindicated in persons under treatment with monoamine oxidase inhibitors within 2 weeks of stopping such treatment.
									Patients with severe hypertension or severe coronary artery disease
	Side effects : Central nervous system (CNS) depression or excitation may occur. Sleep disturbance and rarely hallucination have been reported. Skin rashes, tachycardia, dryness of mouth, nose and throat have occasionally been reported. Urinary retention has been reported occasionally in men receiving pseudoephedrine; prostatic enlargement could have been an important predisposing factor.
	Precaution :  It may cause drowsiness and impair performance in tests of auditory vigilance. It may also impair the patients ability to drive and also to use machineries. So, driving and operation of machineries should be avoided during treatment with Aquaphen. Although there are no objective data, Avoid the concomitant use of alcohol or other centrally acting sedatives.
				Although Pseudoephedrine has virtually no pressor effect in patients with normal blood pressure, Aquaphen should be used with caution in patients taking antihypertensive agents, tricyclic antidepressants or other sympathomimetic agents such as decongestant, appetite suppressants and amphetamine-like psychostimulants.  It effects   on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment.
				As with other sympathomimetic agents, caution should be exercised in patients with hypertension, heart disease, diabetes, hyperthyroidism, elevated intraocular pressure and prostatic enlargement.  It should not be used for persistent or chronic cough such as occurs with smoking, asthma or emphysema or where cough is accompanied by excessive secretions unless directed by a physician.
	Pregnancy category : 3
	Mode of action : Triprolidine hydrochloride is a potent competitive histamine H1-receptor antagonist with antimuscarinic and mild sedative properties.
									
									Pseudoephedrine is both an ?-and ?-adrenergic receptor agonist. It causes vasoconstriction via direct stimulation of ?-adrenergic receptors of the respiratory mucosa. It also directly stimulates ?-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility.
									
									Guaifenesin increases the volume and reduce the viscosity of tenacious sputum and is used as an expectorant for productive cough.
	Interaction : Sympathomimetics eg decongestants, TCAs, appetite suppressants, amphetamine-like psychostimulants; may increase BP w/ MAOIs. Bretylium, bethanidine, guanethidine, debrisoquine, methyldopa, ?- & ?-adrenergic blocker; furazolidone, alcohol, sedatives.
	Therapeutic class : Combined cough expectorants
	Packsize : 100ml bot
Aquavit
	n : Vitamin A, D, B1, B2, B6, C, E, Nicotinamide, Cod liver oil (Multivitamin with Cod Liver Oil)
	Indications : Vitamin/mineral deficiency. Prevention of vitamin lacking symptom for growing child, lack of appetite child, including patient under rehabilitating period.
	Doses and administration : Infants (<1 year): Half teaspoonful daily. Children (1 - 4 years): One teaspoonful daily. Children (> 4 years): One & half teaspoonful daily. Adults: Two teaspoonful daily. Women of child bearing age (including pregnancy & lactation): One teaspoonful daily. It can be taken with water or milk if desired.
									
	Contara-indications : This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. However, a few allergic reactions may be seen.
	Precaution : This medicine may accumulate in the body, which cause danger. So, it should not use over dosage or use continuously except recommended by physicians
	Pregnancy category : 0
	Mode of action : It contains 8 vitamins and fatty acid (cod liver oil). Cod liver oil is composed of vitamin A, D, EPA and DHA. Both EPA & DHA are omega-3 fatty acids. These omega-3 fatty acids keep blood triglycerides in check (high triglycerides are generally linked with increased risk of heart diseases) and may inhibit the progression of atherosclerosis. They also have anti-inflammatory activity; as a result they are also helpful in Crohn's disease and rheumatoid arthritis. It has been also found that omega- 3 fatty acids are needed for prostaglandin formation. Probably as a result of their effect on prostaglandin they are responsible for blood vessel dilation. A double blind trial found that omega- 3 fatty acids helped to treat patient with Raynaud's disease. It has been also found that EPA & DHA have some preventive role in cancer and prevent cardiac arrhythmia.
	Interaction : None
	Therapeutic class : Nonspecific multivitamin preparations
	Packsize : 100ml bot
Arafa
	n : Ibuprofen
	Indications : Rheumatoid arthritis, Osteoarthritis, Pain, Fever, Pericarditis, Dysmenorrhea, Patent ductus arteriosus, Inflammation, Musculoskeletal and joint disorders
	Doses and administration : Adult: PO Pain and inflammation 1.2-1.8 g/day in divided doses. Maintenance: 0.6-1.2 g/day. Max: 2.4 g/day. 
									Fever 200-400 mg 4-6 hrly. Max: 1.2 g/day. 
									
									
	Contara-indications : Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).
	Side effects : Oral: Dyspepsia, vomitting, abdominal pain, heart burn, nausea, diarrhoea, epigastric pain, edema, fluid retention, dizziness, rash, tinnitus. Parenteral: Intraventricular hemorrhage, skin irritation, hypocalcemia, hypoglycemia, GI disorders, anemia, apnea, respiratory infection, sepsis.
									Potentially Fatal: Severe CV thrombotic events. Severe GI bleeding, ulceration and perforation.
	Precaution : Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation.
	Pregnancy category : 4
	Mode of action : Ibuprofen inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase-1 and 2. It has anti-inflammatory, analgesic and antipyretic properties.
	Interaction : Increased risk of GI bleeding w/ warfarin, corticosteroids, SSRIs and aspirin. May reduce the natriuretic effects of diuretics. Reduced antihypertensive effect of ACE inhibitors and angiotensin II receptor antagonists. May increase toxicity of lithium and methotrexate. Increased nephrotoxicity w/ ciclosporin and tacrolimus.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 100's pack
Arain
	n : Tolfenamic Acid
	Indications : Mild to moderate pain,  Acute migraine attacks
	Doses and administration : Adult: PO Acute migraine attacks Initial: 200 mg upon onset of symptoms. May repeat once after 1-2 hr. Mild to moderate pain 100-200 mg 3 times/day.
									
									Renal impairment: Dose adjustments may be needed
	Contara-indications : Hypersensitivity to aspirin or other NSAID. Active peptic ulceration. Severe renal or hepatic impairment. Pregnancy (3rd trimester).
	Side effects : Dysuria especially in males; diarrhoea, nausea, epigastric pain, vomiting, dyspepsia, erythema, headache. Tremor, euphoria, fatigue, pulmonary infiltration.
									Potentially Fatal: Blood dyscrasias, toxic hepatitis.
	Precaution : Asthma, bronchospasm, bleeding disorders, CV diseases, history of peptic ulceration, hypertension, patients with infections, liver, cardiac, or renal function impairment. Increase water intake or dose reduction to reduce dysuria. CHF; elderly; lactation.
	Pregnancy category : 3
	Mode of action : Tolfenamic acid, an anthranilic acid derivative, is an NSAID. It has anti-inflammatory, analgesic and antipyretic effects.
	Interaction : Increased rate of absorption of tolfenamic acid with metoclopramide and magnesium hydroxide. Decreased rate of absorption of tolfenamic acid with aluminium hydroxide. Increased risk of bleeding with anticoagulants and other NSAIDs. Decreased antihypertensive response to loop diuretics, ?-blockers and ACE inhibitors. Coadmin increased plasma concentrations of lithium, methotrexate and cardiac glycosides. Increased risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus or diuretics.
	Therapeutic class : Other drugs for migraine
	Packsize : 30's pack
Araten
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
				
Araten PLUS 12.5/50
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Arb
	n : Candesartan Cilexetil
	Indications : Hypertension, Congestive heart failure
	Doses and administration : Oral
									Hypertension
									Adult: Initially, 8 mg once daily adjusted according to response. Maintenance: 8 mg once daily. Max: 32 mg/day as single or in 2 divided doses. Patients w/ intravascular volume depletion: Initially, 4 mg once daily.
									Child: 1 to <6 yr Initially, 200 mcg/kg/day. May increase according to response to 50-400 mcg/kg/day. >6 yr <50 kg: 4-8 mg/day, adjusted according to response to 2-16 mg/day; >50 kg: 8-16 mg/day, adjusted according response to 4-32 mg/day. All doses may be given as single or in 2 divided doses.
									Hepatic impairment: Mild to moderate: Initially, 4 mg once daily. Severe: Contraindicated.
									
									Heart failure
									Adult: Initially, 4 mg once daily, may be doubled at intervals of not <2 wk. Max: 32 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Hypersensitivity. Pregnancy (2nd and 3rd trimester) and lactation.
	Side effects : Dizziness, headache, vertigo, depression, somnolence, fever, back pain, upper respiratory tract infections, 1st dose orthostatic hypotension, rash, diarrhoea, decreased haemoglobin, renal impairment, hepatitis.
	Precaution : Volume or sodium depletion, preexisting renal insufficiency; aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy, renal artery stenosis, primary hyperaldosteronism. Patients with a history of angioedema, urticaria. Monitor serum potassium levels especially in elderly and renally impaired patients. Hypotension may occur during major surgery and anaesthesia due to suppression of the renin-angiotensin system.
	Pregnancy category : 4
	Mode of action : Candesartan inhibits the binding of angiotensin II to AT1 receptors in many tissues (e.g. vascular smooth muscles, adrenal gland) which leads to vasoconstriction blockade and aldosterone release.
	Interaction : NSAIDs may reduce antihypertensive effect and result in deterioration of renal function including possible acute renal failure. May increase serum lithium concentration. K-sparing diuretics, K supplements or salt substitutes containing K may increase risk of hyperkalaemia.
				Potentially Fatal: Coadministration w/ aliskiren in diabetic patients may increase risk of renal impairment, hypotension and hyperkalaemia.
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Arb
	n : Candesartan Cilexetil
	Indications : Hypertension, Congestive heart failure
	Doses and administration : Oral
									Hypertension
									Adult: Initially, 8 mg once daily adjusted according to response. Maintenance: 8 mg once daily. Max: 32 mg/day as single or in 2 divided doses. Patients w/ intravascular volume depletion: Initially, 4 mg once daily.
									Child: 1 to <6 yr Initially, 200 mcg/kg/day. May increase according to response to 50-400 mcg/kg/day. >6 yr <50 kg: 4-8 mg/day, adjusted according to response to 2-16 mg/day; >50 kg: 8-16 mg/day, adjusted according response to 4-32 mg/day. All doses may be given as single or in 2 divided doses.
									Hepatic impairment: Mild to moderate: Initially, 4 mg once daily. Severe: Contraindicated.
									
									Heart failure
									Adult: Initially, 4 mg once daily, may be doubled at intervals of not <2 wk. Max: 32 mg once daily.
									Hepatic impairment: Severe: Contraindicated.
	Contara-indications : Hypersensitivity. Pregnancy (2nd and 3rd trimester) and lactation.
	Side effects : Dizziness, headache, vertigo, depression, somnolence, fever, back pain, upper respiratory tract infections, 1st dose orthostatic hypotension, rash, diarrhoea, decreased haemoglobin, renal impairment, hepatitis.
	Precaution : Volume or sodium depletion, preexisting renal insufficiency; aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy, renal artery stenosis, primary hyperaldosteronism. Patients with a history of angioedema, urticaria. Monitor serum potassium levels especially in elderly and renally impaired patients. Hypotension may occur during major surgery and anaesthesia due to suppression of the renin-angiotensin system.
	Pregnancy category : 4
	Mode of action : Candesartan inhibits the binding of angiotensin II to AT1 receptors in many tissues (e.g. vascular smooth muscles, adrenal gland) which leads to vasoconstriction blockade and aldosterone release.
	Interaction : NSAIDs may reduce antihypertensive effect and result in deterioration of renal function including possible acute renal failure. May increase serum lithium concentration. K-sparing diuretics, K supplements or salt substitutes containing K may increase risk of hyperkalaemia.
				Potentially Fatal: Coadministration w/ aliskiren in diabetic patients may increase risk of renal impairment, hypotension and hyperkalaemia.
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Arbit
	n : Irbesartan
	Indications : Diabetic nephropathy, Hypertension
	Doses and administration : Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.
	Contara-indications : Hypersensitivity; pregnancy and lactation.
	Side effects : Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.
	Precaution : Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
	Pregnancy category : 4
	Mode of action : Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
	Interaction : May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Arbit
	n : Irbesartan
	Indications : Diabetic nephropathy, Hypertension
	Doses and administration : Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.
	Contara-indications : Hypersensitivity; pregnancy and lactation.
	Side effects : Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.
	Precaution : Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
	Pregnancy category : 4
	Mode of action : Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
	Interaction : May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Arbitain Plus 75
	n : Hydrochlorothiazide + Irbesartan
	Indications : Diabetic nephropathy, Hypertension
	Doses and administration : Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.
	Contara-indications : Hypersensitivity; pregnancy and lactation.
	Side effects : Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.
	Precaution : Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions.
									
									Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
	Interaction : Other antihypertensives, lithium, K-sparing diuretics, K supplements, salt substitutes containing K. CNS depressants, antidiabetics, cholestyramine & colestipol resins, corticosteroids, ACTH, digitalis glycosides, antiarrhythmics, NSAIDs, tubocurarine, antigout medications, Ca salts. Alcohol; ?-blockers, diazoxide, atropine, beperiden, amantadine, cyclophosphamide, methotrexate.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Arbitan
	n : Irbesartan
	Indications : Diabetic nephropathy, Hypertension
	Doses and administration : Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.
	Contara-indications : Hypersensitivity; pregnancy and lactation.
	Side effects : Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.
	Precaution : Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
	Pregnancy category : 4
	Mode of action : Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
	Interaction : May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Arbitan
	n : Irbesartan
	Indications : Diabetic nephropathy, Hypertension
	Doses and administration : Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.
	Contara-indications : Hypersensitivity; pregnancy and lactation.
	Side effects : Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.
	Precaution : Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
	Pregnancy category : 4
	Mode of action : Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
	Interaction : May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 20's pack
Arbitan
	n : Irbesartan
	Indications : Diabetic nephropathy, Hypertension
	Doses and administration : Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.
	Contara-indications : Hypersensitivity; pregnancy and lactation.
	Side effects : Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.
	Precaution : Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
	Pregnancy category : 4
	Mode of action : Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
	Interaction : May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Arbitan PLUS 150
	n : Hydrochlorothiazide + Irbesartan
	Indications : Diabetic nephropathy, Hypertension
	Doses and administration : Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.
	Contara-indications : Hypersensitivity; pregnancy and lactation.
	Side effects : Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.
	Precaution : Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions.
									
									Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
	Interaction : Other antihypertensives, lithium, K-sparing diuretics, K supplements, salt substitutes containing K. CNS depressants, antidiabetics, cholestyramine & colestipol resins, corticosteroids, ACTH, digitalis glycosides, antiarrhythmics, NSAIDs, tubocurarine, antigout medications, Ca salts. Alcohol; ?-blockers, diazoxide, atropine, beperiden, amantadine, cyclophosphamide, methotrexate.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Arbitan Plus 300
	n : Hydrochlorothiazide + Irbesartan
	Indications : Diabetic nephropathy, Hypertension
	Doses and administration : Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.
	Contara-indications : Hypersensitivity; pregnancy and lactation.
	Side effects : Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.
	Precaution : Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions.
									
									Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
	Interaction : Other antihypertensives, lithium, K-sparing diuretics, K supplements, salt substitutes containing K. CNS depressants, antidiabetics, cholestyramine & colestipol resins, corticosteroids, ACTH, digitalis glycosides, antiarrhythmics, NSAIDs, tubocurarine, antigout medications, Ca salts. Alcohol; ?-blockers, diazoxide, atropine, beperiden, amantadine, cyclophosphamide, methotrexate.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 20's pack
Arbium
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 30's pack
Arbium
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 50's pack
Arbium
	n : Losartan Potassium
	Indications : Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure
	Doses and administration : Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. 
									
									Losartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. 
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.
									
									Diabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.
									
									Heart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.
									
									If blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. 
									
									Chronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.
									Maximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. 
									
									Nephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.
	Contara-indications : Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.
	Side effects : The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.
	Precaution : Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.
	Pregnancy category : 3
	Mode of action : Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
	Interaction : May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
				Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
	Therapeutic class : Angiotensin-II receptor blocker
	Packsize : 50's pack
Arbium Plus 100/12.50
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Arbium Plus 100/25
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Arbium Plus 50/12.5
	n : Hydrochlorothiazide + Losartan Potassium
	Indications : Hypertension, Stroke risk reduction of hypertensive or LVH patients
	Doses and administration : Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.
									
									Stroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.
									
									Renal impairment: Dialysis patients: Avoid.
									CrCl (ml/min)	
									<20	Avoid.
	Contara-indications : Pregnancy, lactation; intravascular volume depletion.
	Side effects : Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
									Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
	Precaution : Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
	Pregnancy category : 4
	Mode of action : Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
	Interaction : Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. 
				
				Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. 
				
				Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
	Therapeutic class : Combined antihypertensive preparations
	Packsize : 30's pack
Arcet
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 100's pack
Arcet
	n : Cetirizine Dihydrochloride
	Indications : Allergic rhinitis, Hay fever, Allergies, Urticaria
	Doses and administration : Tablet:
									Oral
									Allergic conditions
									Adult: 10 mg once daily or 5 mg bid.
									Child: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.
									
									Elderly: Initially, 5 mg once daily.
									Hepatic impairment: Initially, 5 mg once daily.
									
									Syrup:
									Adults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.
									Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.
	Contara-indications : Hypersensitivity; lactation.
	Side effects : Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.
	Precaution : Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.
	Pregnancy category : 2
	Mode of action : Cetirizine is a potent and highly selective antagonist of the peripheral histamine H1-receptor on effector cells in the GI tract, blood vessels and resp tract.
	Interaction : Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
	Therapeutic class : Non - sedating Anti-histamines
	Packsize : 60ml bot
Archi
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 60ml bot
Archi
	n : Paracetamol
	Indications : Mild to moderate pain and fever
	Doses and administration : Tablet
									Adult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily
									Children (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily
									
									Syrup
									Children: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;
									Under 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)
									3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),
									1 - 5 years : 1 - 2 measuring spoonful
									6 - 12 years : 2 - 4 measuring spoonful
									
									Paediatric Drops
									Children Up to 3 months: 0.5 ml (40 mg) 
									4 to 11 months:  1.0 ml (80 mg) 
									1 to 2 years: 1.5 ml (120 mg) 
									2 to 3 years: 2 ml (160mg)
									4 to 5 years: 3 ml (240 mg)
									Dose can be repeated, every 4 hours.
									
									For Suppository: Suppository should be administered rectally.
									Children: 3 months-1 year: 60-125 mg
									1-5 years: 125-250 mg
									5-12 years: 250-500 mg
									These doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).
									Adults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.
	Contara-indications : Hypersensitivity. 
	Side effects : Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
									Potentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.
	Precaution : Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.
	Pregnancy category : 2
	Mode of action : Paracetamol exhibits analgesic action by peripheral blockage of pain impulse generation. It produces antipyresis by inhibiting the hypothalamic heat-regulating centre. Its weak anti-inflammatory activity is related to inhibition of prostaglandin synthesis in the CNS.
	Interaction : May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
	Therapeutic class : Non-Opioid Analgesics
	Packsize : 200's pack
Arilol
	n : Carvedilol
	Indications : Hypertension, Congestive heart failure, Myocardial infarction, Left ventricular dysfunction, Angina pectoris
	Doses and administration : Hypertension
									Adult: Initially, 12.5 mg once daily increased to 25 mg once daily after 2 days. Alternatively, initial dose of 6.25 mg bid increased to 12.5 mg bid after 1-2 wk, increased further if necessary to 50 mg once daily or in divided doses.
									Elderly: 12.5 mg once daily.
									Angina pectoris
									Adult: Initially, 12.5 mg bid increased to 25 mg bid after 2 days.
									Heart failure
									Adult: Initially, 3.125 mg bid, doubled to 6.25 mg bid after 2 wk if tolerated, then gradually increased to the max dose the patient can tolerate at intervals of not <2>85 kg: 50 mg bid; &lt;85 kg: 25 mg bid.
									Left ventricular dysfunction post myocardial infarction
									Adult: Initially: 6.25 mg bid, if tolerated, after 3-10 days, increase to 12.5 mg bid and then to a target dose of 25 mg bid.
	Contara-indications : Hypersensitivity; severe chronic heart failure, bronchial asthma or related bronchospastic conditions; severe hepatic impairment. Patients with NYHA class IV cardiac failure, 2nd or 3rd  AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia. Lactation.
	Side effects : Bradycardia, AV block, angina pectoris, hypervolaemia, leucopenia, hypotension, peripheral oedema, allergy, malaise, fluid overload, melena, periodontitis, hyperuricaemia, hyponatraemia, increased alkaline phosphatase, glycosuria, prothrombin time, SGPT and SGOT levels, purpura, somnolence, impotence, albuminuria, hypokinesia, nervousness, sleep disorder, skin reaction, tinnitus, dry mouth, anaemia, sweating, fatigue, arthralgia, aggravation, dizziness. Diarrhoea, nausea, vomiting, insomnia, hypercholesterolaemia, weight gain, abnormal vision, rhinitis, pharyngitis and hypertriglyceridaemia.
	Precaution : Avoid abrupt withdrawal as it may precipitate thyroid storm or exacerbate hyperthyroidism. Liver injury; vascular disease, renal failures, suspected phaeochromocytoma and prinzmetal's variable angina; worsening cardiac failure or fluid retention during increase in dosage of carvedilol; diabetic patients. Pregnancy.
	Pregnancy category : 4
	Mode of action : Carvedilol is a nonselective beta-adrenoreceptor and alpha-adrenergic blocking activity.  It exerts antihypertensive effect partly by reducing total peripheral resistance and vasodilation.
	Interaction : Decreased serum levels w/ rifampicin. Combination w/ Ca channel blockers (e.g. verapamil and diltiazem) can lead to bradycardia and myocardial depression. Potentiates insulin-induced hypoglycaemic action. May increase hypoglycaemic effects of antidiabetic agents. Increased risk of bradycardia w/ digoxin. Increased risk of hypotension and bradycardia w/ reserpine, MAOIs, clonidine. May increase ciclosporin concentrations. Concurrent use w/ ether, cyclopropane, trichloroethylene may increase the risk of hypotension and heart failure.
	Therapeutic class : Beta-blockers
	Packsize : 30's pack
Arilol
	n : Carvedilol
	Indications : Hypertension, Congestive heart failure, Myocardial infarction, Left ventricular dysfunction, Angina pectoris
	Doses and administration : Hypertension
									Adult: Initially, 12.5 mg once daily increased to 25 mg once daily after 2 days. Alternatively, initial dose of 6.25 mg bid increased to 12.5 mg bid after 1-2 wk, increased further if necessary to 50 mg once daily or in divided doses.
									Elderly: 12.5 mg once daily.
									Angina pectoris
									Adult: Initially, 12.5 mg bid increased to 25 mg bid after 2 days.
									Heart failure
									Adult: Initially, 3.125 mg bid, doubled to 6.25 mg bid after 2 wk if tolerated, then gradually increased to the max dose the patient can tolerate at intervals of not <2>85 kg: 50 mg bid; &lt;85 kg: 25 mg bid.
									Left ventricular dysfunction post myocardial infarction
									Adult: Initially: 6.25 mg bid, if tolerated, after 3-10 days, increase to 12.5 mg bid and then to a target dose of 25 mg bid.
	Contara-indications : Hypersensitivity; severe chronic heart failure, bronchial asthma or related bronchospastic conditions; severe hepatic impairment. Patients with NYHA class IV cardiac failure, 2nd or 3rd  AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia. Lactation.
	Side effects : Bradycardia, AV block, angina pectoris, hypervolaemia, leucopenia, hypotension, peripheral oedema, allergy, malaise, fluid overload, melena, periodontitis, hyperuricaemia, hyponatraemia, increased alkaline phosphatase, glycosuria, prothrombin time, SGPT and SGOT levels, purpura, somnolence, impotence, albuminuria, hypokinesia, nervousness, sleep disorder, skin reaction, tinnitus, dry mouth, anaemia, sweating, fatigue, arthralgia, aggravation, dizziness. Diarrhoea, nausea, vomiting, insomnia, hypercholesterolaemia, weight gain, abnormal vision, rhinitis, pharyngitis and hypertriglyceridaemia.
	Precaution : Avoid abrupt withdrawal as it may precipitate thyroid storm or exacerbate hyperthyroidism. Liver injury; vascular disease, renal failures, suspected phaeochromocytoma and prinzmetal's variable angina; worsening cardiac failure or fluid retention during increase in dosage of carvedilol; diabetic patients. Pregnancy.
	Pregnancy category : 4
	Mode of action : Carvedilol is a nonselective beta-adrenoreceptor and alpha-adrenergic blocking activity.  It exerts antihypertensive effect partly by reducing total peripheral resistance and vasodilation.
	Interaction : Decreased serum levels w/ rifampicin. Combination w/ Ca channel blockers (e.g. verapamil and diltiazem) can lead to bradycardia and myocardial depression. Potentiates insulin-induced hypoglycaemic action. May increase hypoglycaemic effects of antidiabetic agents. Increased risk of bradycardia w/ digoxin. Increased risk of hypotension and bradycardia w/ reserpine, MAOIs, clonidine. May increase ciclosporin concentrations. Concurrent use w/ ether, cyclopropane, trichloroethylene may increase the risk of hypotension and heart failure.
	Therapeutic class : Beta-blockers
	Packsize : 30's pack
Arilol
	n : Carvedilol
	Indications : Hypertension, Congestive heart failure, Myocardial infarction, Left ventricular dysfunction, Angina pectoris
	Doses and administration : Hypertension
									Adult: Initially, 12.5 mg once daily increased to 25 mg once daily after 2 days. Alternatively, initial dose of 6.25 mg bid increased to 12.5 mg bid after 1-2 wk, increased further if necessary to 50 mg once daily or in divided doses.
									Elderly: 12.5 mg once daily.
									Angina pectoris
									Adult: Initially, 12.5 mg bid increased to 25 mg bid after 2 days.
									Heart failure
									Adult: Initially, 3.125 mg bid, doubled to 6.25 mg bid after 2 wk if tolerated, then gradually increased to the max dose the patient can tolerate at intervals of not <2>85 kg: 50 mg bid; &lt;85 kg: 25 mg bid.
									Left ventricular dysfunction post myocardial infarction
									Adult: Initially: 6.25 mg bid, if tolerated, after 3-10 days, increase to 12.5 mg bid and then to a target dose of 25 mg bid.
	Contara-indications : Hypersensitivity; severe chronic heart failure, bronchial asthma or related bronchospastic conditions; severe hepatic impairment. Patients with NYHA class IV cardiac failure, 2nd or 3rd  AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia. Lactation.
	Side effects : Bradycardia, AV block, angina pectoris, hypervolaemia, leucopenia, hypotension, peripheral oedema, allergy, malaise, fluid overload, melena, periodontitis, hyperuricaemia, hyponatraemia, increased alkaline phosphatase, glycosuria, prothrombin time, SGPT and SGOT levels, purpura, somnolence, impotence, albuminuria, hypokinesia, nervousness, sleep disorder, skin reaction, tinnitus, dry mouth, anaemia, sweating, fatigue, arthralgia, aggravation, dizziness. Diarrhoea, nausea, vomiting, insomnia, hypercholesterolaemia, weight gain, abnormal vision, rhinitis, pharyngitis and hypertriglyceridaemia.
	Precaution : Avoid abrupt withdrawal as it may precipitate thyroid storm or exacerbate hyperthyroidism. Liver injury; vascular disease, renal failures, suspected phaeochromocytoma and prinzmetal's variable angina; worsening cardiac failure or fluid retention during increase in dosage of carvedilol; diabetic patients. Pregnancy.
	Pregnancy category : 4
	Mode of action : Carvedilol is a nonselective beta-adrenoreceptor and alpha-adrenergic blocking activity.  It exerts antihypertensive effect partly by reducing total peripheral resistance and vasodilation.
	Interaction : Decreased serum levels w/ rifampicin. Combination w/ Ca channel blockers (e.g. verapamil and diltiazem) can lead to bradycardia and myocardial depression. Potentiates insulin-induced hypoglycaemic action. May increase hypoglycaemic effects of antidiabetic agents. Increased risk of bradycardia w/ digoxin. Increased risk of hypotension and bradycardia w/ reserpine, MAOIs, clonidine. May increase ciclosporin concentrations. Concurrent use w/ ether, cyclopropane, trichloroethylene may increase the risk of hypotension and heart failure.
	Therapeutic class : Beta-blockers
	Packsize : 30's pack
Arinet
	n : Artesunate
	Indications : Malaria, Schistosomiasis
	Doses and administration : Parenteral
									Falciparum malaria especially in quinidine-resistant patients
									Adult: PO: 4 mg/kg once daily x3 days (with mefloquine)
									
	Contara-indications : Hypersensitivity.
	Side effects : Hepatic or renal insufficiency. Pregnancy and lactation.
	Precaution : Hepatic or renal insufficiency. Pregnancy and lactation.
	Pregnancy category : 0
	Mode of action : Artesunate is a potent and rapidly-acting blood schizontocide derived from the leaves of the chinese herb, Armesia annua. The exact mode of action is not clear but clinical studies have confirmed the effectiveness of artesunate in P. vivax and falciparum malaria. Unclear, may inhibit DNA replication & transcription.
	Interaction :  	Antimalarial potentiating action seen with mefloquine, primaquine and tetracycline. Additive effect with chloroquine. Antagonistic effect with pyrimethamine and sulphonamides.
	Therapeutic class : Anti-malarial drugs
	Packsize : 20's pack
Aripen
	n : Aripiprazole
	Indications : Major depressive disorder, Schizophrenia, Acute manic episodes of bipolar disorder, Agitation, Irritability in autism
	Doses and administration : Adult: PO Schizophrenia Initial: 10-15 mg once daily. Maintenance: 15 mg once daily. Max: 30 mg once daily without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.  
									
									Bipolar mania 30 mg once daily. May reduce to 15 mg once daily according to tolerability.
	Contara-indications : Hypersensitivity. Lactation. Children <18 yr.
	Side effects : Headache, agitation, insomnia, somnolence; dyspepsia, constipation, pain, nausea, vomiting; asthaenia, dizziness, abdominal pain; dry mouth; anxiety, akathisia; orthostatic hypotension; hypertonia, tremor and blurred vision.
	Precaution : Patients with known CV diseases (e.g. history of MI, IHD, CCF or conduction abnormalities), cerebrovascular diseases or conditions which would predispose patients to hypotension; Alzheimer's disease and dementia. Caution when operating hazardous machinery, including automobiles when taking aripiprazole. Pregnancy.
	Pregnancy category : 3
	Mode of action : Aripiprazole acts as a partial agonist at D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors.
	Interaction : Drugs that induce CYP3A4 (e.g. carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g. ketoconazole) or CYP2D6 (e.g. quinidine, fluoxetine or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Increased CNS depression with ethanol.
	Therapeutic class : Atypical neuroleptic drugs
	Packsize : 30's pack
Aripen
	n : Aripiprazole
	Indications : Major depressive disorder, Schizophrenia, Acute manic episodes of bipolar disorder, Agitation, Irritability in autism
	Doses and administration : Adult: PO Schizophrenia Initial: 10-15 mg once daily. Maintenance: 15 mg once daily. Max: 30 mg once daily without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.  
									
									Bipolar mania 30 mg once daily. May reduce to 15 mg once daily according to tolerability.
	Contara-indications : Hypersensitivity. Lactation. Children <18 yr.
	Side effects : Headache, agitation, insomnia, somnolence; dyspepsia, constipation, pain, nausea, vomiting; asthaenia, dizziness, abdominal pain; dry mouth; anxiety, akathisia; orthostatic hypotension; hypertonia, tremor and blurred vision.
	Precaution : Patients with known CV diseases (e.g. history of MI, IHD, CCF or conduction abnormalities), cerebrovascular diseases or conditions which would predispose patients to hypotension; Alzheimer's disease and dementia. Caution when operating hazardous machinery, including automobiles when taking aripiprazole. Pregnancy.
	Pregnancy category : 3
	Mode of action : Aripiprazole acts as a partial agonist at D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors.
	Interaction : Drugs that induce CYP3A4 (e.g. carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g. ketoconazole) or CYP2D6 (e.g. quinidine, fluoxetine or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Increased CNS depression with ethanol.
	Therapeutic class : Atypical neuroleptic drugs
	Packsize : 20's pack
Aripra 10
	n : Aripiprazole
	Indications : Major depressive disorder, Schizophrenia, Acute manic episodes of bipolar disorder, Agitation, Irritability in autism
	Doses and administration : Adult: PO Schizophrenia Initial: 10-15 mg once daily. Maintenance: 15 mg once daily. Max: 30 mg once daily without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.  
									
									Bipolar mania 30 mg once daily. May reduce to 15 mg once daily according to tolerability.
	Contara-indications : Hypersensitivity. Lactation. Children <18 yr.
	Side effects : Headache, agitation, insomnia, somnolence; dyspepsia, constipation, pain, nausea, vomiting; asthaenia, dizziness, abdominal pain; dry mouth; anxiety, akathisia; orthostatic hypotension; hypertonia, tremor and blurred vision.
	Precaution : Patients with known CV diseases (e.g. history of MI, IHD, CCF or conduction abnormalities), cerebrovascular diseases or conditions which would predispose patients to hypotension; Alzheimer's disease and dementia. Caution when operating hazardous machinery, including automobiles when taking aripiprazole. Pregnancy.
	Pregnancy category : 3
	Mode of action : Aripiprazole acts as a partial agonist at D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors.
	Interaction : Drugs that induce CYP3A4 (e.g. carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g. ketoconazole) or CYP2D6 (e.g. quinidine, fluoxetine or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Increased CNS depression with ethanol.
	Therapeutic class : Atypical neuroleptic drugs
	Packsize : 50's pack
Aripra 15
	n : Aripiprazole
	Indications : Major depressive disorder, Schizophrenia, Acute manic episodes of bipolar disorder, Agitation, Irritability in autism
	Doses and administration : Adult: PO Schizophrenia Initial: 10-15 mg once daily. Maintenance: 15 mg once daily. Max: 30 mg once daily without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.  
									
									Bipolar mania 30 mg once daily. May reduce to 15 mg once daily according to tolerability.
	Contara-indications : Hypersensitivity. Lactation. Children <18 yr.
	Side effects : Headache, agitation, insomnia, somnolence; dyspepsia, constipation, pain, nausea, vomiting; asthaenia, dizziness, abdominal pain; dry mouth; anxiety, akathisia; orthostatic hypotension; hypertonia, tremor and blurred vision.
	Precaution : Patients with known CV diseases (e.g. history of MI, IHD, CCF or conduction abnormalities), cerebrovascular diseases or conditions which would predispose patients to hypotension; Alzheimer's disease and dementia. Caution when operating hazardous machinery, including automobiles when taking aripiprazole. Pregnancy.
	Pregnancy category : 3
	Mode of action : Aripiprazole acts as a partial agonist at D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors.
	Interaction : Drugs that induce CYP3A4 (e.g. carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g. ketoconazole) or CYP2D6 (e.g. quinidine, fluoxetine or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Increased CNS depression with ethanol.
	Therapeutic class : Atypical neuroleptic drugs
	Packsize : 50's pack
Ariprazole
	n : Aripiprazole
	Indications : Major depressive disorder, Schizophrenia, Acute manic episodes of bipolar disorder, Agitation, Irritability in autism
	Doses and administration : Adult: PO Schizophrenia Initial: 10-15 mg once daily. Maintenance: 15 mg once daily. Max: 30 mg once daily without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.  
									
									Bipolar mania 30 mg once daily. May reduce to 15 mg once daily according to tolerability.
	Contara-indications : Hypersensitivity. Lactation. Children <18 yr.
	Side effects : Headache, agitation, insomnia, somnolence; dyspepsia, constipation, pain, nausea, vomiting; asthaenia, dizziness, abdominal pain; dry mouth; anxiety, akathisia; orthostatic hypotension; hypertonia, tremor and blurred vision.
	Precaution : Patients with known CV diseases (e.g. history of MI, IHD, CCF or conduction abnormalities), cerebrovascular diseases or conditions which would predispose patients to hypotension; Alzheimer's disease and dementia. Caution when operating hazardous machinery, including automobiles when taking aripiprazole. Pregnancy.
	Pregnancy category : 3
	Mode of action : Aripiprazole acts as a partial agonist at D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors.
	Interaction : Drugs that induce CYP3A4 (e.g. carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g. ketoconazole) or CYP2D6 (e.g. quinidine, fluoxetine or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Increased CNS depression with ethanol.
	Therapeutic class : Atypical neuroleptic drugs
	Packsize : 30's pack
Ariprazole
	n : Aripiprazole
	Indications : Major depressive disorder, Schizophrenia, Acute manic episodes of bipolar disorder, Agitation, Irritability in autism
	Doses and administration : Adult: PO Schizophrenia Initial: 10-15 mg once daily. Maintenance: 15 mg once daily. Max: 30 mg once daily without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.  
									
									Bipolar mania 30 mg once daily. May reduce to 15 mg once daily according to tolerability.
	Contara-indications : Hypersensitivity. Lactation. Children <18 yr.
	Side effects : Headache, agitation, insomnia, somnolence; dyspepsia, constipation, pain, nausea, vomiting; asthaenia, dizziness, abdominal pain; dry mouth; anxiety, akathisia; orthostatic hypotension; hypertonia, tremor and blurred vision.
	Precaution : Patients with known CV diseases (e.g. history of MI, IHD, CCF or conduction abnormalities), cerebrovascular diseases or conditions which would predispose patients to hypotension; Alzheimer's disease and dementia. Caution when operating hazardous machinery, including automobiles when taking aripiprazole. Pregnancy.
	Pregnancy category : 3
	Mode of action : Aripiprazole acts as a partial agonist at D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors.
	Interaction : Drugs that induce CYP3A4 (e.g. carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g. ketoconazole) or CYP2D6 (e.g. quinidine, fluoxetine or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Increased CNS depression with ethanol.
	Therapeutic class : Atypical neuroleptic drugs
	Packsize : 50's pack
Aristo GOLD
	n : Multivitamin and Multimineral A-Z Gold preparations
	Indications : Vitamin/mineral deficiency
	Doses and administration : 1 tablet daily or as recommended by the physician.
	Contara-indications :  Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. 
	Precaution : Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.
	Pregnancy category : 0
	Mode of action : Vitamin A: Helps form and maintain healthy skin, eyes, teeth, gums, hair, mucous membranes and glands.
									
									Vitamin C (Ascorbic Acid): Collagen formation: without it, protocollagen does not cross- link properly, resulting in impaired wound healing.
									
									Vitamin D: Vitamin D helps to regulate calcium metabolism and normal calcification of the bones in the body as well as influencing our utilization of the mineral phosphorus
									
									Vitamin E: Necessary for the formation of normal red blood cells, muscle, and tissue and necessary for immune functions
									
									Vitamin K: Necessary for normal blood coagulation
									
									Vitamin B-Complexes
									
									Thiamine (Vitamin B1): Aids in energy utilization from food by promoting proper carbohydrate metabolism.
									
									Riboflavin (Vitamin B2): Aids in energy utilization from food
									
									Niacin (Vitamin B3): Present in all cells in the body helps convert food into energy; involved in fat, protein, and carbohydrate metabolism
									
									Pyridoxine (Vitamin B6): Important in protein and amino acid metabolism
									
									Folic Acid: Adequate amounts of this B vitamin (folic acid) as part of a healthy diet can help reduce the risk of birth defects of the brain and spine
									
									Cyanocobalamin (Vitamin B12): Helps form red blood cells and build vital genetic material (nucleic acids) for the cell nucleus
									
									Biotin: Necessary for formation of fatty acids & for production of
									
									energy from glucose
									
									Pantothenic Acid (Vitamin B5): Involved in converting carbohydrates, fats and proteins into energy
									
									Calcium: Helps build and maintain strong teeth and bones.
									
									Iron: Necessary for proper formation of oxygen-rich red blood cells & plays important role in the transport of oxygen
									
									Phosphorous: Helps build and maintain teeth and bones
									
									Iodine: Essential for formation of thyroid hormone thyroxin which governs metabolism and growth
									
									Magnesium: Maintains proper levels of calcium and potassium
									
									Zinc: The important antioxidant enzyme, superoxide dismutase (SOD), requires zinc, together with copper and manganese, to function. Zinc is also essential for the metabolism of vitamin A, another important antioxidant, enhance wound healing.
									
									Selenium: Role as an antioxidant in the enzyme selenium-glutathione-peroxidase.
									
									Copper: Involved in brain and red cell function, iron metabolism, bone health and protein synthesis
									
									Manganese: Necessary for normal growth and development, reproduction and cell function
									
									Chromium: Necessary for normal carbohydrate, protein and fat metabolism
									
									Molybdenum: Important for normal cell function
									
									Potassium: It is part of a number of metabolic actions, especially those that involve release of energy
									
									Boron: Boron affects calcium, magnesium, and phosphorus balance and the mineral movement and make up of the bones by regulating the hormones, mainly parathyroid that control these functions.
									
									Nickel: Enhances the body's use of iron
									
									Silicon: May be necessary for normal cartilage, collagen and bone formation. Silicon promotes firmness and strength in the tissues.
									
									Tin: Necessary for normal growth & Cell metabolism.
									
									Vanadium: Pharmacological studies in animals suggest that vanadium may be involved in hormone, glucose, fat, bone and tooth metabolism as well as reproduction and growth.
									
									Lutein: Super antioxidant that provides protection against free radicals.
	Interaction : None
	Therapeutic class : Multi-vitamin & Multi-mineral combined preparations
	Packsize : 15's pack / 30's pack
Aristo Kid
	n : Multivitamin and Multimineral A-Z Syrup preparations
	Indications : Vitamin/mineral deficiency
	Doses and administration : Infants up to 1 year: 1 tea-spoon daily
									Children 1-4 years: 1-2 tea-spoons daily
									Children 4-12 years: 2-3 tea-spoons daily
									Adult : 3-4 tea-spoons daily
	Contara-indications : Known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. However, a few allergic reactions may be seen.
	Precaution : Over dose is prohibited or the physicians should adjust doses.
	Pregnancy category : 0
	Mode of action : Vitamins and minerals are essential for normal metabolic functions including hematopoiesis. Depending on ingredients in the formulaiton may support metabolic functions as well as protein and DNA synthesis.
	Interaction : None
	Therapeutic class : Multi-vitamin & Multi-mineral combined preparations
	Packsize :  100ml bot / 200 ml bot
Aristo Mom
	n : Multivitamin & Multimineral prep for Nursing mother
	Indications : Improving the nutritional status of women throughout the pregnancy and for lactating mothers. 
	Doses and administration : 1-2 tablet daily or as recommended by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. 
	Precaution : Should not use in over dosage.
	Pregnancy category : 0
	Mode of action : Vitamins and minerals are essential for normal metabolic functions including hematopoiesis. Depending on ingredients in the formulaiton may support metabolic functions as well as protein and DNA synthesis.
	Interaction : None
	Therapeutic class : Multi-vitamin & Multi-mineral combined preparations
	Packsize : 50's pack
Aristobet N
	n : Betamethasone  0.1% + Neomycin Sulphate 0.5 E/E prep
	Indications : Allergic and inflammatory conditions of the eye & ear, otitis externa, uveitis, marginal keratitis, allergic conjunctivitis, blepharitis and episcleritis
	Doses and administration : Eye, Ear & Nasal Drops: Eye: 1 drop instilled into the eye every one or two hours until control is achieved, when the frequency may be reduced. Ear: 2 or 3 drops instilled into the ear, every two or three hours until control is achieved, when the frequency can be reduced. Nose: 2 or 3 drops instilled into each nostril two or three times daily.
									
									Eye Ointment: It should be applied thinly and evenly to the conjunctival sac at night (If eye drops used during day) or 3-4 times daily (if ointment used alone).
	Contara-indications : Skin lesions of viral, fungal or bacterial origin, acne rosacea and perioral dermatitis.
	Side effects : Prolonged intensive treatment may cause local atrophic changes in the skin e.g. striae, thining and dilatation of superficial blood vessels. Dryness, itching, irritation, hypopigmentation, burning sensation at the site of application or miliaria.
	Precaution : Avoid prolonged continuous treatment especially in infants and children. Extended treatment may increase the risk of contact sensitisation and development of antibiotic resistance. Not to be used for >7 days if there is no clinical improvement. Increased risk of glaucoma if preparation enters the eye(s). Pregnancy and lactation.
	Pregnancy category : 0
	Mode of action : Betamethasone valerate is a corticosteroid which is effective in inflammatory dermatoses. It is also effective in less responsive conditions such as psoriasis. Neomycin sulfate is a broad spectrum antibiotic. It is bactericidal against many bacteria which are commonly associated with skin infections.
	Interaction : If there is significant systemic absorption, neomycin sulfate may increase the respiratory depressant effects of neuromuscular blockers.
	Therapeutic class : Aural Steroid & Steroid/Antibiotic combined preparations
	Packsize : 5  ml drop
Aristocal 500
	n : Calcium Carbonate
	Indications : Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset
	Doses and administration : Adult: PO Hyperacidity: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets. 
									
									Hyperphosphataemia in chronic renal failure Initial: 2.5 g/day, up to 17 g/day in divided doses.
									
									Renal impairment:
									CrCl (ml/min)	
									<25	Dosage adjustments may be needed depending on serum calcium levels. 
	Contara-indications : Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.
	Side effects : Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).
	Precaution : Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.
	Pregnancy category : 3
	Mode of action : Calcium carbonate can neutralise gastric acid rapidly and effectively. However, it may adversely activate Ca dependent processes, leading to secretion of gastric and hydrochloric acid. It can induce rebound acid secretion and, prolonged high doses may cause hypercalcemia, alkalosis and milk-alkali syndrome.
	Interaction : Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
	Therapeutic class : Specific mineral preparations
	Packsize : 100's pack
Aristocal D
	n : Calcium + Vitamin D3
	Indications : Postmenopausal osteoporosis, Osteoporosis, Osteomalacia/rickets, Hypoparathyroidism, Latent tetany, Hypocalcaemia, Calcium and vitamin D deficiency
	Doses and administration : Adult: PO Per tab contains Ca carbonate 1,500 mg and vitamin D3 10 mcg: 1 tab twice daily.
	Contara-indications : Patients with hypercalcaemia and/or hypercalciuria. Nephrolithiasis, hypervitaminosis D, hypophosphataemia.
	Side effects : Constipation, flatulence, nausea, abdominal pain and diarrhoea, pruritus, rash and urticaria.
	Precaution : Impaired calcium absorption in achlorhydria which is common in elderly. Increased risk of hypercalcaemia and hypercalciuria in hypoparathyroid patients receiving high doses of vitamin D. Caution when using in patients with history of kidney stones. Renal impairment; frequent monitoring of serum calcium and phosphorus is recommended.
	Pregnancy category : 3
	Mode of action : Calcium /vitamin D3 prevents or treats negative Ca balance. It also helps facilitate nerve and muscle performance as well as normal cardiac function. Bone mineral component; cofoactor in enzymatic reactions, essential for neurotransmission, muscle contraction, and many signal transduction pathways. Vitamin D3 is a fat-soluble sterol. It is necessary for the regulation and regulation of calcium and phosphate homoeostasis and bone mineralisation. Vitamin D is also essential for healthy bones as it aids in Calcium absorption from the GI tract. In addition to this it stimulates bone formation. Clinical studies also show that Calcium and Vitamin D has synergistic effects on bone growth as well as in Osteoporosis and fracture prevention.
	Interaction : May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 50's pack
Aristocal M
	n : Calcium + Vitamin D + Minerals
	Indications : Osteoporosis, Calcium deficiency, Post-menopausal osteoporosis, Rickets, Osteocalcaemia, Mineral supplement
	Doses and administration : Adults and Elderly and children above 12 years of age: 2 tablets per day, preferably one tablet each morning and evening.
									
									Children: Not recommended for children under 12 years.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Mild and transient effects of gastrointestinal disturbances, like constipation, flatulence, nausea, diarrhoea may be seen in some individuals. Following administration of vitamin D supplements may cause skin rash in some rare cases. Hypercalciuria have been seen with long term use at high dosage.
	Precaution : Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. Periodic checks of plasma calcium levels and urinary calcium excretion should be made in patients with mild to moderate renal failure or mild hypercalciuria. 
				
				Urinary calcium excretion should also be measured. In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria. With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5mmol/24 hours. 
	Pregnancy category : 3
	Mode of action : Calcium gluconate/lactate is used to prevent or treat negative calcium balance. It also helps facilitate nerve and muscle performance as well as normal cardiac function. Bone mineral component; cofoactor in enzymatic reactions, essential for neurotransmission, muscle contraction, and many signal transduction pathways.
									Vitamin D is also essential for healthy bones as it aids in Calcium absorption from the GI tract. In addition to this it stimulates bone formation. Clinical studies also show that Calcium and Vitamin D has synergistic effects on bone growth as well as in Osteoporosis and fracture prevention.
									
	Interaction : May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 20's pack
Aristocort
	n : Triamcinolone Acetonide 0.1% Topical
	Indications : Inflammatory skin conditions
	Doses and administration : Inflammatory skin conditions
									Adult: As acetonide: Apply a 0.025-0.5% cream/lotion/ointment sparingly onto affected area 2-3 times daily. Lower concentrations may be used up to 4 times daily.
									
	Contara-indications : Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. 
	Side effects :  Topical: Systemic absorption if applied to large areas, broken skin or under occlusive dressing.
									
	Precaution : Diabetes; hypertension, renal and liver impairment; glaucoma; psychosis; delayed tissue healing; cirrhosis; heart failure; recent MI; hypothyroidism; osteoporosis; peptic ulceration; thromboembolic disorders. Monitor height in children on prolonged therapy. Avoid rapid drug withdrawal. Elderly, children, pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation.
	Interaction : Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
	Therapeutic class : Triamcinolone & Combined preparations
	Packsize : 10gm tube
Aristocort
	n : Triamcinolone Acetonide Mouth prep
	Indications : Mouth ulceration
	Doses and administration : Mouth ulceration Adult: A small amount (about 0.6 cm) of the 0.1% paste is pressed onto the lesion without rubbing until a thin film develops. Apply 2 or 3 times daily, preferably after meals. Re-evaluate if recovery does not occur after 7 days of treatment.
	Contara-indications : Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity.
	Side effects : None
	Precaution : Diabetes; hypertension, renal and liver impairment; glaucoma; psychosis; delayed tissue healing; cirrhosis; heart failure; recent MI; hypothyroidism; osteoporosis; peptic ulceration; thromboembolic disorders. Monitor height in children on prolonged therapy. Avoid rapid drug withdrawal. Elderly, children, pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation.
	Interaction : Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
	Therapeutic class : Mouth & Throat preparations
	Packsize : 5g tube / 10ml tube
Aristocort 0.1%
	n : Triamcinolone Acetonide 0.1% Topical
	Indications : Inflammatory skin conditions
	Doses and administration : Inflammatory skin conditions
									Adult: As acetonide: Apply a 0.025-0.5% cream/lotion/ointment sparingly onto affected area 2-3 times daily. Lower concentrations may be used up to 4 times daily.
									
	Contara-indications : Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. 
	Side effects :  Topical: Systemic absorption if applied to large areas, broken skin or under occlusive dressing.
									
	Precaution : Diabetes; hypertension, renal and liver impairment; glaucoma; psychosis; delayed tissue healing; cirrhosis; heart failure; recent MI; hypothyroidism; osteoporosis; peptic ulceration; thromboembolic disorders. Monitor height in children on prolonged therapy. Avoid rapid drug withdrawal. Elderly, children, pregnancy, lactation.
	Pregnancy category : 3
	Mode of action : Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation.
	Interaction : Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
	Therapeutic class : Triamcinolone & Combined preparations
	Packsize : 10gm tube
Aristocort PLUS
	n : Econazole Nitrate 1% + Triamcinolone Acetonide 0.1 Topical
	Indications :  Steroid-responsive inflammatory dermatoses, Tinea pedis, Tinea cruris, Tinea corporis, Pityriasis versicolor, Cutaneous candidiasis, Onychomycoses
	Doses and administration : For topical administration only.Adults: Apply twice daily to the affected area and rub on the skin gently with the finger. Continue the applications for 14 days or as directed by the doctor.Children: Suitable for topical application to children.
	Contara-indications : Not to be used in the treatment of tuberculous lesions and viral diseases of the skin (herpes, vaccinia, varicella).True hypersensitivity.
	Side effects : Rarely, transient local mild irritation, itching & redness may occur immediately after application. Econazole has minimal allergenic effect and is well tolerated, even by delicate skin. Adrenal suppression on long term continuous topical steroid therapy may occur, particularly in infants or children, or when occlusive dressings are applied. It should be noted that an infant's napkin may act as an occlusive dressing.
	Precaution : Hypersensitivity has rarely been recorded. If it occurs, application of the product should be discontinued. The infected area should be kept clean and dry during treatment.
	Pregnancy category : 3
	Mode of action : Econazole modifies the permeability of cell wall membrane in fungi; may interfere w/ RNA and protein synthesis, and lipid metabolism.
									Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation.
	Interaction : Econazole: Theoretical potential for compd metabolized by CYP3A4/2C9, oral anticoagulants eg warfarin & acenocoumarol.
				
				Triamcinolone: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
				
	Therapeutic class : Triamcinolone & Combined preparations
	Packsize : 5gm tube/10gm tube
Aristocrom
	n : Sodium Cromoglycate 2%  Eye/Nasal prep
	Indications : Allergic rhinitis, Allergic conjuntivitis
	Doses and administration : For eyes:
									For Child and Adult: 1 to 2 drops into each eye 2 to 3 times daily.
									
									For nose:
									For Child and Adult: 1-2 drop to each nostril 2 to 4 times daily.
	Contara-indications : This drop is contraindicated in patient with hypersensitivity to Sodium Cromoglicate .
	Side effects : Mild throat irritation, coughing, & transient bronchospasm with a marked fall in pulmonary functions has been reported. In such cases treatment should be stopped and should not be re-introduced.Transient stinging and burning may occur after instillation of this drops. Other symptoms of local irritation have been reported rarely.
	Precaution : As this drop contains benzalkonium chloride, patients should not wear contact lenses during treatment with this drop.
	Pregnancy category : 2
	Mode of action : Sodium Cromoglycate inhibits degranulation of mast cells and therefore suppresses the release of histamine, leukotrienes and slow-reacting substance of anaphylaxis.
	Interaction : None
	Therapeutic class : Ophthalmic Non-Steroid drugs
	Packsize : 10 ml drop
Aristoferon
	n : Ferrous Sulphate
	Indications : Iron deficiency anemia
	Doses and administration : Adult: PO 400-600 mg/day in divided doses. Prevention: 200 mg/day.
	Contara-indications : Patients receiving repeated blood transfusions; anaemia not due to iron deficiency.
	Side effects : GI irritation, abdominal pain and cramps, nausea, vomiting, constipation, diarrhoea, dark stool and discoloration of urine; heartburn.
	Precaution : Elderly. Avoid admin for >6 mth except in patients with continuous bleeding. Avoid concomitant oral and parenteral iron therapy. Iron-storage or iron-absorption diseases (e.g. haemochromatosis), haemoglobinopathies); existing GI diseases (e.g. inflammatory bowel disease, intestinal strictures, diverticulae, peptic ulcer disease, enteritis or ulcerative colitis). Liquid preparations may stain teeth.
	Pregnancy category : 0
	Mode of action : Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
									
	Interaction : None
	Therapeutic class : Oral Iron preparations
	Packsize : 250ml bot
Aristofol Fe
	n : Ferrous Fumarate + Folic Acid
	Indications : Iron deficiency anemia, Iron supplement, Iron deficiency in pregnancy
	Doses and administration : Adult: PO Each tab contains ferrous fumurate 322 mg and folic acid 0.35 mg: 1 tab/day starting from the 13th wk of gestation.
	Contara-indications : Paroxysmal nocturnal haemoglobinuria, haemosiderosis, haemochromatosis.
	Side effects : GI discomfort, anorexia, nausea, vomiting, constipation, diarrhoea. Stool darkening may occur.
	Precaution : Avoid use in patients with active peptic ulcer, repeated blood transfusion, regional enteritis and ulcerative colitis. Caution when used in patients with folate-dependent tumours. Not recommended for use during 1st trimester of pregnancy.
	Pregnancy category : 0
	Mode of action : Ferrous fumarate is an iron preparation that is used in the prevention and treatment of iron deficiency. The amount of elemental iron is 330 mg/g of ferrous fumarate.
									Folic acid: Required for nucleoprotein synthesis and the maintenance of normal erythropoiesis; folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase; prevents neural tube defects in women of childbearing potential and higher doses required during pregnancy.
	Interaction : Ferrous Fumarate:  Oral absorption of iron may be increased when taken with ascorbic acid. May reduce the absorption of quinolones and tetracyclines when taken concurrently via the oral route. Concurrent admin with antacids may reduce the absorption of ferrous fumarate from the GI tract. May reduce the absorption of penicillamine in the gut when taken concurrently.
				
				Folic Acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
	Therapeutic class : Iron & Vitamin Combined preparations
	Packsize : 100's pack
Aristomol 0.5%
	n : Timolol Maleate 0.5% Eye prep
	Indications : Open-angle glaucoma, Ocular hypertension
	Doses and administration : Adult: Ophth Open-angle glaucoma; Ocular HTN As eye drop soln: Initial: The usual starting dose is one drop of Timopress 0.5 in the affected eye(s) twice a day. Reduce to 1 drop/day if controlled. 
	Contara-indications : Present or history of bronchial asthma, severe COPD, sinus bradycardia, 2nd and 3rd degree heart block, sick sinus syndrome, overt heart failure, cardiogenic shock, severe peripheral vascular disease/Raynaud's disease), Prinzmetal angina, untreated pheochromocytoma, metabolic acidosis, hypotension.
	Side effects : Ophthalmic use: Burning, stinging, blurred vision, ocular irritation (e.g. conjunctivitis, blepharitis, crusting), decreased corneal sensitivity, visual disturbances, diplopia, ptosis, cystoid macular oedema, pseudopemphigoid, choroidal detachment following filtration surgery. Adverse reactions associated with systemic administration of beta-blocker may occur with ophthalmic use. Potentially Fatal: Heart failure, intensification of heart block, bronchospasm, respiratory failure.
	Precaution : Due to systemic absorption of ophthalmic preparations, adverse reactions associated with systemic administration of beta-blockers may occur. Abrupt withdrawal of beta-blocker may cause exacerbation of angina, and myocardial infarctions have occurred in some cases. Ophthalmic Timolol should not be used alone for treatment of angle-closure glaucoma. beta-blocker therapy may increase sensitivity towards allergen in patients with history of atrophy or severe anaphylaxis reactions. Safety and efficacy have not been established in paediatric patients.
	Pregnancy category : 3
	Mode of action : Exact mechanism of ocular hypotensive effect is unclear, but it is thought to be related to reduction of aqueous humour formation. ?-blockade also causes lowering of BP.
	Interaction : Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).
	Therapeutic class : Drugs for miotics and glaucoma
	Packsize : 5  ml drop
Aristomox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100ml bot
Aristomox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 100's pack
Aristomox
	n : Amoxicillin
	Indications : Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat
	Doses and administration : Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. 
									
									Uncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. 
									
									Severe or recurrent resp tract infections 3 g twice daily. 
									
									H.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. 
									
									Child:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.
									
									IV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.
									
									Child: >10 yr: 50-100 mg/kg daily in divided doses.
									
									Renal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.
									CrCl (ml/min)	
									10-30	250-500 mg every 12 hr.
									<10	        250-500 mg every 24 hr. 
	Contara-indications : Hypersensitivity
	Side effects : Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.
									Potentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.
	Precaution : Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.
	Pregnancy category : 2
	Mode of action : Amoxicillin inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting in bacterial lysis.
	Interaction : May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
	Therapeutic class : Broad spectrum penicillins
	Packsize : 50's pack
Aristophen
	n : Chloramphenicol 0.5%  Eye drops
	Indications : Bacterial Conjunctivitis
	Doses and administration : Ocular infections
									Adult: Instill 1 drop of a 0.5% solution every 2 hr. Increase dosage interval upon improvement. To continue treatment for at least 48 hr after complete healing. Reduce dose once symptoms are controlled or apply a 1% ointment 3-4 times daily.
									Renal impairment: Dose reduction may be required.
									Hepatic impairment: Dose reduction may be required.
									
	Contara-indications : History of hypersensitivity or toxic reaction to the drug; Herpes simplex and other virul conditions of the eye or ear, mycosis.
	Side effects : Ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. 
	Precaution : Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. 
	Pregnancy category : 3
	Mode of action : Chloramphenicol inhibits bacterial protein synthesis by binding to 50s subunit of the bacterial ribosome, thus preventing peptide bond formation by peptidyl transferase. It has both bacteriostatic and bactericidal action against H. influenzae, N. meningitidis and S. pneumoniae.
	Interaction : Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.
				Potentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
	Therapeutic class : Ophthalmic Anti-bacterial products
	Packsize : 10 ml bot
Aristophen
	n : Chloramphenicol 1%  Eye prep
	Indications : Bacterial Conjunctivitis
	Doses and administration : Ocular infections Adult: Apply a 1% ointment 3-4 times daily. 
									Renal impairment: Dose reduction may be required. Hepatic impairment: Dose reduction may be required. 
	Contara-indications : History of hypersensitivity to the drug; Herpes simplex and other virul conditions of the eye, mycosis.
	Side effects :  Ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. 
	Precaution : Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. 
	Pregnancy category : 3
	Mode of action : Chloramphenicol inhibits bacterial protein synthesis by binding to 50s subunit of the bacterial ribosome, thus preventing peptide bond formation by peptidyl transferase. It has both bacteriostatic and bactericidal action against H. influenzae, N. meningitidis and S. pneumoniae.
	Interaction : Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.
				Potentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
	Therapeutic class : Ophthalmic Anti-bacterial products
	Packsize : 3gm tube
Aristoplex
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 100ml bot/200ml bot
Aristovit B
	n : Vitamin B complex
	Indications : Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.
	Doses and administration : Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. 
	Contara-indications : Contraindicated in patients hypersensitive to any of its components.
	Side effects : Generally well tolerated.
	Precaution : Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.
	Pregnancy category : 1
	Mode of action : Vitamin B: Plays a role in the synthesis and maintenance of coenzyme A. Necessary for lipid metabolism, carbohydrate metabolism, tissue respiration, glycogenolysis, inhibition of very low-density lipoprotein (VLDL) synthesis. May increaase chylomicron triglyceride removal from plasma. Vitamin B12 (cyanocobalamin): Required for the maintenance of normal erthropoiesis, nucleprotein and myelin synthesis, cell reproduction and normal growth; intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the GI tract. Necessary for normal tissue respiration; plays a role in activation of pyridoxine and conversion of tryptophan to niacin.
	Interaction : None
	Therapeutic class : Specific combined vitamin preparations
	Packsize : 45's pack
Aristovit M
	n : Multivitamins + Multiminerals
	Indications : Vitamin/mineral deficiency
	Doses and administration : One tablet/capsule daily or as directed by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated.
	Precaution : Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.
	Pregnancy category : 0
	Mode of action : Vitamins and minerals are essential for normal metabolic functions including hematopoiesis. The members of Vitamin B-group are components of enzyme system that regulates various stages of carbohydrate, fat and protein metabolism, each of the components playing a specific biological role. Vitamin C is involved in tissue repair and collagen formation. Vitamin A plays an essential role in the function of retina and is essential for growh and differentiation of epithelial tissue. Vitamin E is an antioxidant which preserves essential cellular constituents. Vitamin D is supplemented for prevention and cure of nutritional and metabolic rickets and for treatment of hypoparathyroidism. Iron, copper, manganese and zinc serve as catalysts in enzyme systems which perform vital cellular functions. Potassium and calcium are essential for normal excitability of muscle tissue, specially cardiac muscle. Iodine is essential in the development and functioning of the thyroid gland and for formation of thyroxine hormone.
									
									
	Interaction : None
	Therapeutic class : Specific mineral & vitamin combined preparations
	Packsize : 30's pack
Aristovit X
	n : Super Antioxidant Vitamins & Multimineral (Vitamin A + C + E + K ) + Copper  + Zinc + Manganese + Selenium
	Indications : To develop immune system.To prevent aging.Prevent certain types of cancer. Vitamin/mineral deficiency
	Doses and administration : One tablet daily or as recommended by the physician.
	Contara-indications : Patients with a known hypersensitivity to any of the ingredients.
	Side effects : Generally well tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.
	Precaution : Hypervitaminosis, Should not use in over dosage or use continiously.
	Pregnancy category : 0
	Mode of action : Vitamin A plays an essential role in the function of retina and is essential for growh and differentiation of epithelial tissue.
									Vitamin C: Necessary for collagen formation and tissue repair; plays a role in oxidation/reduction reactions as well as other metabolic pathways including synthesis of catecholamines, carnitine, and steroids; also plays a role in conversion of folic acid to folinic acid.
									Vitamin E plays a role in protecting red blood cells against hemolysis; has protective effects against free radicals on polyunsaturated fatty acids found in cell membranes; plays a role in preventing oxidation of vitamin A and C.
									Vitamins and minerals are essential for normal metabolic functions including hematopoiesis.
									Zinc is a cofactor in over 100 enzymes; plays a role in DNA synthesis; supports a healthy immune system. Copper cofactor in many enzymes, including ceruloplasmin; involved in formation of iron carrier protein, transferrin. Helps maintain normal rates of red and white blood cell formation and helps prevent development of deficiency symptoms. 
									
	Interaction : None
	Therapeutic class : Anti-oxidant Multivitamin Multimineral preparations
	Packsize : 30's pack
Arixon IM
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with lidocaine
Arixon IM
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with lidocaine
Arixon IM
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with lidocaine
Arixon IV
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with water
Arixon IV
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with water
Arixon IV
	n : Ceftriaxone
	Indications : Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis
	Doses and administration : Adult: IV Typhoid fever 2 g once daily for 14 days. 
									IV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. 
									Surgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. 
									IM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.
									
									Children under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. 
									
									The total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. 
									As soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. 
									
									Renal impairment:
									CrCl (ml/min)	
									<10	     Max: 2 g daily. 
	Contara-indications : Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
	Side effects : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Precaution : History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
	Pregnancy category : 2
	Mode of action : Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
	Interaction : May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
				
				Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
	Therapeutic class : Third generation Cephalosporins
	Packsize : 1 vial with water
Arlin
	n : Linezolid
	Indications : Community-acquired pneumonia, Skin and skin structure infections, Nosocomial pneumonia
	Doses and administration : Adults and Adolescents (12 Years and Older): PO Uncomplicated skin infections 400 mg 12 hrly for 10-14 days. 
									
									PO/IV Community-acquired pneumonia; Complicated skin and skin structure infections; Nosocomial pneumonia 600 mg 12 hrly for 10-14 days. 
									
									For Pediatric Patients (Birth through 11 Years of Age):
									 Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV or oral b.i.d. for 10 to 14 days.
									 Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV or oral b.i.d.for 14-28.
									Neonates < 7 days: Most pre-term neonates < 7 days of age (gestational age < 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg in every eight hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg t.i.d. by 7 days of life.
									
									Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococci infections 600 mg 12 hrly. Treatment duration for vancomycin-resistant enterococci: 14-28 day.
	Contara-indications : Hypersensitivity.
	Side effects : Diarrhoea (antibiotic associated colitis reported), headache, nausea, vomiting, constipation, abnormal liver function tests, fever, vaginal and oral candidiasis, skin rash, pruritus, dizziness, insomnia, anaemia, tongue discoloration, taste disturbance, lactic acidosis, optic and peripheral neuropathy (particularly if used > 28 days).
									Potentially Fatal: Reversible myelosuppression including anaemia, leukopenia, pancytopenia and thrombocytopenia (particularly if using > 10-14 days), transient ischaemic attacks, renal failure, Stevens-Johnson syndrome.
	Precaution : Preexisting myelosuppression, renal impairment (CrCl < 30ml/min), uncontrolled hypertension, phaeochromocytoma, carcinoid syndrome, untreated hyperthyroidism, chronic infection, history of seizures, bipolar depression, schizophrenia or acute confusional states. Pregnancy and lactation. Monitor complete blood counts weekly. Give after haemodialysis. Not known if linezolid or metabolites removed during peritoneal dialysis.
	Pregnancy category : 3
	Mode of action : Linezolid is a bacteriostatic oxazolidinone which acts by inhibiting ribosomal protein synthesis. It is active against gm+ve bacteria including vancomycin-resistant enterococci and MRSA. It has limited in vitro activity against gm-ve bacteria.
	Interaction : May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).
	Therapeutic class : Oxazolidinones
	Packsize : 100ml bot
Arlin
	n : Linezolid
	Indications : Community-acquired pneumonia, Skin and skin structure infections, Nosocomial pneumonia
	Doses and administration : Adults and Adolescents (12 Years and Older): PO Uncomplicated skin infections 400 mg 12 hrly for 10-14 days. 
									
									PO/IV Community-acquired pneumonia; Complicated skin and skin structure infections; Nosocomial pneumonia 600 mg 12 hrly for 10-14 days. 
									
									For Pediatric Patients (Birth through 11 Years of Age):
									 Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV or oral b.i.d. for 10 to 14 days.
									 Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV or oral b.i.d.for 14-28.
									Neonates < 7 days: Most pre-term neonates < 7 days of age (gestational age < 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg in every eight hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg t.i.d. by 7 days of life.
									
									Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococci infections 600 mg 12 hrly. Treatment duration for vancomycin-resistant enterococci: 14-28 day.
	Contara-indications : Hypersensitivity.
	Side effects : Diarrhoea (antibiotic associated colitis reported), headache, nausea, vomiting, constipation, abnormal liver function tests, fever, vaginal and oral candidiasis, skin rash, pruritus, dizziness, insomnia, anaemia, tongue discoloration, taste disturbance, lactic acidosis, optic and peripheral neuropathy (particularly if used > 28 days).
									Potentially Fatal: Reversible myelosuppression including anaemia, leukopenia, pancytopenia and thrombocytopenia (particularly if using > 10-14 days), transient ischaemic attacks, renal failure, Stevens-Johnson syndrome.
	Precaution : Preexisting myelosuppression, renal impairment (CrCl < 30ml/min), uncontrolled hypertension, phaeochromocytoma, carcinoid syndrome, untreated hyperthyroidism, chronic infection, history of seizures, bipolar depression, schizophrenia or acute confusional states. Pregnancy and lactation. Monitor complete blood counts weekly. Give after haemodialysis. Not known if linezolid or metabolites removed during peritoneal dialysis.
	Pregnancy category : 3
	Mode of action : Linezolid is a bacteriostatic oxazolidinone which acts by inhibiting ribosomal protein synthesis. It is active against gm+ve bacteria including vancomycin-resistant enterococci and MRSA. It has limited in vitro activity against gm-ve bacteria.
	Interaction : May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).
	Therapeutic class : Oxazolidinones
	Packsize : 20's pack
Arlin
	n : Linezolid
	Indications : Community-acquired pneumonia, Skin and skin structure infections, Nosocomial pneumonia
	Doses and administration : Adults and Adolescents (12 Years and Older): PO Uncomplicated skin infections 400 mg 12 hrly for 10-14 days. 
									
									PO/IV Community-acquired pneumonia; Complicated skin and skin structure infections; Nosocomial pneumonia 600 mg 12 hrly for 10-14 days. 
									
									For Pediatric Patients (Birth through 11 Years of Age):
									 Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV or oral b.i.d. for 10 to 14 days.
									 Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV or oral b.i.d.for 14-28.
									Neonates < 7 days: Most pre-term neonates < 7 days of age (gestational age < 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg in every eight hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg t.i.d. by 7 days of life.
									
									Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococci infections 600 mg 12 hrly. Treatment duration for vancomycin-resistant enterococci: 14-28 day.
	Contara-indications : Hypersensitivity.
	Side effects : Diarrhoea (antibiotic associated colitis reported), headache, nausea, vomiting, constipation, abnormal liver function tests, fever, vaginal and oral candidiasis, skin rash, pruritus, dizziness, insomnia, anaemia, tongue discoloration, taste disturbance, lactic acidosis, optic and peripheral neuropathy (particularly if used > 28 days).
									Potentially Fatal: Reversible myelosuppression including anaemia, leukopenia, pancytopenia and thrombocytopenia (particularly if using > 10-14 days), transient ischaemic attacks, renal failure, Stevens-Johnson syndrome.
	Precaution : Preexisting myelosuppression, renal impairment (CrCl < 30ml/min), uncontrolled hypertension, phaeochromocytoma, carcinoid syndrome, untreated hyperthyroidism, chronic infection, history of seizures, bipolar depression, schizophrenia or acute confusional states. Pregnancy and lactation. Monitor complete blood counts weekly. Give after haemodialysis. Not known if linezolid or metabolites removed during peritoneal dialysis.
	Pregnancy category : 3
	Mode of action : Linezolid is a bacteriostatic oxazolidinone which acts by inhibiting ribosomal protein synthesis. It is active against gm+ve bacteria including vancomycin-resistant enterococci and MRSA. It has limited in vitro activity against gm-ve bacteria.
	Interaction : May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol.
				Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).
	Therapeutic class : Oxazolidinones
	Packsize : 20's pack
Armomet 1
	n : Metformin Hydrochloride + Rosiglitazone
	Indications : Type 2 DM
	Doses and administration : The dosage  should be individualized on the basis of effectiveness and tolerability while not exceeding the maximum recommended daily dose of 8mg/2000 mg (Rosiglitazone/Metformin).
									
									 In Drug-Naive Patients: The recommended starting dose of  is 2 mg/500 mg once or twice daily. 
									
									For patients with HbA1c >11% or FPG>270 mg/dL, a starting dose of 2 mg/500 mg twice daily may be considered. The dose may be increased by increment of 2 mg/500 mg per day to a maximum of 8 mg/2,000 mg per day in divided doses if patients are not adequately controlled after 4 weeks.
									
									For patients inadequately controlled on Metformin monotherapy, the usual starting dose  is 4 mg Rosiglitazone (daily dose) plus the dose of Metformin already being taken.
									
									For patients inadequately controlled on Rosiglitazone monotherapy, the usual starting dose is 1000 mg Metformin (daily dose) plus the dose of Rosiglitazone already being taken.
									
									When switching from combination therapy of Rosiglitazone plus Metformin as separate tablets, the usual starting dose  is the dose of Rosiglitazone and Metformin already being taken. If additional glycemic control is needed, the daily dose may be increased by increment of 4 mg Rosiglitazone and/or 500 mg Metformin, up to the maximum recommended total daily dose of 8 mg/2000 mg.
	Contara-indications : It is contraindicated in patients with renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels .1.5 mg/dl (males), 1.4 mg/dl (females), or abnormal creatinine clearance), acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma & known hypersensitivity to rosiglitazone maleate or metformin HCl.
	Side effects : Rosiglitazone: The commonly reported adverse events are upper respiratory tract infections, injury, headache, back pain, fatigue, sinusitis, diarrhoea and hypoglycemia. There were a small number of patients who had anemia and edema. All these events were generally mild to moderate in severity and usually do not require discontinuation of treatment with Rosiglitazone.
									Metformin: Some patients may develop asymptomatic subnormal levels of serum vitamin B12.
									Incidence of lactic acidosis is also very rare. Diarrhoea, nausea, vomiting, abdominal bloating, flatulence and anorexia are common reactions to Metformin.
	Precaution : Rosiglitazone: should not be used in patients with type 1 diabetes. This should be used with caution in patients with edema. Dose-related weight gain was seen with rosiglitazone alone and rosiglitazone together with other hypoglycemic agents.
				
				Metformin: Monitoring of renal function: Patients with serum creatinine levels above the upper limit of normal should not receive this tablet. In patients with advanced age, the dose should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. 
	Pregnancy category : 13
	Mode of action : Rosiglitazone: Lowers glucose by improving target cell response to insulin without increasing pancreatic cell secretion; activates nuclear peroxisome proliferator-activated receptor gamma, which influences the production of gene products involved in glucose and lipid metabolism.
									
									Metformin: Biguanide; acts by decreasing endogenous hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; improves glucose tolerance and lowers both basal and postprandial plasma glucose .
	Interaction : Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.
				Potentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
	Therapeutic class : Combination Oral hypoglycemic preparations
	Packsize : 30's pack
Armomet 2
	n : Metformin Hydrochloride + Rosiglitazone
	Indications : Type 2 DM
	Doses and administration : The dosage  should be individualized on the basis of effectiveness and tolerability while not exceeding the maximum recommended daily dose of 8mg/2000 mg (Rosiglitazone/Metformin).
									
									 In Drug-Naive Patients: The recommended starting dose of  is 2 mg/500 mg once or twice daily. 
									
									For patients with HbA1c >11% or FPG>270 mg/dL, a starting dose of 2 mg/500 mg twice daily may be considered. The dose may be increased by increment of 2 mg/500 mg per day to a maximum of 8 mg/2,000 mg per day in divided doses if patients are not adequately controlled after 4 weeks.
									
									For patients inadequately controlled on Metformin monotherapy, the usual starting dose  is 4 mg Rosiglitazone (daily dose) plus the dose of Metformin already being taken.
									
									For patients inadequately controlled on Rosiglitazone monotherapy, the usual starting dose is 1000 mg Metformin (daily dose) plus the dose of Rosiglitazone already being taken.
									
									When switching from combination therapy of Rosiglitazone plus Metformin as separate tablets, the usual starting dose  is the dose of Rosiglitazone and Metformin already being taken. If additional glycemic control is needed, the daily dose may be increased by increment of 4 mg Rosiglitazone and/or 500 mg Metformin, up to the maximum recommended total daily dose of 8 mg/2000 mg.
	Contara-indications : It is contraindicated in patients with renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels .1.5 mg/dl (males), 1.4 mg/dl (females), or abnormal creatinine clearance), acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma & known hypersensitivity to rosiglitazone maleate or metformin HCl.
	Side effects : Rosiglitazone: The commonly reported adverse events are upper respiratory tract infections, injury, headache, back pain, fatigue, sinusitis, diarrhoea and hypoglycemia. There were a small number of patients who had anemia and edema. All these events were generally mild to moderate in severity and usually do not require discontinuation of treatment with Rosiglitazone.
									Metformin: Some patients may develop asymptomatic subnormal levels of serum vitamin B12.
									Incidence of lactic acidosis is also very rare. Diarrhoea, nausea, vomiting, abdominal bloating, flatulence and anorexia are common reactions to Metformin.
	Precaution : Rosiglitazone: should not be used in patients with type 1 diabetes. This should be used with caution in patients with edema. Dose-related weight gain was seen with rosiglitazone alone and rosiglitazone together with other hypoglycemic agents.
				
				Metformin: Monitoring of renal function: Patients with serum creatinine levels above the upper limit of normal should not receive this tablet. In patients with advanced age, the dose should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. 
	Pregnancy category : 13
	Mode of action : Rosiglitazone: Lowers glucose by improving target cell response to insulin without increasing pancreatic cell secretion; activates nuclear peroxisome proliferator-activated receptor gamma, which influences the production of gene products involved in glucose and lipid metabolism.
									
									Metformin: Biguanide; acts by decreasing endogenous hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; improves glucose tolerance and lowers both basal and postprandial plasma glucose .
	Interaction : Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.
				Potentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
	Therapeutic class : Combination Oral hypoglycemic preparations
	Packsize : 30's pack
Arnex
	n : Naproxen
	Indications : Rheumatoid arthritis, Ankylosing spondylitis, Post-operative pain, Dysmenorrhea, Acute gout, Acute migraine attacks, Renal colic, Cutaneous candidiasis, Mild to moderate pain, Tendonitis, Osteoarthritis (degenerative arthritis), Acute musculoskeletal disorders, Bursitis
	Doses and administration : Adults
									Oral:
									For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis
									The usual dose is 500-1000 mg per day taken in 2 doses at 12 hours intervals after meals.
									For acute gout
									750 mg should be given initially, followed in 8 hours with 500 mg, and thereafter 250 mg at 12 hours intervals until the attack has passed.
									For dysmennorhoea
									500 mg should be given initially, followed by 250 mg at 6-8 hour intervals for up to 5 days.
									For analgesia and acute muscular skeletal disorders
									500 mg should be given initially, followed by 250 mg at 6-8 hour intervals.
									
									Children over 5 years
									For juvenile rheumatoid arthritis
									10mg/kg/day given as 2 divided doses at 12 hour intervals.
									SR tablet: For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis
									500mg or 1000mg (500mg  2) SR tablet once daily (morning or evening) after meals.
									SR tablet is also indicated after the acute condition is subsided for long term use.
									
									Naproxen suspension
									Adults
									Dosage is the same as Naproxen tablet.
									Children over 5 years
									10 mg/kg/day given as 2 divided doses at 12 hours intervals.
									
									
	Contara-indications : Hypersensitivity. Aspirin or NSAID allergy. Perioperative pain in the setting of CABG surgery. Pregnancy (3rd trimester).
	Side effects : Oedema, palpitation, dizziness, drowsiness, headache, light headedness, vertigo, pruritus, skin eruption, ecchymosis, purpura, rash, fluid retention, abdominal pain, constipation, nausea, heartburn, diarrhoea, dyspepsia, stomatitis, flatulence, gross bleeding/perforation, indigestion, ulcers, vomiting, abnormal renal function, haemolysis, anaemia, increased bleeding time, elevated LFTs, visual disturbances, tinnitus, hearing disturbances, dyspnoea, diaphoresis, thirst.
									Potentially Fatal: Anaphylactic/anaphylactoid reactions. Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
	Precaution : Pre-existing CV risk factors or disease e.g. fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment. Elderly. Lactation.
	Pregnancy category : 4
	Mode of action : Naproxen, a propionic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It can inhibit platelet aggregation, has anti-inflammatory, analgesic and antipyretic actions.
	Interaction : May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. 
				
				Delayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 30's pack
Arobid HFA
	n : Salmeterol
	Indications : Chronic asthma, COPD
	Doses and administration : Adult: Inhalation Chronic asthma; COPD As metered-dose aerosol or dry powd inhalation:Adults and children over 4 years : 50 micrograms twice daily (two puffs with one minute gap in between every puff ) up to 100 mcg twice daily if needed.
	Contara-indications : Contraindicated in patients with hypersensitivity to Salmeterol or to the any excipient of this preparation.
	Side effects : Fine skeletal muscle tremor especially hands, tachycardia, palpitations, muscle cramps, headache, paradoxical bronchospasm, angioedema, urticaria, hypotension and collapse.
	Precaution : Pregnancy. Arrhythmias, hyperthyroidism, hypertension, DM, myocardial insufficiency, susceptibility to QT-interval prolongation. May cause paradoxical bronchospasm. Not to be used for treatment of acute bronchospasm or patients with deteriorating asthma. Monitor serum potassium concentrations in severe asthma.
	Pregnancy category : 3
	Mode of action : Salmeterol is a direct-acting sympathomimetic which relaxes bronchial smooth muscle by its selective action on beta 2 receptors with little effect on heart rate.
	Interaction : Diuretics, corticosteroids and xanthines may augment hypokalaemia. Risk of severe hypertension when used with MAOIs, TCAs and other sympathomimetics. Increased susceptibility to cardiac arrhythmias caused by digoxin and other cardiac glycosides.
	Therapeutic class : Long-acting selective beta2-adrenoceptor stimulants
	Packsize : 120 inhalations unit
Arocaine-A DC
	n : Articaine Hydrochloride + Epinephrine
	Indications : Local anesthesia
	Doses and administration : Dosage depends on several factors such as route, type and extent of surgical procedure, duration of anaesthesia and patient's condition and age.
									
									Local Infiltration: 0.5-2.5 mL injection of 4% solution; 20-100 mg total dose
									
									Nerve block: 0.5-3.4 mL injection of 4% solution; 20-136 mg total dose
									
									Oral surgery: 1-5.1 mL injection of 4% solution; 40-204 mg total dose
									
									No more than 7 mg/kg (0.175 mL/kg)
	Contara-indications : Tachycardia, hypertension, cerebral arteriosclerosis, ischaemic heart disease, IV admin, anaesthetise digits or appendages, myasthenia gravis.
	Side effects : Severity of adverse effects in CNS and CVS are directly related to blood levels of lidocaine; dizziness; muscle twitching; 
									local anaesthetic of mouth/throat impairs swallowing and increases the risk of aspiration (patients cautioned against eating or drinking for 3-4 hr after anaesthesia); transient effect on auditory system of neonate; erythema; pigmentation; pain; headache; palpitations; local necrosis; pulmonary oedema; hyperglycaemia; bradycardia; reduced cardiac output; anxiety. 
									Epidural may cause hypotension, bradycardia, nausea and vomiting. Intraoral inj may cause stress reactions such as diaphoresis, palpitation, hyperventilation, generalised pallor and faintness. 
									Topically: papules, burns, rash, skin irritation, burning sensation and blanching.
									Potentially Fatal: CNS toxicity (due to inadvertent IV admin), medullary depression with tonic & clonic convulsions; ventricular fibrillation; severe hypertension with cerebral haemorrhage and pulmonary oedema; unconsciousness; possibly respiratory arrest. Allergic reactions including anaphylactic symptoms and possibly life threatening asthmatic episodes in susceptible patients may occur due to sodium metabisulphate constituent. Central nerve blocks may cause CV depression (especially in hypovolaemia). Retrobulbar inj may reach subarachnoid space causing CV collapse, apnoea, convulsions, temporary blindness. Paracervical block may cause foetal bradycardia/tachycardia (careful monitoring of foetal heart rate is necessary).
	Precaution : Epilepsy, impaired cardiac conduction, CHF, DM, closed angle glaucoma, impaired liver function (if site of admin is likely to result in high blood levels), severe renal dysfunction. Local anaesthetic effect may be reduced if injected into an inflamed or infected area. Cerebrovascular insufficiency, hyperthyroidism. Neonates, elderly, patients in poor general condition (optimise patient's condition before major block), pregnancy.
	Pregnancy category : 3
	Mode of action : Local anesthetics prevent generation/conduction of nerve impulses by reducing sodium permeability and increasing action potential threshold.
	Interaction : The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should be avoided; however, in situations when concurrent therapy is necessary, careful patient monitoring is essential.
	Therapeutic class : Local & Surface anesthesia
	Packsize : 1.8ml cratridge x 5's pack
Arocef
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 15ml bot
Arocef
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 100ml bot
Arocef
	n : Cefadroxil
	Indications : Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections
	Doses and administration :  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. 
									Children: 30 mg/kg/day in equally divided doses every 12 hours.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	0.5-1 g bid.
									11-25	0.5-1 g once daily.
									<10	0.5-1 g every 36 hr. 
	Contara-indications : Hypersensitivity to cephalosporins.
	Side effects : Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.
									Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
	Precaution : Impaired renal function; pregnancy and lactation.
	Pregnancy category : 2
	Mode of action : Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes.
	Interaction : Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
	Therapeutic class : First generation Cephalosporins
	Packsize : 24's pack
Arodex
	n : Anastrozole
	Indications : Breast cancer, Ovulation induction
	Doses and administration : Oral
									Advanced or locally advanced breast cancer, Adjuvant treatment in early breast cancer
									Adult: In postmenopausal women: 1 mg daily. Adjuvant treatment may be continued for up to 5 yr.
	Contara-indications : Pregnancy. Hypersensitivity, premenopausal women.
	Side effects : Hot flushes, vaginal dryness, vaginal bleeding, hair thinning, anorexia, nausea, vomiting, diarrhoea, headache, arthralgia, bone fractures, rash, oedema, myalgia, fever, weight gain, leucopenia, flu-like syndrome, asthenia, dizziness, drowsiness, abnormal liver enzyme values, thrombophloebitis, anaphylaxis.
	Precaution : Lactation. Moderate or severe hepatic impairment, hyperlipidaemias. Laboratory test for menopause if status is doubtful. Bone mass density test should be conducted at the start of the therapy and at regular intervals thereafter.
	Pregnancy category : 5
	Mode of action : Anastrozole prevents conversion of androstenedione to estrone and testosterone to oestradiol by inhibiting aromatase, thus leading to significantly reduced serum oestradiol concentrations.
	Interaction : Efficacy decreased by oestrogens. Plasma concentrations decreased by tamoxifen.
	Therapeutic class : Hormonal Chemotherapy
	Packsize : 30's pack
Arodin
	n : Povidone Iodine 10% Topical
	Indications :  Use as an antiseptic skin cleanser for major and minor surgical procedures, Skin infections, Wound infection, Decubitus ulcers, Candidal & Trichomonal vaginitis.
	Doses and administration : Treatment and prophylaxis of wound infection
									Adult: Apply 5-10% topical solutions on affected area. The site may be covered with gauze or adhesive bandage
									Vaginal:.
									Vaginal candidiasis
									Adult: 5 gm of   (10%) gel, one applicator full every night for up tp 14 days.
	Contara-indications : Hypersensitivity; prolonged use in patients with thyroid disorders or on lithium therapy. 
	Side effects : Local irritation and sensitivity to skin & mucus membrane. Application to large areas of denuded skin may produce systemic effects due to iodine absorption.
	Precaution :  Pregnancy, lactation; neonates. Renal impairement.
	Pregnancy category : 4
	Mode of action : Povidone-iodine is an iodophore with a powerful broad-spectrum germicidal activity against a wide range of bacteria, viruses, fungi, protozoa and spores. Microbicidal; oxidizes cell constituents; iodinates proteins and inactivates them.
	Interaction : None
	Therapeutic class : Drugs used in Vaginal and Vulval conditions
	Packsize : 100ml bot/1 liter pack/5  liter pack
Arodin
	n : Povidone Iodine 5% Topical
	Indications : Primary or secondary topical infections, infected surgical incisions, infected decubitus or stasis ulcers, pyodermas, secondarily infected dermatoses, and infected traumatic lesions. Prevention of infections in cuts and abrasions, wounds.
									
									
	Doses and administration : Adult: As Oinement: For the treatment of infection: Apply once or twice daily or at dressing changes for a maximum of 14 days.
									For the prevention of infection: Apply once or twice a week for as long as necessary. Apply ointment directly to the affected area after being cleaned and dried. May be covered with a dressing or bandage.
									
									
									As powd: Apply as often as required directed.May be covered with a dressing or bandage.
									
									
	Contara-indications :  Regular use is contraindicated in patients or users with thyroid disorders (in particular nodular colloid goitre, endemic goiter and Hashimotos thyroiditis). Not for use in infants under 2 years. Special caution is needed when regular applications to broken skin are made to patients with pre-existing renal insufficiency. Regular use should be avoided in patients on concurrent lithium therapy.
	Side effects :  Local skin irritation and sensitivity. Application to large areas of denuded skin may produce systemic effects due to iodine absorption.The application of povidone iodine to large wounds or severe burns may producesystemic adverse effectssuch as metabolic acidosis, hypernatraemia and impairment of renal function.
									
									Occasionally mild-transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions are reported. 
									
	Precaution : Pregnancy, lactation; neonates.
	Pregnancy category : 4
	Mode of action : Povidone-iodine is an iodophore with a powerful broad-spectrum germicidal activity against a wide range of bacteria, viruses, fungi, protozoa and spores. Microbicidal; oxidizes cell constituents; iodinates proteins and inactivates them. 
	Interaction : None
	Therapeutic class : Iodine compounds (Anti-septic Preparations)
	Packsize : 10gm tube/20gm tube
Arodin
	n : Povidone Iodine 1%  Mouth-Wash
	Indications : Oral candidiasis
	Doses and administration : Adult: Mouth/Throat Oral hygiene As 0.1% soln: Rinse mouth w/ 10 mL undiluted soln or diluted w/ an equal amount of water 4 times/day for 14 days. Oral candidiasis As 1% soln: Rinse mouth as directed. 
	Contara-indications : Hypersensitivity; prolonged use in patients with thyroid disorders or on lithium therapy. Premature neonates or neonates weighing <1.5 kg.
	Side effects : Local irritation and sensitivity (rare). Idiosyncratic mucosal irritation and hypersensitivity reactions rarely, may interfere with thyroid-function tests.
	Precaution : Avoid contact with eyes; should not be used under occlusive dressing. Pregnancy, lactation; neonates.
	Pregnancy category : 4
	Mode of action : Povidone-iodine is an iodophore with a powerful broad-spectrum germicidal activity against a wide range of bacteria, viruses, fungi, protozoa and spores. Microbicidal; oxidizes cell constituents; iodinates proteins and inactivates them.
	Interaction : None
	Therapeutic class : Mouth & Throat preparations
	Packsize : 100ml bot
Arofil 200 SR
	n : Theophylline
	Indications : Asthma, Chronic obstructive pulmonary disease, Bronchospasm, Apnoea
	Doses and administration : Adult: PO: usually controlled release tablet 12 hourly or as directed by the physicians.  10-15mg/Kg/day, 2 times daily.  
									
									Child:  
									1-6 months: 	10mg/Kg/day,   
									6 m-1 year: 	15mg/Kg/day,  
									1-9 years: 	        24mg/Kg/day,  
									10-l6 years: 	18mg/Kg/day, in divided doses.
	Contara-indications : Hypersensitivity to xanthine derivatives, porphyria.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness, tremor, palpitations.Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV inj.
	Precaution : Smoking and alcohol consumption can increase the clearance of Theophylline and a higher dosage may be necessary.Careful monitoring is recommended for patients with congestive heart failure, chronic alcoholism, hepatic dysfunction or viral infections as they may have lower total clearance of Theophylline which could lead to higher than normal plasma levels.Caution should be exercised in patients with hyperthyroidism, cardiac arrhythmia, hypertension or other cardiovascular diseases.
	Pregnancy category : 3
	Mode of action : Theophylline competitively blocks phosphodiesterase which increases cAMP tissue concentrations causing bronchodilatation, diuresis, CNS and cardiac stimulation, and gastric acid secretion.
	Interaction : Other xanthines. Theophylline clearance reduced by high dose allopurinol, some antiarrhythmics, cimetidine, disulfiram, propranolol, methotrexate, aciclovir, mexiletine, pentoxifylline, tacrine, ticlopidine, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Theophylline clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, aminoglutethimide, barbiturates, ipriflavone, cigarette smoking. Concurrent use decreased lithium, alprazolam levels. Increased risk of arrhythmias with ephedrine, sympathomimetic, general anaesthetics. Increased heart rate with tadalafil.
	Therapeutic class : Theophylline & related drugs
	Packsize : 100's pack
Arofil 400 SR
	n : Theophylline
	Indications : Asthma, Chronic obstructive pulmonary disease, Bronchospasm, Apnoea
	Doses and administration : Adult: PO: usually controlled release tablet 12 hourly or as directed by the physicians.  10-15mg/Kg/day, 2 times daily.  
									
									Child:  
									1-6 months: 	10mg/Kg/day,   
									6 m-1 year: 	15mg/Kg/day,  
									1-9 years: 	        24mg/Kg/day,  
									10-l6 years: 	18mg/Kg/day, in divided doses.
	Contara-indications : Hypersensitivity to xanthine derivatives, porphyria.
	Side effects : Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness, tremor, palpitations.Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV inj.
	Precaution : Smoking and alcohol consumption can increase the clearance of Theophylline and a higher dosage may be necessary.Careful monitoring is recommended for patients with congestive heart failure, chronic alcoholism, hepatic dysfunction or viral infections as they may have lower total clearance of Theophylline which could lead to higher than normal plasma levels.Caution should be exercised in patients with hyperthyroidism, cardiac arrhythmia, hypertension or other cardiovascular diseases.
	Pregnancy category : 3
	Mode of action : Theophylline competitively blocks phosphodiesterase which increases cAMP tissue concentrations causing bronchodilatation, diuresis, CNS and cardiac stimulation, and gastric acid secretion.
	Interaction : Other xanthines. Theophylline clearance reduced by high dose allopurinol, some antiarrhythmics, cimetidine, disulfiram, propranolol, methotrexate, aciclovir, mexiletine, pentoxifylline, tacrine, ticlopidine, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Theophylline clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, aminoglutethimide, barbiturates, ipriflavone, cigarette smoking. Concurrent use decreased lithium, alprazolam levels. Increased risk of arrhythmias with ephedrine, sympathomimetic, general anaesthetics. Increased heart rate with tadalafil.
	Therapeutic class : Theophylline & related drugs
	Packsize : 50's pack
Arokast
	n : Montelukast
	Indications : Asthma, Allergic rhinitis
	Doses and administration : Adults (15 years of age or over): 10 mg daily to be taken in the evening.
									
									Chronic asthma; Allergic rhinitis 10 mg/day once in the evening. Prophylaxis of exercise-induced asthma 10 mg at least 2 hr before exercise; do not admin additional doses w/in 24 hr.
									
									Children (6-14 years of age): 5 mg daily to be taken in the evening.
									Children (2-5 years of age): 4 mg daily to be taken in the evening
	Contara-indications : Hypersensitivity.
	Side effects : Dizziness, fatigue, fever; rash; abdominal pain, dyspepsia, dental pain, gastroenteritis; increased AST; weakness; cough, nasal congestion. Aggression, agitation, angioedema, arthralgia, bleeding tendency, bruising, cholestasis, diarrhoea, dream abnormalities, drowsiness, oedema, eosinophilia, hallucinations, hepatic eosinophilic infiltration (rare), hepatitis, hypersensitivity, hypoaesthesia, insomnia, irritability, muscle cramps, myalgia, nausea, palpitation, pancreatitis, paraesthesia, pruritus, restlessness, seizure, urticaria, vasculitis, vomiting.
									Potentially Fatal: Anaphylaxis, Churg-Strauss syndrome.
	Precaution : Not for the relief of acute bronchospasm. Not to be used as monotherapy for the prevention of exercise-induced bronchospasm. Patients in whom asthma is precipitated by aspirin or other NSAIDs should continue to avoid aspirin and NSAIDs. Do not abruptly substitute for oral or inhaled corticosteroids. Be alert for any signs of Churg-Strauss syndrome. Pregnancy and lactation. Children <6 mth.
	Pregnancy category : 2
	Mode of action : Montelukast is a selective leukotriene receptor antagonist that blocks the effects of cysteinyl leukotrienes in the airways.
	Interaction : nduced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).
	Therapeutic class : Leukotriene receptor antagonists
	Packsize : 10's pack
Arokast
	n : Montelukast
	Indications : Asthma, Allergic rhinitis
	Doses and administration : Adults (15 years of age or over): 10 mg daily to be taken in the evening.
									
									Chronic asthma; Allergic rhinitis 10 mg/day once in the evening. Prophylaxis of exercise-induced asthma 10 mg at least 2 hr before exercise; do not admin additional doses w/in 24 hr.
									
									Children (6-14 years of age): 5 mg daily to be taken in the evening.
									Children (2-5 years of age): 4 mg daily to be taken in the evening
	Contara-indications : Hypersensitivity.
	Side effects : Dizziness, fatigue, fever; rash; abdominal pain, dyspepsia, dental pain, gastroenteritis; increased AST; weakness; cough, nasal congestion. Aggression, agitation, angioedema, arthralgia, bleeding tendency, bruising, cholestasis, diarrhoea, dream abnormalities, drowsiness, oedema, eosinophilia, hallucinations, hepatic eosinophilic infiltration (rare), hepatitis, hypersensitivity, hypoaesthesia, insomnia, irritability, muscle cramps, myalgia, nausea, palpitation, pancreatitis, paraesthesia, pruritus, restlessness, seizure, urticaria, vasculitis, vomiting.
									Potentially Fatal: Anaphylaxis, Churg-Strauss syndrome.
	Precaution : Not for the relief of acute bronchospasm. Not to be used as monotherapy for the prevention of exercise-induced bronchospasm. Patients in whom asthma is precipitated by aspirin or other NSAIDs should continue to avoid aspirin and NSAIDs. Do not abruptly substitute for oral or inhaled corticosteroids. Be alert for any signs of Churg-Strauss syndrome. Pregnancy and lactation. Children <6 mth.
	Pregnancy category : 2
	Mode of action : Montelukast is a selective leukotriene receptor antagonist that blocks the effects of cysteinyl leukotrienes in the airways.
	Interaction : nduced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).
	Therapeutic class : Leukotriene receptor antagonists
	Packsize : 30's pack
Arokast
	n : Montelukast
	Indications : Asthma, Allergic rhinitis
	Doses and administration : Adults (15 years of age or over): 10 mg daily to be taken in the evening.
									
									Chronic asthma; Allergic rhinitis 10 mg/day once in the evening. Prophylaxis of exercise-induced asthma 10 mg at least 2 hr before exercise; do not admin additional doses w/in 24 hr.
									
									Children (6-14 years of age): 5 mg daily to be taken in the evening.
									Children (2-5 years of age): 4 mg daily to be taken in the evening
	Contara-indications : Hypersensitivity.
	Side effects : Dizziness, fatigue, fever; rash; abdominal pain, dyspepsia, dental pain, gastroenteritis; increased AST; weakness; cough, nasal congestion. Aggression, agitation, angioedema, arthralgia, bleeding tendency, bruising, cholestasis, diarrhoea, dream abnormalities, drowsiness, oedema, eosinophilia, hallucinations, hepatic eosinophilic infiltration (rare), hepatitis, hypersensitivity, hypoaesthesia, insomnia, irritability, muscle cramps, myalgia, nausea, palpitation, pancreatitis, paraesthesia, pruritus, restlessness, seizure, urticaria, vasculitis, vomiting.
									Potentially Fatal: Anaphylaxis, Churg-Strauss syndrome.
	Precaution : Not for the relief of acute bronchospasm. Not to be used as monotherapy for the prevention of exercise-induced bronchospasm. Patients in whom asthma is precipitated by aspirin or other NSAIDs should continue to avoid aspirin and NSAIDs. Do not abruptly substitute for oral or inhaled corticosteroids. Be alert for any signs of Churg-Strauss syndrome. Pregnancy and lactation. Children <6 mth.
	Pregnancy category : 2
	Mode of action : Montelukast is a selective leukotriene receptor antagonist that blocks the effects of cysteinyl leukotrienes in the airways.
	Interaction : nduced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).
	Therapeutic class : Leukotriene receptor antagonists
	Packsize : 30's pack
Arolax
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 60ml bot/100ml bot
Arolax
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 100's pack
Arolax
	n : Levosalbutamol
	Indications : Asthma, Chronic obstructive pulmonary disease (COPD)
	Doses and administration : Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.
									Children (6 -11 years): 5 ml (1 mg), three times daily.
									Adults and adolescents above 12 years: 1-2 mg, three times daily. 
	Contara-indications : Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.
	Side effects : Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. 
	Precaution : Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. 
	Pregnancy category : 3
	Mode of action : Salbutamol is a direct-acting sympathomimetic with ?-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.
	Interaction : None
	Therapeutic class : Short-acting selective beta2-adrenoceptor stimulants
	Packsize : 100's pack
Arolef
	n : Leflunomide
	Indications : Rheumatoid arthritis, Psoriatic arthritis
	Doses and administration : Adult: PO Rheumatoid arthritis; Psoriatic arthritis: Loading dose of 100 mg once daily for 3 days, the maintenance dose is 20 mg once daily. Leflunomide does not require stepwise dose increment over time. The dose may be decreased to 10 mg daily if tolerability issues arise.
	Contara-indications : Significant hepatic impairment, compromised immune function including bone marrow dysplasia or severe uncontrolled infection; concurrent vaccination with live vaccines. Pregnancy, lactation.
	Side effects : Thrombocytopenia, anaphylaxis, eosinophilia, leukopenia, pancytopenia. Headache, dizziness, weakness, bronchitis, urinary tract infection, alopecia, rash, dry skin, eczema, pruritus, hypokalaemia, weight loss, arthralgia, joint disorder, leg cramps, rhinitis, sinusitis, hypertension, diarrhoea, nausea, abdominal pain, synovitis, tenosynovitis, paraesthesia, pharyngitis, anorexia, vomiting, oral thrush, stomatitis.Potentially Fatal: Hepatotoxicity.
	Precaution : Renal and hepatic impairment; Women with childbearing potential. Caution should be taken for those female with child bearing potential who are not using reliable contraception and for the subject of renal insufficiency. Leflunomide should be stopped before becoming pregnant. Liver function should be monitored before starting treatment. Monitor blood counts and BP regularly. Avoid alcohol.
	Pregnancy category : 5
	Mode of action : Leflunomide is an immunomodulating agent and DMARD. It inhibits pyrimidine synthesis by inhibiting dihydroorotate dehydrogenase enzyme activity resulting in antiproliferative and anti-inflammatory effects.
	Interaction : Cholestyramine and activated charcoal may decrease plasma concentration of active metabolite. Concurrent use of methotrexate and other hepatotoxic drugs may increase the risk of hepatotoxicity. Rifampicin increases serum levels of the active metabolite.
				Potentially Fatal: May enhance the adverse effects of live vaccines. 
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 3's pack
Arolef
	n : Leflunomide
	Indications : Rheumatoid arthritis, Psoriatic arthritis
	Doses and administration : Adult: PO Rheumatoid arthritis; Psoriatic arthritis: Loading dose of 100 mg once daily for 3 days, the maintenance dose is 20 mg once daily. Leflunomide does not require stepwise dose increment over time. The dose may be decreased to 10 mg daily if tolerability issues arise.
	Contara-indications : Significant hepatic impairment, compromised immune function including bone marrow dysplasia or severe uncontrolled infection; concurrent vaccination with live vaccines. Pregnancy, lactation.
	Side effects : Thrombocytopenia, anaphylaxis, eosinophilia, leukopenia, pancytopenia. Headache, dizziness, weakness, bronchitis, urinary tract infection, alopecia, rash, dry skin, eczema, pruritus, hypokalaemia, weight loss, arthralgia, joint disorder, leg cramps, rhinitis, sinusitis, hypertension, diarrhoea, nausea, abdominal pain, synovitis, tenosynovitis, paraesthesia, pharyngitis, anorexia, vomiting, oral thrush, stomatitis.Potentially Fatal: Hepatotoxicity.
	Precaution : Renal and hepatic impairment; Women with childbearing potential. Caution should be taken for those female with child bearing potential who are not using reliable contraception and for the subject of renal insufficiency. Leflunomide should be stopped before becoming pregnant. Liver function should be monitored before starting treatment. Monitor blood counts and BP regularly. Avoid alcohol.
	Pregnancy category : 5
	Mode of action : Leflunomide is an immunomodulating agent and DMARD. It inhibits pyrimidine synthesis by inhibiting dihydroorotate dehydrogenase enzyme activity resulting in antiproliferative and anti-inflammatory effects.
	Interaction : Cholestyramine and activated charcoal may decrease plasma concentration of active metabolite. Concurrent use of methotrexate and other hepatotoxic drugs may increase the risk of hepatotoxicity. Rifampicin increases serum levels of the active metabolite.
				Potentially Fatal: May enhance the adverse effects of live vaccines. 
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Aronem
	n : Meropenem
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Skin and skin structure infections, Diabetic foot infection
	Doses and administration : Adult: IV Susceptible infections 0.5-1 g 8 hrly. Meningitis 2 g 8 hrly. Cystic fibrosis Up to 2 g 8 hrly. Skin infections 500 mg 8 hrly. Diabetic foot; Intra-abdominal infections 1 g 8 hrly.
									
									Children: 3 months to 12 years. 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogen(s) and the condition of the patient.
									Intra-abdominal infections: 20 mg/kg every 8 hours.
									Cystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours.
									Meningitis: 40 mg/kg IV every 8 hours.
									
									Children over 50 kg weight: use adult dosage.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	Usual dose 12 hrly.
									10-25	Half the usual dose 12 hrly.
									<10	        Half the usual dose 24 hrly.
									
									Hepatic impairment: No dosage adjustment needed.
	Contara-indications : Hypersensitivity.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment.
									Potentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome.
	Precaution : History of hypersensitivity to carbapenem, pencillins or other ?-lactam antibiotics; infants <3 mth; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.
	Pregnancy category : 2
	Mode of action : Meropenem is a synthetic carbapenem ?-lactam antibiotic that exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in gm+ve and gm-ve bacteria through binding to several penicillin-binding proteins (PBPs).
	Interaction : Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
	Therapeutic class : Other beta-lactam Antibiotics
	Packsize : 1gm vial X 1's pack
Aronem
	n : Meropenem
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Skin and skin structure infections, Diabetic foot infection
	Doses and administration : Adult: IV Susceptible infections 0.5-1 g 8 hrly. Meningitis 2 g 8 hrly. Cystic fibrosis Up to 2 g 8 hrly. Skin infections 500 mg 8 hrly. Diabetic foot; Intra-abdominal infections 1 g 8 hrly.
									
									Children: 3 months to 12 years. 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogen(s) and the condition of the patient.
									Intra-abdominal infections: 20 mg/kg every 8 hours.
									Cystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours.
									Meningitis: 40 mg/kg IV every 8 hours.
									
									Children over 50 kg weight: use adult dosage.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	Usual dose 12 hrly.
									10-25	Half the usual dose 12 hrly.
									<10	        Half the usual dose 24 hrly.
									
									Hepatic impairment: No dosage adjustment needed.
	Contara-indications : Hypersensitivity.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment.
									Potentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome.
	Precaution : History of hypersensitivity to carbapenem, pencillins or other ?-lactam antibiotics; infants <3 mth; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.
	Pregnancy category : 2
	Mode of action : Meropenem is a synthetic carbapenem ?-lactam antibiotic that exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in gm+ve and gm-ve bacteria through binding to several penicillin-binding proteins (PBPs).
	Interaction : Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
	Therapeutic class : Other beta-lactam Antibiotics
	Packsize : 500mg vial X 1's pack
Aropen
	n : Meropenem
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Skin and skin structure infections, Diabetic foot infection
	Doses and administration : Adult: IV Susceptible infections 0.5-1 g 8 hrly. Meningitis 2 g 8 hrly. Cystic fibrosis Up to 2 g 8 hrly. Skin infections 500 mg 8 hrly. Diabetic foot; Intra-abdominal infections 1 g 8 hrly.
									
									Children: 3 months to 12 years. 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogen(s) and the condition of the patient.
									Intra-abdominal infections: 20 mg/kg every 8 hours.
									Cystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours.
									Meningitis: 40 mg/kg IV every 8 hours.
									
									Children over 50 kg weight: use adult dosage.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	Usual dose 12 hrly.
									10-25	Half the usual dose 12 hrly.
									<10	        Half the usual dose 24 hrly.
									
									Hepatic impairment: No dosage adjustment needed.
	Contara-indications : Hypersensitivity.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment.
									Potentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome.
	Precaution : History of hypersensitivity to carbapenem, pencillins or other ?-lactam antibiotics; infants <3 mth; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.
	Pregnancy category : 2
	Mode of action : Meropenem is a synthetic carbapenem ?-lactam antibiotic that exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in gm+ve and gm-ve bacteria through binding to several penicillin-binding proteins (PBPs).
	Interaction : Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
	Therapeutic class : Other beta-lactam Antibiotics
	Packsize : 1gm vial X 1's pack
Aropen IV
	n : Meropenem
	Indications : Cystic fibrosis, Intra-abdominal infections, Meningitis, Skin and skin structure infections, Diabetic foot infection
	Doses and administration : Adult: IV Susceptible infections 0.5-1 g 8 hrly. Meningitis 2 g 8 hrly. Cystic fibrosis Up to 2 g 8 hrly. Skin infections 500 mg 8 hrly. Diabetic foot; Intra-abdominal infections 1 g 8 hrly.
									
									Children: 3 months to 12 years. 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogen(s) and the condition of the patient.
									Intra-abdominal infections: 20 mg/kg every 8 hours.
									Cystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours.
									Meningitis: 40 mg/kg IV every 8 hours.
									
									Children over 50 kg weight: use adult dosage.
									
									Renal impairment:
									CrCl (ml/min)	
									26-50	Usual dose 12 hrly.
									10-25	Half the usual dose 12 hrly.
									<10	        Half the usual dose 24 hrly.
									
									Hepatic impairment: No dosage adjustment needed.
	Contara-indications : Hypersensitivity.
	Side effects : Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment.
									Potentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome.
	Precaution : History of hypersensitivity to carbapenem, pencillins or other ?-lactam antibiotics; infants <3 mth; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.
	Pregnancy category : 2
	Mode of action : Meropenem is a synthetic carbapenem ?-lactam antibiotic that exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in gm+ve and gm-ve bacteria through binding to several penicillin-binding proteins (PBPs).
	Interaction : Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
	Therapeutic class : Other beta-lactam Antibiotics
	Packsize : 500mg vial X 1's pack
Aros
	n : Aceclofenac
	Indications : Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;
	Doses and administration : Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.
	Contara-indications : Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.
	Side effects : Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
									Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
	Precaution : Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.
	Pregnancy category : 0
	Mode of action : Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.
	Interaction : May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
	Therapeutic class : Drugs used for Rheumatoid Arthritis
	Packsize : 50's pack
Arotide 125 125/25
